PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jeffery, AN; Voss, LD; Metcalf, BS; Alba, S; Wilkin, TJ				Jeffery, AN; Voss, LD; Metcalf, BS; Alba, S; Wilkin, TJ			Parents' awareness of overweight in themselves and their children: cross sectional study within a cohort (EarlyBird 21)	BRITISH MEDICAL JOURNAL			English	Article									Derriford Hosp, Peninsula Med Sch, Plymouth PL6 8DH, Devon, England	Derriford Hospital; University of Plymouth	Jeffery, AN (corresponding author), Derriford Hosp, Peninsula Med Sch, Plymouth PL6 8DH, Devon, England.	alison.jeffery@pms.ac.uk						BUNDRED P, 2001, BRIT MED J, V10, P322; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; *NAT AUD OFF, 2001, TACKL OB ENGL; Saxena S, 2004, ARCH DIS CHILD, V89, P30; Voss LD, 2003, J PEDIATR ENDOCR MET, V16, P1211	5	170	171	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 1	2005	330	7481					23	24		10.1136/bmj.38315.451539.F7	http://dx.doi.org/10.1136/bmj.38315.451539.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15567804	Green Published, Bronze			2022-12-28	WOS:000226176700014
J	Hien, TT; de Jong, M; Farrar, J				Hien, TT; de Jong, M; Farrar, J			Avian influenza - A challenge to global health care structures	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							H5N1 INFLUENZA; VIRUSES		Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam	University of Oxford	Hien, TT (corresponding author), Univ Oxford, Hosp Trop Dis, Clin Res Unit, Ho Chi Minh City, Vietnam.		Farrar, Jeremy J./HGA-7610-2022	Farrar, Jeremy/0000-0002-2700-623X				Chen H, 2004, P NATL ACAD SCI USA, V101, P10452, DOI 10.1073/pnas.0403212101; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Kuiken T, 2004, SCIENCE, V306, P241, DOI 10.1126/science.1102287; Li KS, 2004, NATURE, V430, P209, DOI 10.1038/nature02746	5	70	82	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2363	2365		10.1056/NEJMp048267	http://dx.doi.org/10.1056/NEJMp048267			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575048				2022-12-28	WOS:000225429000001
J	Smith, ML; Cavenagh, JD; Lister, TA; Fitzgibbon, J				Smith, ML; Cavenagh, JD; Lister, TA; Fitzgibbon, J			Brief report - Mutation of CEBPA in familial acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BINDING-PROTEIN-ALPHA; ACUTE MYELOGENOUS LEUKEMIA; C/EBP-ALPHA; GRANULOCYTIC DIFFERENTIATION; PROGENITORS; INDUCTION; GENE	We describe a family in whom three members affected by acute myeloid leukemia (AML) had an identical, 212delC mutation in CEBPA, the gene encoding the granulocytic differentiation factor C/EBP(alpha). Unaffected family members did not have this mutation. Latent periods of 10, 18, and 30 years elapsed before the onset of overt leukemia in the three patients. One of them had a second CEBPA mutation, but only at the time of diagnosis. All three patients are currently well, with no abnormalities in the bone marrow. CEBPA mutation is apparently the primary event in the development of AML in this family.	St Bartholomews Hosp, Canc Res UK, Med Oncol Unit, Barts & London Sch Med & Dent, London EC1A 7BE, England; St Bartholomews Hosp, Dept Haematol, London EC1A 7BE, England	Cancer Research UK; University of London; Queen Mary University London; University of London; Queen Mary University London	Smith, ML (corresponding author), St Bartholomews Hosp, Canc Res UK, Med Oncol Unit, Barts & London Sch Med & Dent, W Smithfield, London EC1A 7BE, England.	matthew.smith@cancer.org.uk		Fitzgibbon, Jude/0000-0002-9069-1866				Barjesteh van Waalwijk van Doorn-Khosrovani S, 2003, HEMATOL J, V4, P31; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; Iwasaki-Arai J, 2002, BLOOD, V100, p61A; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Preudhomme C, 2002, BLOOD, V100, P2717, DOI 10.1182/blood-2002-03-0990; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Schwieger M, 2004, BLOOD, V103, P2744, DOI 10.1182/blood-2003-07-2280; Snaddon J, 2003, GENE CHROMOSOME CANC, V37, P72, DOI 10.1002/gcc.10185; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406	16	219	226	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2403	2407		10.1056/NEJMoa041331	http://dx.doi.org/10.1056/NEJMoa041331			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575056	Bronze			2022-12-28	WOS:000225429000009
J	Thurin, A; Hausken, J; Hillensjo, T; Jablonowska, B; Pinborg, A; Strandell, A; Bergh, C				Thurin, A; Hausken, J; Hillensjo, T; Jablonowska, B; Pinborg, A; Strandell, A; Bergh, C			Elective single-embryo transfer versus double-embryo transfer in in vitro fertilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE BIRTHS; TWIN PREGNANCY; CHILDREN BORN; MALFORMATIONS; RISK; IVF	BACKGROUND: The risks of premature birth and perinatal death are increased after in vitro fertilization. These risks are mainly due to the high incidence of multiple births, which relates to the number of embryos transferred. METHODS: We performed a randomized, multicenter trial to assess the equivalence of two approaches to in vitro fertilization with respect to the rates of pregnancy that result in at least one live birth and to compare associated rates of multiple gestation. Women less than 36 years of age who had at least two good-quality embryos were randomly assigned either to undergo transfer of a single fresh embryo and, if there was no live birth, subsequent transfer of a single frozen-and-thawed embryo, or to undergo a single transfer of two fresh embryos. Equivalence was defined as a difference of no more than 10 percentage points in the rates of pregnancy resulting in at least one live birth. RESULTS: Pregnancy resulting in at least one live birth occurred in 142 of 331 women (42.9 percent) in the double-embryo-transfer group as compared with 128 of 330 women (38.8 percent) in the single-embryo-transfer group (difference, 4.1 percentage points; 95 percent confidence interval, -3.4 to 11.6 percentage points); rates of multiple births were 33.1 percent and 0.8 percent, respectively (P<0.001). These results do not demonstrate equivalence of the two approaches in rates of live births, but they do indicate that any reduction in the rate of live births with the transfer of single embryos is unlikely to exceed 11.6 percentage points. CONCLUSIONS: In women under 36 years of age, transferring one fresh embryo and then, if needed, one frozen-and-thawed embryo dramatically reduces the rate of multiple births while achieving a rate of live births that is not substantially lower than the rate that is achievable with a double-embryo transfer.	Sahlgrens Univ Hosp, Inst Hlth Women & Children, Dept Obstet & Gynecol, SE-41345 Gothenburg, Sweden; Haugesund Hosp, Fertil Unit, Haugesund, Norway; Carlanderska Hosp, Fertil Ctr Scandinavia, Gothenburg, Sweden; Univ Hosp, Dept Mol & Clin Med, Div Obstet & Gynecol, Linkoping, Sweden; Rigshosp, Fertil Clin, DK-2100 Copenhagen, Denmark	Sahlgrenska University Hospital; Rigshospitalet; University of Copenhagen	Bergh, C (corresponding author), Sahlgrens Univ Hosp, Inst Hlth Women & Children, Dept Obstet & Gynecol, SE-41345 Gothenburg, Sweden.	christina.bergh@vgregion.se		Pinborg, Anja/0000-0002-8340-104X				Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Coetsier T, 1998, HUM REPROD, V13, P2663, DOI 10.1093/humrep/13.10.2663; De Sutter P, 2003, Reprod Biomed Online, V6, P464; Ericson A, 2001, HUM REPROD, V16, P504, DOI 10.1093/humrep/16.3.504; Gardner DK, 1998, HUM REPROD, V13, P3434, DOI 10.1093/humrep/13.12.3434; Gerris J, 2002, HUM REPROD, V17, P2626, DOI 10.1093/humrep/17.10.2626; Gerris J, 1999, HUM REPROD, V14, P2581, DOI 10.1093/humrep/14.10.2581; GISSLER M, 1995, HUM REPROD, V10, P1856, DOI 10.1093/oxfordjournals.humrep.a136191; Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE; Jackson RA, 2004, OBSTET GYNECOL, V103, P551, DOI 10.1097/01.AOG.0000114989.84822.51; Martikainen H, 2001, HUM REPROD, V16, P1900, DOI 10.1093/humrep/16.9.1900; Pinborg A, 2003, HUM REPROD, V18, P621, DOI 10.1093/humrep/deg145; Pocock SJ., 2013, CLIN TRIALS PRACTICA; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Smeenk JMJ, 2001, HUM REPROD, V16, P1420, DOI 10.1093/humrep/16.7.1420; Soc As Reprod Tech Amer Reprod Med, 2004, FERTIL STERIL, V81, P1207, DOI 10.1016/j.fertnstert.2004.01.017; Soderstrom-Antilla V, 2003, HUM REPROD, V18, P1858, DOI 10.1093/humrep/deg384; STEER CV, 1992, HUM REPROD, V7, P117, DOI 10.1093/oxfordjournals.humrep.a137542; Strandell A, 2000, HUM REPROD, V15, P2520, DOI 10.1093/humrep/15.12.2520; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; The National Board of Health and Welfare in Sweden, OFF STAT SWED; Tiitinen A, 2003, HUM REPROD, V18, P1449, DOI 10.1093/humrep/deg301; Tiitinen A, 2001, HUM REPROD, V16, P1140, DOI 10.1093/humrep/16.6.1140; Van Royen E, 1999, HUM REPROD, V14, P2345, DOI 10.1093/humrep/14.9.2345; Vilska S, 1999, HUM REPROD, V14, P2392, DOI 10.1093/humrep/14.9.2392; WENNERHOLM UB, 2004, FETAL MATERN MED REV, V15, P27; Westergaard HB, 1999, HUM REPROD, V14, P1896, DOI 10.1093/humrep/14.7.1896	29	448	470	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2392	2402		10.1056/NEJMoa041032	http://dx.doi.org/10.1056/NEJMoa041032			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575055				2022-12-28	WOS:000225429000008
J	Mohd-Sarip, A; Verrijzer, CP				Mohd-Sarip, A; Verrijzer, CP			A higher order of silence	SCIENCE			English	Editorial Material							POLYCOMB; CHROMATIN; COMPLEXES		Erasmus Med Ctr, Dept Biochem, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Mohd-Sarip, A (corresponding author), Erasmus Med Ctr, Dept Biochem, Rotterdam, Netherlands.	c.verrijzer@erasmusmc.nl						Dorigo B, 2004, SCIENCE, V306, P1571, DOI 10.1126/science.1103124; Fitzgerald DP, 2001, MOL CELL BIOL, V21, P6585, DOI 10.1128/MCB.21.19.6585-6597.2001; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Richmond TJ, 2000, CHROMATIN STRUCTURE, P1; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009	10	16	16	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1484	1485		10.1126/science.1106767	http://dx.doi.org/10.1126/science.1106767			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567842				2022-12-28	WOS:000225442700036
J	Ricci, R; Sumara, G; Sumara, I; Rozenberg, I; Kurrer, M; Akhmedov, A; Hersberger, M; Eriksson, U; Eberli, FR; Becher, B; Boren, J; Chen, M; Cybulsky, MI; Moore, KJ; Freeman, MW; Wagner, EF; Matter, CM; Luscher, TF				Ricci, R; Sumara, G; Sumara, I; Rozenberg, I; Kurrer, M; Akhmedov, A; Hersberger, M; Eriksson, U; Eberli, FR; Becher, B; Boren, J; Chen, M; Cybulsky, MI; Moore, KJ; Freeman, MW; Wagner, EF; Matter, CM; Luscher, TF			Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis	SCIENCE			English	Article							VASCULAR PROLIFERATION; DEFICIENT MICE; ATHEROSCLEROSIS; DIFFERENTIATION; EXPRESSION; LDL; INFLAMMATION; ACTIVATION; ADHESION	In vitro studies suggest a role for c-Jun N-terminal kinases (JNKs) in proatherogenic cellular processes. We show that atherosclerosis-prone ApoE(-/-) mice simultaneously lacking JNK2 (ApoE(-/-) JNK2(-/-) mice), but not ApoE(-/-) JNK1(-/-) mice, developed less atherosclerosis than do ApoE(-/-) mice. Pharmacological inhibition of JNK activity efficiently reduced plaque formation. Macrophages lacking JNK2 displayed suppressed foam cell formation caused by defective uptake and degradation of modified lipoproteins and showed increased amounts of the modified lipoprotein-binding and -internalizing scavenger receptor A (SR-A), whose phosphorylation was markedly decreased. Macrophage-restricted deletion of JNK2 was sufficient to decrease atherogenesis. Thus, JNK2-dependent phosphorylation of SR-A promotes uptake of lipids in macrophages, thereby regulating foam cell formation, a critical step in atherogenesis.	Univ Zurich Hosp, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich Hosp, Div Cardiol, CH-8057 Zurich, Switzerland; ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; ETH, Inst Biochem, CH-8093 Zurich, Switzerland; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Inst Clin Chem, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Neurol, Neuroimmunol Unit, CH-8091 Zurich, Switzerland; Univ Basel Hosp, Dept Res & Med A, CH-4031 Basel, Switzerland; Univ Gothenburg, Wallenberg Lab Cardiovasc Res, S-4345 Gothenburg, Sweden; Univ Toronto, Toronto Gen Res Inst, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lipid Metab Unit, Boston, MA 02114 USA; Inst Mol Pathol, A-1030 Vienna, Austria	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Basel; University of Gothenburg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; Harvard University; Harvard Medical School; Massachusetts General Hospital; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Ricci, R (corresponding author), Univ Zurich Hosp, Inst Physiol, CH-8057 Zurich, Switzerland.	romeo.ricci@cetll.biol.ethz.ca	Becher, Burkhard/ABE-4225-2020; Cybulsky, Myron I./AAD-6539-2019; Ricci, Romeo/K-3009-2013; Moore, Kathryn/ABE-6416-2020	Becher, Burkhard/0000-0002-1541-7867; Ricci, Romeo/0000-0002-9766-4369; Moore, Kathryn/0000-0003-2505-2547; Sumara, Grzegorz/0000-0003-1502-6265; Eriksson, Urs/0000-0003-1217-9696; Cybulsky, Myron/0000-0002-1696-2867; Sumara, Izabela/0000-0002-5968-3358; Wagner, Erwin F/0000-0001-7872-0196; Hersberger, Martin/0000-0002-4472-329X				Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Dong ZM, 2000, CIRCULATION, V101, P2290, DOI 10.1161/01.CIR.101.19.2290; Dzau VJ, 2002, NAT MED, V8, P1249, DOI 10.1038/nm1102-1249; Fong LG, 1999, J BIOL CHEM, V274, P36808, DOI 10.1074/jbc.274.51.36808; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Gough PJ, 1998, J LIPID RES, V39, P531; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han ZN, 2002, ARTHRITIS RHEUM, V46, P818, DOI 10.1002/art.10104; Heider H, 2001, FEBS LETT, V505, P185, DOI 10.1016/S0014-5793(01)02819-8; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137; Kosswig N, 2003, J BIOL CHEM, V278, P34219, DOI 10.1074/jbc.M303465200; Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200; Li AC, 2002, NAT MED, V8, P1235, DOI 10.1038/nm1102-1235; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Post SR, 2002, J LIPID RES, V43, P1829, DOI 10.1194/jlr.M200231-JLR200; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Whitman SC, 2002, J LIPID RES, V43, P1201, DOI 10.1194/jlr.M200116-JLR200; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Zhan YM, 2003, ARTERIOSCL THROM VAS, V23, P795, DOI 10.1161/01.ATV.0000066132.32063.F2	27	218	232	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1558	1561		10.1126/science.1101909	http://dx.doi.org/10.1126/science.1101909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567863				2022-12-28	WOS:000225442700060
J	Maurer, M; Wedemeyer, J; Metz, M; Piliponsky, AM; Weller, K; Chatterjea, D; Clouthier, DE; Yanagisawa, MM; Tsai, M; Galli, SJ				Maurer, M; Wedemeyer, J; Metz, M; Piliponsky, AM; Weller, K; Chatterjea, D; Clouthier, DE; Yanagisawa, MM; Tsai, M; Galli, SJ			Mast cells promote homeostasis by limiting endothelin-1-induced toxicity	NATURE			English	Article							EMBRYONIC STEM-CELLS; ENDOTHELIAL-CELLS; KIT-LIGAND; IN-VITRO; MICE; RELEASE; PEPTIDE; SYSTEM; SEPSIS; PERITONITIS	Endothelin-1 (ET-1) is a 21-amino-acid peptide, derived from vascular endothelial cells, with potent vasoconstrictor activity(1). ET-1 has been implicated in diverse physiological or pathological processes(2,3), including the vascular changes associated with sepsis(2-5). However, the factors that regulate ET-1-associated toxicity during bacterial infections, or in other settings, are not fully understood(2-5). Both the pathology associated with certain allergic and autoimmune disorders(6,7), and optimal host defence against bacterial and parasitic infections(8-10) are mediated by mast cells. In vitro, mast cells can produce ET-1 (ref. 11), undergo ET-1-dependent and endothelin-A receptor (ETA)-dependent activation(12,13), and release proteases that degrade ET-1 (ref. 14). Although the potential relationships between mast cells and the ET-1 system thus may be complex, the importance of interactions between ET-1 and mast cells in vivo is obscure. Here we show that ETA-dependent mast-cell activation can diminish both ET-1 levels and ET-1-induced pathology in vivo, and also can contribute to optimal survival during acute bacterial peritonitis. These findings identify a new biological function for mast cells: promotion of homeostasis by limiting the toxicity associated with an endogenous mediator.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Mainz, Dept Dermatol, D-55101 Mainz, Germany; Humboldt Univ, Univ Hosp Charite, Dept Dermatol & Allergy, D-10117 Berlin, Germany; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Hannover Med Sch, Ctr Internal Med, Dept Gastroenterol Hepatol & Endocrinol, D-30623 Hannover, Germany; Univ Louisville, Dept Mol Cellular & Craniofacial Biol, Louisville, KY 40292 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX 75390 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Johannes Gutenberg University of Mainz; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Stanford University; Hannover Medical School; University of Louisville; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Galli, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	sgalli@stanford.edu	Metz, Martin/M-5237-2013; Metz, Martin/B-8799-2009; Maurer, Marcus/ABG-2174-2020	Metz, Martin/0000-0002-4070-9976; Metz, Martin/0000-0002-4070-9976; Maurer, Marcus/0000-0002-4121-481X; Weller, Karsten/0000-0003-4437-0313; Tsai, Mindy/0000-0002-8421-4721				Ahn Gun Young, 1998, Journal of Dermatology (Tokyo), V25, P78; Benoist C, 2002, NATURE, V420, P875, DOI 10.1038/nature01324; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; BOTOS M, 2002, CLIN SCI LOND S48, V103, pS31; Clouthier DE, 2003, DEV BIOL, V261, P506, DOI 10.1016/S0012-1606(03)00128-3; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GALLI SJ, 2004, INNATE IMMUNE RESPON, P111; HIGGINBOTHAM RD, 1965, J IMMUNOL, V95, P867; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kedzierski RM, 2001, ANNU REV PHARMACOL, V41, P851, DOI 10.1146/annurev.pharmtox.41.1.851; KITAMURA Y, 1978, BLOOD, V52, P447; LUNDBLAD R, 1995, EUR J SURG, V161, P9; Maguire JJ, 2001, BRIT J PHARMACOL, V134, P1360, DOI 10.1038/sj.bjp.0704384; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Maurer M, 1998, J EXP MED, V188, P2343, DOI 10.1084/jem.188.12.2343; Metsarinne KP, 2002, ARTERIOSCL THROM VAS, V22, P268, DOI 10.1161/hq0202.103994; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Opgenorth T J, 1995, Adv Pharmacol, V33, P1, DOI 10.1016/S1054-3589(08)60665-1; Ornan DA, 2000, BBA-MOL BASIS DIS, V1501, P211, DOI 10.1016/S0925-4439(00)00025-9; Prodeus AP, 1997, NATURE, V390, P172, DOI 10.1038/36586; SUGIURA M, 1989, BIOCHEM BIOPH RES CO, V161, P1220, DOI 10.1016/0006-291X(89)91372-7; Szalay L, 1998, SHOCK, V10, P123, DOI 10.1097/00024382-199808000-00007; Tsai M, 2000, P NATL ACAD SCI USA, V97, P9186, DOI 10.1073/pnas.160254997; Tsai M, 2002, INT J HEMATOL, V75, P345, DOI 10.1007/BF02982122; Wanecek M, 2000, EUR J PHARMACOL, V407, P1, DOI 10.1016/S0014-2999(00)00675-0; YAMAMURA H, 1994, EUR J PHARMACOL, V265, P9, DOI 10.1016/0014-2999(94)90217-8; YAMAMURA H, 1995, EUR J PHARM-MOLEC PH, V288, P269; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	30	238	244	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					512	516		10.1038/nature03085	http://dx.doi.org/10.1038/nature03085			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15543132				2022-12-28	WOS:000225322100049
J	van Boekel, R; Min, M; Leinert, C; Waters, LBFM; Richichi, A; Chesneau, O; Dominik, C; Jaffe, W; Dutrey, A; Graser, U; Henning, T; de Jong, J; Kohler, R; de Koter, A; Lopez, B; Malbet, F; Morel, S; Paresce, F; Perrin, G; Preibisch, T; Przygodda, F; Scholler, M; Wittkowski, M				van Boekel, R; Min, M; Leinert, C; Waters, LBFM; Richichi, A; Chesneau, O; Dominik, C; Jaffe, W; Dutrey, A; Graser, U; Henning, T; de Jong, J; Kohler, R; de Koter, A; Lopez, B; Malbet, F; Morel, S; Paresce, F; Perrin, G; Preibisch, T; Przygodda, F; Scholler, M; Wittkowski, M			The building blocks of planets within the 'terrestrial' region of protoplanetary disks	NATURE			English	Article							INTERSTELLAR SILICATE MINERALOGY; DUST; PARTICLES; SCATTERING; SPECTRUM; STARS; STEPS; MIDI; IV	Our Solar System was formed from a cloud of gas and dust. Most of the dust mass is contained in amorphous silicates(1), yet crystalline silicates are abundant throughout the Solar System, reflecting the thermal and chemical alteration of solids during planet formation. (Even primitive bodies such as comets contain crystalline silicates(2).) Little is known about the evolution of the dust that forms Earth-like planets. Here we report spatially resolved detections and compositional analyses of these building blocks in the innermost two astronomical units of three proto-planetary disks. We find the dust in these regions to be highly crystallized, more so than any other dust observed in young stars until now. In addition, the outer region of one star has equal amounts of pyroxene and olivine, whereas the inner regions are dominated by olivine. The spectral shape of the inner-disk spectra shows surprising similarity with Solar System comets. Radial-mixing models naturally explain this resemblance as well as the gradient in chemical composition. Our observations imply that silicates crystallize before any terrestrial planets are formed, consistent with the composition of meteorites in the Solar System.	Univ Amsterdam, Astron Inst Anton Pannekoek, NL-1098 SJ Amsterdam, Netherlands; European So Observ, D-85748 Garching, Germany; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Katholieke Univ Leuven, Inst Sterrenkunde, B-3001 Heverlee, Belgium; Leiden Observ, NL-2333 CA Leiden, Netherlands; Observ Bordeaux, F-33270 Floirac, France; Observ Cote Azur, Dept Fresnel UMR 6528, F-06034 Nice 4, France; Observ Paris, Sect Meudon, Lab Etud Spatiales & Instrumentat Astrophys, F-92190 Meudon, France; Max Planck Inst Radioastron, D-53121 Bonn, Germany	University of Amsterdam; European Southern Observatory; Max Planck Society; KU Leuven; Leiden University; Leiden University - Excl LUMC; UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Sorbonne Universite; Max Planck Society	van Boekel, R (corresponding author), Univ Amsterdam, Astron Inst Anton Pannekoek, Kruislaan 403, NL-1098 SJ Amsterdam, Netherlands.	vboekel@science.uva.nl	Köhler, Rainer/L-6037-2018; Malbet, Fabien/ABF-1483-2020	Köhler, Rainer/0000-0002-8955-520X; Preibisch, Thomas/0000-0003-3130-7796; Dominik, Carsten/0000-0002-3393-2459; Min, Michiel/0000-0001-5778-0376; Schoeller, Markus/0000-0002-5379-1286; Wittkowski, Markus/0000-0002-7952-9550; Malbet, Fabien/0000-0002-8029-4226; Perrin, Guy/0000-0003-0680-0167				ACKE B, 2004, IN PRESS ASTRON ASTR; Beckwith S. V. W., 2000, Protostars and planets 4, P533; Bouwman J, 2001, ASTRON ASTROPHYS, V375, P950, DOI 10.1051/0004-6361:20010878; Bradley J, 2003, LECT NOTES PHYS, V609, P217; Brearley A. J., 1998, PLANETARY MAT; Chihara H, 2001, PUBL ASTRON SOC JPN, V53, P243, DOI 10.1093/pasj/53.2.243; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; Desch SJ, 2000, ICARUS, V143, P87, DOI 10.1006/icar.1999.6245; DORSCHNER J, 1995, ASTRON ASTROPHYS, V300, P503; Eisner JA, 2003, ASTROPHYS J, V588, P360, DOI 10.1086/373923; Gail HP, 2004, ASTRON ASTROPHYS, V413, P571, DOI 10.1051/0004-6361:20031554; Grady C. A., 2000, PROTOSTARS PLANETS, P613; Haisch KE, 2001, ASTROPHYS J, V553, pL153, DOI 10.1086/320685; HANNER MS, 1994, ASTROPHYS J, V425, P274, DOI 10.1086/173984; Harker DE, 2002, ASTROPHYS J, V565, pL109, DOI 10.1086/339363; Jager C, 1998, ASTRON ASTROPHYS, V339, P904; Kemper F, 2004, ASTROPHYS J, V609, P826, DOI 10.1086/421339; Leinert C, 2004, ASTRON ASTROPHYS, V423, P537, DOI 10.1051/0004-6361:20047178; Leinert C, 2003, P SOC PHOTO-OPT INS, V4838, P893, DOI 10.1117/12.457027; Malfait K, 1998, ASTRON ASTROPHYS, V332, pL25; Min M, 2003, ASTRON ASTROPHYS, V404, P35, DOI 10.1051/0004-6361:20030456; Molster FJ, 2003, LECT NOTES PHYS, V609, P121; Molster FJ, 2002, ASTRON ASTROPHYS, V382, P241, DOI 10.1051/0004-6361:20011552; Nuth JA, 2002, METEORIT PLANET SCI, V37, P1579, DOI 10.1111/j.1945-5100.2002.tb00812.x; Pilipp W, 1998, ASTRON ASTROPHYS, V331, P121; SANDFORD SA, 1985, ASTROPHYS J, V291, P838, DOI 10.1086/163120; SERVOIN JL, 1973, PHYS STATUS SOLIDI B, V55, P677, DOI 10.1002/pssb.2220550224; SPITZER WG, 1961, PHYS REV, V121, P1324, DOI 10.1103/PhysRev.121.1324; WETHERILL GW, 1990, ANNU REV EARTH PL SC, V18, P205, DOI 10.1146/annurev.ea.18.050190.001225	29	254	255	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					479	482		10.1038/nature03088	http://dx.doi.org/10.1038/nature03088			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565147				2022-12-28	WOS:000225322100039
J	Clayton, GM; Silverman, WR; Heginbotham, L; Morais-Cabral, JH				Clayton, GM; Silverman, WR; Heginbotham, L; Morais-Cabral, JH			Structural basis of ligand activation in a cyclic nucleotide regulated potassium channel	CELL			English	Article							CRYSTAL-STRUCTURE; PROTEIN-KINASE; FUNCTIONAL RECONSTITUTION; MOLECULAR-BASIS; GATED CHANNELS; ALPHA SUBUNIT; CAMP; MECHANISM; REVEALS; DOMAINS	Here we describe the initial functional characterization of a cyclic nucleotide regulated ion channel from the bacterium Mesorhizobium loti and present two structures of its cyclic nucleotide binding domain, with and without cAMP. The domains are organized as dimers with the interface formed by the linker regions that connect the nucleotide binding pocket to the pore domain. Together, structural and functional data suggest the domains form two dimers on the cytoplasmic face of the channel. We propose a model for gating in which ligand binding alters the structural relationship within a dimer, directly affecting the position of the adjacent transmembrane helices.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Heginbotham, L (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 260 Whitney Ave, New Haven, CT 06520 USA.	lise.heginbotham@yale.edu; joao.cabral@yale.edu	Silverman, William/AAE-4799-2019; Morais-Cabral, Joao H/J-4914-2013	Morais-Cabral, Joao H/0000-0002-4461-9716	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047147] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47147] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1; BACON DJ, 1998, J MOL GRAPHICS, V6, P219; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biel M, 2002, TRENDS CARDIOVAS MED, V12, P206, DOI 10.1016/S1050-1738(02)00162-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dani VS, 2003, PROTEIN ENG, V16, P187, DOI 10.1093/proeng/gzg024; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Gordon SE, 1997, NEURON, V19, P431, DOI 10.1016/S0896-6273(00)80951-4; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu DT, 1998, NEURON, V21, P235, DOI 10.1016/S0896-6273(00)80530-9; MacKinnon R, 2003, FEBS LETT, V555, P62, DOI 10.1016/S0014-5793(03)01104-9; Maduke M, 1999, J GEN PHYSIOL, V114, P713, DOI 10.1085/jgp.114.5.713; Matulef K, 2003, ANNU REV CELL DEV BI, V19, P23, DOI 10.1146/annurev.cellbio.19.110701.154854; Nimigean CM, 2004, J GEN PHYSIOL, V124, P203, DOI 10.1085/jgp.200409133; Passner JM, 2000, J MOL BIOL, V304, P847, DOI 10.1006/jmbi.2000.4231; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P1863, DOI 10.1107/S0907444999010033; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Wu J, 2004, STRUCTURE, V12, P1057, DOI 10.1016/j.str.2004.03.022; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; Zheng J, 2000, NEURON, V28, P369, DOI 10.1016/S0896-6273(00)00117-3	35	107	111	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					615	627		10.1016/j.cell.2004.10.030	http://dx.doi.org/10.1016/j.cell.2004.10.030			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550244	Bronze			2022-12-28	WOS:000225389500008
J	McNutt, RA				McNutt, RA			Shared medical decision making - Problems, process, progress	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOCALIZED PROSTATE-CANCER; RADICAL PROSTATECTOMY; INFORMED CONSENT; RANDOMIZED-TRIAL; PREFERENCES; OUTCOMES; SURGERY; RISK		Rush Univ, Sch Med, Dept Med, Chicago, IL 60612 USA	Rush University	McNutt, RA (corresponding author), 1653 W Congress Pkwy, Chicago, IL 60612 USA.	robert_mcnutt@rush.edu						Brothers TE, 2004, J SURG RES, V120, P278, DOI 10.1016/j.jss.2004.01.004; Carrozza JP, 2004, JAMA-J AM MED ASSOC, V292, P2506, DOI 10.1001/jama.292.20.2506; Chamot E, 2004, MED DECIS MAKING, V24, P379, DOI 10.1177/0272989X04267011; Cotler SJ, 2001, AM J GASTROENTEROL, V96, P2730, DOI 10.1111/j.1572-0241.2001.04132.x; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Lloyd A, 2001, MED DECIS MAKING, V21, P141, DOI 10.1177/0272989X0102100207; Man-Son-Hing M, 2000, MED DECIS MAKING, V20, P394, DOI 10.1177/0272989X0002000403; MAZUR DJ, 1994, MED DECIS MAKING, V14, P255, DOI 10.1177/0272989X9401400307; Mazur DJ, 1999, MED DECIS MAKING, V19, P394, DOI 10.1177/0272989X9901900407; MCNUTT RA, 1989, PATIENT EDUC COUNS, V13, P271, DOI 10.1016/0738-3991(89)90021-9; Montgomery AA, 2003, BRIT J GEN PRACT, V53, P446; OCONNOR A, EFFECTIVENESS DECISI; Rovner DR, 2004, MED DECIS MAKING, V24, P359, DOI 10.1177/0272989X04267010; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Ubel PA, 1997, SOC SCI MED, V44, P647, DOI 10.1016/S0277-9536(96)00217-1; Whelan T, 2004, JAMA-J AM MED ASSOC, V292, P435, DOI 10.1001/jama.292.4.435; Whitney SN, 2003, MED DECIS MAKING, V23, P275, DOI 10.1177/0272989X03256006; ZARIN DA, 1984, J MED PHILOS, V9, P181, DOI 10.1093/jmp/9.2.181	19	136	139	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2516	2518		10.1001/jama.292.20.2516	http://dx.doi.org/10.1001/jama.292.20.2516			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562133				2022-12-28	WOS:000225303000029
J	Bird, SM				Bird, SM			Military and public-health sciences need to ally	LANCET			English	Editorial Material									MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit	Bird, SM (corresponding author), MRC, Biostat Unit, Cambridge CB2 2SR, England.	sheila.bird@mrc-bsu.cam.ac.uk						DOWARD J, 2004, OBSERVER        1107, P14; Dyer O, 2004, BRIT MED J, V329, P1066, DOI 10.1136/bmj.329.7474.1066-f; GOW D, 2004, GUARDIAN        1106, P2; The Royal Statistical Society Working Party on Performance Monitoring of Public Services, 2003, PERF IND GOOD BAD UG; WINTOUR P, 2004, GUARDIAN        1030, P18	5	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1831	1833		10.1016/S0140-6736(04)17452-7	http://dx.doi.org/10.1016/S0140-6736(04)17452-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555647				2022-12-28	WOS:000225269300004
J	Kastan, MB; Bartek, J				Kastan, MB; Bartek, J			Cell-cycle checkpoints and cancer	NATURE			English	Article							STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; ATM ACTIVATION; TUMOR-SUPPRESSOR; MRE11 COMPLEX; HISTONE H2AX; PROTEIN; REPLICATION	All life on earth must cope with constant exposure to DNA-damaging agents such as the Sun's radiation. Highly conserved DNA-repair and cell-cycle checkpoint pathways allow cells to deal with both endogenous and exogenous sources of DNA damage. How much an individual is exposed to these agents and how their cells respond to DNA damage are critical determinants of whether that individual will develop cancer. These cellular responses are also important for determining toxicities and responses to current cancer therapies, most of which target the DNA.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Danish Canc Soc, Inst Canc Biol, Dept Cell Cycle & Canc, DK-2100 Copenhagen, Denmark	St Jude Children's Research Hospital; Danish Cancer Society	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	michael.kastan@stjude.org; jb@cancer.dk	Bartek, Jiri/G-5870-2014					Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bobabilla-Morales L, 2003, AM J MED GENET A, V123A, P148, DOI 10.1002/ajmg.a.20341; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Canman CE, 2003, CURR BIOL, V13, pR488, DOI 10.1016/S0960-9822(03)00410-X; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Chini CCS, 2004, DNA REPAIR, V3, P1033, DOI 10.1016/j.dnarep.2004.03.001; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; D'Andrea AD, 2003, GENE DEV, V17, P1933, DOI 10.1101/gad.1128303; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fang Y, 2004, EMBO J, V23, P3164, DOI 10.1038/sj.emboj.7600315; FORD JM, 2004, CLIN ONCOLOGY, P191; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Huyen Y, 2004, NATURE, V432, P406, DOI 10.1038/nature03114; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KATSUHIRO U, IN PRESS EMBO J; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kita Y., 2001, RADICALS ORGANIC SYN, V1, P1; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee J, 2003, MOL CELL, V11, P329, DOI 10.1016/S1097-2765(03)00045-5; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu QH, 2000, GENE DEV, V14, P1448; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McPherson JP, 2004, GENE DEV, V18, P1144, DOI 10.1101/gad.1192704; Mochan TA, 2004, DNA REPAIR, V3, P945, DOI 10.1016/j.dnarep.2004.03.017; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pichierri P, 2004, EMBO J, V23, P1178, DOI 10.1038/sj.emboj.7600113; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Sorensen CS, 2004, CELL CYCLE, V3, P941; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Treuner K, 2004, ONCOGENE, V23, P4655, DOI 10.1038/sj.onc.1207604; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	96	2065	2144	10	282	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					316	323		10.1038/nature03097	http://dx.doi.org/10.1038/nature03097			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549093				2022-12-28	WOS:000225161400041
J	Lange, RA; Hillis, LD				Lange, RA; Hillis, LD			Acute pericarditis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSIENT CONSTRICTIVE PERICARDITIS; ASSOCIATION TASK-FORCE; ST-SEGMENT ELEVATION; CARDIAC TROPONIN-I; RECURRENT PERICARDITIS; ADENOSINE-DEAMINASE; INTRAPERICARDIAL TREATMENT; SYMPTOMATIC PERICARDITIS; MYOCARDIAL-INFARCTION; CLINICAL-APPLICATION		Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Johns Hopkins Med Inst, Dept Internal Med, Div Cardiol, Baltimore, MD 21205 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Johns Hopkins University; Johns Hopkins Medicine	Hillis, LD (corresponding author), Univ Texas, SW Med Ctr, Rm G5-232,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dhilli@parknet.pmh.org	Mumoli, Nicola/J-4652-2019; Lange, Richard/AAM-9594-2021	Mumoli, Nicola/0000-0001-7166-5630; 				Adler Y, 1998, CIRCULATION, V97, P2183, DOI 10.1161/01.CIR.97.21.2183; Aggeli C, 2000, CARDIOLOGY, V94, P81, DOI 10.1159/000047296; ALLARIA A, 1992, EUR J PEDIATR, V151, P250, DOI 10.1007/BF02072222; ARUNASALAM S, 1993, AM HEART J, V125, P1455, DOI 10.1016/0002-8703(93)91032-A; BERMAN J, 1981, AM HEART J, V101, P750, DOI 10.1016/0002-8703(81)90610-4; Bonnefoy E, 2000, EUR HEART J, V21, P832, DOI 10.1053/euhj.1999.1907; BROWN EJ, 1983, AM J CARDIOL, V51, P877, DOI 10.1016/S0002-9149(83)80148-9; BRUCE MA, 1980, J ELECTROCARDIOL, V13, P61, DOI 10.1016/S0022-0736(80)80011-2; Burgess LJ, 2002, CHEST, V122, P900, DOI 10.1378/chest.122.3.900; Cegielski JP, 1997, J CLIN MICROBIOL, V35, P3254, DOI 10.1128/JCM.35.12.3254-3257.1997; Cheitlin MD, 2003, CIRCULATION, V108, P1146, DOI 10.1161/01.CIR.0000073597.57414.A9; Cheitlin MD, 1997, CIRCULATION, V95, P1686; CLEMENTY J, 1979, ARCH MAL COEUR VAISS, V72, P857; Dogan R, 1999, J CARDIOVASC SURG, V40, P501; GINZTON LE, 1982, CIRCULATION, V65, P1004, DOI 10.1161/01.CIR.65.5.1004; GODEAU P, 1975, SEM HOP PARIS, V51, P2393; Haley JH, 2004, J AM COLL CARDIOL, V43, P271, DOI 10.1016/j.jacc.2003.08.032; HAMMERMAN H, 1983, CIRCULATION, V67, P1290, DOI 10.1161/01.CIR.67.6.1290; Imazio M, 2004, J AM COLL CARDIOL, V43, P1042, DOI 10.1016/j.jacc.2003.09.055; Imazio M, 2003, J AM COLL CARDIOL, V42, P2144, DOI 10.1016/j.jacc.2003.02.001; JUGDUTT BI, 1989, CAN J CARDIOL, V5, P211; KILBOURNE ED, 1956, J CLIN INVEST, V35, P362, DOI 10.1172/JCI103286; Launbjerg J, 1996, CARDIOLOGY, V87, P60, DOI 10.1159/000177061; LORELL BH, 1997, HEART DIS TXB CARDIO, P1478; Maisch B, 2002, EUR HEART J, V23, P1503, DOI 10.1053/euhj.2002.3152; MARCOLONGO R, 1995, J AM COLL CARDIOL, V26, P1276, DOI 10.1016/0735-1097(95)00302-9; MILLAIRE A, 1994, EUR HEART J, V15, P120, DOI 10.1093/oxfordjournals.eurheartj.a060363; Newby LK, 2000, EUR HEART J, V21, P798, DOI 10.1053/euhj.1999.2056; OH JK, 1993, MAYO CLIN PROC, V68, P1158, DOI 10.1016/S0025-6196(12)60065-2; Permanyer-Miralda G, 2004, HEART, V90, P252, DOI 10.1136/hrt.2003.024802; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; Raatikka M, 2003, J AM COLL CARDIOL, V42, P759, DOI 10.1016/S0735-1097(03)00778-2; SAGRISTASAULEDA J, 1987, AM J CARDIOL, V59, P961, DOI 10.1016/0002-9149(87)91134-9; Schifferdecker Branislav, 2003, Cardiol Rev, V11, P211, DOI 10.1097/01.CRD.0000077500.07781.C9; SPODICK DH, 1975, AM J CARDIOL, V35, P357, DOI 10.1016/0002-9149(75)90027-2; Spodick DH, 2003, JAMA-J AM MED ASSOC, V289, P1150, DOI 10.1001/jama.289.9.1150; Spodick DH, 2002, EUR HEART J, V23, P1481, DOI 10.1053/euhj.2002.3228; SPODICK DH, 1973, CIRCULATION, V48, P575, DOI 10.1161/01.CIR.48.3.575; STUBBS DF, 1986, J INT MED RES, V14, P25, DOI 10.1177/03000605860140S105; SURAWICZ B, 1970, AM J CARDIOL, V26, P471, DOI 10.1016/0002-9149(70)90704-6; Wang K, 2003, NEW ENGL J MED, V349, P2128, DOI 10.1056/NEJMra022580; Woods T, 1999, CLIN CARDIOL, V22, P316, DOI 10.1002/clc.4960220414; ZAYAS R, 1995, AM J CARDIOL, V75, P378, DOI 10.1016/S0002-9149(99)80558-X	43	195	204	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2195	2202		10.1056/NEJMcp041997	http://dx.doi.org/10.1056/NEJMcp041997			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548780				2022-12-28	WOS:000225160600010
J	Lowe, SW; Cepero, E; Evan, G				Lowe, SW; Cepero, E; Evan, G			Intrinsic tumour suppression	NATURE			English	Article							MYC-INDUCED APOPTOSIS; C-MYC; CELL-CYCLE; P53-DEPENDENT APOPTOSIS; ONCOGENIC RAS; HUMAN FIBROBLASTS; P53 APOPTOSIS; MOUSE MODEL; DNA-DAMAGE; CANCER	Mutations that drive uncontrolled cell-cycle progression are requisite events in tumorigenesis. But evolution has installed in the proliferative programmes of mammalian cells a variety of innate tumour-suppressive mechanisms that trigger apoptosis or senescence, should proliferation become aberrant. These contingent processes rely on a series of sensors and transducers that act in a coordinated network to target the machinery responsible for apoptosis and cell-cycle arrest at different points. Although oncogenic mutations that disable such networks can have profound and varied effects on tumour evolution, they may leave intact latent tumour-suppressive potential that can be harnessed therapeutically.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA	Cold Spring Harbor Laboratory; University of California System; University of California San Francisco	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu			NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Benanti JA, 2004, MOL CELL BIOL, V24, P2842, DOI 10.1128/MCB.24.7.2842-2852.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bykov VJN, 2003, ANN MED, V35, P458, DOI 10.1080/07853890310017152; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; Conn CW, 2004, DEV CELL, V7, P275, DOI 10.1016/j.devcel.2004.07.003; Conner EA, 2000, ONCOGENE, V19, P5054, DOI 10.1038/sj.onc.1203885; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Ferbeyre G, 2000, GENE DEV, V14, P2015; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Horner SM, 2004, J VIROL, V78, P4063, DOI 10.1128/JVI.78.8.4063-4073.2004; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Itahana K, 2003, MOL CELL BIOL, V23, P389, DOI 10.1128/MCB.23.1.389-401.2003; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Klefstrom J, 2002, J BIOL CHEM, V277, P43224, DOI 10.1074/jbc.M206967200; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Liao MJ, 1999, MOL CELL BIOL, V19, P3095; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Pakunlu RI, 2003, PHARMACEUT RES, V20, P351, DOI 10.1023/A:1022687617318; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Urist M, 2002, CANCER CELL, V1, P311, DOI 10.1016/S1535-6108(02)00064-8; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	99	1003	1049	2	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					307	315		10.1038/nature03098	http://dx.doi.org/10.1038/nature03098			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549092				2022-12-28	WOS:000225161400040
J	Brashares, JS; Arcese, P; Sam, MK; Coppolillo, PB; Sinclair, ARE; Balmford, A				Brashares, JS; Arcese, P; Sam, MK; Coppolillo, PB; Sinclair, ARE; Balmford, A			Bushmeat hunting, wildlife declines, and fish supply in West Africa	SCIENCE			English	Article							CONSERVATION; HARVEST	The multibillion-dollar trade in bushmeat is among the most immediate threats to the persistence of tropical vertebrates, but our understanding of its underlying drivers and effects on human welfare is limited by a lack of empirical data. We used 30 years of data from Ghana to link mammal declines to the bushmeat trade and to spatial and temporal changes in the availability of fish. We show that years of poor fish supply coincided with increased hunting in nature reserves and sharp declines in biomass of 41 wildlife species. Local market data provide evidence of a direct link between fish supply and subsequent bushmeat demand in villages and show bushmeat's role as a dietary staple in the region. Our results emphasize the urgent need to develop cheap protein alternatives to bushmeat and to improve fisheries management by foreign and domestic fleets to avert extinctions of tropical wildlife.	Univ Cambridge, Dept Zool, Conservat Biol Grp, Cambridge CB2 3EJ, England; Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; Univ British Columbia, Ctr Appl Conservat Res, Vancouver, BC V6T 1Z4, Canada; Ghana Wildlife Div, Accra, Ghana; Wildlife Conservat Soc, Bronx, NY 10460 USA; Univ British Columbia, Ctr Biodivers Res, Vancouver, BC V6T 1Z4, Canada; Univ Cape Town, Percy Fitzpatrick Inst African Ornithol, ZA-7701 Cape Town, South Africa	University of Cambridge; University of California System; University of California Berkeley; University of British Columbia; Wildlife Conservation Society; University of British Columbia; University of Cape Town	Brashares, JS (corresponding author), Univ Cambridge, Dept Zool, Conservat Biol Grp, Downing St, Cambridge CB2 3EJ, England.	brashares@nature.berkeley.edu		Coppolillo, Peter/0000-0002-1502-8503; Balmford, Andrew/0000-0002-0144-3589				[Anonymous], 1996, SHAP 21 CENT CONTR D; Atta-Mills J, 2004, NAT RESOUR FORUM, V28, P13, DOI 10.1111/j.0165-0203.2004.00068.x; Barrett CB, 1998, LAND ECON, V74, P449, DOI 10.2307/3146878; Bennett EL, 2002, CONSERV BIOL, V16, P590, DOI 10.1046/j.1523-1739.2002.01637.x; Brashares JS, 2001, P ROY SOC B-BIOL SCI, V268, P2473, DOI 10.1098/rspb.2001.1815; CHRISTENSEN V, 2004, PECHERIES MARITIMES; DEI GJS, 1989, ECOL FOOD NUTR, V22, P225, DOI 10.1080/03670244.1989.9991071; *FAO, FISH DAT; FAO, STAT WORLD FISH AQ 2; Food and Agriculture Organization, COUNTR PROF; *IUCN, 2000, WORLD CONS UN; Kaczynski VM, 2002, MAR POLICY, V26, P75, DOI 10.1016/S0308-597X(01)00039-2; Milner-Gulland EJ, 2003, TRENDS ECOL EVOL, V18, P351, DOI 10.1016/S0169-5347(03)00123-X; Ntiamoa-Baidu Y., 1998, WILDLIFE DEV PLAN 19; Pauly D, 2002, NATURE, V418, P689, DOI 10.1038/nature01017; Pimm SL, 2001, SCIENCE, V293, P2207, DOI 10.1126/science.1061626; Robinson J., 2000, HUNTING SUSTAINABILI; Robinson JG, 1999, SCIENCE, V284, P595, DOI 10.1126/science.284.5414.595; *SAUP, WEB PROD MAR DAT; *UNEP, AFR ENV OUTL; Wilkie DS, 2000, SCIENCE, V287, P975; *WWF, 2001, W AFR PUTS EU SHAM	22	371	384	3	244	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1180	1183		10.1126/science.1102425	http://dx.doi.org/10.1126/science.1102425			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539602				2022-12-28	WOS:000225193100048
J	Du, QS; Macara, IG				Du, QS; Macara, IG			Mammalian pins is a conformational switch that links NuMA to heterotrimeric G proteins	CELL			English	Article							ASYMMETRIC CELL-DIVISION; CAENORHABDITIS-ELEGANS EMBRYOS; DROSOPHILA NERVOUS-SYSTEM/; MITOTIC SPINDLE; G-ALPHA; BETA-GAMMA; POLARITY; MITOSIS; MICROTUBULES; POSITION	During asymmetric cell divisions, mitotic spindles align along the axis of polarization. In invertebrates, spindle positioning requires Pins or related proteins and a G protein a subunit. A mammalian Pins, called LGN, binds Galphai and also interacts through an N-terminal domain with the microtubule binding protein NuMA. During mitosis, LGN recruits NuMA to the cell cortex, while cortical association of LGN itself requires the C-terminal Galpha binding domain. Using a FRET biosensor, we find that LGN behaves as a conformational switch: in its closed state, the N and C termini interact, but NuMA or Galphai can disrupt this association, allowing LGN to interact simultaneously with both proteins, resulting in their cortical localization. Overexpression of Galphai or YFP-LGN causes a pronounced oscillation of metaphase spindles, and NuMA binding to LGN is required for these spindle movements. We propose that a related switch mechanism might operate in asymmetric cell divisions in the fly and nematode.	Univ Virginia, Sch Med, Dept Microbiol, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia	Macara, IG (corresponding author), Univ Virginia, Sch Med, Dept Microbiol, Ctr Cell Signaling, Charlottesville, VA 22908 USA.	igm9c@virginia.edu		Du, Quansheng/0000-0003-4079-8662	NCI NIH HHS [P01CA40042] Funding Source: Medline; NIGMS NIH HHS [GM070902] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070902] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RJ, 1996, J NEUROSCI, V16, P7610; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Cayouette M, 2002, NAT NEUROSCI, V5, P1265, DOI 10.1038/nn1202-1265; Colombo K, 2003, SCIENCE, V300, P1957, DOI 10.1126/science.1084146; Compton DA, 2000, ANNU REV BIOCHEM, V69, P95, DOI 10.1146/annurev.biochem.69.1.95; COMPTON DA, 1995, J CELL SCI, V108, P621; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Du QS, 2002, CURR BIOL, V12, P1928, DOI 10.1016/S0960-9822(02)01298-8; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gordon MB, 2001, J CELL BIOL, V152, P425, DOI 10.1083/jcb.152.3.425; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Grill SW, 2003, SCIENCE, V301, P518, DOI 10.1126/science.1086560; Haren L, 2002, J CELL SCI, V115, P1815; Jan YN, 2001, NAT REV NEUROSCI, V2, P772, DOI 10.1038/35097516; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kaushik R, 2003, MOL BIOL CELL, V14, P3144, DOI 10.1091/mbc.E03-04-0212; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Miyawaki A, 2003, DEV CELL, V4, P295, DOI 10.1016/S1534-5807(03)00060-1; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Srinivasan DG, 2003, GENE DEV, V17, P1225, DOI 10.1101/gad.1081203; Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Willard FS, 2004, ANNU REV BIOCHEM, V73, P925, DOI 10.1146/annurev.biochem.73.011303.073756; Yoshizaki H, 2003, J CELL BIOL, V162, P223, DOI 10.1083/jcb.200212049; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Yu FW, 2003, J CELL SCI, V116, P887, DOI 10.1242/jcs.00297	38	295	300	2	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					503	516		10.1016/j.cell.2004.10.028	http://dx.doi.org/10.1016/j.cell.2004.10.028			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537540	Green Published, Bronze			2022-12-28	WOS:000225183200009
J	Jia, ST; Yamada, T; Grewal, SIS				Jia, ST; Yamada, T; Grewal, SIS			Heterochromatin regulates cell type-specific long-range chromatin interactions essential for directed recombination	CELL			English	Article							MATING-TYPE INTERCONVERSION; BETA-GLOBIN LOCUS; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; MEIOTIC RECOMBINATION; LYSINE-9 METHYLATION; V(D)J RECOMBINATION; EPIGENETIC CONTROL; DNA-REPLICATION; CHROMOSOME-III	Mating-type switching in Schizosaccharomyces pombe involves replacing genetic information at the expressed mat1 locus with sequences copied from one of two silent donor loci, mat2-P or mat3-M, located within a 20-kb heterochromatic domain. Donor selection is dictated by cell type: mat2 is the preferred donor in M cells, and mat3 is the preferred donor in P cells. Here we show that a recombination-promoting complex (RPC) containing Swi2 and Swi5 proteins exhibits cell type-specific localization pattern at the silent mating-type region and this differential localization modulates donor preference during mating-type switching. In P cells, RPC localization is restricted to a recombination enhancer located adjacent to mat3, but in M cells, RPC spreads in cis across the entire silent mating-type interval in a heterochromatin-dependent manner. Our analyses implicate heterochromatin in long-range regulatory interactions and suggest that heterochromatin imposes at the mating-type region structural organization that is important for the donor-choice mechanism.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grewal, SIS (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov		Grewal, Shiv/0000-0002-4552-9261	NATIONAL CANCER INSTITUTE [Z01BC010523, ZIABC010523] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P15770, DOI 10.1073/pnas.2632890100; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; Arcangioli B, 1998, EMBO J, V17, P4503, DOI 10.1093/emboj/17.15.4503; ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; Ayoub N, 1999, GENETICS, V152, P495; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BRESCH C, 1968, MOL GEN GENET, V102, P301, DOI 10.1007/BF00433721; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; Carter D, 2002, NAT GENET, V32, P623, DOI 10.1038/ng1051; Courey AJ, 2001, GENE DEV, V15, P2786; Dalgaard JZ, 2000, CELL, V102, P745, DOI 10.1016/S0092-8674(00)00063-5; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; ENGELKE U, 1987, CURR GENET, V12, P535, DOI 10.1007/BF00419563; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Grewal SIS, 1997, GENETICS, V146, P1221; Grewal SIS, 2000, J CELL PHYSIOL, V184, P311, DOI 10.1002/1097-4652(200009)184:3<311::AID-JCP4>3.0.CO;2-D; Grishchuk AL, 2004, CURR GENET, V44, P317, DOI 10.1007/s00294-003-0439-7; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Ivanova AV, 1998, NAT GENET, V19, P192, DOI 10.1038/566; Jia ST, 2004, SCIENCE, V304, P1971, DOI 10.1126/science.1099035; Kaykov A, 2004, EMBO J, V23, P930, DOI 10.1038/sj.emboj.7600099; Klar A.J., 1989, MOBILE DNA, P671; KLAR AJS, 1991, GENETICS, V129, P1033; Lu BY, 2000, GENETICS, V155, P699; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; Mizuno K, 1997, GENE DEV, V11, P876, DOI 10.1101/gad.11.7.876; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nakayama J, 2001, EMBO J, V20, P2857, DOI 10.1093/emboj/20.11.2857; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Park Y, 2001, SCIENCE, V293, P1083, DOI 10.1126/science.1063073; Shankaranarayana GD, 2003, CURR BIOL, V13, P1240, DOI 10.1016/S0960-9822(03)00489-5; Stam M, 2002, GENE DEV, V16, P1906, DOI 10.1101/gad.1006702; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Szeto L, 1997, GENE DEV, V11, P1899, DOI 10.1101/gad.11.15.1899; Thon G, 2000, GENETICS, V155, P551; THON G, 1993, GENETICS, V134, P1045; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Tuzon CT, 2004, J CELL BIOL, V165, P759, DOI 10.1083/jcb.200312061; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Wu XH, 1996, CELL, V87, P277, DOI 10.1016/S0092-8674(00)81345-8	48	69	74	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					469	480		10.1016/j.cell.2004.10.020	http://dx.doi.org/10.1016/j.cell.2004.10.020			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537537	Bronze			2022-12-28	WOS:000225183200006
J	Pak, W; Hindges, R; Lim, YS; Pfaff, SL; O'Leary, DDM				Pak, W; Hindges, R; Lim, YS; Pfaff, SL; O'Leary, DDM			Magnitude of binocular vision controlled by islet-2 repression of a genetic program that specifies laterality of retinal axon pathfinding	CELL			English	Article							MAMMALIAN OPTIC CHIASM; VISUAL-SYSTEM; UNCROSSED AXONS; GANGLION-CELLS; IN-VITRO; MOUSE; PROJECTIONS; DIVERGENCE; RETINOGENICULATE; GUIDANCE	Pathfinding of retinal ganglion cell (RGC) axons at the midline optic chiasm determines whether RGCs project to ipsilateral or contralateral brain visual centers, critical for binocular vision. Using IsI2(tau-lac)Z knockin mice, we show that the LIM-homeodomain transcription factor IsI2 marks only contralaterally projecting RGCs. The transcription factor Zic2 and guidance receptor EphB1, required by RGCs to project ipsilaterally, colocalize in RGCs distinct from IsI2 RGCs in the ventral-temporal crescent (VTC), the source of ipsilateral projections. IsI2 knockout mice have an increased ipsilateral projection originating from significantly more RGCs limited to the VTC. IsI2 knockouts also have increased Zic2 and EphB1 expression and significantly more Zic2 RGCs in the VTC. We conclude that IsI2 specifies RGC laterality by repressing an ipsilateral pathfinding program unique to VTC RGCs and involving Zic2 and EphB1. This genetic hierarchy controls binocular vision by regulating the magnitude and source of ipsilateral projections and reveals unique retinal domains.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute; Salk Institute	O'Leary, DDM (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.	doleary@salk.edu	Hindges, Robert/C-5344-2009	Hindges, Robert/0000-0003-0095-7913	NEI NIH HHS [R01 EY07025] Funding Source: Medline; NINDS NIH HHS [R01 NS37116] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007025] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037116] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Brown LY, 2003, GENE EXPR PATTERNS, V3, P361, DOI 10.1016/S1567-133X(03)00043-7; COLELLO RJ, 1990, DEVELOPMENT, V108, P515; DRAGER UC, 1980, J COMP NEUROL, V191, P383, DOI 10.1002/cne.901910306; DRAGER UC, 1985, PROC R SOC SER B-BIO, V224, P57, DOI 10.1098/rspb.1985.0021; Erkman L, 2000, NEURON, V28, P779, DOI 10.1016/S0896-6273(00)00153-7; FUKUDA Y, 1989, J NEUROSCI, V9, P2353; GODEMENT P, 1984, J COMP NEUROL, V230, P552, DOI 10.1002/cne.902300406; GODEMENT P, 1990, NEURON, V5, P173, DOI 10.1016/0896-6273(90)90307-2; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Herrera E, 2003, CELL, V114, P545, DOI 10.1016/S0092-8674(03)00684-6; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Marcus RC, 2000, DEV BIOL, V221, P132, DOI 10.1006/dbio.2000.9660; MARCUS RC, 1995, J NEUROSCI, V15, P3716; Mason CA, 1997, CURR OPIN NEUROBIOL, V7, P647, DOI 10.1016/S0959-4388(97)80084-0; Muir-Robinson G, 2002, J NEUROSCI, V22, P5259; Nakagawa S, 2000, NEURON, V25, P599, DOI 10.1016/S0896-6273(00)81063-6; OLEARY DDM, 1986, DEV BRAIN RES, V30, P96, DOI 10.1016/0165-3806(86)90136-7; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Plump AS, 2002, NEURON, V33, P219, DOI 10.1016/S0896-6273(01)00586-4; REID RC, 2003, FUNDAMENTALS NEUROSC, P469; SRETAVAN DW, 1990, J NEUROSCI, V10, P1995; SRETAVAN DW, 1993, NEURON, V10, P761, DOI 10.1016/0896-6273(93)90176-R; Thaler JP, 2004, NEURON, V41, P337, DOI 10.1016/S0896-6273(04)00011-X; Wang LC, 1995, NEURON, V15, P1349, DOI 10.1016/0896-6273(95)90013-6; Williams SE, 2003, NEURON, V39, P919, DOI 10.1016/j.neuron.2003.08.017; Wong ROL, 1999, ANNU REV NEUROSCI, V22, P29, DOI 10.1146/annurev.neuro.22.1.29; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868	29	122	123	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					567	578		10.1016/j.cell.2004.10.026	http://dx.doi.org/10.1016/j.cell.2004.10.026			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537545	Bronze			2022-12-28	WOS:000225183200014
J	Partridge, T				Partridge, T			Reenthronement of the muscle satellite cell	CELL			English	Editorial Material							STEM-CELL; SKELETAL-MUSCLE; BONE-MARROW; DYSTROPHIN EXPRESSION; REGENERATION		MRC, Ctr Clin Sci, Muscle Cell Biol Grp, London W12 0NN, England		Partridge, T (corresponding author), MRC, Ctr Clin Sci, Muscle Cell Biol Grp, Du Cane Rd, London W12 0NN, England.							Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; GROUNDS MD, 1983, CELL TISSUE RES, V234, P713; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Partridge TA, 2003, MUSCLE NERVE, V27, P133, DOI 10.1002/mus.10243; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Torrente Y, 2004, J CLIN INVEST, V114, P182, DOI 10.1172/JCI200420325; Zammit PS, 2001, DIFFERENTIATION, V68, P193, DOI 10.1046/j.1432-0436.2001.680407.x	10	24	25	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	2004	119	4					447	448		10.1016/j.cell.2004.10.022	http://dx.doi.org/10.1016/j.cell.2004.10.022			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537532	Bronze			2022-12-28	WOS:000225183200001
J	Bloche, MG				Bloche, MG			Race-based therapeutics	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Georgetown Univ, Ctr Law, Washington, DC 20057 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bloche, MG (corresponding author), Georgetown Univ, Ctr Law, Washington, DC 20057 USA.							Cacioppo JT, 2003, PERSPECT BIOL MED, V46, pS39, DOI 10.1353/pbm.2003.0049; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Kahn Jonathan, 2004, Yale J Health Policy Law Ethics, V4, P1; Lifton R. J., 1986, NAZI DOCTORS MED KIL	5	109	112	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2035	2037		10.1056/NEJMp048271	http://dx.doi.org/10.1056/NEJMp048271			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15533852				2022-12-28	WOS:000225007200001
J	Celis, C; Scurrah, M; Cowgill, S; Chumbiauca, S; Green, J; Franco, J; Main, G; Kiezebrink, D; Visser, RGF; Atkinson, HJ				Celis, C; Scurrah, M; Cowgill, S; Chumbiauca, S; Green, J; Franco, J; Main, G; Kiezebrink, D; Visser, RGF; Atkinson, HJ			Environmental biosafety and transgenic potato in a centre of diversity for this crop	NATURE			English	Article							LEVEL PHYSIOLOGICAL PROFILES; GENETICALLY-MODIFIED CROPS; NEMATODE RESISTANCE; MICROBIAL COMMUNITY; GLOBODERA-PALLIDA; NONTARGET APHIDS; PLANT CYSTATIN; RISK; VARIABILITY; RHIZOSPHERE	The Nuffield Council on Bioethics(1,2) suggests that introgression of genetic material into related species in centres of crop biodiversity is an insufficient justification to bar the use of genetically modified crops in the developing world. They consider that a precautionary approach to forgo the possible benefits invokes the fallacy of thinking that doing nothing is itself without risk to the poor. Here we report findings relevant to this and other aspects of environmental biosafety for genetically modified potato in its main centre of biodiversity, the central Andes. We studied genetically modified potato clones that provide resistance to nematodes, principal pests of Andean potato crops(3). We show that there is no harm to many non-target organisms, but gene flow occurs to wild relatives growing near potato crops. If stable introgression were to result, the fitness of these wild species could be altered. We therefore transformed the male sterile cultivar Revolucion to provide a genetically modified nematode-resistant potato to evaluate the benefits that this provides until the possibility of stable introgression to wild relatives is determined. Thus, scientific progress is possible without compromise to the precautionary principle.	Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Wageningen & Res Ctr, Lab Plant Breeding, NL-6700 AJ Wageningen, Netherlands; Minist Agr, SENASA, Lima 11, Peru; Fdn PROINPA, Cochabamba, Bolivia	University of Leeds; Wageningen University & Research	Atkinson, HJ (corresponding author), Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England.	h.j.atkinson@leeds.ac.uk	Visser, Richard GF/B-3423-2012	Visser, Richard GF/0000-0002-0213-4016				[Anonymous], 1986, LAB METHODS WORK PLA; Atkinson HJ, 2004, J NUTR, V134, P431, DOI 10.1093/jn/134.2.431; Atkinson HJ, 2001, TRENDS BIOTECHNOL, V19, P91, DOI 10.1016/S0167-7799(00)01547-X; Balser TC, 2002, SOIL SCI SOC AM J, V66, P519, DOI 10.2136/sssaj2002.0519; BATRA SWT, 1993, J KANSAS ENTOMOL SOC, V66, P252; Bernatzky R., 1986, PLANT MOL BIOL REP, V4, P37, DOI [10.1007/BF02672487, DOI 10.1007/BF02672487]; Bongers T, 1999, PLANT SOIL, V212, P13, DOI 10.1023/A:1004571900425; Cowgill SE, 2004, MOL ECOL, V13, P639, DOI 10.1046/j.1365-294X.2004.02078.x; Cowgill SE, 2003, TRANSGENIC RES, V12, P439, DOI 10.1023/A:1024215922148; Cowgill SE, 2002, J APPL ECOL, V39, P915, DOI 10.1046/j.1365-2664.2002.00774.x; Cowgill SE, 2002, MOL ECOL, V11, P821, DOI 10.1046/j.1365-294X.2002.01482.x; Cresswell JE, 2002, OIKOS, V98, P375, DOI 10.1034/j.1600-0706.2002.980302.x; Garland JL, 2001, SOIL BIOL BIOCHEM, V33, P1059, DOI 10.1016/S0038-0717(01)00011-6; Griffiths BS, 2000, J APPL ECOL, V37, P159, DOI 10.1046/j.1365-2664.2000.00481.x; Hancock JF, 2003, BIOSCIENCE, V53, P512, DOI 10.1641/0006-3568(2003)053[0512:AFFATR]2.0.CO;2; Heeres P, 2002, EUPHYTICA, V124, P13, DOI 10.1023/A:1015689112703; Human Z, 2002, AM J BOT, V89, P947, DOI 10.3732/ajb.89.6.947; Jackson SA, 1999, EUPHYTICA, V109, P51, DOI 10.1023/A:1003710817938; Lilley CJ, 2004, PLANT BIOTECHNOL J, V2, P3, DOI 10.1046/j.1467-7652.2003.00037.x; MCPARTLAN HC, 1994, TRANSGENIC RES, V3, P216, DOI 10.1007/BF02336774; *NUFF BIOETH COMM, 1999, GEN MOD CROPS ETH SO; Nuffield Bioethics Committee, 2004, US GEN MOD CROPS DEV; Osborne JL, 1999, J APPL ECOL, V36, P519, DOI 10.1046/j.1365-2664.1999.00428.x; Soderberg KH, 2004, APPL SOIL ECOL, V25, P135, DOI 10.1016/j.apsoil.2003.08.005; Spooner DM, 2001, AM J POTATO RES, V78, P237, DOI 10.1007/BF02875691; Stewart CN, 2003, NAT REV GENET, V4, P806, DOI 10.1038/nrg1179; Urwin PE, 2003, MOL BREEDING, V12, P263, DOI 10.1023/A:1026352620308; Urwin PE, 2001, MOL BREEDING, V8, P95, DOI 10.1023/A:1011942003994; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407	29	44	54	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					222	225		10.1038/nature03048	http://dx.doi.org/10.1038/nature03048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538370				2022-12-28	WOS:000225020200047
J	Smith, GCS; Crossley, JA; Aitken, DA; Pell, JP; Cameron, AD; Connor, JM; Dobbie, R				Smith, GCS; Crossley, JA; Aitken, DA; Pell, JP; Cameron, AD; Connor, JM; Dobbie, R			First-trimester placentation and the risk of antepartum stillbirth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA-PROTEIN-A; GROWTH; BIRTH; IGF	Context Preterm birth and low birth weight are determined, at least in part, during the first trimester of pregnancy. However, it is unknown whether the risk of stillbirth is also determined during the first trimester. Objective To determine whether the risk of antepartum stillbirth varies in relation to circulating markers of placental function measured during the first trimester of pregnancy. Design, Setting, and Participants Multicenter, prospective cohort study (conducted in Scotland from 1998 through 2000) of 7934 women who had singleton births at or after 24 weeks' gestation, who had blood taken during the first 10 weeks after conception, and who were entered into national registries of births and perinatal deaths. Main Outcome Measures Antepartum stillbirths and stillbirths due to specific causes. Results There were 8 stillbirths among the 400 women with levels of pregnancy-associated plasma protein A (PAPP-A) in the lowest fifth percentile compared with 17 among the remaining 7534 women (incidence rate per 10000 women per week of gestation: 13.4 vs 1.4, respectively; hazard ratio [HR], 9.2 [95% confidence interval {CI}, 4.0-21.4]; P<.001). When analyzed by cause of stillbirth, low level of PAPP-A was strongly associated with stillbirth due to placental dysfunction, defined as abruption or unexplained stillbirth associated with growth restriction (incidence rate: 11.7 vs 0.3, respectively; HR, 46.0 [95% CI, 11.9-178.0]; P<.001), but was not associated with other causes of stillbirth (incidence rate: 1.7 vs 1.1, respectively; HR, 1.4 [95% CI, 0.2-10.6]; P=.75). There was no relationship between having a low level of PAPP-A and maternal age, ethnicity, parity, height, body mass index, race, or marital status. Adjustment for maternal factors did not attenuate the strength of associations observed. There was no association between maternal circulating levels of the free p subunit of human chorionic gonadotropin and stillbirth risk. Conclusion The risk of stillbirth in late pregnancy may be determined by placental function in the first 10 weeks after conception.	Univ Cambridge, Rosie Matern Hosp, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England; Yorkhill NHS Trust, Inst Med Genet, Glasgow, Lanark, Scotland; Greater Glasgow NHS Board, Dept Publ Hlth, Glasgow, Lanark, Scotland; Queen Mothers Hosp, Dept Fetal Med, Glasgow, Lanark, Scotland; Common Serv Agcy, Informat & Stat Div, Edinburgh, Midlothian, Scotland	University of Cambridge; University of Glasgow	Smith, GCS (corresponding author), Univ Cambridge, Rosie Matern Hosp, Dept Obstet & Gynaecol, Robinson Way, Cambridge CB2 2SW, England.	gcss2@cam.ac.uk	Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997; Pell, Jill/0000-0002-8898-7035				BONNO M, 1994, LAB INVEST, V71, P560; Cnattingius S, 2002, SEMIN PERINATOL, V26, P25, DOI 10.1053/sper.2002.29841; COLE SK, 1980, PERINATAL AUDIT SURV, P39; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Crossley JA, 2002, BJOG-INT J OBSTET GY, V109, P667, DOI 10.1016/S1470-0328(02)01394-0; Crowley P, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000065; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hosmer D. W., 1999, APPL SURVIVAL ANAL; *INF STAT DIV NHS, 2001, SCOTT PER INF MORT R; Irwin JC, 1999, HUM REPROD, V14, P90, DOI 10.1093/humrep/14.suppl_2.90; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Maller RA., 1996, SURVIVAL ANAL LONG T; May S, 1998, LIFETIME DATA ANAL, V4, P109, DOI 10.1023/A:1009612305785; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Neilson JP, 2000, COCHRANE DB SYST REV, V2; Neveux LM, 1996, PRENATAL DIAG, V16, P1115, DOI 10.1002/(SICI)1097-0223(199612)16:12<1115::AID-PD3>3.0.CO;2-6; Pocock SJ, 2002, LANCET, V359, P1686, DOI 10.1016/S0140-6736(02)08594-X; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; Smith GCS, 1998, NEW ENGL J MED, V339, P1817, DOI 10.1056/NEJM199812173392504; Smith GCS, 2002, J CLIN ENDOCR METAB, V87, P1762, DOI 10.1210/jc.87.4.1762; Smith GCS, 2001, AM J OBSTET GYNECOL, V184, P489, DOI 10.1067/mob.2001.109735; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R; YUDKIN PL, 1987, LANCET, V1, P1192	23	96	97	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2249	2254		10.1001/jama.292.18.2249	http://dx.doi.org/10.1001/jama.292.18.2249			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536112	Bronze			2022-12-28	WOS:000225070000026
J	Murray, CJL; Lopez, AD; Wibulpolprasert, S				Murray, CJL; Lopez, AD; Wibulpolprasert, S			Monitoring global health: time for new solutions	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIOUS-DISEASES; CONSEQUENCES; BURDEN; POLICY		Harvard Univ, Harvard Initiat Global Hlth, Cambridge, MA 02138 USA; Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia; Minist Publ Hlth, Off Permanent Secretary, Nonthaburi 11000, Thailand	Harvard University; University of Queensland; Ministry of Public Health - Thailand	Murray, CJL (corresponding author), Harvard Univ, Harvard Initiat Global Hlth, 104 Mt Auburn St, Cambridge, MA 02138 USA.	christopher_murray@harvard.edu	Lopez, Alan/AAA-2734-2022; Lopez, Alan D/F-1487-2010	Lopez, Alan D/0000-0001-5818-6512				Almeida C, 2001, LANCET, V357, P1692, DOI 10.1016/S0140-6736(00)04825-X; Anand S., 2003, HLTH SYSTEMS PERFORM, P839; [Anonymous], 2002, WORLD MORTALITY 2000; [Anonymous], GLOB TUB CONTR SURV; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Boerma J T, 1993, World Health Stat Q, V46, P222; Boerma JT, 2003, LANCET, V362, P1929, DOI 10.1016/S0140-6736(03)14967-7; Cash RA, 2000, B WORLD HEALTH ORGAN, V78, P1358; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Enserink M, 2004, SCIENCE, V303, P1605, DOI 10.1126/science.303.5664.1605; Gakidou E, 2004, INT J EPIDEMIOL, V33, P710, DOI 10.1093/ije/dyh099; *GLOB ALL VACC IMM, 2004, PROGR CHALL 2004; Gostin LO, 2004, JAMA-J AM MED ASSOC, V291, P2623, DOI 10.1001/jama.291.21.2623; Heymann D L, 2001, Lancet Infect Dis, V1, P345, DOI 10.1016/S1473-3099(01)00148-7; HILL AG, 1992, ANAL MATERNITY HIST; INDEPTH Network, 2002, POP HLTH DEV COUNTR, V1; *LATH CONS, 2001, IMM DAT QUAL AUD EV; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; MALISON MD, 2000, LEADERSHIP PUBLIC HL, V5, P24; Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; NAIK G, 2004, WALL STREET J   0712, pB2; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; *UN DEV PROGR, 2000, HUM DEV REP 2003 MIL; *USAID MACR INT, DEM HLTH SURV; VARMUS H, 2004, NEW ENGL J MED, V351, P1275; Williams A, 2001, HEALTH ECON, V10, P93, DOI 10.1002/hec.594; World Health Organization, 2004, ICD 10 INT STAT CLAS, V2nd; World Health Organization (WHO), WORLD HLTH REP	29	82	85	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1096	1100		10.1136/bmj.329.7474.1096	http://dx.doi.org/10.1136/bmj.329.7474.1096			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528624	Green Published			2022-12-28	WOS:000225070300027
J	Weller, M; Brahams, D				Weller, M; Brahams, D			The UK Draft Mental Health Bill 2004: a compromise that pleases no one	LANCET			English	Editorial Material									Old Sq Chambers, London WC1R 5LQ, England; Middlesex Univ, Sch Hlth & Soial Sci, Enfield, Middx, England	Middlesex University	Brahams, D (corresponding author), Old Sq Chambers, London WC1R 5LQ, England.	brahams@oldsquarechambers.co.uk						*DEP HLTH SOC SEC, 1974, REV REP WORK PART SE; GENKEER L, 2003, LONDONS MENTAL HLTH; *HOM OFF DEP HLTH, 1975, CM6244; Johnson S., 1997, LONDONS MENTAL HLTH; MCCULLOUGH J, 1986, ALL ENGL LAW REP, V2, P306; *REED COMM, 1992, REV HLTH SOC SERV ME, V2; Richardson G., 1999, REV MENTAL HLTH ACT; WELLER MPI, 1987, NATURE, V339, P249	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1651	1652		10.1016/S0140-6736(04)17373-X	http://dx.doi.org/10.1016/S0140-6736(04)17373-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530612				2022-12-28	WOS:000224921600010
J	Connolly, MA; Gayer, M; Ryan, MJ; Salama, P; Spiegel, P; Heymann, DL				Connolly, MA; Gayer, M; Ryan, MJ; Salama, P; Spiegel, P; Heymann, DL			Communicable diseases in complex emergencies: impact and challenges	LANCET			English	Review							RESPIRATORY-TRACT INFECTIONS; SMEAR-POSITIVE TUBERCULOSIS; TREATED BED NETS; REFUGEE CAMP; DEVELOPING-COUNTRIES; PUBLIC-HEALTH; DOUBLE-BLIND; VITAMIN-A; MORTALITY; CHILDREN	Communicable diseases, alone or in combination with malnutrition, account for most deaths in complex emergencies. Factors promoting disease transmission interact synergistically leading to high incidence rates of diarrhoea, respiratory infection, malaria, and measles. This excess morbidity and mortality is avoidable as effective interventions are available. Adequate shelter, water, food, and sanitation linked to effective case management, immunisation, health education, and disease surveillance are crucial. However, delivery mechanisms are often compromised by loss of health staff, damage to infrastructure, insecurity, and poor co-ordination. Although progress has been made in the control of specific communicable diseases in camp settings, complex emergencies affecting large geographical areas or entire countries pose a greater challenge. Available interventions need to be implemented more systematically in complex emergencies with higher levels of coordination between governments, UN agencies, and non-governmental organisations. In addition, further research is needed to adapt and simplify interventions, and to explore novel diagnostics, vaccines, and therapies.	WHO, Complex Emergencies Programme, CH-1211 Geneva 27, Switzerland; UNICEF, Kabul, Afghanistan; UNHCR, Geneva, Switzerland	World Health Organization	Connolly, MA (corresponding author), WHO, Complex Emergencies Programme, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	connollyma@who.int	Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				AABY P, 1988, REV INFECT DIS, V10, P478; Aaby P, 1999, BRIT MED J, V319, P878, DOI 10.1136/bmj.319.7214.878; Ahmad K, 2000, LANCET, V355, P1439, DOI 10.1016/S0140-6736(05)74645-6; ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1993, T ROY SOC TROP MED H, V87, P37, DOI 10.1016/0035-9203(93)90174-O; *AM PUBL HLTH ASS, 2000, CONTR COMM DIS MAN, P525; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P363; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; Colebunders R, 2002, BRIT MED J, V324, P802, DOI 10.1136/bmj.324.7341.802; Connolly MA, 2002, LANCET, V360, pS23, DOI 10.1016/S0140-6736(02)11807-1; DIAZ T, 1989, TROP DOCT, V19, P14, DOI 10.1177/004947558901900105; DUALEH MW, 1995, LANCET, V346, P1369, DOI 10.1016/S0140-6736(95)92386-1; Fawzi WW, 2000, J PEDIATR-US, V137, P660, DOI 10.1067/mpd.2000.110136; GESSNER BD, 1994, JAMA-J AM MED ASSOC, V272, P382, DOI 10.1001/jama.272.5.382; Graham K, 2002, MED VET ENTOMOL, V16, P404, DOI 10.1046/j.1365-2915.2002.00395.x; GRAVES PM, 1987, B WORLD HEALTH ORGAN, V65, P869; HARRELLBOND B, 1998, FORCED MIGRATION REV, V2, P22; HATCH DL, 1994, INT J EPIDEMIOL, V23, P1292, DOI 10.1093/ije/23.6.1292; Hazir T, 2002, LANCET, V360, P835; Holt BY, 2003, DISASTERS, V27, P1, DOI 10.1111/1467-7717.00216; Hopkins DR, 2002, LANCET, V360, pS21, DOI 10.1016/S0140-6736(02)11806-X; *IASC HIV AIDS EM, 2004, GUID HIV AIDS INT EM; *IASC HIV AIDS EM, 2002, MATR HIV AIDS INT EM, P12; Jamison D.T., 1993, DIS CONTROL PRIORITI; Julien MR, 1999, TROP MED INT HEALTH, V4, P794, DOI 10.1046/j.1365-3156.1999.00493.x; KAISER R, 2002, HIV SEROPREVALENCE B; Kessler C., TUBERCULOSIS CONTROL; Khaw AJ, 2000, DISASTERS, V24, P181, DOI 10.1111/1467-7717.00141; LEDUC JW, 1989, REV INFECT DIS, V11, pS730; Legros D, 1999, B WORLD HEALTH ORGAN, V77, P837; Macintyre K, 2003, INT J EPIDEMIOL, V32, P157, DOI 10.1093/ije/dyg019; MARFIN AA, 1994, JAMA-J AM MED ASSOC, V272, P377, DOI 10.1001/jama.272.5.377; MERCER A, 1992, DISASTERS, V16, P28, DOI 10.1111/j.1467-7717.1992.tb00373.x; Naficy A, 1998, JAMA-J AM MED ASSOC, V279, P521, DOI 10.1001/jama.279.7.521; Paquet C, 1998, B I PASTEUR, V96, P3, DOI 10.1016/S0020-2452(98)80024-9; Peterson EA, 1998, INT J EPIDEMIOL, V27, P520, DOI 10.1093/ije/27.3.520; Reintjes R, 2002, EMERG INFECT DIS, V8, P69, DOI 10.3201/eid0801.010131; Roberts L, 2001, B WORLD HEALTH ORGAN, V79, P280; Rodger AJ, 2002, B WORLD HEALTH ORGAN, V80, P451; Ronald C, 1999, BMJ, V318; Rowland M, 1999, T ROY SOC TROP MED H, V93, P465, DOI 10.1016/S0035-9203(99)90341-3; Rowland M, 1999, T ROY SOC TROP MED H, V93, P133, DOI 10.1016/S0035-9203(99)90285-7; Rutta E, 2001, INT J TUBERC LUNG D, V5, P628; Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563; Santaniello-Newton A, 2000, EPIDEMIOL INFECT, V124, P75, DOI 10.1017/S0950268899003398; Seaman J, 1996, INT J EPIDEMIOL, V25, P862, DOI 10.1093/ije/25.4.862; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; Soares J L, 1994, Med Trop (Mars), V54, P319; Sobsey MD, 2003, WATER SCI TECHNOL, V47, P221, DOI 10.2166/wst.2003.0199; Spiegel P, 2002, LANCET, V360, P1927, DOI 10.1016/S0140-6736(02)11915-5; Spiegel P, 2003, HIV AIDS REFUGEES RE; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; Spiegel PB, 2001, LANCET, V357, P714, DOI 10.1016/S0140-6736(00)04143-X; Steering Committee for Humanitarian Response, 2004, SPHER PROJ HUM CHART; SUKRAKANCHANATRIKHAM P, 1992, TUBERCLE LUNG DIS, V73, P384, DOI 10.1016/0962-8479(92)90045-L; Talley L., 2001, J REFUG STUD, V14, P412; Tangermann RH, 2000, B WORLD HEALTH ORGAN, V78, P330; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1995, LANCET, V345, P339, DOI 10.1016/S0140-6736(95)90338-0; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; *UNHCR UNAIDS, 2003, HIV AIDS STI PREV CA; *UNHCR WHO UNAIDS, 1995, GUID HIV INT EM SETT; Van Nieuwenhove S, 2001, TROP MED INT HEALTH, V6, P335, DOI 10.1046/j.1365-3156.2001.00731.x; VANDAMME W, 1995, LANCET, V346, P360; *WHO, 1997, TUB CONTR REF SIT IN; [WHO UNICEF], 2001, WHOVB0113 UNICEF; WHO, 2002, 3 M TECHN SUPP NETW; WHO, ROLL BACK MAL; *WHO, 1995, M 13 14 FEBR 1995 GE; World Health Organization, 1999, WHOCDSCSRISR991; World Health Organization, 2002, COMM DIS PROF AFGH N; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1996, REV EPIDEMIO SANTE P, V44, P358	76	263	271	2	55	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1974	1983		10.1016/S0140-6736(04)17481-3	http://dx.doi.org/10.1016/S0140-6736(04)17481-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567014				2022-12-28	WOS:000225327000036
J	Hammerman, C; Kaplan, M				Hammerman, C; Kaplan, M			Primum non nocere: prophylactic versus curative ibuprofen	LANCET			English	Editorial Material							PATENT DUCTUS-ARTERIOSUS; PRETERM INFANTS; INDOMETHACIN		Shaare Zedek Med Ctr, Dept Neonatol, IL-91031 Jerusalem, Israel; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; Hebrew Univ Jerusalem, Jerusalem, Israel	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Ben Gurion University; Hebrew University of Jerusalem	Hammerman, C (corresponding author), Shaare Zedek Med Ctr, Dept Neonatol, IL-91031 Jerusalem, Israel.	cathy@cc.huji.ac.il						Dani C, 2000, ACTA PAEDIATR, V89, P1369, DOI 10.1080/080352500300002598; Fowlie PW, 2003, ARCH DIS CHILD-FETAL, V88, pF464, DOI 10.1136/fn.88.6.F464; Gournay V, 2002, LANCET, V359, P1486, DOI 10.1016/S0140-6736(02)08424-6; Pezzati M, 1999, J PEDIATR-US, V135, P733, DOI 10.1016/S0022-3476(99)70093-4; Romagnoli C, 2000, CLIN PHARMACOL THER, V67, P676, DOI 10.1067/mcp.2000.107048; SHAH SS, 2003, COCHRANE DB SYST REV; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Varvarigou A, 1996, JAMA-J AM MED ASSOC, V275, P539, DOI 10.1001/jama.275.7.539	8	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1920	1922		10.1016/S0140-6736(04)17492-8	http://dx.doi.org/10.1016/S0140-6736(04)17492-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566994				2022-12-28	WOS:000225327000008
J	Oransky, I				Oransky, I			Sol Londe - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com						LONDE S, 1966, CLIN PEDIATR, V5, P71, DOI 10.1177/000992286600500204; Londe S, 1999, PEDIATRICS, V103, P532	2	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1932	1932		10.1016/S0140-6736(04)17500-4	http://dx.doi.org/10.1016/S0140-6736(04)17500-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15570702	Bronze			2022-12-28	WOS:000225327000016
J	Barnard, DC; Ryan, K; Manley, JL; Richter, JD				Barnard, DC; Ryan, K; Manley, JL; Richter, JD			Symplekin and xGLD-2 are required for CPEB-mediated cytoplasmic polyadenylation	CELL			English	Article							MESSENGER-RNA POLYADENYLATION; POLY(A) POLYMERASE; SPECIFICITY FACTOR; OOCYTE MATURATION; 160-KD SUBUNIT; TRANSLATION; PHOSPHORYLATION; CLEAVAGE; PROTEIN; COMPLEX	Cytoplasmic polyadenylation-induced mRNA translation is a hallmark of early animal development. In Xenopus oocytes, where the molecular mechanism has been defined, the core factors that control this process include CPEB, an RNA binding protein whose association with the CPE specifies which mRNAs undergo polyadenylation; CPSF, a multifactor complex that interacts with the near-ubiquitous polyadenylation hexanucleotide AAUAAA; and maskin, a CPEB and eIF4E binding protein whose regulation of initiation is governed by poly(A) tail length. Here, we define two new factors that are essential for polyadenylation. The first is symplekin, a CPEB and CPSF binding protein that serves as a scaffold upon which regulatory factors are assembled. The second is xGLD-2, an unusual poly(A) polymerase that is anchored to CPEB and CPSF even before polyadenylation begins. The identification of these factors has broad implications for biological process that employ polyadenylation-regulated translation, such as gametogenesis, cell cycle progression, and synaptic plasticity.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	University of Massachusetts System; University of Massachusetts Worcester; Columbia University	Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	joel.richter@umassmed.edu	Ryan, Kevin/K-6527-2012	Ryan, Kevin/0000-0001-5304-2026; Manley, James/0000-0002-8341-1459	NICHD NIH HHS [HD37267] Funding Source: Medline; NIDDK NIH HHS [DK32520] Funding Source: Medline; NIGMS NIH HHS [GM28983, GM46779, F32-GM64872] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD037267, R01HD037267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028983, F32GM064872, R01GM046779] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; BALLANTYNE S, 1995, RNA, V1, P64; Cao QP, 2002, EMBO J, V21, P3852, DOI 10.1093/emboj/cdf353; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; GEBAUER F, 1995, MOL CELL BIOL, V15, P1422; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Helming S, 2001, MOL CELL BIOL, V21, P2026, DOI 10.1128/MCB.21.6.2026-2037.2001; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Huang YS, 2003, GENE DEV, V17, P638, DOI 10.1101/gad.1053003; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kaufmann I, 2004, EMBO J, V23, P616, DOI 10.1038/sj.emboj.7600070; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kim H, 2003, EMBO J, V22, P5208, DOI 10.1093/emboj/cdg486; Kwak JE, 2004, P NATL ACAD SCI USA, V101, P4407, DOI 10.1073/pnas.0400779101; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; Read RL, 2002, P NATL ACAD SCI USA, V99, P12079, DOI 10.1073/pnas.192467799; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; Ryan K, 2002, MOL CELL BIOL, V22, P1684, DOI 10.1128/MCB.22.6.1684-1692.2002; Saitoh S, 2002, CELL, V109, P563, DOI 10.1016/S0092-8674(02)00753-5; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; StebbinsBoaz B, 1996, EMBO J, V15, P2582, DOI 10.1002/j.1460-2075.1996.tb00616.x; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Wang LT, 2002, NATURE, V419, P312, DOI 10.1038/nature01039; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Xing HY, 2004, J BIOL CHEM, V279, P10551, DOI 10.1074/jbc.M311719200; Zhao J, 1999, MOL CELL BIOL, V19, P7733; Zhao WQ, 1996, MOL CELL BIOL, V16, P2378	42	250	259	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					641	651		10.1016/j.cell.2004.10.029	http://dx.doi.org/10.1016/j.cell.2004.10.029			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550246	Bronze			2022-12-28	WOS:000225389500010
J	Buckley, NA; Roberts, D; Eddleston, M				Buckley, NA; Roberts, D; Eddleston, M			Overcoming apathy in research on organophosphate poisoning	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PESTICIDES; SUICIDE; TRAGEDY		Canberra Hosp, Dept Clin Pharmacol & Toxicol, S Asian Clin Toxicol Res Collaborat, Woden, ACT 2606, Australia; Univ Colombo, Dept Clin Med, Ox Col Collaborat, Colombo, Sri Lanka	Australian National University; Canberra Hospital; University of Colombo	Buckley, NA (corresponding author), Canberra Hosp, Dept Clin Pharmacol & Toxicol, S Asian Clin Toxicol Res Collaborat, POB 11, Woden, ACT 2606, Australia.	Nick.Buckley@act.gov.au	Roberts, Darren/A-8986-2013; Buckley, Nicholas A/D-4030-2012	Roberts, Darren/0000-0001-9101-7577; Buckley, Nicholas A/0000-0002-6326-4711				Balali-Mood M, 1998, J PHYSIOLOGY-PARIS, V92, P375, DOI 10.1016/S0928-4257(99)80008-4; Ballantyne B., 1992, CLIN EXPT TOXICOLOGY, P3; Brown MA, 1998, J APPL TOXICOL, V18, P393, DOI 10.1002/(SICI)1099-1263(199811/12)18:6<393::AID-JAT528>3.0.CO;2-0; Buckley NA, 2004, J TOXICOL-CLIN TOXIC, V42, P113, DOI 10.1081/CLT-120028756; Eddleston M, 2000, QJM-INT J MED, V93, P715, DOI 10.1093/qjmed/93.11.715; Eddleston M, 2004, BMJ-BRIT MED J, V328, P42, DOI 10.1136/bmj.328.7430.42; Eddleston M, 1998, BRIT MED J, V317, P133, DOI 10.1136/bmj.317.7151.133; Eddleston M, 2002, LANCET, V360, P1163, DOI 10.1016/S0140-6736(02)11204-9; Eddleston Michael, 2003, Clin Evid, P1652; Gunnell D, 2003, INT J EPIDEMIOL, V32, P902, DOI 10.1093/ije/dyg307; Johnson MK., 2000, EMERGEN MED, V12, P22, DOI [DOI 10.1046/J.1442-2026.2000.00087.X, 10.1046/j.1442-2026.2000.00087.x]; Lashof JC, 1998, JAMA-J AM MED ASSOC, V280, P1010, DOI 10.1001/jama.280.11.1010; Lee EC, 2003, JAMA-J AM MED ASSOC, V290, P659, DOI 10.1001/jama.290.5.659; Marino MT, 1998, MIL MED, V163, P743, DOI 10.1093/milmed/163.11.743; Okumura T, 1996, ANN EMERG MED, V28, P129, DOI 10.1016/S0196-0644(96)70052-5; Phillips MR, 2002, LANCET, V359, P835, DOI 10.1016/S0140-6736(02)07954-0; Roberts DM, 2003, B WORLD HEALTH ORGAN, V81, P789; US Food and Drug Administration, FDA APPR PYR BROM PR; 2003, JAMA, V290, P3190	19	48	49	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1231	1233		10.1136/bmj.329.7476.1231	http://dx.doi.org/10.1136/bmj.329.7476.1231			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15550429	Green Published			2022-12-28	WOS:000225335700022
J	Moya-Sola, S; Kohler, M; Alba, DM; Casanovas-Vilar, I; Galindo, J				Moya-Sola, S; Kohler, M; Alba, DM; Casanovas-Vilar, I; Galindo, J			Pierolapithecus catalaunicus, a new Middle Miocene great ape from Spain	SCIENCE			English	Article							HOMINOID GENUS; SKULL MATERIAL; LOCOMOTION; SKELETON; PRIMATES; ORIGINS	We describe a partial skeleton with facial cranium of Pierolapithecus catalaunicus gen. et sp. nov., a new Middle Miocene (12.5 to 13 million years ago) ape from Barranc de Can Vita 1 (Barcelona, Spain). It is the first known individual of this age that combines well-preserved cranial, dental, and postcranial material. The thorax, lumbar region, and wrist provide evidence of modern ape-like orthograde body design, and the facial morphology includes the basic derived great ape features. The new skeleton reveals that early great apes retained primitive monkeylike characters associated with a derived body structure that permits upright postures of the trunk. Pierolapithecus, hence, does not fit the theoretical model that predicts that all characters shared by extant great apes were present in their last common ancestor, but instead points to a large amount of homoplasy in ape evolution. The,overall pattern suggests that Pierolapithecus is probably close to the last common ancestor of great apes and humans.	Escola Ind 23, Inst Paleontol M Crusafont, Barcelona 08201, Spain; Palaeotheria, Barcelona 08019, Spain		Moya-Sola, S (corresponding author), Escola Ind 23, Inst Paleontol M Crusafont, Barcelona 08201, Spain.	moyass@diba.es	Galindo, Jordi/ABG-2299-2020; Alba, David/G-9716-2015; Casanovas-Vilar, Isaac/J-2517-2012	Galindo, Jordi/0000-0002-8796-3584; Alba, David/0000-0002-8886-5580; Casanovas-Vilar, Isaac/0000-0001-7092-9622; Kohler, Meike/0000-0002-6816-6651; Moya-Sola, Salvador/0000-0001-8506-1061; Kohler, Meike/0000-0001-9228-3164				Agusti J, 2001, EARTH-SCI REV, V52, P247, DOI 10.1016/S0012-8252(00)00025-8; Alpagut B, 1996, NATURE, V382, P349, DOI 10.1038/382349a0; ANDREWS P, 1992, NATURE, V360, P641, DOI 10.1038/360641a0; BEARD KC, 1986, FOLIA PRIMATOL, V47, P97; Begun David R., 1994, Yearbook of Physical Anthropology, V37, P11; Begun David R., 1997, P389; BEGUN DR, 1993, J HUM EVOL, V24, P373, DOI 10.1006/jhev.1993.1028; CRUSAFONT M, 1961, CR HEBD ACAD SCI, V252, P562; Daams R, 1999, EARTH PLANET SC LETT, V165, P287, DOI 10.1016/S0012-821X(98)00273-8; DEBONIS L, 1990, NATURE, V345, P712, DOI 10.1038/345712a0; FLEAGLE JG, 1976, FOLIA PRIMATOL, V26, P245, DOI 10.1159/000155756; Gebo DL, 1997, SCIENCE, V276, P401, DOI 10.1126/science.276.5311.401; GINGERICH PD, 1982, AM J PHYS ANTHROPOL, V58, P81, DOI 10.1002/ajpa.1330580110; HARRISON T, 1987, J HUM EVOL, V16, P41, DOI 10.1016/0047-2484(87)90060-1; HARRISON T, 1986, J HUM EVOL, V15, P541, DOI 10.1016/S0047-2484(86)80073-2; Ishida H, 2004, J HUM EVOL, V46, P69, DOI 10.1016/j.jhevol.2003.10.001; Kordos L, 2001, J HUM EVOL, V41, P689, DOI 10.1006/jhev.2001.0523; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Kunimatsu Y, 2004, J HUM EVOL, V46, P365, DOI 10.1016/j.jhevol.2003.12.008; Le Gros Clark W.E., 1951, FOSSIL MAMMALS AFR, V1, P1; LEAKEY MG, 1991, FOLIA PRIMATOL, V28, P519; LEAKEY RE, 1986, NATURE, V324, P143, DOI 10.1038/324143a0; Lewis O.J., 1974, P143; MCCROSSIN ML, 1997, FUNCTION PHYLOGENY F, P225; Mones A., 1989, Journal of Vertebrate Paleontology, V9, P232; Moya-Sola S, 1999, P NATL ACAD SCI USA, V96, P313, DOI 10.1073/pnas.96.1.313; MoyaSola S, 1996, NATURE, V379, P156, DOI 10.1038/379156a0; Napier J. R., 1959, Fossil Mammals of Africa, V16, P1; Pickford M., 2002, Human Evolution, V17, P1, DOI 10.1007/BF02436425; Pilbeam D, 1996, MOL PHYLOGENET EVOL, V5, P155, DOI 10.1006/mpev.1996.0010; PILBEAM D, 1982, NATURE, V295, P232, DOI 10.1038/295232a0; Pilbeam David, 1997, P13; SANDERS WJ, 1994, J HUM EVOL, V26, P203, DOI 10.1006/jhev.1994.1012; SARMIENTO EE, 1988, INT J PRIMATOL, V9, P281, DOI 10.1007/BF02737381; Schultz A. H., 1961, pUnpaginated; SCHULTZ AH, 1960, Z MORPHOL ANTHROPOL, V50, P136; Smith RJ, 1997, J HUM EVOL, V32, P523, DOI 10.1006/jhev.1996.0122; SOLA SM, 2001, HOMINOID EVOLUTION C, V2, P192; Stauffer RL, 2001, J HERED, V92, P469, DOI 10.1093/jhered/92.6.469; van der Meulen Albert Jan, 2003, Coloquios de Paleontologia Volumen Extraordinario, V1, P385; VILLALTA JF, 1944, NOTAS COM I GEOL MIN, V13, P1; VILLALTA JF, 1941, B I GEOL MIN ESP, V55, P129; WALKER A, 1968, NATURE, V217, P980, DOI 10.1038/217980a0; WARD CV, 1993, AM J PHYS ANTHROPOL, V92, P291, DOI 10.1002/ajpa.1330920306; Ward S, 1999, SCIENCE, V285, P1382, DOI 10.1126/science.285.5432.1382; Young NM, 2004, J HUM EVOL, V46, P163, DOI 10.1016/j.jhevol.2003.11.002	46	170	174	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1339	1344		10.1126/science.1103094	http://dx.doi.org/10.1126/science.1103094			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550663	Green Submitted			2022-12-28	WOS:000225301600042
J	Wilson, JF				Wilson, JF			The health care revival in Iraq	ANNALS OF INTERNAL MEDICINE			English	News Item												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					825	828		10.7326/0003-4819-141-10-200411160-00027	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545690				2022-12-28	WOS:000225206900019
J	Giudice, LC; Kao, LC				Giudice, LC; Kao, LC			Endometriosis	LANCET			English	Review							MATRIX-METALLOPROTEINASE EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; PERITONEAL-FLUID; IN-VITRO; PROGESTERONE-RECEPTORS; INFERTILE WOMEN; TREATING ENDOMETRIOSIS; OVARIAN ENDOMETRIOSIS; MILD ENDOMETRIOSIS; SURGICAL INDUCTION	Endometriosis is an oestrogen-dependent disorder that can result in substantial morbidity, including pelvic pain, multiple operations, and infertility. New findings on the genetics, the possible roles of the environment and the immune system, and intrinsic abnormalities in the endometrium of affected women and secreted products of endometriotic lesions have given insight into the pathogenesis of this disorder and serve as the background for new treatments for disease-associated pain and infertility. Affected women are at higher risk than the general female population of developing ovarian cancer, and they also may be at increased risk of breast and other cancers as well as autoimmune and atopic disorders. Clinicians should assess and follow up affected women for these and other associated disorders. There will probably be a new repertoire of approaches for treatment and perhaps cure of this enigmatic disorder in the near future.	Stanford Univ, Sch Med,Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Ctr Res Womens Hlth & Reprod, Stanford, CA 94305 USA	Stanford University	Giudice, LC (corresponding author), Stanford Univ, Sch Med,Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Ctr Res Womens Hlth & Reprod, Stanford, CA 94305 USA.	giudice@stanford.edu			NICHD NIH HHS [U54-HD 31398-08] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aeby TC, 1996, AM J OBSTET GYNECOL, V174, P1779, DOI 10.1016/S0002-9378(96)70210-7; Ailawadi RK, 2004, FERTIL STERIL, V81, P290, DOI 10.1016/j.fertnstert.2003.09.029; [Anonymous], 1979, FERTIL STERIL, V32, P633; Attia GR, 2000, J CLIN ENDOCR METAB, V85, P2897, DOI 10.1210/jc.85.8.2897; BADAWY SZA, 1987, J REPROD MED, V32, P194; Barnhart K, 2002, FERTIL STERIL, V77, P1148, DOI 10.1016/S0015-0282(02)03112-6; BARTOSIK D, 1987, AM J OBSTET GYNECOL, V156, P11, DOI 10.1016/0002-9378(87)90194-3; Baxter SW, 2001, CARCINOGENESIS, V22, P63, DOI 10.1093/carcin/22.1.63; Bedaiwy M A, 2003, Minerva Ginecol, V55, P333; Bergqvist A, 2002, HUM REPROD UPDATE, V8, P79, DOI 10.1093/humupd/8.1.79; BERQVIST A, 1999, HUM REPROD, V8, P2211; Bischoff FZ, 2000, HUM REPROD UPDATE, V6, P37, DOI 10.1093/humupd/6.1.37; Bischoff FZ, 2002, FERTIL STERIL, V77, pS17, DOI 10.1016/S0015-0282(01)03059-X; Blumenfeld Z, 2004, FERTIL STERIL, V81, P487, DOI 10.1016/j.fertnstert.2003.07.038; Blumenthal RD, 2000, AM J PATHOL, V156, P1581, DOI 10.1016/S0002-9440(10)65030-4; Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7; Brosens I, 2004, FERTIL STERIL, V81, P1198, DOI 10.1016/j.fertnstert.2003.09.071; Bulun SE, 2000, HUM REPROD UPDATE, V6, P413, DOI 10.1093/humupd/6.5.413; Bulun SE, 2000, TRENDS ENDOCRIN MET, V11, P22, DOI 10.1016/S1043-2760(99)00216-7; CANDIANI GB, 1991, OBSTET GYNECOL, V77, P421; Chegini N, 2002, FRONT BIOSCI-LANDMRK, V7, pE91, DOI 10.2741/chegini; CHWALISZ K, 2001, ANN NY ACAD SCI, V955, P373; Clauw DJ, 1997, NEUROIMMUNOMODULAT, V4, P134, DOI 10.1159/000097332; CRAMER DW, 1987, ENDOMETRIOSIS, P5; Cullinan EB, 1996, P NATL ACAD SCI USA, V93, P3115, DOI 10.1073/pnas.93.7.3115; de Boer EJ, 2003, HUM REPROD, V18, P1544, DOI 10.1093/humrep/deg278; de la Cuesta RS, 2004, EUR J OBSTET GYN R B, V113, P87, DOI 10.1016/S0301-2115(03)00367-1; DEATON JL, 1990, FERTIL STERIL, V54, P1083; DEVEROEY P, 2004, J GYNECOL OBST BIO R, V32, pS42; DHooghe TM, 1997, FERTIL STERIL, V68, P613, DOI 10.1016/S0015-0282(97)00277-X; DLUGI AM, 1990, FERTIL STERIL, V54, P419; Dogan S, 2004, FERTIL STERIL, V81, P1411, DOI 10.1016/j.fertnstert.2003.10.026; Donnez J, 2003, ANN NY ACAD SCI, V997, P274, DOI 10.1196/annals.1290.031; Donnez J, 2004, BEST PRACT RES CL OB, V18, P329; Donnez J, 1998, HUM REPROD, V13, P1686, DOI 10.1093/humrep/13.6.1686; Eskenazi B, 2002, ENVIRON HEALTH PERSP, V110, P629, DOI 10.1289/ehp.02110629; EVERS JLH, 1989, FERTIL STERIL, V52, P906; FANTON JW, 1991, RADIAT RES, V126, P141, DOI 10.2307/3577812; FEDELE L, 1992, FERTIL STERIL, V58, P28; Garcia-Velasco JA, 2004, FERTIL STERIL, V81, P1194, DOI 10.1016/j.fertnstert.2003.04.006; Garcia-Velasco JA, 2003, SEMIN REPROD MED, V21, P165; Gazvani R, 2002, REPRODUCTION, V123, P217, DOI 10.1530/rep.0.1230217; Gibbons WE, 2004, FERTIL STERIL, V81, P1204, DOI 10.1016/j.fertnstert.2003.10.031; GIUDICE LC, 2002, MOL BIOL REPROD MED, P439; GLEICHER N, 1987, OBSTET GYNECOL, V70, P115; Gogusev J, 1999, HUM GENET, V105, P444, DOI 10.1007/s004390051129; GROSSKINSKY CM, 1993, BAILLIERE CLIN OB GY, V7, P701, DOI 10.1016/S0950-3552(05)80459-6; Hadfield R, 1996, HUM REPROD, V11, P878; Hadfield RM, 1997, FERTIL STERIL, V68, P941, DOI 10.1016/S0015-0282(97)00359-2; HAHN DW, 1986, AM J OBSTET GYNECOL, V155, P1109, DOI 10.1016/0002-9378(86)90360-1; HALME J, 1984, OBSTET GYNECOL, V64, P151; Hornstein MD, 1997, HUM REPROD, V12, P143, DOI 10.1093/humrep/12.1.143; Hornung D, 2000, J CLIN ENDOCR METAB, V85, P2604, DOI 10.1210/jc.85.7.2604; Hornung D, 2003, GYNECOL OBSTET INVES, V55, P20, DOI 10.1159/000068952; Hornung D, 2001, J CLIN ENDOCR METAB, V86, P3108, DOI 10.1210/jc.86.7.3108; HOUSTON DE, 1984, EPIDEMIOL REV, V6, P167, DOI 10.1093/oxfordjournals.epirev.a036270; HUGHES E, 2000, COCHRANE LIB; HUGHES EG, 1993, FERTIL STERIL, V59, P963; Illera MJ, 2000, FERTIL STERIL, V74, P41, DOI 10.1016/S0015-0282(00)00552-5; JANSEN RPS, 1986, FERTIL STERIL, V46, P141; Jiang XX, 1996, CANCER RES, V56, P3534; Jimbo H, 1997, AM J PATHOL, V150, P1173; Jimbo H, 1997, INT J GYNECOL OBSTET, V59, P245, DOI 10.1016/S0020-7292(97)00238-5; Kao LC, 2003, ENDOCRINOLOGY, V144, P2870, DOI 10.1210/en.2003-0043; Kennedy S, 2003, SEMIN REPROD MED, V21, P111; KENNEDY S, 1995, J ASSIST REPROD GEN, V12, P32, DOI 10.1007/BF02214126; Kennedy S, 2001, HUM REPROD UPDATE, V7, P411, DOI 10.1093/humupd/7.4.411; Koninckx PR, 1998, HUM REPROD UPDATE, V4, P741, DOI 10.1093/humupd/4.5.741; KONINCKX PR, 1994, HUM REPROD; Kosugi Y, 1999, AM J OBSTET GYNECOL, V180, P792, DOI 10.1016/S0002-9378(99)70649-6; Kuohung W, 2002, FERTIL STERIL, V78, P767, DOI 10.1016/S0015-0282(02)03342-3; Lebovic DI, 2001, FERTIL STERIL, V75, P1, DOI 10.1016/S0015-0282(00)01630-7; Lessey BA, 1996, FERTIL STERIL, V65, P477, DOI 10.1016/S0015-0282(16)58140-0; LESSEY BA, 1994, J CLIN ENDOCR METAB, V79, P643, DOI 10.1210/jc.79.2.643; LESSEY BA, 1992, J CLIN INVEST, V90, P188, DOI 10.1172/JCI115835; Lessey BA, 2000, FERTIL STERIL, V73, P1089, DOI 10.1016/S0015-0282(00)00519-7; LESSEY BA, 1989, FERTIL STERIL, V49, P229; Marcoux S, 1997, NEW ENGL J MED, V337, P217, DOI 10.1056/NEJM199707243370401; MOEN MH, 1994, ACTA OBSTET GYN SCAN, V73, P59, DOI 10.3109/00016349409013396; Moen MH, 2002, FERTIL STERIL, V78, P773, DOI 10.1016/S0015-0282(02)03336-8; MORCOS RN, 1985, FERTIL STERIL, V44, P678; Mote PA, 1999, J CLIN ENDOCR METAB, V84, P2963, DOI 10.1210/jc.84.8.2963; Mote PA, 2000, HUM REPROD, V15, P48, DOI 10.1093/humrep/15.suppl_3.48; Murray MJ, 2004, FERTIL STERIL, V81, P1333, DOI 10.1016/j.fertnstert.2003.11.030; MYERS JP, 2003, SCI CULTURE SERIES; Nakago S, 2001, MOL HUM REPROD, V7, P1079, DOI 10.1093/molehr/7.11.1079; Nap AW, 2004, BEST PRACT RES CL OB, V18, P233, DOI 10.1016/j.bpobgyn.2004.01.005; Nisolle M, 1997, FERTIL STERIL, V68, P585, DOI 10.1016/S0015-0282(97)00191-X; Noble LS, 1997, J CLIN ENDOCR METAB, V82, P600, DOI 10.1210/jc.82.2.600; Nothnick WB, 2001, FERTIL STERIL, V76, P223, DOI 10.1016/S0015-0282(01)01878-7; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; NUNLEY WC, 1980, ARCH SURG-CHICAGO, V115, P757, DOI 10.1001/archsurg.1980.01380060055015; OATA K, 1997, CANCER RES, V58, P2095; Olive DL, 2004, BEST PRACT RES CL OB, V18, P319, DOI 10.1016/j.bpobgyn.2004.03.005; Olive DL, 2002, ANN NY ACAD SCI, V955, P360, DOI 10.1111/j.1749-6632.2002.tb02797.x; OLIVE DL, 2002, OB GYN MANAGEMENT, P14; Olivennes F, 2003, J Gynecol Obstet Biol Reprod (Paris), V32, pS45; OMOEI A, 2004, J SOC GYNECOL INVEST, V11, P232; OOSTERLYNCK DJ, 1991, FERTIL STERIL, V56, P45; Oral E, 1996, FERTIL STERIL, V66, P787, DOI 10.1016/S0015-0282(16)58637-3; Osteen KG, 1999, GYNECOL OBSTET INVES, V48, P2, DOI 10.1159/000052863; Ota H, 2002, FERTIL STERIL, V78, P804, DOI 10.1016/S0015-0282(02)03344-7; Ota H, 2000, FERTIL STERIL, V74, P313, DOI 10.1016/S0015-0282(00)00638-5; Parazzini F, 1999, HUM REPROD, V14, P1332; PAULSON JD, 1991, J REPROD MED, V36, P151; Pauwels A, 2001, HUM REPROD, V16, P2050, DOI 10.1093/humrep/16.10.2050; Piva M, 2001, J CLIN ENDOCR METAB, V86, P2553, DOI 10.1210/jc.86.6.2553; Practice Comm American Soc, 2004, FERTIL STERIL, V81, P1441, DOI 10.1016/j.fertnstert.2004.01.019; PRENTICE A, 2003, COCHRANE LIB; Razzi S, 2004, BJOG-INT J OBSTET GY, V111, P182, DOI 10.1046/j.1471-0528.2003.00038.x; *REPR MED NETW, IN PRESS FERTIL STER; Rice VM, 2002, ANN NY ACAD SCI, V955, P343, DOI 10.1111/j.1749-6632.2002.tb02795.x; RIER SE, 1993, FUND APPL TOXICOL, V21, P433, DOI 10.1006/faat.1993.1119; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; SALAMANCA A, 1995, FERTIL STERIL, V64, P193, DOI 10.1016/S0015-0282(16)57680-8; Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X; Sampson JA, 1922, BOSTON MED SURG J, V186, P445, DOI 10.1056/NEJM192204061861401; Santanam N, 2002, ANN NY ACAD SCI, V955, P183, DOI 10.1111/j.1749-6632.2002.tb02779.x; SCHENKEN RS, 1980, FERTIL STERIL, V34, P581; Sensky T E, 1980, Int J Gynaecol Obstet, V17, P573; Sharpe RM, 2002, NAT MED, V8, P33; Sharpe-Timms KL, 1998, BIOL REPROD, V58, P988, DOI 10.1095/biolreprod58.4.988; Sharpe-Timms KL, 2002, FERTIL STERIL, V78, P810, DOI 10.1016/S0015-0282(02)03317-4; Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112; Shippen ER, 2004, FERTIL STERIL, V81, P1395, DOI 10.1016/j.fertnstert.2003.11.027; SIMPSON JL, 1980, AM J OBSTET GYNECOL, V137, P327, DOI 10.1016/0002-9378(80)90917-5; Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715; Soysal S, 2004, HUM REPROD, V19, P160, DOI 10.1093/humrep/deh035; Stefanson H, 2002, HUM REPROD, V17, P555, DOI 10.1093/humrep/17.3.555; STEINLEITNER A, 1990, FERTIL STERIL, V53, P926; Stokstad E, 2004, SCIENCE, V304, P1892, DOI 10.1126/science.304.5679.1892; Sugawara J, 1997, FERTIL STERIL, V68, P468, DOI 10.1016/S0015-0282(97)00226-4; Surrey ES, 2003, OBSTET GYN CLIN N AM, V30, P193, DOI 10.1016/S0889-8545(02)00061-X; Swiersz LM, 2002, ANN NY ACAD SCI, V955, P281, DOI 10.1111/j.1749-6632.2002.tb02788.x; Tabibzadeh S, 2000, J CLIN ENDOCR METAB, V85, P2526, DOI 10.1210/jc.85.7.2526; Takayama K, 1998, FERTIL STERIL, V69, P709, DOI 10.1016/S0015-0282(98)00022-3; TAKETANI Y, 1992, AM J OBSTET GYNECOL, V167, P265, DOI 10.1016/S0002-9378(11)91672-X; Tamura M, 1998, LAB INVEST, V78, P213; Taylor HS, 1999, HUM REPROD, V14, P1328, DOI 10.1093/humrep/14.5.1328; TAYLOR RN, 2001, ANN NY ACAD SCI, V955, P89; Telimaa S, 1987, Gynecol Endocrinol, V1, P13, DOI 10.3109/09513598709082692; TOKI T, 1997, GYNECOL OBSTET IN S1, V50, P33; Treloar S, 2002, FERTIL STERIL, V78, P679, DOI 10.1016/S0015-0282(02)03341-1; Treloar SA, 1999, FERTIL STERIL, V71, P701, DOI 10.1016/S0015-0282(98)00540-8; Tummon IS, 1997, FERTIL STERIL, V68, P8, DOI 10.1016/S0015-0282(97)81467-7; Valle RF, 2003, ANN NY ACAD SCI, V997, P229, DOI 10.1196/annals.1290.026; Van Gorp T, 2004, BEST PRACT RES CL OB, V18, P349, DOI 10.1016/j.bpobgyn.2003.03.001; Van Langendonckt A, 2002, FERTIL STERIL, V77, P861, DOI 10.1016/S0015-0282(02)02959-X; Vercellini P, 2004, J AM ASSOC GYN LAP, V11, P153, DOI 10.1016/S1074-3804(05)60190-9; VERCELLINI P, 1993, AM J OBSTET GYNECOL, V169, P181, DOI 10.1016/0002-9378(93)90159-G; VERNON MW, 1985, FERTIL STERIL, V44, P684; Vigano Paola, 2003, Curr Opin Investig Drugs, V4, P1209; von Rokitansky C., 1860, Z GESELLSCHAFT AERZT, V37, P577; Wang YD, 2004, FRONT BIOSCI, V9, P540, DOI 10.2741/1186; Weiss HA, 1999, INT J EPIDEMIOL, V28, P816, DOI 10.1093/ije/28.5.816; WELSHONS WV, 2003, ENV HLTH PERSPECT, V222, P994; WILD RA, 1985, AM J REPROD IM MIC, V8, P84; Witz CA, 2002, FERTIL STERIL, V78, P796, DOI 10.1016/S0015-0282(02)03340-X; Witz CA, 1999, FERTIL STERIL, V71, P56, DOI 10.1016/S0015-0282(98)00400-2; Witz CA, 1999, CLIN OBSTET GYNECOL, V42, P566, DOI 10.1097/00003081-199909000-00013; Witz CA, 2000, FERTIL STERIL, V74, P579, DOI 10.1016/S0015-0282(00)00701-9; WYSHAK G, 1989, INT J DERMATOL, V28, P527, DOI 10.1111/j.1365-4362.1989.tb04606.x; Zeitoun K, 1998, J CLIN ENDOCR METAB, V83, P4474, DOI 10.1210/jc.83.12.4474; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; Zeitoun KM, 1999, FERTIL STERIL, V72, P961, DOI 10.1016/S0015-0282(99)00393-3; Zondervan KT, 2004, HUM REPROD, V19, P448, DOI 10.1093/humrep/deh052; Zondervan KT, 2002, HUM REPROD, V17, P1415, DOI 10.1093/humrep/17.6.1415	167	2287	2406	19	451	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1789	1799		10.1016/S0140-6736(04)17403-5	http://dx.doi.org/10.1016/S0140-6736(04)17403-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541453				2022-12-28	WOS:000225070600033
J	McKenzie, K; Patel, V; Araya, R				McKenzie, K; Patel, V; Araya, R			Learning from low income countries: mental health	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; DEPRESSION; SCHIZOPHRENIA		UCL Royal Free & Univ Coll Med Sch, London NW3 2PF, England; Barnet Enfield & Haringey Mental Hlth NHS Trust, Dept Mental Hlth Sci, London NW3 2PF, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Cotham House, Div Psychiat, Bristol BS6 6JL, Avon, England	University of London; University College London; UCL Medical School; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of Bristol	McKenzie, K (corresponding author), UCL Royal Free & Univ Coll Med Sch, London NW3 2PF, England.	k.mckenzie@rfc.ucl.ac.uk	Araya, Ricardo/S-3144-2019	Araya, Ricardo/0000-0002-0420-5148; mckenzie, kwame/0000-0001-6419-8130; Patel, Vikram/0000-0003-1066-8584				Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; BECKER AE, 2002, WORLD MENTAL HLTH CA; Chatterjee S, 2003, BRIT J PSYCHIAT, V182, P57, DOI 10.1192/bjp.182.1.57; *GUIA CLIN AT PRIM, 2002, PROGR DIAGN TRAT INT; Hickling FW, 2000, PSYCHIATR SERV, V51, P659, DOI 10.1176/appi.ps.51.5.659; KLEINMAN A, 1995, WORLD MENTAL HLTH PR; Lee DTS, 2004, BRIT J PSYCHIAT, V184, P34, DOI 10.1192/bjp.184.1.34; MACARTHUR C, 2003, HEALTH TECHNOL ASSES, V7, P37; Ustun TB, 2004, BRIT J PSYCHIAT, V184, P386, DOI 10.1192/bjp.184.5.386; Wells K, 2004, ARCH GEN PSYCHIAT, V61, P378, DOI 10.1001/archpsyc.61.4.378; WHO, 2001, WORLD HLTH REPORT 20	11	41	41	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1138	1140		10.1136/bmj.329.7475.1138	http://dx.doi.org/10.1136/bmj.329.7475.1138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	871XJ	15539667	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000225169600018
J	Willcox, ML; Bodeker, G				Willcox, ML; Bodeker, G			Traditional herbal medicines for malaria	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHLOROQUINE; EFFICACY; TRIAL		Res Initiat Tradit Antimalarial Methods, Buckingham MK18 7EW, England; Univ Oxford, John Radcliffe Hosp, Div Med Sci, Med Sci Off, Oxford OX3 9DU, England	University of Oxford; University of Oxford	Willcox, ML (corresponding author), Res Initiat Tradit Antimalarial Methods, Buckingham MK18 7EW, England.	merlinwillcox@doctors.org.uk	Willcox, Merlin/I-6255-2019	Willcox, Merlin/0000-0002-5227-3444				Benoit-Vical F, 2003, J ETHNOPHARMACOL, V89, P111, DOI 10.1016/S0378-8741(03)00277-0; Bodeker G, 2000, J ALTERN COMPLEM MED, V6, P127, DOI [10.1089/acm.2000.6.127, 10.1089/acm.2000.6.195]; Bruhn JG, 1981, P INT S E W MED SEOU, P405; *CENTR COUNC RES A, 1987, AYUSH 64 NEW ANT HER; Guindo M, 1988, THESIS NATL SCH MED; Kidane G, 2000, LANCET, V356, P550, DOI 10.1016/S0140-6736(00)02580-0; KOITA N, 1991, P INT C EXP DEV COUN; Leaman DJ, 1995, J ETHNOPHARMACOL, V49, P1, DOI 10.1016/0378-8741(95)01289-3; Mueller MS, 2004, T ROY SOC TROP MED H, V98, P318, DOI 10.1016/j.trstmh.2003.09.001; THIOMBIANO A, 1991, SEM CREDES PAR 4 9 N; TSU CF, 1947, TROP MED HYG, V50, P75; Valecha N, 2000, CURR SCI INDIA, V78, P1120; Wan Y D, 1992, Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi, V10, P290; WHO, 2003, ASS MON ANT DRUG EFF; Willcox M, 2004, TRADITIONAL MED PLAN; Williams MS, 2001, GENET MED, V3, P318, DOI 10.1097/00125817-200107000-00010	16	202	206	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1156	1159		10.1136/bmj.329.7475.1156	http://dx.doi.org/10.1136/bmj.329.7475.1156			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539672	Green Published			2022-12-28	WOS:000225169600023
J	Adams, WM; Aveling, R; Brockington, D; Dickson, B; Elliott, J; Hutton, J; Roe, D; Vira, B; Wolmer, W				Adams, WM; Aveling, R; Brockington, D; Dickson, B; Elliott, J; Hutton, J; Roe, D; Vira, B; Wolmer, W			Biodiversity conservation and the eradication of poverty	SCIENCE			English	Review							COSTS; ECOLOGY	It is widely accepted that biodiversity loss and poverty are linked problems and that conservation and poverty reduction should be tackled together. However, success with integrated strategies is elusive. There is sharp debate about the social impacts of conservation programs and the success of community-based approaches to conservation. Clear conceptual frameworks are needed if policies in these two areas are to be combined. We review the links between poverty alleviation and biodiversity conservation and present a conceptual typology of these relationships.	Univ Cambridge, Dept Geog, Cambridge CB2 3EN, England; Fauna & Flora Int, Cambridge CB1 2RS, England; Univ Oxford, Sch Geog & Environm, Oxford OX1 3TB, England; Resource Africa, Cambridge CB3 0TF, England; Dept Int Dev, London SW1E 5HE, England; Int Inst Environm & Dev, London WC1H 0DD, England; Univ Sussex, Inst Dev Studies, Brighton BN1 9RE, E Sussex, England	University of Cambridge; University of Oxford; University of Sussex	Adams, WM (corresponding author), Univ Cambridge, Dept Geog, Downing Pl, Cambridge CB2 3EN, England.		Brockington, Dan/AAK-9065-2021; /ADO-3246-2022	Brockington, Dan/0000-0001-5692-0154; Roe, Dilys/0000-0002-6547-6427; Adams, William/0000-0002-1559-0379				Adams W.M., 2004, EXTINCTION STORY CON, DOI 10.4324/9781849770415; Adams William, 2001, GREEN DEV ENV SUSTAI; [Anonymous], 2000, DEV FREEDOM; Balmford A, 2003, ORYX, V37, P238, DOI 10.1017/S0030605303000413; Balmford A, 2002, SCIENCE, V297, P950, DOI 10.1126/science.1073947; BARRETT CB, 1995, WORLD DEV, V23, P1073, DOI 10.1016/0305-750X(95)00031-7; Berkes F, 2004, CONSERV BIOL, V18, P621, DOI 10.1111/j.1523-1739.2004.00077.x; BOJO J, 2002, 86 WORLD BANK ENV DE; Brockington D, 2004, ORYX, V38, P140, DOI 10.1017/S0030605304000250; Brockington D., 2003, POLICY MATTERS, V12; Brockington Dan, 2002, FORTRESS CONSERVATIO; Bruner AG, 2001, SCIENCE, V291, P125, DOI 10.1126/science.291.5501.125; Campbell B.M., 2002, PEOPLE PLANTS CONSER; COLCHESTER M, 2002, SALVAGING NATURE IND; Daily GC, 1997, NATURES SERVICES SOC, DOI DOI 10.12987/9780300188479-039; DASMANN R, 1973, ECOLOGICAL PRINCIPLE; Ferraro PJ, 2002, SCIENCE, V298, P1718, DOI 10.1126/science.1078104; FORTWANGLER CL, 2003, CONTESTED NATURE PRO, P25; FRANKS T, 2003, ISSUES NAT RESOUR MA, V1, P2; Geisler C, 2001, PUBLIC ADMIN DEVELOP, V21, P159, DOI 10.1002/pad.158; GEISLER C, CONTESTED NATURE PRO, P217; Gossling S, 1999, ECOL ECON, V29, P303, DOI 10.1016/S0921-8009(99)00012-9; Hutton JM, 2003, ORYX, V37, P215, DOI 10.1017/S0030605303000395; Imhoff ML, 2004, NATURE, V429, P870, DOI 10.1038/nature02619; IUCN, 2002, RHET PUTT CONS WORK; Jones B., 2001, AFRICAN WILDLIFE LIV; Kepe T, 2004, ORYX, V38, P143, DOI 10.1017/S0030605304000262; Koziell I., 2001, LIVING OFF BIODIVERS; *LIV WILDL ADV GRO, 2002, WILDL POV STUD; Margules CR, 2000, NATURE, V405, P243, DOI 10.1038/35012251; Murombedzi J. C., 1999, Journal of International Development, V11, P287, DOI 10.1002/(SICI)1099-1328(199903/04)11:2&lt;287::AID-JID584&gt;3.0.CO;2-M; NORTONGRIFFITHS M, 1995, ECOL ECON, V12, P125, DOI 10.1016/0921-8009(94)00041-S; Oates J. F., 1999, MYTH REALITY RAIN FO; Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786; PHILLIPS A, 2002, G WRIGHT FORUM, V20, P8; Pimbert M. P., 1997, SOCIAL CHANGE CONSER; RAMPHAL S, 1993, 4 WORLD C NAT PARKS, P56; Rees W.E., 1996, OUR ECOLOGICAL FOOTP; Rodrigues ASL, 2004, NATURE, V428, P640, DOI 10.1038/nature02422; Roe D, 2004, ORYX, V38, P137, DOI 10.1017/S0030605304000249; ROE D, 2003, POLICY MATTERS, V12, P52; Roe D., 2003, MILLENNIUM DEV GOALS, P55; Sanderson S, 2004, ORYX, V38, P146, DOI 10.1017/S0030605304000274; Sanderson SE, 2003, ORYX, V37, P389, DOI 10.1017/S003060530300070X; Steiner A, 2003, NEW SCI, V180, P21; TERBORGH J, 1999, REQUIEM NATURE; WELLS M, 1992, AMBIO, V21, P237; Wells M., 1992, PEOPLE PARKS LINKING; WILKIE DS, 1999, ORYX, V3, P338; Wilshusen PR, 2002, SOC NATUR RESOUR, V15, P17, DOI 10.1080/089419202317174002; World Bank, 1992, WORLD DEV REP 1992 D	51	722	773	10	440	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1146	1149		10.1126/science.1097920	http://dx.doi.org/10.1126/science.1097920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	872FM	15539593				2022-12-28	WOS:000225193100036
J	Omary, MB; Coulombe, PA; McLean, WHI				Omary, MB; Coulombe, PA; McLean, WHI			Mechanisms of disease: Intermediate filament proteins and their associated diseases	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EPIDERMOLYSIS-BULLOSA SIMPLEX; LAMIN A/C GENE; MARIE-TOOTH-DISEASE; POINT MUTATIONS; HEAD DOMAIN; DESMIN; MICE; CYTOSKELETON; EXPRESSION; KERATIN-8		Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Palo Alto, CA 94304 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA; Univ Dundee, Ninewells Hosp & Med Sch, Human Genet Unit, Dundee DD1 9SY, Scotland	US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Johns Hopkins University; Johns Hopkins University; University of Dundee	Omary, MB (corresponding author), Vet Affairs Med Ctr, Dept Med, 3801 Miranda Ave,Mail Code 154J, Palo Alto, CA 94304 USA.		McLean, William HI/C-6352-2009	Omary, Bishr/0000-0002-8624-2347; McLean, William Henry Irwin/0000-0001-5539-5757	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042047, R55AR042047, R01AR044232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047918, R01DK052951] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44232, AR42047] Funding Source: Medline; NIDDK NIH HHS [DK47918, DK52951] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Chalabi A, 2003, BIOESSAYS, V25, P346, DOI 10.1002/bies.10251; ALBERS K, 1987, J CELL BIOL, V105, P791, DOI 10.1083/jcb.105.2.791; Ameen NA, 2001, J CELL SCI, V114, P563; ANTONLAMPRECHT I, 1982, DERMATOLOGICA, V164, P221, DOI 10.1159/000250096; Ausmees N, 2003, CELL, V115, P705, DOI 10.1016/S0092-8674(03)00935-8; BARIBAULT H, 1994, GENE DEV, V8, P2964, DOI 10.1101/gad.8.24.2964; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Brenner M, 2001, NAT GENET, V27, P117, DOI 10.1038/83679; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; Cao TY, 2001, J CELL BIOL, V152, P651, DOI 10.1083/jcb.152.3.651; Cavestro GM, 2003, DIGEST LIVER DIS, V35, P416, DOI 10.1016/S1590-8658(03)00159-2; Chapalain V, 2002, ARCH DERMATOL, V138, P501, DOI 10.1001/archderm.138.4.501; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; Conley YP, 2000, AM J HUM GENET, V66, P1426, DOI 10.1086/302871; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Csoka AB, 2004, J MED GENET, V41, P304, DOI 10.1136/jmg.2003.015651; D'Alessandro M, 2004, GENE THER, V11, P1290, DOI 10.1038/sj.gt.3302301; D'Alessandro M, 2002, J CELL SCI, V115, P4341, DOI 10.1242/jcs.00120; Dalakas MC, 2000, NEW ENGL J MED, V342, P770, DOI 10.1056/NEJM200003163421104; De Sandre-Giovannoli A, 2003, SCIENCE, V300, P2055, DOI 10.1126/science.1084125; De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274; Denk H, 2000, J HEPATOL, V32, P689, DOI 10.1016/S0168-8278(00)80233-0; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P17381, DOI 10.1074/jbc.C200038200; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; Erber A, 1998, J MOL EVOL, V47, P751, DOI 10.1007/PL00006434; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Fatkin D, 1999, NEW ENGL J MED, V341, P1715, DOI 10.1056/NEJM199912023412302; Fickert P, 2003, J HEPATOL, V38, P387, DOI 10.1016/S0168-8278(02)00439-7; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Garg A, 2004, NEW ENGL J MED, V350, P1220, DOI 10.1056/NEJMra025261; Gilbert S, 2004, MOL CELL BIOL, V24, P7072, DOI 10.1128/MCB.24.16.7072-7081.2004; Goebel HH, 2003, MUSCLE NERVE, V27, P527, DOI 10.1002/mus.10322; Grant P, 2000, J NEUROCYTOL, V29, P843, DOI 10.1023/A:1010999509251; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; GROSLOUIS F, IN PRESS J BIOL CHEM; Hegele RA, 2003, NAT MED, V9, P644, DOI 10.1038/nm0603-644; Helfand BT, 2003, ANNU REV CELL DEV BI, V19, P445, DOI 10.1146/annurev.cellbio.19.111401.092306; Herrmann H, 2003, INT REV CYTOL, V223, P83; Hesse M, 2001, J CELL SCI, V114, P2569; Hoffmann K, 2002, NAT GENET, V31, P410, DOI 10.1038/ng925; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; Hutchison CJ, 2002, NAT REV MOL CELL BIO, V3, P848, DOI 10.1038/nrm950; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jakobs PM, 2000, AM J HUM GENET, V66, P1432, DOI 10.1086/302872; Jefferson JJ, 2004, NAT REV MOL CELL BIO, V5, P542, DOI 10.1038/nrm1425; Jonkman MF, 1996, J INVEST DERMATOL, V107, P764, DOI 10.1111/1523-1747.ep12365805; Jonkman MF, 1999, J DERMATOL SCI, V20, P103, DOI 10.1016/S0923-1811(99)00017-1; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Kirfel J, 2002, DIFFERENTIATION, V70, P56, DOI 10.1046/j.1432-0436.2002.700106.x; Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455; Krimm I, 2002, STRUCTURE, V10, P811, DOI 10.1016/S0969-2126(02)00777-3; Ku NO, 1999, AM J PHYSIOL-GASTR L, V277, pG1108, DOI 10.1152/ajpgi.1999.277.6.G1108; Ku NO, 2003, P NATL ACAD SCI USA, V100, P6063, DOI 10.1073/pnas.0936165100; Ku NO, 2003, HEPATOLOGY, V37, P1006, DOI 10.1053/jhep.2003.50181; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; Lariviere RC, 2004, J NEUROBIOL, V58, P131, DOI 10.1002/neu.10270; Leers MPG, 2002, J CLIN PATHOL, V55, P359, DOI 10.1136/jcp.55.5.359; Li R, 2002, INT J DEV NEUROSCI, V20, P259, DOI 10.1016/S0736-5748(02)00019-9; Lloyd DJ, 2002, HUM MOL GENET, V11, P769, DOI 10.1093/hmg/11.7.769; Ma LL, 2001, NAT CELL BIOL, V3, P503, DOI 10.1038/35074576; McGowan KM, 2002, GENE DEV, V16, P1412, DOI 10.1101/gad.979502; Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962; Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283; Moll R, 1998, Subcell Biochem, V31, P205; Mounkes LC, 2003, NATURE, V423, P298, DOI 10.1038/nature01631; Muchir A, 2003, EXP CELL RES, V291, P352, DOI 10.1016/j.yexcr.2003.07.002; Munoz-Marmol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312; Novelli G, 2003, TRENDS MOL MED, V9, P370, DOI 10.1016/S1471-4914(03)00162-X; Novelli G, 2002, AM J HUM GENET, V71, P426, DOI 10.1086/341908; Oshima RG, 2002, CELL DEATH DIFFER, V9, P486, DOI 10.1038/sj.cdd.4400988; Owens DW, 2004, J CELL SCI, V117, P1989, DOI 10.1242/jcs.01043; Perez-Olle R, 2004, HUM MOL GENET, V13, P2207, DOI 10.1093/hmg/ddh236; Porter RM, 2003, TRENDS GENET, V19, P278, DOI 10.1016/S0168-9525(03)00071-4; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; TANIURA H, 1995, J CELL BIOL, V131, P33, DOI 10.1083/jcb.131.1.33; Terron-Kwiatkowski A, 2002, J INVEST DERMATOL, V119, P966, DOI 10.1046/j.1523-1747.2002.00186.x; Toivola DA, 2004, HEPATOLOGY, V40, P459, DOI 10.1002/hep.20277; Toivola DM, 2004, J CELL BIOL, V164, P911, DOI 10.1083/jcb.200308103; Uitto J, 2003, TRENDS MOL MED, V9, P339, DOI 10.1016/S1471-4914(03)00137-0; Uttam J, 1996, P NATL ACAD SCI USA, V93, P9079, DOI 10.1073/pnas.93.17.9079; van der Kooi AJ, 2002, NEUROLOGY, V59, P620, DOI 10.1212/WNL.59.4.620; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101; Werner NS, 2004, MOL BIOL CELL, V15, P990, DOI 10.1091/mbc.E03-09-0687; Wiche G, 1998, J CELL SCI, V111, P2477; Winter H, 2004, J INVEST DERMATOL, V122, P652, DOI 10.1111/j.0022-202X.2004.22309.x; Winter H, 1997, NAT GENET, V16, P372, DOI 10.1038/ng0897-372; Wong P, 2003, J CELL BIOL, V163, P327, DOI 10.1083/jcb.200305032; Worman HJ, 2004, J CLIN INVEST, V113, P349, DOI 10.1172/JCI200420832; Zastrow MS, 2004, J CELL SCI, V117, P979, DOI 10.1242/jcs.01102; Zhong BH, 2004, J CELL SCI, V117, P1709, DOI 10.1242/jcs.01016; Zhou Q, 2003, MOL BIOL CELL, V14, P2959, DOI 10.1091/mbc.E03-02-0059; Zobel ATC, 2003, HUM MOL GENET, V12, P1609, DOI 10.1093/hmg/ddg173	104	372	378	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2087	2100		10.1056/NEJMra040319	http://dx.doi.org/10.1056/NEJMra040319			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537907				2022-12-28	WOS:000225007200010
J	Bakris, GL; Fonseca, V; Katholi, RE; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT; Oakes, R; Lukas, MA; Anderson, KM; Bell, DSH				Bakris, GL; Fonseca, V; Katholi, RE; McGill, JB; Messerli, FH; Phillips, RA; Raskin, P; Wright, JT; Oakes, R; Lukas, MA; Anderson, KM; Bell, DSH		GEMINI Investigators	Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONVERTING-ENZYME-INHIBITION; CARDIOVASCULAR MORTALITY; BLOOD-PRESSURE; ANTIHYPERTENSIVE DRUGS; OXIDATIVE STRESS; LIPID-METABOLISM; RISK-FACTORS; DISEASE; MICROALBUMINURIA; INTERVENTION	Context beta-Blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however, some components of the metabolic syndrome are worsened by some beta-blockers. Objective To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors. Design, Setting, and Participants A randomized, double-blind, parallel-group trial (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives [GEMINI]) conducted between June 1, 2001, and April 6, 2004, at 205 US sites that compared the effects of carvedilol and metoprolol tartrate on glycemic control. The 1235 participants were aged 36 to 85 years with hypertension (>130/80 mm Hg) and type 2 DM (glycosylated hemoglobin [HbA(1c)], 6.5%-8.5%) and were receiving RAS blockers. Participants were followed up for 35 weeks. Interventions Participants were randomized to receive a 6.25- to 25-mg dose of carvedilol (n=498)or 50- to 200-mg dose of metoprolol tartrate (n=737),each twice daily. open-label hydrochlorothiazide and a dihydropyridine calcium antagonist were added, if needed, to achieve blood pressure target. Main Outcome Measures Difference between groups in mean change from baseline HbA(1c) following 5 months of maintenance therapy. Additional prespecified comparisons included change from baseline HbA(1c) in individual treatment groups, treatment effect on insulin sensitivity, and microalbuminuria. Results The 2 groups differed in mean change in HbA(1c) from baseline (0.13%; 95% confidence interval [CI],-0.22% to-0.04%; P=.004; modified intention-to-treat analysis). The mean (SD) HbA(1c) increased with metoprolol (0.15% [0.04%]; P<.001) but not carvedilol (0.02% [0.04%]; P=.65). Insulin sensitivity improved with carvedilol (-9.1%; P=.004) but not metoprolol (-2.0%; P=.48); the between-group difference was -7.2% (95% CI, -13.8% to -0.2%; P=.004). Blood pressure was similar between groups. Progression to microalbuminuria was less frequent with carvedilol than with metoprolol (6.4% vs 10.3%; odds ratio, 0.60; 95% CI, 0.36-0.97; P=.04). Conclusions Both beta-blockers were well tolerated; use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension. The effects of the 2 beta-blockers on clinical outcomes need to be compared in long-term clinical trials.	Univ Alabama Birmingham, Birmingham, AL 35294 USA; Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL USA; Tulane Univ, Dept Med, New Orleans, LA 70118 USA; St Johns Hosp, Dept Med, Springfield, IL USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; St Lukes Roosevelt Hosp, Dept Med, New York, NY 10025 USA; Mt Sinai Sch Med, Dept Med, New York, NY USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX USA; Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Dept Med, Cleveland, OH USA; GlaxoSmithKline, Philadelphia, PA USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; Rush University; Tulane University; Washington University (WUSTL); Mount Sinai St. Luke's; Mount Sinai West; Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University Hospitals of Cleveland; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; GlaxoSmithKline; University of Alabama System; University of Alabama Birmingham	Bell, DSH (corresponding author), Univ Alabama Birmingham, Room 702,Fac Off Tower 510,20th St S, Birmingham, AL 35294 USA.	dshbell@uab.edu	Messerli, Franz/AAR-4783-2021	Patt, Mitchell/0000-0001-9696-4477; Katholi, Richard/0000-0002-5625-7417	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR005096] Funding Source: NIH RePORTER	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arauz-Pacheco C, 2002, DIABETES CARE, V25, P134, DOI 10.2337/diacare.25.1.134; BAKRIS G, IN PRESS J DIAB COMP; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Colagiuri S, 2002, DIABETES CARE, V25, P1378, DOI 10.2337/diacare.25.8.1378; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; DORNHORST A, 1985, LANCET, V1, P123; Ehmer B, 1988, Drugs, V36 Suppl 6, P136; FEHER M, 1990, J HUM HYPERTENS, V4, P7; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Galletti F, 1999, J HYPERTENS, V17, P439, DOI 10.1097/00004872-199917030-00018; Garg JP, 2002, VASC MED, V7, P35, DOI 10.1191/1358863x02vm412ra; GIORDANO M, 1995, DIABETES, V44, P665, DOI 10.2337/diabetes.44.6.665; Giugliano D, 1997, ANN INTERN MED, V126, P955, DOI 10.7326/0003-4819-126-12-199706150-00004; Giugliano D, 1998, DIABETES CARE, V21, P631, DOI 10.2337/diacare.21.4.631; Haffner SM, 1996, DIABETES CARE, V19, P1138, DOI 10.2337/diacare.19.10.1138; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; HAWKINS CM, 1983, CIRCULATION, V67, P94; Holzgreve H, 2003, AM J HYPERTENS, V16, P381, DOI 10.1016/S0895-7061(03)00062-1; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Khaw KT, 2004, ANN INTERN MED, V141, P413, DOI 10.7326/0003-4819-141-6-200409210-00006; Khaw KT, 2001, BMJ-BRIT MED J, V322, P15, DOI 10.1136/bmj.322.7277.15; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; Manley S, 2003, CLIN CHEM LAB MED, V41, P1182, DOI 10.1515/CCLM.2003.182; Ostman J, 1998, J INTERN MED, V244, P95; Packer M, 2003, J CARD FAIL, V9, P429, DOI 10.1016/j.cardfail.2003.08.003; Pedrinelli R, 2002, J HUM HYPERTENS, V16, P79, DOI 10.1038/sj.jhh.1001316; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; Saydah SH, 2004, JAMA-J AM MED ASSOC, V291, P335, DOI 10.1001/jama.291.3.335; Song SH, 2004, DIABETIC MED, V21, P238, DOI 10.1111/j.1464-5491.2004.01116.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stuveling EM, 2004, HYPERTENSION, V43, P791, DOI 10.1161/01.HYP.0000120125.08867.42; Wright JT, 2002, JAMA-J AM MED ASSOC, V288, P2421, DOI 10.1001/jama.288.19.2421; Yasunari K, 2004, AM J MED, V116, P460, DOI 10.1016/j.amjmed.2003.10.029; Yasunari K, 2002, HYPERTENS RES, V25, P419, DOI 10.1291/hypres.25.419; Yuyun MF, 2004, INT J EPIDEMIOL, V33, P189, DOI 10.1093/ije/dyh008; 2004, DIABETES CARE S1, V27, pS1	38	570	613	2	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2227	2236		10.1001/jama.292.18.2227	http://dx.doi.org/10.1001/jama.292.18.2227			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536109	Bronze			2022-12-28	WOS:000225070000023
J	Leinders-Zufall, T; Brennan, P; Widmayer, P; Chandramani, P; Maul-Pavicic, A; Jager, M; Li, XH; Breer, H; Zufall, F; Boehm, T				Leinders-Zufall, T; Brennan, P; Widmayer, P; Chandramani, P; Maul-Pavicic, A; Jager, M; Li, XH; Breer, H; Zufall, F; Boehm, T			MHC class I peptides as chemosensory signals in the vomeronasal organ	SCIENCE			English	Article							ACCESSORY OLFACTORY SYSTEM; PHEROMONE RECEPTORS; SENSORY NEURONS; MUTANT MICE; MOUSE; GENES; COEXPRESSION; TRANSDUCTION; RECOGNITION; BEHAVIORS	The mammalian vomeronasal organ detects social information about gender, status, and individuality. The molecular cues carrying this information remain largely unknown. Here, we show that small peptides that serve as ligands for major histocompatibility complex (MHC) class I molecules function also as sensory stimuli for a subset of vomeronasal sensory neurons located in the basal Galphao- and V2R receptor-expressing zone of the vomeronasal epithelium. In behaving mice, the same peptides function as individuality signals underlying mate recognition in the context of pregnancy block. MHC peptides constitute a previously unknown family of chemosensory stimuli by which MHC genotypic diversity can influence social behavior.	Max Planck Inst Immunbiol, Dept Dev Immunol, D-79108 Freiburg, Germany; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England; Univ Hohenheim, Inst Physiol, D-70593 Stuttgart, Germany	Max Planck Society; University System of Maryland; University of Maryland Baltimore; University of Cambridge; University Hohenheim	Zufall, F (corresponding author), Max Planck Inst Immunbiol, Dept Dev Immunol, D-79108 Freiburg, Germany.	fzufa001@umaryland.edu; boehm@immunbio.mpg.de	Leinders-Zufall, Trese/B-4103-2009; Zufall, Frank/AAE-5290-2021; Leinders-Zufall, Trese/S-3664-2019	Leinders-Zufall, Trese/0000-0002-0678-362X; Zufall, Frank/0000-0002-4383-8618; Leinders-Zufall, Trese/0000-0002-0678-362X				Bargmann CI, 1997, CELL, V90, P585, DOI 10.1016/S0092-8674(00)80518-8; Beauchamp GK, 2003, BIOCHEM SOC T, V31, P147; Boehm T, 2003, IMMUNOL REV, V195, P15, DOI 10.1034/j.1600-065X.2003.00070.x; Boschat C, 2002, NAT NEUROSCI, V5, P1261, DOI 10.1038/nn978; Brennan PA, 2004, CURR BIOL, V14, pR81, DOI 10.1016/j.cub.2003.12.052; BRUCE HM, 1959, NATURE, V184, P105, DOI 10.1038/184105a0; Del Punta K, 2002, NATURE, V419, P70, DOI 10.1038/nature00955; Dulac C, 2003, NAT REV NEUROSCI, V4, P551, DOI 10.1038/nrn1140; He XL, 2001, STRUCTURE, V9, P1213, DOI 10.1016/S0969-2126(01)00689-X; Holy TE, 2000, SCIENCE, V289, P1569, DOI 10.1126/science.289.5484.1569; Hurst JL, 2001, NATURE, V414, P631, DOI 10.1038/414631a; Ishii T, 2003, CURR BIOL, V13, P394, DOI 10.1016/S0960-9822(03)00092-7; Lau YE, 2000, NEUROREPORT, V11, P27, DOI 10.1097/00001756-200001170-00006; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; LLOYDTHOMAS A, 1982, NEUROSCIENCE, V7, P907, DOI 10.1016/0306-4522(82)90051-3; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Lucas P, 2003, NEURON, V40, P551, DOI 10.1016/S0896-6273(03)00675-5; Luo MM, 2003, SCIENCE, V299, P1196, DOI 10.1126/science.1082133; Martini S, 2001, J NEUROSCI, V21, P843, DOI 10.1523/JNEUROSCI.21-03-00843.2001; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; OCONNELL RJ, 1984, BEHAV NEUROSCI, V98, P1083, DOI 10.1037/0735-7044.98.6.1083; Penn D, 1998, ADV IMMUNOL, V69, P411, DOI 10.1016/S0065-2776(08)60612-4; Potter SM, 2001, J NEUROSCI, V21, P9713, DOI 10.1523/JNEUROSCI.21-24-09713.2001; RAMMENSEE HG, 1997, MHC LIGANDS PEPTIDE; SINGH PB, 1987, NATURE, V327, P161, DOI 10.1038/327161a0; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Spehr M, 2002, J NEUROSCI, V22, P8429; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Wysocki C.J., 1987, P125	31	422	438	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1033	1037		10.1126/science.1102818	http://dx.doi.org/10.1126/science.1102818			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528444				2022-12-28	WOS:000225001100043
J	Shen, BZ; Goodman, HM				Shen, BZ; Goodman, HM			Uridine addition after microRNA-directed cleavage	SCIENCE			English	Article							MESSENGER-RNA; ARABIDOPSIS; TARGETS; MIRNA		Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Goodman, HM (corresponding author), Harvard Univ, Sch Med, Dept Genet, 50 Blossom St, Boston, MA 02114 USA.	goodman@motbio.mgh.harvard.edu						FURNARI FB, 1993, P NATL ACAD SCI USA, V90, P378, DOI 10.1073/pnas.90.2.378; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; SHEN B, UNPUB; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434	6	161	173	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					997	997		10.1126/science.1103521	http://dx.doi.org/10.1126/science.1103521			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528436				2022-12-28	WOS:000225001100032
J	Gournay, V; Roze, JC; Kuster, A; Daoud, P; Cambonie, G; Hascoet, JM; Chamboux, C; Blanc, T; Fichtner, C; Savagner, C; Gouyon, JB; Flurin, V; Thiriez, G				Gournay, V; Roze, JC; Kuster, A; Daoud, P; Cambonie, G; Hascoet, JM; Chamboux, C; Blanc, T; Fichtner, C; Savagner, C; Gouyon, JB; Flurin, V; Thiriez, G			Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							PATENT DUCTUS-ARTERIOSUS; LOW-BIRTH-WEIGHT; PRETERM INFANTS; INTRAVENTRICULAR HEMORRHAGE; INDOMETHACIN; PHARMACOKINETICS; PREVENTION; THERAPY; CLOSURE	Background Patent ductus arteriosus is a common complication of prematurity that frequently requires surgical or medical treatment. The benefit of prophylactic treatment by indometacin, a cyclo-oxygenase inhibitor, remains uncertain compared with curative treatment. This benefit could be improved with ibuprofen, another cyclooxygenase inhibitor with fewer adverse effects than indometacin on renal, mesenteric, and cerebral perfusion. We aimed to compare prophylactic and curative ibuprofen in the treatment of this abnormality in very premature infants. Methods We did a randomised controlled trial in infants younger than 28 weeks of gestation, who were randomly assigned to receive either three doses of ibuprofen or placebo within 6 h of birth. After day 3, symptomatic patent ductus arteriosus was treated first by open curative ibuprofen, then back-up indometacin, surgery, or both. The primary endpoint was need for surgical ligation. Analysis was per protocol. Findings The study was stopped prematurely after 135 enrolments because of three cases of severe pulmonary hypertension in the prophylactic group. 65 infants received prophylactic ibuprofen, and 66 received placebo. Prophylaxis reduced the need for surgical ligation from six (9%) to zero (p=0.03), and decreased the rate of severe intraventricular haemorrhage from 15 (23%) to seven (11%) (p=0.10). However, survival was not improved (47 [71%] placebo vs 47 [72%] treatment, p=1.00), because of high frequency of adverse respiratory, renal, and digestive events. Interpretation In premature infants, prophylactic ibuprofen reduces the need for surgical ligation of patent ductus arteriosus, but does not reduce mortality or morbidity. Therefore, it should not be preferred to early curative ibuprofen.	CHU Nantes, Hop Mere & Enfant, Serv Reanimat Pediat & Neonatale, F-44000 Nantes, France; CHU Nantes, Ctr Invest Clin, F-44000 Nantes, France; CHIC Montreuil, Montreuil, France; CHU Montpellier, Montpellier, France; CHU Nancy, Vandoeuvre Les Nancy, France; CHU Tours, Tours, France; CHU Rouen, Rouen, France; CHU St Etienne, St Etienne, France; CHU Angers, Angers, France; CHU Dijon, Dijon, France; CHU Mans, Le Mans, France; CHU Besancon, F-25030 Besancon, France	Nantes Universite; CHU de Nantes; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Universite de Montpellier; CHU de Montpellier; CHU de Nancy; CHU Tours; CHU de Rouen; CHU de St Etienne; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Dijon Bourgogne; Universite de Franche-Comte; CHU Besancon	Gournay, V (corresponding author), CHU Nantes, Hop Mere & Enfant, Serv Reanimat Pediat & Neonatale, F-44000 Nantes, France.	veronique.gournay@chu-nantes.fr	Rozé, Jean-Christophe/AAS-1314-2021; roze, jean christophe/B-5433-2012	Roze, Jean-Christophe/0000-0003-3367-512X; CAMBONIE, GILLES/0000-0002-1360-7915				Aranda JV, 1997, ACTA PAEDIATR, V86, P289, DOI 10.1111/j.1651-2227.1997.tb08892.x; BANDSTRA ES, 1988, PEDIATRICS, V82, P533; BETKERUR MV, 1981, PEDIATRICS, V68, P99; Clyman RI, 1996, J PEDIATR-US, V128, P601, DOI 10.1016/S0022-3476(96)80123-5; Dani C, 2000, ACTA PAEDIATR, V89, P1369, DOI 10.1080/080352500300002598; De Carolis MP, 2000, EUR J PEDIATR, V159, P364, DOI 10.1007/s004310051288; Desfrere L, 2003, PEDIATR RES, V53, p420A; Fowlie PW, 2003, ARCH DIS CHILD-FETAL, V88, pF464, DOI 10.1136/fn.88.6.F464; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; Gournay V, 2002, LANCET, V359, P1486, DOI 10.1016/S0140-6736(02)08424-6; Knight D B, 2001, Semin Neonatol, V6, P63, DOI 10.1053/siny.2000.0036; Lago P, 2002, EUR J PEDIATR, V161, P202, DOI 10.1007/s00431-002-0915-y; MAHONY L, 1985, J PEDIATR-US, V106, P801, DOI 10.1016/S0022-3476(85)80361-9; MENT LR, 1994, PEDIATRICS, V93, P543; Mosca F, 1997, J PEDIATR-US, V131, P549, DOI 10.1016/S0022-3476(97)70060-X; Narayanan M, 2000, J PEDIATR-US, V136, P330, DOI 10.1067/mpd.2000.103414; Patel J, 2000, PEDIATR RES, V47, P36, DOI 10.1203/00006450-200001000-00009; Pezzati M, 1999, J PEDIATR-US, V135, P733, DOI 10.1016/S0022-3476(99)70093-4; RENNIE JM, 1986, ARCH DIS CHILD, V61, P233, DOI 10.1136/adc.61.3.233; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Stubbe J, 2003, AM J PHYSIOL-REG I, V284, pR1179, DOI 10.1152/ajpregu.00340.2002; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Van Overmeire B, 2001, CLIN PHARMACOL THER, V70, P336, DOI 10.1067/mcp.2001.118453; Varvarigou A, 1996, JAMA-J AM MED ASSOC, V275, P539, DOI 10.1001/jama.275.7.539; VOLPE JJ, 1987, NEUROLOGY NEWBORN, P331	25	103	106	0	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1939	1944		10.1016/S0140-6736(04)17476-X	http://dx.doi.org/10.1016/S0140-6736(04)17476-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567009				2022-12-28	WOS:000225327000031
J	Fost, N				Fost, N			Institutionalization of children: America's Gulag archipelago	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med Hist & Bioeth, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Fost, N (corresponding author), Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI 53706 USA.							Advisory Committee on Human Radiation Experiments, 1995, FIN REP; Kevles Daniel J., 1985, NAME EUGENICS GENETI	2	0	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2369	2370		10.1056/NEJMp048207	http://dx.doi.org/10.1056/NEJMp048207			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575051				2022-12-28	WOS:000225429000004
J	Asphaug, E				Asphaug, E			Nothing simple about asteroids	SCIENCE			English	Editorial Material							EROS		Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Asphaug, E (corresponding author), Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA.	asphaug@es.ucsc.edu	Asphaug, Erik/AAC-9455-2020					Asphaug E, 2002, ASTEROIDS, P463; ASPHAUG E, 2001, 32 LUN PLAN SCI C 12; BELL JF, 2001, 32 LUN PLAN SCI C 12; Belton M. J. S., 2004, MITIGATION HAZARDOUS; BELTON MJS, 1992, SCIENCE, V257, P1647, DOI 10.1126/science.257.5077.1647; BELTON MJS, 1994, SCIENCE, V265, P1543, DOI 10.1126/science.265.5178.1543; FUJIWARA A, 1991, ICARUS, V89, P384, DOI 10.1016/0019-1035(91)90185-V; Richardson JE, 2004, SCIENCE, V306, P1526, DOI 10.1126/science.1104731; Robinson MS, 2001, NATURE, V413, P396, DOI 10.1038/35096518; SCHEERES DJ, 2003, 34 LUN PLAN SCI C 17; Veverka J, 2000, SCIENCE, V289, P2088, DOI 10.1126/science.289.5487.2088; Walker JD, 2004, ADV SPACE RES, V33, P1564, DOI 10.1016/S0273-1177(03)00454-X	12	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1489	+		10.1126/science.1106674	http://dx.doi.org/10.1126/science.1106674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567845				2022-12-28	WOS:000225442700039
J	Cai, WJ; Dai, M				Cai, WJ; Dai, M			Comment on "Enhanced open ocean storage of CO2 from shelf sea pumping"	SCIENCE			English	Editorial Material							CONTINENTAL-SHELF; ATMOSPHERIC CO2; CARBON-DIOXIDE; EXCHANGE; WATERS; SYSTEM; PCO(2); SINKS; PLUME; FLUX		Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA; Xiamen Univ, Key Lab Marine Environm Sci, Minist Educ, Xiamen 361005, Peoples R China	University System of Georgia; University of Georgia; Xiamen University	Cai, WJ (corresponding author), Univ Georgia, Dept Marine Sci, Athens, GA 30602 USA.	wcai@uga.edu	DAI, M/GPS-8291-2022; Cai, Wei-Jun/C-1361-2013; Dai, Minhan/G-3343-2010	Cai, Wei-Jun/0000-0003-3606-8325; Dai, Minhan/0000-0003-0550-0701				ANDERSON LG, 1990, J GEOPHYS RES-OCEANS, V95, P1703, DOI 10.1029/JC095iC02p01703; Borges AV, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2000GB001385; Borges AV, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017143; Borges AV, 2002, BIOGEOCHEMISTRY, V59, P41, DOI 10.1023/A:1015517428985; Cai WJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016312; Cai WJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017633; CODISPOTI LA, 1986, CONT SHELF RES, V5, P133, DOI 10.1016/0278-4343(86)90013-0; DAI MC, UNPUB; DeGrandpre MD, 2002, DEEP-SEA RES PT II, V49, P4355, DOI 10.1016/S0967-0645(02)00122-4; Frankignoulle M, 2001, GLOBAL BIOGEOCHEM CY, V15, P569, DOI 10.1029/2000GB001307; Goyet C, 1998, DEEP-SEA RES PT I, V45, P609, DOI 10.1016/S0967-0637(97)00085-X; HALES B, 2003, NEWSL COASTAL OCEAN; Hoppema M, 2004, GLOBAL PLANET CHANGE, V40, P219, DOI 10.1016/j.gloplacha.2003.08.001; KEMPE S, 1991, TELLUS B, V43, P224, DOI 10.1034/j.1600-0889.1991.00015.x; Lefevre N, 2002, J GEOPHYS RES-OCEANS, V107, DOI 10.1029/2000JC000395; Lendt R, 2003, J GEOPHYS RES-OCEANS, V108, DOI 10.1029/2000JC000771; Murata A, 2003, CONT SHELF RES, V23, P753, DOI 10.1016/S0278-4343(03)00046-3; Ternon JF, 2000, MAR CHEM, V68, P183, DOI 10.1016/S0304-4203(99)00077-8; Thomas H, 2004, SCIENCE, V304, P1005, DOI 10.1126/science.1095491; Tsunogai S, 1999, TELLUS B, V51, P701, DOI 10.1034/j.1600-0889.1999.t01-2-00010.x; van Geen A, 2000, DEEP-SEA RES PT II, V47, P975, DOI 10.1016/S0967-0645(99)00133-2; Walsh J.J., 1988, NATURE CONTINENTAL S; Wang SL, 2000, CONT SHELF RES, V20, P525, DOI 10.1016/S0278-4343(99)00084-9; Yool A, 2001, GLOBAL BIOGEOCHEM CY, V15, P831, DOI 10.1029/2000GB001359	24	60	75	5	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1477	1477						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567839				2022-12-28	WOS:000225442700024
J	McGuire, W; Henderson, G; Fowlie, PW				McGuire, W; Henderson, G; Fowlie, PW			ABC of preterm birth - Feeding the preterm infant	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DIET		Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Neonatal Intens Care Unit, Dundee DD1 9SY, Scotland; Perth Royal Infirm, Perth, Scotland	University of Dundee; University of Dundee	Henderson, G (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland.			McGuire, William/0000-0001-8572-3467				Ainsworth SB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004219.pub3; Cooke RJ, 2000, ARCH DIS CHILD-FETAL, V83, pF215, DOI 10.1136/fn.83.3.F215; KENNEDY KA, 2003, COCHRANE DB SYST REV; KENNEDY KA, 2003, COCHRANE DB SYST REV; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; MCGUIRE W, 2003, COCHRANE DATABASE SY; Moore ER, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub2; Morley R, 2000, AM J CLIN NUTR, V71, P822, DOI 10.1093/ajcn/71.3.822; TYSON JE, 2004, COCHRANE DATABASE SY	9	36	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1227	1230		10.1136/bmj.329.7476.1227	http://dx.doi.org/10.1136/bmj.329.7476.1227			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15550428	Green Published			2022-12-28	WOS:000225335700021
J	Oberholzer-Gee, F; Inamdar, SN				Oberholzer-Gee, F; Inamdar, SN			Merck's recall of rofecoxib - A strategic perspective	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Business, Boston, MA 02163 USA	Harvard University	Oberholzer-Gee, F (corresponding author), Harvard Univ, Sch Business, Boston, MA 02163 USA.							DANZON PM, W10536 NBER; Grabowski H, 2002, PHARMACOECONOMICS, V20, P11, DOI 10.2165/00019053-200220003-00002; PISANO GP, 97105 HARV BUS SCH	3	26	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2147	2149		10.1056/NEJMp048284	http://dx.doi.org/10.1056/NEJMp048284			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548771				2022-12-28	WOS:000225160600001
J	Polak, JF				Polak, JF			Ultrasound energy and the dissolution of thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Tufts Univ New England Med Ctr, Dept Radiol, Boston, MA 02111 USA; Tufts Sch Med, Boston, MA USA	Tufts Medical Center	Polak, JF (corresponding author), Tufts Univ New England Med Ctr, Dept Radiol, 750 Washington St, Boston, MA 02111 USA.							Hacke W, 2004, LANCET, V363, P768; Sakharov DV, 1999, THROMB HAEMOSTASIS, V81, P605	2	45	47	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2154	2155		10.1056/NEJMp048249	http://dx.doi.org/10.1056/NEJMp048249			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548774				2022-12-28	WOS:000225160600004
J	Baron, R; Janig, W				Baron, R; Janig, W			Complex regional pain syndromes - how do we escape the diagnostic trap?	LANCET			English	Editorial Material							REFLEX SYMPATHETIC DYSTROPHY; CRITERIA; CRPS		Univ Kiel, Neurol Klin, Dept Neurol Pain Res & Therapy, D-24105 Kiel, Germany; Univ Kiel, Dept Physiol, D-24105 Kiel, Germany	University of Kiel; University of Kiel	Baron, R (corresponding author), Univ Kiel, Neurol Klin, Dept Neurol Pain Res & Therapy, D-24105 Kiel, Germany.	r.baron@neurologie.uni-kiel.de	Baron, Ralf/E-4298-2010					Bruehl S, 1999, PAIN, V81, P147, DOI 10.1016/S0304-3959(99)00011-1; Bruehl S, 2002, PAIN, V95, P119, DOI 10.1016/S0304-3959(01)00387-6; Cocchiarella L., 2001, GUIDES EVALUATION PE; Graif M, 1998, SKELETAL RADIOL, V27, P262, DOI 10.1007/s002560050378; Harden R, 2001, COMPLEX REGIONAL PAI; Harden RN, 1999, PAIN, V83, P211, DOI 10.1016/S0304-3959(99)00104-9; HARDEN RN, IN PRESS CRPS CURREN; Huygen FJPM, 2002, MEDIAT INFLAMM, V11, P47, DOI 10.1080/09629350210307; Janig W, 2003, LANCET NEUROL, V2, P687, DOI 10.1016/S1474-4422(03)00557-X; Maihofner C, 2004, NEUROLOGY, V63, P693, DOI 10.1212/01.WNL.0000134661.46658.B0; Schattschneider J, 2001, PROG PAIN RES MANAG, V22, P119; STANTONHICKS M, 1995, PAIN, V63, P127, DOI 10.1016/0304-3959(95)00110-E; van de Beek WJT, 2003, PAIN, V103, P93, DOI 10.1016/S0304-3959(02)00444-X; van Hilten JJ, 2000, ANN NEUROL, V48, P113, DOI 10.1002/1531-8249(200007)48:1<113::AID-ANA18>3.0.CO;2-9; Wasner G, 2002, PAIN, V98, P19, DOI 10.1016/S0304-3959(01)00470-5; Wasner G, 2001, BRAIN, V124, P587, DOI 10.1093/brain/124.3.587; Zyluk A, 1999, J HAND SURG-BRIT EUR, V24B, P16, DOI 10.1016/S0266-7681(99)90011-6	17	44	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1739	1741		10.1016/S0140-6736(04)17416-3	http://dx.doi.org/10.1016/S0140-6736(04)17416-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541435				2022-12-28	WOS:000225070600009
J	Vamvakas, EC				Vamvakas, EC			Platelet transfusion and adverse outcomes	LANCET			English	Editorial Material							ALLOGENEIC BLOOD-TRANSFUSION; RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE INFECTION; CARDIAC-SURGERY		Univ Ottawa, Dept Pathol & Lab Med, Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada	Canadian Blood Services; University of Ottawa	Vamvakas, EC (corresponding author), Univ Ottawa, Dept Pathol & Lab Med, Canadian Blood Serv, Ottawa, ON K1G 4J5, Canada.	stephen.vamvakas@bloodservices.ca						Akbiyik F, 2004, BLOOD, V104, P1361, DOI 10.1182/blood-2004-03-0926; Bilgin YM, 2004, CIRCULATION, V109, P2755, DOI 10.1161/01.CIR.0000130162.11925.21; BORDIN JO, 1994, BLOOD, V84, P344; Bracey AW, 2002, TRANSFUSION, V42, p5S; Magee CC, 1997, CURR OPIN IMMUNOL, V9, P669, DOI 10.1016/S0952-7915(97)80047-7; MVAKAS EC, 2003, TRANSFUSION, V43, P963; Rao SV, 2004, JAMA-J AM MED ASSOC, V292, P1555, DOI 10.1001/jama.292.13.1555; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; Vamvakas EC, 2002, TRANSFUS MED REV, V16, P304, DOI 10.1053/tmrv.2002.35209; Vamvakas EC, 2001, BLOOD, V97, P1180, DOI 10.1182/blood.V97.5.1180; van de Watering LMG, 1998, CIRCULATION, V97, P562; van Hilten JA, 2004, BMJ-BRIT MED J, V328, P1281, DOI 10.1136/bmj.38103.735266.55; Wallis JP, 2002, TRANSFUSION, V42, P1127, DOI 10.1046/j.1537-2995.2002.00181.x	13	14	14	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1736	1738		10.1016/S0140-6736(04)17414-X	http://dx.doi.org/10.1016/S0140-6736(04)17414-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541433				2022-12-28	WOS:000225070600007
J	Leach, J; Dennis, MR; Courtial, J; Padgett, MJ				Leach, J; Dennis, MR; Courtial, J; Padgett, MJ			Laser beams: Knotted threads of darkness	NATURE			English	Editorial Material							PHASE SINGULARITIES; VORTEX RINGS		Univ Glasgow, Dept Phys & Astron, Glasgow G12 8QQ, Lanark, Scotland; Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; Univ Southampton, Sch Math, Highfield SO17 1BJ, England	University of Glasgow; University of Bristol; University of Southampton	Leach, J (corresponding author), Univ Glasgow, Dept Phys & Astron, Glasgow G12 8QQ, Lanark, Scotland.	j.leach@physics.gla.ac.uk	Dennis, Mark R/F-9292-2010; Padgett, Miles J/B-7625-2008; Courtial, Johannes/B-4597-2009	Dennis, Mark R/0000-0003-1147-1804; Padgett, Miles J/0000-0001-6643-0618; Courtial, Johannes/0000-0002-5990-7972				Adams C. C., 1994, KNOT BOOK; ALLEN L, 1992, PHYS REV A, V45, P8185, DOI 10.1103/PhysRevA.45.8185; Berry MV, 2001, J PHYS A-MATH GEN, V34, P8877, DOI 10.1088/0305-4470/34/42/311; Berry MV, 2001, P ROY SOC A-MATH PHY, V457, P2251, DOI 10.1098/rspa.2001.0826; Fadeev L., 1997, NATURE, V387, P58; MOFFATT HK, 1969, J FLUID MECH, V35, P117; NYE JF, 1974, P ROY SOC LOND A MAT, V336, P165, DOI 10.1098/rspa.1974.0012; Poole DR, 2003, J LOW TEMP PHYS, V132, P97, DOI 10.1023/A:1023797226059; Ricca RL, 1999, J FLUID MECH, V391, P29, DOI 10.1017/S0022112099005224; Ruostekoski J, 2001, PHYS REV LETT, V86, P3934, DOI 10.1103/PhysRevLett.86.3934; Thomson W., 1867, PHILOS MAG, V34, P15, DOI DOI 10.1080/14786446708639836; WINFREE AT, 1994, NATURE, V371, P233, DOI 10.1038/371233a0	12	166	169	3	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					165	165		10.1038/432165a	http://dx.doi.org/10.1038/432165a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538357	Bronze, Green Accepted			2022-12-28	WOS:000225020200030
J	Whitington, PF; Hibbard, JU				Whitington, PF; Hibbard, JU			High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis	LANCET			English	Article							INTRAVENOUS IMMUNOGLOBULIN; PERINATAL HEMOCHROMATOSIS; FOLATE RECEPTORS; GAMMA-GLOBULIN; LIVER-DISEASE; FETAL; ANTIBODIES; IRON; AUTOANTIBODIES; DIAGNOSIS	Background Neonatal haemochromatosis is a rare disease of gestation that results in severe fetal liver injury. We hypothesised an alloimmune aetiology for the disorder on the basis of its high recurrence rate in sibships. In this study, we assessed the effectiveness in preventing or changing the severity of recurrent neonatal haemochromatosis of administering during pregnancy high-dose intravenous immunoglobulin (IVIG) derived from pooled serum of multiple donors. Methods Women whose most recent pregnancy ended in documented neonatal haemochromatosis were treated With IVIG, 1 g/kg bodyweight, weekly from the 18th week until the end of gestation in their subsequent pregnancy. The outcomes of treated pregnancies were compared with those of randomly selected previous affected pregnancies for each woman, which were used as historical controls. Findings 15 women were treated through 16 pregnancies. All pregnancies progressed uneventfully and resulted in live babies with normal physical examinations and birthweights that were appropriate for gestational age. 12 babies had evidence of liver involvement with neonatal haemochromatosis: 11 had higher than. normal concentrations of serum alpha-fetoprotein and ferritin or serum a-fetoprotein alone, including four with coagulopathy (international normalised ratio >1.5), and one had coagulopathy alone. All babies survived with medical or no treatment and were healthy at follow-up within the past 6 months. In analysis on a per-mother basis comparing outcomes of treated gestations with those of randomly selected previous affected gestations, gestational IVIG therapy was associated with better infant survival (15 good outcomes vs two in previous pregnancies; p=0.0009). Interpretation Treatment with high-dose IVIG during gestation appears to have modified recurrent neonatal haemochromatosis so that it was not lethal to the fetus or neonate. These results further support an alloimmune mechanism for recurrent neonatal haemochromatosis.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Childrens Mem Hosp, Chicago, IL 60614 USA; Univ Chicago Hosp, Pritzker Sch Med, Dept Obstet & Gynecol, Chicago, IL 60637 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University of Chicago; University of Illinois System	Whitington, PF (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, Childrens Mem Hosp, 2300 Childrens Plaza Box 57, Chicago, IL 60614 USA.	p-whitington@northwestern.edu						ALLEN K, 1998, FETAL NEONATAL PHYSL, P1530; Bagdasarian A, 1998, VOX SANG, V74, P74, DOI 10.1046/j.1423-0410.1998.7420074.x; BERLIN G, 1985, LANCET, V1, P1153; Branch DW, 2001, J ALLERGY CLIN IMMUN, V108, pS133, DOI 10.1067/mai.2001.117821; BURKS AW, 1986, NEW ENGL J MED, V314, P560, DOI 10.1056/NEJM198602273140907; Collins J, 1990, Hepatology, V12, P176, DOI 10.1002/hep.1840120131; Cox TM, 2002, BLOOD CELL MOL DIS, V29, P411, DOI 10.1006/bcmd.2002.0580; da Costa M, 2003, BIRTH DEFECTS RES A, V67, P837, DOI 10.1002/bdra.10088; Debiec H, 2002, NEW ENGL J MED, V346, P2053, DOI 10.1056/NEJMoa012895; DEBOISSIEU D, 2001, LIVER DIS CHILDREN, P641; FERRELL L, 1992, AM J MED GENET, V44, P429, DOI 10.1002/ajmg.1320440408; Flynn DM, 2003, ARCH DIS CHILD-FETAL, V88, pF124, DOI 10.1136/fn.88.2.F124; GITLIN D, 1975, ANN NY ACAD SCI, V259, P7, DOI 10.1111/j.1749-6632.1975.tb25397.x; GOLDFISCHER S, 1981, HEPATOLOGY, V1, P58, DOI 10.1002/hep.1840010110; HOOGSTRATEN J, 1990, GASTROENTEROLOGY, V98, P1699, DOI 10.1016/0016-5085(90)91110-R; Kaplan C, 1996, TRANSFUS MED REV, V10, P233, DOI 10.1016/S0887-7963(96)80062-9; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kelly AL, 2001, J MED GENET, V38, P599, DOI 10.1136/jmg.38.9.599; Knisely AS, 2003, GASTROENTEROL CLIN N, V32, P877, DOI 10.1016/S0889-8553(03)00050-5; MARGULIES M, 1991, OBSTET GYNECOL, V77, P804; MARGULIES M, 1991, VOX SANG, V61, P181, DOI 10.1111/j.1423-0410.1991.tb00944.x; METZMAN R, 1989, J PEDIATR GASTR NUTR, V9, P112; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; OBIEKWE BC, 1985, ACTA OBSTET GYN SCAN, V64, P251, DOI 10.3109/00016348509155123; Powell LW, 1998, ANN INTERN MED, V129, P925, DOI 10.7326/0003-4819-129-11_Part_2-199812011-00002; Riemersma S, 1996, J CLIN INVEST, V98, P2358, DOI 10.1172/JCI119048; Rothenberg SP, 2004, NEW ENGL J MED, V350, P134, DOI 10.1056/NEJMoa031145; RUCHELLI ED, 1991, HUM PATHOL, V22, P1274, DOI 10.1016/0046-8177(91)90111-2; SCHOENLEBE J, 1993, AM J DIS CHILD, V147, P1072, DOI 10.1001/archpedi.1993.02160340058014; SEKUL EA, 1994, ANN INTERN MED, V121, P259, DOI 10.7326/0003-4819-121-4-199408150-00004; SHAMIEH I, 1993, PEDIATR RES, V33, P109; Shneider Benjamin L, 2002, J Pediatr Gastroenterol Nutr, V34, P328; Shneider Benjamin L., 1996, Current Opinion in Pediatrics, V8, P495, DOI 10.1097/00008480-199610000-00013; SHNEIDER BL, 1994, J PEDIATR-US, V124, P234, DOI 10.1016/S0022-3476(94)70310-8; Sigurdsson L, 1998, J PEDIATR GASTR NUTR, V26, P85, DOI 10.1097/00005176-199801000-00015; SILVER MM, 1987, AM J PATHOL, V128, P538; Sundaram SS, 2003, LIVER TRANSPLANT, V9, P783, DOI 10.1053/jlts.2003.50104; TAUCHER SC, 1994, AM J MED GENET, V50, P213, DOI 10.1002/ajmg.1320500215; Verloes A, 1997, AM J MED GENET, V68, P391, DOI 10.1002/(SICI)1096-8628(19970211)68:4<391::AID-AJMG3>3.0.CO;2-P; Vohra P, 2000, J PEDIATR-US, V136, P537, DOI 10.1016/S0022-3476(00)90020-9; WITZLEBEN CL, 1989, HUM PATHOL, V20, P335, DOI 10.1016/0046-8177(89)90042-7	41	105	110	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1690	1698		10.1016/S0140-6736(04)17356-X	http://dx.doi.org/10.1016/S0140-6736(04)17356-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530630				2022-12-28	WOS:000224921600032
J	Kerr, T; Wodak, A; Elliott, R; Montaner, JS; Wood, E				Kerr, T; Wodak, A; Elliott, R; Montaner, JS; Wood, E			Opioid substitution and HIV/AIDS treatment and prevention	LANCET			English	Editorial Material							INJECTING DRUG-USERS; METHADONE-MAINTENANCE; BUPRENORPHINE; PROGRAMS; THERAPY; RISK; AIDS		St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Canadian HIV AIDS Legal Network, Montreal, PQ, Canada; St Vincents Hosp, Alcohol & Durg Serv, Sydney, NSW 2010, Australia; Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; St Vincents Hospital Sydney; University of British Columbia	Kerr, T (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	tkerr@cfenet.ubc.ca	Montaner, Julio/K-7621-2012					[Anonymous], 2004, 2004 REP GLOB AIDS E; Antela A, 1997, AIDS, V11, P1405; Ball A L, 1998, Public Health Rep, V113 Suppl 1, P170; BALL J, 1991, EFF METH MAINT TREAT; Bell J, 2000, DRUG SAFETY, V22, P179, DOI 10.2165/00002018-200022030-00002; Caplehorn JRM, 1996, SUBST USE MISUSE, V31, P177, DOI 10.3109/10826089609045806; Johnson RE, 2000, NEW ENGL J MED, V343, P1290, DOI 10.1056/NEJM200011023431802; Judd LL, 1998, JAMA-J AM MED ASSOC, V280, P1936; Kerr T, 2004, LANCET, V364, P11, DOI 10.1016/S0140-6736(04)16610-5; Moatti JP, 2000, AIDS, V14, P151, DOI 10.1097/00002030-200001280-00010; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Moreno A, 2001, AIDS, V15, P1068, DOI 10.1097/00002030-200105250-00021; *WHO, 2004, INV COMPR HLTH SECT; *WHO, 2004, ESS DRUG POL PROGR; *WHO, 2003, ESS MED WHO MOD LIST; *WHO UN OFF DRUG C, 2004, SUBST MAINT THER MAN; Wood E, 2000, LANCET, V355, P2095, DOI 10.1016/S0140-6736(00)02375-8; Wood E, 2003, AIDS, V17, P2419, DOI 10.1097/00002030-200311210-00003; World Health Organization, 2004, SCAL ANT THER RES LT	19	46	46	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1918	1919		10.1016/S0140-6736(04)17490-4	http://dx.doi.org/10.1016/S0140-6736(04)17490-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566992				2022-12-28	WOS:000225327000006
J	Hampton, T				Hampton, T			Shuffling mouse's genetic deck may illuminate causes of complex diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2568	2568		10.1001/jama.292.21.2568	http://dx.doi.org/10.1001/jama.292.21.2568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572704				2022-12-28	WOS:000225409100005
J	Moffett, A; Regan, L; Braude, P				Moffett, A; Regan, L; Braude, P			Natural killer cells, miscarriage, and infertility	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREGNANCY; WOMEN; POPULATION; LEUKOCYTES		Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; St Marys Hosp, Imperial Coll Sch Med, Acad Dept Obstet & Gynaecol, Recurrent Miscarriage Clin, London W2 1NY, England; Guys Kings & St Thomas Sch Med, Acad Dept Womens Hlth, Assisted Concept Unit, London SE1 7EH, England	University of Cambridge; Imperial College London; University of London; King's College London	Moffett, A (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	am485@cam.ac.uk						AOKI K, 1995, LANCET, V345, P1340, DOI 10.1016/S0140-6736(95)92539-2; Biron CA, 2002, CURR TOP MICROBIOL, V263, P7; Bisset LR, 2004, EUR J HAEMATOL, V72, P203, DOI 10.1046/j.0902-4441.2003.00199.x; Clifford K, 1997, HUM REPROD, V12, P387, DOI 10.1093/humrep/12.2.387; *CTR BIOL EV RES, LYMPH IMM THER; Daya S, 1998, AM J REPROD IMMUNOL, V39, P69; Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214; King A, 2000, HUM REPROD UPDATE, V6, P28, DOI 10.1093/humupd/6.1.28; Kwak J Y, 2000, Early Pregnancy, V4, P154; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Ntrivalas EI, 2001, HUM REPROD, V16, P855, DOI 10.1093/humrep/16.5.855; Parham P, 2004, J EXP MED, V200, P951, DOI 10.1084/jem.20041783; PIJNENBORG R, 2003, PREECLAMPSIA, P15; Quenby S, 2003, HUM REPROD, V18, P2562, DOI 10.1093/humrep/deg502; Quenby S, 1999, HUM REPROD, V14, P2386, DOI 10.1093/humrep/14.9.2386; *RCOG SCI ADV COMM, 2003, 5 RCOG SCI ADV COMM; Scott JR, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000112; Shimada S, 2004, HUM REPROD, V19, P1018, DOI 10.1093/humrep/deh159; 2004, SUNDAY TIMES    0321	19	115	120	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2004	329	7477					1283	1285		10.1136/bmj.329.7477.1283	http://dx.doi.org/10.1136/bmj.329.7477.1283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15564263	Green Published			2022-12-28	WOS:000225480900024
J	Houghton, J; Stoicov, C; Nomura, S; Rogers, AB; Carlson, J; Li, HC; Cai, X; Fox, JG; Goldenring, JR; Wang, TC				Houghton, J; Stoicov, C; Nomura, S; Rogers, AB; Carlson, J; Li, HC; Cai, X; Fox, JG; Goldenring, JR; Wang, TC			Gastric cancer originating from bone marrow-derived cells	SCIENCE			English	Article							STEM-CELLS; PREMALIGNANT LESIONS; MICE; ADENOCARCINOMA	Epithelial cancers are believed to originate from transformation of tissue stem cells. However, bone marrow-derived cells (BMDCs), which are frequently recruited to sites of tissue injury and inflammation, might also represent a potential source of malignancy. We show that although acute injury, acute inflammation, or transient parietal cell loss within the stomach do not lead to BMDC recruitment, chronic infection of C57BL/6 mice with Helicobacter, a known carcinogen, induces repopulation of the stomach with BMDCs. Subsequently, these cells progress through metaplasia and dysplasia to intraepithelial cancer. These findings suggest that epithelial cancers can originate from marrow-derived sources and thus have broad implications for the multistep model of cancer progression.	Univ Massachusetts, Sch Med, Dept Med & Canc Biol, Worcester, MA 01605 USA; Vanderbilt Univ, Sch Med, Dept Surg, Epithelial Biol Program, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Univ Tokyo, Grad Sch Med, Dept Gastrointestinal Surg, Bunkyo Ku, Tokyo 1138655, Japan; MIT, Div Comparat Med, Cambridge, MA 02139 USA; Vet Adm Med Ctr, Nashville, TN 37232 USA	University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University; Vanderbilt University; University of Tokyo; Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA)	Houghton, J (corresponding author), Univ Massachusetts, Sch Med, Dept Med & Canc Biol, Worcester, MA 01605 USA.	jeanmarie.houghton@umassmed.edu; tcw2l@columbia.edu		Wang, Timothy/0000-0001-5730-3019; Nomura, Sachiyo/0000-0003-4293-6205	NATIONAL CANCER INSTITUTE [P50CA095103] Funding Source: NIH RePORTER; NCI NIH HHS [CA95103, K22 CA90518, R01 CA87958] Funding Source: Medline; NIDDK NIH HHS [R01 DK58] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Clouston AD, 2001, PATHOLOGY, V33, P271; Couzin J, 2003, SCIENCE, V299, P1002, DOI 10.1126/science.299.5609.1002; Fox JG, 2003, CANCER RES, V63, P942; Fox JG, 2002, CANCER RES, V62, P696; Goldenring JR, 2000, GASTROENTEROLOGY, V118, P1080, DOI 10.1016/S0016-5085(00)70361-1; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Li QT, 1996, J BIOL CHEM, V271, P3671, DOI 10.1074/jbc.271.7.3671; Normile D, 2002, SCIENCE, V298, P1869, DOI 10.1126/science.298.5600.1869; Okamoto R, 2002, NAT MED, V8, P1011, DOI 10.1038/nm755; Schmidt PH, 1999, LAB INVEST, V79, P639; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9; Wang TC, 1998, GASTROENTEROLOGY, V114, P675, DOI 10.1016/S0016-5085(98)70581-5	18	907	1031	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1568	1571		10.1126/science.1099513	http://dx.doi.org/10.1126/science.1099513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567866				2022-12-28	WOS:000225442700063
J	Peters, C; Baars, TL; Buhler, S; Mayer, A				Peters, C; Baars, TL; Buhler, S; Mayer, A			Mutual control of membrane fission and fusion proteins	CELL			English	Article							HOMOTYPIC VACUOLE FUSION; TRANS-COMPLEX FORMATION; SACCHAROMYCES-CEREVISIAE; YEAST VACUOLE; V-SNARES; ACTIN CYTOSKELETON; SECRETORY GRANULES; MAMMALIAN-CELLS; PLASMA-MEMBRANE; BINDING-PROTEIN	Membrane fusion and fission are antagonistic reactions controlled by different proteins. Dynamins promote membrane fission by GTP-driven changes of conformation and polymerization state, while SNAREs fuse membranes by forming complexes between t- and v-SNAREs from apposed vesicles. Here, we describe a role of the dynamin-like GTPase Vps1p in fusion of yeast vacuoles. Vps1p forms polymers that couple several t-SNAREs together. At the onset of fusion, the SNARE-activating ATPase Sec18p/NSF and the t-SNARE depolymerize Vps1p and release it from the membrane. This activity is independent of the SNARE coactivator Sec17p/alpha-SNAP and of the v-SNARE. Vps1p release liberates the t-SNAREs for initiating fusion and at the same time disrupts fission activity. We propose that reciprocal control between fusion and fission components exists, which may prevent futile cycles of fission and fusion.	Univ Lausanne, Dept Biochim, CH-1066 Epalinges, Switzerland	University of Lausanne	Peters, C (corresponding author), Univ Lausanne, Dept Biochim, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.	christopher.peters@unil.ch; andreas.mayer@unil.ch	Mayer, Andreas/AAE-4315-2020	Mayer, Andreas/0000-0001-6131-313X				BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Bayer MJ, 2003, J CELL BIOL, V162, P211, DOI 10.1083/jcb.200212004; Boeddinghaus C, 2002, J CELL BIOL, V157, P79, DOI 10.1083/jcb.200112098; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; Cao H, 2000, J CELL SCI, V113, P1993; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; David D, 1998, J CELL BIOL, V143, P1167, DOI 10.1083/jcb.143.5.1167; Dietrich LEP, 2004, EMBO J, V23, P45, DOI 10.1038/sj.emboj.7600015; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Galas MC, 2000, J NEUROCHEM, V75, P1511, DOI 10.1046/j.1471-4159.2000.0751511.x; Graham ME, 2002, P NATL ACAD SCI USA, V99, P7124, DOI 10.1073/pnas.102645099; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hoepfner D, 2001, J CELL BIOL, V155, P979, DOI 10.1083/jcb.200107028; Holroyd P, 2002, P NATL ACAD SCI USA, V99, P16806, DOI 10.1073/pnas.222677399; Hua YY, 2001, P NATL ACAD SCI USA, V98, P8065, DOI 10.1073/pnas.131214798; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; LIU JP, 1994, J BIOL CHEM, V269, P21043; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Merrifield CJ, 2002, NAT CELL BIOL, V4, P691, DOI 10.1038/ncb837; Merz AJ, 2004, J CELL BIOL, V164, P195, DOI 10.1083/jcb.200310105; Morsomme P, 2003, J CELL BIOL, V162, P403, DOI 10.1083/jcb.200212101; Muller JMM, 1999, NAT CELL BIOL, V1, P335, DOI 10.1038/14025; Muller JMM, 2002, J CELL BIOL, V157, P1161, DOI 10.1083/jcb.200202082; Muller O, 2002, EMBO J, V21, P259, DOI 10.1093/emboj/21.3.259; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; Salazar MA, 2003, J BIOL CHEM, V278, P49031, DOI 10.1074/jbc.M308104200; Sanyal S, 2001, NEUROSCI LETT, V311, P21, DOI 10.1016/S0304-3940(01)02125-5; SCHMID SL, 1995, FASEB J, V9, P1445, DOI 10.1096/fasebj.9.14.7589986; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Song BD, 2004, MOL BIOL CELL, V15, P2243, DOI 10.1091/mbc.E04-01-0015; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; WADA Y, 1992, J BIOL CHEM, V267, P18665; Wang YX, 2001, J BIOL CHEM, V276, P35133, DOI 10.1074/jbc.M103937200; Weisman LS, 2003, ANNU REV GENET, V37, P435, DOI 10.1146/annurev.genet.37.050203.103207; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Zenisek D, 2002, NEURON, V35, P1085, DOI 10.1016/S0896-6273(02)00896-6	61	103	106	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					667	678		10.1016/j.cell.2004.11.023	http://dx.doi.org/10.1016/j.cell.2004.11.023			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550248	Bronze			2022-12-28	WOS:000225389500012
J	van Roessel, P; Elliott, DA; Robinson, LM; Prokop, A; Brand, AH				van Roessel, P; Elliott, DA; Robinson, LM; Prokop, A; Brand, AH			Independent regulation of synaptic size and activity by the anaphase-promoting complex	CELL			English	Article							UBIQUITIN PROTEASOME SYSTEM; CELL-CYCLE; SUBSTRATE RECOGNITION; MITOTIC REGULATION; DROSOPHILA FIZZY; DNA-REPLICATION; PROTEIN-KINASE; KEN BOX; GENE; GROWTH	Neuronal plasticity relies on tightly regulated control of protein levels at synapses. One mechanism to control protein abundance is the ubiquitin-proteasome degradation system. Recent studies have implicated ubiquitin-mediated protein degradation in synaptic development, function, and plasticity, but little is known about the regulatory mechanisms controlling ubiquitylation in neurons. In contrast, ubiquitylation has long been studied as a central regulator of the eukaryotic cell cycle. A critical mediator of cell-cycle transitions, the anaphase-promoting complex/cyclosome (APC/C), is an E3 ubiquitin ligase. Although the APC/C has been detected in several differentiated cell types, a functional role for the complex in postmitotic cells has been elusive. We describe a novel postmitotic role for the APC/C at Drosophila neuromuscular synapses: independent regulation of synaptic growth and synaptic transmission. In neurons, the APC/C controls synaptic size via a downstream effector Liprin-alpha; in muscles, the APC/C regulates synaptic transmission, controlling the concentration of a postsynaptic glutamate receptor.	Univ Cambridge, Wellcome Trust Canc Res UK, Gurdon Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Anat, Cambridge CB2 1QR, England; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Extracellular Matrix Res, Manchester M13 9PT, Lancs, England	Cancer Research UK; University of Cambridge; University of Cambridge; Case Western Reserve University; University of Manchester	Brand, AH (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QR, England.	ahb@mole.bio.cam.ac.uk	Elliott, David/H-3334-2012; Brand, Andrea H/F-8220-2014	Elliott, David/0000-0003-1052-7407; Brand, Andrea H/0000-0002-2089-6954; Prokop, Andreas/0000-0001-8482-3298				BRAND AH, 1993, DEVELOPMENT, V118, P401; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Burton JL, 2001, GENE DEV, V15, P2381, DOI 10.1101/gad.917901; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; CHAIN DG, 1995, J NEUROSCI, V15, P7592; Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Ehlers MD, 2003, NAT NEUROSCI, V6, P231, DOI 10.1038/nn1013; Fergestad T, 2001, J NEUROSCI, V21, P1218; Gieffers C, 1999, P NATL ACAD SCI USA, V96, P11317, DOI 10.1073/pnas.96.20.11317; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Grosskortenhaus R, 2002, DEV CELL, V2, P29, DOI 10.1016/S1534-5807(01)00104-6; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hedge Ashok N., 1997, Cell, V89, P115; Hegde AN, 2002, NAT REV NEUROSCI, V3, P854, DOI 10.1038/nrn961; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; Huang JY, 2002, J CELL SCI, V115, P2847; Huang JY, 1999, EMBO J, V18, P2184, DOI 10.1093/emboj/18.8.2184; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jaquenoud M, 2002, EMBO J, V21, P6515, DOI 10.1093/emboj/cdf634; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kashevsky H, 2002, P NATL ACAD SCI USA, V99, P11217, DOI 10.1073/pnas.172391099; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kennerdell JR, 2000, NAT BIOTECHNOL, V18, P896, DOI 10.1038/78531; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MARTIN AR, 1955, J PHYSIOL-LONDON, V130, P114, DOI 10.1113/jphysiol.1955.sp005397; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; Murphey RK, 2002, NEURON, V36, P5, DOI 10.1016/S0896-6273(02)00943-1; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Pfleger CM, 2000, GENE DEV, V14, P655; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Pinto S, 1999, NEURON, V23, P45, DOI 10.1016/S0896-6273(00)80752-7; Reed BH, 1997, DEVELOPMENT, V124, P3543; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Rohrbough J, 1999, NEURON, V23, P55, DOI 10.1016/S0896-6273(00)80753-9; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Saitoe M, 2001, SCIENCE, V293, P514, DOI 10.1126/science.1061270; Schwab M, 2001, EMBO J, V20, P5165, DOI 10.1093/emboj/20.18.5165; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Speese SD, 2003, CURR BIOL, V13, P899, DOI 10.1016/S0960-9822(03)00338-5; Stroschein SL, 2001, GENE DEV, V15, P2822; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; VANROESSEL P, 2002, THESIS U CAMBRIDGE C; Vodermaier HC, 2003, CURR BIOL, V13, P1459, DOI 10.1016/S0960-9822(03)00581-5; Wan HI, 2000, NEURON, V26, P313, DOI 10.1016/S0896-6273(00)81166-6; Wan Y, 2001, P NATL ACAD SCI USA, V98, P13066, DOI 10.1073/pnas.231487598; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Watts RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu MN, 1998, EMBO J, V17, P127, DOI 10.1093/emboj/17.1.127; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Yanagida M, 1999, PHILOS T R SOC B, V354, P1559, DOI 10.1098/rstb.1999.0499; Zhao YL, 2003, CURR BIOL, V13, P887, DOI 10.1016/S0960-9822(03)00332-4; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886; Zhou Y, 2003, J BIOL CHEM, V278, P12530, DOI 10.1074/jbc.M212853200; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	78	182	185	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					707	718		10.1016/j.cell.2004.11.028	http://dx.doi.org/10.1016/j.cell.2004.11.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550251	Bronze			2022-12-28	WOS:000225389500015
J	Diddams, SA; Bergquist, JC; Jefferts, SR; Oates, CW				Diddams, SA; Bergquist, JC; Jefferts, SR; Oates, CW			Standards of time and frequency at the outset of the 21st century	SCIENCE			English	Review							LASERS; SPECTROSCOPY; UNCERTAINTY; OSCILLATOR; GENERATION; CONTINUUM	After 50 years of development, microwave atomic clocks based on cesium have achieved fractional uncertainties below 1 part in 10(15), a level unequaled in all of metrology. The past 5 years have seen the accelerated development of optical atomic clocks, which may enable even greater improvements in timekeeping. Time and frequency standards with various levels of performance are ubiquitous in our society, with applications in many technological fields as well as in the continued exploration of the frontiers of basic science. We review state-of-the-art atomic time and frequency standards and discuss some of their uses in science and technology.	Natl Inst Stand & Technol, Div Time & Frequency, Boulder, CO 80305 USA	National Institute of Standards & Technology (NIST) - USA	Diddams, SA (corresponding author), Natl Inst Stand & Technol, Div Time & Frequency, 325 Broadway, Boulder, CO 80305 USA.	sdiddams@boulder.nist.gov	Diddams, Scott A/L-2819-2013	Diddams, Scott A/0000-0002-2144-0764				Audion C., 2001, MEASUREMENT TIME TIM; Bartels A, 2002, OPT LETT, V27, P1839, DOI 10.1364/OL.27.001839; BARTELS A, 2004, OSA TRENDS OPTICS PH, V96; Bauch A, 1998, METROLOGIA, V35, P829, DOI 10.1088/0026-1394/35/6/6; BEEHLER RE, 1967, PR INST ELECTR ELECT, V55, P792, DOI 10.1109/PROC.1967.5692; Biraben F, 2001, LECT NOTES PHYS, V570, P17; Bize S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150802; BIZE S, 2002, P 6 S FREQ STAND MET, P53; BULLARD EC, 1955, NATURE, V176, P282, DOI 10.1038/176282a0; Chartier JM, 2001, PROC SPIE, V4269, P123, DOI 10.1117/12.424462; Clairon A., 1996, Proceedings of the Fifth Symposium on Frequency Standards and Metrology, P49; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83, DOI 10.1109/TIM.1982.6312526; Diddams SA, 2000, PHYS REV LETT, V84, P5102, DOI 10.1103/PhysRevLett.84.5102; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; DIEDRICH F, 1989, PHYS REV LETT, V62, P403, DOI 10.1103/PhysRevLett.62.403; ESSEN L, 1955, NATURE, V176, P281; Fischer M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.230802; Fortier TM, 2003, OPT LETT, V28, P2198, DOI 10.1364/OL.28.002198; Gilbert SL, 2001, PROC SPIE, V4269, P184, DOI 10.1117/12.424468; GILL P, 2002, P 6 S FREQ STAND MET, P12703; HALL JL, 1978, SCIENCE, V202, P147, DOI 10.1126/science.202.4364.147; HALL JL, 1976, PHYS REV LETT, V37, P1339, DOI 10.1103/PhysRevLett.37.1339; HEAVNER TP, 2002, P 6 S FREQ STAND MET, P253; HEAVNER TP, IN PRESS IEEE T INST; *IEEE, 2004, P C PREC EL MAGN MEA; JENNINGS DA, 1986, P IEEE, V74, P168, DOI 10.1109/PROC.1986.13430; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; KASEVICH MA, 1989, PHYS REV LETT, V63, P612, DOI 10.1103/PhysRevLett.63.612; Katori H, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.173005; LAURENT P, 2002, P 6 S FREQ STAND MET, P241; Levi F, 2004, IEEE T ULTRASON FERR, V51, P1216, DOI 10.1109/TUFFC.2004.1350948; LYONS H, 1949, NBS TECH NEWS B, V33, P17; Ma LS, 2004, SCIENCE, V303, P1843, DOI 10.1126/science.1095092; Marion H, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150801; Mermin ND, 2001, PHYS TODAY, V54, P14, DOI 10.1063/1.4796218; Metcalf HJ., 1999, LASER COOLING TRAPPI; Morgner U, 2001, PHYS REV LETT, V86, P5462, DOI 10.1103/PhysRevLett.86.5462; Peik E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.170801; QUINN TJ, 1991, P IEEE, V79, P894, DOI 10.1109/5.84965; Rafac RJ, 2000, PHYS REV LETT, V85, P2462, DOI 10.1103/PhysRevLett.85.2462; Ramsey N. F., 1956, MOL BEAMS; RAMSEY NF, 1983, J RES NAT BUR STAND, V88, P301, DOI 10.6028/jres.088.015; RAMSEY NF, 1980, PHYS TODAY, V33, P25, DOI 10.1063/1.2914161; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; STERR U, IN PRESS C R PHYS; TAYLOR JH, 1997, NOBEL LECT 1991 1995, P73; TELLE HR, 1990, OPT LETT, V15, P532, DOI 10.1364/OL.15.000532; TERRIEN J, 1968, METROLOGIA, V4, P41, DOI 10.1088/0026-1394/4/1/006; Udem T, 1999, PHYS REV LETT, V82, P3568, DOI 10.1103/PhysRevLett.82.3568; UDERN T, 2001, HYDROGEN ATOM PRECIS, P125; VESSOT RFC, 1980, PHYS REV LETT, V45, P2081, DOI 10.1103/PhysRevLett.45.2081; Walz J, 2003, APPL PHYS B-LASERS O, V77, P713, DOI 10.1007/s00340-003-1344-y; Weyers S, 2001, METROLOGIA, V38, P343, DOI 10.1088/0026-1394/38/4/7; WINELAND DJ, 1980, OPT LETT, V5, P245, DOI 10.1364/OL.5.000245; Ye J, 2003, IEEE J SEL TOP QUANT, V9, P1041, DOI 10.1109/JSTQE.2003.819109; Young BC, 1999, PHYS REV LETT, V82, P3799, DOI 10.1103/PhysRevLett.82.3799	56	189	208	4	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1318	1324		10.1126/science.1102330	http://dx.doi.org/10.1126/science.1102330			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550659				2022-12-28	WOS:000225301600038
J	Als, TD; Vila, R; Kandul, NP; Nash, DR; Yen, SH; Hsu, YF; Mignault, AA; Boomsma, JJ; Pierce, NE				Als, TD; Vila, R; Kandul, NP; Nash, DR; Yen, SH; Hsu, YF; Mignault, AA; Boomsma, JJ; Pierce, NE			The evolution of alternative parasitic life histories in large blue butterflies	NATURE			English	Article							MYRMICA HOST ANTS; MACULINEA-ALCON; SPECIFICITY; LEPIDOPTERA; FORMICIDAE; LYCAENIDAE; ADOPTION	Large blue (Maculinea) butterflies are highly endangered throughout the Palaearctic region, and have been the focus of intense conservation research(1-3). In addition, their extraordinary parasitic lifestyles make them ideal for studies of life history evolution. Early instars consume flower buds of specific host plants, but later instars live in ant nests where they either devour the brood (predators), or are fed mouth-to-mouth by the adult ants (cuckoos). Here we present the phylogeny for the group, which shows that it is a monophyletic clade nested within Phengaris, a rare Oriental genus whose species have similar life histories(4,5). Cuckoo species are likely to have evolved from predatory ancestors. As early as five million years ago, two Maculinea clades diverged, leading to the different parasitic strategies seen in the genus today. Contrary to current belief, the two recognized cuckoo species show little genetic divergence and are probably a single ecologically differentiated species(6-10). On the other hand, some of the predatory morphospecies exhibit considerable genetic divergence and may contain cryptic species. These findings have important implications for conservation and reintroduction efforts.	Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA; Aarhus Univ, Dept Ecol & Genet, DK-8000 Aarhus C, Denmark; Univ Copenhagen, Inst Biol, Dept Populat Biol, DK-2100 Copenhagen, Denmark; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England; Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 804, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei 116, Taiwan	Harvard University; Aarhus University; University of Copenhagen; Imperial College London; National Sun Yat Sen University; National Taiwan Normal University	Pierce, NE (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.	npierce@fas.harvard.edu	Vila, Roger/A-1817-2012; Boomsma, Jacobus J/M-2785-2014; Nash, David R./B-2916-2009	Vila, Roger/0000-0002-2447-4388; Boomsma, Jacobus J/0000-0002-3598-1609; Nash, David R./0000-0002-0462-6794; Kandul, Nikolay/0000-0001-7347-5558				Als TD, 2002, ECOL ENTOMOL, V27, P403, DOI 10.1046/j.1365-2311.2002.00427.x; Als TD, 2001, ANIM BEHAV, V62, P99, DOI 10.1006/anbe.2001.1716; Eastwood R, 2003, MOL PHYLOGENET EVOL, V27, P93, DOI 10.1016/S1055-7903(02)00370-6; Elfferich Nico W., 1998, Deinsea, V4, P97; ELIOT J N, 1973, Bulletin of the British Museum (Natural History) Entomology, V28, P371; ELMES GW, 1992, BIODIVERS CONSERV, V1, P155, DOI 10.1007/BF00695913; ELMES GW, 1991, J ZOOL, V223, P447, DOI 10.1111/j.1469-7998.1991.tb04775.x; Elmes GW, 2002, OECOLOGIA, V130, P525, DOI 10.1007/s00442-001-0857-5; Fiedler K, 1991, BONN ZOOL MONOGR, V31, P1; Fiedler K, 1998, J INSECT CONSERV, V2, P3, DOI 10.1023/A:1009618721239; Gadeberg RME, 1997, J INSECT CONSERV, V1, P99, DOI 10.1023/A:1018439211244; Geissler-Strobel Sabine, 1999, Neue Entomologische Nachrichten, V44, P1; IGARASHI S, 2000, LIFE HIST ASIAN BUTT, V2, P552; Jean J., 1996, ECOLOGICAL STUDIES 2; Munguira ML, 1999, ACTION PLAN MACULINE; Pierce Naomi E., 1995, Journal of the Lepidopterists' Society, V49, P412; Pierce NE, 2002, ANNU REV ENTOMOL, V47, P733, DOI 10.1146/annurev.ento.47.091201.145257; Quek SP, 2004, EVOLUTION, V58, P554, DOI 10.1111/j.0014-3820.2004.tb01678.x; RADCHENKO AG, 1994, ZOOL ZH, V73, P39; Sibatani Atuhiro, 1994, Tyo To Ga, V44, P157; Steiner FM, 2003, J INSECT CONSERV, V7, P1, DOI 10.1023/A:1024763305517; THOMAS JA, 1992, OECOLOGIA, V91, P101, DOI 10.1007/BF00317247; Thomas JA, 1998, ECOL ENTOMOL, V23, P457, DOI 10.1046/j.1365-2311.1998.00153.x; THOMAS JA, 1989, OECOLOGIA, V79, P452, DOI 10.1007/BF00378660; THOMAS JA, 1995, ECOLOGY AND CONSERVATION OF BUTTERFLIES, P180; TILDEN JW, 1947, PAN PACIFIC ENTOMOLO, V23, P42; Uchida H., 1995, BEAUTIFUL BUTTERFLY; VANSWAAY C, 1999, RED DATA BOOK EUROPE, P124; Wynhoff I, 1998, J INSECT CONSERV, V2, P15, DOI 10.1023/A:1009636605309; Yamaguchi S., 1988, LIFE HIST 5 MYRMECOP, P21	30	149	167	0	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					386	390		10.1038/nature03020	http://dx.doi.org/10.1038/nature03020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549104				2022-12-28	WOS:000225161400054
J	Smeets, NWJ; Krekels, GAM; Ostertag, JU; Essers, BAB; Dirksen, CD; Nieman, FHM; Neumann, HAM				Smeets, NWJ; Krekels, GAM; Ostertag, JU; Essers, BAB; Dirksen, CD; Nieman, FHM; Neumann, HAM			Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial	LANCET			English	Article							NONMELANOMA SKIN-CANCER; MARGINS; PREDICTION; CURETTAGE; EFFICACY	Background Rates of recurrence of facial basal-cell carcinoma are consistently lower after Mobs' micrographic surgery (MMS) than after other treatments, such as surgical excision (SE). However, MMS is more time-consuming and therefore more expensive than SE. We investigated the types of facial basal-cell carcinomas in which MMS was more effective than SE. Methods 408 primary and 204 recurrent facial carcinomas (374 and 191 patients, respectively) were analysed separately in this prospective randomised study. Patients were assigned SE or MMS (each 204 primary, 102 recurrent), and received treatment at two hospitals in the Netherlands. The primary outcome was recurrence of carcinoma. Analysis was by intention to treat. Findings Of the basal-cell carcinomas included in the trial, 397 primary (198 MMS, 199 SE) and 201 recurrent (99,102) tumours were actually treated. Of patients with primary carcinomas, 21 had both MMS and SE on different tumours. Nine with recurrent carcinomas had both treatments on different skin tumours. 66 primary and 13 recurrent carcinomas were lost to follow-up. Of the primary carcinomas, five (3%) recurred after SE compared with three (2%) after MMS during 30 months of follow-up. Of the recurrent carcinomas, three (3%) recurred after SE and none after MMS during 18 months of follow-up. Four recurrent carcinomas randomly assigned to the SE group were treated with MMS. Although both differences favoured MMS, they were not significant (primary, difference 1% [95% CI -2.5% to 3.7%], p=0.724; recurrent, 3.2% [-2.0% to 5.0%], p = 0.119). Total operative costs of MMS were higher than those of SE (primary C405.79 vs C216.86, recurrent C489.06 vs C323.49; both p<0.001). Interpretation No definitive conclusion on recurrence rates of primary or recurrent basal-cell carcinomas is yet possible. Although recurrence rates were lower after MMS than after SE, the differences were not significant.	Univ Hosp Maastricht, Dept Dermatol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, NL-6202 AZ Maastricht, Netherlands; Catharina Hosp Eindhoven, Eindhoven, Netherlands; Erasmus MC Rotterdam, Rotterdam, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Catharina Hospital; Erasmus University Rotterdam; Erasmus MC	Smeets, NWJ (corresponding author), Univ Hosp Maastricht, Dept Dermatol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	nsme@sder.azm.nl						Avril MF, 1997, BRIT J CANCER, V76, P100, DOI 10.1038/bjc.1997.343; Batra RS, 2002, ARCH DERMATOL, V138, P1043, DOI 10.1001/archderm.138.8.1043; Bisson MA, 2002, BRIT J PLAST SURG, V55, P293, DOI 10.1054/bjps.2002.3829; BREUNINGER H, 1991, J DERMATOL SURG ONC, V17, P574, DOI 10.1111/j.1524-4725.1991.tb03655.x; Chiller K, 2000, ARCH DERMATOL, V136, P1327, DOI 10.1001/archderm.136.11.1327; DESILVA SP, 1985, J SURG ONCOL, V28, P72, DOI 10.1002/jso.2930280117; EPSTEIN E, 1973, BRIT J DERMATOL, V89, P37, DOI 10.1111/j.1365-2133.1973.tb01915.x; Friedman HI, 1997, ANN PLAS SURG, V38, P232, DOI 10.1097/00000637-199703000-00008; Goldberg LH, 1996, LANCET, V347, P663, DOI 10.1016/S0140-6736(96)91208-8; Grabski WJ, 1998, DERMATOL SURG, V24, P921, DOI 10.1111/j.1524-4725.1998.tb04276.x; Holme SA, 2000, BRIT J DERMATOL, V143, P1224, DOI 10.1046/j.1365-2133.2000.03892.x; JACOBS GH, 1982, CANCER, V49, P533, DOI 10.1002/1097-0142(19820201)49:3<533::AID-CNCR2820490322>3.0.CO;2-O; KO CB, 1994, BRIT J DERMATOL, V130, P269, DOI 10.1111/j.1365-2133.1994.tb02920.x; Kumar P, 2002, BRIT J PLAST SURG, V55, P616, DOI 10.1054/bjps.2002.3948; Lalloo MT, 2000, CLIN OTOLARYNGOL, V25, P370, DOI 10.1046/j.1365-2273.2000.00376.x; Lawrence CM, 1999, CLIN EXP DERMATOL, V24, P130; MOTLEY RJ, 1995, BRIT J DERMATOL, V132, P437, DOI 10.1111/j.1365-2133.1995.tb08679.x; RAPINI RP, 1990, J AM ACAD DERMATOL, V23, P288, DOI 10.1016/0190-9622(90)70212-Z; Ratner D, 2003, DERMATOL SURG, V29, P899, DOI 10.1046/j.1524-4725.2003.29272.x; Robinson JK, 2000, ARCH DERMATOL, V136, P1318, DOI 10.1001/archderm.136.11.1318; Robinson JK, 2003, ARCH DERMATOL, V139, P643, DOI 10.1001/archderm.139.5.643; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; SEXTON M, 1990, J AM ACAD DERMATOL, V23, P1118, DOI 10.1016/0190-9622(90)70344-H; Shriner DL, 1998, J AM ACAD DERMATOL, V39, P79, DOI 10.1016/S0190-9622(98)70405-0; Shuster S, 1999, ACTA DERM-VENEREOL, V79, P2; Telfer NR, 1999, BRIT J DERMATOL, V141, P415; Thissen MRTM, 1999, ARCH DERMATOL, V135, P1177, DOI 10.1001/archderm.135.10.1177; Thomas DJ, 2003, PLAST RECONSTR SURG, V112, P57, DOI 10.1097/01.PRS.0000067479.77859.31; WOLF DJ, 1987, ARCH DERMATOL, V123, P340, DOI 10.1001/archderm.123.3.340	30	238	244	1	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1766	1772		10.1016/S0140-6736(04)17399-6	http://dx.doi.org/10.1016/S0140-6736(04)17399-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541449				2022-12-28	WOS:000225070600029
J	Sherwood, RI; Christensen, JL; Conboy, IM; Conboy, MJ; Rando, TA; Weissman, IL; Wagers, AJ				Sherwood, RI; Christensen, JL; Conboy, IM; Conboy, MJ; Rando, TA; Weissman, IL; Wagers, AJ			Isolation of adult mouse myogenic progenitors: Functional heterogeneity of cells within and engrafting skeletal muscle	CELL			English	Article							HEMATOPOIETIC STEM-CELLS; BONE-MARROW; SATELLITE CELLS; REGENERATION; EXPRESSION; MICE; TRANSPLANTATION; IDENTIFICATION; SPECIFICATION; POPULATION	Skeletal muscle regeneration in adults is thought to occur through the action of myogenic satellite cells located in close association with mature musclefibers; however, these precursor cells have not been prospectively isolated, and recent studies have suggested that additional muscle progenitors, including cells of bone marrow or hematopoietic origin, may exist. To clarify the origin(s) of adult myogenic cells, we used phenotypic, morphological, and functional criteria to identify and prospectively isolate a subset of myofiber-associated cells capable at the single cell level of generating myogenic colonies at high frequency. Importantly, although muscle-engrafted cells from marrow and/or circulation localized to the same anatomic compartment as myogenic satellite cells and expressed some though not all satellite cell markers, they displayed no intrinsic myogenicity. Together, these studies describe the clonal isolation of functional adult myogenic progenitors and demonstrate that these cells do not arise from hematopoietic or other bone marrow or circulating precursors.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Vet Affairs Palo alto Hlth Care Syst, GRECC, Palo Alto, CA 94304 USA; Vet Affairs Palo alto Hlth Care Syst, Serv Neurol, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Wagers, AJ (corresponding author), Joslin Diabet Ctr, Sect Dev & Stem Cell Biol, Boston, MA 02215 USA.	amy.wagers@joslin.harvard.edu		Rando, Thomas/0000-0001-5843-8564	NCI NIH HHS [CA86065] Funding Source: Medline; NIA NIH HHS [AG05902] Funding Source: Medline; NINDS NIH HHS [R01-NS36409] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Beauchamp JR, 1999, J CELL BIOL, V144, P1113, DOI 10.1083/jcb.144.6.1113; BISCHOFF R, 1994, SATELLITE CELL MUSCL, P97; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bunster E, 1933, ANAT REC, V57, P339, DOI 10.1002/ar.1090570404; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008; Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534-5807(02)00254-X; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Ferrari G, 2001, NATURE, V411, P1014, DOI 10.1038/35082631; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fukada S, 2002, J CELL SCI, V115, P1285; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; IRINTCHEV A, 1994, DEV DYNAM, V199, P326, DOI 10.1002/aja.1001990407; Jankowski RJ, 2002, GENE THER, V9, P642, DOI 10.1038/sj.gt.3301719; JOHNSON P, 1997, WEIRS HDB EXPT IMMUN, V2; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Morgan JE, 2003, INT J BIOCHEM CELL B, V35, P1151, DOI 10.1016/S1357-2725(03)00042-6; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Qu-Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150; SHERWOOD RI, 2004, IN PRESS STEM CELLS; Shi DQ, 2004, BLOOD, V104, P290, DOI 10.1182/blood-2003-03-0688; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STAUBER WT, 1988, MED SCI SPORT EXER, V20, P345, DOI 10.1249/00005768-198808000-00004; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Wright DE, 2001, BLOOD, V97, P2278, DOI 10.1182/blood.V97.8.2278	35	360	377	0	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					543	554		10.1016/j.cell.2004.10.021	http://dx.doi.org/10.1016/j.cell.2004.10.021			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537543	Bronze			2022-12-28	WOS:000225183200012
J	Denli, AM; Tops, BBJ; Plasterk, RHA; Ketting, RF; Hannon, GJ				Denli, AM; Tops, BBJ; Plasterk, RHA; Ketting, RF; Hannon, GJ			Processing of primary microRNAs by the Microprocessor complex	NATURE			English	Article							RNAI EFFECTOR COMPLEXES; DSRNA-BINDING-PROTEIN; NUCLEAR EXPORT; C-ELEGANS; CAENORHABDITIS-ELEGANS; MESSENGER-RNA; INTERFERENCE; INITIATION; EXPRESSION; DICER	Mature microRNAs (miRNAs) are generated via a two-step processing pathway to yield similar to22-nucleotide small RNAs that regulate gene expression at the post-transcriptional level(1). Initial cleavage is catalysed by Drosha, a nuclease of the RNase III family, which acts on primary miRNA transcripts (pri-miRNAs) in the nucleus(2). Here we show that Drosha exists in a multiprotein complex, the Microprocessor, and begin the process of deconstructing that complex into its constituent components. Along with Drosha, the Microprocessor also contains Pasha (partner of Drosha), a double-stranded RNA binding protein. Suppression of Pasha expression in Drosophila cells or Caenorhabditis elegans interferes with pri-miRNA processing, leading to an accumulation of pri-miRNAs and a reduction in mature miRNAs. Finally, depletion or mutation of pash-1 in C. elegans causes de-repression of a let-7 reporter and the appearance of phenotypic defects overlapping those observed upon examination of worms with lesions in Dicer (dcr-1) or Drosha (drsh-1). Considered together, these results indicate a role for Pasha in miRNA maturation and miRNA-mediated gene regulation.	Cold Spring Harbor Lab, Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA; Hubrecht Lab Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands	Cold Spring Harbor Laboratory; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Hannon, GJ (corresponding author), Cold Spring Harbor Lab, Watson Sch Biol Sci, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	hannon@cshl.org	Hannon, Gregory/AAB-3568-2019; Tops, Bastiaan/L-4697-2015	Ketting, Rene/0000-0001-6161-5621; Tops, Bastiaan/0000-0002-1699-8210				Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Han MH, 2004, P NATL ACAD SCI USA, V101, P1093, DOI 10.1073/pnas.0307969100; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shiohama A, 2003, BIOCHEM BIOPH RES CO, V304, P184, DOI 10.1016/S0006-291X(03)00554-0; SIOLAS D, UNPUB NATURE BIOTECH; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017	29	1836	1985	1	159	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					231	235		10.1038/nature03049	http://dx.doi.org/10.1038/nature03049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15531879				2022-12-28	WOS:000225020200049
J	Szarewski, A; Sasieni, P				Szarewski, A; Sasieni, P			Cervical screening in adolescents - at least do no harm	LANCET			English	Editorial Material							HUMAN-PAPILLOMAVIRUS INFECTION; PSYCHOLOGICAL IMPACT; NATURAL-HISTORY; YOUNG-WOMEN		Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol Math & Stat, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Szarewski, A (corresponding author), Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol Math & Stat, London EC1M 6BQ, England.	anne.szarewski@cancer.org.uk		Sasieni, Peter/0000-0003-1509-8744				Cuzick J, 2003, LANCET, V362, P1871, DOI 10.1016/S0140-6736(03)14955-0; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Kjaer SK, 2016, BMJ-BRIT MED J, V353, DOI [10.1136/bmj.325.7364.572, 10.1136/bmj.i2820]; Maissi E, 2004, BMJ-BRIT MED J, V328, P1293, DOI 10.1136/bmj.328.7451.1293; MCCAFFERY K, IN PRESS BR J OBSTET; Moscicki AB, 2001, JAMA-J AM MED ASSOC, V285, P2995, DOI 10.1001/jama.285.23.2995; PETO J, IN PRESS BR J CANC; Rogstad KE, 2002, BJOG-INT J OBSTET GY, V109, P364, DOI 10.1111/j.1471-0528.2002.99023.x; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4	11	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1642	1644		10.1016/S0140-6736(04)17366-2	http://dx.doi.org/10.1016/S0140-6736(04)17366-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530605				2022-12-28	WOS:000224921600004
J	Corke, CF; Stow, PJ; Green, DT; Agar, JW; Henry, MJ				Corke, CF; Stow, PJ; Green, DT; Agar, JW; Henry, MJ			How doctors discuss major interventions with high risk patients: an observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							END	Objective To investigate the difficulties doctors face in discussing treatment options with patients with acute, life threatening illness and major comorbidities. Design Observational study of doctor-patient interviews based on a standardised clinical scenario involving high risk surgery in a hypothetical patient (played by an actor) with serious comorbidities. Participants 30 trainee doctors 3-5 years after graduation. Main outcome measures Adequacy of coverage of various aspects was scored from 3 (good) to 0 (not discussed). Results The medical situation was considered to be well described (median score 2.7 (interquartile range 2.1-3.0)), whereas the patient's functional status, values, and fears were poorly or minimally addressed (scores 0.5 (0.0-1.0), 0.5 (0.0-1.0), and 0.0 (0.0-1.5), respectively; all P < 0.001 v score for describing the medical situation). Twenty nine of the doctors, indicated that they wished to include the patient's family in the discussion, but none identified a preferred surrogate decision maker. Six doctors suggested that the patient alone should speak with his family to reach a decision without the doctor being present. The doctors were reluctant to give advice, despite it being directly requested: two doctors stated that a doctor could not give advice, while 17 simply restated the medical risks, without advocating any particular course. Of the 11 who did offer advice, eight advocated intervention. Conclusions Doctors focused on technical medical issues and placed much less emphasis on patient issues such as functional status, values, wishes, and fears. This limits doctors' ability to offer suitable advice about treatment options. Doctors need to improve their communication skills in this difficult but common clinical situation.	Geelong Hosp, Barwon Hlth, Intens Care Unit, Geelong, Vic 3220, Australia; Geelong Hosp, Barwon Hlth, Renal Serv, Geelong, Vic 3220, Australia; Univ Melbourne, Geelong Hosp, Barwon Hlth, Dept Clin & Biomed Sci, Geelong, Vic 3220, Australia	Geelong Hospital; Geelong Hospital; Geelong Hospital; University of Melbourne	Corke, CF (corresponding author), Geelong Hosp, Barwon Hlth, Intens Care Unit, Geelong, Vic 3220, Australia.	charliec@barwonhealth.org.au		Henry, Assoc Prof Margaret J/0000-0002-1233-6754				Carmel S, 1999, SOC SCI MED, V49, P1401, DOI 10.1016/S0277-9536(99)00221-X; Curtis J, 2000, PARASITOL TODAY, V16, P68, DOI 10.1016/S0169-4758(99)01553-7; Curtis JR, 2001, J GEN INTERN MED, V16, P41; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; Heyland DK, 2003, J CRIT CARE, V18, P3, DOI 10.1053/jcrc.2003.YJCRC2; Johnston SC, 1998, J GEN INTERN MED, V13, P43, DOI 10.1046/j.1525-1497.1998.00008.x; Pochard F, 2003, CRIT CARE MED, V31, P662, DOI 10.1097/01.CCM.0000051516.04625.DE; Schneider CE, 1998, PRACTICE AUTONOMY PA; Schwartz Charles E, 2003, J Palliat Med, V6, P37, DOI 10.1089/10966210360510109; Thistlethwaite Jill E, 2002, Educ Health (Abingdon), V15, P170, DOI 10.1080/13576280210133099	10	27	27	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2005	330	7484					182	184B		10.1136/bmj.38293.435069.DE	http://dx.doi.org/10.1136/bmj.38293.435069.DE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15564228	Bronze, Green Published			2022-12-28	WOS:000226590800020
J	Tomita, J; Nakajima, M; Kondo, T; Iwasaki, H				Tomita, J; Nakajima, M; Kondo, T; Iwasaki, H			No transcription-translation feedback in circadian rhythm of KaiC phosphorylation	SCIENCE			English	Article							SYNECHOCOCCUS-ELONGATUS; CLOCK SYSTEM; CYANOBACTERIA; EXPRESSION	An autoregulatory transcription-translation feedback loop is thought to be essential in generating circadian rhythms in any model organism. In the cyanobacterium Synechococcus elongatus, the essential clock protein KaiC is proposed to form this type of transcriptional negative feedback. Nevertheless, we demonstrate here temperature-compensated, robust circadian cycling of KaiC phosphorylation even without kaiBC messenger RNA accumulation under continuous dark conditions. This rhythm persisted in the presence of a transcription or translation inhibitor. Moreover, kinetic profiles in the ratio of KaiC autophosphorylation-dephosphorylation were also temperature compensated in vitro. Thus, the cyanobacterial clock can keep time independent of de novo transcription. and translation processes.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Iwasaki, H (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	iwasaki@bio.nagoya-u.ac.jp	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Iwasaki, Hideo/0000-0002-3754-4955				Doolittle W F, 1979, Adv Microb Physiol, V20, P1; Dunlap J.C., 2004, CHRONOBIOLOGY BIOL T; Imai K, 2004, J BIOL CHEM, V279, P36534, DOI 10.1074/jbc.M405861200; Ishiura M, 1998, SCIENCE, V281, P1519, DOI 10.1126/science.281.5382.1519; Iwasaki H, 2000, CELL, V101, P223, DOI 10.1016/S0092-8674(00)80832-6; Iwasaki H, 2002, P NATL ACAD SCI USA, V99, P15788, DOI 10.1073/pnas.222467299; Kageyama H, 2003, J BIOL CHEM, V278, P2388, DOI 10.1074/jbc.M208899200; Kitayama Y, 2003, EMBO J, V22, P2127, DOI 10.1093/emboj/cdg212; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; Mori T, 2001, SEMIN CELL DEV BIOL, V12, P271, DOI 10.1006/scdb.2001.0254; Nakahira Y, 2004, P NATL ACAD SCI USA, V101, P881, DOI 10.1073/pnas.0307411100; Nishiwaki T, 2004, P NATL ACAD SCI USA, V101, P13927, DOI 10.1073/pnas.0403906101; Nishiwaki T, 2000, P NATL ACAD SCI USA, V97, P495, DOI 10.1073/pnas.97.1.495; RODRIGUEZLOPEZ M, 1970, FEBS LETT, V9, P171, DOI 10.1016/0014-5793(70)80346-5; Schmitz O, 2000, SCIENCE, V289, P765, DOI 10.1126/science.289.5480.765; Williams SB, 2002, P NATL ACAD SCI USA, V99, P15357, DOI 10.1073/pnas.232517099; Xu Y, 2000, EMBO J, V19, P3349, DOI 10.1093/emboj/19.13.3349; Xu Y, 2004, P NATL ACAD SCI USA, V101, P13933, DOI 10.1073/pnas.0404768101; Xu Y, 2003, EMBO J, V22, P2117, DOI 10.1093/emboj/cdg168; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	21	346	369	3	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					251	254		10.1126/science.1102540	http://dx.doi.org/10.1126/science.1102540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15550625				2022-12-28	WOS:000226361900042
J	Rape, M; Kirschner, MW				Rape, M; Kirschner, MW			Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry	NATURE			English	Article							CYCLIN-A; CELL-CYCLE; MITOTIC REGULATION; ACCUMULATION; DEGRADATION; PROTEOLYSIS; DROSOPHILA; COMPLEX/CYCLOSOME; PROMETAPHASE; PROGRESSION	Oscillations in cyclin-dependent kinase (CDK) activity drive the somatic cell cycle. After entry into mitosis, CDKs activate the anaphase-promoting complex (APC), which then promotes cyclin degradation and mitotic exit. The re-accumulation of cyclin A causes the inactivation of APC and entry into S phase, but how cyclin A can accumulate in the presence of active APC has remained unclear. Here we show that, during G1, APC autonomously switches to a state permissive for cyclin A accumulation. Crucial to this transition is the APC(Cdh1)-dependent autoubiquitination and proteasomal degradation of the ubiquitin-conjugating enzyme (E2) UbcH10. Because APC substrates inhibit the autoubiquitination of UbcH10, but not its E2 function, APC activity is maintained as long as G1 substrates are present. Thus, through UbcH10 degradation and cyclin A stabilization, APC autonomously downregulates its activity. This indicates that the core of the metazoan cell cycle could be described as a self-perpetuating but highly regulated oscillator composed of alternating CDK and APC activities.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, 240 Longwood Ave, Boston, MA 02115 USA.	marc@hms.harvard.edu		Rape, Michael/0000-0003-4849-6343				Araki M, 2003, EMBO J, V22, P6115, DOI 10.1093/emboj/cdg573; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Erlandsson F, 2000, EXP CELL RES, V259, P86, DOI 10.1006/excr.2000.4889; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Kraft C, 2003, EMBO J, V22, P6598, DOI 10.1093/emboj/cdg627; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Listovsky T, 2004, EMBO J, V23, P1619, DOI 10.1038/sj.emboj.7600149; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Sorensen CS, 2001, MOL CELL BIOL, V21, P3692, DOI 10.1128/MCB.21.11.3692-3703.2001; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Yamanaka A, 2000, MOL BIOL CELL, V11, P2821, DOI 10.1091/mbc.11.8.2821	21	238	243	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	2004	432	7017					588	595		10.1038/nature03023	http://dx.doi.org/10.1038/nature03023			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875PL	15558010				2022-12-28	WOS:000225433200037
J	Le Galliard, JF; Clobert, J; Ferriere, R				Le Galliard, JF; Clobert, J; Ferriere, R			Physical performance and darwinian fitness in lizards	NATURE			English	Article							LACERTA-VIVIPARA; NATURAL-SELECTION; BODY-SIZE; LOCOMOTOR CAPACITY; FOOD-CONSUMPTION; TRAITS; POPULATION; ADAPTATION; MORPHOLOGY; ENDURANCE	Strong evidence for a genetic basis of variation in physical performance has accumulated(1,2). Considering one of the basic tenets of evolutionary physiology-that physical performance and darwinian fitness are tightly linked(3)-one may expect phenotypes with exceptional physiological capacities to be promoted by natural selection. Why then does physical performance remain considerably variable in human and other animal populations(1,2,4)? Our analysis of locomotor performance in the common lizard (Lacerta vivipara) demonstrates that initial endurance (running time to exhaustion measured at birth) is indeed highly heritable, but natural selection in favour of this trait can be unexpectedly weak. A manipulation of dietary conditions unravels a proximate mechanism explaining this pattern. Fully fed individuals experience a marked reversal of performance within only one month after birth: juveniles with low endurance catch up, whereas individuals with high endurance lose their advantage. In contrast, dietary restriction allows highly endurant neonates to retain their locomotor superiority as they age. Thus, the expression of a genetic predisposition to high physical performance strongly depends on the environment experienced early in life.	Ecole Normale Super, CNRS, UMR 7625, Lab Fonctionnement & Evolut Syst Ecol, F-75230 Paris 05, France; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Sorbonne Universite; University of Arizona	Le Galliard, JF (corresponding author), Univ Oslo, Dept Biol, Ctr Ecol & Evolutionary Synth, POB 1050,Blindern, N-0316 Oslo, Norway.	j.f.l.galliard@bio.uio.no	Ferriere, Regis/S-8050-2017; Le Galliard, Jean-François/E-8702-2011	Ferriere, Regis/0000-0002-5806-5566; Le Galliard, Jean-François/0000-0002-5965-9868				ARNOLD SJ, 1983, AM ZOOL, V23, P347, DOI 10.1093/icb/23.2.347; AVERY RA, 1971, J ANIM ECOL, V40, P351, DOI 10.2307/3250; Bennett A.F., 1990, Oxford Surveys in Evolutionary Biology, V7, P251; BOUCHARD C, 1997, HUMAN KINETICS, P408; Clobert J, 2000, FUNCT ECOL, V14, P675, DOI 10.1046/j.1365-2435.2000.00477.x; CURETON KJ, 1980, MED SCI SPORT EXER, V12, P288; Falconer D. S., 1989, Introduction to quantitative genetics.; GARLAND T, 1984, AM J PHYSIOL, V247, pR806, DOI 10.1152/ajpregu.1984.247.5.R806; Garland Theodore Jr., 1994, P240; HUEY RB, 1984, ANIM BEHAV, V32, P41, DOI 10.1016/S0003-3472(84)80322-X; Irschick DJ, 2001, ANNU REV ECOL SYST, V32, P367, DOI 10.1146/annurev.ecolsys.32.081501.114048; Irschick DJ, 2002, INTEGR COMP BIOL, V42, P278, DOI 10.1093/icb/42.2.278; Janzen FJ, 1998, EVOLUTION, V52, P1564, DOI 10.1111/j.1558-5646.1998.tb02237.x; Janzen FJ, 2000, ECOLOGY, V81, P2290; JAYNE BC, 1990, EVOLUTION, V44, P1204, DOI 10.1111/j.1558-5646.1990.tb05226.x; KHODADOOST M, 1987, REV ECOL-TERRE VIE, V42, P193; Le Galliard JF, 2003, FUNCT ECOL, V17, P877, DOI 10.1046/j.0269-8463.2003.00800.x; Le Galliard JF, 2003, P ROY SOC B-BIOL SCI, V270, P1163, DOI 10.1098/rspb.2003.2360; Littell R. C, 1996, SAS SYSTEM MIXED MOD; Lorenzon P, 2001, EVOLUTION, V55, P392; MASSOT M, 1994, J ANIM ECOL, V63, P431, DOI 10.2307/5560; PRICE TD, 1984, EVOLUTION, V38, P483, DOI 10.1111/j.1558-5646.1984.tb00314.x; RICE WR, 1994, TRENDS ECOL EVOL, V9, P235, DOI 10.1016/0169-5347(94)90258-5; RISKA B, 1989, EVOLUTION, V43, P1172, DOI [10.2307/2409355, 10.1111/j.1558-5646.1989.tb02567.x]; Rupert JL, 2003, COMP BIOCHEM PHYS A, V136, P191, DOI 10.1016/S1095-6433(02)00349-5; SCHLUTER D, 1988, EVOLUTION, V42, P849, DOI [10.2307/2408904, 10.1111/j.1558-5646.1988.tb02507.x]; Sorci G, 1999, EVOL ECOL RES, V1, P303; SORCI G, 1995, PHYSIOL ZOOL, V68, P698, DOI 10.1086/physzool.68.4.30166352; Swallow JG, 2001, J COMP PHYSIOL B, V171, P651, DOI 10.1007/s003600100216; White GC, 1999, BIRD STUDY, V46, P120, DOI 10.1080/00063659909477239	30	174	175	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					502	505		10.1038/nature03057	http://dx.doi.org/10.1038/nature03057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565154				2022-12-28	WOS:000225322100046
J	Cheng, CJ; Chu, PL; Huang, GS; Lin, SH				Cheng, CJ; Chu, PL; Huang, GS; Lin, SH			Diffuse bone pain in a young woman	LANCET			English	Editorial Material							RENAL TUBULAR-ACIDOSIS; SJOGRENS-SYNDROME		Natl Def Univ, Natl Def Med Coll, Tri Serv Gen Hosp, Dept Med,Div Nephrol, Taipei, Taiwan; Natl Def Univ, Natl Def Med Coll, Tri Serv Gen Hosp, Dept Radiol, Taipei, Taiwan	National Defense Medical Center; National Defense University - Taiwan; Tri-Service General Hospital; National Defense Medical Center; National Defense University - Taiwan; Tri-Service General Hospital	Lin, SH (corresponding author), Natl Def Univ, Natl Def Med Coll, Tri Serv Gen Hosp, Dept Med,Div Nephrol, Taipei, Taiwan.	shihhualin@yahoo.com	Cheng, Chih-Jen/AAM-3305-2021					DEFRANCO PE, 1995, J AM SOC NEPHROL, V6, P295; Fulop M, 2004, ARCH INTERN MED, V164, P905, DOI 10.1001/archinte.164.8.905; KRIEGER NS, 1992, AM J PHYSIOL, V262, P442; Pertovaara M, 1999, RHEUMATOLOGY, V38, P1113, DOI 10.1093/rheumatology/38.11.1113; PINES KL, 1951, AM J MED, V11, P302, DOI 10.1016/0002-9343(51)90167-2	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1910	1910		10.1016/S0140-6736(04)17448-5	http://dx.doi.org/10.1016/S0140-6736(04)17448-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555672				2022-12-28	WOS:000225269300033
J	Holmes, DR				Holmes, DR			Strokes and holes and headaches: are they a package deal?	LANCET			English	Editorial Material							PATENT FORAMEN OVALE; RECURRENT CEREBROVASCULAR EVENTS; ATRIAL SEPTAL ANEURYSM; TO-LEFT SHUNTS; TRANSCATHETER CLOSURE; PARADOXICAL EMBOLISM; MIGRAINE; PREVENTION		Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Holmes, DR (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.	Holmes.david@mayo.edu						Brandt RR, 2002, J AM SOC ECHOCARDIOG, V15, P1094, DOI 10.1067/mje.2002.121666; Bruch L, 2002, CIRCULATION, V105, P2845, DOI 10.1161/01.CIR.0000019069.32964.0E; Cohnheim J, 1877, THROMBOSE EMBOLIE VO, P134; Dearani JA, 1999, CIRCULATION, V100, P171; Del Sette M, 1998, CEREBROVASC DIS, V8, P327, DOI 10.1159/000015875; Fabricius Alex M, 2002, Asian Cardiovasc Thorac Ann, V10, P342; HOLMES DR, 1909, CURR PROB CARDIOLOGY, V29, P49; Mas JL, 2001, NEW ENGL J MED, V345, P1740, DOI 10.1056/NEJMoa011503; MAS JL, 1995, AM HEART J, V130, P1083, DOI 10.1016/0002-8703(95)90212-0; Overell JR, 2000, NEUROLOGY, V55, P1172, DOI 10.1212/WNL.55.8.1172; Post MC, 2004, NEUROLOGY, V62, P1439, DOI 10.1212/01.WNL.0000120756.25236.37; Schwerzmann M, 2004, NEUROLOGY, V62, P1399, DOI 10.1212/01.WNL.0000120677.64217.A9; Sztajzel R, 2002, CEREBROVASC DIS, V13, P102, DOI 10.1159/000047758; Wilmshurst P, 2001, CLIN SCI, V100, P215, DOI 10.1042/CS20000231; Wilmshurst PT, 2000, LANCET, V356, P1648, DOI 10.1016/S0140-6736(00)03160-3; ZAHN FW, 1881, REV MED SUISSE ROMAN, V1, P227	16	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1840	1842		10.1016/S0140-6736(04)17457-6	http://dx.doi.org/10.1016/S0140-6736(04)17457-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555653				2022-12-28	WOS:000225269300009
J	Young, B; Krahn, A				Young, B; Krahn, A			Implications of defibrillation	LANCET			English	Editorial Material							HOSPITAL CARDIAC-ARREST; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS		Univ Western Ontario, London, ON N6A 5A5, Canada	Western University (University of Western Ontario)	Young, B (corresponding author), Univ Western Ontario, London, ON N6A 5A5, Canada.	bryan.young@lhsc.on.ca						Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Grubb NR, 1996, BMJ-BRIT MED J, V313, P143, DOI 10.1136/bmj.313.7050.143; Guglin ME, 2004, PACE, V27, P1072, DOI 10.1111/j.1540-8159.2004.00586.x; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kapp M B, 1989, Issues Law Med, V5, P337; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; Virkkunen I, 2004, RESUSCITATION, V62, P299, DOI 10.1016/j.resuscitation.2004.04.003	9	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1836	1837		10.1016/S0140-6736(04)17454-0	http://dx.doi.org/10.1016/S0140-6736(04)17454-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555650				2022-12-28	WOS:000225269300006
J	Hamel, MB; Epstein, AM				Hamel, MB; Epstein, AM			Prior-authorization programs for controlling drug spending	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*HJ KAIS FAM FDN K, MED DRUG BEN HIGHL K; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; Levit K, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.1.154; Mello MM, 2004, NEW ENGL J MED, V350, P608, DOI 10.1056/NEJMlim035683	4	23	23	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2156	2158		10.1056/NEJMp048294	http://dx.doi.org/10.1056/NEJMp048294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548775				2022-12-28	WOS:000225160600005
J	Devereux, RB; Wachtell, K; Gerdts, E; Boman, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Harris, K; Aurup, P; Dahlof, B				Devereux, RB; Wachtell, K; Gerdts, E; Boman, K; Nieminen, MS; Papademetriou, V; Rokkedal, J; Harris, K; Aurup, P; Dahlof, B			Prognostic significance of left ventricular mass change during treatment of hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-POINT REDUCTION; LOSARTAN INTERVENTION; ECHOCARDIOGRAPHIC-ASSESSMENT; CARDIOVASCULAR RISK; BLOOD-PRESSURE; SERIAL CHANGES; HYPERTROPHY; REGRESSION; GEOMETRY; ATENOLOL	Context Increased baseline left ventricular (LV) mass predicts cardiovascular (CV) complications of hypertension, but the relation between lower LV mass and outcome during treatment for hypertension is uncertain. Objective To determine whether reduction of LV mass during antihypertensive treatment modifies risk of major CV events independent of blood pressure change. Design, Setting, and Participants Prospective cohort substudy of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) randomized clinical trial, conducted from 1995 to 2001. A total of 941 prospectively identified patients aged 55 to 80 years with essential hypertension and electrocardiographic LV hypertrophy had LV mass measured by echocardiography at enrollment in the LIFE trial and thereafter were followed up annually for a mean (SD) of 4.8 (1.0) years for CV events. Main Outcome Measures Composite end point of CV death, fatal or nonfatal myocardial infarction, and fatal or nonfatal stroke. Results The composite end point occurred in 104 patients (11%). The multivariable Cox regression model showed a strong association between lower in-treatment LV mass index and reduced rate of the composite CV end point (hazard ratio [HR], 0.78 per 1-SD (25.3) decrease in LV mass index; 95% confidence interval [CI], 0.65-0.94; P=.009) over and above that predicted by reduction in blood pressure. There were parallel associations between lower in-treatment LV mass index and lower CV mortality (HR, 0.62; 95% CI, 0.47-0.82; P=.001), stroke (HR, 0.76; 95% CI, 0.60-0.96; P=.02), myocardial infarction (HR, 0.85; 95% CI, 0.62-1.17, P=.33), and all-cause mortality (HR, 0.72; 95% CI, 0.59-0.88, P=.002), independent of systolic blood pressure and assigned treatment. Results were confirmed in analyses adjusting for additional CV risk factors, electrocardiographic changes, or when only considering events after the first year of study treatment. Conclusion In patients with essential hypertension and baseline electrocardiographic LV hypertrophy, lower LV mass during anti hypertensive treatment is associated with lower rates of clinical end points, additional to effects of blood pressure lowering and treatment modality.	Cornell Med Ctr, Dept Med, New York, NY USA; Glostrup Univ Hosp, Dept Med, Glostrup, Denmark; Haukeland Hosp, N-5021 Bergen, Norway; Skelleftea Lasarett, Skelleftea, Sweden; Umea Univ, Skelleftea, Sweden; Univ Helsinki, Cent Hosp, Dept Cardiol, Helsinki, Finland; Vet Adm Hosp, Washington, DC USA; Merck Res Labs, West Point, PA USA; Sahlgrens Univ Hosp, Ostrava, Czech Republic; Univ Gothenburg, Gothenburg, Sweden	Cornell University; University of Copenhagen; Umea University; University of Helsinki; Helsinki University Central Hospital; Merck & Company; University of Gothenburg	Devereux, RB (corresponding author), New York Presbyterian Hosp, Weill Cornell Med Ctr, 525 E 68th St, New York, NY 10021 USA.	rbdevere@med.cornell.edu		Papademetriou, Vasilios/0000-0002-2882-2757				[Anonymous], 1980, LANCET, V1, P1261; BOLOGNESE L, 1994, AM J CARDIOL, V73, P1, DOI 10.1016/0002-9149(94)90717-X; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CUTLER JA, 1989, HYPERTENSION S1, V13, P136; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; Devereux RB, 2004, CIRCULATION, V110, P1456, DOI 10.1161/01.CIR.0000141573.44737.5A; Devereux RB, 1996, J HYPERTENS, V14, pS95, DOI 10.1097/00004872-199609002-00018; DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444; Devereux RB, 1997, CIRCULATION, V96, P1416, DOI 10.1161/01.CIR.96.5.1416; Devereux RB, 2001, BLOOD PRESSURE, V10, P74, DOI 10.1080/08037050152112050; DEVEREUX RB, 1986, AM J CARDIOL, V57, P450, DOI 10.1016/0002-9149(86)90771-X; Devereux Richard B., 1995, P1969; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; Gerdts E, 2004, J AM COLL CARDIOL, V43, p448A, DOI 10.1016/S0735-1097(04)91887-6; GHALI JK, 1992, ANN INTERN MED, V117, P831, DOI 10.7326/0003-4819-117-10-831; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Ilercil A, 2001, J AM SOC ECHOCARDIOG, V14, P601, DOI 10.1067/mje.2001.113258; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LIAO YL, 1995, JAMA-J AM MED ASSOC, V273, P1592, DOI 10.1001/jama.273.20.1592; MACMAHON S, 1989, AM J CARDIOL, V63, P202, DOI 10.1016/0002-9149(89)90286-5; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MUIESAN ML, 1995, J HYPERTENS, V13, P1091, DOI 10.1097/00004872-199510000-00003; Okin PM, 2003, CIRCULATION, V108, P684, DOI 10.1161/01.CIR.0000083724.28630.C3; Okin PM, 2004, JAMA-J AM MED ASSOC, V292, P2343, DOI 10.1001/jama.292.19.2343; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Palmieri V, 2001, CIRCULATION, V103, P102; Palmieri V, 1999, J AM COLL CARDIOL, V34, P1625, DOI 10.1016/S0735-1097(99)00396-4; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; Vakili BA, 2001, AM HEART J, V141, P334, DOI 10.1067/mhj.2001.113218; VERDECCHIA P, 1994, HYPERTENSION, V24, P793, DOI 10.1161/01.HYP.24.6.793; Verdecchia P, 1998, CIRCULATION, V97, P48, DOI 10.1161/01.CIR.97.1.48; Wachtell K, 2000, HYPERTENSION, V35, P6, DOI 10.1161/01.HYP.35.1.6; YURENEV AP, 1992, AM J HYPERTENS, V5, pS182, DOI 10.1093/ajh/5.6.182S; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1985, HYPERTENSION, V7, P105	41	634	666	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2350	2356		10.1001/jama.292.19.2350	http://dx.doi.org/10.1001/jama.292.19.2350			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547162				2022-12-28	WOS:000225070100023
J	Wei, L; MacDonald, TM; Walker, BR				Wei, L; MacDonald, TM; Walker, BR			Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease	ANNALS OF INTERNAL MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TYPE-2 DIABETES-MELLITUS; RHEUMATOID-ARTHRITIS; BLOOD-PRESSURE; INSULIN-RESISTANCE; CUSHINGS-DISEASE; RISK-FACTORS; MORTALITY; POPULATION; COHORT	Background: Glucocorticoids have adverse systemic effects, including obesity, hypertension, and hyperglycemia, that may predispose to cardiovascular disease. The effect of glucocorticoid use on cardiovascular disease has not been quantified. Objective: To test the hypothesis that users of exogenous glucocorticoids have an increased risk for cardiovascular disease. Design: A cohort study using a record linkage database. Setting: Tayside, Scotland, United Kingdom. Patients: 68 781 glucocorticoid users and 82 202 nonusers without previous hospitalization for cardiovascular disease who were studied between 1993 and 1996. Measurements: The average daily dose of glucocorticoid exposure during follow-up was categorized as low (inhaled, nasal, and topical only), medium (oral, rectal, or parenteral <7.5 mg of prednisolone equivalent), or high (greater than or equal to7.5 mg of prednisolone equivalent). Poisson regression model, sensitivity analysis, and propensity score methods were used to investigate the association between glucocorticoid exposure and cardiovascular outcome. Results: 4383 cardiovascular events occurred in 257 487 person-years of follow-up for a rate of 17.0 (95% CI, 16.5 to 17.5) per 1000 person-years in the comparator group, and 5068 events occurred in 212 287 person-years for a rate of 23.9 (CI, 23.2 to 24.5) per 1000 person-years in the group exposed to glucocorticoids (22.1, 27.2, and 76.5 in low, medium, and high groups, respectively). The absolute risk difference was 6.9 (CI, 6.0 to 7.7) per 1000 person-years (5.1, 10.1, and 59.4, respectively). After adjustment for known covariates, the relative risk for a cardiovascular event in patients receiving high-dose glucocorticoids was 2.56 (CI, 2.18 to 2.99). Limitations: Because the data were observational, residual confounding cannot be excluded. Conclusion: Treatment with high-dose glucocorticoids seemed to be associated with increased risk for cardiovascular disease.	Univ Dundee, Ninewells Hosp & Med Sch, Med Monitoring Unit, Div Med & Therapeut, Dundee DD1 9SY, Scotland; Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland	University of Dundee; University of Edinburgh; University of Edinburgh	MacDonald, TM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Med Monitoring Unit, Div Med & Therapeut, Dundee DD1 9SY, Scotland.	t.m.macdonald@dundee.ac.uk		MacDonald, Thomas/0000-0001-5189-6669				Andrews RC, 1999, CLIN SCI, V96, P513, DOI 10.1042/cs0960513; Au DH, 2000, AM J RESP CRIT CARE, V161, P827, DOI 10.1164/ajrccm.161.3.9904006; Bjorntorp P, 1999, DIABETIC MED, V16, P373, DOI 10.1046/j.1464-5491.1999.00067.x; *BRIT MED ASSM, 1998, BRIT NAT FORM; Colao A, 1999, J CLIN ENDOCR METAB, V84, P2664, DOI 10.1210/jc.84.8.2664; DeMaria AN, 2002, AM J CARDIOL, V89, p33D; ETXABE J, 1994, CLIN ENDOCRINOL, V40, P479, DOI 10.1111/j.1365-2265.1994.tb02486.x; Evans JMM, 2000, DIABETIC MED, V17, P478, DOI 10.1046/j.1464-5491.2000.00309.x; EVANS JMM, 2000, PHARMACOEPIDEM DR S, P361; Fraser R, 1999, HYPERTENSION, V33, P1364, DOI 10.1161/01.HYP.33.6.1364; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P34; Hole DJ, 1996, BRIT MED J, V313, P711; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; MacDonald TM, 1997, BMJ-BRIT MED J, V315, P1333, DOI 10.1136/bmj.315.7119.1333; MAXWELL SRJ, 1994, POSTGRAD MED J, V70, P863, DOI 10.1136/pgmj.70.830.863; McEntegart A, 2001, RHEUMATOLOGY, V40, P640, DOI 10.1093/rheumatology/40.6.640; McMahon AD, 1998, PHARMACOEPIDEM DR S, V7, P275, DOI 10.1002/(SICI)1099-1557(199807/08)7:4<275::AID-PDS363>3.0.CO;2-N; MUTRU O, 1985, BMJ-BRIT MED J, V290, P1797, DOI 10.1136/bmj.290.6484.1797; NASHEL DJ, 1986, AM J MED, V80, P925, DOI 10.1016/0002-9343(86)90639-X; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; RAB ST, 1991, J AM COLL CARDIOL, V18, P1524, DOI 10.1016/0735-1097(91)90685-3; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Souverein PC, 2004, HEART, V90, P859, DOI 10.1136/hrt.2003.020180; Toren K, 1996, INT J EPIDEMIOL, V25, P617, DOI 10.1093/ije/25.3.617; TURNER R, 1997, SCOTLANDS HLTH SCOTT, V1, P140; Uddhammar A, 2002, J RHEUMATOL, V29, P737; Versaci F, 2002, J AM COLL CARDIOL, V40, P1935, DOI 10.1016/S0735-1097(02)02562-7; Walker BR, 1998, HYPERTENSION, V31, P891, DOI 10.1161/01.HYP.31.4.891; Wallberg-Jonsson S, 1999, J RHEUMATOL, V26, P2562; Wang JX, 2001, PHARMACOEPIDEM DR S, V10, P105, DOI 10.1002/pds.572; Whitworth JA, 2000, HYPERTENSION, V36, P912, DOI 10.1161/01.HYP.36.5.912; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; 1998, SCOTTISH HLTH STAT	34	506	525	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					764	770		10.7326/0003-4819-141-10-200411160-00007	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545676				2022-12-28	WOS:000225206900003
J	Marsh, DR; Schroeder, DG; Dearden, KA; Sternin, J; Sternin, M				Marsh, DR; Schroeder, DG; Dearden, KA; Sternin, J; Sternin, M			The power of positive deviance	BMJ-BRITISH MEDICAL JOURNAL			English	Article								The most efficient way to improve health is to use locally available, sustainable, and effective approaches. In the 1970s policy developers tested the concept that public health interventions could be designed around uncommon, beneficial health behaviours that some community members already practised.(1 2) This concept-known as positive deviance(3 4)-was used successfully to improve the nutritional status of children in several settings in the 1990s.(5-10) Recently, the approach has also been applied to newborn care, child nutrition, rates of contraception, safe sexual practices, and educational outcomes.(11-13) In this article we describe how the approach works, the evidence that it is effective, and possible future applications.	Save Childrens Federat USA, Westport, CT USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Brigham Young Univ, Provo, UT 84602 USA; Tufts Univ, Medford, MA 02155 USA	Save the Children; Emory University; Rollins School Public Health; Brigham Young University; Tufts University	Marsh, DR (corresponding author), 31 Wildflower Dr, Amherst, MA 01002 USA.	dmarsh@savechildren.org						Ahrari Mahshid, 2002, Food and Nutrition Bulletin, V23, P83; Berggren Warren L, 2002, Food Nutr Bull, V23, P9; Bolles Kathryn, 2002, Food Nutr Bull, V23, P11; Dearden Kirk A, 2002, Food Nutr Bull, V23, P119; Dorsey D., 2000, FAST CO, V41, P284; Evans T., 2001, CHALLENGING INEQUITI; *FOOD HUNGR INT, FY2001 ANN REP; Hendrickson Julia L, 2002, Food Nutr Bull, V23, P86; Lapping Karin, 2002, Food Nutr Bull, V23, P130; MACKINTOSH AT, 2002, FOOD NUTR B S4, V23, P18; Macklis R. M, 2001, GROUP PRACT J, V50, P1; Marsh David R, 2002, Food Nutr Bull, V23, P36; Marsh David R, 2002, Food Nutr Bull, V23, P5; Marsh David R, 2002, Food Nutr Bull, V23, P109; MARSH DR, 2002, POSITIVE DEVIANCE HE, P157; Mathews R., 2002, DEVIANTS ADVANTAGE F; Pachon Helena, 2002, Food Nutr Bull, V23, P62; *PD HEARTH, 2001, FIND COMM BAS SOL MA; Schroeder Dirk G, 2002, Food Nutr Bull, V23, P53; SHEKAR M, 1992, INT J EPIDEMIOL, V21, P707, DOI 10.1093/ije/21.4.707; Sripaipan Teerada, 2002, Food Nutr Bull, V23, P70; Sternin J, 2002, J CORPORATE CITI SPR, P57; STERNIN M, 1999, SCALING SCALING CAPA; Sternin M., 1997, HEARTH NUTR MODEL AP, P1997; Sternin M, 1998, FIELD GUIDE DESIGNIN; Vani Sethi, 2003, Pakistan Journal of Nutrition, V2, P164; WISHIK SM, 1976, AM J PUBLIC HEALTH, V66, P38, DOI 10.2105/AJPH.66.1.38; WRAY JD, 1972, J TROP PEDIAT ENV CH, V18, P27; ZEWITLIN M, 1990, POSITIVE DEVIANCE CH	29	335	338	0	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1177	1179		10.1136/bmj.329.7475.1177	http://dx.doi.org/10.1136/bmj.329.7475.1177			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539680	Green Published			2022-12-28	WOS:000225169600033
J	Opie, LH				Opie, LH			The metabolic vicious cycle in heart failure	LANCET			English	Editorial Material							LEFT-VENTRICULAR DYSFUNCTION; FATTY-ACID; GLUCOSE		Univ Cape Town, Sch Med, Fac Hlth Sci, Dept Med,Hatter Inst, ZA-7925 Cape Town, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Sch Med, Fac Hlth Sci, Dept Med,Hatter Inst, ZA-7925 Cape Town, South Africa.	Opie@capeheart.uct.ac.za						Beanlands RSB, 2000, CIRCULATION, V102, P2070, DOI 10.1161/01.CIR.102.17.2070; BERSIN RM, 1994, J AM COLL CARDIOL, V23, P1617, DOI 10.1016/0735-1097(94)90665-3; Bristow M, 2000, LANCET, V356, P1621, DOI 10.1016/S0140-6736(00)03149-4; Cross HR, 1996, CIRC RES, V78, P482, DOI 10.1161/01.RES.78.3.482; Dyck JRB, 2004, CIRC RES, V94, pE78, DOI 10.1161/01.RES.0000129255.19569.8f; Nikolaidis LA, 2004, CIRCULATION, V109, P962, DOI 10.1161/01.CIR.0000120505.91348.58; OLIVER MF, 1994, LANCET, V343, P155, DOI 10.1016/S0140-6736(94)90939-3; RANDLE PJ, 1963, LANCET, V1, P785; SHIPP JC, 1961, NATURE, V189, P1018, DOI 10.1038/1891018a0; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Vitale C, 2004, EUR HEART J, V25, P1814, DOI 10.1016/j.ehj.2004.06.034	11	70	71	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1733	1734		10.1016/S0140-6736(04)17412-6	http://dx.doi.org/10.1016/S0140-6736(04)17412-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541431				2022-12-28	WOS:000225070600005
J	Sharp, D				Sharp, D			Hearts and minds, from Darfur to locusts	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Sharp, D (corresponding author), Lancet, London NW1 7BY, England.							Depoortere E, 2004, LANCET, V364, P1315, DOI 10.1016/S0140-6736(04)17187-0; International Strategy for Disaster Reduction, 2005, WORLD C DIS RED 18 2; *UN OFF COORD HUM, RELIEFWEB COMPL EM N	3	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1741	1742		10.1016/S0140-6736(04)17417-5	http://dx.doi.org/10.1016/S0140-6736(04)17417-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541436				2022-12-28	WOS:000225070600010
J	Hampoelz, B; Knoblich, JA				Hampoelz, B; Knoblich, JA			Heterotrimeric G proteins: New tricks for an old dog	CELL			English	Review							ASYMMETRIC CELL-DIVISION; G-ALPHA; C-ELEGANS; DROSOPHILA; ORIENTATION; POLARITY	Heterotrimeric G proteins are well known for their function in signal transduction downstream of seven transmembrane receptors. More recently, however, genetic analysis in C. elegans and in Drosophila has revealed a second, essential function of these molecules in positioning the mitotic spindle and attaching microtubules to the cell cortex. Five new publications in Cell (Afshar et al., 2004; Du and Macara, 2004 [this issue of Cell]; Hess et al., 2004), Developmental Cell (Martin-McCaffrey et al., 2004), and Current Biology (Couwenbergs et al., 2004) show that this function is conserved in vertebrates and-like the classical pathway- involves cycling of G proteins between GDP and GTP bound conformations.	Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Knoblich, JA (corresponding author), Austrian Acad Sci, Inst Mol Biotechnol, Dr Bohn Gasse 3-5, A-1030 Vienna, Austria.	knoblich@imp.univie.ac.at	Knoblich, Juergen A/C-2974-2015	Knoblich, Juergen A/0000-0002-6751-3404; Hampoelz, Bernhard/0000-0001-7491-0080				Afshar K, 2004, CELL, V119, P219, DOI 10.1016/j.cell.2004.09.026; Betschinger J, 2004, CURR BIOL, V14, pR674, DOI 10.1016/j.cub.2004.08.017; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; Couwenbergs C, 2004, CURR BIOL, V14, P1871, DOI 10.1016/j.cub.2004.09.059; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Du QS, 2004, CELL, V119, P503, DOI 10.1016/j.cell.2004.10.028; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hess HA, 2004, CELL, V119, P209, DOI 10.1016/j.cell.2004.09.025; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; Martin-McCaffrey L, 2004, DEV CELL, V7, P763, DOI 10.1016/j.devcel.2004.10.004; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Schneider SQ, 2003, ANNU REV GENET, V37, P221, DOI 10.1146/annurev.genet.37.110801.142443; Tall GG, 2003, J BIOL CHEM, V278, P8356, DOI 10.1074/jbc.M211862200; Wodarz A, 2003, MECH DEVELOP, V120, P1297, DOI 10.1016/j.mod.2003.06.003; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	18	59	69	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					453	456		10.1016/j.cell.2004.10.025	http://dx.doi.org/10.1016/j.cell.2004.10.025			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537535	Bronze			2022-12-28	WOS:000225183200004
J	Singleton, MR; Dillingham, MS; Gaudier, M; Kowalczykowski, SC; Wigley, DB				Singleton, MR; Dillingham, MS; Gaudier, M; Kowalczykowski, SC; Wigley, DB			Crystal structure of RecBCD enzyme reveals a machine for processing DNA breaks	NATURE			English	Article							SINGLE-STRANDED-DNA; RECOMBINATION HOTSPOT-CHI; ESCHERICHIA-COLI; ATP HYDROLYSIS; HELICASE ACTIVITY; NUCLEASE ACTIVITY; RECD SUBUNIT; STEP-SIZE; TRANSLOCATION; SEQUENCE	RecBCD is a multi-functional enzyme complex that processes DNA ends resulting from a double-strand break. RecBCD is a bipolar helicase that splits the duplex into its component strands and digests them until encountering a recombinational hotspot (Chi site). The nuclease activity is then attenuated and RecBCD loads RecA onto the 3' tail of the DNA. Here we present the crystal structure of RecBCD bound to a DNA substrate. In this initiation complex, the DNA duplex has been split across the RecC subunit to create a fork with the separated strands each heading towards different helicase motor subunits. The strands pass along tunnels within the complex, both emerging adjacent to the nuclease domain of RecB. Passage of the 3' tail through one of these tunnels provides a mechanism for the recognition of a Chi sequence by RecC within the context of double-stranded DNA. Gating of this tunnel suggests how nuclease activity might be regulated.	London Res Inst, Canc Res UK Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Natl Inst Med Res, London NW7 1AA, England; Univ Calif Davis, Ctr Genet & Dev, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Ctr Genet & Dev, Sect Mol & Cellular Biol, Davis, CA 95616 USA	Cancer Research UK; MRC National Institute for Medical Research; University of California System; University of California Davis; University of California System; University of California Davis	Wigley, DB (corresponding author), London Res Inst, Canc Res UK Clare Hall Labs, Potters Bar EN6 3LD, Herts, England.	dale.wigley@cancer.org.uk		Dillingham, Mark/0000-0002-4612-7141; Singleton, Martin/0000-0001-5716-7715				Amundsen SK, 2002, GENETICS, V161, P483; Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Anderson DG, 1997, GENE DEV, V11, P571, DOI 10.1101/gad.11.5.571; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; Arnold DA, 2000, J MOL BIOL, V300, P469, DOI 10.1006/jmbi.2000.3861; Arnold DA, 1998, J BIOL CHEM, V273, P16476, DOI 10.1074/jbc.273.26.16476; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bianco PR, 1997, P NATL ACAD SCI USA, V94, P6706, DOI 10.1073/pnas.94.13.6706; Bianco PR, 2000, NATURE, V405, P368, DOI 10.1038/35012652; BOEHMER PE, 1992, J BIOL CHEM, V267, P4981; BOEHMER PE, 1991, GENE, V102, P1, DOI 10.1016/0378-1119(91)90529-K; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen HW, 1997, J BIOL CHEM, V272, P10072; Churchill JJ, 2000, J MOL BIOL, V297, P537, DOI 10.1006/jmbi.2000.3590; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dillingham MS, 2003, NATURE, V423, P893, DOI 10.1038/nature01673; Dillingham MS, 2000, BIOCHEMISTRY-US, V39, P205, DOI 10.1021/bi992105o; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; DIXON DA, 1993, CELL, V73, P87, DOI 10.1016/0092-8674(93)90162-J; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Handa N, 1997, GENES CELLS, V2, P525, DOI 10.1046/j.1365-2443.1997.1410339.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KORANGY F, 1994, BIOCHEMISTRY-US, V33, P9552, DOI 10.1021/bi00198a022; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kovall R, 1997, SCIENCE, V277, P1824, DOI 10.1126/science.277.5333.1824; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KUHN B, 1979, J BIOL CHEM, V254, P1343; Kulkarni A, 2004, NUCLEIC ACIDS RES, V32, P3672, DOI 10.1093/nar/gkh675; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2873, DOI 10.1021/bi00433a019; ROSAMOND J, 1979, J BIOL CHEM, V254, P8646; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHULTZ DW, 1983, J BACTERIOL, V155, P664, DOI 10.1128/JB.155.2.664-680.1983; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Spies M, 2003, CELL, V114, P647, DOI 10.1016/S0092-8674(03)00681-0; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TAYLOR AF, 1995, J BIOL CHEM, V270, P24451, DOI 10.1074/jbc.270.41.24451; Taylor AF, 2003, NATURE, V423, P889, DOI 10.1038/nature01674; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1995, J BIOL CHEM, V270, P24459, DOI 10.1074/jbc.270.41.24459; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Weeks CM, 1999, ACTA CRYSTALLOGR D, V55, P492, DOI 10.1107/S0907444998012633; Yu M, 1998, J MOL BIOL, V283, P797, DOI 10.1006/jmbi.1998.2127; Yu M, 1998, P NATL ACAD SCI USA, V95, P981, DOI 10.1073/pnas.95.3.981	50	306	315	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					187	193		10.1038/nature02988	http://dx.doi.org/10.1038/nature02988			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538360				2022-12-28	WOS:000225020200037
J	Montori, VM; Jaeschke, R; Schunemann, HJ; Bhandari, M; Brozek, JL; Devereaux, PJ; Guyatt, GH				Montori, VM; Jaeschke, R; Schunemann, HJ; Bhandari, M; Brozek, JL; Devereaux, PJ; Guyatt, GH			Users' guide to detecting misleading claims in clinical research reports	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED-TRIALS; QUALITY; NEPHROPATHY; IRBESARTAN; OUTCOMES; DESIGN		McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada; Jagiellonian Univ, Sch Med, Polish Inst Evidence Based Med, Krakow, Poland; McMaster Univ, Dept Med, Hamilton, ON, Canada; Mayo Clin, Coll Med, Dept Med, Rochester, MN USA	McMaster University; Jagiellonian University; McMaster University; Mayo Clinic	Guyatt, GH (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8S 4L8, Canada.	guyatt@mcmaster.ca	Bhandari, Mohit/AAQ-1675-2021; Devereaux, PJ/AAY-1757-2021; Devereaux, PJ/AAF-2862-2019	Montori, Victor/0000-0003-0595-2898; Schunemann, Holger/0000-0003-3211-8479; Devereaux, PJ/0000-0003-2935-637X				Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bero LA, 1996, INT J TECHNOL ASSESS, V12, P209, DOI 10.1017/S0266462300009582; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Christiansen PE, 1996, ACTA PSYCHIAT SCAND, V93, P158, DOI 10.1111/j.1600-0447.1996.tb10623.x; Clarke M, 2002, JAMA-J AM MED ASSOC, V287, P2799, DOI 10.1001/jama.287.21.2799; Cook D, 2001, ANN INTERN MED, V135, P205, DOI 10.7326/0003-4819-135-3-200108070-00013; Devereaux PJ, 2001, CAN MED ASSOC J, V164, P1573; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Docherty M, 1999, BRIT MED J, V318, P1224; Geddes J, 2000, BRIT MED J, V321, P1371, DOI 10.1136/bmj.321.7273.1371; GREENHALGH T, 2001, READ PAPER; Guyatt G., 2015, USERS GUIDES MED LIT; HORTON R, 1995, BRIT MED J, V310, P985, DOI 10.1136/bmj.310.6985.985; Hostetter TH, 2001, NEW ENGL J MED, V345, P910, DOI 10.1056/NEJM200109203451209; Johansen HK, 1999, JAMA-J AM MED ASSOC, V282, P1752, DOI 10.1001/jama.282.18.1752; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; MANN H, J LIND LIB; McCormack J, 2000, BMJ-BRIT MED J, V320, P1720, DOI 10.1136/bmj.320.7251.1720; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Oxman A, 2002, USERS GUIDES INTERAC; Parving HH, 2001, NEW ENGL J MED, V345, P870, DOI 10.1056/NEJMoa011489; Safer DJ, 2002, J NERV MENT DIS, V190, P583, DOI 10.1097/00005053-200209000-00002; Shaughnessy AF, 2003, BRIT MED J, V327, P266, DOI 10.1136/bmj.327.7409.266; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Waksman R, 2002, NEW ENGL J MED, V346, P1194, DOI 10.1056/NEJMoa012579; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Wing LMH, 2003, NEW ENGL J MED, V348, P583, DOI 10.1056/NEJMoa021716; [No title captured], DOI DOI 10.1002/14651858.CD001208	31	71	74	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1093	1096		10.1136/bmj.329.7474.1093	http://dx.doi.org/10.1136/bmj.329.7474.1093			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528623	Green Published			2022-12-28	WOS:000225070300026
J	Heemsbergen, DA; Berg, MP; Loreau, M; van Haj, JR; Faber, JH; Verhoef, HA				Heemsbergen, DA; Berg, MP; Loreau, M; van Haj, JR; Faber, JH; Verhoef, HA			Biodiversity effects on soil processes explained by interspecific functional dissimilarity	SCIENCE			English	Article								The loss of biodiversity can have significant impacts on ecosystem functioning, but the mechanisms involved lack empirical confirmation. Using soil microcosms, we show experimentally that functional dissimilarity among detritivorous species, not species number, drives community compositional effects on leaf litter mass loss and soil respiration, two key soil ecosystem processes. These experiments confirm theoretical predictions that biodiversity effects on ecosystem functioning can be predicted by the degree of functional differences among species.	Vrije Univ Amsterdam, Inst Ecol Sci, Dept Anim Ecol, NL-1081 HV Amsterdam, Netherlands; Univ Wageningen & Res Ctr, Alterra, NL-6700 AA Wageningen, Netherlands; Ecole Normale Super, Ecol Lab, F-75230 Paris, France	Vrije Universiteit Amsterdam; Wageningen University & Research; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Verhoef, HA (corresponding author), Vrije Univ Amsterdam, Inst Ecol Sci, Dept Anim Ecol, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	herman.verhoef@ecology.fatw.vu.nl	Collison, Elizabeth/F-6146-2011	van Hal, J.R./0000-0002-9466-8997; Berg, Matty P./0000-0001-8442-8503				Andren O, 1999, APPL SOIL ECOL, V13, P105, DOI 10.1016/S0929-1393(99)00025-6; Bradford MA, 2002, SCIENCE, V298, P615, DOI 10.1126/science.1075805; Coleman DC, 2018, FUNDAMENTALS SOIL EC, P77, DOI DOI 10.1016/B978-0-12-805251-8.00004; FABER JH, 1991, SOIL BIOL BIOCHEM, V23, P15, DOI 10.1016/0038-0717(91)90157-F; Laakso J, 1999, OIKOS, V87, P57, DOI 10.2307/3546996; Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573; Mikola J, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P169; Tilman D, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P21; Walker B, 1999, ECOSYSTEMS, V2, P95, DOI 10.1007/s100219900062; Wardle DA, 1997, SCIENCE, V277, P1296, DOI 10.1126/science.277.5330.1296	10	394	431	15	287	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1019	1020		10.1126/science.1101865	http://dx.doi.org/10.1126/science.1101865			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528441				2022-12-28	WOS:000225001100039
J	Kirkevold, O; Engedal, K				Kirkevold, O; Engedal, K			Concealment of drugs in food and beverages in nursing homes: cross sectional study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COVERT MEDICATION; RESTRAINTS; SCALE; CARE	Objective To examine the practice of concealing drugs in patients' foodstuff in nursing homes. Design Structured interview study with data collected by structured interview. Setting All five health regions in Norway. Participants Professional carers of 1362 patients in 160 regular nursing home units and 564 patients in 90 special care units for people with dementia. Main outcome measures Frequency of concealment of drugs; who decided to conceal the drugs; how this practice was documented in the patients' records; and what types of drugs were given this way. Results 11% of the patients in regular nursing home units and 17% of the patients in special care units for people with dementia received drugs mixed in their food or beverages at least once during seven days. In 95% of cases, drugs were routinely mixed in the food or beverages. The practice was documented in patients' records in 40% (96/241) of cases. The covert administration of drugs was more often documented when the physician took the decision to hide the drugs in the patient's foodstuff (57%; 27/47) than when the person who made the decision was unknown or not recorded (23%; 7/30). Patients who got drugs covertly more often received antiepileptics, antipsychotics, and anxiolytics compared with patients who were given their drugs openly. Conclusions The covert administration of drugs is common in Norwegian nursing homes. Routines for such practice are arbitrary, and the practice is poorly documented in the patients' records.	Vestfold Mental Hlth Care Trust, Norwegian Ctr Dementia Res, N-3107 Sem, Norway; Ullevaal Univ Hosp, Dept Geriatr Med, Norwegian Ctr Dementia Res, Oslo, Norway	University of Oslo	Kirkevold, O (corresponding author), Vestfold Mental Hlth Care Trust, Norwegian Ctr Dementia Res, Postbox 64, N-3107 Sem, Norway.	oyvind.kirkevold@nordemens.no		Kirkevold, Oyvind/0000-0001-5698-5636				Blythe J, 2000, BRIT MED J, V321, P402, DOI 10.1136/bmj.321.7258.402; FINKEL SI, 1993, J AM GERIATR SOC, V41, P50, DOI 10.1111/j.1532-5415.1993.tb05948.x; Honkanen L, 2001, WESTERN J MED, V174, P229, DOI 10.1136/ewjm.174.4.229; Hox J.J., 2017, MULTILEVEL ANAL TECH, V3rd ed., P1, DOI [10.4324/9781315650982, DOI 10.4324/9781315650982]; Hughes CM, 2000, MED CARE, V38, P1164, DOI 10.1097/00005650-200012000-00003; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Kirkevold O, 2003, INT J GERIATR PSYCH, V18, P491, DOI 10.1002/gps.883; Kow JV, 2000, CAN MED ASSOC J, V162, P339; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lindesay J, 2003, INT J GERIATR PSYCH, V18, P511, DOI 10.1002/gps.871; MCCULLA MM, 1989, ARCH NEUROL-CHICAGO, V46, P1210, DOI 10.1001/archneur.1989.00520470070029; Middleton H, 1999, J Gerontol Nurs, V25, P26; NYGAARD HA, 1994, INT J GERIATR PSYCH, V9, P387, DOI 10.1002/gps.930090507; Phillips CD, 2000, AM J PUBLIC HEALTH, V90, P92, DOI 10.2105/AJPH.90.1.92; Ramsay S, 2001, LANCET, V358, P900, DOI 10.1016/S0140-6736(01)06092-5; Ruths S, 2001, EUR J CLIN PHARMACOL, V57, P523; Schmidt IK, 2002, SOC SCI MED, V54, P1767, DOI 10.1016/S0277-9536(01)00146-0; Sorensen L, 2001, INT J GERIATR PSYCH, V16, P615, DOI 10.1002/gps.390; Thurmond JA, 1999, APPL NURS RES, V12, P159, DOI 10.1016/S0897-1897(99)80078-0; Treloar A, 2000, J ROY SOC MED, V93, P408, DOI 10.1177/014107680009300805	20	36	36	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					20	22A		10.1136/bmj.38268.579097.55	http://dx.doi.org/10.1136/bmj.38268.579097.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15561732	Bronze, Green Published			2022-12-28	WOS:000226176700013
J	Mandel, SJ				Mandel, SJ			A 64-year-old woman with a thyroid nodule	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINE-NEEDLE-ASPIRATION; LEVOTHYROXINE SUPPRESSIVE THERAPY; PROSPECTIVE RANDOMIZED-TRIAL; COLD NODULES; DOUBLE-BLIND; ULTRASOUND; BIOPSY; MANAGEMENT; DISEASE; RISK		Hosp Univ Penn, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Mandel, SJ (corresponding author), Hosp Univ Penn, Div Endocrinol Diabet & Metab, 1 Maloney,3400 Spruce St, Philadelphia, PA 19104 USA.	smandel@mail.med.upenn.edu						Alexander EK, 2003, ANN INTERN MED, V138, P315, DOI 10.7326/0003-4819-138-4-200302180-00010; Alexander EK, 2002, J CLIN ENDOCR METAB, V87, P4924, DOI 10.1210/jc.2002-020865; ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P297, DOI 10.1002/hed.2890030406; ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P216, DOI 10.1002/hed.2890030309; Baloch ZW, 1998, THYROID, V8, P565, DOI 10.1089/thy.1998.8.565; Baloch ZW, 2001, DIAGN CYTOPATHOL, V25, P231, DOI 10.1002/dc.2044; Baskin HJ, 2002, ENDOCR PRACT, V8, P457; BELFIORE A, 1992, AM J MED, V93, P363, DOI 10.1016/0002-9343(92)90164-7; Belfiore A, 2001, ENDOCRIN METAB CLIN, V30, P361, DOI 10.1016/S0889-8529(05)70191-2; Bennedbaek FN, 2000, J CLIN ENDOCR METAB, V85, P2493, DOI 10.1210/jc.85.7.2493; Braga M, 2001, J CLIN ENDOCR METAB, V86, P4089, DOI 10.1210/jc.86.9.4089; BRANDER A, 1992, J CLIN ULTRASOUND, V20, P37, DOI 10.1002/jcu.1870200107; BRANDER A, 1991, RADIOLOGY, V181, P683, DOI 10.1148/radiology.181.3.1947082; BRUSH B, 1952, ANN INTERN MED, V12, P1380; Burch HB, 1996, ACTA CYTOL, V40, P1176; BURCH HB, 1995, ENDOCRIN METAB CLIN, V24, P663, DOI 10.1016/S0889-8529(18)30019-7; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Cap J, 1999, CLIN ENDOCRINOL, V51, P509; Carmeci C, 1998, THYROID, V8, P283, DOI 10.1089/thy.1998.8.283; Castro MR, 2002, J CLIN ENDOCR METAB, V87, P4154, DOI 10.1210/jc.2001-011762; Chehade J M, 2001, Endocr Pract, V7, P237; COCHANDPRIOLLET B, 1994, AM J MED, V97, P152, DOI 10.1016/0002-9343(94)90025-6; Danese D, 1998, THYROID, V8, P15, DOI 10.1089/thy.1998.8.15; Deandrea Maurilio, 2002, Endocr Pract, V8, P282; DEGROOT LJ, 1989, J CLIN ENDOCR METAB, V69, P925, DOI 10.1210/jcem-69-5-925; Erdogan MF, 1998, THYROID, V8, P1087, DOI 10.1089/thy.1998.8.1087; FABER J, 1994, EUR J ENDOCRINOL, V130, P350, DOI 10.1530/eje.0.1300350; Gallo Marco, 2003, Endocr Pract, V9, P194; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GHARIB H, 1993, CLIN LAB MED, V13, P699, DOI 10.1016/S0272-2712(18)30434-7; Gharib H, 2001, CLIN G MED MANAG, P187; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; Hagag P, 1998, THYROID, V8, P989, DOI 10.1089/thy.1998.8.989; HALL TL, 1989, CANCER, V63, P718, DOI 10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N; HAMBERGER B, 1982, AM J MED, V73, P381, DOI 10.1016/0002-9343(82)90731-8; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; HAMMING JF, 1990, ARCH INTERN MED, V150, P113, DOI 10.1001/archinte.150.1.113; Hatada T, 1998, AM J SURG, V175, P133, DOI 10.1016/S0002-9610(97)00274-2; Hermus AR, 1998, NEW ENGL J MED, V338, P1438, DOI 10.1056/NEJM199805143382007; Hollowell JG, 1998, J CLIN ENDOCR METAB, V83, P3401, DOI 10.1210/jc.83.10.3401; HORST W, 1967, J NUCL MED, V8, P515; INGBAR S H, 1985, P682; JARLOV AE, 1993, BRIT J RADIOL, V66, P625, DOI 10.1259/0007-1285-66-787-625; Kloos RT, 2001, CLIN G MED MANAG, P227; Knudsen N, 2002, THYROID, V12, P879, DOI 10.1089/105072502761016502; KUMA K, 1992, WORLD J SURG, V16, P583, DOI 10.1007/BF02067327; Larijani B, 1999, Endocr Pract, V5, P251; LAROSA GL, 1995, ANN INTERN MED, V122, P1, DOI 10.7326/0003-4819-122-1-199501010-00001; LUCAS A, 1995, EUR J ENDOCRINOL, V132, P677, DOI 10.1530/eje.0.1320677; Malchoff CD, 2002, J CLIN ENDOCR METAB, V87, P2455, DOI 10.1210/jc.87.6.2455; Mandel Susan J, 2004, Endocr Pract, V10, P246; Marqusee E, 2000, ANN INTERN MED, V133, P696, DOI 10.7326/0003-4819-133-9-200011070-00011; MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MCCALL A, 1986, SURGERY, V100, P1128; METTLER FA, 1992, JAMA-J AM MED ASSOC, V268, P616, DOI 10.1001/jama.268.5.616; MISKIN M, 1973, ANN INTERN MED, V79, P505, DOI 10.7326/0003-4819-79-4-505; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; NAGATAKI S, 1994, JAMA-J AM MED ASSOC, V272, P364, DOI 10.1001/jama.272.5.364; Orija Israel B, 2004, Endocr Pract, V10, P317; PAPINI E, 1993, CLIN ENDOCRINOL, V38, P507, DOI 10.1111/j.1365-2265.1993.tb00347.x; Papini E, 1998, J CLIN ENDOCR METAB, V83, P780, DOI 10.1210/jc.83.3.780; Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941, DOI 10.1210/jc.87.5.1941; REVERTER JL, 1992, CLIN ENDOCRINOL, V36, P25, DOI 10.1111/j.1365-2265.1992.tb02898.x; RIDGWAY EC, 1992, J CLIN ENDOCR METAB, V74, P231, DOI 10.1210/jc.74.2.231; Sachmechi I, 2000, Endocr Pract, V6, P5; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901; SCHNEIDER AB, 1990, ENDOCRIN METAB CLIN, V19, P495, DOI 10.1016/S0889-8529(18)30307-4; SHAPIRO SJ, 1970, CANCER, V26, P1261, DOI 10.1002/1097-0142(197012)26:6<1261::AID-CNCR2820260613>3.0.CO;2-P; Solbiati L, 2001, EUR RADIOL, V11, P2411, DOI 10.1007/s00330-001-1163-7; TAKASHIMA S, 1994, J CLIN ULTRASOUND, V22, P535, DOI 10.1002/jcu.1870220904; TAN GH, 1995, ARCH INTERN MED, V155, P2418, DOI 10.1001/archinte.155.22.2418; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; VANHERLE AJ, 1982, ANN INTERN MED, V96, P221, DOI 10.7326/0003-4819-96-2-221; Werga P, 2000, WORLD J SURG, V24, P907, DOI 10.1007/s002680010163; YOKOZAWA T, 1995, THYROID, V5, P141, DOI 10.1089/thy.1995.5.141; Zelmanovitz F, 1998, J CLIN ENDOCR METAB, V83, P3881, DOI 10.1210/jc.83.11.3881	77	94	100	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2632	2642		10.1001/jama.292.21.2632	http://dx.doi.org/10.1001/jama.292.21.2632			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572721				2022-12-28	WOS:000225409100026
J	Lee, I; Date, SV; Adai, AT; Marcotte, EM				Lee, I; Date, SV; Adai, AT; Marcotte, EM			A probabilistic functional network of yeast genes	SCIENCE			English	Article							PROTEIN-PROTEIN INTERACTIONS; DATABASE; ORGANIZATION; COMPLEXES; ALGORITHM; MODULES; GENOMES	A conceptual framework for integrating diverse functional genomics data was developed by reinterpreting experiments to provide numerical likelihoods that genes are functionally linked. This allows direct comparison and integration of different classes of data. The resulting probabilistic gene network estimates the functional coupling between genes. Within this framework, we reconstructed an extensive, high-quality functional gene network for Saccharomyces cerevisiae, consisting of 4681 (similar to81%) of the known yeast genes linked by similar to34,000 probabilistic linkages comparable in accuracy to small-scale interaction assays. The integrated linkages distinguish true from false-positive interactions in earlier data sets; new interactions emerge from genes' network contexts, as shown for genes in chromatin modification and ribosome biogenesis.	Univ Texas, Ctr Syst & Synthet Biol, Austin, TX 78712 USA; Univ Texas, Inst Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Marcotte, EM (corresponding author), Univ Texas, Ctr Syst & Synthet Biol, Austin, TX 78712 USA.	marcotte@icmb.utexas.edu	Lee, Insuk/F-7722-2010	Marcotte, Edward/0000-0001-8808-180X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067779] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067779-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adai AT, 2004, J MOL BIOL, V340, P179, DOI 10.1016/j.jmb.2004.04.047; Dwight SS, 2002, NUCLEIC ACIDS RES, V30, P69, DOI 10.1093/nar/30.1.69; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Fraser AG, 2004, NAT GENET, V36, P559, DOI 10.1038/ng1370; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Goldberg DS, 2003, P NATL ACAD SCI USA, V100, P4372, DOI 10.1073/pnas.0735871100; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Martin A, 2002, J BIOL CHEM, V277, P17743, DOI 10.1074/jbc.M200762200; Mewes HW, 2002, NUCLEIC ACIDS RES, V30, P31, DOI 10.1093/nar/30.1.31; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Pereira-Leal JB, 2004, PROTEINS, V54, P49, DOI 10.1002/prot.10505; Rives AW, 2003, P NATL ACAD SCI USA, V100, P1128, DOI 10.1073/pnas.0237338100; Samanta MP, 2003, P NATL ACAD SCI USA, V100, P12579, DOI 10.1073/pnas.2132527100; Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403; Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100; Stevens S, COMMUNICATION; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; THOMPSON M, 2000, CURRENTS COMPUTATION; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; von Mering C, 2002, NATURE, V417, P399, DOI 10.1038/nature750; von Mering C, 2003, P NATL ACAD SCI USA, V100, P15428, DOI 10.1073/pnas.2136809100; von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303	34	498	512	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1555	1558		10.1126/science.1099511	http://dx.doi.org/10.1126/science.1099511			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567862				2022-12-28	WOS:000225442700059
J	Koshland, DE				Koshland, DE			Crazy, but correct	NATURE			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Koshland, DE (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.								0	13	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	2004	432	7016					447	447		10.1038/432447a	http://dx.doi.org/10.1038/432447a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565132	Bronze			2022-12-28	WOS:000225322100023
J	Stoler, JM; Leach, NT; Donahoe, PK; Harris, NL				Stoler, JM; Leach, NT; Donahoe, PK; Harris, NL			Case 36-2004: A 23-day-old infant with hypospadias and failure to thrive - Congenital abnormalities due to a chromosomal imbalance, karyotype 46,XY,rec(16)dup(16q)inv(16)(p13q22)pat, resulting from the recombination between the normal chromosome 16 and the inverted chromosome 16 in the patient's father.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LEMLI-OPITZ SYNDROME; PERICENTRIC-INVERSION; ALCOHOL-CONSUMPTION; PREGNANCY		Massachusetts Gen Hosp, Dept Med Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Stoler, JM (corresponding author), Massachusetts Gen Hosp, Dept Med Genet, Boston, MA 02114 USA.							BIANCHI DW, 1992, AM J MED GENET, V43, P791, DOI 10.1002/ajmg.1320430507; FRANK DA, 1988, PEDIATR CLIN N AM, V35, P1187; GARDNER RJM, 1996, CHROMOSOME ABNORMALI, P137; GONZALEZ CH, 1977, EUR J PEDIATR, V125, P1, DOI 10.1007/BF00470600; HANSON JW, 1978, J PEDIATR-US, V92, P457, DOI 10.1016/S0022-3476(78)80449-1; HASSOLD TJ, 1989, MOL CYTOGENETIC STUD, P115; HOMER C, 1981, AM J DIS CHILD, V135, P848, DOI 10.1001/archpedi.1981.02130330058019; JACOBS PA, 1992, J MED GENET, V29, P103, DOI 10.1136/jmg.29.2.103; JOSEPH DB, 1987, J UROLOGY, V137, P719, DOI 10.1016/S0022-5347(17)44188-7; KIRKLAND RT, 1999, OSKIS PEDIAT PRINCIP, P752; MALFAZ FC, 2001, AN ESP PEDIATR, V54, P582; MARCOVITCH H, 1994, BRIT MED J, V308, P35, DOI 10.1136/bmj.308.6920.35; MILLS JL, 1984, JAMA-J AM MED ASSOC, V252, P1875, DOI 10.1001/jama.252.14.1875; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; Olsen EM, 2002, UGESKRIFT LAEGER, V164, P5654; OPITZ JM, 1994, AM J MED GENET, V50, P344, DOI 10.1002/ajmg.1320500408; ROBIN NH, 1995, NAT GENET, V11, P459, DOI 10.1038/ng1295-459; STALLINGS RL, 1994, AM J MED GENET, V52, P346, DOI 10.1002/ajmg.1320520318; Stoler JM, 1999, J PEDIATR-US, V135, P430, DOI 10.1016/S0022-3476(99)70164-2; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; WILCOX WD, 1989, CLIN PEDIATR, V28, P391, DOI 10.1177/000992288902800901	21	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2319	2326		10.1056/NEJMcpc049028	http://dx.doi.org/10.1056/NEJMcpc049028			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564548				2022-12-28	WOS:000225298100013
J	Tomari, Y; Matranga, C; Haley, B; Martinez, N; Zamore, PD				Tomari, Y; Matranga, C; Haley, B; Martinez, N; Zamore, PD			A protein sensor for siRNA asymmetry	SCIENCE			English	Article							SEQUENCE-SPECIFIC INHIBITION; SMALL INTERFERING RNA; DISTINCT ROLES; ENZYME COMPLEX; DROSOPHILA; PATHWAYS; CELLS; ENDONUCLEASE; INITIATION; CLEAVAGE	To act as guides in the RNA interference (RNAi) pathway, small interfering RNAs (siRNAs) must be unwound into their component strands, then assembled with proteins to form the RNA-induced silencing complex (RISC), which catalyzes target messenger RNA cleavage. Thermodynamic differences in the base-pairing stabilities of the 5' ends of the two similar to21-nucleotide siRNA strands determine which siRNA strand is assembled into the RISC. We show that in Drosophila, the orientation of the Dicer-2/R2D2 protein heterodimer on the siRNA duplex determines which siRNA strand associates with the core RISC protein Argonaute 2. R2D2 binds the siRNA end with the greatest double-stranded character, thereby orienting the heterodimer on the siRNA duplex. Strong R2D2 binding requires a 5'-phosphate on the siRNA strand that is excluded from the RISC. Thus, R2D2 is both a protein sensor for siRNA thermodynamic asymmetry and a licensing factor for entry of authentic siRNAs into the RNAi pathway.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA.	phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013; Tomari, Yukihide/A-8009-2009	Tomari, Yukihide/0000-0001-8442-0851; Zamore, Phillip/0000-0002-4505-9618; Matranga, Christian/0000-0002-9037-5468	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062862, R01GM065236, R01GM062862] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62862-01, GM65236-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aza-Blanc P, 2003, MOL CELL, V12, P627, DOI 10.1016/S1097-2765(03)00348-4; Boutla A, 2001, CURR BIOL, V11, P1776, DOI 10.1016/S0960-9822(01)00541-3; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	23	445	486	5	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1377	1380		10.1126/science.1102755	http://dx.doi.org/10.1126/science.1102755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550672				2022-12-28	WOS:000225301600053
J	Jauhar, S				Jauhar, S			House calls	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Long Isl Jewish Med Ctr, Heart Failure Program, New Hyde Pk, NY 11042 USA	Northwell Health	Jauhar, S (corresponding author), Long Isl Jewish Med Ctr, Heart Failure Program, New Hyde Pk, NY 11042 USA.							Leff B, 2001, J GERONTOL A-BIOL, V56, pM603, DOI 10.1093/gerona/56.10.M603	1	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2149	2151		10.1056/NEJMp048109	http://dx.doi.org/10.1056/NEJMp048109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548772				2022-12-28	WOS:000225160600002
J	Fraser, HSF; Jazayeri, D; Nevil, P; Karacaoglu, Y; Farmer, PE; Lyon, E; Fawzi, MKCS; Leandre, F; Choi, SS; Mukherjee, JS				Fraser, HSF; Jazayeri, D; Nevil, P; Karacaoglu, Y; Farmer, PE; Lyon, E; Fawzi, MKCS; Leandre, F; Choi, SS; Mukherjee, JS			An information system and medical record to support HIV treatment in rural Haiti	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUB-SAHARAN AFRICA; TELEMEDICINE; TECHNOLOGY; GUIDELINES; COUNTRIES; INFECTION; INTERNET; ACCESS	Lack of infrastructure, including information and communication systems, is considered a barrier to successful HIV treatment programmes in resource poor areas. The authors describe how they set up a web based medical record system linking remote areas in rural Haiti and how it is used to track clinical outcomes, laboratory tests, and drug supplies and to create reports for funding agencies.	Brigham & Womens Hosp, Div Social Med & Healthcare Inequal, Boston, MA 02115 USA; Partners Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Infect Dis & Social Change, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System; Harvard University; Harvard Medical School	Fraser, HSF (corresponding author), Brigham & Womens Hosp, Div Social Med & Healthcare Inequal, 75 Francis St, Boston, MA 02115 USA.	Hamish_fraser@hms.harvard.edu	Fraser, Hamish HS/E-3773-2013; Fraser, Hamish/AGP-6129-2022	Fraser, Hamish/0000-0003-4383-2854				Bates DW, 2001, J AM MED INFORM ASSN, V8, P299, DOI 10.1136/jamia.2001.0080299; Carnall D, 2000, BRIT MED J, V321, P976, DOI 10.1136/bmj.321.7267.976; Della Mea V, 1999, J TELEMED TELECARE, V5, P84, DOI 10.1258/1357633991933378; Dolin RH, 2001, J AM MED INFORM ASSN, V8, P552, DOI 10.1136/jamia.2001.0080552; DOUGLAS G, 2003, P AMIA S, P833; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; FRASER HS, 2001, MEDINFO 1, V10, P815; Fraser HSF, 2000, BRIT MED J, V321, P465, DOI 10.1136/bmj.321.7259.465; Fraser HSF, 2002, AMIA 2002 SYMPOSIUM, PROCEEDINGS, P270; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Geissbuhler Antoine, 2003, AMIA Annu Symp Proc, P249; Halamka JD, 1997, J AM MED INFORM ASSN, V4, P458, DOI 10.1136/jamia.1997.0040458; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; *JOINT UN PROGR HI, 2000, REP GLOB HIV AIDS EP; Loewenson R, 2004, BMJ-BRIT MED J, V328, P241, DOI 10.1136/bmj.328.7434.241; Marins JRP, 2003, AIDS, V17, P1675, DOI 10.1097/00002030-200307250-00012; MILBERG J, 2003, P HEL 2003 JOH JOH I, P44; *MIN HLTH BRAZ, NAT AIDS DRUG POL JU; Oberholzer Martin, 2003, Curr Probl Dermatol, V32, P102; OLSON C, 1997, MANAGING DRUG SUPPLY, P184; PakenhamWalsh N, 1997, BRIT MED J, V314, P90, DOI 10.1136/bmj.314.7074.90; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Peleg M, 2004, J AM MED INFORM ASSN, V11, P1, DOI 10.1197/jamia.M1399; Richards T, 2001, BRIT MED J, V322, P1321, DOI 10.1136/bmj.322.7298.1321; Rind DM, 1997, ANN INTERN MED, V127, P138, DOI 10.7326/0003-4819-127-2-199707150-00008; Rotich JK, 2003, J AM MED INFORM ASSN, V10, P295, DOI 10.1197/jamia.M1301; SAFRAN C, 1995, LANCET, V346, P341, DOI 10.1016/S0140-6736(95)92226-1; TASSIE JM, 2002, INT C AIDS, V14; *WHO, 2003, EV BAS REC POL MAK H, P2; 2003, NY TIMES        0904, P22	30	68	69	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1142	1146		10.1136/bmj.329.7475.1142	http://dx.doi.org/10.1136/bmj.329.7475.1142			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	871XJ	15539669	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000225169600020
J	Marlow, N				Marlow, N			Commentary: Family friendly care	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Nottingham, Queens Med Ctr, Sch Human Dev, Nottingham NG7 2UH, England	University of Nottingham	Marlow, N (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Human Dev, Nottingham NG7 2UH, England.	neil.marlow@nottingham.ac.uk	Marlow, Neil/D-2918-2009	Marlow, Neil/0000-0001-5890-2953				Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Israel C, 1997, PARENT BABY INTERACT; Kennell JH, 1998, PEDIAT REV, V19, P433; MINDE K, 1980, J PEDIATR-US, V96, P933; Pinelli, 2003, COCHRANE DB SYST REV; PINELLI J, 2001, COCHRANE DB SYST REV; Ruiz-Pelaez JG, 2004, BMJ-BRIT MED J, V329, P1179, DOI 10.1136/bmj.329.7475.1179	7	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1182	1182A		10.1136/bmj.329.7475.1182	http://dx.doi.org/10.1136/bmj.329.7475.1182			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539682	Green Published			2022-12-28	WOS:000225169600035
J	Samavat, A; Modell, B				Samavat, A; Modell, B			Iranian national thalassaemia screening programme	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRENATAL-DIAGNOSIS; BETA-THALASSEMIA		UCL, Ctr Hlth Informat & Multiprofess Educ, London N19 5LW, England; Minist Hlth & Med Educ, Dis Management Ctr, Genet Off, Tehran, Iran	University of London; University College London; Ministry of Health & Medical Education (MOHME)	Modell, B (corresponding author), UCL, Ctr Hlth Informat & Multiprofess Educ, London N19 5LW, England.	b.modell@pcps.ucl.ac.uk						Ahmed S, 2002, NEW ENGL J MED, V347, P1162, DOI 10.1056/NEJMsa013234; AKBARI M, 1997, AM J HUM GENET S, V61; Alwan A, 2003, NAT REV GENET, V4, P61, DOI 10.1038/nrg978; Alwan A, 1997, EMRO TECHNICAL PUBLI; ANGASTINIOTIS M, 1986, World Health Forum, V7, P291; ANGASTINIOTIS MA, 1981, LANCET, V1, P369; Bain BJ, 1998, BRIT J HAEMATOL, V101, P783, DOI 10.1046/j.1365-2141.1998.00809.x; CAO A, 1993, BAILLIERE CLIN HAEM, V6, P263, DOI 10.1016/S0950-3536(05)80072-1; Farhud D. D., 1997, Iranian Journal of Public Health, V26, P1; Gohari LH, 2003, HEMOGLOBIN, V27, P129, DOI 10.1081/HEM-120021548; Loukopoulos D, 1996, SEMIN HEMATOL, V33, P76; MAGGIO A, 1992, LANCET, V339, P1361, DOI 10.1016/0140-6736(92)92012-5; Modell B, 2000, BMJ-BRIT MED J, V320, P337, DOI 10.1136/bmj.320.7231.337; Modell B, 2001, B WORLD HEALTH ORGAN, V79, P1006; MODELL B, 1980, BRIT MED J, V2, P737; Modell B., 2000, COMM GEN, V3, P144; Najmabadi H, 2001, HEMOGLOBIN, V25, P285, DOI 10.1081/HEM-100105221; Shadpour K., 1994, PHC EXPERIENCE IRAN; WHO M ETH ISS MED GE	19	185	191	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1134	1137		10.1136/bmj.329.7475.1134	http://dx.doi.org/10.1136/bmj.329.7475.1134			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539666	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000225169600017
J	Carranza, J; Alarcos, S; Sanchez-Prieto, CB; Valencia, J; Mateos, C				Carranza, J; Alarcos, S; Sanchez-Prieto, CB; Valencia, J; Mateos, C			Disposable-soma senescence mediated by sexual selection in an ungulate	NATURE			English	Article							DEER CERVUS-ELAPHUS; RED DEER; TOOTH WEAR; EVOLUTION; DENSITY; AGE; SEGREGATION	Senescence may result from an optimal balance between current reproductive investment and bodily repair processes required for future reproduction(1), a theoretical prediction difficult to prove especially in large, long-lived animals. Here we propose that teeth that have fixed dimensions early in life, but that wear during chewing, can be taken as a measure of total lifetime 'repair', and their wear rate as a measure of current expenditure in performance. Our approach also considers the sexual selection process to investigate the advance of senescence in males compared with females, when selection favouring competition over mates reduces the reproductive lifespan of males(2). We studied carcasses of 2,141 male and 739 female red deer (Cervus elaphus) of different ages, finding that male molariform teeth emerged at a far smaller size than expected from body size dimorphism. This led to higher workload, steeper wear rate and earlier depletion of male teeth than in females, in concordance with sex-specific patterns of lifetime performance and reproduction. These findings provide the empirical support for the disposable-soma hypothesis of senescence(3), which predicts that investment in bodily repair will decrease when the return from this investment may not be realized as a result of other causes that limit survival or reproduction.	Univ Extremadura, Biol & Ethol Unit, F-10071 Caceres, Spain	Universidad de Extremadura	Carranza, J (corresponding author), Univ Extremadura, Biol & Ethol Unit, F-10071 Caceres, Spain.	carranza@unex.es	Carranza, Juan/E-4472-2010	Valencia, Juliana/0000-0002-8774-8315; Carranza, Juan/0000-0002-0368-7173				Bonenfant C, 2003, BEHAV ECOL, V14, P862, DOI 10.1093/beheco/arg077; Clutton-Brock T.H., 1988, P325; CLUTTONBROCK TH, 1987, J ZOOL, V211, P275, DOI 10.1111/j.1469-7998.1987.tb01534.x; EDNEY EB, 1968, NATURE, V220, P281, DOI 10.1038/220281a0; Ericsson G, 2001, ECOSCIENCE, V8, P157, DOI 10.1080/11956860.2001.11682641; Fortelius M., 1985, ACTA ZOOL FENN, V180, P1; GAILLARD JM, 1993, J ANIM ECOL, V62, P778; Gompertz B., 1825, PHILOS T R SOC LOND, V115, P513, DOI [10.1098/rstl.1825.0026, DOI 10.1098/RSTL.1825.0026]; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Kirkwood T., 1985, HDB BIOL AGING, P2743; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Loe LE, 2003, OECOLOGIA, V135, P346, DOI 10.1007/s00442-003-1192-9; Medawar P. B., 1952, MODERN Q, V1, P30; MITCHELL B, 1967, J ANIM ECOL, V36, P279, DOI 10.2307/2912; Mysterud A, 2000, OECOLOGIA, V124, P40, DOI 10.1007/s004420050023; Mysterud Atle, 2001, Proceedings of the Royal Society Biological Sciences Series B, V268, P911; Ricklefs RE, 1998, AM NAT, V152, P24, DOI 10.1086/286147; SKOGLAND T, 1988, OIKOS, V51, P238, DOI 10.2307/3565648; STAINES BW, 1978, J ZOOL, V185, P253; [No title captured]; [No title captured]	22	113	114	2	44	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					215	218		10.1038/nature03004	http://dx.doi.org/10.1038/nature03004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538368				2022-12-28	WOS:000225020200045
J	Taylor, AL; Ziesche, S; Yancy, C; Carson, P; D'Agostino, R; Ferdinand, K; Taylor, M; Adams, K; Sabolinski, M; Worcel, M; Cohn, JN				Taylor, AL; Ziesche, S; Yancy, C; Carson, P; D'Agostino, R; Ferdinand, K; Taylor, M; Adams, K; Sabolinski, M; Worcel, M; Cohn, JN		African-Amer Heart Failure Trial I	Combination of isosorbide dinitrate and hydralazine in blacks with heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; TRIAL A-HEFT; NITRIC-OXIDE; NITROGLYCERIN TOLERANCE; MYOCARDIAL-INFARCTION; CORONARY-CIRCULATION; RACIAL-DIFFERENCES; RACE; SUPEROXIDE; NO	Background: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. Methods: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. Results: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). Conclusions: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.	Univ Minnesota, Sch Med, Dept Med Cardiol, Minneapolis, MN 55455 USA; Minneapolis Vet Affairs Hosp, Minneapolis, MN USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Vet Affairs Med Ctr, Washington, DC 20422 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Heartbeats Life Ctr, New Orleans, LA USA; Xavier Univ, New Orleans, LA 70125 USA; Jackson Cardiol Associates, Jackson, MS USA; Assoc Black Cardiologists, Atlanta, GA USA; Univ N Carolina, Chapel Hill, NC USA; NitroMed, Lexington, MA USA	University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); Wake Forest University; Wake Forest Baptist Medical Center; Xavier University of Louisiana; University of North Carolina; University of North Carolina Chapel Hill	Taylor, AL (corresponding author), Univ Minnesota, Sch Med, Dept Med Cardiol, 420 Delaware St SE,MMC 293, Minneapolis, MN 55455 USA.	taylo135@umn.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395				BAUER JA, 1991, CIRCULATION, V84, P35, DOI 10.1161/01.CIR.84.1.35; BELCH JJF, 1991, BRIT HEART J, V65, P245; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Cardillo C, 1998, HYPERTENSION, V31, P1235, DOI 10.1161/01.HYP.31.6.1235; Carson P, 1999, J Card Fail, V5, P178, DOI 10.1016/S1071-9164(99)90001-5; Chen ZQ, 2002, P NATL ACAD SCI USA, V99, P8306, DOI 10.1073/pnas.122225199; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Cui L, 1999, BIOMETRICS, V55, P853, DOI 10.1111/j.0006-341X.1999.00853.x; DiazVelez CR, 1996, AM HEART J, V131, P146, DOI 10.1016/S0002-8703(96)90063-0; Dixon LJ, 2003, CIRCULATION, V107, P1725, DOI 10.1161/01.CIR.0000066283.13253.78; DREXLER H, 1992, AM J CARDIOL, V69, P1596, DOI 10.1016/0002-9149(92)90710-G; Drexler H, 1999, CIRCULATION, V99, P2972, DOI 10.1161/01.CIR.99.23.2972; Dries DL, 2002, J AM COLL CARDIOL, V40, P311, DOI 10.1016/S0735-1097(02)01943-5; Dries DL, 1999, NEW ENGL J MED, V340, P609, DOI 10.1056/NEJM199902253400804; Dries DL, 2002, J AM COLL CARDIOL, V40, P1019; Dries DL, 1999, NEW ENGL J MED, V341, P298; Eichhorn E, 2001, NEW ENGL J MED, V344, P1659; Exner DV, 2001, NEW ENGL J MED, V344, P1351, DOI 10.1056/NEJM200105033441802; Franciosa JA, 2002, J CARD FAIL, V8, P128, DOI 10.1054/jcaf.2002.124730; GILLUM RF, 1979, HYPERTENSION, V1, P468, DOI 10.1161/01.HYP.1.5.468; GOGIA H, 1995, J AM COLL CARDIOL, V26, P1575, DOI 10.1016/0735-1097(95)00368-1; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hinderliter AL, 1996, AM J CARDIOL, V78, P208, DOI 10.1016/S0002-9149(96)90397-5; Hjalmarson A, 1999, LANCET, V353, P2001; Houghton JL, 1997, HYPERTENSION, V29, P706, DOI 10.1161/01.HYP.29.3.706; Ignarro LJ, 2002, CIRC RES, V90, P21, DOI 10.1161/hh0102.102330; Janssens S, 2004, CIRC RES, V94, P1256, DOI 10.1161/01.RES.0000126497.38281.23; Jones SP, 2003, P NATL ACAD SCI USA, V100, P4891, DOI 10.1073/pnas.0837428100; Kahn DF, 2002, HYPERTENSION, V40, P195, DOI 10.1161/01.HYP.0000024571.69634.ED; Kalinowski L, 2004, CIRCULATION, V109, P2511, DOI 10.1161/01.CIR.0000129087.81352.7A; Keith M, 1998, J AM COLL CARDIOL, V31, P1352, DOI 10.1016/S0735-1097(98)00101-6; KUBO SH, 1991, CIRCULATION, V84, P1589, DOI 10.1161/01.CIR.84.4.1589; LAN KKG, 1994, COMMUN STAT THEORY, V23, P403, DOI 10.1080/03610929408831263; Liu YH, 2002, HYPERTENSION, V39, P375, DOI 10.1161/hy02t2.102796; Loke KE, 1999, CIRCULATION, V100, P1291, DOI 10.1161/01.CIR.100.12.1291; McVeigh GE, 2002, CIRCULATION, V106, P208, DOI 10.1161/01.CIR.0000021600.84149.78; Mohri M, 1997, HYPERTENSION, V30, P50, DOI 10.1161/01.HYP.30.1.50; Munzel T, 1996, J CLIN INVEST, V98, P1465, DOI 10.1172/JCI118935; Munzel T, 1999, CIRCULATION, V100, P216, DOI 10.1161/01.CIR.100.3.216; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 2001, J CARD FAIL, V7, P176, DOI 10.1054/jcaf.2001.25652; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Prabhu SD, 2004, CIRC RES, V94, P1155, DOI 10.1161/01.RES.0000129569.07667.89; Recchia FA, 2002, AM J PHYSIOL-ENDOC M, V282, pE197, DOI 10.1152/ajpendo.2002.282.1.E197; RECTOR TS, 1992, AM HEART J, V124, P1017, DOI 10.1016/0002-8703(92)90986-6; Scherrer-Crosbie M, 2001, CIRCULATION, V104, P1286, DOI 10.1161/hc3601.094298; Sharma Rajesh, 2002, Congest Heart Fail, V8, P165, DOI 10.1111/j.1527-5299.2002.00714.x; Stein CM, 1997, CLIN PHARMACOL THER, V62, P436, DOI 10.1016/S0009-9236(97)90122-3; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Sydow K, 2004, J CLIN INVEST, V113, P482, DOI 10.1172/JCI200419267; Taylor AL, 2003, J CARD FAIL, V9, P481; Taylor AL, 2003, J CARD FAIL, V9, pS216, DOI 10.1054/S1071-9164(03)00591-8; WANG J, 1994, AM J PHYSIOL, V266, pH670, DOI 10.1152/ajpheart.1994.266.2.H670; Yancy CW, 2001, NEW ENGL J MED, V344, P1358, DOI 10.1056/NEJM200105033441803; Yancy CW, 2000, J CARD FAIL, V6, P183, DOI 10.1054/jcaf.2000.17610; Yancy CW, 2003, AM HEART J, V146, P203, DOI 10.1016/S0002-8703(03)00241-2	60	1108	1153	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2049	2057		10.1056/NEJMoa042934	http://dx.doi.org/10.1056/NEJMoa042934			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15533851	Green Published			2022-12-28	WOS:000225007200006
J	Shintani, T; Klionsky, DJ				Shintani, T; Klionsky, DJ			Autophagy in health and disease: A double-edged sword	SCIENCE			English	Review							PROGRAMMED CELL-DEATH; LEGIONELLA-PNEUMOPHILA; TUMOR-SUPPRESSOR; ENDOPLASMIC-RETICULUM; ALPHA-SYNUCLEIN; DAP KINASE; C-ELEGANS; LIFE-SPAN; MACROAUTOPHAGY; POLYGLUTAMINE	Autophagy, the process by which cells recycle cytoplasm and dispose of excess or defective organelles, has entered the research spotlight largely owing to the discovery of the protein components that drive this process. Identifying the autophagy genes in yeast and finding orthologs in other organisms reveals the conservation of the mechanism of autophagy in eukaryotes and allows the use of molecular genetics and biology in different model systems to study this process. By mostly morphological studies, autophagy has been linked to disease processes. Whether autophagy protects from or causes disease is unclear. Here, we summarize current knowledge about the role of autophagy in disease and health.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	klionsky@umich.edu	SHINTANI, Takahiro/ABE-1267-2020	Shintani, Takahiro/0000-0001-6630-5892	NIGMS NIH HHS [R01 GM053396, GM53396] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alva AS, 2004, CELL DEATH DIFFER, V11, P1046, DOI 10.1038/sj.cdd.4401445; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bergamini E, 2004, INT J BIOCHEM CELL B, V36, P2392, DOI 10.1016/j.biocel.2004.05.007; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cataldo AM, 1997, J NEUROSCI, V17, P6142; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; Coers J, 1999, NAT CELL BIOL, V1, P451, DOI 10.1038/15687; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; Eskelinen EL, 2004, MOL BIOL CELL, V15, P3132, DOI 10.1091/mbc.E04-02-0103; Fortun J, 2003, J NEUROSCI, V23, P10672; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Juhasz G, 2003, FEBS LETT, V543, P154, DOI 10.1016/S0014-5793(03)00431-9; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; KLIONSKY DJ, 2004, AUTOPHAGY, P1; Kumamoto T, 2004, ACTA NEUROPATHOL, V107, P59, DOI 10.1007/s00401-003-0774-2; Lee CY, 2001, DEVELOPMENT, V128, P1443; Leib DA, 2000, P NATL ACAD SCI USA, V97, P6097, DOI 10.1073/pnas.100415697; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lipinski MM, 2004, CURR OPIN PHARMACOL, V4, P85, DOI 10.1016/j.coph.2003.09.008; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Otto GP, 2004, MOL MICROBIOL, V51, P63, DOI 10.1046/j.1365-2958.2003.03826.x; Paglin S, 2001, CANCER RES, V61, P439; Prentice E, 2004, J BIOL CHEM, V279, P10136, DOI 10.1074/jbc.M306124200; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; Rodriguez-Enriquez S, 2004, INT J BIOCHEM CELL B, V36, P2463, DOI 10.1016/j.biocel.2004.04.009; Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200; Selimi F, 2000, J NEUROSCI, V20, P5339, DOI 10.1523/JNEUROSCI.20-14-05339.2000; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sun XM, 2004, MOL CELL, V14, P81, DOI 10.1016/S1097-2765(04)00156-X; Suzuki T, 2002, J BIOCHEM, V131, P647, DOI 10.1093/oxfordjournals.jbchem.a003147; SWANSON MS, 1995, INFECT IMMUN, V63, P3609, DOI 10.1128/IAI.63.9.3609-3620.1995; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Terman A, 2004, EXP GERONTOL, V39, P701, DOI 10.1016/j.exger.2004.01.005; UENO T, 2004, AUTOPHAGY, P264; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Venkatraman P, 2004, MOL CELL, V14, P95, DOI 10.1016/S1097-2765(04)00151-0; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Webb JL, 2003, J BIOL CHEM, V278, P25009, DOI 10.1074/jbc.M300227200; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	63	2079	2280	6	356	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					990	995		10.1126/science.1099993	http://dx.doi.org/10.1126/science.1099993			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528435	Green Accepted			2022-12-28	WOS:000225001100031
J	Son, DH; Hughes, SM; Yin, YD; Alivisatos, AP				Son, DH; Hughes, SM; Yin, YD; Alivisatos, AP			Cation exchange reactions-in ionic nanocrystals	SCIENCE			English	Article							SEMICONDUCTOR NANOCRYSTALS; GROWTH; NANORODS; SIZE; GOLD	Cation exchange has been investigated in a wide range of nanocrystals of varying composition, size, and shape. Complete and fully reversible exchange occurs, and the rates of the reactions are much faster than in bulk cation exchange processes. A critical size has been identified below which the shapes of complex nanocrystals evolve toward the equilibrium shape with lowest energy during the exchange reaction. Above the critical size, the anion sublattice remains intact and the basic shapes of the initial nanocrystals are retained throughout the cation exchange. The size-dependent shape change can also be used to infer features of the microscopic mechanism.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Sci Mat, Berkeley, CA 94720 USA.	alivis@berkeley.edu	Son, Dong Hee/AAC-6395-2021; Alivisatos, Paul/N-8863-2015; Yin, Yadong/D-5987-2011; Son, Dong Hee/C-2234-2015	Son, Dong Hee/0000-0001-9002-5188; Alivisatos, Paul/0000-0001-6895-9048; Yin, Yadong/0000-0003-0218-3042; Son, Dong Hee/0000-0001-9002-5188				Backhaus-Ricoult M, 2003, ANNU REV MATER RES, V33, P55, DOI 10.1146/annurev.matsci.33.013102.094710; Baldinozzi G, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.216103; Burgess J, 1978, METAL IONS SOLUTION; Chen CC, 1997, SCIENCE, V276, P398, DOI 10.1126/science.276.5311.398; Dloczik L, 2003, NANO LETT, V3, P651, DOI 10.1021/nl0340879; Feng SH, 2001, ACCOUNTS CHEM RES, V34, P239, DOI 10.1021/ar0000105; GOLDSTEIN AN, 1992, SCIENCE, V256, P1425, DOI 10.1126/science.256.5062.1425; Hamilton MA, 2001, J PHYS-CONDENS MAT, V13, P2425, DOI 10.1088/0953-8984/13/11/301; Hu M, 2002, J PHYS CHEM B, V106, P7029, DOI 10.1021/jp020581+; Jana NR, 2001, J PHYS CHEM B, V105, P4065, DOI 10.1021/jp0107964; Jin RC, 2001, SCIENCE, V294, P1901, DOI 10.1126/science.1066541; KOBAYASHI M, 1990, SOLID STATE IONICS, V39, P121, DOI 10.1016/0167-2738(90)90392-5; Manna L, 2002, J AM CHEM SOC, V124, P7136, DOI 10.1021/ja025946i; Manna L, 2003, NAT MATER, V2, P382, DOI 10.1038/nmat902; MARADUDIN AA, 1964, PHYS REV, V133, P1188; MEWS A, 1994, J PHYS CHEM-US, V98, P934, DOI 10.1021/j100054a032; Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695; Mokari T, 2004, SCIENCE, V304, P1787, DOI 10.1126/science.1097830; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; PEDROV VA, 1993, PHYS STATUS SOLIDI, V139, P9; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Redl FX, 2003, NATURE, V423, P968, DOI 10.1038/nature01702; Schaak RE, 2002, CHEM MATER, V14, P1455, DOI 10.1021/cm010689m; Schmalzried H., 1981, SOLID STATE REACTION; Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229; Van Hove MA, 2004, J PHYS CHEM B, V108, P14265, DOI 10.1021/jp040047x; Yin YD, 2004, SCIENCE, V304, P711, DOI 10.1126/science.1096566; 1999, LANDOLTBORNSTEIN, V19	28	1005	1023	22	590	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2004	306	5698					1009	1012		10.1126/science.1103755	http://dx.doi.org/10.1126/science.1103755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528440				2022-12-28	WOS:000225001100036
J	Halperin, DT; Steiner, MJ; Cassell, MM; Green, EC; Hearst, N; Kirby, D; Gayle, HD; Cates, W				Halperin, DT; Steiner, MJ; Cassell, MM; Green, EC; Hearst, N; Kirby, D; Gayle, HD; Cates, W			The time has come for common ground on preventing sexual transmission of HIV	LANCET			English	Editorial Material							PARTNER REDUCTION; RISK; INFECTION; WOMEN; AGE		Univ Calif San Francisco, San Francisco, CA 94143 USA; Family Hlth Int, Res Triangle Pk, NC 27709 USA; Harvard Univ, Cambridge, MA 02138 USA; ETR Associates, Sacramento, CA USA; Int AIDS Soc, Seattle, WA USA	University of California System; University of California San Francisco; Harvard University	Halperin, DT (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.	dhalp@worldwidedialup.net						CATES W, 2003, NETWORK, P22; Cohen J, 2004, SCIENCE, V304, P1932, DOI 10.1126/science.304.5679.1932; COHEN S, 2004, GUTTMACHER REPORT PU, P7; Cote AM, 2004, AIDS, V18, P917, DOI [10.1097/01.aids.0000111475.61782.98, 10.1097/00002030-200404090-00009]; EPSTEIN H, 2004, NY TIMES MAGAZI 0613; Green Edward, 2003, RETHINKING AIDS PREV; Halperin DT, 2004, LANCET, V364, P4, DOI 10.1016/S0140-6736(04)16606-3; Hearst N, 2004, STUD FAMILY PLANN, V35, P39, DOI 10.1111/j.1728-4465.2004.00004.x; *INT FED RED CROSS, REN OUR VOIC COD GOO; Kelly RJ, 2003, JAIDS-J ACQ IMM DEF, V32, P446, DOI 10.1097/00126334-200304010-00016; Leclerc-Madlala S, 2003, SOC DYNAMICS, V29, P213, DOI 10.1080/02533950308628681; Longfield K, 2004, STUD FAMILY PLANN, V35, P125, DOI 10.1111/j.1728-4465.2004.00014.x; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; Pettifor AE, 2004, AIDS, V18, P1435, DOI 10.1097/01.aids.0000131338.61042.b8; Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384; Shelton JD, 2004, BMJ-BRIT MED J, V328, P891, DOI 10.1136/bmj.328.7444.891; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; *US AG INT DEV BUR, 2003, ADD FAM PLANN PMTCT; WELLER S, 2002, COCHRANE LIB; Wilson D, 2004, BRIT MED J, V328, P848, DOI 10.1136/bmj.328.7444.848; 2003, MEASURE EVALUATION S	21	81	83	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1913	1915		10.1016/S0140-6736(04)17487-4	http://dx.doi.org/10.1016/S0140-6736(04)17487-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566989				2022-12-28	WOS:000225327000003
J	Henquet, C; Krabbendam, L; Spauwen, J; Kaplan, C; Lieb, R; Wittchen, HU; van Os, J				Henquet, C; Krabbendam, L; Spauwen, J; Kaplan, C; Lieb, R; Wittchen, HU; van Os, J			Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DRUG-USE; POPULATION; SCHIZOPHRENIA; VULNERABILITY	Objective To investigate the relation between cannabis use mid psychotic symptoms in individuals with above average predisposition for psychosis who first used cannabis during adolescence. Design Analysis of prospective data from a population based sample. Assessment of substance use, predisposition for psychosis, and psychotic symptoms was based on standardised personal interviews at baseline and at follow tip four years later. Participants 2437 young people (aged 14 to 24 years) with and without predisposition for psychosis. Main outcome measure Psychotic symptoms at follow up as a function of cannabis use mid predisposition for psychosis at baseline. Results After adjustment for age, sex, socioeconomic status, urbanicity childhood trauma, predisposition for psychosis at baseline, and use of other drugs, tobacco, and alcohol, cannabis use at baseline increased the cumulative incidence of psychotic symptoms at follow up four years later (adjusted odds ratio 1.67, 95% confidence interval 1.13 to 2.46). The effect of cannabis use was much stronger in those with any predisposition for psychosis at baseline (23.8% ad. Listed difference in risk, 95% confidence interval 7.9 to 39.7, P = 0.003) than in those without (5.6%, 0.4 to 10.8, P = 0.033). The risk difference in the "predisposition" group was significantly greater than the risk difference in the "no predisposition" group (test for interaction 18.2%, 1.6 to 34.8, P = 0.032). There was a close-response relation with increasing., frequency of cannabis use. Predisposition for psychosis at baseline did not significantly predict cannabis use four years later (adjusted odds ratio 1.42, 95% confidence interval 0.88 to 2.31). Conclusion Cannabis use moderately increases the risk of psychotic symptoms in young people but has a much stronger effect ill those with evidence of predisposition for psychosis.	Maastricht Univ, EURON, S Limburg Mental Hlth Res & Teaching Network, Dept Psychiat & Neuropsychol, NL-6200 MD Maastricht, Netherlands; Max Planck Inst Psychiat, Clin Psychol & Epidemiol Unit, D-80804 Munich, Germany; Tech Univ Dresden, Inst Clin Psychol & Psychotherapy, D-01187 Dresden, Germany	Maastricht University; Max Planck Society; Technische Universitat Dresden	van Os, J (corresponding author), Maastricht Univ, EURON, S Limburg Mental Hlth Res & Teaching Network, Dept Psychiat & Neuropsychol, POB 616, NL-6200 MD Maastricht, Netherlands.	j.vanos@spunimaas.nl	van Os, Jim/V-8884-2019; van Os, Jim/I-9496-2012; Wittchen, Hans-Ulrich/A-8507-2014; van Os, Jim/C-2113-2014; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; Wittchen, Hans-Ulrich/ABA-8901-2020; Krabbendam, Lydia/F-9163-2010	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586; Wittchen, Hans-Ulrich/0000-0002-6311-7711; Krabbendam, Lydia/0000-0003-4074-5149	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA016977] Funding Source: NIH RePORTER; NIDA NIH HHS [R01DA016977-01] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Breslow N. E., 1994, STAT METHODS CANC RE, VII; CHEN JP, 1990, EUR J PHARMACOL, V190, P259; Dean B, 2001, NEUROSCIENCE, V103, P9, DOI 10.1016/S0306-4522(00)00552-2; Degenhardt L, 2001, PSYCHOL MED, V31, P659, DOI 10.1017/S0033291701003865; Derogatis J, 1983, SCL 90 R ADM SCORING; DEROGATIS JR, 1983, SLC 90 R ADM STORING; Johns LC, 2001, CLIN PSYCHOL REV, V21, P1125, DOI 10.1016/S0272-7358(01)00103-9; Kendler KS, 1996, SCHIZOPHRENIA BULL, V22, P511, DOI 10.1093/schbul/22.3.511; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; Leweke FM, 1999, NEUROREPORT, V10, P1665, DOI 10.1097/00001756-199906030-00008; Lieb R, 2000, EUR ADDICT RES, V6, P170, DOI 10.1159/000052043; Macleod J, 2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; Poulton R, 2000, ARCH GEN PSYCHIAT, V57, P1053, DOI 10.1001/archpsyc.57.11.1053; Read John, 2003, J Am Acad Psychoanal Dyn Psychiatry, V31, P247, DOI 10.1521/jaap.31.1.247.21938; Schneider M, 2003, NEUROPSYCHOPHARMACOL, V28, P1760, DOI 10.1038/sj.npp.1300225; Sharpley M, 2001, BRIT J PSYCHIAT, V178, pS60, DOI 10.1192/bjp.178.40.s60; van Os J, 2002, AM J EPIDEMIOL, V156, P319, DOI 10.1093/aje/kwf043; van Os J, 2003, AM J PSYCHIAT, V160, P477, DOI 10.1176/appi.ajp.160.3.477; Verdoux H, 2003, SCHIZOPHR RES, V59, P77, DOI 10.1016/S0920-9964(01)00401-7; Verdoux H, 2003, PSYCHOL MED, V33, P23, DOI 10.1017/S0033291702006384; Wittchen HU, 1998, SOC PSYCH PSYCH EPID, V33, P568, DOI 10.1007/s001270050095	22	514	523	1	85	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					11	14		10.1136/bmj.38267.664086.63	http://dx.doi.org/10.1136/bmj.38267.664086.63			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15574485	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000226176700009
J	Baumberger, F; Auwarter, W; Greber, T; Osterwalder, J				Baumberger, F; Auwarter, W; Greber, T; Osterwalder, J			Electron. coherence in a melting lead monolayer	SCIENCE			English	Article							2 DIMENSIONS; TRANSITION; SYSTEMS; GAS	We used angle-resolved photoemission spectroscopy to measure the electronic dispersion and single-particle spectral, function in a liquid metal. A lead monolayer supported on a copper (111) surface was investigated as the temperature was raised through the melting transition of the film. Electron spectra and momentum distribution maps of the liquid film revealed three key features of the electronic structure of liquids: the persistence of a Fermi surface, the filling of band gaps, and the localization of the wave functions upon melting. Distinct coherence lengths for different sheets of the Fermi surface were found, indicating a strong dependence of the localization lengths on the character of the constituent atomic wave functions.	Univ Zurich, Inst Phys, CH-8057 Zurich, Switzerland	University of Zurich	Osterwalder, J (corresponding author), Univ Zurich, Inst Phys, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	osterwal@physik.unizh.ch	Greber, Thomas/D-9509-2015; Auwärter, Willi/I-2551-2012; Baumberger, Felix/A-5170-2008	Greber, Thomas/0000-0002-5234-1937; Baumberger, Felix/0000-0001-7104-7541; Auwarter, Willi/0000-0001-9452-4662				AEBI P, 1994, SURF SCI, V307, P917, DOI 10.1016/0039-6028(94)91515-6; ANDERSON PW, 1958, PHYS REV, V109, P1492, DOI 10.1103/PhysRev.109.1492; Baumberger F, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.196805; Baumberger F, 2003, SURF SCI, V532, P82, DOI 10.1016/S0039-6028(03)00129-8; BIRGENEAU RJ, 1986, SCIENCE, V232, P329, DOI 10.1126/science.232.4748.329; BOSE SK, 1993, PHYS REV B, V48, P4265, DOI 10.1103/PhysRevB.48.4265; EDWARDS SF, 1961, PHILOS MAG, V6, P617, DOI 10.1080/14786436108244414; FRANK FC, 1952, PROC R SOC LON SER-A, V215, P43, DOI 10.1098/rspa.1952.0194; Greber T, 1997, REV SCI INSTRUM, V68, P4549, DOI 10.1063/1.1148429; Hafner J., 1999, Physical properties of quasicrystals, P209; Kosterlitz JM, 1973, J PHYS C SOLID STATE, V6, P1181, DOI 10.1088/0022-3719/6/7/010; KRESSE G, 1994, PHYS REV B, V49, P14251, DOI 10.1103/PhysRevB.49.14251; LEE PA, 1985, REV MOD PHYS, V57, P2287; MOTT NF, 1967, ADV PHYS, V16, P49, DOI 10.1080/00018736700101265; Muller BH, 1997, SURF SCI, V376, P123, DOI 10.1016/S0039-6028(96)01308-8; NELSON DR, 1979, PHYS REV B, V19, P2457, DOI 10.1103/PhysRevB.19.2457; Oelhafen P, 2002, J ELECTRON SPECTROSC, V124, P211, DOI 10.1016/S0368-2048(02)00055-5; Reichert H, 2000, NATURE, V408, P839, DOI 10.1038/35048537; Reinert F, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.115415; Rotenberg E, 2000, NATURE, V406, P602, DOI 10.1038/35020519; YOUNG AP, 1979, PHYS REV B, V19, P1855, DOI 10.1103/PhysRevB.19.1855; [No title captured]	22	19	19	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	2004	306	5705					2221	2224		10.1126/science.1103984	http://dx.doi.org/10.1126/science.1103984			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	882PE	15564313				2022-12-28	WOS:000225950000035
J	Kato, YK; Myers, RC; Gossard, AC; Awschalom, DD				Kato, YK; Myers, RC; Gossard, AC; Awschalom, DD			Observation of the spin hall effect in semiconductors	SCIENCE			English	Article								Electrically induced electron-spin polarization near the edges of a semiconductor channel was detected and imaged with the use of Kerr rotation microscopy. The polarization is out-of-plane and has opposite sign for the two edges, consistent with the predictions of the spin Hall effect. Measurements of unstrained gallium arsenide and strained indium gallium arsenide samples reveal that strain modifies spin accumulation at zero magnetic field. A weak dependence on crystal orientation for the strained samples suggests that the mechanism is the extrinsic spin Hall effect.	Univ Calif Santa Barbara, Ctr Spinatron & Quantum Computat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Ctr Spinatron & Quantum Computat, Santa Barbara, CA 93106 USA.	awsch@physics.ucsb.edu	Kato, Yuichiro K./B-5051-2008; Myers, Roberto/B-4431-2008	Kato, Yuichiro K./0000-0002-9942-1459; Myers, Roberto/0000-0002-3695-2244				BERNEVIG BA, 2004, CONDMAT0408442; CHAZALVIEL JN, 1975, PHYS REV B, V11, P3918, DOI 10.1103/PhysRevB.11.3918; Chien C., 2013, HALL EFFECT ITS APPL; Crooker SA, 1997, PHYS REV B, V56, P7574, DOI 10.1103/PhysRevB.56.7574; DYAKONOV MI, 1971, PHYS LETT A, VA 35, P459, DOI 10.1016/0375-9601(71)90196-4; DYAKONOV MI, 1971, JETP LETT-USSR, V13, P467; Hirsch JE, 1999, PHYS REV LETT, V83, P1834, DOI 10.1103/PhysRevLett.83.1834; HUCKESTEIN B, 1995, REV MOD PHYS, V67, P357, DOI 10.1103/RevModPhys.67.357; Inoue J, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.041303; Jain SC, 1996, SEMICOND SCI TECH, V11, P641, DOI 10.1088/0268-1242/11/5/004; Kato Y, 2004, NATURE, V427, P50, DOI 10.1038/nature02202; Kato YK, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.176601; KAVANAGH KL, 1988, J APPL PHYS, V64, P4843, DOI 10.1063/1.341232; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Lee WL, 2004, SCIENCE, V303, P1647, DOI 10.1126/science.1094383; Meier F., 1984, OPTICAL ORIENTATION; Murakami S, 2003, SCIENCE, V301, P1348, DOI 10.1126/science.1087128; Nitta J, 1997, PHYS REV LETT, V78, P1335, DOI 10.1103/PhysRevLett.78.1335; Popovic R.S., 2004, HALL EFFECT DEVICES, V2nd; Rashba EI, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.241315; Schliemann J, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.165315; Sinova J, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.126603; Stephens J, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.041307; Stormer HL, 1999, REV MOD PHYS, V71, pS298, DOI 10.1103/RevModPhys.71.S298; Zhang SF, 2000, PHYS REV LETT, V85, P393, DOI 10.1103/PhysRevLett.85.393	26	1991	2061	31	651	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2004	306	5703					1910	1913		10.1126/science.1105514	http://dx.doi.org/10.1126/science.1105514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	879DC	15539563				2022-12-28	WOS:000225695600036
J	Alboni, P; Botto, GL; Baldi, N; Luzi, M; Russo, V; Gianfranchi, L; Marchi, P; Calzolari, M; Solano, A; Baroffio, R; Gaggioli, G				Alboni, P; Botto, GL; Baldi, N; Luzi, M; Russo, V; Gianfranchi, L; Marchi, P; Calzolari, M; Solano, A; Baroffio, R; Gaggioli, G			Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket'' approach	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINUS RHYTHM; ORAL PROPAFENONE; RANDOMIZED-TRIAL; HEART-DISEASE; CONVERSION; FLECAINIDE; QUINIDINE	BACKGROUND: In-hospital administration of flecainide and propafenone in a single oral loading dose has been shown to be effective and superior to placebo in terminating atrial fibrillation. We evaluated the feasibility and the safety of self-administered oral loading of flecainide and propafenone in terminating atrial fibrillation of recent onset outside the hospital. METHODS: We administered either flecainide or propafenone orally to restore sinus rhythm in 268 patients with mild heart disease or none who came to the emergency room with atrial fibrillation of recent onset that was hemodynamically well tolerated. Of these patients, 58 (22 percent) were excluded from the study because of treatment failure or side effects. Out-of-hospital self-administration of flecainide or propafenone -- the "pill-in-the-pocket'' approach -- after the onset of heart palpitations was evaluated in the remaining 210 patients (mean age [+/-SD], 59+/-11 years). RESULTS: During a mean follow-up of 15+/-5 months, 165 patients (79 percent) had a total of 618 episodes of arrhythmia; of those episodes, 569 (92 percent) were treated 36+/-93 minutes after the onset of symptoms. Treatment was successful in 534 episodes (94 percent); the time to resolution of symptoms was 113+/-84 minutes. Among the 165 patients with recurrences, the drug was effective during all the arrhythmic episodes in 139 patients (84 percent). Adverse effects were reported during one or more arrhythmic episodes by 12 patients (7 percent), including atrial flutter at a rapid ventricular rate in 1 patient and noncardiac side effects in 11 patients. The numbers of monthly visits to the emergency room and hospitalizations were significantly lower during follow-up than during the year before the target episode (P<0.001 for both comparisons). CONCLUSIONS: In a selected, risk-stratified population of patients with recurrent atrial fibrillation, pill-in-the-pocket treatment is feasible and safe, with a high rate of compliance by patients, a low rate of adverse events, and a marked reduction in emergency room visits and hospital admissions.	Osped Civile, Div Cardiol, I-44042 Cento, Italy; Osped S Anna Como, Div Cardiol, Como, Italy; Osped SS Annunziata, Div Cardiol, Taranto, Italy; Osped Delta, Div Cardiol, Lagosanto, Italy; Arcispedale Santa Maria Nuova, Div Cardiol, Reggio Emilia, Italy; Osped Riuniti, Div Cardiol, Lavagna, Italy; Osped Galmarini, Div Cardiol, Tradate, Italy; Osped Civile, Div Cardiol, Sampierdarena, Italy	Ospedale Sant'Anna di Como; IRCCS Arcispedale S. Maria Nuova	Alboni, P (corresponding author), Osped Civile, Div Cardiol, I-44042 Cento, Italy.	p.alboni@ausl.fe.it						Azpitarte J, 1997, EUR HEART J, V18, P1649; Blanc JJ, 1999, AM J CARDIOL, V84, P1029, DOI 10.1016/S0002-9149(99)00493-2; BORIANI G, 1995, CHEST, V108, P355, DOI 10.1378/chest.108.2.355; Boriani G, 1997, ANN INTERN MED, V126, P621, DOI 10.7326/0003-4819-126-8-199704150-00006; Botto GL, 1998, PACE, V21, P2480, DOI 10.1111/j.1540-8159.1998.tb01205.x; Botto GL, 1997, INT J CARDIOL, V58, P55, DOI 10.1016/S0167-5273(96)02841-0; Botto GL, 1996, PACE, V19, P1939, DOI 10.1111/j.1540-8159.1996.tb03257.x; BOTTO GL, 1994, PACE, V17, P2114, DOI 10.1111/j.1540-8159.1994.tb03810.x; CAPUCCI A, 1994, INT J CARDIOL, V43, P305, DOI 10.1016/0167-5273(94)90211-9; CAPUCCI A, 1992, AM J CARDIOL, V70, P69, DOI 10.1016/0002-9149(92)91392-H; CAPUCCI A, 1994, AM J CARDIOL, V74, P503, DOI 10.1016/0002-9149(94)90915-6; Capucci A, 2003, AM J CARDIOL, V92, P1345, DOI 10.1016/j.amjcard.2003.08.024; CAPUCCI A, 1990, CARDIOVASC DRUG THER, V4, P281, DOI 10.1007/BF01857646; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HALINEN MO, 1995, AM J CARDIOL, V76, P495, DOI 10.1016/S0002-9149(99)80137-4; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Jais P, 2003, EUR HEART J SUPPL, V5, pH34, DOI 10.1016/S1520-765X(03)90021-6; Khan IA, 2001, J AM COLL CARDIOL, V37, P542, DOI 10.1016/S0735-1097(00)01116-5; Kishikawa T, 1999, INT J CARDIOL, V68, P57, DOI 10.1016/S0167-5273(98)00334-9; MANNINO MM, 1994, AM HEART J, V127, P475, DOI 10.1016/0002-8703(94)90151-1; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Villani G Q, 1990, G Ital Cardiol, V20, P564; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; ZEGER SL, 1989, BIOMETRICS, V45, P347; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	26	305	315	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2384	2391		10.1056/NEJMoa041233	http://dx.doi.org/10.1056/NEJMoa041233			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575054				2022-12-28	WOS:000225429000007
J	Julsgaard, B; Sherson, J; Cirac, JI; Fiurasek, J; Polzik, ES				Julsgaard, B; Sherson, J; Cirac, JI; Fiurasek, J; Polzik, ES			Experimental demonstration of quantum memory for light	NATURE			English	Article							TELEPORTATION; ENTANGLEMENT; STORAGE; PHOTON; STATE; COMMUNICATION	The information carrier of today's communications, a weak pulse of light, is an intrinsically quantum object. As a consequence, complete information about the pulse cannot be perfectly recorded in a classical memory, even in principle. In the field of quantum information, this has led to the long-standing challenge of how to achieve a high-fidelity transfer of an independently prepared quantum state of light onto an atomic quantum state(1-4). Here we propose and experimentally demonstrate a protocol for such a quantum memory based on atomic ensembles. Recording of an externally provided quantum state of light onto the atomic quantum memory is achieved with 70 per cent fidelity, significantly higher than the limit for classical recording. Quantum storage of light is achieved in three steps: first, interaction of the input pulse and an entangling field with spin-polarized caesium atoms; second, subsequent measurement of the transmitted light; and third, feedback onto the atoms using a radio-frequency magnetic pulse conditioned on the measurement result. The density of recorded states is 33 per cent higher than the best classical recording of light onto atoms, with a quantum memory lifetime of up to 4 milliseconds.	Univ Copenhagen, Danish Quantum Opt Ctr QUANTOP, Niels Bohr Inst, DK-2100 Copenhagen O, Denmark; Aarhus Univ, Danish Quantum Opt Ctr QUANTOP, Dept Phys, DK-8000 Aarhus C, Denmark; Max Planck Inst Quantum Opt, D-85748 Garching, Germany; Free Univ Brussels, Ecole Polytech, QUIC, B-1050 Brussels, Belgium; Palacky Univ, Dept Opt, Olomouc 77200, Czech Republic	University of Copenhagen; Niels Bohr Institute; Aarhus University; Max Planck Society; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Palacky University Olomouc	Polzik, ES (corresponding author), Univ Copenhagen, Danish Quantum Opt Ctr QUANTOP, Niels Bohr Inst, DK-2100 Copenhagen O, Denmark.	polzik@nbi.dk	Cirac, J. Ignacio/A-9105-2017; Polzik, Eugene/M-4724-2014	Cirac, J. Ignacio/0000-0003-3359-1743; Polzik, Eugene/0000-0001-9859-6591				Blinov BB, 2004, NATURE, V428, P153, DOI 10.1038/nature02377; Briegel HJ, 1998, PHYS REV LETT, V81, P5932, DOI 10.1103/PhysRevLett.81.5932; Cirac JI, 1997, PHYS REV LETT, V78, P3221, DOI 10.1103/PhysRevLett.78.3221; Fleischhauer M, 2002, PHYS REV A, V65, DOI 10.1103/PhysRevA.65.022314; FLURASEK J, 2004, IN PRESS PHYS REV LE; Furusawa A, 1998, SCIENCE, V282, P706, DOI 10.1126/science.282.5389.706; Hald J, 1999, PHYS REV LETT, V83, P1319, DOI 10.1103/PhysRevLett.83.1319; HAMMERER K, 2004, IN PRESS PHYS REV A; HAMMERER K, 2004, QUANTUM BENCHMARK ST; Julsgaard B, 2004, J OPT B-QUANTUM S O, V6, P5, DOI 10.1088/1464-4266/6/1/002; Julsgaard B, 2001, NATURE, V413, P400, DOI 10.1038/35096524; Julsgaard B, 2003, QUANTUM INF COMPUT, V3, P518; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kozhekin AE, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.033809; Kuzmich A, 2003, QUANTUM INFORMATION WITH CONTINUOUS VARIABLES, P231; Kuzmich A, 2003, NATURE, V423, P731, DOI 10.1038/nature01714; Kuzmich A, 2000, PHYS REV LETT, V85, P5639, DOI 10.1103/PhysRevLett.85.5639; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; Schori C, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.057903; van der Wal CH, 2003, SCIENCE, V301, P196, DOI 10.1126/science.1085946; van Loock P, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.022309	22	676	690	2	90	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					482	486		10.1038/nature03064	http://dx.doi.org/10.1038/nature03064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565148	Green Submitted			2022-12-28	WOS:000225322100040
J	Roberts, L; Lafta, R; Garfield, R; Khudhairi, J; Burnham, G				Roberts, L; Lafta, R; Garfield, R; Khudhairi, J; Burnham, G			Mortality before and after the 2003 invasion of Iraq: cluster sample survey	LANCET			English	Article								Background in March, 2003, military forces, mainly from the USA and the UK, invaded Iraq. We did a survey to compare mortality during the period of 14.6 months before the invasion with the 17.8 months after it. Methods A cluster sample survey was undertaken throughout Iraq during September, 2004. 33 clusters of 30 households each were interviewed about household composition, births, and deaths since January, 2002. In those households reporting deaths, the date, cause, and circumstances of violent deaths were recorded. We assessed the relative risk of death associated with the 2003 invasion and occupation by comparing mortality in the 17.8 months after the invasion with the 14.6-month period preceding it. Findings The risk of death was estimated to be 2.5-fold (95% Cl 1.6-4.2) higher after the invasion when compared with the preinvasion period. Two-thirds of all violent deaths were reported in one cluster in the city of Falluja. If we exclude the Falluja data, the risk of death is 1.5-fold (1.1-2.3) higher after the invasion. We estimate that 98 000 more deaths than expected (8000-194 000) happened after the invasion outside of Falluja and far more if the outlier Falluja cluster is included. The major causes of death before the invasion were myocardial infarction, cerebrovascular accidents, and other chronic disorders whereas after the invasion violence was the primary cause of death. Violent deaths were widespread, reported in 15 of 33 clusters, and were mainly attributed to coalition forces. Most individuals reportedly killed by coalition forces were women and children. The risk of death from violence in the period after the invasion was 58 times higher (95% CI 8.1-419) than in the period before the war. Interpretation Making conservative assumptions, we think that about 100 000 excess deaths, or more have happened since the 2003 invasion of Iraq. Violence accounted for most of the excess deaths and air strikes from coalition forces accounted for most violent deaths. We have shown that collection of public-health information is possible even during periods of extreme violence. Our results need further verification and should lead to changes to reduce noncombatant deaths from air strikes.	Johns Hopkins Sch Publ Hlth, Ctr Int Emergency Disaster & Refugee Studies, Baltimore, MD USA; Al Mustansiriya Univ, Coll Med, Dept Community Med, Baghdad, Iraq; Columbia Univ, Sch Nursing, New York, NY USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Mustansiriya University; Columbia University	Roberts, L (corresponding author), Johns Hopkins Sch Publ Hlth, Ctr Int Emergency Disaster & Refugee Studies, Baltimore, MD USA.	les@a-znet.com						Ali HM, 2000, LANCET, V355, P1851, DOI 10.1016/S0140-6736(00)02289-3; Ali MM, 2003, POP STUD-J DEMOG, V57, P217, DOI 10.1080/0032472032000097119; Baram A, 2000, MIDDLE EAST J, V54, P194; BECKER LB, 1993, ANN EMERG MED, V22, P1, DOI 10.1016/S0196-0644(05)80239-2; BERENSON A, 2004, NY TIMES        0926; *CDC, 2003, MMWR-MORBID MORTAL W, V52, P467; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; CLAWSON P, 1998, POLICYWATCH, V303, P1; CORDESMAN AH, 1997, SANCTIONS IRAQI PEOP; CPA, HIST REV CPA ACC; DAVIS M, COUNTING CIVILIAN CO; Diggle P., 2002, ANAL LONGITUDINAL DA, DOI DOI 10.2307/2983303; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; GARFIELD R, MORBIDITY MORTALITY; *GLOB POL FOR, SAV CHILDR UK IR SAN; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; *REUT NEWS SERV, IR SAYS SANCT HAV KI; RUBIN M, 2001, NEW REPUBLIC    0618, P18; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; TAYLOR WR, 1993, INT J EPIDEMIOL, V22, pS15, DOI 10.1093/ije/22.Supplement_1.S15; WELCH M, 2002, REASON MAGAZINE, P52; *WHO, HLTH ACT CRIS; CAMPAIGN SANCTIONS I	23	233	235	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1857	1864		10.1016/S0140-6736(04)17441-2	http://dx.doi.org/10.1016/S0140-6736(04)17441-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555665				2022-12-28	WOS:000225269300026
J	Pendry, JB				Pendry, JB			A chiral route to negative refraction	SCIENCE			English	Article							PHOTONIC CRYSTALS; LENS	Negative refraction is currently achieved by driving the magnetic permeability and electrical permittivity simultaneously negative, thus requiring two separate resonances in the refracting material. The introduction of a single chiral resonance leads to negative refraction of one polarization, resulting in improved and simplified designs of negatively refracting materials and opening previously unknown avenues of investigation in this fast-growing subject.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, London SW7 2AZ, England	Imperial College London	Pendry, JB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, Prince Consort Rd, London SW7 2AZ, England.			Pendry, John/0000-0001-5145-5441	Engineering and Physical Sciences Research Council [GR/S49537/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Cubukcu E, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207401; Cubukcu E, 2003, NATURE, V423, P604, DOI 10.1038/423604b; Grbic A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117403; Houck AA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.137401; Parimi PV, 2003, NATURE, V426, P404, DOI 10.1038/426404a; Parimi PV, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.127401; Pendry JB, 1996, PHYS REV LETT, V76, P4773, DOI 10.1103/PhysRevLett.76.4773; Pendry JB, 2003, J PHYS-CONDENS MAT, V15, P6345, DOI 10.1088/0953-8984/15/37/004; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; Svirko Y, 2001, APPL PHYS LETT, V78, P498, DOI 10.1063/1.1342210; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Wiltshire MCK, 2001, SCIENCE, V291, P849, DOI 10.1126/science.291.5505.849	15	1168	1272	24	379	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1353	1355		10.1126/science.1104467	http://dx.doi.org/10.1126/science.1104467			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550665				2022-12-28	WOS:000225301600045
J	Massague, J				Massague, J			G1 cell-cycle control and cancer	NATURE			English	Article							STEM-CELLS; TGF-BETA; C-MYC; P53-DEPENDENT APOPTOSIS; SIGNAL-TRANSDUCTION; KINASE INHIBITORS; HEDGEHOG RESPONSE; TUMOR SUPPRESSION; ID PROTEINS; RAS	Before replicating DNA during their reproductive cycle, our cells enter a phase called G1 during which they interpret a flood of signals that influence cell division and cell fate. Mistakes in this process lead to cancer. An increasingly complex and coherent view of G1 signalling networks, which coordinate cell growth, proliferation, stress management and survival, is helping to define the roots of malignancies and shows promise for the development of better cancer therapies.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Massague, J (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, Box 116,1275 York Ave, New York, NY 10021 USA.	j-massague@ski.mskcc.org		Massague, Joan/0000-0001-9324-8408				Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Arden KC, 2004, MOL CELL, V14, P416, DOI 10.1016/S1097-2765(04)00213-8; Arteaga CL, 2004, CANCER CELL, V5, P525, DOI 10.1016/j.ccr.2004.05.028; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Blain SW, 2003, CANCER CELL, V3, P111, DOI 10.1016/S1535-6108(03)00026-6; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chiosis G, 2003, CURR CANCER DRUG TAR, V3, P371, DOI 10.2174/1568009033481778; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KERNEY AM, 2003, DEVELOPMENT, V130, P15; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Prasanth SG, 2004, PHILOS T R SOC B, V359, P7, DOI 10.1098/rstb.2003.1360; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; RAPE M, IN PRESS NATURE; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruzinova MB, 2003, TRENDS CELL BIOL, V13, P410, DOI 10.1016/S0962-8924(03)00147-8; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Schlessinger Joseph, 2003, Sci STKE, V2003, pRE12, DOI 10.1126/stke.2003.191.re12; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Senoo M, 2004, CANCER CELL, V6, P85, DOI 10.1016/j.ccr.2004.06.005; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	98	929	974	1	120	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					298	306		10.1038/nature03094	http://dx.doi.org/10.1038/nature03094			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549091				2022-12-28	WOS:000225161400039
J	Grigera, SA; Gegenwart, P; Borzi, RA; Weickert, F; Schofield, AJ; Perry, RS; Tayama, T; Sakakibara, T; Maeno, Y; Green, AG; Mackenzie, AP				Grigera, SA; Gegenwart, P; Borzi, RA; Weickert, F; Schofield, AJ; Perry, RS; Tayama, T; Sakakibara, T; Maeno, Y; Green, AG; Mackenzie, AP			Disorder-sensitive phase formation linked to metamagnetic quantum criticality	SCIENCE			English	Article							FERMI-LIQUID; RUTHENATE SR3RU2O7; SUPERCONDUCTIVITY; INSTABILITY; TRANSITIONS; ELECTRON; ORDER	Condensed systems of strongly interacting electrons are idea[ for the study of quantum complexity. It has become possible to promote the formation of new quantum phases by explicitly tuning systems toward special low-temperature quantum critical points. So far, the clearest examples have been appearances of superconductivity near pressure-tuned antiferromagnetic quantum critical points. We present experimental evidence for the formation of a non-superconducting phase in the vicinity of a magnetic field-tuned quantum critical point in ultrapure crystals of the ruthenate metal Sr3Ru2O7,and we discuss the possibility that the observed phase is due to a spin-dependent symmetry-breaking Fermi surface distortion.	Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland; Max Planck Inst Chem Phys Solids, D-01187 Dresden, Germany; Univ Birmingham, Sch Phys & Astron, Birmingham B15 2TT, W Midlands, England; Kyoto Univ, Int Innovat Ctr, Kyoto 6068501, Japan; Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; Univ Tokyo, Inst Solid State Phys, Chiba 2778581, Japan	University of St Andrews; Max Planck Society; University of Birmingham; Kyoto University; Kyoto University; University of Tokyo	Grigera, SA (corresponding author), Univ St Andrews, Sch Phys & Astron, N Haugh, St Andrews KY16 9SS, Fife, Scotland.	sag2@st-and.ac.uk; apm9@st-and.ac.uk	Mackenzie, Andrew P/K-6742-2015; Weickert, Franziska/F-3557-2015; Green, Andrew G/A-2731-2013; grigera, santiago a/A-4932-2010; Schofield, Andy/AAL-7382-2020; Schofield, Andy J/C-5004-2009; Gegenwart, Philipp/A-7291-2017	Mackenzie, Andrew P/0000-0001-8000-4949; Weickert, Franziska/0000-0002-1545-9645; Schofield, Andy/0000-0002-1218-8560; Schofield, Andy J/0000-0002-1218-8560; Gegenwart, Philipp/0000-0003-4180-3785; Green, Andrew/0000-0002-3923-5291; Grigera, Santiago/0000-0002-1343-5885				Belitz D, 2002, J LOW TEMP PHYS, V126, P1107, DOI 10.1023/A:1013867329948; Binz B, 2004, EUROPHYS LETT, V65, P816, DOI 10.1209/epl/i2003-10127-x; Borzi RA, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.216403; Chandra P, 2002, NATURE, V417, P831, DOI 10.1038/nature00795; Flouquet J, 2002, PHYSICA B, V319, P251, DOI 10.1016/S0921-4526(02)01126-2; GORKOV LP, 1992, PHYS REV LETT, V69, P2586, DOI 10.1103/PhysRevLett.69.2586; Goto T, 2001, PHYSICA B, V300, P167, DOI 10.1016/S0921-4526(01)00579-8; GREEN AM, UNPUB; Grigera SA, 2001, SCIENCE, V294, P329, DOI 10.1126/science.1063539; GRIGERA SA, UNPUB; Halboth CJ, 2000, PHYS REV LETT, V85, P5162, DOI 10.1103/PhysRevLett.85.5162; Harrison N, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.096402; Ikeda S, 2000, PHYS REV B, V62, pR6089, DOI 10.1103/PhysRevB.62.R6089; Jaime M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.287201; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; Mathur ND, 1998, NATURE, V394, P39, DOI 10.1038/27838; Millis AJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.217204; Oganesyan V, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.195109; Perry RS, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.166602; Perry RS, 2001, PHYS REV LETT, V86, P2661, DOI 10.1103/PhysRevLett.86.2661; POMERANCHUK II, 1959, SOV PHYS JETP-USSR, V8, P361; Sachdev S., 1999, QUANTUM PHASE TRANSI; Senthil T, 2004, SCIENCE, V303, P1490, DOI 10.1126/science.1091806; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; Stormer HL, 1999, REV MOD PHYS, V71, pS298, DOI 10.1103/RevModPhys.71.S298	26	213	214	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1154	1157		10.1126/science.1104306	http://dx.doi.org/10.1126/science.1104306			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539596	Green Submitted			2022-12-28	WOS:000225193100039
J	Yaffe, K; Kanaya, A; Lindquist, K; Simonsick, EM; Harris, T; Shorr, RI; Tylavsky, FA; Newman, AB				Yaffe, K; Kanaya, A; Lindquist, K; Simonsick, EM; Harris, T; Shorr, RI; Tylavsky, FA; Newman, AB			The metabolic syndrome, inflammation, and risk of cognitive decline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							C-REACTIVE PROTEIN; 3RD NATIONAL-HEALTH; DEMENTIA; DISEASE; POPULATION; CHOLESTEROL; PREVALENCE; AMERICAN; MARKERS; MODELS	Context Several studies have reported an association between the metabolic syndrome and cardiovascular disease. Despite an increasing awareness that cardiovascular risk factors increase risk of cognitive decline and dementia, there are few data on the metabolic syndrome and cognition. Objective To determine if the metabolic syndrome is a risk factor for cognitive decline and if this association is modified by inflammation. Design and Setting A 5-year prospective observational study conducted from 1997 to 2002 at community clinics at 2 sites. Participants A total of 2632 black and white elders (mean age, 74 years). Main Outcome Measures Association of the metabolic syndrome (measured using National Cholesterol Education Program guidelines) and high inflammation (defined as above median serum level of interleukin 6 and C-reactive protein) with change in cognition (Modified Mini-Mental State Examination [3MS]) at 3 and 5 years. Cognitive impairment was defined as at least a 5-point decline. Results Compared with those without the metabolic syndrome (n=1616), elders with the metabolic syndrome (n=1016) were more likely to have cognitive impairment (26% vs 21%, multivariate adjusted relative risk [RR], 1.20; 95% confidence interval [CI], 1.02-1.41). There was a statistically significant interaction with inflammation and the metabolic syndrome (P=.03) on cognitive impairment. After stratifying for inflammation, those with the metabolic syndrome and high inflammation (n=348) had an increased likelihood of cognitive impairment compared with those without the metabolic syndrome (multivariate adjusted RR, 1.66; 95% CI, 1.19-2.32). Those with the metabolic syndrome and low inflammation (n=668) did not exhibit an increased likelihood of impairment (multivariate adjusted RR, 1.08; 95% CI, 0.89-1.30). Stratified multivariate random-effects models demonstrated that participants with the metabolic syndrome and high inflammation had greater 4-year decline on 3MS (P=.04) compared with those without the metabolic syndrome, whereas those with the metabolic syndrome and low inflammation did not (P=.44). Conclusion These findings support the hypothesis that the metabolic syndrome contributes to cognitive impairment in elders, but primarily in those with high level of inflammation.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Geriatr, San Francisco, CA 94143 USA; NIA, Clin Res Branch, Baltimore, MD USA; NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD USA; Univ Tennessee, Dept Prevent Med, Memphis, TN USA; Univ Pittsburgh, Sch Med, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Tennessee System; University of Tennessee Health Science Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Psychiat, Box 181,4150 Clement St, San Francisco, CA 94121 USA.	kyaffe@itsa.ucsf.edu	Simonsick, Eleanor/W-6864-2019; Newman, Anne B./C-6408-2013	Newman, Anne B./0000-0002-0106-1150; Lindquist, Karla/0000-0002-1971-2273	NATIONAL INSTITUTE ON AGING [R01AG021918, N01AG062101, N01AG002106, N01AG002103] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-2103, N01-AG-2106, N01-AG-6-2101, R01 AG021918-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barzilay JI, 2001, DIABETES, V50, P2384, DOI 10.2337/diabetes.50.10.2384; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Das UN, 2002, NUTRITION, V18, P430, DOI 10.1016/S0899-9007(01)00747-X; Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668; Evans RM, 2000, NEUROLOGY, V54, P240, DOI 10.1212/WNL.54.1.240; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Gregg EW, 2000, ARCH INTERN MED, V160, P174, DOI 10.1001/archinte.160.2.174; Grodstein F, 2001, DIABETES CARE, V24, P1060, DOI 10.2337/diacare.24.6.1060; Grundy SM, 2003, JAMA-J AM MED ASSOC, V290, P3000, DOI 10.1001/jama.290.22.3000; Jones RW, 2001, LANCET, V358, P436, DOI 10.1016/S0140-6736(01)05667-7; Kalmijn S, 2000, ARTERIOSCL THROM VAS, V20, P2255, DOI 10.1161/01.ATV.20.10.2255; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; Kanaya AM, 2004, ARCH INTERN MED, V164, P1327, DOI 10.1001/archinte.164.12.1327; Knopman D, 2001, NEUROLOGY, V56, P42, DOI 10.1212/WNL.56.1.42; Kuller LH, 2003, NEUROEPIDEMIOLOGY, V22, P13, DOI 10.1159/000067109; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; Launer LJ, 2002, AGEING RES REV, V1, P61, DOI 10.1016/S0047-6374(01)00364-5; Little RJA, 1996, BIOMETRICS, V52, P98, DOI 10.2307/2533148; McGeer EG, 1999, CURR PHARM DESIGN, V5, P821; Moroney JT, 1999, JAMA-J AM MED ASSOC, V282, P254, DOI 10.1001/jama.282.3.254; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ridker PM, 2003, CIRCULATION, V107, P391, DOI 10.1161/01.CIR.0000055014.62083.05; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; SCHWARZ G, 1978, ANN STAT, V6, P461, DOI 10.1214/aos/1176344136; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Yaffe K, 2002, ARCH NEUROL-CHICAGO, V59, P378, DOI 10.1001/archneur.59.3.378; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7; Zandi PP, 2002, NEUROLOGY, V59, P880, DOI 10.1212/WNL.59.6.880; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	34	726	750	5	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2237	2242		10.1001/jama.292.18.2237	http://dx.doi.org/10.1001/jama.292.18.2237			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536110	Bronze			2022-12-28	WOS:000225070000024
J	Edwards, M				Edwards, M			Historical keywords - Trial	LANCET			English	Editorial Material									UCL, Wellcome Trust Ctr Hist Med, London, England	University of London; University College London	Edwards, M (corresponding author), UCL, Wellcome Trust Ctr Hist Med, London, England.	martin.edwards@ucl.ac.uk							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1659	1659		10.1016/S0140-6736(04)17337-6	http://dx.doi.org/10.1016/S0140-6736(04)17337-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530614				2022-12-28	WOS:000224921600013
J	Stuck, AE; Beck, JC; Egger, M				Stuck, AE; Beck, JC; Egger, M			Preventing disability in elderly people	LANCET			English	Editorial Material							COMPREHENSIVE GERIATRIC ASSESSMENT; OLDER-PEOPLE; MRC TRIAL; HOME VISITS; COMMUNITY; MANAGEMENT; CARE; HEARING; DECLINE		Univ Bern, Dept Geriatr, Spital Bern Ziegler, CH-3001 Bern, Switzerland; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; Univ Bristol, MRC, Hlth Serv Res Collaborat, Dept Social Med, Bristol BS8 1TH, Avon, England	University of Bern; University of California System; University of California Los Angeles; University of Bern; University of Bristol	Stuck, AE (corresponding author), Univ Bern, Dept Geriatr, Spital Bern Ziegler, CH-3001 Bern, Switzerland.	andreas.stuck@spitalbern.ch		Egger, Matthias/0000-0001-7462-5132				Alessi CA, 1997, J AM GERIATR SOC, V45, P1044, DOI 10.1111/j.1532-5415.1997.tb05964.x; ANDERSSON G, 1994, SCAND AUDIOL, V23, P249, DOI 10.3109/01050399409047516; Department of Health, 2001, NAT SERV FRAM OLD PE; Dickinson E, 1996, BRIT MED J, V312, P862; Egger M, 2001, BRIT MED J, V323, P724; Smeeth L, 2002, CONTROL CLIN TRIALS, V23, P409, DOI 10.1016/S0197-2456(02)00208-8; Smeeth L, 2002, LANCET, V359, P1466, DOI 10.1016/S0140-6736(02)08433-7; Smeeth L, 2001, BRIT MED J, V323, P1403, DOI 10.1136/bmj.323.7326.1403; Stuck AE, 1999, SOC SCI MED, V48, P445, DOI 10.1016/S0277-9536(98)00370-0; Stuck AE, 2002, AGE AGEING, V31, P463, DOI 10.1093/ageing/31.6.463; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; WILLIAMSON J, 1964, LANCET, V1, P1117	14	25	26	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1641	1642		10.1016/S0140-6736(04)17365-0	http://dx.doi.org/10.1016/S0140-6736(04)17365-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	868NZ	15530604				2022-12-28	WOS:000224921600003
J	Hogg, RC; Bertrand, D				Hogg, RC; Bertrand, D			What genes tell us about nicotine addiction	SCIENCE			English	Editorial Material							HUMAN EPILEPSY; MUTATIONS; NACHRS		Ctr Med Univ Geneva, Dept Neurosci, Geneva, Switzerland	University of Geneva	Hogg, RC (corresponding author), Ctr Med Univ Geneva, Dept Neurosci, Geneva, Switzerland.	daniel.bertrand@medecine.unige.ch						Bertrand D, 2002, EPILEPSIA, V43, P112, DOI 10.1046/j.1528-1157.43.s.5.16.x; Laviolette SR, 2004, NAT REV NEUROSCI, V5, P55, DOI 10.1038/nrn1298; Le Novere N, 2002, J NEUROBIOL, V53, P447, DOI 10.1002/neu.10153; Lena C, 1999, ANN NY ACAD SCI, V868, P611, DOI 10.1111/j.1749-6632.1999.tb11333.x; Scheffer IE, 2003, TRENDS PHARMACOL SCI, V24, P428, DOI 10.1016/S0165-6147(03)00194-9; Steinlein OK, 2004, PROG BRAIN RES, V145, P275, DOI 10.1016/S0079-6123(03)45019-X; Tapper AR, 2004, SCIENCE, V306, P1029, DOI 10.1126/science.1099420	7	23	24	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					983	+		10.1126/science.1106030	http://dx.doi.org/10.1126/science.1106030			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528431				2022-12-28	WOS:000225001100027
J	Declercq, E; Menacker, F; MacDorman, M				Declercq, E; Menacker, F; MacDorman, M			Rise in "no indicated risk" primary caesareans in the United States, 1991-2001: cross sectional analysis	BRITISH MEDICAL JOURNAL			English	Article							BIRTH		Boston Univ, Sch Publ Hlth, Maternal & Child Hlth Dept, Boston, MA 02118 USA; Natl Ctr Hlth Stat, Div Vital Stat, Hyattsville, MD 20782 USA	Boston University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Declercq, E (corresponding author), Boston Univ, Sch Publ Hlth, Maternal & Child Hlth Dept, 715 Albany St, Boston, MA 02118 USA.	declercq@bu.edu		Declercq, Eugene/0000-0001-5411-3033				Bewley S, 2002, BJOG-INT J OBSTET GY, V109, P597, DOI 10.1016/S1470-0328(02)07106-9; O'Boyle AL, 2002, AM J OBSTET GYNECOL, V187, P981, DOI 10.1067/mob.2002.128085; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; Zinberg S, 2001, CLIN OBSTET GYNECOL, V44, P561, DOI 10.1097/00003081-200109000-00013	4	85	86	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 8	2005	330	7482					71	72		10.1136/bmj.38279.705336.0B	http://dx.doi.org/10.1136/bmj.38279.705336.0B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	887GR	15556953	Green Published, Bronze			2022-12-28	WOS:000226294300013
J	Peltola, H; Salo, E; Saxen, H				Peltola, H; Salo, E; Saxen, H			Incidence of Haemophilus influenzae type b meningitis during 18 years of vaccine use: observational study using routine hospital data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							POLYSACCHARIDE		Univ Helsinki, Childrens Hosp, Hosp Children & Adolescents, Helsinki 00029, Finland	University of Helsinki	Peltola, H (corresponding author), Univ Helsinki, Childrens Hosp, Hosp Children & Adolescents, POB 281, Helsinki 00029, Finland.	heikki.peltola@hus.fi						KAYHTY H, 1983, J INFECT DIS, V147, P1100; McVernon J, 2003, BRIT MED J, V326, P285; Peltola H, 2000, CLIN MICROBIOL REV, V13, P302, DOI 10.1128/CMR.13.2.302-317.2000; Rijkers GT, 2003, LANCET, V361, P1563, DOI 10.1016/S0140-6736(03)13201-1; SCHMITT HJ, 1995, 35 INT C ANT AG CHEM, P169	5	33	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					18	19		10.1136/bmj.38301.657014.79	http://dx.doi.org/10.1136/bmj.38301.657014.79			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15564230	Green Published, Bronze			2022-12-28	WOS:000226176700012
J	Furber, AS; Hodgson, IJ; Desclaux, A; Mukasa, DS				Furber, AS; Hodgson, IJ; Desclaux, A; Mukasa, DS			Barriers to better care for people with AIDS in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL TREATMENT; HIV TREATMENT; HIV/AIDS; THERAPY; AFRICA; ACCESS		Univ Sheffield, Sch Hlth & Related Res, Publ Hlth GIS Unit, Sheffield S1 4DA, S Yorkshire, England; Univ Bradford, Sch Hlth Studies, Bradford BD7 1DP, W Yorkshire, England; Univ Aix Marseille, Ctr Rech Cultures Sante Soc, Maison Mediterraneenne Sci Homme, F-13094 Aix En Provence 2, France; Uganda Red Cross Soc, Kampala, Uganda	University of Sheffield; University of Bradford; UDICE-French Research Universities; Aix-Marseille Universite	Furber, AS (corresponding author), Univ Sheffield, Sch Hlth & Related Res, Publ Hlth GIS Unit, Sheffield S1 4DA, S Yorkshire, England.	A.Furber@sheffield.ac.uk	Desclaux, Alice/D-9566-2017	Desclaux, Alice/0000-0002-4268-2818				BECKER C, 1999, VIVRE PENSER SIDA AF; Chen XY, 2004, LANCET, V364, P417; Desclaux A., 2003, STUDIES REPORTS SPEC, V20, P1; DESCLAUX A, 2004, SENEGALESE ANTIRETRO, P109; DESCLAUX A, 2003, UNHEALTHY HLTH POLIC; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Gayle H, 2004, LANCET, V364, P6, DOI 10.1016/S0140-6736(04)16607-5; Goffman E., 1963, BEHAV PUBLIC PLACES, P3; Gupta R, 2004, LANCET, V363, P320, DOI 10.1016/S0140-6736(03)15394-9; Harding R, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-33; Holmes W, 2004, LANCET, V363, P1072, DOI 10.1016/S0140-6736(04)15847-9; Kitahata MM, 2002, BMJ-BRIT MED J, V325, P954, DOI 10.1136/bmj.325.7370.954; Kumar Sanjay, 2004, BMJ, V328, P70; LANIECE I, 2003, AIDS S, V7, pS103; LEANDRE F, 2002, 14 INT AIDS C BARC; Loewenson R, 2004, BMJ-BRIT MED J, V328, P241, DOI 10.1136/bmj.328.7434.241; Mukherjee J, 2004, LANCET, V363, P1071, DOI 10.1016/S0140-6736(04)15846-7; Mukherjee JS, 2003, BMJ-BRIT MED J, V327, P1104, DOI 10.1136/bmj.327.7423.1104; NGUYEN VK, 2003, AIDS S, V7, pS109; Nyblade L, 2003, DISENTANGLING HIV AI; Osborne CM, 1997, AIDS, V11B, P135; Parker R, 2003, SOC SCI MED, V57, P13, DOI 10.1016/S0277-9536(02)00304-0; PIALOUX G, 2001, TRANSCRIPTASE, V7, P2; PIOT P, 2004, CORRESPONDENT   0712, P11; Sharma DC, 2003, LANCET, V362, P1988, DOI 10.1016/S0140-6736(03)15092-1; SOW K, 2004, SENEGALESE ANTIRETRO, P147; Stanley L, 1999, ANTHROPOL MED, V6, P103, DOI DOI 10.1080/13648470.1999.9964576; Stevens W, 2004, BMJ-BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280; *UN INT REG INF NE, 2004, 14000 SUBS AIDS DRUG; *UNAID, 2004, UNAIDS WHO POL STAT; *UNAIDS, 2003, STIGM DISCR FACT SHE; Walley JD, 2001, LANCET, V357, P664, DOI 10.1016/S0140-6736(00)04129-5; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, 2003, MOBCOMM ACH 3 5; *WHO, 2000, HIV AIDS CONFR EP RE; *WHO, 2003, TREAT 3 MILL 2005 MA; *WHO, 2003, EM SCAL UP ANT THER; World Health Organization, 2003, SCAL UP ANT THER RES; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	39	23	23	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2004	329	7477					1281	1283		10.1136/bmj.329.7477.1281	http://dx.doi.org/10.1136/bmj.329.7477.1281			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	876FC	15564262	Green Published, Green Accepted			2022-12-28	WOS:000225480900023
J	Hippisley-Cox, J; O'Hanlon, S; Coupland, C				Hippisley-Cox, J; O'Hanlon, S; Coupland, C			Association of deprivation, ethnicity, and sex with quality indicators for diabetes: population based survey of 53 000 patients in primary care	BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the effect of deprivation and ethnicity on the achievement of quality indicators for patients with diabetes and the extent of any inequalities between the sexes. Design Population based cross sectional survey using electronic general practice records. Setting 237 UK practices contributing to the QRESEARCH database. Participants 54 180 patients with diabetes, derived from a population of 1.8 million patients. Main outcome measures Adjusted odds ratios for 18 indicators for diabetes from the new general medical services contract for UK general practitioners and comparisons between patients from the most, deprived and most affluent fifths (areas of high and low ethnicity) and between men and women. Results The prevalence of diabetes was 3.0%, and there was a large variation between practices in achievement of indicators. Compared with patients from affluent areas, those from deprived areas were less likely to have body mass index and smoking status recorded. They were also less likely to have records for HbA(1c) concentration; an HbA(1c) value < 7.5% or < 10%; retinal screening; blood pressure; testing for neuropathy or microalbuminuria, or flu vaccination. Compared with patients from areas of low ethnicity those from areas of high ethnicity were less likely to have many measures recorded. Women were significantly less likely to have records for body mass index; pulses; blood pressure values below 145/85 mm Hg; testing for microalbuminuria; serum cholesterol concentration; serum cholesterol values < 5 mmol/l; and angiotensin converting enzyme inhibitors given in the presence of proteinuria or microalbuminuria. Conclusions Practices in areas of high deprivation and high ethnicity will have to work harder to achieve the quality indicators for diabetes, and it is possible that those practices that most need the resources are the ones least likely to get them.	Div Primary Care, Nottingham NG2 7RD, England; The Surgery, Guildford GU5 0PE, Surrey, England		Hippisley-Cox, J (corresponding author), Div Primary Care, Tower Bldg,Univ Pk, Nottingham NG2 7RD, England.	julia.hippisley-cox@nottingham.ac.uk	Hippisley-Cox, Julia/AAY-2788-2020	Hippisley-Cox, Julia/0000-0002-2479-7283; Coupland, Carol/0000-0002-2327-3306				[Anonymous], 2002, HLTH STAT Q; Department of Health, 2003, NAT SERV FRAM DIAB D; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; Hippisley-Cox J, 2003, BRIT MED J, V326, P1439, DOI 10.1136/bmj.326.7404.1439	4	94	97	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 27	2004	329	7477					1267	1269		10.1136/bmj.38279.588125.7C	http://dx.doi.org/10.1136/bmj.38279.588125.7C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15548561	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225480900016
J	Norman, PE; Jamrozik, K; Lawrence-Brown, MM; Le, MTQ; Spencer, CA; Tuohy, RJ; Parsons, RW; Dickinson, JA				Norman, PE; Jamrozik, K; Lawrence-Brown, MM; Le, MTQ; Spencer, CA; Tuohy, RJ; Parsons, RW; Dickinson, JA			Population based randomised controlled trial on impact of screening on mortality from abdominal aortic aneurysm	BRITISH MEDICAL JOURNAL			English	Article							WESTERN-AUSTRALIA; INCREASING INCIDENCE; PROGRAM; MEN; PREVALENCE; MASS	Objective To assess whether screening for abdominal aortic aneurysms in men reduces mortality. Design Population based randomised controlled trial of ultrasound screening, with intention to treat analysis of age standardised mortality. Setting Community based screening programme in Western Australia. Participants 41000 men aged 65-83 years randomised to intervention and control groups. Intervention Invitation to ultrasound screening. Main outcome measure Deaths from abdominal aortic aneurysm in the five years after the start of screening. Results The corrected response to invitation to screening was 70%. The crude prevalence was 7.2% for aortic diameter greater than or equal to 30 mm and 0.5% for diameter greater than or equal to 55. mm. Twice as many men in the intervention group than in the control group underwent elective surgery for abdominal aortic aneurysm (107 v 54, P = 0.002, chi(2) test.). Between scheduled screening and the end of follow up 18 men in the intervention group and 25 in the control group died from abdominal aortic aneurysm, yielding a mortality ratio of 0.61 (95% confidence interval 0.33 to 1.11). Any benefit was almost entirely in men aged between 65 and 75 years, where the ratio was reduced to 0.19 (0.04 to 0.89). Conclusions At a whole population level screening for abdominal aortic aneurysms was not effective in men aged 65-83 years and did not reduce overall death rates. The success of screening depends on choice of target age group and the exclusion of ineligible men. It is also important to assess the cur-rent rate of elective surgery for abdominal aortic aneurysm as in some communities this may already approach a level that reduces the potential benefit of population based screening.	Univ Western Australia, Fremantle Hosp, Sch Surg & Pathol, Fremantle, WA 6959, Australia; Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia; Mt Med Ctr, Perth, WA 6005, Australia; Univ Western Australia, Sch Populat Hlth, Crawley, WA 6009, Australia; Univ Calgary, Dept Family Med, Calgary, AB T2N 1M7, Canada	University of Western Australia; University of Queensland; University of Western Australia; University of Calgary	Norman, PE (corresponding author), Univ Western Australia, Fremantle Hosp, Sch Surg & Pathol, POB 480, Fremantle, WA 6959, Australia.	pnorman@cyllene.uwa.edu.au	Norman, Paul E/C-5485-2013	Norman, Paul E/0000-0003-3406-0506; Dickinson, James/0000-0003-3675-6865				Ashton HA, 2002, LANCET, V360, P1531, DOI 10.1016/S0140-6736(02)11522-4; Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135; Cheatle TR, 1997, ANN ROY COLL SURG, V79, P90; COLLIN J, 1988, LANCET, V2, P613; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; FOWKES FGR, 1992, BRIT MED J, V305, P1013, DOI 10.1136/bmj.305.6860.1013; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; Heather BP, 2000, BRIT J SURG, V87, P750, DOI 10.1046/j.1365-2168.2000.01476.x; Jamrozik K, 2000, MED J AUSTRALIA, V173, P345, DOI 10.5694/j.1326-5377.2000.tb125684.x; Lederle FA, 1997, ANN INTERN MED, V126, P441, DOI 10.7326/0003-4819-126-6-199703150-00004; Lindholt JS, 2002, EUR J VASC ENDOVASC, V23, P55, DOI 10.1053/ejvs.2001.1534; NICHOLLS EA, 1992, AUST NZ J SURG, V62, P858, DOI 10.1111/j.1445-2197.1992.tb06939.x; Norman PE, 1998, BMJ-BRIT MED J, V317, P852, DOI 10.1136/bmj.317.7162.852; Reitsma JB, 1996, EUR J VASC ENDOVASC, V12, P446, DOI 10.1016/S1078-5884(96)80012-8; SCOTT RAP, 1995, BRIT J SURG, V82, P1066, DOI 10.1002/bjs.1800820821; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; Semmens JB, 2000, BRIT J SURG, V87, P191, DOI 10.1046/j.1365-2168.2000.01346.x; Semmens JB, 1998, AUST NZ J SURG, V68, P404, DOI 10.1111/j.1445-2197.1998.tb04787.x; Wilmink TBM, 1999, J VASC SURG, V30, P203, DOI 10.1016/S0741-5214(99)70129-1	19	396	400	0	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 27	2004	329	7477					1259	1262A		10.1136/bmj.38272.478438.55	http://dx.doi.org/10.1136/bmj.38272.478438.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15545293	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225480900013
J	Loudet, JC; Hanusse, P; Poulin, P				Loudet, JC; Hanusse, P; Poulin, P			Stokes drag on a sphere in a nematic liquid crystal	SCIENCE			English	Article									CNRS, Ctr Rech Paul Pascal, F-33600 Pessac, France	Centre de Recherche Paul Pascal; Centre National de la Recherche Scientifique (CNRS)	Loudet, JC (corresponding author), CNRS, Ctr Rech Paul Pascal, Ave A Schweitzer, F-33600 Pessac, France.	toudet@crpp-bordeaux.cnrs.fr		Poulin, Philippe/0000-0001-7748-8671				[Anonymous], 2007, PRINCIPLES CONDENSED; Crocker JC, 1996, J COLLOID INTERF SCI, V179, P298, DOI 10.1006/jcis.1996.0217; Happel J, 1991, LOW REYNOLDS NUMBER; Loudet JC, 2000, NATURE, V407, P611, DOI 10.1038/35036539; Loudet JC, 2003, TOP CURR CHEM, V226, P173, DOI 10.1007/b10828; Poulin P, 1997, SCIENCE, V275, P1770, DOI 10.1126/science.275.5307.1770; Ruhwandl RW, 1996, PHYS REV E, V54, P5204, DOI 10.1103/PhysRevE.54.5204; Stark H, 2001, PHYS REP, V351, P387, DOI 10.1016/S0370-1573(00)00144-7; Stark H, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.031711	9	151	153	2	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1525	1525		10.1126/science.1102864	http://dx.doi.org/10.1126/science.1102864			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567855				2022-12-28	WOS:000225442700049
J	Laughlin, MJ; Eapen, M; Rubinstein, P; Wagner, JE; Zhang, MJ; Champlin, RE; Stevens, C; Barker, JN; Gale, RP; Lazarus, HM; Marks, DI; van Rood, JJ; Scaradavou, A; Horowitz, MM				Laughlin, MJ; Eapen, M; Rubinstein, P; Wagner, JE; Zhang, MJ; Champlin, RE; Stevens, C; Barker, JN; Gale, RP; Lazarus, HM; Marks, DI; van Rood, JJ; Scaradavou, A; Horowitz, MM			Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; PLACENTAL-BLOOD; RECIPIENTS; SURVIVAL; CHILDREN; ENGRAFTMENT; RECOVERY	BACKGROUND Data regarding the outcome of cord-blood transplantation in adults are scant, despite the fact that these grafts are increasingly used in adults. METHODS We compared the outcomes of the transplantation of hematopoietic stem cells from unrelated donors in adults with leukemia who had received cord blood that was mismatched for one HLA antigen ( 34 patients) or two antigens ( 116 patients), bone marrow that had one HLA mismatch ( 83 patients), and HLA-matched bone marrow ( 367 patients). We used Cox proportional-hazards models to analyze the data. RESULTS Cord-blood recipients were younger and more likely to have advanced leukemia than were bone marrow recipients, and they received lower doses of nucleated cells. Hematopoietic recovery was slower with transplantation of mismatched bone marrow and cord blood than with matched marrow transplantations. Acute graft-versus-host disease (GVHD) was more likely to occur after mismatched marrow transplantation, and chronic GVHD was more likely to occur after cord-blood transplantation. The rates of treatment-related mortality, treatment failure, and overall mortality were lowest among patients who received matched marrow transplants. Patients who received mismatched bone marrow transplants and those who received mismatched cord-blood transplants had similar rates of treatment-related mortality (P = 0.96), treatment failure (P = 0.69), and overall mortality (P = 0.62). There were no differences in the rate of recurrence of leukemia among the groups. There were no differences in outcome after cord-blood transplantation between patients with one HLA mismatch and those with two HLA mismatches. CONCLUSIONS HLA-mismatched cord blood should be considered an acceptable source of hematopoietic stem-cell grafts for adults in the absence of an HLA-matched adult donor.	Med Coll Wisconsin, Hlth Policy Inst, Int Bone Marrow Transplant Registry, Milwaukee, WI 53226 USA; Case Comprehens Canc Ctr, Cleveland, OH USA; Univ Hosp Cleveland, Ireland Canc Ctr, Cleveland, OH 44106 USA; New York Blood Ctr, Natl Cord Blood Program, New York, NY 10021 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; MD Anderson Canc Res Ctr, Houston, TX USA; Ctr Adv Studies Leukemia, Los Angeles, CA USA; United Bristol Hlth Care Trust, Adult Blood & Marrow Transplant Unit, Bristol, Avon, England; Leiden Univ, Med Ctr, Leiden, Netherlands	Medical College of Wisconsin; Case Western Reserve University; University Hospitals of Cleveland; New York Blood Center; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; UTMD Anderson Cancer Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Horowitz, MM (corresponding author), Med Coll Wisconsin, Hlth Policy Inst, Int Bone Marrow Transplant Registry, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.	marymh@mcw.edu	horowitz, Mary/ABH-2173-2021	Eapen, Mary/0000-0001-6193-4243	NATIONAL CANCER INSTITUTE [U24CA076518] Funding Source: NIH RePORTER; NCI NIH HHS [U24-CA76518] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen PK, 1999, STAT MED, V18, P1489, DOI 10.1002/(SICI)1097-0258(19990630)18:12<1489::AID-SIM140>3.0.CO;2-#; Barker JN, 2002, BIOL BLOOD MARROW TR, V8, P257, DOI 10.1053/bbmt.2002.v8.pm12064362; Barker JN, 2003, BLOOD, V102, P1915, DOI 10.1182/blood-2002-11-3337; Barker JN, 2001, BLOOD, V97, P2957, DOI 10.1182/blood.V97.10.2957; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; COX DR, 1972, J R STAT SOC B, V34, P187; Fernandez MN, 2003, EXP HEMATOL, V31, P535, DOI 10.1016/S0301-472X(03)00067-5; Flowers MED, 1999, HEMATOL ONCOL CLIN N, V13, P1091, DOI 10.1016/S0889-8588(05)70111-8; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Government Accountability Office, 2002, GAO PUBL, V02-445; Hamza NS, 2004, BRIT J HAEMATOL, V124, P488, DOI 10.1046/j.1365-2141.2003.04792.x; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Jaroscak J, 2003, BLOOD, V101, P5061, DOI 10.1182/blood-2001-12-0290; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Klein JP., SURVIVAL ANAL TECHNI; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Laughlin MJ, 2001, NEW ENGL J MED, V344, P1815, DOI 10.1056/NEJM200106143442402; Locatelli F, 1999, BLOOD, V93, P3662; MCGLAVE P, 1993, BLOOD, V81, P543; Ooi J, 2002, BRIT J HAEMATOL, V118, P140, DOI 10.1046/j.1365-2141.2002.03650.x; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Rocha V, 2001, BLOOD, V97, P2962, DOI 10.1182/blood.V97.10.2962; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; Saavedra S, 2002, BONE MARROW TRANSPL, V30, P937, DOI 10.1038/sj.bmt.1703764; Sanz GF, 2001, BLOOD, V98, P2332, DOI 10.1182/blood.V98.8.2332; Shpall EJ, 2002, BIOL BLOOD MARROW TR, V8, P368, DOI 10.1053/bbmt.2002.v8.pm12171483; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; Wagner JE, 1996, BLOOD, V88, P795	29	843	891	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2265	2275		10.1056/NEJMoa041276	http://dx.doi.org/10.1056/NEJMoa041276			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564543	Bronze			2022-12-28	WOS:000225298100005
J	Mora, CV; Davison, M; Wild, JM; Walker, MM				Mora, CV; Davison, M; Wild, JM; Walker, MM			Magnetoreception and its trigeminal mediation in the homing pigeon	NATURE			English	Article							DISCRIMINATION; NAVIGATION	Two conflicting hypotheses compete to explain how a homing pigeon can return to its loft over great distances. One proposes the use of atmospheric odours(1) and the other the Earth's magnetic field(2-4) in the 'map' step of the map and compass' hypothesis of pigeon homing(5). Although magnetic effects on pigeon orientation(6,7) provide indirect evidence for a magnetic 'map', numerous conditioning experiments(8) have failed to demonstrate reproducible responses to magnetic fields by pigeons. This has led to suggestions that homing pigeons and other birds have no useful sensitivity to the Earth's magnetic field(9-11). Here we demonstrate that homing pigeons (Columba livia) can discriminate between the presence and absence of a magnetic anomaly in a conditioned choice experiment. This discrimination is impaired by attachment of a magnet to the cere, local anaesthesia of the upper beak area, and bilateral section of the ophthalmic branch of the trigeminal nerve, but not of the olfactory nerve. These results suggest that magnetoreception (probably magnetite-based) occurs in the upper beak area of the pigeon. Traditional methods of rendering pigeons anosmic might therefore cause simultaneous impairment of magnetoreception so that future orientation experiments will require independent evaluation of the pigeon's magnetic and olfactory systems.	Univ Auckland, Sch Biol Sci, Auckland 1, New Zealand; Univ Auckland, Sch Med, Dept Psychol, Auckland 1, New Zealand; Univ Auckland, Sch Med, Dept Anat, Auckland 1, New Zealand	University of Auckland; University of Auckland; University of Auckland	Mora, CV (corresponding author), Univ N Carolina, Dept Biol, Coker Hall,CB 3280, Chapel Hill, NC 27599 USA.	cvmora@email.unc.edu	Davison, Michael/A-9717-2008	Davison, Michael/0000-0003-0452-2044; Walker, Michael/0000-0001-9631-9128				Beason RC, 1997, AUK, V114, P405, DOI 10.2307/4089242; Beason RC, 1996, J EXP BIOL, V199, P1241; Benhamou S, 2003, ANIM BEHAV, V65, P729, DOI 10.1006/anbe.2003.2092; Bonadonna F, 2002, J EXP BIOL, V205, P2519; CARMAN GJ, 1987, ANIM LEARN BEHAV, V15, P124, DOI 10.3758/BF03204957; DAVISON MC, 1978, J EXP ANAL BEHAV, V29, P331, DOI 10.1901/jeab.1978.29-331; Delius J.D., 1983, P327; Diebel CE, 2000, NATURE, V406, P299, DOI 10.1038/35018561; Fleissner G, 2003, J COMP NEUROL, V458, P350, DOI 10.1002/cne.10579; GOULD JL, 1980, AM SCI, V68, P256; GRIFFIN DR, 1982, Q REV BIOL, V57, P293; KEETON WT, 1974, J COMP PHYSIOL, V95, P95, DOI 10.1007/BF00610108; Kramer G., 1953, Journal fuer Ornithologie, V94, P201, DOI 10.1007/BF01922508; MOORE BR, 1980, NATURE, V285, P69, DOI 10.1038/285069a0; Mouritsen H, 2003, J EXP BIOL, V206, P4155, DOI 10.1242/jeb.00650; PAPI F, 1972, Monitore Zoologico Italiano, V6, P85; Papi F, 2000, J EXP BIOL, V203, P3435; Papi F., 1992, ANIMAL HOMING, DOI [DOI 10.1007/978-94-011-1588-9_1, 10.1007/978-94-011-1588-9_1]; Ritz T, 2002, NEURON, V34, P503, DOI 10.1016/S0896-6273(02)00707-9; Schmidt-Koenig K., 1983, P267; WALCOTT C, 1979, SCIENCE, V205, P1027, DOI 10.1126/science.472725; WALCOTT C, 1980, IEEE T MAGN, V16, P1008, DOI 10.1109/TMAG.1980.1060868; Walcott C., 1978, ANIMAL MIGRATION NAV, P143, DOI 10.1007/978-3-662-11147-5_13; WALKER MM, 1984, J COMP PHYSIOL, V155, P673, DOI 10.1007/BF00610853; Walker MM, 1997, NATURE, V390, P371, DOI 10.1038/37057; Walker MM, 1998, J THEOR BIOL, V192, P341, DOI 10.1006/jtbi.1998.0653; WALKER MM, 1985, J COMP PHYSIOL A, V157, P67, DOI 10.1007/BF00611096; WALLRAFF HG, 1989, J THEOR BIOL, V138, P511, DOI 10.1016/S0022-5193(89)80048-7; Williams MN, 2001, BRAIN RES, V889, P243, DOI 10.1016/S0006-8993(00)03114-0; Wiltschko R., 1995, TIEROSYCHOL	30	208	230	1	71	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					508	511		10.1038/nature03077	http://dx.doi.org/10.1038/nature03077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565156				2022-12-28	WOS:000225322100048
J	Petersen, LR; Hayes, EB				Petersen, LR; Hayes, EB			Westward ho? The spread of West Nile virus	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Dis Control & Prevent, Ft Collins, CO 80522 USA	Centers for Disease Control & Prevention - USA	Petersen, LR (corresponding author), Ctr Dis Control & Prevent, Ft Collins, CO 80522 USA.								0	63	65	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2257	2259		10.1056/NEJMp048261	http://dx.doi.org/10.1056/NEJMp048261			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564540				2022-12-28	WOS:000225298100002
J	Rocha, V; Labopin, M; Sanz, G; Arcese, W; Schwerdtfeger, R; Bosi, A; Jacobsen, N; Ruutu, T; de Lima, M; Finke, J; Frassoni, F; Gluckman, E				Rocha, V; Labopin, M; Sanz, G; Arcese, W; Schwerdtfeger, R; Bosi, A; Jacobsen, N; Ruutu, T; de Lima, M; Finke, J; Frassoni, F; Gluckman, E		Acute Leukemia Working Party Euro; Marrow Transplant Grp Eurocord Net	Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMATOPOIETIC STEM-CELLS; VERSUS-HOST-DISEASE; PLACENTAL-BLOOD; CLASS-I; GRAFT; RECIPIENTS; CHILDREN; OUTCOMES; RECONSTITUTION; SECONDARY	BACKGROUND Promising results of cord-blood transplants from unrelated donors have been reported in adults. METHODS We compared outcomes in 682 adults with acute leukemia who received a hematopoietic stem-cell transplant from an unrelated donor: 98 received cord blood and 584 received bone marrow. The transplantations were performed from 1998 through 2002 and reported to Eurocord and the European Blood and Marrow Transplant Group. RESULTS Recipients of cord blood were younger than recipients of bone marrow ( median, 24.5 vs. 32 years of age; P< 0.001), weighed less ( median, 58 vs. 68 kg; P< 0.001), and had more advanced disease at the time of transplantation ( 52 percent vs. 33 percent, P< 0.001). All marrow transplants were HLA matched, whereas 94 percent of cord-blood grafts were HLA mismatched ( P< 0.001). The median number of nucleated cells that were infused was 0.23 x 10(8) per kilogram of the recipient's body weight for cord blood and 2.9 x 10(8) per kilogram for bone marrow ( P< 0.001). Multivariate analysis showed lower risks of grade II, III, or IV acute graft-versus-host disease (GVHD) after cord-blood transplantation ( relative risk, 0.57; 95 percent confidence interval, 0.37 to 0.87; P = 0.01), but neutrophil recovery was significantly delayed ( relative risk, 0.49; 95 percent confidence interval, 0.41 to 0.58; P< 0.001). The incidence of chronic GVHD, transplantation-related mortality, relapse rate, and leukemia-free survival were not significantly different in the two groups. CONCLUSIONS Cord blood from an unrelated donor is an alternative source of hematopoietic stem cells for adults with acute leukemia who lack an HLA-matched bone marrow donor.	Assistance Publ Hop Paris, Hop St Louis, Hematol Bone Marrow Transplant Dept, F-75475 Paris 10, France; Assistance Publ Hop Paris, Hop St Antoine, F-75475 Paris 10, France; Univ Paris, F-75252 Paris, France; Hosp Univ La Fe, Valencia, Spain; Univ Roma Tor Vergata, Rome, Italy; Deutsch Klin Diagnost, D-6200 Wiesbaden, Germany; Osped Careggi, Florence, Italy; Rigshosp, Univ Hosp Internal Med, DK-2100 Copenhagen, Denmark; Univ Helsinki, Cent Hosp, Helsinki, Finland; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Univ Freiburg, Freiburg, Germany; Osped San Martino Genova, Genoa, Italy	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Hospital Universitari i Politecnic La Fe; University of Rome Tor Vergata; University of Florence; Azienda Ospedaliero Universitaria Careggi; Rigshospitalet; University of Copenhagen; University of Helsinki; Helsinki University Central Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Freiburg; University of Genoa; IRCCS AOU San Martino IST	Gluckman, E (corresponding author), Assistance Publ Hop Paris, Hop St Louis, Hematol Bone Marrow Transplant Dept, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	eliane.gluckman@sls.ap-hop-paris.fr	Rocha, Vanderson/AAO-1691-2020; Frassoni, Francesco/K-3971-2018	Frassoni, Francesco/0000-0003-1262-0648; SANZ, GUILLERMO/0000-0002-2767-8191; BOSI, ALBERTO/0000-0002-5486-4838				Barker JN, 2002, BIOL BLOOD MARROW TR, V8, P257, DOI 10.1053/bbmt.2002.v8.pm12064362; Barker JN, 2001, BLOOD, V97, P2957, DOI 10.1182/blood.V97.10.2957; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Frassoni F, 2003, BLOOD, V102, P1138, DOI 10.1182/blood-2003-03-0720; Gluckman E, 2004, EXP HEMATOL, V32, P397, DOI 10.1016/j.exphem.2004.01.002; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Gluckman E, 2000, EXP HEMATOL, V28, P1197, DOI 10.1016/S0301-472X(00)00540-3; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; Grewal SS, 2003, BLOOD, V101, P4233, DOI 10.1182/blood-2002-08-2510; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Klein AK, 2001, BIOL BLOOD MARROW TR, V7, P454, DOI 10.1016/S1083-8791(01)80013-6; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; LANSDORP PM, 1993, J EXP MED, V178, P787, DOI 10.1084/jem.178.3.787; Laughlin MJ, 2001, NEW ENGL J MED, V344, P1815, DOI 10.1056/NEJM200106143442402; Lewis ID, 2001, BLOOD, V97, P3441, DOI 10.1182/blood.V97.11.3441; Long GD, 2003, BIOL BLOOD MARROW TR, V9, P772, DOI 10.1016/j.bbmt.2003.08.007; Madrigal JA, 1997, HUM IMMUNOL, V56, P1, DOI 10.1016/S0198-8859(97)00125-0; Ooi J, 2004, BLOOD, V103, P489, DOI 10.1182/blood-2003-07-2420; Ooi J, 2001, BRIT J HAEMATOL, V114, P834, DOI 10.1046/j.1365-2141.2001.03049.x; Petersdorf EW, 1998, BLOOD, V92, P3515, DOI 10.1182/blood.V92.10.3515.422k49_3515_3520; RISDON G, 1994, CELL IMMUNOL, V154, P14, DOI 10.1006/cimm.1994.1053; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Rocha V, 2001, BLOOD, V97, P2962, DOI 10.1182/blood.V97.10.2962; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; SANZ G, 2003, CURR OPIN ORGAN TRAN, V8, P109; Sanz GF, 2001, BLOOD, V98, P2332, DOI 10.1182/blood.V98.8.2332; Sasazuki T, 1998, NEW ENGL J MED, V339, P1177, DOI 10.1056/NEJM199810223391701; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; Wagner JE, 2002, BLOOD, V100, P1611, DOI 10.1182/blood-2002-01-0294	32	853	894	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2276	2285		10.1056/NEJMoa041469	http://dx.doi.org/10.1056/NEJMoa041469			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564544	Bronze			2022-12-28	WOS:000225298100006
J	Alexandrov, AV; Molina, CA; Grotta, JC; Garami, Z; Ford, SR; Alvarez-Sabin, J; Montaner, J; Saqqur, M; Demchuk, AM; Moye, LA; Hill, MD; Wojner, AW; Al-Senani, F; Burgin, S; Calleja, S; Campbell, M; Chen, CI; Chernyshev, O; Choi, J; El-Mitwalli, A; Felberg, R; Ford, S; Garami, Z; Irr, W; Grotta, J; Hall, C; Iguchi, Y; Ireland, J; Labiche, L; Malkoff, M; Morgenstern, L; Noser, E; Okon, N; Piriyawat, P; Robinson, D; Shaltoni, H; Shaw, S; Uchino, K; Yatsu, F; Alvarez-Sabin, J; Arenillas, JF; Huertas, R; Molina, C; Montaner, J; Ribo, M; Rubiera, M; Santamarina, E; Saqqur, M; Alchtar, N; O'Rourke, F; Hussain, S; Shuaib, A; Abdalla, E; Demchuk, A; Fischer, K; Hill, MD; Kennedy, J; Roy, J; Ryckborst, KJ; Schebel, M				Alexandrov, AV; Molina, CA; Grotta, JC; Garami, Z; Ford, SR; Alvarez-Sabin, J; Montaner, J; Saqqur, M; Demchuk, AM; Moye, LA; Hill, MD; Wojner, AW; Al-Senani, F; Burgin, S; Calleja, S; Campbell, M; Chen, CI; Chernyshev, O; Choi, J; El-Mitwalli, A; Felberg, R; Ford, S; Garami, Z; Irr, W; Grotta, J; Hall, C; Iguchi, Y; Ireland, J; Labiche, L; Malkoff, M; Morgenstern, L; Noser, E; Okon, N; Piriyawat, P; Robinson, D; Shaltoni, H; Shaw, S; Uchino, K; Yatsu, F; Alvarez-Sabin, J; Arenillas, JF; Huertas, R; Molina, C; Montaner, J; Ribo, M; Rubiera, M; Santamarina, E; Saqqur, M; Alchtar, N; O'Rourke, F; Hussain, S; Shuaib, A; Abdalla, E; Demchuk, A; Fischer, K; Hill, MD; Kennedy, J; Roy, J; Ryckborst, KJ; Schebel, M		CLOTBUST Investigators	Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; FLOW; RECANALIZATION; CRITERIA; FIBRINOLYSIS; OCCLUSION; RECOVERY; THERAPY	Background: Transcranial Doppler ultrasonography that is aimed at residual obstructive intracranial blood flow may help expose thrombi to tissue plasminogen activator (t-PA). Our objective was to determine whether ultrasonography can safely enhance the thrombolytic activity of t-PA. Methods: We treated all patients who had acute ischemic stroke due to occlusion of the middle cerebral artery with intravenous t-PA within three hours after the onset of symptoms. The patients were randomly assigned to receive continuous 2-MHz transcranial Doppler ultrasonography (the target group) or placebo (the control group). The primary combined end point was complete recanalization as assessed by transcranial Doppler ultrasonography or dramatic clinical recovery. Secondary end points included recovery at 24 hours, a favorable outcome at three months, and death at three months. Results: A total of 126 patients were randomly assigned to receive continuous ultrasonography (63 patients) or placebo (63 patients). Symptomatic intracerebral hemorrhage occurred in three patients in the target group and in three in the control group. Complete recanalization or dramatic clinical recovery within two hours after the administration of a t-PA bolus occurred in 31 patients in the target group (49 percent), as compared with 19 patients in the control group (30 percent; P=0.03). Twenty-four hours after treatment of the patients eligible for follow-up, 24 in the target group (44 percent) and 21 in the control group (40 percent) had dramatic clinical recovery (P=0.7). At three months, 22 of 53 patients in the target group who were eligible for follow-up analysis (42 percent) and 14 of 49 in the control group (29 percent) had favorable outcomes (as indicated by a score of 0 to 1 on the modified Rankin scale) (P=0.20). Conclusions: In patients with acute ischemic stroke, continuous transcranial Doppler augments t-PA-induced arterial recanalization, with a nonsignificant trend toward an increased rate of recovery from stroke, as compared with placebo.	Univ Texas, Sch Med, Stroke Treatment Team, Houston, TX 77030 USA; Vall Hebron Hosp, Neurovasc Unit, Barcelona, Spain; Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada; Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ Texas, Sch Publ Hlth, Dept Biostat, Houston, TX USA	University of Texas System; Hospital Universitari Vall d'Hebron; University of Alberta; University of Calgary; University of Calgary; University of Calgary; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Alexandrov, AV (corresponding author), Univ Texas, Sch Med, Stroke Treatment Team, MSB 7-044,6431 Fannin St, Houston, TX 77030 USA.	avalexandrov@att.net	Malkoff, Marc/ABA-2754-2021; Demchuk, Andrew M/E-1103-2012; El-Mitwalli, Ashraf/ABB-2877-2022; Uchino, Ken/ABC-1611-2021; Arenillas, Juan F./AAE-1142-2020; Grotta, James/AAH-7423-2021; Montaner, Joan/D-3063-2015; Hill, Michael D/C-9073-2012	Demchuk, Andrew M/0000-0002-4930-7789; Uchino, Ken/0000-0001-9468-4172; Montaner, Joan/0000-0003-4845-2279; Hill, Michael D/0000-0002-6269-1543; Alvarez-Sabin, Jose/0000-0002-8054-9209; Alexandrov, Andrei V/0000-0001-8871-1023	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS044227, K23NS002229] Funding Source: NIH RePORTER; NINDS NIH HHS [1K23NS02229-01, 1P50NS044227] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Akiyama M, 1998, NEUROSURGERY, V43, P828, DOI 10.1097/00006123-199810000-00062; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 2000, STROKE, V31, P610, DOI 10.1161/01.STR.31.3.610; Alexandrov AV, 2004, J NEUROIMAGING, V14, P108, DOI 10.1177/1051228403261459; Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Alexandrov AV, 2001, CIRCULATION, V103, P2897, DOI 10.1161/01.CIR.103.24.2897; Behrens S, 2001, ULTRASOUND MED BIOL, V27, P1683, DOI 10.1016/S0301-5629(01)00481-1; BLINC A, 1993, BLOOD, V81, P2636; BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230; Burgin WS, 2000, STROKE, V31, P1128, DOI 10.1161/01.STR.31.5.1128; Caplan LR, 1997, NEW ENGL J MED, V337, P1309; Cintas P, 2002, STROKE, V33, P626, DOI 10.1161/hs0202.103073; Daffertshofer M, 2003, LANCET NEUROL, V2, P283, DOI 10.1016/S1474-4422(03)00380-6; DAFFERTSHOFER M, IN PRESS CEREBROVASC; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; Demchuk AM, 2001, STROKE, V32, P89, DOI 10.1161/01.STR.32.1.89; Demchuk AM, 2000, J NEUROIMAGING, V10, P1; Eggers J, 2003, ANN NEUROL, V53, P797, DOI 10.1002/ana.10590; FRANCIS CW, 1995, ULTRASOUND MED BIOL, V21, P419, DOI 10.1016/0301-5629(94)00119-X; Francis CW, 2001, ECHOCARDIOGR-J CARD, V18, P239, DOI 10.1046/j.1540-8175.2001.00239.x; Grolimund P., 1986, TRANSCRANIAL DOPPLER, P10; KIMURA M, 1994, BIOL PHARM BULL, V17, P126; LAUER CG, 1992, CIRCULATION, V86, P1257, DOI 10.1161/01.CIR.86.4.1257; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moehring MA, 2002, ULTRASOUND MED BIOL, V28, P49, DOI 10.1016/S0301-5629(01)00486-0; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; Saqqur M, 2003, STROKE, V34, P267; Sloan MA, 2004, NEUROLOGY, V62, P1468, DOI 10.1212/WNL.62.9.1468; Suchkova V, 1998, CIRCULATION, V98, P1030, DOI 10.1161/01.CIR.98.10.1030; Suchkova VN, 2002, THROMB HAEMOSTASIS, V88, P865, DOI 10.1055/s-0037-1613315; TACHIBANA S, 1981, THROMB HAEMOSTASIS, V46, P211; TRUBESTEIN G, 1976, CLIN SCI MOL MED, V51, pS697	33	760	792	3	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2170	2178		10.1056/NEJMoa041175	http://dx.doi.org/10.1056/NEJMoa041175			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548777				2022-12-28	WOS:000225160600007
J	Beachy, PA; Karhadkar, SS; Berman, DM				Beachy, PA; Karhadkar, SS; Berman, DM			Tissue repair and stem cell renewal in carcinogenesis	NATURE			English	Article							HEDGEHOG SIGNALING PATHWAY; ACUTE MYELOID-LEUKEMIA; RECEPTOR-RELATED PROTEIN-5; SMALL-MOLECULE INHIBITOR; BETA-CATENIN EXPRESSION; E-CADHERIN EXPRESSION; BONE-MARROW-CELLS; WNT GENE FAMILY; SONIC-HEDGEHOG; SELF-RENEWAL	Cancer is increasingly being viewed as a stem cell disease, both in its propagation by a minority of cells with stem-cell-like properties and in its possible derivation from normal tissue stem cells. But stem cell activity is tightly controlled, raising the question of how normal regulation might be subverted in carcinogenesis. The long-known association between cancer and chronic tissue injury, and the more recently appreciated roles of Hedgehog and Wnt signalling pathways in tissue regeneration, stem cell renewal and cancer growth together suggest that carcinogenesis proceeds by misappropriating homeostatic mechanisms that govern tissue repair and stem cell self-renewal.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.	pbeachy@jhmi.edu	berman, david/HIR-4177-2022; Karhadkar, Sunil/Y-9235-2019	Karhadkar, Sunil/0000-0001-7943-0203; berman, david/0000-0001-5985-3698				Akazawa C, 2004, J NEUROSCI, V24, P7923, DOI 10.1523/JNEUROSCI.1784-04.2004; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; American Cancer Society, CANC FACTS FIG; Austin TW, 1997, BLOOD, V89, P3624, DOI 10.1182/blood.V89.10.3624.3624_3624_3635; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Blair A, 1997, CANCER CAUSE CONTROL, V8, P473, DOI 10.1023/A:1018417623867; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Bulgakov OV, 2004, DEVELOPMENT, V131, P2149, DOI 10.1242/dev.01122; Burak K, 2004, AM J GASTROENTEROL, V99, P523, DOI 10.1111/j.1572-0241.2004.04067.x; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dahmane N, 2001, DEVELOPMENT, V128, P5201; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Eggenschwiler JT, 2001, NATURE, V412, P194, DOI 10.1038/35084089; EKBOM A, 1990, NEW ENGL J MED, V323, P1228, DOI 10.1056/NEJM199011013231802; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hamed S, 2004, CANCER RES, V64, P1938, DOI 10.1158/0008-5472.CAN-03-2031; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6; Imokawa Y, 1997, P NATL ACAD SCI USA, V94, P9159, DOI 10.1073/pnas.94.17.9159; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Ito H, 1999, BIOCHEM BIOPH RES CO, V262, P443, DOI 10.1006/bbrc.1999.1197; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kai TS, 2003, P NATL ACAD SCI USA, V100, P4633, DOI 10.1073/pnas.0830856100; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Laforest L, 1998, DEVELOPMENT, V125, P4175; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; LIEBER CS, 1979, CANCER RES, V39, P2863; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Machold R, 2003, NEURON, V40, P189, DOI 10.1016/S0896-6273(03)00593-2; Mann RK, 2004, ANNU REV BIOCHEM, V73, P891, DOI 10.1146/annurev.biochem.73.011303.073933; Miyaji T, 2003, HISTOCHEM CELL BIOL, V119, P233, DOI 10.1007/s00418-003-0501-z; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; Moshiri A, 2004, J NEUROSCI, V24, P229, DOI 10.1523/JNEUROSCI.2980-03.2004; MUENKE M, 2001, METABOLIC MOL BASES, P6203; Nishimaki H, 2004, BIOCHEM BIOPH RES CO, V314, P313, DOI 10.1016/j.bbrc.2003.12.097; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; PARK CH, 1971, JNCI-J NATL CANCER I, V46, P411; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Pola R, 2003, CIRCULATION, V108, P479, DOI 10.1161/01.CIR.0000080338.60981.FA; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Quint E, 2002, P NATL ACAD SCI USA, V99, P8713, DOI 10.1073/pnas.122571799; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Roy S, 2002, J EXP ZOOL, V293, P186, DOI 10.1002/jez.10110; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shackel NA, 2001, GUT, V49, P565, DOI 10.1136/gut.49.4.565; Singh SK, 2003, CANCER RES, V63, P5821; Surendran K, 2003, AM J PHYSIOL-RENAL, V284, pF653, DOI 10.1152/ajprenal.00343.2002; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tas S, 2004, EUR J DERMATOL, V14, P96; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Tsonis PA, 2004, DEV BIOL, V267, P450, DOI 10.1016/j.ydbio.2003.12.005; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Watkins DN, 2003, CELL CYCLE, V2, P196, DOI 10.4161/cc.2.3.378; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Wilson AJ, 1997, CLIN SCI, V93, P97, DOI 10.1042/cs0930097; Wu AH, 2001, CANCER CAUSE CONTROL, V12, P721, DOI 10.1023/A:1011290704728; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; Zhang Y, 2001, NATURE, V410, P599, DOI 10.1038/35069099	100	928	1041	2	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					324	331		10.1038/nature03100	http://dx.doi.org/10.1038/nature03100			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549094				2022-12-28	WOS:000225161400042
J	Coloma, JM; Harris, E				Coloma, JM; Harris, E			Innovative low cost technologies for biomedical research and diagnosis in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CLINICAL SPECIMENS; PCR; LEISHMANIA; ASSAY; SERUM		Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA; Sustainable Sci Inst, San Francisco, CA USA	University of California System; University of California Berkeley	Harris, E (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis, Berkeley, CA 94720 USA.	eharris@socrates.berkeley.edu			FIC NIH HHS [TW-00905] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Aviles H, 1999, J PARASITOL, V85, P181, DOI 10.2307/3285616; *AZONANO, LAB ON A CHIP US DET; Balmaseda A, 2003, CLIN DIAGN LAB IMMUN, V10, P317, DOI 10.1128/CDLI.10.2.317-322.2003; Belli A, 1998, AM J TROP MED HYG, V58, P102, DOI 10.4269/ajtmh.1998.58.102; COLOMA J, 2002, SCI NEXT WAVE   0927; Harris E, 2004, EMBO REP, V5, P7, DOI 10.1038/sj.embor.7400058; Harris E, 1998, J CLIN MICROBIOL, V36, P2634, DOI 10.1128/JCM.36.9.2634-2639.1998; Harris E., 1998, LOW COST APPROACH PC; Huang TS, 1996, J CLIN MICROBIOL, V34, P3092, DOI 10.1128/JCM.34.12.3092-3096.1996; Miagostovich MP, 1999, J CLIN VIROL, V14, P183, DOI 10.1016/S1386-6532(99)00059-1; *ORNL, INCR SHRINK LABS CHI; RUSSOMANDO G, 1992, J CLIN MICROBIOL, V30, P2864, DOI 10.1128/JCM.30.11.2864-2868.1992	12	12	12	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1160	1162		10.1136/bmj.329.7475.1160	http://dx.doi.org/10.1136/bmj.329.7475.1160			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539673	Green Published			2022-12-28	WOS:000225169600026
J	Perlman, ZE; Slack, MD; Feng, Y; Mitchison, TJ; Wu, LF; Altschuler, SJ				Perlman, ZE; Slack, MD; Feng, Y; Mitchison, TJ; Wu, LF; Altschuler, SJ			Multidimensional drug profiling by automated microscopy	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR PHARMACOLOGY; PROTEIN COMPLEXES; CELL BIOLOGY; IDENTIFICATION; YEAST; CANCER; TARGET; CLASSIFICATION; INHIBITORS	We present a method for high-throughput cytological profiling by microscopy. Our system provides quantitative multidimensional measures of individual cell states over wide ranges of perturbations. We profile dose-dependent phenotypic effects of drugs in human cell culture with a titration-invariant similarity score (TISS). This method successfully categorized blinded drugs and suggested targets for drugs of uncertain mechanism. Multivariate single-cell analysis is a starting point for identifying relationships among drug effects at a systems level and a step toward phenotypic profiting at the single-cell level. Our methods will be useful for discovering the mechanism and predicting the toxicity of new drugs.	Harvard Univ, Bauer Ctr Gen Res, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Inst Chem & Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wu, LF (corresponding author), Harvard Univ, Bauer Ctr Gen Res, Cambridge, MA 02138 USA.	lwu@cgr.harvard.edu; saltschuter@cgr.harvard.edu			NATIONAL CANCER INSTITUTE [P01CA078048] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA078048] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham VC, 2004, TRENDS BIOTECHNOL, V22, P15, DOI 10.1016/j.tibtech.2003.10.012; Conrad C, 2004, GENOME RES, V14, P1130, DOI 10.1101/gr.2383804; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FIELD CM, 1995, J CELL BIOL, V131, P165, DOI 10.1083/jcb.131.1.165; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Gunther EC, 2003, P NATL ACAD SCI USA, V100, P9608, DOI 10.1073/pnas.1632587100; Haggarty SJ, 2003, J AM CHEM SOC, V125, P10543, DOI 10.1021/ja035413p; HARDMAN JG, 2001, PHARMACOL BASIS THER, P39; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Kaina B, 2003, BIOCHEM PHARMACOL, V66, P1547, DOI 10.1016/S0006-2952(03)00510-0; Lahav G, 2004, NAT GENET, V36, P147, DOI 10.1038/ng1293; Laskin JD, 2002, TOXICOL SCI, V69, P289, DOI 10.1093/toxsci/69.2.289; Leung D, 2003, NAT BIOTECHNOL, V21, P687, DOI 10.1038/nbt826; Lindsay MA, 2003, NAT REV DRUG DISCOV, V2, P831, DOI 10.1038/nrd1202; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; Murphy RF, 2003, J VLSI SIG PROC SYST, V35, P311, DOI 10.1023/B:VLSI.0000003028.71666.44; Noble MEM, 2004, SCIENCE, V303, P1800, DOI 10.1126/science.1095920; PAULL KD, 1992, CANCER RES, V52, P3892; Price JH, 2002, J CELL BIOCHEM, P194, DOI 10.1002/jcb.10448; Root DE, 2003, CHEM BIOL, V10, P881, DOI 10.1016/j.chembiol.2003.08.009; Saito TL, 2004, NUCLEIC ACIDS RES, V32, pD319, DOI 10.1093/nar/gkh113; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Thomas CJ, 2004, BIOORGAN MED CHEM, V12, P1585, DOI 10.1016/j.bmc.2003.11.036; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vera MD, 2002, MED RES REV, V22, P102, DOI 10.1002/med.10003; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	30	489	504	3	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1194	1198		10.1126/science.1100709	http://dx.doi.org/10.1126/science.1100709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539606				2022-12-28	WOS:000225193100053
J	Westover, KD; Bushnell, DA; Kornberg, RD				Westover, KD; Bushnell, DA; Kornberg, RD			Structural basis of transcription: Nucleotide selection by rotation in the RNA polymerase II active center	CELL			English	Article							3.3 ANGSTROM RESOLUTION; ELONGATION COMPLEX; CRYSTAL-STRUCTURE; MECHANISM; DNA; CLEAVAGE; DISCRIMINATION; TRANSLOCATION; ARCHITECTURE; BINDING	Binding of a ribonucleoside triphosphate to an RNA polymerase II transcribing complex, with base pairing to the template DNA, was revealed by X-ray crystallography. Binding of a mismatched nucleoside triphosphate was also detected, but in an adjacent site, inverted with respect to the correctly paired nucleotide. The results are consistent with a two-step mechanism of nucleotide selection, with initial binding to an entry (E) site beneath the active center in an inverted orientation, followed by rotation into the nucleotide addition (A) site for pairing with the template DNA. This mechanism is unrelated to that of single subunit RNA polymerases and so defines a new paradigm for the large, multisubunit enzymes. Additional findings from these studies include a third nucleotide binding site that may define the length of backtracked RNA; DNA double helix unwinding in advance of the polymerase active center; and extension of the diffraction limit of RNA polymerase II crystals to 2.3 A.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA	Stanford University	Kornberg, RD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	kornberg@stanford.edu	Westover, Ken/AAZ-1795-2020	Westover, Ken/0000-0003-3653-5923	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM49985] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2004, CELL, V117, P299, DOI 10.1016/S0092-8674(04)00401-5; BONNER G, 1994, J BIOL CHEM, V269, P25120; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dudev T, 2003, CHEM REV, V103, P773, DOI 10.1021/cr020467n; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Fish RN, 2002, BBA-GENE STRUCT EXPR, V1577, P287, DOI 10.1016/S0167-4781(02)00459-1; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kettenberger H, 2003, CELL, V114, P347, DOI 10.1016/S0092-8674(03)00598-1; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Santangelo TJ, 2004, MOL CELL, V14, P117, DOI 10.1016/S1097-2765(04)00154-6; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; Sosunov V, 2003, EMBO J, V22, P2234, DOI 10.1093/emboj/cdg193; Tahirov TH, 2002, NATURE, V420, P43, DOI 10.1038/nature01129; Temiakov D, 2004, CELL, V116, P381, DOI 10.1016/S0092-8674(04)00059-5; Temiakov D, 2003, ACTA CRYSTALLOGR D, V59, P185, DOI 10.1107/S0907444902019777; Westover KD, 2004, SCIENCE, V303, P1014, DOI 10.1126/science.1090839; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	31	217	236	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					481	489		10.1016/j.cell.2004.10.016	http://dx.doi.org/10.1016/j.cell.2004.10.016			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537538	Bronze			2022-12-28	WOS:000225183200007
J	Annas, GJ				Annas, GJ			Extremely preterm birth and parental authority to refuse treatment - The case of Sidney Miller	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Dept Hlth Law Bioeth & Human Rights, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				Annas GJ, 2004, RIGHT PATIENTS, P273; ATKINSON J, 2002, TEXAS MONTHLY    DEC, P88; Cole FS, 2000, NEW ENGL J MED, V343, P429, DOI 10.1056/NEJM200008103430609; Hansmann G, 2004, LANCET, V364, P1293, DOI 10.1016/S0140-6736(04)17203-6; Linden Dana Wechsler, 2002, N Y Times Web, pF8; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DEC FOR LIF SUST TRE, P218; Robertson JA, 2004, HASTINGS CENT REP, V34, P32, DOI 10.2307/3528691; Weir Robert F., 1984, SELECTIVE NONTREATME; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601	9	31	32	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2118	2123		10.1056/NEJMlim041201	http://dx.doi.org/10.1056/NEJMlim041201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537910	Green Published			2022-12-28	WOS:000225007200016
J	Gershon, D				Gershon, D			In the market-place	NATURE			English	Article																			0	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					243	245		10.1038/432243b	http://dx.doi.org/10.1038/432243b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538372	Bronze			2022-12-28	WOS:000225020200052
J	Yoshie, T; Scherer, A; Hendrickson, J; Khitrova, G; Gibbs, HM; Rupper, G; Ell, C; Shchekin, OB; Deppe, DG				Yoshie, T; Scherer, A; Hendrickson, J; Khitrova, G; Gibbs, HM; Rupper, G; Ell, C; Shchekin, OB; Deppe, DG			Vacuum Rabi splitting with a single quantum dot in a photonic crystal nanocavity	NATURE			English	Article							SPONTANEOUS EMISSION; PHOTOLUMINESCENCE	Cavity quantum electrodynamics (QED) systems allow the study of a variety of fundamental quantum-optics phenomena, such as entanglement, quantum decoherence and the quantum-classical boundary(1-9). Such systems also provide test beds for quantum information science. Nearly all strongly coupled cavity QED experiments have used a single atom in a high-quality-factor (high-Q) cavity. Here we report the experimental realization of a strongly coupled system in the solid state: a single quantum dot embedded in the spacer of a nanocavity, showing vacuum-field Rabi splitting exceeding the decoherence linewidths of both the nanocavity and the quantum dot. This requires a small-volume cavity and an atomic-like two-level system(5,10). The photonic crystal(11) slab nanocavity-which traps photons when a defect is introduced inside the two-dimensional photonic bandgap by leaving out one or more holes(12)-has both high Q and small modal volume V, as required for strong light-matter interactions(13). The quantum dot has two discrete energy levels with a transition dipole moment much larger than that of an atom(14-16), and it is fixed in the nanocavity during growth.	Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA; CALTECH, Pasadena, CA 91125 USA; Univ Texas, Dept Elect & Comp Engn, Ctr Microelect Res, Austin, TX 78712 USA	University of Arizona; California Institute of Technology; University of Texas System; University of Texas Austin	Khitrova, G (corresponding author), Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA.	galina@optics.arizona.edu	Yoshie, Tomoyuki/C-3567-2008					Akahane Y, 2003, NATURE, V425, P944, DOI 10.1038/nature02063; Bayer M, 2001, PHYS REV LETT, V86, P3168, DOI 10.1103/PhysRevLett.86.3168; Berman P., 1994, CAVITY QUANTUM ELECT; Brune M, 1996, PHYS REV LETT, V76, P1800, DOI 10.1103/PhysRevLett.76.1800; BRUNNER K, 1994, PHYS REV LETT, V73, P1138, DOI 10.1103/PhysRevLett.73.1138; CARMICHAEL HJ, 1989, PHYS REV A, V40, P5516, DOI 10.1103/PhysRevA.40.5516; Gammon D, 2002, PHYS TODAY, V55, P36, DOI 10.1063/1.1522165; Gammon D, 1996, PHYS REV LETT, V76, P3005, DOI 10.1103/PhysRevLett.76.3005; Happ TD, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.041303; Haroche S, 1998, PHYS TODAY, V51, P36, DOI 10.1063/1.882326; Keller M, 2003, APPL PHYS B-LASERS O, V76, P125, DOI 10.1007/s00340-003-1114-x; Khitrova G, 1999, REV MOD PHYS, V71, P1591, DOI 10.1103/RevModPhys.71.1591; Kiraz A, 2001, APPL PHYS LETT, V78, P3932, DOI 10.1063/1.1379987; Kreuter A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.203002; Lee ES, 2001, J APPL PHYS, V89, P807, DOI 10.1063/1.1330758; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; MARZIN JY, 1994, PHYS REV LETT, V73, P716, DOI 10.1103/PhysRevLett.73.716; McKeever J, 2003, NATURE, V425, P268, DOI 10.1038/nature01974; Moreau E, 2001, APPL PHYS LETT, V79, P2865, DOI 10.1063/1.1415346; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Petroff PM, 2001, PHYS TODAY, V54, P46, DOI 10.1063/1.1381102; Raimond JM, 2001, REV MOD PHYS, V73, P565, DOI 10.1103/RevModPhys.73.565; Stanley RP, 1996, PHYS REV B, V53, P10995, DOI 10.1103/PhysRevB.53.10995; Vahala KJ, 2003, NATURE, V424, P839, DOI 10.1038/nature01939; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851; WEISBUCH C, 1992, PHYS REV LETT, V69, P3314, DOI 10.1103/PhysRevLett.69.3314; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Yoshie T, 2004, IEICE T ELECTRON, VE87C, P300; Zrenner A, 2002, NATURE, V418, P612, DOI 10.1038/nature00912	30	1794	1816	13	570	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					200	203		10.1038/nature03119	http://dx.doi.org/10.1038/nature03119			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538363				2022-12-28	WOS:000225020200040
J	Colman, I; Brown, MD; Innes, GD; Grafstein, E; Roberts, TE; Rowe, BH				Colman, I; Brown, MD; Innes, GD; Grafstein, E; Roberts, TE; Rowe, BH			Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEADACHE; DIHYDROERGOTAMINE; GUIDELINES; EMERGENCY; PROCHLORPERAZINE; MEPERIDINE; QUALITY; THERAPY; ATTACKS	Objective To assess the evidence from controlled trials on the efficacy and tolerability of parenteral metoclopramide for acute migraine in adults. Data sources Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS, CINAHL. conference proceedings, clinical practice guidelines, and other sources. Selection criteria Randomised controlled trials of parenteral metoclopramide for acute migraine in adults. Results We reviewed 596 potentially relevant abstracts and found 13 eligible trials totalling 655 adults. In studies comparing metoclopramide with placebo, metoclopramide was more likely to provide significant reduction in migraine pain (odds ratio 2.84, 95% confidence interval 1.05 to 7.68). Used as the only agent, metoclopramide showed mixed effectiveness when compared with other single agents. Heterogeneity of studies for combination treatment prevented statistical pooling. Treatments that did include metoclopramide were as, or more, effective than comparison treatments for pain, nausea, and relapse outcomes reported in all studies. Conclusions Metoclopramide is an effective treatment for migraine headache and may be effective when combined with other treatments. Given its non-narcotic and antiemetic properties, metoclopramide should be considered a primary agent in the treatment of acute migraines in emergency departments.	Univ Alberta, Walter Mackenzie Hlth Sci Ctr 1G1 43, Div Emergency Med, Edmonton, AB T6G 2B7, Canada; Univ Cambridge, Dept Psychiat, Cambridge CB2 2QQ, England; Michigan State Univ, Program Emergency Med, Grand Rapids, MI 49503 USA; Providence Hlth Care, Dept Emergency Med, Vancouver, BC, Canada; St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada	University of Alberta; University of Cambridge; Michigan State University; St. Paul's Hospital; University of Saskatchewan; University of Alberta	Rowe, BH (corresponding author), Univ Alberta, Walter Mackenzie Hlth Sci Ctr 1G1 43, Div Emergency Med, 8440-112 St, Edmonton, AB T6G 2B7, Canada.	brian.rowe@ualberta.ca		Colman, Ian/0000-0001-5924-0277; Brown, Michael/0000-0001-6893-350X				BELGRADE MJ, 1989, NEUROLOGY, V39, P590, DOI 10.1212/WNL.39.4.590; CAMERON JD, 1995, ACAD EMERG MED, V2, P597, DOI 10.1111/j.1553-2712.1995.tb03596.x; COLMAN I, 2003, COCHRANE DATABASE SY; COPPOLA M, 1995, ANN EMERG MED, V26, P541, DOI 10.1016/S0196-0644(95)70001-3; DESMOND PV, 1986, MED J AUSTRALIA, V144, P366, DOI 10.5694/j.1326-5377.1986.tb115923.x; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; EDMEADS J, 1993, CAN J NEUROL SCI, V20, P131, DOI 10.1017/S0317167100047697; Edwards KR, 2001, HEADACHE, V41, P976, DOI 10.1046/j.1526-4610.2001.01191.x; ELLIS GL, 1993, ANN EMERG MED, V22, P191, DOI 10.1016/S0196-0644(05)80201-X; ESTABANMORALES A, 1999, REV SANIDAD MILITAR, V53, P36; HAUGH MJ, 1992, HEADACHE, V32, P251; Hu XH, 1999, ARCH INTERN MED, V159, P813, DOI 10.1001/archinte.159.8.813; HUGHES JB, 1977, MED J AUSTRALIA, V2, P580; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jones J, 1996, AM J EMERG MED, V14, P262, DOI 10.1016/S0735-6757(96)90171-0; KLAPPER JA, 1993, HEADACHE, V33, P560, DOI 10.1111/j.1526-4610.1993.hed3310560.x; KLAPPER JA, 1991, HEADACHE, V31, P523, DOI 10.1111/j.1526-4610.1991.hed3108523.x; PHILLIPS WEP, 1997, CMAJ, V156, P1273; PrysePhillips WEM, 1997, CAN MED ASSOC J, V156, P1273; SCHERL ER, 1995, HEADACHE, V35, P256, DOI 10.1111/j.1526-4610.1995.hed3505256.x; SCHWARZBERG MN, 1994, HEADACHE, V34, P439, DOI 10.1111/j.1526-4610.1994.hed3407439.x; Silberstein SD, 2000, NEUROLOGY, V55, P754, DOI 10.1212/WNL.55.6.754; STEWART WF, 1994, NEUROLOGY, V44, P17; TEK DS, 1990, ANN EMERG MED, V19, P1083, DOI 10.1016/S0196-0644(05)81508-2; Tfelt-Hansen P, 2000, CEPHALALGIA, V20, P765; TFELTHANSEN P, 1980, J NEUROL NEUROSUR PS, V43, P369, DOI 10.1136/jnnp.43.4.369	26	114	118	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1369	1372		10.1136/bmj.38281.595718.7C	http://dx.doi.org/10.1136/bmj.38281.595718.7C			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15550401	Green Published, Green Submitted			2022-12-28	WOS:000225785000016
J	Logan, PA; Gladman, JRF; Avery, A; Walker, MF; Dyas, J; Groom, L				Logan, PA; Gladman, JRF; Avery, A; Walker, MF; Dyas, J; Groom, L			Randomised controlled trial of an occupational therapy intervention to increase outdoor mobility after stroke	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE	Objective To evaluate an occupational therapy intervention to improve outdoor mobility after stroke. Design Randomised controlled trial. Setting General practice registers, social services departments, a primary care rehabilitation service, and a geriatric day hospital. Participants 168 community dwelling people with a clinical diagnosis of stroke in previous 36 months: 86 were allocated to the intervention group and 82 to the control group. Interventions Leaflets describing local transport services for disabled people (control group) and leaflets with assessment and up to seven intervention sessions by an occupational therapist (intervention group). Main outcome measures Responses to postal questionnaires at four and 10 months: primary outcome measure was response to whether participant got out of the house as much as he or she would like, and secondary outcome measures were response to how many journeys outdoors had been made in the past month and scores on the Nottingham extended activities of daily living scale, Nottingham leisure questionnaire, and general health questionnaire. Results Participants in the treatment group were more likely to get out of the house as often as they wanted at both four months (relative risk 1.72, 95% confidence interval 1.25 to 2.37) and 10 months (1.74, 1.24 to 2.44). The treatment group reported more journeys outdoors in the month before assessment at both four months (median 37 in intervention group, 14 in control group: P < 0.0 1) and 10 months (median 42 in intervention group, 14 in control group: P < 0.01). At four months the mobility scores on the Nottingham extended activities of daily living scale were significantly higher in the intervention group, but there Were no significant differences in the other secondary outcomes. No significant differences were observed in these measures at 10 months. Conclusion A targeted occupational therapy intervention at home increases outdoor mobility in people after stroke.	Univ Nottingham, Sch Community Hlth Sci, Nottingham NG7 2RD, England; Hucknall Hlth Ctr, Broxtowe & Hucknall Primary Care Trust, Off Res & Dev, Nottingham NG15 7JE, England	University of Nottingham	Gladman, JRF (corresponding author), Univ Nottingham, Sch Community Hlth Sci, Nottingham NG7 2RD, England.	john.gladman@nottingham.ac.uk	; Gladman, John/M-7429-2015	Logan, Philippa/0000-0002-6657-2381; Avery, Anthony/0000-0001-7591-4438; Gladman, John/0000-0002-8506-7786; Walker, Marion/0000-0002-3534-591X				Collin C, 1988, Int Disabil Stud, V10, P61; Drummond A, 2001, CLIN REHABIL, V15, P647, DOI 10.1191/0269215501cr438oa; Goldberg D., 1992, GEN HLTH QUESTIONNAI; Legg L, 2004, LANCET, V363, P352; Logan PA, 2004, CLIN REHABIL, V18, P703, DOI 10.1191/0269215504cr742oa; Logan PA., 2001, BRIT J OCCUP THER, V64, P261; Nouri F., 1987, CLIN REHABIL, V1, P301, DOI [DOI 10.1177/026921558700100409, 10.1177/026921558700100409]; Parker CJ, 2001, CLIN REHABIL, V15, P42, DOI 10.1191/026921501666968247; Parker CJ, 2000, INT J EPIDEMIOL, V29, P1065, DOI 10.1093/ije/29.6.1065; Pound P, 1998, CLIN REHABIL, V12, P338, DOI 10.1191/026921598677661555; Steultjens EMJ, 2003, STROKE, V34, P676, DOI 10.1161/01.STR.0000057576.77308.30; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	12	77	80	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1372	1374A		10.1136/bmj.38264.679560.8F	http://dx.doi.org/10.1136/bmj.38264.679560.8F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15564229	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000225785000017
J	Yang, LH				Yang, LH			Periodical cicadas as resource pulses in North American forests	SCIENCE			English	Article							TRANSIENT DYNAMICS; PREDATOR SATIATION; RIPARIAN FOREST; NITROGEN; MAGICICADA; HOMOPTERA; EMERGENCE; CICADIDAE; DENSITIES; RODENT	Resource pulses are occasional events of ephemeral resource superabundance that occur in many ecosystems. Aboveground consumers in diverse communities often respond strongly to resource pulses, but few studies have investigated the belowground consequences of resource pulses in natural ecosystems. This study shows that resource pulses of 17-year periodical cicadas (Magicicada spp.) directly increase microbial biomass and nitrogen availability in forest soils, with indirect effects on growth and reproduction in forest plants. These findings suggest that pulses of periodical cicadas create "bottom-up cascades," resulting in strong and reciprocal links between the aboveground and belowground components of a North American forest ecosystem.	Univ Calif Davis, Ctr Populat Biol, Sect Evolut & Ecol, Davis, CA 95616 USA	University of California System; University of California Davis	Yang, LH (corresponding author), Univ Calif Davis, Ctr Populat Biol, Sect Evolut & Ecol, 1 Shields Ave, Davis, CA 95616 USA.	lhyang@ucdavis.edu		Yang, Louie/0000-0002-9237-5357				Ben-David M, 1998, OIKOS, V83, P47, DOI 10.2307/3546545; Black C.A., 1968, SOIL PLANT RELATIONS, V2nd ed; BROWN JJ, 1973, J INSECT PHYSIOL, V19, P607, DOI 10.1016/0022-1910(73)90069-3; Chen X, 2001, P ROY SOC B-BIOL SCI, V268, P869, DOI 10.1098/rspb.2001.1596; COLEMAN DC, 1996, FOOD WEBS INTEGRATIO, pCH3; DYBAS HS, 1962, ECOLOGY, V43, P432, DOI 10.2307/1933372; Elkinton JS, 1996, ECOLOGY, V77, P2332, DOI 10.2307/2265735; Galloway LF, 2001, ECOLOGY, V82, P2781, DOI 10.1890/0012-9658(2001)082[2781:PEEOLH]2.0.CO;2; Galloway LF, 2001, AM J BOT, V88, P832, DOI 10.2307/2657035; HAHUS SC, 1990, J MAMMAL, V71, P249, DOI 10.2307/1382177; Hastings A, 2001, ECOL LETT, V4, P215, DOI 10.1046/j.1461-0248.2001.00220.x; Helfield JM, 2001, ECOLOGY, V82, P2403, DOI 10.1890/0012-9658(2001)082[2403:EOSDNO]2.0.CO;2; Holmgren M, 2001, TRENDS ECOL EVOL, V16, P89, DOI 10.1016/S0169-5347(00)02052-8; Jones CG, 1998, SCIENCE, V279, P1023, DOI 10.1126/science.279.5353.1023; KARBAN R, 1982, ECOLOGY, V63, P321, DOI 10.2307/1938949; Koenig WD, 2003, CAN J FOREST RES, V33, P1084, DOI 10.1139/X03-037; Lima M, 1999, ECOGRAPHY, V22, P213, DOI 10.1111/j.1600-0587.1999.tb00470.x; Lovett GM, 2002, BIOSCIENCE, V52, P335, DOI 10.1641/0006-3568(2002)052[0335:IDANCI]2.0.CO;2; McShea WJ, 2000, ECOLOGY, V81, P228, DOI 10.1890/0012-9658(2000)081[0228:TIOACO]2.0.CO;2; MOORE JC, 1988, ANNU REV ENTOMOL, V33, P419, DOI 10.1146/annurev.en.33.010188.002223; Ostfeld RS, 2000, TRENDS ECOL EVOL, V15, P232, DOI 10.1016/S0169-5347(00)01862-0; RICHARDSON TE, 1992, EVOLUTION, V46, P1731, DOI [10.2307/2410027, 10.1111/j.1558-5646.1992.tb01165.x]; Rodenhouse NL, 1997, AM MIDL NAT, V137, P124, DOI 10.2307/2426761; Schimel JP, 2004, ECOLOGY, V85, P591, DOI 10.1890/03-8002; Stapp P, 2003, OIKOS, V102, P111, DOI 10.1034/j.1600-0706.2003.12445.x; SWEENEY BW, 1982, EVOLUTION, V36, P810, DOI 10.1111/j.1558-5646.1982.tb05447.x; Wardle D., 2002, COMMUNITIES ECOSYSTE; WHEELER GL, 1992, FOREST ECOL MANAG, V51, P339, DOI 10.1016/0378-1127(92)90333-5; Whiles MR, 2001, AM MIDL NAT, V145, P176, DOI 10.1674/0003-0031(2001)145[0176:EOPCMC]2.0.CO;2; WILLIAMS KS, 1995, ANNU REV ENTOMOL, V40, P269, DOI 10.1146/annurev.en.40.010195.001413; WILLIAMS KS, 1993, ECOLOGY, V74, P1143, DOI 10.2307/1940484; Wolff JO, 1996, J MAMMAL, V77, P850, DOI 10.2307/1382690; Wright SJ, 1999, ECOLOGY, V80, P1632, DOI 10.2307/176552; Zackrisson O, 1999, OIKOS, V84, P17, DOI 10.2307/3546862	34	145	153	4	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1565	1567		10.1126/science.1103114	http://dx.doi.org/10.1126/science.1103114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567865				2022-12-28	WOS:000225442700062
J	Cooper, CL; Davis, H; Cameron, DW				Cooper, CL; Davis, H; Cameron, DW			Influenza vaccination with 1/10th the full dose	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Univ Ottawa, Ottawa, ON K1H 8L6, Canada; Coley Pharmaceut Grp, Ottawa, ON K2K 3A2, Canada	University of Ottawa; Coley Pharmaceutical Group	Cooper, CL (corresponding author), Univ Ottawa, Ottawa, ON K1H 8L6, Canada.		Cameron, Bill/E-9180-2010	Cameron, Bill/0000-0002-0090-3539				Cooper CL, 2004, VACCINE, V22, P3136, DOI 10.1016/j.vaccine.2004.01.058; Deng YP, 2004, J IMMUNOL, V172, P3437, DOI 10.4049/jimmunol.172.6.3437; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; 2004, MMWR DISPATCH, V53, P1; 1920, MMWR MORB MORTAL WKL, V53, P547	5	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2339	2340		10.1056/NEJM200411253512219	http://dx.doi.org/10.1056/NEJM200411253512219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564552				2022-12-28	WOS:000225298100018
J	Sato, M; Sievers, AJ				Sato, M; Sievers, AJ			Direct observation of the discrete character of intrinsic localized modes in an antiferromagnet	NATURE			English	Article							LATTICES; BREATHERS; RESONANCE; SOLITONS; ARRAYS; ENERGY	In a strongly nonlinear discrete system, the spatial size of an excitation can become comparable to, and influenced by, the lattice spacing. Such intrinsic localized modes (ILMs)-also called 'discrete breathers' or 'lattice solitons'-are responsible for energy localization in the dynamics of discrete nonlinear lattices1-5. Their energy profiles resemble those of localized modes of defects in a harmonic lattice but, like solitons, they can move ( although, unlike solitons, some energy is exchanged during collisions between them). The manipulation of these localized energy 'hotspots' has been achieved in systems as diverse as annular arrays of coupled Josephson junctions(6,7), optical waveguide arrays(8), two-dimensional nonlinear photonic crystals(9) and micromechanical cantilever arrays(10). There is also some evidence for the existence of localized excitations in atomic lattices(11-15), although individual ILMs have yet to be identified. Here we report the observation of countable localized excitations in an antiferromagnetic spin lattice by means of a nonlinear spectroscopic technique. This detection capability permits the properties of individual ILMs to be probed; the disappearance of each ILM registers as a step in the time-dependent signal, with the surprising result that the energy staircase of ILM excitations is uniquely defined.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14850 USA; Cornell Univ, Cornell Ctr Mat Res, Ithaca, NY 14850 USA	Cornell University; Cornell University	Sievers, AJ (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14850 USA.	sievers@ccmr.cornell.edu	Sato, Masayuki/C-3378-2015	Sato, Masayuki/0000-0003-3364-5270				ALMEIDA NS, 1987, PHYS REV B, V36, P2015, DOI 10.1103/PhysRevB.36.2015; Binder P, 2000, PHYS REV LETT, V84, P745, DOI 10.1103/PhysRevLett.84.745; Campbell DK, 2004, PHYS TODAY, V57, P43, DOI 10.1063/1.1650069; CHIKAMATSU M, 1981, J PHYS SOC JPN, V50, P2876, DOI 10.1143/JPSJ.50.2876; DEJONGH LJ, 1990, PHYS CHEM MAT LOW DI, P1; Eisenberg HS, 1998, PHYS REV LETT, V81, P3383, DOI 10.1103/PhysRevLett.81.3383; ENGLISH LQ, 2003, THESIS CORNELL U; Fehske H, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.245121; Flach S, 1998, PHYS REP, V295, P181, DOI 10.1016/S0370-1573(97)00068-9; FLACH S, 2004, ENERGY LOCALIZATION, P1; Fleischer JW, 2003, NATURE, V422, P147, DOI 10.1038/nature01452; Kiselev S. A., 1995, Comments on Condensed Matter Physics, V17, P135; Lai R, 1997, PHYS REV B, V55, P11937, DOI 10.1103/PhysRevB.55.R11937; Lai R, 1999, PHYS REP, V314, P147, DOI 10.1016/S0370-1573(98)00090-8; Lim SC, 2000, J PHYS D APPL PHYS, V33, P2899, DOI 10.1088/0022-3727/33/22/306; Markovich T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.195301; ROSSLER T, 1995, PHYS LETT A, V204, P418, DOI 10.1016/0375-9601(95)00519-9; Sato M, 2004, EUROPHYS LETT, V66, P318, DOI 10.1209/epl/i2003-10224-x; Sato M, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.044102; Sato M, 2002, J APPL PHYS, V91, P8676, DOI 10.1063/1.1448795; Schwarz UT, 1999, PHYS REV LETT, V83, P223, DOI 10.1103/PhysRevLett.83.223; Shen Y. R., 1984, PRINCIPLES NONLINEAR; Swanson BI, 1999, PHYS REV LETT, V82, P3288, DOI 10.1103/PhysRevLett.82.3288; Trias E, 2000, PHYS REV LETT, V84, P741, DOI 10.1103/PhysRevLett.84.741; Xie AH, 2000, PHYS REV LETT, V84, P5435, DOI 10.1103/PhysRevLett.84.5435	25	123	128	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	2004	432	7016					486	488		10.1038/nature03038	http://dx.doi.org/10.1038/nature03038			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565149				2022-12-28	WOS:000225322100041
J	Wong, TY; Mitchell, P				Wong, TY; Mitchell, P			Current concepts - Hypertensive retinopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RETINAL MICROVASCULAR ABNORMALITIES; CORONARY HEART-DISEASE; ATHEROSCLEROSIS RISK; VASCULAR CHANGES; BLOOD-PRESSURE; OLDER PERSONS; POPULATION; CLASSIFICATION; PREVALENCE; SIGNS		Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia; Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore; Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia	Centre for Eye Research Australia; University of Melbourne; National University of Singapore; Singapore National Eye Center; University of Sydney	Wong, TY (corresponding author), Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.	twong@unimelb.edu.au	Wong, Tien Yin/AAC-9724-2020; Mitchell, Paul/P-1498-2014	Wong, Tien Yin/0000-0002-8448-1264; 				August P, 2003, NEW ENGL J MED, V348, P610, DOI 10.1056/NEJMcp010357; Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113; Black HR, 1997, ARCH INTERN MED, V157, P2413; BOCK KD, 1984, HYPERTENSION, V6, P158; BRESLIN DJ, 1966, J AMER MED ASSOC, V195, P335, DOI 10.1001/jama.195.5.335; Chalmers J, 1999, J HYPERTENS, V17, P151; Chatterjee S, 2002, J HUM HYPERTENS, V16, P667, DOI 10.1038/sj.jhh.1001472; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Couper DJ, 2002, AM J OPHTHALMOL, V133, P78, DOI 10.1016/S0002-9394(01)01315-0; Dahlof B, 1992, Blood Press, V1, P35, DOI 10.3109/08037059209065122; DIMMITT SB, 1989, LANCET, V1, P1103; Dodson PM, 1996, J HUM HYPERTENS, V10, P93; Duncan BB, 2002, BRIT J OPHTHALMOL, V86, P1002, DOI 10.1136/bjo.86.9.1002; FUCHS FD, 1995, J HUM HYPERTENS, V9, P547; GILLUM RF, 1991, AM HEART J, V122, P262, DOI 10.1016/0002-8703(91)90796-K; GOTO I, 1975, STROKE, V6, P263, DOI 10.1161/01.STR.6.3.263; Gunn RM, 1892, T OPHTHAL SOC UK, V12, P124; Hamada Yoh, 1995, Clinical and Experimental Pharmacology and Physiology, V22, pS132, DOI 10.1111/j.1440-1681.1995.tb02851.x; Houben AJHM, 1995, J HYPERTENS, V13, P1729; Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0; *JOIT NAT COMM PRE, 1998, ARCH INTERN MED, V158, P573; KAGAN A, 1966, B WORLD HEALTH ORGAN, V34, P955; Keith NM, 1939, AM J MED SCI, V197, P332, DOI 10.1097/00000441-193903000-00006; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026; Klein R, 1997, Trans Am Ophthalmol Soc, V95, P329; Klein R, 2000, ARTERIOSCL THROM VAS, V20, P1644, DOI 10.1161/01.ATV.20.6.1644; Leibowitz H M, 1980, Surv Ophthalmol, V24, P335; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; Morishita R, 1992, Blood Press Suppl, V3, P41; Nakayama T, 1997, STROKE, V28, P45, DOI 10.1161/01.STR.28.1.45; Pache M, 2002, J HUM HYPERTENS, V16, P405, DOI 10.1038/sj.jhh.1001402; Ramsay LE, 1999, BMJ-BRIT MED J, V319, P630, DOI 10.1136/bmj.319.7210.630; SCHEIE HG, 1953, AMA ARCH OPHTHALMOL, V49, P117; SCHNEIDER R, 1993, STROKE, V24, P1874, DOI 10.1161/01.STR.24.12.1874; Schubert H D, 1998, Curr Opin Ophthalmol, V9, P69; SHARP PS, 1995, HYPERTENSION, V25, P1322, DOI 10.1161/01.HYP.25.6.1322; Sharrett AR, 1999, AM J EPIDEMIOL, V150, P263; STOLK RP, 1995, DIABETES, V44, P11, DOI 10.2337/diabetes.44.1.11; TSO MOM, 1982, OPHTHALMOLOGY, V89, P1132; van Leiden HA, 2003, ARCH OPHTHALMOL-CHIC, V121, P245, DOI 10.1001/archopht.121.2.245; WALSH JB, 1982, OPHTHALMOLOGY, V89, P1127; Wang JJ, 2003, HYPERTENSION, V42, P534, DOI 10.1161/01.HYP.0000090122.38230.41; Wong TY, 2002, JAMA-J AM MED ASSOC, V288, P67, DOI 10.1001/jama.288.1.67; Wong TY, 2004, ANN INTERN MED, V140, P248, DOI 10.7326/0003-4819-140-4-200402170-00006; Wong TY, 2003, INVEST OPHTH VIS SCI, V44, P4644, DOI 10.1167/iovs.03-0079; Wong TY, 2003, NEUROLOGY, V61, P806, DOI 10.1212/01.WNL.0000086372.05488.8D; Wong TY, 2003, OPHTHALMOLOGY, V110, P933, DOI 10.1016/S0161-6420(03)00084-8; Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0; Wong TY, 2003, HYPERTENSION, V41, P1086, DOI 10.1161/01.HYP.0000064181.63546.53; Wong TY, 2002, BRIT J OPHTHALMOL, V86, P1007, DOI 10.1136/bjo.86.9.1007; Wong TY, 2002, JAMA-J AM MED ASSOC, V287, P1153, DOI 10.1001/jama.287.9.1153; Wong TY, 2002, STROKE, V33, P1487, DOI 10.1161/01.STR.0000016789.56668.43; Wong TY, 2001, SURV OPHTHALMOL, V46, P59, DOI 10.1016/S0039-6257(01)00234-X; Wong TY, 2001, LANCET, V358, P1134, DOI 10.1016/S0140-6736(01)06253-5; Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83	55	468	492	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2310	2317		10.1056/NEJMra032865	http://dx.doi.org/10.1056/NEJMra032865			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564546				2022-12-28	WOS:000225298100010
J	Baudrier-Raybaut, M; Haidar, R; Kupecek, P; Lemasson, P; Rosencher, E				Baudrier-Raybaut, M; Haidar, R; Kupecek, P; Lemasson, P; Rosencher, E			Random quasi-phase-matching in bulk polycrystalline isotropic nonlinear materials	NATURE			English	Article							DIFFERENCE-FREQUENCY-GENERATION; 2ND-HARMONIC GENERATION; HARMONIC-GENERATION; CRYSTALS	Three-wave mixing in nonlinear materials-the interaction of two light waves to produce a third-is a convenient way of generating new optical frequencies from common laser sources. However, the resulting optical conversion yield is generally poor, because the relative phases of the three interacting waves change continuously as they propagate through the material(1). This phenomenon, known as phase mismatch, is a consequence of optical dispersion ( wave velocity is frequency dependent), and is responsible for the poor optical conversion potential of isotropic nonlinear materials(2). Here we show that exploiting the random motion of the relative phases in highly transparent polycrystalline materials can be an effective strategy for achieving efficient phase matching in isotropic materials. Distinctive features of this 'random quasi-phase-matching' approach are a linear dependence of the conversion yield with sample thickness (predicted in ref. 3), the absence of the need for either preferential materials orientation or specific polarization selection rules, and the existence of a wavelength-dependent resonant size for the polycrystalline grains.	Off Natl Etud & Rech Aerosp, DMPH, F-91761 Palaiseau, France; Off Natl Etud & Rech Aerosp, DOTA, ONERA, F-91761 Palaiseau, France; Univ Paris 06, F-75005 Paris, France; CNRS, LPSC, F-92195 Meudon, France; Ecole Polytech, Dept Phys, F-91228 Palaiseau, France	National Office for Aerospace Studies & Research (ONERA); UDICE-French Research Universities; Universite Paris Saclay; National Office for Aerospace Studies & Research (ONERA); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Institut National Polytechnique de Grenoble; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Rosencher, E (corresponding author), Off Natl Etud & Rech Aerosp, DMPH, Chemin Huniere, F-91761 Palaiseau, France.	rosencher@onera.fr	ROSENCHER, Emmanuel/A-9222-2012					AGRANOVICH VM, 1991, PHYS REV B, V43, P13691, DOI 10.1103/PhysRevB.43.13691; ARMSTRONG JA, 1962, PHYS REV, V127, P1918, DOI 10.1103/PhysRev.127.1918; Dunn MH, 1999, SCIENCE, V286, P1513, DOI 10.1126/science.286.5444.1513; Eyres LA, 2001, APPL PHYS LETT, V79, P904, DOI 10.1063/1.1389326; FEJER MM, 1994, PHYS TODAY, V47, P25, DOI 10.1063/1.881430; FEJER MM, 1992, IEEE J QUANTUM ELECT, V28, P2631, DOI 10.1109/3.161322; Fiore A, 1998, NATURE, V391, P463, DOI 10.1038/35091; Haidar R, 2002, J APPL PHYS, V91, P2550, DOI 10.1063/1.1435412; KRAVTSOV VE, 1991, PHYS REV B, V44, P4931, DOI 10.1103/PhysRevB.44.4931; KURTZ SK, 1968, J APPL PHYS, V39, P3798, DOI 10.1109/JQE.1968.1075108; Levi O, 2002, OPT LETT, V27, P2091, DOI 10.1364/OL.27.002091; Makeev EV, 2003, OPT COMMUN, V224, P139, DOI 10.1016/S0030-4018(03)01756-5; Mel'Nikov VA, 2004, APPL PHYS B-LASERS O, V79, P225, DOI 10.1007/s00340-004-1530-6; Morozov EY, 2001, JETP LETT+, V73, P647, DOI 10.1134/1.1397747; Rosencher E, 1996, SCIENCE, V271, P168, DOI 10.1126/science.271.5246.168; Rosencher E., 2002, OPTOELECTRONICS; Rzepka E, 1999, J CRYST GROWTH, V197, P480, DOI 10.1016/S0022-0248(98)00773-8; Shoji I, 1997, J OPT SOC AM B, V14, P2268, DOI 10.1364/JOSAB.14.002268; Vodopyanov KL, 2004, OPT LETT, V29, P1912, DOI 10.1364/OL.29.001912; Wiersma DS, 2001, NATURE, V414, P708, DOI 10.1038/414708a	20	283	290	3	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					374	376		10.1038/nature03027	http://dx.doi.org/10.1038/nature03027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549100				2022-12-28	WOS:000225161400050
J	Jones, JM; Widmann, M				Jones, JM; Widmann, M			Atmospheric science - Early peak in Antarctic oscillation index	NATURE			English	Editorial Material							HEMISPHERE CLIMATE-CHANGE		GKSS Forschungszentrum Geesthacht GmbH, Inst Coastal Res, D-21502 Geesthacht, Germany	Helmholtz Association; Helmholtz-Zentrum Geesthacht - Zentrum fur Material- und Kustenforschung	Jones, JM (corresponding author), GKSS Forschungszentrum Geesthacht GmbH, Inst Coastal Res, D-21502 Geesthacht, Germany.	jones@gkss.de	Widmann, Martin/P-5178-2015	Widmann, Martin/0000-0001-5447-5763; Jones, Julie/0000-0003-2892-8647				Gillett NP, 2003, SCIENCE, V302, P273, DOI 10.1126/science.1087440; Jones JM, 2003, J CLIMATE, V16, P3511, DOI [10.1175/1520-0442(2003)016<3511:IATEOT>2.0.CO;2, 10.1175/1520-0442(2003)016&lt;3511:IATEOT&gt;2.0.CO;2]; JONES PD, 1991, INT J CLIMATOL, V11, P585, DOI 10.1002/joc.3370110603; Kushner PJ, 2001, J CLIMATE, V14, P2238, DOI 10.1175/1520-0442(2001)014<0001:SHACRT>2.0.CO;2; Marshall GJ, 2003, J CLIMATE, V16, P4134, DOI 10.1175/1520-0442(2003)016<4134:TITSAM>2.0.CO;2; Stone DA, 2001, J CLIMATE, V14, P3551, DOI 10.1175/1520-0442(2001)014<3551:POCCOM>2.0.CO;2; Thompson DWJ, 2002, SCIENCE, V296, P895, DOI 10.1126/science.1069270	7	49	51	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					290	291		10.1038/432290b	http://dx.doi.org/10.1038/432290b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549086				2022-12-28	WOS:000225161400032
J	Goldenberg, DL; Burckhardt, C; Crofford, L				Goldenberg, DL; Burckhardt, C; Crofford, L			Management of fibromyalgia syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CHRONIC WIDESPREAD PAIN; COGNITIVE-BEHAVIORAL TREATMENT; RANDOMIZED CONTROLLED-TRIAL; CONTROLLED CLINICAL-TRIAL; BLIND CROSSOVER TRIAL; AEROBIC EXERCISE; HYPOTHALAMIC-PITUITARY; VENLAFAXINE TREATMENT; TEMPORAL SUMMATION; EMG-BIOFEEDBACK	Context The optimal management of fibromyalgia syndrome (FMS) is unclear and comprehensive evidence-based guidelines have not been reported. Objective To provide up-to-date evidence-based guidelines for the optimal treatment of FMS. Data Sources, Selection, and Extraction A search of all human trials (randomized controlled trials and meta-analyses of randomized controlled trials) of FMS was made using Cochrane Collaboration Reviews (1993-2004), MEDLINE (1966-2004), CINAHL (1982-2004), EMBASE (1988-2004), PubMed (1966-2004), Healthstar (1975-2000), Current Contents (2000-2004), Web of Science (1980-2004), PsychInfo (1887-2004), and Science Citation Indexes (1996-2004). The literature review was performed by an interdisciplinary panel, composed of 13 experts in various pain management disciplines, selected by the American Pain Society (APS), and supplemented by selected literature reviews by APS staff members and the Utah Drug Information Service. A total of 505 articles were reviewed. Data Synthesis There are major limitations to the FMS literature, with many treatment trials compromised by short duration and lack of masking. There are no medical therapies that have been specifically approved by the US Food and Drug Administration for management of FMS. Nonetheless, current evidence suggests efficacy of low-dose tricyclic antidepressants, cardiovascular exercise, cognitive behavioral therapy, and patient education. A number of other commonly used FMS therapies, such as trigger point injections, have not been adequately evaluated. Conclusions Despite the chronicity and complexity of FMS, there are pharmacological and non pharmacological interventions available that have clinical benefit. Based on current evidence, a stepwise program emphasizing education, certain medications, exercise, cognitive therapy, or all 4 should be recommended.	Newton Wellesley Hosp, Dept Rheumatol, Newton, MA 02462 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR USA; Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA	Newton Wellesley Hospital; Tufts University; Oregon Health & Science University; University of Michigan System; University of Michigan	Goldenberg, DL (corresponding author), Newton Wellesley Hosp, Dept Rheumatol, 2000 Washington St, Newton, MA 02462 USA.	dgoldenb@massmed.org	Crofford, Leslie J/J-8010-2013	Crofford, Leslie J/0000-0002-6347-5738				Adler GK, 1999, AM J MED, V106, P534, DOI 10.1016/S0002-9343(99)00074-1; Alamo MM, 2002, PATIENT EDUC COUNS, V48, P23, DOI 10.1016/S0738-3991(02)00095-2; Almeida TF, 2003, PAIN, V104, P665, DOI 10.1016/S0304-3959(03)00139-8; Arnold LM, 2000, PSYCHOSOMATICS, V41, P104, DOI 10.1176/appi.psy.41.2.104; Arnold LM, 2004, ARTHRITIS RHEUM, V50, P2974, DOI 10.1002/art.20485; Arnold LM, 2002, AM J MED, V112, P191, DOI 10.1016/S0002-9343(01)01089-0; Bailey A, 1999, ARTHRIT CARE RES, V12, P336, DOI 10.1002/1529-0131(199910)12:5<336::AID-ART5>3.0.CO;2-E; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Benjamin S, 2000, ARTHRITIS RHEUM-US, V43, P561, DOI 10.1002/1529-0131(200003)43:3<561::AID-ANR12>3.0.CO;2-O; Bennett RA, 2003, AM J MED, V114, P537, DOI 10.1016/S0002-9343(03)00116-5; Bennett RM, 1998, AM J MED, V104, P227, DOI 10.1016/S0002-9343(97)00351-3; BENNETT RM, 1988, ARTHRITIS RHEUM, V31, P1535, DOI 10.1002/art.1780311210; Bennett RM, 1996, RHEUM DIS CLIN N AM, V22, P351, DOI 10.1016/S0889-857X(05)70276-3; Bennett Robert, 1996, Arthritis and Rheumatism, V39, pS212; Berman BM, 1999, J FAM PRACTICE, V48, P213; Biasi G, 1998, INT J CLIN PHARM RES, V18, P13; Blunt KL, 1997, J MANIP PHYSIOL THER, V20, P389; Bradley Laurence A, 2002, Curr Pain Headache Rep, V6, P106, DOI 10.1007/s11916-002-0006-9; Brattberg G, 1999, EUR J PAIN, V3, P235, DOI 10.1016/S1090-3801(99)90050-2; Buckelew SP, 1998, ARTHRIT CARE RES, V11, P196, DOI 10.1002/art.1790110307; BURCKHARDT CS, 1994, BAILLIERE CLIN RHEUM, V8, P935, DOI 10.1016/S0950-3579(05)80055-X; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; BURCKHARDT CS, 1994, J RHEUMATOL, V21, P714; Busch A, 2003, COCHRANE DB SYST REV, V3; Buskila D, 2001, RHEUMATOL INT, V20, P105, DOI 10.1007/s002960000085; Cantini F, 1994, Minerva Med, V85, P97; CARETTE S, 1986, ARTHRITIS RHEUM-US, V29, P655, DOI 10.1002/art.1780290510; CARETTE S, 1994, ARTHRITIS RHEUM, V37, P32, DOI 10.1002/art.1780370106; CARUSO I, 1990, J INT MED RES, V18, P201, DOI 10.1177/030006059001800304; Celiker R, 2000, ARTHRITIS RHEUM, V43, pS332; CLARK S, 1985, J RHEUMATOL, V12, P980; Creamer P, 2000, ARTHRIT CARE RES, V13, P198, DOI 10.1002/1529-0131(200008)13:4<198::AID-ANR4>3.0.CO;2-P; Crofford L, 2002, ARTHRITIS RHEUM-US, V46, pS613; CROFFORD LJ, 1994, ARTHRITIS RHEUM-US, V37, P1583, DOI 10.1002/art.1780371105; Crofford LJ, 2002, ARTHRITIS RHEUM-US, V46, P1136, DOI 10.1002/art.10217; CROFT P, 1993, J RHEUMATOL, V20, P710; CROFT P, 1994, BRIT MED J, V309, P696, DOI 10.1136/bmj.309.6956.696; de Gier M, 2003, PAIN, V104, P121, DOI 10.1016/S0304-3959(02)00487-6; DELUZE C, 1992, BRIT MED J, V305, P1249, DOI 10.1136/bmj.305.6864.1249; Dunkl PR, 2000, J RHEUMATOL, V27, P2683; Dwight MM, 1998, PSYCHOSOMATICS, V39, P14, DOI 10.1016/S0033-3182(98)71375-1; Ehrlich GE, 2003, J RHEUMATOL, V30, P1666; FERRACCIOLI G, 1987, J RHEUMATOL, V14, P820; Fors EA, 2002, J PSYCHIATR RES, V36, P179, DOI 10.1016/S0022-3956(02)00003-1; Gamber Russell G., 2002, Journal of the American Osteopathic Association, V102, P321; Geisser ME, 2003, PAIN, V102, P243, DOI 10.1016/S0304-3959(02)00417-7; Gendreau RM, 2003, ARTHRITIS RHEUM, V48, pS616; Giesecke T, 2003, ARTHRITIS RHEUM, V48, P2916, DOI 10.1002/art.11272; Goldenberg D, 2003, J RHEUMATOL, V30, P151; Goldenberg D, 1996, ARTHRITIS RHEUM, V39, P1852, DOI 10.1002/art.1780391111; GOLDENBERG DL, 1986, ARTHRITIS RHEUM, V29, P1371, DOI 10.1002/art.1780291110; Gowans SE, 2001, ARTHRIT RHEUM-ARTHR, V45, P519, DOI 10.1002/1529-0131(200112)45:6<519::AID-ART377>3.0.CO;2-3; Gowans SE, 2002, ARTHRIT RHEUM-ARTHR, V47, P603, DOI 10.1002/art.10789; Gowans SE, 1999, ARTHRIT CARE RES, V12, P120, DOI 10.1002/1529-0131(199904)12:2<120::AID-ART7>3.0.CO;2-4; Gracely RH, 2003, BEST PRACT RES CL RH, V17, P593, DOI 10.1016/S1521-6942(03)00036-6; Gracely RH, 2002, ARTHRITIS RHEUM-US, V46, P1333, DOI 10.1002/art.10225; GUNTHER V, 1994, CLIN RHEUMATOL, V13, P573, DOI 10.1007/BF02242996; Gursoy S, 2001, RHEUMATOL INT, V21, P58, DOI 10.1007/s002960100130; Gursoy S, 2003, RHEUMATOL INT, V23, P104, DOI 10.1007/s00296-002-0260-5; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; HAANEN HCM, 1991, J RHEUMATOL, V18, P72; Hadhazy VA, 2000, J RHEUMATOL, V27, P2911; Hakkinen A, 2001, ANN RHEUM DIS, V60, P21, DOI 10.1136/ard.60.1.21; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris RE, 2003, ARTHRITIS RHEUM, V48, pS692; Hudson JI, 2003, ARCH GEN PSYCHIAT, V60, P170, DOI 10.1001/archpsyc.60.2.170; ISOMERI R, 1993, J MUSCULOSKELET PAIN, V1, P253; JAESCHKE R, 1991, J RHEUMATOL, V18, P447; Jensen MP, 2003, PAIN, V104, P529, DOI 10.1016/S0304-3959(03)00092-7; Jentoft ES, 2001, ARTHRIT RHEUM-ARTHR, V45, P42; Jones KD, 2002, J RHEUMATOL, V29, P1041; KAPLAN KH, 1993, GEN HOSP PSYCHIAT, V15, P284, DOI 10.1016/0163-8343(93)90020-O; Keel PJ, 1998, CLIN J PAIN, V14, P232, DOI 10.1097/00002508-199809000-00010; King SJ, 2002, J RHEUMATOL, V29, P2620; Kroenke K, 2001, ANN INTERN MED, V134, P801, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00001; Mannerkorpi K, 2002, SCAND J RHEUMATOL, V31, P306, DOI 10.1080/030097402760375223; Mannerkorpi K, 2003, BEST PRACT RES CL RH, V17, P629, DOI 10.1016/S1521-6942(03)00038-X; MARDER WD, 1991, ARTHRITIS RHEUM, V34, P1209, DOI 10.1002/art.1780341002; Martin L, 1996, J RHEUMATOL, V23, P1050; Martinez-Lavin M, 1998, ARTHRITIS RHEUM-US, V41, P1966, DOI 10.1002/1529-0131(199811)41:11<1966::AID-ART11>3.0.CO;2-O; MCCAIN GA, 1988, ARTHRITIS RHEUM, V31, P1135, DOI 10.1002/art.1780310908; MCCAIN GA, 1986, AM J MED, V81, P73, DOI 10.1016/0002-9343(86)90881-8; MENGSHOEL AM, 1992, CLIN EXP RHEUMATOL, V10, P345; MENGSHOEL AM, 1995, CLIN RHEUMATOL, V14, P165, DOI 10.1007/BF02214937; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; Nicassio PM, 1997, J RHEUMATOL, V24, P2000; NIELSON WR, 1992, J RHEUMATOL, V19, P98; O'Malley PG, 2000, J GEN INTERN MED, V15, P659, DOI 10.1046/j.1525-1497.2000.06279.x; Offenbaecher M, 1999, ARTHRITIS RHEUM-US, V42, P2482, DOI 10.1002/1529-0131(199911)42:11<2482::AID-ANR27>3.0.CO;2-B; Pfeiffer A, 2003, AM J PHYS MED REHAB, V82, P186, DOI 10.1097/01.PHM.0000046625.72055.35; Price DD, 2002, PAIN, V99, P49, DOI 10.1016/S0304-3959(02)00053-2; PUTTINI PS, 1992, J INT MED RES, V20, P182, DOI 10.1177/030006059202000210; Rossy LA, 1999, ANN BEHAV MED, V21, P180, DOI 10.1007/BF02908299; Russell IJ, 2000, JCR-J CLIN RHEUMATOL, V6, P250, DOI 10.1097/00124743-200010000-00004; RUSSELL IJ, 1994, ARTHRITIS RHEUM-US, V37, P1593, DOI 10.1002/art.1780371106; Sarnoch H, 1997, PERCEPT MOTOR SKILL, V84, P1043, DOI 10.2466/pms.1997.84.3.1043; Sayar K, 2003, ANN PHARMACOTHER, V37, P1561, DOI 10.1345/aph.1D112; Schachter CL, 2003, PHYS THER, V83, P340, DOI 10.1093/ptj/83.4.340; Singh BB, 1998, ALTERN THER HEALTH M, V4, P67; Spath M, 2004, SCAND J RHEUMATOL, V33, P267, DOI 10.1080/03009740410005818; Staud R, 2003, PAIN, V102, P87, DOI 10.1016/s0304-3959(02)00344-5; Sukenik S, 1999, RHEUM DIS CLIN N AM, V25, P883, DOI 10.1016/S0889-857X(05)70108-3; Tofferi JK, 2004, ARTHRIT RHEUM-ARTHR, V51, P9, DOI 10.1002/art.20076; Turk DC, 1998, ARTHRIT CARE RES, V11, P397, DOI 10.1002/art.1790110511; Turk DC, 1996, J RHEUMATOL, V23, P1255; Valim V, 2003, J RHEUMATOL, V30, P1060; Volkmann H, 1997, SCAND J RHEUMATOL, V26, P206, DOI 10.3109/03009749709065682; White KP, 2002, ARTHRIT RHEUM-ARTHR, V47, P260, DOI 10.1002/art.10400; WHITE KP, 1995, J RHEUMATOL, V22, P717; Wigers SH, 1996, SCAND J RHEUMATOL, V25, P77, DOI 10.3109/03009749609069212; Wik G, 1999, EUR J PAIN, V3, P7, DOI 10.1016/S1090-3801(99)90183-0; Williams DA, 2003, BEST PRACT RES CL RH, V17, P649, DOI 10.1016/S1521-6942(03)00034-2; WOLFE F, 1994, SCAND J RHEUMATOL, V23, P255, DOI 10.3109/03009749409103725; WOLFE F, 1985, J RHEUMATOL, V12, P1164; ZIJSLTRA TR, 2002, ARTHRITIS RHEUM, V46, pS105	115	507	534	2	81	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2388	2395		10.1001/jama.292.19.2388	http://dx.doi.org/10.1001/jama.292.19.2388			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547167	Bronze			2022-12-28	WOS:000225070100028
J	Frimerman, A; Meisel, SR				Frimerman, A; Meisel, SR			Peripartum dissection of the right coronary artery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hillel Yaffe Med Ctr, IL-38100 Hadera, Israel		Frimerman, A (corresponding author), Hillel Yaffe Med Ctr, IL-38100 Hadera, Israel.		Meisel, Simcha/AAH-8985-2021	Meisel, Simcha/0000-0002-2041-2833					0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					E18	E18		10.1056/ENEJMicm020585	http://dx.doi.org/10.1056/ENEJMicm020585			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537901				2022-12-28	WOS:000225007200012
J	Chen, AE; Ginty, DD; Fan, CM				Chen, AE; Ginty, DD; Fan, CM			Protein kinase A signalling via CREB controls myogenesis induced by Wnt proteins	NATURE			English	Article							SKELETAL-MUSCLE; SONIC HEDGEHOG; BETA-CATENIN; EXPRESSION; MYOD; TRANSCRIPTION; PATHWAY; FAMILY; GENES; MYF-5	Select members of the Wnt family of secreted glycoproteins have been implicated in inducing the myogenic determinant genes Pax3, MyoD and Myf5 during mammalian embryogenesis(1,2), but the mechanism of induction has not been defined. We describe an unexpected role for protein kinase A (PKA) signalling via CREB in this induction. Using a combination of in vitro explant assays, mutant analysis and gene delivery into mouse embryos cultured ex vivo, we demonstrate that adenylyl cyclase signalling via PKA and its target transcription factor CREB are required for Wnt-directed myogenic gene expression. Wnt proteins can also stimulate CREB-mediated transcription, providing evidence for a Wnt signalling pathway involving PKA and CREB. Our findings raise the possibility that PKA/CREB signalling may also contribute to other Wnt-regulated processes in embryonic patterning, stem cell renewal and cancer(3).	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA	Carnegie Institution for Science; Howard Hughes Medical Institute; Johns Hopkins University	Fan, CM (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	fan@ciwemb.edu						Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Barnes MR, 1998, TRENDS PHARMACOL SCI, V19, P399, DOI 10.1016/S0165-6147(98)01246-2; BOBER E, 1994, DEVELOPMENT, V120, P603; Buttitta L, 2003, DEVELOPMENT, V130, P6233, DOI 10.1242/dev.00851; Buttitta L, 2003, DEV BIOL, V258, P91, DOI 10.1016/S0012-1606(03)00116-7; Capdevila J, 1998, DEV BIOL, V193, P182, DOI 10.1006/dbio.1997.8806; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Ikeya M, 1998, DEVELOPMENT, V125, P4969; IYENGAR R, 1994, METHODS ENZYMOLOGY H, V237, P26; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Manning D.R., 1999, G PROTEINS TECHNIQUE; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Ordahl C., 2000, SOMITOGENESIS 2, P129; OTT MO, 1991, DEVELOPMENT, V111, P1097; PARR BA, 1993, DEVELOPMENT, V119, P247; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434	28	247	256	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 20	2005	433	7023					317	322		10.1038/nature03126	http://dx.doi.org/10.1038/nature03126			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888NK	15568017				2022-12-28	WOS:000226381300056
J	Goyenvalle, A; Vulin, A; Fougerousse, F; Leturcq, F; Kaplan, JC; Garcia, L; Danos, O				Goyenvalle, A; Vulin, A; Fougerousse, F; Leturcq, F; Kaplan, JC; Garcia, L; Danos, O			Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping	SCIENCE			English	Article							PRE-MESSENGER-RNA; DUCHENNE MUSCULAR-DYSTROPHY; MDX MOUSE MUSCLE; SKELETAL-MUSCLE; GENE-TRANSFER; HEMOPHILIA-B; DELIVERY; EXPRESSION; MUTATION; VECTOR	Most mutations in the, dystrophin gene create a frameshift or a stop in the mRNA and are associated with severe Duchenne muscular dystrophy. Exon skipping that naturally occurs at low frequency sometimes eliminates the mutation and leads to the production of a rescued protein. We have achieved persistent exon skipping that removes the mutated exon on the dystrophin messenger mRNA of the mdx mouse, by a single administration of an AAV vector expressing antisense sequences linked to a modified U7 small nuclear RNA. We report the sustained production of functional dystrophin at physiological levels in entire groups of muscles and the correction of the muscular dystrophy.	Genethon, Evry, France; CNRS, UMR 8115, Evry, France; Hop & Int Cochin, Lab Biochim & Genet Mol, Paris, France	Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP	Danos, O (corresponding author), Genethon, 1 Rue Int, Evry, France.	danos@genethon.fr	Goyenvalle, Aurelie/G-3402-2016	Goyenvalle, Aurelie/0000-0003-3938-1165				Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Allamand V, 1997, HUM MOL GENET, V6, P747, DOI 10.1093/hmg/6.5.747; Brun C, 2003, CELL MOL LIFE SCI, V60, P557, DOI 10.1007/s000180300047; Chao HJ, 2000, MOL THER, V2, P619, DOI 10.1006/mthe.2000.0219; Chenuaud P, 2004, MOL THER, V9, P410, DOI 10.1016/j.ymthe.2003.12.015; De Angelis FG, 2002, P NATL ACAD SCI USA, V99, P9456, DOI 10.1073/pnas.142302299; Dunckley MG, 1998, HUM MOL GENET, V7, P1083, DOI 10.1093/hmg/7.7.1083; Gebski BL, 2003, HUM MOL GENET, V12, P1801, DOI 10.1093/hmg/ddg196; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; GOYENVALLE A, UNPUB; Gregorevic P, 2004, NAT MED, V10, P828, DOI 10.1038/nm1085; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Liu SK, 2004, NUCLEIC ACIDS RES, V32, P3752, DOI 10.1093/nar/gkh715; Lu QL, 2000, J CELL BIOL, V148, P985, DOI 10.1083/jcb.148.5.985; Lu QL, 2003, NAT MED, V9, P1009, DOI 10.1038/nm897; Mann CJ, 2002, J GENE MED, V4, P644, DOI 10.1002/jgm.295; Manno CS, 2003, BLOOD, V101, P2963, DOI 10.1182/blood-2002-10-3296; Muntoni F, 2003, LANCET NEUROL, V2, P731, DOI 10.1016/S1474-4422(03)00585-4; NICHOLSON LVB, 1993, NEUROMUSCULAR DISORD, V3, P525, DOI 10.1016/0960-8966(93)90109-W; Parrish EP, 1996, GENE THER, V3, P13; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Suter D, 1999, HUM MOL GENET, V8, P2415, DOI 10.1093/hmg/8.13.2415; Vacek MM, 2003, BLOOD, V101, P104, DOI 10.1182/blood-2002-06-1869; Vincent-Lacaze N, 1999, J VIROL, V73, P1949, DOI 10.1128/JVI.73.3.1949-1955.1999; Wells KE, 2003, FEBS LETT, V552, P145, DOI 10.1016/S0014-5793(03)00904-9; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4	29	366	429	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2004	306	5702					1796	1799		10.1126/science.1104297	http://dx.doi.org/10.1126/science.1104297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878FA	15528407				2022-12-28	WOS:000225630800059
J	Hsu, LF; Jais, P; Sanders, P; Garrigue, S; Hocini, M; Sacher, F; Takahashi, Y; Rotter, M; Pasquie, J; Scavee, C; Bordachar, P; Clementy, J; Haissaguerre, M				Hsu, LF; Jais, P; Sanders, P; Garrigue, S; Hocini, M; Sacher, F; Takahashi, Y; Rotter, M; Pasquie, J; Scavee, C; Bordachar, P; Clementy, J; Haissaguerre, M			Catheter ablation for atrial fibrillation in congestive heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY VEIN ISOLATION; LEFT-VENTRICULAR FUNCTION; LONG-TERM SURVIVAL; PACEMAKER IMPLANTATION; ATRIOVENTRICULAR NODE; PERMANENT PACEMAKER; SINUS RHYTHM; MORTALITY; CARDIOMYOPATHY; DOFETILIDE	BACKGROUND: Congestive heart failure and atrial fibrillation often coexist, and each adversely affects the other with respect to management and prognosis. We prospectively evaluated the effect of catheter ablation for atrial fibrillation on left ventricular function in patients with heart failure. METHODS: We studied 58 consecutive patients with congestive heart failure and a left ventricular ejection fraction of less than 45 percent who were undergoing catheter ablation for atrial fibrillation. We selected as controls 58 patients without congestive heart failure who were undergoing ablation for atrial fibrillation, matched according to age, sex, and classification of atrial fibrillation. We evaluated the patients' left ventricular function and dimensions, symptom score, exercise capacity, and quality of life at baseline and at months 1, 3, 6, and 12. RESULTS: After a mean (+/-SD) of 12+/-7 months, 78 percent of the patients with congestive heart failure and 84 percent of the controls remained in sinus rhythm (P=0.34) (69 percent and 71 percent, respectively, were in sinus rhythm without the administration of antiarrhythmic drugs). The patients with congestive heart failure had significant improvement in left ventricular function (increases in the ejection fraction and fractional shortening of 21+/-13 percent and 11+/-7 percent, respectively; P<0.001 for both comparisons), left ventricular dimensions (decreases in the diastolic and systolic diameters of 6+/-6 mm and 8+/-7 mm, respectively; P=0.03 and P<0.001, respectively), exercise capacity, symptoms, and quality of life. The ejection fraction improved significantly not only in patients without concurrent structural heart disease (24+/-10 percent, P<0.001) and those with inadequate rate control before ablation (23+/-10 percent, P<0.001), but also in those with coexisting heart disease (16+/-14 percent, P<0.001) and adequate rate control before ablation (17+/-15 percent, P<0.001). CONCLUSIONS: Restoration and maintenance of sinus rhythm by catheter ablation without the use of drugs in patients with congestive heart failure and atrial fibrillation significantly improve cardiac function, symptoms, exercise capacity, and quality of life.	Hop Cardiol Haut Leveque, F-33604 Bordeaux, France; Univ Bordeaux 2, F-33076 Bordeaux, France	CHU Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Jais, P (corresponding author), Hop Cardiol Haut Leveque, Ave Magellan, F-33604 Bordeaux, France.	pierre.jais@chu-bordeaux.fr	Sanders, Prashanthan/D-7641-2013; Pasquié, Jean Luc/O-2216-2018	Sanders, Prashanthan/0000-0003-3803-8429; Pasquié, Jean Luc/0000-0003-3773-5804				[Anonymous], 2001, CIRCULATION, V104, P2118; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Brignole M, 1998, CIRCULATION, V98, P953, DOI 10.1161/01.CIR.98.10.953; Bubien RS, 1996, CIRCULATION, V94, P1585, DOI 10.1161/01.CIR.94.7.1585; Chen MS, 2004, J AM COLL CARDIOL, V43, P1004, DOI 10.1016/j.jacc.2003.09.056; Clark DM, 1997, J AM COLL CARDIOL, V30, P1039, DOI 10.1016/S0735-1097(97)00254-4; Corley SD, 2004, CIRCULATION, V109, P1509, DOI 10.1161/01.CIR.0000121736.16643.11; Deedwania PC, 1998, CIRCULATION, V98, P2574, DOI 10.1161/01.CIR.98.23.2574; DOSHI R, 2004, AM COLL CARD ANN SCI; Ehrlich JR, 2002, J CARDIOVASC ELECTR, V13, P399, DOI 10.1046/j.1540-8167.2002.00399.x; Falk RH, 2001, NEW ENGL J MED, V344, P1067, DOI 10.1056/NEJM200104053441407; Greene HL, 2003, J AM COLL CARDIOL, V42, P20, DOI 10.1016/S0735-1097(03)00559-X; Haissaguerre M, 2000, CIRCULATION, V101, P1409, DOI 10.1161/01.CIR.101.12.1409; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Jais P, 2004, CIRCULATION, V110, P2996, DOI 10.1161/01.CIR.0000146917.75041.58; Kanagaratnam L, 2001, PACE, V24, P1774, DOI 10.1046/j.1460-9592.2001.01774.x; Kay GN, 1998, J INTERV CARD ELECTR, V2, P121, DOI 10.1023/A:1009795330454; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; MIDDLEKAUFF HR, 1991, CIRCULATION, V84, P40, DOI 10.1161/01.CIR.84.1.40; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; Ozcan C, 2003, AM J CARDIOL, V92, P33, DOI 10.1016/S0002-9149(03)00460-0; Ozcan C, 2001, NEW ENGL J MED, V344, P1043, DOI 10.1056/NEJM200104053441403; Pappone C, 2001, CIRCULATION, V104, P2539, DOI 10.1161/hc4601.098517; Pedersen OD, 2001, CIRCULATION, V104, P292, DOI 10.1161/01.CIR.104.3.292; Pozzoli M, 1998, J AM COLL CARDIOL, V32, P197, DOI 10.1016/S0735-1097(98)00221-6; Redfield MM, 2000, MAYO CLIN PROC, V75, P790, DOI 10.4065/75.8.790; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Shinbane JS, 1997, J AM COLL CARDIOL, V29, P709, DOI 10.1016/S0735-1097(96)00592-X; Stevenson WG, 1999, NEW ENGL J MED, V341, P910, DOI 10.1056/NEJM199909163411209; Torp-Pedersen C, 1999, NEW ENGL J MED, V341, P857, DOI 10.1056/NEJM199909163411201; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Vasan RS, 1999, J AM COLL CARDIOL, V33, P1948, DOI 10.1016/S0735-1097(99)00118-7; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; Ware J, 1994, SF 36 PHYS MENTAL SU; Wood MA, 2000, CIRCULATION, V101, P1138, DOI 10.1161/01.CIR.101.10.1138; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328	37	603	631	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2373	2383		10.1056/NEJMoa041018	http://dx.doi.org/10.1056/NEJMoa041018			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575053				2022-12-28	WOS:000225429000006
J	Vivier, E; Nunes, JA; Vely, F				Vivier, E; Nunes, JA; Vely, F			Natural killer cell signaling pathways	SCIENCE			English	Article							INHIBITORY RECEPTORS; MEDIATED CYTOTOXICITY; NK CELLS; PROTEINS; NKG2D	Natural killer (NK) cells are lymphocytes of the innate immune system that are involved in the early defenses against foreign cells, as well as autologous cells undergoing various forms of stress, such as microbial infection or tumor transformation. NK cell activation is controlled by a dynamic balance between complementary and antagonistic pathways that are initiated upon interaction with potential target cells. NK cells express an array of activating cell surface receptors that can trigger cytolytic programs, as well as cytokine or chemokine secretion. Some of these activating cell surface receptors initiate protein tyrosine kinase (PTK)-dependent pathways through noncovalent associations with transmembrane signaling adaptors that harbor intracytoplasmic ITAMs (immunoreceptor tyrosine-based activation motifs). Additional cell surface receptors that are not directly coupled to ITAMs also participate in NK cell activation. These include NKG2D, which is noncovalently associated to the DAP10 transmembrane signaling adaptor, as well as integrins and cytokine receptors. NK cells also express cell surface inhibitory receptors that antagonize activating pathways through protein tyrosine phosphatases (PTPs). These inhibitory cell surface receptors are characterized by intracytoplasmic ITIMs (immunoreceptor tyrosine-based inhibition motifs). The tyrosine-phosphorylation status of several signaling components that are substrates for both PTKs and PTPs is thus key to the propagation of the NK cell effector pathways. Understanding the integration of these multiple signals is central to the understanding and manipulation of NK cell effector signaling pathways.	Univ Mediterranee, Ctr Immunol Marseille Luminy, CNRS, INSERM, F-13288 Marseille 09, France; Inst Cancerol Marseille, INSERM, UMR 599, F-13009 Marseille, France; Univ Mediterranee, Fac Pharm, INSERM, U608, F-13005 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Vivier, E (corresponding author), Univ Mediterranee, Ctr Immunol Marseille Luminy, CNRS, INSERM, Campus Luminy,Case 906, F-13288 Marseille 09, France.	vivier@ciml.univ-mrs.fr	Vély, Frédéric/HHM-3894-2022; NUNES, Jacques A/F-4952-2013; Vivier, Eric/F-8939-2010	NUNES, Jacques A/0000-0003-4865-0400; Vivier, Eric/0000-0001-7022-8287; Vely, Frederic/0000-0002-1682-0949				Augugliaro R, 2003, EUR J IMMUNOL, V33, P1235, DOI 10.1002/eji.200323896; Billadeau DD, 2003, NAT IMMUNOL, V4, P557, DOI 10.1038/ni929; Blery M, 1997, J BIOL CHEM, V272, P8989; Cella M, 2004, J EXP MED, V200, P817, DOI 10.1084/jem.20031847; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; Jevremovic D, 1999, J IMMUNOL, V162, P2453; Jevremovic D, 2001, J IMMUNOL, V166, P7219, DOI 10.4049/jimmunol.166.12.7219; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Lanier LL, 2003, CURR OPIN IMMUNOL, V15, P308, DOI 10.1016/S0952-7915(03)00039-6; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Moretta L, 2002, EUR J IMMUNOL, V32, P1205, DOI 10.1002/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y; Perez OD, 2004, BLOOD, V104, P1083, DOI 10.1182/blood-2003-08-2652; Tomasello E, 2000, SEMIN IMMUNOL, V12, P139, DOI 10.1006/smim.2000.0216; VELY F, 1963, J IMMUNOL, V2075, P97; WANGE RL, 2000, SCI STKE, pRE1; Zompi S, 2003, NAT IMMUNOL, V4, P565, DOI 10.1038/ni930	17	479	500	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1517	1519		10.1126/science.1103478	http://dx.doi.org/10.1126/science.1103478			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567854				2022-12-28	WOS:000225442700048
J	Bowen, GJ; Beerling, DJ; Koch, PL; Zachos, JC; Quattlebaum, T				Bowen, GJ; Beerling, DJ; Koch, PL; Zachos, JC; Quattlebaum, T			A humid climate state during the Palaeocene/Eocene thermal maximum	NATURE			English	Article							CARBON-ISOTOPE COMPOSITION; MASSIVE DISSOCIATION; SEA-LEVEL; EOCENE; TEMPERATURE; MODEL; ASSIMILATION; METHANE; LEAVES; FOSSIL	An abrupt climate warming of 5 to 10 degreesC during the Palaeocene/Eocene boundary thermal maximum (PETM) 55 Myr ago is linked to the catastrophic release of similar to1,050-2,100 Gt of carbon from sea-floor methane hydrate reservoirs(1). Although atmospheric methane, and the carbon dioxide derived from its oxidation, probably contributed to PETM warming, neither the magnitude nor the timing of the climate change is consistent with direct greenhouse forcing by the carbon derived from methane hydrate. Here we demonstrate significant differences between marine(2,3) and terrestrial(4-6) carbon isotope records spanning the PETM. We use models of key carbon cycle processes(7-9) to identify the cause of these differences. Our results provide evidence for a previously unrecognized discrete shift in the state of the climate system during the PETM, characterized by large increases in mid-latitude tropospheric humidity and enhanced cycling of carbon through terrestrial ecosystems. A more humid atmosphere helps to explain PETM temperatures, but the ultimate mechanisms underlying the shift remain unknown.	Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England	University of California System; University of California Santa Cruz; University of Sheffield	Bowen, GJ (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	gbowen@biology.utah.edu	Beerling, David J/C-2840-2009; Zachos, James C/A-7674-2008; Bowen, Gabriel J/C-1708-2008	Beerling, David J/0000-0003-1869-4314; Zachos, James C/0000-0001-8439-1886; 				BEERLING DJ, 1995, GLOB CHANGE BIOL, V1, P289, DOI 10.1111/j.1365-2486.1995.tb00027.x; Bolle MP, 2001, CLAY MINER, V36, P249, DOI 10.1180/000985501750177979; Bowen GJ, 2004, GLOBAL BIOGEOCHEM CY, V18, DOI 10.1029/2003GB002117; Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; Bowen GJ., 2001, PALEOCENE EOCENE STR, P73; CERLING TE, 1984, EARTH PLANET SC LETT, V71, P229, DOI 10.1016/0012-821X(84)90089-X; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; Farley KA, 2003, EARTH PLANET SC LETT, V208, P135, DOI 10.1016/S0012-821X(03)00017-7; FARQUHAR GD, 1989, ANNU REV PLANT PHYS, V40, P503, DOI 10.1146/annurev.pp.40.060189.002443; FARQUHAR GD, 1980, PLANTA, V149, P78, DOI 10.1007/BF00386231; Fricke HC, 2004, AM J SCI, V304, P612, DOI 10.2475/ajs.304.7.612; Friedman I., 1977, COMPILATION STABLE I, P1; Granier A, 1996, GLOBAL CHANGE BIOL, V2, P265, DOI 10.1111/j.1365-2486.1996.tb00078.x; Grocke DR, 1999, GEOLOGY, V27, P155, DOI 10.1130/0091-7613(1999)027<0155:CICOLC>2.3.CO;2; Hesselbo SP, 2000, NATURE, V406, P392, DOI 10.1038/35019044; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KOCH PL, 1995, PALAEOGEOGR PALAEOCL, V115, P61, DOI 10.1016/0031-0182(94)00107-J; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; LEUNING R, 1995, PLANT CELL ENVIRON, V18, P339, DOI 10.1111/j.1365-3040.1995.tb00370.x; MACDONALD NW, 1995, SOIL SCI SOC AM J, V59, P233, DOI 10.2136/sssaj1995.03615995005900010036x; Magioncalda R, 2004, GEOLOGY, V32, P553, DOI 10.1130/G20476.1; Renssen H, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000968; Schafer KVR, 2003, GLOBAL CHANGE BIOL, V9, P1378, DOI 10.1046/j.1365-2486.2003.00662.x; Schmidt GA, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000757; Schmitz B, 2003, GEOLOGY, V31, P689, DOI 10.1130/G19527.1; Sewall JO, 2000, GLOBAL PLANET CHANGE, V26, P445, DOI 10.1016/S0921-8181(00)00056-4; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; Tu TTN, 2004, PALAEOGEOGR PALAEOCL, V212, P199, DOI 10.1016/j.palaeo.2004.05.023; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110	30	232	243	2	121	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					495	499		10.1038/nature03115	http://dx.doi.org/10.1038/nature03115			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565152				2022-12-28	WOS:000225322100044
J	Desai, ND; Cohen, EA; Naylor, CD; Fremes, SE				Desai, ND; Cohen, EA; Naylor, CD; Fremes, SE			A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL-MAMMARY-ARTERY; AORTOCORONARY BYPASS; MYOCARDIAL REVASCULARIZATION; OPERATION; PATENCY; ANGIOGRAPHY; SURGERY; SERIAL	BACKGROUND In the past decade, the radial artery has frequently been used for coronary bypass surgery despite concern regarding the possibility of graft spasm. Graft patency is a key predictor of long-term survival. We therefore sought to determine the relative patency rate of radial-artery and saphenous-vein grafts in a randomized trial in which we controlled for bias in the selection of patients and vessels. METHODS We enrolled 561 patients at 13 centers. The left internal thoracic artery was used to bypass the anterior circulation. The radial-artery graft was randomly assigned to bypass the major vessel in either the inferior ( right coronary) territory or the lateral ( circumflex) territory, with the saphenous-vein graft used for the opposing territory ( control). The primary end point was graft occlusion, determined by angiography 8 to 12 months postoperatively. RESULTS Angiography was performed at one year in 440 patients: 8.2 percent of radial-artery grafts and 13.6 percent of saphenous-vein grafts were completely occluded ( P = 0.009). Diffuse narrowing of the graft ( the angiographic "string sign") was present in 7.0 percent of radial-artery grafts and only 0.9 percent of saphenous-vein grafts ( P = 0.001). The absence of severe native-vessel stenosis was associated with an increased risk of occlusion of the radial-artery graft and diffuse narrowing of the graft. Harvesting of the radial artery was well tolerated. CONCLUSIONS Radial-artery grafts are associated with a lower rate of graft occlusion at one year than are saphenous-vein grafts. Because the patency of radial-artery grafts depends on the severity of native-vessel stenosis, such grafts should preferentially be used for target vessels with high-grade lesions.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Cardiac Surg, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Cardiol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Gen Internal Med, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Fremes, SE (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Div Cardiac Surg, Rm H410 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	stephen.fremes@sw.ca	Fremes, Stephen E/P-7928-2015	Fremes, Stephen E/0000-0003-1723-3049				ACAR C, 1992, ANN THORAC SURG, V54, P652, DOI 10.1016/0003-4975(92)91007-V; BOURASSA MG, 1982, CIRCULATION, V65, P90, DOI 10.1161/01.CIR.65.7.90; Carpentier A, 1973, Ann Thorac Surg, V16, P111; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; CHIU CJ, 1976, ANN THORAC SURG, V22, P520, DOI 10.1016/S0003-4975(10)64468-2; Cohen E, 2000, CONTROL CLIN TRIALS, V21, P397; CURTIS JJ, 1975, ANN THORAC SURG, V20, P628, DOI 10.1016/S0003-4975(10)65754-2; FITZGIBBON GM, 1978, CIRCULATION, V57, P1070, DOI 10.1161/01.CIR.57.6.1070; FREMES SE, 1993, EUR J CARDIO-THORAC, V7, P169, DOI 10.1016/1010-7940(93)90155-5; FREMES SE, 1995, J CARDIAC SURG, V10, P537, DOI 10.1111/j.1540-8191.1995.tb00629.x; GRONDIN CM, 1974, J THORAC CARDIOV SUR, V67, P1; Hudak PL, 1996, AM J IND MED, V30, P372; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; Khot UN, 2004, CIRCULATION, V109, P2086, DOI 10.1161/01.CIR.0000127570.20508.5C; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; LYTLE BW, 1985, J THORAC CARDIOV SUR, V89, P248; Meharwal ZS, 2001, ANN THORAC SURG, V72, P1557, DOI 10.1016/S0003-4975(01)03088-0; Moran SV, 2001, ANN THORAC SURG, V72, P1552, DOI 10.1016/S0003-4975(01)03090-9; Parolari A, 2000, ANN THORAC SURG, V69, P1288, DOI 10.1016/S0003-4975(99)01089-9; Possati G, 1998, J THORAC CARDIOV SUR, V116, P1015, DOI 10.1016/S0022-5223(98)70054-6; Possati G, 2003, CIRCULATION, V108, P1350, DOI 10.1161/01.CIR.0000087402.13786.D0; Royse AG, 2000, EUR J CARDIO-THORAC, V17, P294, DOI 10.1016/S1010-7940(99)00364-4; Sabik JF, 2003, ANN THORAC SURG, V76, P1490, DOI 10.1016/S0003-4975(03)01022-1; Uchida N, 1996, ANN THORAC SURG, V62, P1342, DOI 10.1016/0003-4975(96)00480-8; ZEFF RH, 1988, ANN THORAC SURG, V45, P533, DOI 10.1016/S0003-4975(10)64526-2	25	385	414	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2302	2309		10.1056/NEJMoa040982	http://dx.doi.org/10.1056/NEJMoa040982			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564545				2022-12-28	WOS:000225298100009
J	Broach, JR				Broach, JR			Making the right choice - Long-range chromosomal interactions in development	CELL			English	Editorial Material							MATING-TYPE INTERCONVERSION; BETA-GLOBIN LOCUS; FISSION YEAST; LEFT ARM; RECOMBINATION; DIRECTIONALITY; SACCHAROMYCES; TRANSCRIPTION; PATTERN; REPAIR	Schizosaccharomyces pombe has the remarkable potential to switch mating type as often as every generation, through selective interaction of an expressor locus with either of two transcriptionally silent donor loci. Recent results demonstrate that selection of the appropriate donor locus likely occurs through mating-type and heterochromatin-dependent spreading of a protein complex that marks the correct donor locus.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08558 USA	Princeton University	Broach, JR (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08558 USA.	jbroach@molbio.princeton.edu		Broach, James/0000-0003-1197-0312				Akamatsu Y, 2003, P NATL ACAD SCI USA, V100, P15770, DOI 10.1073/pnas.2632890100; Bressan DA, 2004, J CELL BIOL, V164, P361, DOI 10.1083/jcb.200311063; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Drissen R, 2004, GENE DEV, V18, P2485, DOI 10.1101/gad.317004; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; Haber JE, 1998, ANNU REV GENET, V32, P561, DOI 10.1146/annurev.genet.32.1.561; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; Simon P, 2002, EMBO J, V21, P2282, DOI 10.1093/emboj/21.9.2282; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; Szeto L, 1997, GENE DEV, V11, P1899, DOI 10.1101/gad.11.15.1899; THON G, 1993, GENETICS, V134, P1045; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; Wu XH, 1996, CELL, V87, P277, DOI 10.1016/S0092-8674(00)81345-8	14	18	18	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	2004	119	5					583	586		10.1016/j.cell.2004.11.029	http://dx.doi.org/10.1016/j.cell.2004.11.029			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550239	Bronze			2022-12-28	WOS:000225389500003
J	Kuppers, R				Kuppers, R			Prognosis in follicular lymphoma - It's in the microenvironment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Duisburg Essen Med Sch, Inst Cell Biol Tumor Res, Essen, Germany	University of Duisburg Essen	Kuppers, R (corresponding author), Univ Duisburg Essen Med Sch, Inst Cell Biol Tumor Res, Essen, Germany.			Kuppers, Ralf/0000-0002-6691-7191				Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914	1	30	31	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2152	2153		10.1056/NEJMp048257	http://dx.doi.org/10.1056/NEJMp048257			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548773				2022-12-28	WOS:000225160600003
J	Dexter, PR; Perkins, SM; Maharry, KS; Jones, K; McDonald, CJ				Dexter, PR; Perkins, SM; Maharry, KS; Jones, K; McDonald, CJ			Inpatient computer-based standing orders vs physician reminders to increase influenza and pneumococcal vaccination rates - a randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY PERSONS; COST-EFFECTIVENESS; IMMUNIZATION; CARE; EFFICACY; SYSTEM; HEALTH; METAANALYSIS; MORTALITY; QUALITY	Context Computerized reminder systems increase influenza and pneumococcal vaccination rates, but computerized standing order systems have not been previously described or evaluated. Objective To determine the effects of computerized physician standing orders compared with physician reminders on inpatient vaccination rates. Design, Setting, and Patients Randomized trial of 3777 general medicine patients discharged from 1 of 6 study wards during a 14-month period (November 1, 1998, through December 31, 1999) composed of 2 overlapping influenza seasons at an urban public teaching hospital. Interventions The hospital's computerized physician order entry system identified inpatients eligible for influenza and pneumococcal vaccination. For patients with standing orders, the system automatically produced vaccine orders directed to nurses at the time of patient discharge. For patients with reminders, the computer system provided reminders to physicians that included vaccine orders during routine order entry sessions. Main Outcome Measure Vaccine administration. Results During the approximately 6 months of the influenza season, 50% of all hospitalized patients were identified as eligible for influenza vaccination. Twenty-two percent of patients hospitalized during the entire 14 months of the study were found eligible for pneumococcal vaccination; Patients with standing orders received an influenza vaccine significantly more often (42%) than those patients with reminders (30%) (P<.001). Patients with standing orders received a pneumococcal vaccine significantly more often (51%) than those with reminders (31%) (P<.001). Conclusions Computerized standing orders were more effective than computerized reminders for increasing both influenza and pneumococcal vaccine administration. Our findings suggest that computerized standing orders should be used more widely for this purpose.	Indiana Univ, Sch Med, Indianapolis, IN 46202 USA; Wishard Mem Hosp, Dept Med, Indianapolis, IN USA; Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	McDonald, CJ (corresponding author), Indiana Univ, Sch Med, 1050 Wishard Blvd, Indianapolis, IN 46202 USA.	cmcdonald@regenstrief.org	Tao, Youyou/D-2367-2014		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [N01LM063546, N01LM093542] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*AMA CDC, 2003, FIN REC 2003 NAT INF; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P987; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P958; Christy C, 1997, ARCH PEDIAT ADOL MED, V151, P384, DOI 10.1001/archpedi.1997.02170410058008; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; FEDSON DS, 1983, AM J PUBLIC HEALTH, V73, P442, DOI 10.2105/AJPH.73.4.442; FEDSON DS, 1982, INFECT CONT HOSP EP, V3, P303, DOI 10.1017/S0195941700056381; FINE MJ, 1994, ARCH INTERN MED, V154, P2666, DOI 10.1001/archinte.1994.00420230051007; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; Harper SA, 2004, MMWR RECOMM REP, V53, P743; HERMAN CJ, 1994, J AM GERIATR SOC, V42, P1154, DOI 10.1111/j.1532-5415.1994.tb06981.x; HOEY JR, 1982, CAN MED ASSOC J, V127, P27; KLEIN RS, 1986, ARCH INTERN MED, V146, P327, DOI 10.1001/archinte.146.2.327; LANDIS S, 1995, J FAM PRACTICE, V41, P364; Lawson F, 2000, J GERONTOL A-BIOL, V55, pM522, DOI 10.1093/gerona/55.9.M522; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; McDonald CJ, 1999, INT J MED INFORM, V54, P225, DOI 10.1016/S1386-5056(99)00009-X; MCDONALD CJ, 1980, JAMA-J AM MED ASSOC, V244, P1579, DOI 10.1001/jama.244.14.1579; MCDONALD CJ, 1986, WESTERN J MED, V145, P823; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; National Association of State Public Health Veterinarians Inc. (NASPHV), 2004, MMWR Recomm Rep, V53, P1; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Ostbye T, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-41; Overhage J M, 1995, Proc Annu Symp Comput Appl Med Care, P178; Rhew DC, 1999, J GEN INTERN MED, V14, P351, DOI 10.1046/j.1525-1497.1999.00353.x; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Slobodkin D, 1999, ACAD EMERG MED, V6, P724, DOI 10.1111/j.1553-2712.1999.tb00443.x; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; Wagner C, 2003, GERONTOLOGY, V49, P246, DOI 10.1159/000070405; Watson L, 2002, VACCINE, V20, P2166, DOI 10.1016/S0264-410X(02)00112-3; Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 2004, HLTH PEOPLE 2010	38	149	149	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2366	2371		10.1001/jama.292.19.2366	http://dx.doi.org/10.1001/jama.292.19.2366			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547164	Bronze			2022-12-28	WOS:000225070100025
J	Long, JA; Chang, VW; Ibrahim, SA; Asch, DA				Long, JA; Chang, VW; Ibrahim, SA; Asch, DA			Update on the health disparities literature	ANNALS OF INTERNAL MEDICINE			English	Review							OF-VETERANS-AFFAIRS; RENAL-TRANSPLANTATION; RACIAL-DIFFERENCES; PHYSICAL-ACTIVITY; TRENDS; RACE; MORTALITY; PATIENT; CANCER; CARE		Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Vet Affairs Ctr Hlth Equ Res & Promot,Vet Affairs, Philadelphia, PA 19104 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA; Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA	University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Long, JA (corresponding author), Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Vet Affairs Ctr Hlth Equ Res & Promot,Vet Affairs, Philadelphia, PA 19104 USA.	jalong@mail.med.upenn.edu		Long, Judith/0000-0003-4748-181X; Asch, David/0000-0002-7970-286X	NICHD NIH HHS [5-K12-HD-0435901] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARON DJ, 1993, MED SCI SPORT EXER, V25, P847, DOI 10.1249/00005768-199307000-00014; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Clegg LX, 2002, ARCH INTERN MED, V162, P1985, DOI 10.1001/archinte.162.17.1985; Conigliaro J, 2000, ARCH INTERN MED, V160, P1329, DOI 10.1001/archinte.160.9.1329; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Doescher MP, 2000, ARCH FAM MED, V9, P1156, DOI 10.1001/archfami.9.10.1156; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Escalante A, 2000, ARTHRITIS RHEUM-US, V43, P390, DOI 10.1002/1529-0131(200002)43:2<390::AID-ANR20>3.0.CO;2-R; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Freeman HP, 1998, CANCER, V82, P219, DOI 10.1002/(SICI)1097-0142(19980101)82:1<219::AID-CNCR27>3.0.CO;2-4; GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HEATH GW, 1994, ARCH PEDIAT ADOL MED, V148, P1131, DOI 10.1001/archpedi.1994.02170110017003; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; MANTON KG, 1987, MILBANK Q, V65, P129, DOI 10.2307/3349954; MCCORD C, 1990, NEW ENGL J MED, V322, P173, DOI 10.1056/NEJM199001183220306; MIRVIS DM, 1994, J AM COLL CARDIOL, V24, P1297, DOI 10.1016/0735-1097(94)90112-0; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; Ng-Mak DS, 1999, AM J PUBLIC HEALTH, V89, P1748, DOI 10.2105/AJPH.89.11.1748; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PETERSON MGE, 1992, J BONE JOINT SURG AM, V74A, P1530, DOI 10.2106/00004623-199274100-00012; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57; Wu Y, 2001, TRANSFUSION, V41, P360, DOI 10.1046/j.1537-2995.2001.41030360.x	25	45	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					805	812		10.7326/0003-4819-141-10-200411160-00013	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545681				2022-12-28	WOS:000225206900008
J	Cominelli, F				Cominelli, F			Cytokine-based therapies for Crohn's disease - New paradigms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							APOPTOSIS		Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22903 USA	University of Virginia	Cominelli, F (corresponding author), Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22903 USA.							Fuss IJ, 1999, GASTROENTEROLOGY, V117, P1078, DOI 10.1016/S0016-5085(99)70392-6; Marini M, 2003, P NATL ACAD SCI USA, V100, P8366, DOI 10.1073/pnas.1432897100; Reuter BK, 2004, EUR J IMMUNOL, V34, P2347, DOI 10.1002/eji.200425351; Van Den Brande JMH, 2003, GASTROENTEROLOGY, V124, P1774, DOI 10.1016/S0016-5085(03)00382-2; 2004, MMWR MORB MORTAL WKL, V53, P683	5	74	80	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2045	2048		10.1056/NEJMp048253	http://dx.doi.org/10.1056/NEJMp048253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537904				2022-12-28	WOS:000225007200005
J	Gershon, D				Gershon, D			Probing real-time protein interactions	NATURE			English	Article																			0	0	0	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					249	249		10.1038/432249a	http://dx.doi.org/10.1038/432249a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538375	Bronze			2022-12-28	WOS:000225020200054
J	Mannon, PJ; Fuss, IJ; Mayer, L; Elson, CO; Sandborn, WJ; Present, D; Dolin, B; Goodman, N; Groden, C; Hornung, RL; Quezado, M; Neurath, MF; Salfeld, J; Veldman, GM; Schwertschlag, U; Strober, W				Mannon, PJ; Fuss, IJ; Mayer, L; Elson, CO; Sandborn, WJ; Present, D; Dolin, B; Goodman, N; Groden, C; Hornung, RL; Quezado, M; Neurath, MF; Salfeld, J; Veldman, GM; Schwertschlag, U; Strober, W		Anti-IL-12 Crohn's Dis Study Grp	Anti-interleukin-12 antibody for active Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROPRIA MONONUCLEAR-CELLS; EXPERIMENTAL COLITIS; INTERFERON-GAMMA; IFN-GAMMA; T-CELLS; INTERLEUKIN-12; MICE; EXPRESSION; IL-12; RESPONSES	Background: Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses. Methods: This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, and the rates of clinical response (defined by a reduction in the score for the Crohn's Disease Activity Index [CDAI] of at least 100 points) and remission (defined by a CDAI score of 150 or less) were secondary end points. Results: Seven weeks of uninterrupted treatment with 3 mg of anti-interleukin-12 per kilogram resulted in higher response rates than did placebo administration (75 percent vs. 25 percent, P=0.03). At 18 weeks of follow-up, the difference in response rates was no longer significant (69 percent vs. 25 percent, P=0.08). Differences in remission rates between the group given 3 mg of anti-interleukin-12 per kilogram and the placebo group in Cohort 2 were not significant at either the end of treatment or the end of follow-up (38 percent and 0 percent, respectively, at both times; P=0.07). There were no significant differences in response rates among the groups in Cohort 1. The rates of adverse events among patients receiving anti-interleukin-12 were similar to those among patients given placebo, except for a higher rate of local reactions at injection sites in the former group. Decreases in the secretion of interleukin-12, interferon-(gamma), and tumor necrosis factor (alpha) by mononuclear cells of the colonic lamina propria accompanied clinical improvement in patients receiving anti-interleukin-12. Conclusions: Treatment with a monoclonal antibody against interleukin-12 may induce clinical responses and remissions in patients with active Crohn's disease. This treatment is associated with decreases in Th1-mediated inflammatory cytokines at the site of disease.	NIAID, Mucosal Immun Sect, Host Def Lab, NIH, Bethesda, MD 20892 USA; NCI, Surg Pathol Sect, NIH, Bethesda, MD 20892 USA; CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Gastroenterol, New York, NY 10029 USA; Univ Alabama, Sch Med, Div Gastroenterol, Birmingham, AL USA; Mayo Clin, Rochester, MN USA; Hlth Advance Inst, Peoria, IL USA; Wyeth, Cambridge, MA USA; Sci Applicat Int Corp, Clin Serv Program, Frederick, MD USA; Univ Mainz, Med Klin 1, D-6500 Mainz, Germany; Abbott Biores Ctr, Worcester, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham; Mayo Clinic; Pfizer; Science Applications International Corporation (SAIC); Johannes Gutenberg University of Mainz	Mannon, PJ (corresponding author), NIAID, Mucosal Immun Sect, Host Def Lab, NIH, 10 Ctr Dr,Rm 11-N238, Bethesda, MD 20892 USA.	pmannon@niaid.nih.gov	Sandborn, William/ABE-8342-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000903] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEST WR, 1976, GASTROENTEROLOGY, V70, P439; Brombacher F, 2003, TRENDS IMMUNOL, V24, P207, DOI 10.1016/S1471-4906(03)00067-X; D'Haens GR, 1998, GASTROENTEROLOGY, V114, P262, DOI 10.1016/S0016-5085(98)70476-7; Davidson NJ, 1998, J IMMUNOL, V161, P3143; FAIS S, 1994, J INTERFERON RES, V14, P235, DOI 10.1089/jir.1994.14.235; FRUCHT DM, 2002, SCI STKE, pPE1, DOI DOI 10.1126/STKE.2002.114.PE1; Fuss IJ, 1999, GASTROENTEROLOGY, V117, P1078, DOI 10.1016/S0016-5085(99)70392-6; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Jain A, 1999, J CLIN INVEST, V103, P1151, DOI 10.1172/JCI5891; Marth T, 1997, J EXP MED, V185, P1987, DOI 10.1084/jem.185.11.1987; Monteleone G, 1999, CLIN EXP IMMUNOL, V117, P469; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; NEURATH MF, 1995, J EXP MED, V182, P1281, DOI 10.1084/jem.182.5.1281; Parronchi P, 1997, AM J PATHOL, V150, P823; Plevy SE, 1997, J IMMUNOL, V159, P6276; Rennick DM, 2000, AM J PHYSIOL-GASTR L, V278, pG829, DOI 10.1152/ajpgi.2000.278.6.G829; Simpson SJ, 1998, J EXP MED, V187, P1225, DOI 10.1084/jem.187.8.1225; Su CY, 2004, GASTROENTEROLOGY, V126, P1257, DOI 10.1053/j.gastro.2004.01.024; Trinchieri G, 1998, Int Rev Immunol, V16, P365, DOI 10.3109/08830189809043002	20	642	720	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2069	2079		10.1056/NEJMoa033402	http://dx.doi.org/10.1056/NEJMoa033402			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537905				2022-12-28	WOS:000225007200008
J	Remuzzi, G; Schieppati, A; Boissel, JP; Garattini, S; Horton, R				Remuzzi, G; Schieppati, A; Boissel, JP; Garattini, S; Horton, R			Independent clinical research in Europe	LANCET			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; UNITED-KINGDOM; TRIALS; DRUGS; SPONSORSHIP; OUTCOMES; MEDICINE; NEEDS		Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Lyon 1, Dept Clin Pharmacol, F-69365 Lyon, France; The Lancet, London, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.	gremuzzi@marionegri.it	Garattini, Silvio/AAA-6390-2020; Remuzzi, Giuseppe/V-9766-2017	Garattini, Silvio/0000-0003-0647-9297; Remuzzi, Giuseppe/0000-0002-6194-3446				Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; [Anonymous], 2003, LANCET, V361, P2167; ARLINGTON S, 1998, PHARMA2005 IND REVOL; Bassand JP, 2002, LANCET, V360, P1866, DOI 10.1016/S0140-6736(02)11776-4; Bell J, 2003, BRIT MED J, V327, P1041, DOI 10.1136/bmj.327.7422.1041; Bodenheimer T, 2000, NEW ENGL J MED, V342, P1539, DOI 10.1056/NEJM200005183422024; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Chalmers I, 2003, BRIT MED J, V327, P1017, DOI 10.1136/bmj.327.7422.1017; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Cornu C, 1999, LANCET, V353, P63, DOI 10.1016/S0140-6736(98)07611-9; *CTR MED MED COV, AIR FLUID BEDS PRESS; Davidoff F, 2001, LANCET, V358, P854, DOI 10.1016/S0140-6736(01)06035-4; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Garattini S, 2001, LANCET, V358, P64, DOI 10.1016/S0140-6736(00)05258-2; Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; *INF DIS SOC AM, DEF ANT AV PROBL; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Meldolesi A, 2003, NAT BIOTECHNOL, V21, P838, DOI 10.1038/nbt0803-838; Meunier F, 2003, LANCET, V362, P663, DOI 10.1016/S0140-6736(03)14163-3; Murray CJL, 1992, HLTH ADULTS DEV WORL, P113; *NIH, GRANTS OER HOM PAG M; Perucca E, 2002, EUR J PAIN, V6, P35, DOI 10.1053/eujp.2001.0320; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Schieppati A, 2001, LANCET, V358, P1638, DOI 10.1016/S0140-6736(01)06658-2; Tallon D, 2000, LANCET, V355, P2037, DOI 10.1016/S0140-6736(00)02351-5; The National Institute for Health Care Management Research and Educational Foundation, 2002, CHANG PATT PHARM INN; Trouiller P, 2001, TROP MED INT HEALTH, V6, P945, DOI 10.1046/j.1365-3156.2001.00803.x; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; WEINSTEIN MC, 1991, AM J PUBLIC HEALTH, V81, P414, DOI 10.2105/AJPH.81.4.414; 2003, NAT REV DRUG DISCOV, V2, P87	31	23	25	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1723	1726		10.1016/S0140-6736(04)17360-1	http://dx.doi.org/10.1016/S0140-6736(04)17360-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530634				2022-12-28	WOS:000224921600036
J	Attaran, A				Attaran, A			Rescuing malaria treatment, or not?	LANCET			English	Editorial Material							NEUROLOGICAL SEQUELAE; CEREBRAL MALARIA		Univ Ottawa, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Fac Law, Ottawa, ON K1N 6N5, Canada	University of Ottawa; University of Ottawa	Attaran, A (corresponding author), Univ Ottawa, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada.	aattaran@riia.org						*AG FRANC PRESS WH, 2004, GLOB FUND FIGHT BACK; Attaran A, 2004, LANCET, V363, P237, DOI 10.1016/S0140-6736(03)15330-5; Bloland, 1995, J Travel Med, V2, P16, DOI 10.1111/j.1708-8305.1995.tb00614.x; BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7; CARTER T, 2004, WASHINGTON TIME 0916; Goodman CA, 2001, HEALTH ECON, V10, P731, DOI 10.1002/hec.621; HERBERT B, 2004, COMMUNICATION   0826; Lwin A M, 1999, Asia Pac J Public Health, V11, P94, DOI 10.1177/101053959901100208; Murphy SC, 2001, AM J TROP MED HYG, V64, P57, DOI 10.4269/ajtmh.2001.64.57; WATKINS WM, 2004, IN PRESS AM J TROP M; 2004, M CONV GLOB FUND FIG; 2004, E AFRICAN NETWORK MO	12	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1922	1923		10.1016/S0140-6736(04)17493-X	http://dx.doi.org/10.1016/S0140-6736(04)17493-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566995				2022-12-28	WOS:000225327000009
J	Delanaye, P; Bovy, C; de Leval, L; Fassotte, MF; Witvrouw, N; Dechenne, C; Tassin, F; Krzesinski, JM				Delanaye, P; Bovy, C; de Leval, L; Fassotte, MF; Witvrouw, N; Dechenne, C; Tassin, F; Krzesinski, JM			Back pain and renal failure	LANCET			English	Editorial Material							LEUKEMIA		Univ Hosp Liege, Dept Nephrol, B-4000 Liege, Belgium; Univ Hosp Liege, Dept Pathol, B-4000 Liege, Belgium; Univ Hosp Liege, Dept Haematol, B-4000 Liege, Belgium	University of Liege; University of Liege; University of Liege	Delanaye, P (corresponding author), Univ Hosp Liege, Dept Nephrol, B35, B-4000 Liege, Belgium.	pierre_delanaye@yahoo.fr	Delanaye, Pierre/T-4225-2019; de Leval, Laurence/M-4889-2017	Delanaye, Pierre/0000-0002-1480-5761; de Leval, Laurence/0000-0003-3994-516X				GILBOA N, 1983, J UROLOGY, V129, P364, DOI 10.1016/S0022-5347(17)52099-6; Kirshbaum JD, 1943, ARCH INTERN MED, V71, P777, DOI 10.1001/archinte.1943.00210060038003; KJELLSTRAND CM, 1974, ARCH INTERN MED, V133, P349; LUNDBERG WB, 1977, AM J MED, V62, P636, DOI 10.1016/0002-9343(77)90427-2; Tornroth T, 2003, AM J KIDNEY DIS, V42, P960, DOI 10.1016/S0272-6386(03)01082-5	5	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1992	1992		10.1016/S0140-6736(04)17484-9	http://dx.doi.org/10.1016/S0140-6736(04)17484-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567017	Green Submitted			2022-12-28	WOS:000225327000039
J	Truckses, DM; Garrenton, LS; Thorner, J				Truckses, DM; Garrenton, LS; Thorner, J			Jekyll and Hyde in the microbial world	SCIENCE			English	Article							PROTEIN-COUPLED RECEPTOR; FILAMENTOUS GROWTH; YEAST; KINASE; GPR1; ACT	Fungi are nonmotile organisms that obtain carbon from compounds in their immediate surroundings. Confronted with nutrient limitation, the yeast Saccharomyces cerevisiae undergoes a dimorphic transition, switching from spherical cells to filaments of adherent, elongated cells that can invade the substratum. A complex web of sensing mechanisms and cooperation among signaling networks (including a mitogen-activated protein kinase cascade, cyclic adenosine monophosphate-dependent protein kinase, and 5'-adenosine monophosphate-activated protein kinase) elicits the appropriate changes in physiology, cell cycle progression, cell polarity, and gene expression to achieve this differentiation. Highly related signaling processes control filamentation and virulence of many human fungal pathogens.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	jeremy@socrates.berketey.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R01GM021841] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09041] Funding Source: Medline; NIGMS NIH HHS [GM-21841] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Cullen PJ, 2004, GENE DEV, V18, P1695, DOI 10.1101/gad.1178604; D'Souza CA, 2001, FEMS MICROBIOL REV, V25, P349, DOI 10.1111/j.1574-6976.2001.tb00582.x; Gagiano M, 2002, FEMS YEAST RES, V2, P433, DOI 10.1016/S1567-1356(02)00133-2; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; Kuchin S, 2003, BIOCHEM SOC T, V31, P175, DOI 10.1042/bst0310175; Lemaire K, 2004, MOL CELL, V16, P293, DOI 10.1016/j.molcel.2004.10.004; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Magasanik B, 2003, EUKARYOT CELL, V2, P827, DOI 10.1128/EC.2.5.827-829.2003; Mosch H U, 2000, Contrib Microbiol, V5, P185; Palecek SP, 2002, MICROBIOL-SGM, V148, P893, DOI 10.1099/00221287-148-4-893; Rohde JR, 2003, CURR TOP MICROBIOL, V279, P53; Sanchez-Martinez C, 2001, CURR OPIN MICROBIOL, V4, P214, DOI 10.1016/S1369-5274(00)00191-0; Sudbery P, 2004, TRENDS MICROBIOL, V12, P317, DOI 10.1016/j.tim.2004.05.008; TRUCKSES DM, 2004, SCI STKE         NOV; Wang YQ, 2004, SCIENCE, V306, P1508, DOI 10.1126/science.1104568; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Zarrinpar A, 2004, MOL CELL, V14, P825, DOI 10.1016/j.molcel.2004.06.011	22	20	24	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1509	1511		10.1126/science.1104677	http://dx.doi.org/10.1126/science.1104677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567850				2022-12-28	WOS:000225442700044
J	Reynolds, EE				Reynolds, EE			A 15-month-old child with recurrent otitis media, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Paradise JL, 2002, JAMA-J AM MED ASSOC, V288, P2589, DOI 10.1001/jama.288.20.2589	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2515	2515		10.1001/jama.292.20.2515	http://dx.doi.org/10.1001/jama.292.20.2515			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562132				2022-12-28	WOS:000225303000028
J	Weibezahn, J; Tessarz, P; Schlieker, C; Zahn, R; Maglica, Z; Lee, S; Zentgraf, H; Weber-Ban, EU; Dougan, DA; Tsai, FTF; Mogk, A; Bukau, B				Weibezahn, J; Tessarz, P; Schlieker, C; Zahn, R; Maglica, Z; Lee, S; Zentgraf, H; Weber-Ban, EU; Dougan, DA; Tsai, FTF; Mogk, A; Bukau, B			Thermotolerance requires refolding of aggregated proteins by substrate translocation through the central pore of ClpB	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; HSP100 CHAPERONE; DNAK CHAPERONE; DISAGGREGATION; BINDING; DEGRADATION; PROTEASE; ATPASE; IDENTIFICATION; COMMUNICATION	Cell survival under severe thermal stress requires the activity of the CIpB (Hsp104) AAA+ chaperone that solubilizes and reactivates aggregated proteins in concert with the DnaK (Hsp70) chaperone system. How protein disaggregation is achieved and whether survival is solely dependent on CIpB-mediated elimination of aggregates or also on reactivation of aggregated proteins has been unclear. We engineered a CIpB variant, BAP, which associates with the CIpP peptidase and thereby is converted into a degrading disaggregase. BAP translocates substrates through its central pore directly into CIpP for degradation. CIpB-dependent translocation is demonstrated to be an integral part of the disaggregation mechanism. Protein disaggregation by the BAP/CIpP complex remains dependent on DnaK, defining a role for DnaK at early stages of the disaggregation reaction. The activity switch of BAP to a degrading disaggregase does not support thermotolerance development, demonstrating that cell survival during severe thermal stress requires reactivation of aggregated proteins.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; ETH, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany; La Trobe Univ, Dept Biochem, Melbourne, Vic 3086, Australia	Ruprecht Karls University Heidelberg; Swiss Federal Institutes of Technology Domain; ETH Zurich; Baylor College of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); La Trobe University	Mogk, A (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	a.mogk@zmbh.uni-heidelberg.de; bukau@zmbh.uni-heidelberg.de	Maglica, Željka/S-7423-2018; Tessarz, Peter/I-9035-2014; Tessarz, Peter/ABB-6551-2021; dougan, david/B-3359-2010	Maglica, Željka/0000-0002-6438-861X; Tessarz, Peter/0000-0002-6953-9835; Tessarz, Peter/0000-0002-6953-9835; dougan, david/0000-0001-9313-1904; Weber-Ban, Eilika/0000-0002-5773-9274; Bukau, Bernd/0000-0003-0521-7199	NIGMS NIH HHS [R01GM67672] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067672] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Chin JW, 2002, P NATL ACAD SCI USA, V99, P11020, DOI 10.1073/pnas.172226299; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Friant S, 2003, EMBO J, V22, P3783, DOI 10.1093/emboj/cdg375; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Guo FS, 2002, J BIOL CHEM, V277, P46743, DOI 10.1074/jbc.M207796200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2002, P NATL ACAD SCI USA, V99, P11037, DOI 10.1073/pnas.172378899; Joshi SA, 2004, NAT STRUCT MOL BIOL, V11, P404, DOI 10.1038/nsmb752; Kedzierska S, 2003, BIOCHEMISTRY-US, V42, P14242, DOI 10.1021/bi035573d; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Kim YI, 2001, NAT STRUCT BIOL, V8, P230, DOI 10.1038/84967; Konieczny I, 2002, J BIOL CHEM, V277, P18483, DOI 10.1074/jbc.M107580200; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Maurizi MR, 2004, STRUCTURE, V12, P175, DOI 10.1016/j.str.2004.01.021; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Mogk A, 2003, J BIOL CHEM, V278, P17615, DOI 10.1074/jbc.M209686200; Mogk A, 2003, J BIOL CHEM, V278, P31033, DOI 10.1074/jbc.M303587200; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Reid BG, 2001, P NATL ACAD SCI USA, V98, P3768, DOI 10.1073/pnas.071043698; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Schlee S, 2004, J MOL BIOL, V336, P275, DOI 10.1016/j.jmb.2003.12.013; Schlieker C, 2004, NAT STRUCT MOL BIOL, V11, P607, DOI 10.1038/nsmb787; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; Song HK, 2000, P NATL ACAD SCI USA, V97, P14103, DOI 10.1073/pnas.250491797; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Tomoyasu T, 2001, MOL MICROBIOL, V40, P397, DOI 10.1046/j.1365-2958.2001.02383.x; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Weibezahn J, 2003, J BIOL CHEM, V278, P32608, DOI 10.1074/jbc.M303653200; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Yamada-Inagawa T, 2003, J BIOL CHEM, V278, P50182, DOI 10.1074/jbc.M308327200; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043	41	370	374	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					653	665		10.1016/j.cell.2004.11.027	http://dx.doi.org/10.1016/j.cell.2004.11.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550247	hybrid			2022-12-28	WOS:000225389500011
J	Ashworth, WJ				Ashworth, WJ			Metroloov and the state: Science, revenue, and commerce	SCIENCE			English	Article								"Natural measures of quantity, such as fathoms, cubits, inches, taken from the proportion of the human body, were once in use with every nation," taught Adam Smith in his lecture "Money as the measure of value and medium of exchange," delivered in 1763. "But by a little observation," he continued, "they found that one man's arm was longer or shorter than another's, and that one was not to be compared with the other; and therefore wise men who attended to these things would endeavour to fix upon some more accurate measure, that equal quantities might be of equal values. Their method became absolutely necessary when people came to deal in many commodities, and in great quantities of them (1)." Smith's comments and the rationale underpinning them became increasingly urgent toward the end of the eighteenth century.	Univ Liverpool, Sch Hist, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Ashworth, WJ (corresponding author), Univ Liverpool, Sch Hist, Liverpool L69 3BX, Merseyside, England.	W.J.Ashworth@liverpool.ac.uk						Ashworth WJ, 2001, TECHNOL CULT, V42, P27, DOI 10.1353/tech.2001.0002; ASHWORTH WJ, 2003, CUSTOMS EXCISE TRADE, pCH15; BATEMAN J, 1840, EXCISE OFFICERS MANU, P28; GRAHAM JT, 1993, WEIGHTS MEASURES THE, P1; GRAHAM JT, 1993, WEIGHTS MEASURES THE, P3; HOPPIT J, 1993, ENGL HIST REV, V108, P82; KEITH GS, 1817, DIFFERENT METHODS ES, P2; KEITH GS, 1817, DIFFERENT METHODS ES, V1; KULA W, 1986, MEASURES MEN, P70; LEADBETTER C, 1743, ROYAL GAUGER GAUGING, P119; LEFTWICH BR, CUSTOMS STORY GREAT, P207; LINEBAUGH P, 1991, LONDON HANGED CRIME, P162; McCusker J. J., 1973, WILLIAM MARY Q, V30, P599, DOI DOI 10.2307/1918597; PATLENDEN WD, 1973, B CLEVELAND TEESSIDE, V20, P12; PORTER P, 1995, TRUST NUMBERS PURSUI, P223; RANDALL A, 1996, MARKETS MARKET CULTU, P25; SCHAFFER S, 1993, RETHINKING SOCIAL HI, P128; SMITH A, 1896, LECT JUSTICE POLICE, P183; *US HOUS COMM, 1758, SESS PAP, V19, P376; *US HOUS COMM, 1785, SESS PAP, V44, P18; *US HOUS COMM, 1758, SESS PAP, V19, P352; ZUPKO RE, 1990, MEMOIRS AM PHILOS SO, P26; ZUPKO RE, 1990, MEMOIRS AM PHILOS SO, P107; ZUPKO RE, 1990, MEMOIRS AM PHILOS SO, P5; ZUPKO RE, 1990, MEMOIRS AM PHILOS SO, P105; 1663, SURE GUIDE HIS MAJES, P441; 1742, PHILOS T R SOC, V42, P541; 1817, BRIT REV LONDON CRIT, V9, P159	28	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1314	1317		10.1126/science.1102551	http://dx.doi.org/10.1126/science.1102551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550658				2022-12-28	WOS:000225301600037
J	Elphick, GF; Querbes, W; Jordan, JA; Gee, GV; Eash, S; Manley, K; Dugan, A; Stanifer, M; Bhatnagar, A; Kroeze, WK; Roth, BL; Atwood, WJ				Elphick, GF; Querbes, W; Jordan, JA; Gee, GV; Eash, S; Manley, K; Dugan, A; Stanifer, M; Bhatnagar, A; Kroeze, WK; Roth, BL; Atwood, WJ			The human polyomavirus, JCV, uses serotonin receptors to infect cells	SCIENCE			English	Article							TONSILLAR STROMAL CELLS; FETAL GLIAL-CELLS; CAVEOLAR ENDOCYTOSIS; B-LYMPHOCYTES; HUMAN BRAIN; VIRUS; SIMIAN-VIRUS-40; REVEALS; 5-HT2A; PHARMACOLOGY	The human polyomavirus, JCV, causes the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocompromised patients. We found that the serotonergic receptor SHT2AR could act as the cellular receptor for JCV on human glial cells. The SHT2A receptor antagonists inhibited JCV infection, and monoclonal antibodies directed at 5HT(2A) receptors blocked infection of glial cells by JCV, but not by SV40. Transfection of 5HT(2A) receptor-negative HeLa cells with a 5HT(2A) receptor rescued virus infection, and this infection was blocked by antibody to the 5HT(2A) receptor. A tagged SHT2A receptor colocalized with labeled JCV in an endosomal compartment following internalization. Serotonin receptor antagonists may thus be useful in the treatment of progressive multifocal leukoencephalopathy.	Brown Univ, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Brown Univ, Grad Program Pathobiol, Providence, RI 02912 USA; Brown Univ, Grad Program Mol Biol Cellular Biol & Biochem, Providence, RI 02912 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Brown University; Brown University; Brown University; Case Western Reserve University	Atwood, WJ (corresponding author), Brown Univ, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA.	Walter_Atwood@Brown.edu	Roth, Bryan L/F-3928-2010; Stanifer, Megan/ABB-4254-2020; Roth, Bryan/ABE-7032-2020	Roth, Bryan/0000-0002-0561-6520; Gee, Gretchen/0000-0003-0403-3240; Stanifer, Megan/0000-0002-5606-1297	NCI NIH HHS [R01 CA71878] Funding Source: Medline; NIMH NIH HHS [R01MH61887, R01MH57635] Funding Source: Medline; NINDS NIH HHS [R01 NS43097] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057635, R01MH061887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043097] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baum S, 2003, J NEUROVIROL, V9, P32, DOI 10.1080/13550280390195342; Belachew S, 1998, NEUROREPORT, V9, P973, DOI 10.1097/00001756-199804200-00004; Berger JR, 1999, SEMIN NEUROL, V19, P193, DOI 10.1055/s-2008-1040837; Bhatnagar A, 2004, J BIOL CHEM, V279, P34614, DOI 10.1074/jbc.M404673200; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; BOESS FG, 1994, NEUROPHARMACOLOGY, V33, P275, DOI 10.1016/0028-3908(94)90059-0; Bofill-Mas S, 2000, APPL ENVIRON MICROB, V66, P238, DOI 10.1128/AEM.66.1.238-245.2000; BONHAUS DW, 1995, BRIT J PHARMACOL, V115, P622, DOI 10.1111/j.1476-5381.1995.tb14977.x; Chang M, 2000, J BIOL CHEM, V275, P7021, DOI 10.1074/jbc.275.10.7021; Chen BJ, 2002, VIROLOGY, V300, P282, DOI 10.1006/viro.2002.1522; CHOUDHARY MS, 1992, MOL PHARMACOL, V42, P627; Cohen Z, 1999, J CEREBR BLOOD F MET, V19, P908, DOI 10.1097/00004647-199908000-00010; DUDLEY M, 1990, Society for Neuroscience Abstracts, V16, P1037; Eash S, 2004, AM J PATHOL, V164, P419, DOI 10.1016/S0002-9440(10)63132-X; Fonseca MI, 2001, MOL BRAIN RES, V89, P11; Gillman PK, 1999, J PSYCHOPHARMACOL, V13, P100, DOI 10.1177/026988119901300111; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; HERNDON JL, 1992, J MED CHEM, V35, P4903, DOI 10.1021/jm00104a017; Herrick-Davis K, 2000, J PHARMACOL EXP THER, V295, P226; Holman RC, 1998, NEUROEPIDEMIOLOGY, V17, P303, DOI 10.1159/000026184; HOUFF SA, 1988, NEW ENGL J MED, V318, P301, DOI 10.1056/NEJM198802043180507; HOYER D, 1994, PHARMACOL REV, V46, P157; Kristiansen K, 1996, EUR J PHARMACOL, V306, P195, DOI 10.1016/0014-2999(96)00180-X; Liu CK, 1998, J VIROL, V72, P4643, DOI 10.1128/JVI.72.6.4643-4649.1998; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; Merzak A, 1996, MOL BRAIN RES, V41, P1, DOI 10.1016/0169-328X(96)00058-7; Monaco MCG, 1996, J VIROL, V70, P7004, DOI 10.1128/JVI.70.10.7004-7012.1996; Monao MCG, 1998, J VIROL, V72, P9918, DOI 10.1128/JVI.72.12.9918-9923.1998; Newman-Tancredi A, 2002, J PHARMACOL EXP THER, V303, P815, DOI 10.1124/jpet.102.039883; Norkin LC, 2002, J VIROL, V76, P5156, DOI 10.1128/JVI.76.10.5156-5166.2002; Norkin LC, 1999, IMMUNOL REV, V168, P13, DOI 10.1111/j.1600-065X.1999.tb01279.x; PADGETT BL, 1971, LANCET, V1, P1257; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pho MT, 2000, J VIROL, V74, P2288, DOI 10.1128/JVI.74.5.2288-2292.2000; Querbes W, 2004, J VIROL, V78, P250, DOI 10.1128/JVI.78.1.250-256.2004; Velasco M, 1998, Am J Ther, V5, P37, DOI 10.1097/00045391-199801000-00007; WALKER DL, 1986, PAPOVAVIRIDAE, V1, P327; Wei G, 2000, J NEUROVIROL, V6, P127, DOI 10.3109/13550280009013156	39	331	368	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1380	1383		10.1126/science.1103492	http://dx.doi.org/10.1126/science.1103492			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550673	Green Submitted			2022-12-28	WOS:000225301600054
J	Cheng, YN; Wu, XC; Ji, Q				Cheng, YN; Wu, XC; Ji, Q			Triassic marine reptiles gave birth to live young	NATURE			English	Article							SAUROPTERYGIA	Sauropterygians form the largest and most diverse group of ancient marine reptiles that lived throughout nearly the entire Mesozoic era (from 250 to 65 million years ago)(1,2). Although thousands of specimens of this group have been collected around the world since the description of the first plesiosaur in 1821 (ref. 3), no direct evidence has been found to determine whether any sauropterygians came on shore to lay eggs (oviparity) like sea turtles, or gave birth in the water to live young (viviparity) as ichthyosaurs and mosasauroids (marine lizards) did(4-6). Viviparity has been proposed for plesiosaur, pachypleurosaur and nothosaur sauropterygians(7-10), but until now no concrete evidence has been advanced. Here we report two gravid specimens of Keichousaurus hui Young from the Middle Triassic of China. These exquisitely preserved specimens not only provide the first unequivocal evidence of reproductive mode and sexual dimorphism in sauropterygians, but also indicate that viviparity could have been expedited by the evolution of a movable pelvis in pachypleurosaurs. By extension, this has implications for the reproductive pattern of other sauropterygians and Mesozoic marine reptiles that possessed a movable pelvis.	Canadian Museum Nat, Ottawa, ON K1P 6P4, Canada; Natl Museum Nat Sci, Taichung 404, Taiwan; Chinese Acad Geol Sci, Inst Geol, Beijing 100037, Peoples R China	Chinese Academy of Geological Sciences	Cheng, YN (corresponding author), Canadian Museum Nat, POB 3443 Stn D, Ottawa, ON K1P 6P4, Canada.	joe@mail.nmns.edu.tw; xcwu@mus-nature.ca						Andrews CW, 1910, DESCRIPTIVE CATALO 1; [Anonymous], 2000, HDB PALEOHERPETOLOGY; Bardet N, 1999, PALAEONTOLOGY, V42, P927, DOI 10.1111/1475-4983.00103; BENTON M, 1991, NEW SCI, V132, P40; Bottcher R., 1990, STUTTGARTER BEITRA B, V164, P1; Brown D.S., 1981, Bulletin of the British Museum (Natural History) Geology, V35, P253; Caldwell MW, 2001, P ROY SOC B-BIOL SCI, V268, P2397, DOI 10.1098/rspb.2001.1796; CARROLL RL, 1985, PHILOS T ROY SOC B, V309, P343, DOI 10.1098/rstb.1985.0091; Carroll RL, 1988, VERTEBRATE PALEONTOL; Deeming D. Charles, 1993, Modern Geology, V18, P423; Fox H., 1977, BIOL REPTILIA, P1; JOHNSON R, 1977, CAN J EARTH SCI, V14, P1916, DOI 10.1139/e77-162; Lin JT, 1998, ADV MICROB PHYSIOL, V39, P1; Renesto S, 2003, J VERTEBR PALEONTOL, V23, P957, DOI 10.1671/1840-21; RIEPPEL O, 1989, Philosophical Transactions of the Royal Society of London B Biological Sciences, V323, P1, DOI 10.1098/rstb.1989.0001; Rieppel O, 2003, CAN J EARTH SCI, V40, P621, DOI 10.1139/E02-067; Rieppel O., 1998, FIELDIANA GEOL, V38, P1; SANDER P M, 1989, Philosophical Transactions of the Royal Society of London B Biological Sciences, V325, P561, DOI 10.1098/rstb.1989.0103; Sato T, 2003, J VERTEBR PALEONTOL, V23, P89, DOI 10.1671/0272-4634(2003)23[89:TPANES]2.0.CO;2; SATO T, 2003, VERTEBRAT PALASIATIC, V41, P33; SUES HD, 1985, CAN J EARTH SCI, V22, P1602, DOI 10.1139/e85-169; SUES HD, 1987, ZOOL J LINN SOC-LOND, V90, P109, DOI 10.1111/j.1096-3642.1987.tb01351.x; TAYLOR MA, 1986, NATURE, V319, P179, DOI 10.1038/319179a0; Taylor Michael A., 1997, pxix, DOI 10.1016/B978-012155210-7/50002-8; Wang LT, 2001, ACTA GEOL SIN-ENGL, V75, P349	25	80	94	1	40	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					383	386		10.1038/nature03050	http://dx.doi.org/10.1038/nature03050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549103	Green Published			2022-12-28	WOS:000225161400053
J	Bhutta, ZA; Khan, I; Salat, S; Raza, F; Khan, I; Ara, H				Bhutta, ZA; Khan, I; Salat, S; Raza, F; Khan, I; Ara, H			Reducing length of stay in hospital for very low birthweight infants by involving mothers in a stepdown unit: an experience from Karachi (Pakistan)	BRITISH MEDICAL JOURNAL			English	Article							NEONATAL-MORTALITY; OUTCOMES; BABIES; CARE; NETWORK; RISK; AGE	Problem Clinical care of infants with a very low birth weight (less than 1500 g) in developing Countries can be labour intensive and is often associated with a prolonged stay in hospital. The Aga Khan University Medical Center in Karachi, Pakistan, established a neonatal intensive care unit in 1987. By 1993-4, very low birthweight infants remained in hospital for 18-21 days. Strategies for change A stepdown unit was established in September 1994, with mothers providing all basic nursing care for their infants before being discharged under supervision. Key measures for improvement We analysed neonatal outcomes for the time periods before and after the stepdown unit was created (1987-94 and 1995-2001). We compared these two time periods for survival after birth until discharge, morbidity patterns during hospitalisation, length of stay in hospital, and readmission rates to hospital in the four weeks after discharge. Effects of change of 509 consecutive, very low birthweight infants, 494 (97%) preterm and 140 (28%) weighing < 1000 g at birth), 391 (76%) survived to discharge from the hospital. The length of hospitalisation fell significantly from 1987-90, when it was 34 (SD 18) days, to 16 (SD 14) days in 1999-2001 (P < 0.001). Readmission rates to hospital did not rise, nor did adverse outcomes at 12 months of age. Lessons learnt Our results indicate that it is possible to involve mothers in the active care of their very low birthweight infants before discharge. This may translate into earlier discharge from hospital to home settings without any increase in short term complications and readmissions.	Aga Khan Univ, Neonatal Intens Care Unit, Karachi 74800, Pakistan	Aga Khan University	Bhutta, ZA (corresponding author), Aga Khan Univ, Neonatal Intens Care Unit, Karachi 74800, Pakistan.	zulfiqar.b.hutta@aku.edu						ALI MM, 1988, BANGLADESH J CHILD H, V12, P90; Arce Casas A, 2003, An Pediatr (Barc), V59, P454; Arif MA, 1999, J TROP PEDIATRICS, V45, P278, DOI 10.1093/tropej/45.5.278; Atasay B, 2003, TURKISH J PEDIATR, V45, P283; BALCOM RJ, 1993, PEDIATRICS, V91, P540; Bhutta ZA, 1999, PEDIATR PULM, V27, P305, DOI 10.1002/(SICI)1099-0496(199905)27:5<305::AID-PPUL2>3.0.CO;2-Q; BOO N Y, 1992, SMJ Singapore Medical Journal, V33, P33; Boo NY, 1996, J PAEDIATR CHILD H, V32, P439, DOI 10.1111/j.1440-1754.1996.tb00946.x; Callaghan LA, 2003, ARCH DIS CHILD-FETAL, V88, pF94, DOI 10.1136/fn.88.2.F94; COCKBURN F, 1993, LANCET, V342, P193; Cooper PA, 1997, PEDIATRICS, V99, P537, DOI 10.1542/peds.99.4.537; Darlow BA, 2003, ARCH DIS CHILD-FETAL, V88, pF23, DOI 10.1136/fn.88.1.F23; Fanaroff AA, 2003, SEMIN PERINATOL, V27, P281, DOI 10.1016/S0146-0005(03)00055-7; GRAY RH, 1991, INT J EPIDEMIOL, V20, P467, DOI 10.1093/ije/20.2.467; *GRUP COL NEOC, 2002, J PERINATOL, V22, P2; Ho JJ, 1999, J PAEDIATR CHILD H, V35, P175, DOI 10.1046/j.1440-1754.1999.t01-1-00340.x; Kaiser Jeffrey R, 2004, J Perinatol, V24, P343, DOI 10.1038/sj.jp.7211113; Kambarami R. A., 1999, Central African Journal of Medicine, V45, P56; Kulmala T, 2000, PAEDIATR PERINAT EP, V14, P219, DOI 10.1046/j.1365-3016.2000.00270.x; Lincetto O, 1998, ACTA PAEDIATR, V87, P433; Mbweza E, 1996, Int Nurs Rev, V43, P53; Merritt T Allen, 2003, Semin Neonatol, V8, P95, DOI 10.1016/S1084-2756(02)00219-1; Ravikumara M., 1996, Indian Journal of Pediatrics, V63, P785, DOI 10.1007/BF02730930; Rogowski J, 2003, PEDIATRICS, V111; Tafari N, 1974, J Trop Pediatr Environ Child Health, V20, P73; Yasmin S, 2001, B WORLD HEALTH ORGAN, V79, P608	26	59	60	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1151	1155		10.1136/bmj.329.7475.1151	http://dx.doi.org/10.1136/bmj.329.7475.1151			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539671	Green Published			2022-12-28	WOS:000225169600022
J	Decosas, J; Heap, S				Decosas, J; Heap, S			Health research: what happened to the charcoal?	LANCET			English	Editorial Material									Plan Ghana, Plan W Africa Reg Off, Accra, Ghana; Plan Int Headquarters, Woking, Surrey, England		Decosas, J (corresponding author), Plan Ghana, Plan W Africa Reg Off, PMB Osu Main PO, Accra, Ghana.	josef.decosas@plan-international.org						Marmot MG, 2004, BRIT MED J, V328, P906, DOI 10.1136/bmj.328.7445.906; Navarro V, 2004, LANCET, V363, P1321, DOI 10.1016/S0140-6736(04)16008-X; WASI P, 2004, REGIONAL HLTH F 0412; *WHO, 1978, WHO PRIM HLTH HLTH S, V1, P25; *WORLD BANK, 2000, 18 WORLD BANK; *WORLD BANK, 1994, BETT HLTH AFR; World Health Organization, 2004, WORLD REP KNOWL BETT	7	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1735	1736		10.1016/S0140-6736(04)17413-8	http://dx.doi.org/10.1016/S0140-6736(04)17413-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541432	Green Published, Bronze			2022-12-28	WOS:000225070600006
J	Broecker, W; Barker, S; Clark, E; Hajdas, I; Bonani, G; Stott, L				Broecker, W; Barker, S; Clark, E; Hajdas, I; Bonani, G; Stott, L			Ventilation of the glacial deep Pacific Ocean	SCIENCE			English	Article							CARBON-CYCLE; RADIOCARBON; C-14; HYDROGRAPHY; AGES; SEA	Measurements of the age difference between coexisting benthic and planktic foraminifera from western equatorial Pacific deep-sea cores suggest that during peak glacial time the radiocarbon age of water at 2-kilometers depth was no greater than that of today. These results make unlikely suggestions that a slowdown in deep-ocean ventilation was responsible for a sizable fraction of the increase of the ratio of carbon-14 (C-14) to carbon in the atmosphere and surface ocean during glacial time. Comparison of C-14 ages for coexisting wood and planktic foraminifera from the same site suggests that the atmosphere to surface ocean C-14 to C ratio difference was not substantially different from today's.	Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; ETH Honggerberg, CH-8093 Zurich, Switzerland; Univ So Calif, Los Angeles, CA 90089 USA	Columbia University; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Southern California	Broecker, W (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, 61 Route 9W,POB 1000, Palisades, NY 10964 USA.	broecker@ldeo.columbia.edu	Hajdas, Irka/C-6696-2011; Stephen, Barker/C-2770-2009	Hajdas, Irka/0000-0003-2373-2725; Stephen, Barker/0000-0001-7870-6431				Adkins JF, 1997, PALEOCEANOGRAPHY, V12, P337, DOI 10.1029/97PA00379; Adkins JF, 2002, SCIENCE, V298, P1769, DOI 10.1126/science.1076252; Bard E, 1988, PALEOCEANOGRAPHY, V3, P635, DOI 10.1029/PA003i006p00635; Beaufort L, 2001, SCIENCE, V293, P2440, DOI 10.1126/science.293.5539.2440; Broecker W, 1999, PALEOCEANOGRAPHY, V14, P431, DOI 10.1029/1999PA900019; Broecker WS, 1990, GLOBAL BIOGEOCHEM CY, V4, P103, DOI 10.1029/GB004i001p00103; Broecker WS, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000974; BROECKER WS, 1986, J GEOPHYS RES-OCEANS, V91, P14345, DOI 10.1029/JC091iC12p14345; Goldstein SJ, 2001, EARTH PLANET SC LETT, V193, P167, DOI 10.1016/S0012-821X(01)00494-0; GUILDERSON T, 2004, COMMUNICATION; Guilderson TP, 2004, J CLIMATE, V17, P1147, DOI 10.1175/1520-0442(2004)017<1147:SWMITS>2.0.CO;2; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Keigwin LD, 2002, J OCEANOGR, V58, P421, DOI 10.1023/A:1015830313175; Key RM, 2002, RADIOCARBON, V44, P239, DOI 10.1017/S0033822200064845; Matsumoto K, 2002, QUATERNARY SCI REV, V21, P1693, DOI 10.1016/S0277-3791(01)00142-1; Muscheler R, 2004, EARTH PLANET SC LETT, V219, P325, DOI 10.1016/S0012-821X(03)00722-2; Sikes EL, 2000, NATURE, V405, P555, DOI 10.1038/35014581	17	71	74	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1169	1172		10.1126/science.1102293	http://dx.doi.org/10.1126/science.1102293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539598				2022-12-28	WOS:000225193100044
J	Poy, MN; Eliasson, L; Krutzfeldt, J; Kuwajima, S; Ma, XS; MacDonald, PE; Pfeffer, S; Tuschl, T; Rajewsky, N; Rorsman, P; Stoffel, M				Poy, MN; Eliasson, L; Krutzfeldt, J; Kuwajima, S; Ma, XS; MacDonald, PE; Pfeffer, S; Tuschl, T; Rajewsky, N; Rorsman, P; Stoffel, M			A pancreatic islet-specific microRNA regulates insulin secretion	NATURE			English	Article							PROTEIN; IDENTIFICATION; EXOCYTOSIS; EXPRESSION; LIN-14; RNAS; V-1	MicroRNAs (miRNAs) constitute a growing class of non-coding RNAs that are thought to regulate gene expression by translational repression(1). Several miRNAs in animals exhibit tissue-specific or developmental-stage-specific expression, indicating that they could play important roles in many biological processes(2-4). To study the role of miRNAs in pancreatic endocrine cells we cloned and identified a novel, evolutionarily conserved and islet-specific miRNA (miR-375). Here we show that overexpression of miR-375 suppressed glucose-induced insulin secretion, and conversely, inhibition of endogenous miR-375 function enhanced insulin secretion. The mechanism by which secretion is modified by miR-375 is independent of changes in glucose metabolism or intracellular Ca2+-signalling but correlated with a direct effect on insulin exocytosis. Myotrophin (Mtpn) was predicted to be and validated as a target of miR-375. Inhibition of Mtpn by small interfering (si) RNA mimicked the effects of miR-375 on glucose-stimulated insulin secretion and exocytosis. Thus, miR-375 is a regulator of insulin secretion and may thereby constitute a novel pharmacological target for the treatment of diabetes.	Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Rockefeller Univ, Lab RNA Mol Biol, New York, NY 10021 USA; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden; NYU, Dept Biol Biol & Math, New York, NY 10003 USA; Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Churchill Hosp, Oxford OX3 7LJ, England	Rockefeller University; Rockefeller University; Lund University; New York University; University of Oxford	Stoffel, M (corresponding author), Rockefeller Univ, Lab Metab Dis, 1230 York Ave, New York, NY 10021 USA.	stoffel@rockefeller.edu	Pfeffer, Sebastien/A-6512-2010; Pfeffer, Sébastien/H-3212-2019; Eliasson, Lena/E-9294-2012; Rorsman, Patrik/A-4331-2016; Tuluc, Petronel/C-2527-2011; Poy, Matthew/F-6914-2017; MacDonald, Patrick/A-4154-2008	Pfeffer, Sebastien/0000-0002-8458-348X; Pfeffer, Sébastien/0000-0002-8458-348X; Eliasson, Lena/0000-0002-6467-5029; Rorsman, Patrik/0000-0001-7578-0767; Poy, Matthew/0000-0002-4904-2426; Rajewsky, Nikolaus/0000-0002-4785-4332; MacDonald, Patrick/0000-0002-5439-6288; Stoffel, Markus/0000-0003-1304-5817				Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Antonin W, 2000, J NEUROSCI, V20, P5724, DOI 10.1523/JNEUROSCI.20-15-05724.2000; Barg S, 2000, DIABETES, V49, P1500, DOI 10.2337/diabetes.49.9.1500; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Eliasson L, 2003, J GEN PHYSIOL, V121, P181, DOI 10.1085/jgp.20028707; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P497, DOI 10.1111/j.1469-7793.2000.00497.x; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; Olofsson CS, 2002, PFLUG ARCH EUR J PHY, V444, P43, DOI 10.1007/s00424-002-0781-5; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; PFEFFER S, 2003, CURRENT PROTOCOLS MO; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Taoka M, 2003, J BIOL CHEM, V278, P5864, DOI 10.1074/jbc.M211509200; Tsuboi T, 2003, J BIOL CHEM, V278, P52042, DOI 10.1074/jbc.M307800200; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yamakuni T, 2002, FEBS LETT, V530, P94, DOI 10.1016/S0014-5793(02)03431-2; Zhao C, 2001, DIABETES, V50, P361, DOI 10.2337/diabetes.50.2.361; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	30	1640	1946	2	175	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					226	230		10.1038/nature03076	http://dx.doi.org/10.1038/nature03076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538371				2022-12-28	WOS:000225020200048
J	Reithmaier, JP; Sek, G; Loffler, A; Hofmann, C; Kuhn, S; Reitzenstein, S; Keldysh, LV; Kulakovskii, VD; Reinecke, TL; Forchel, A				Reithmaier, JP; Sek, G; Loffler, A; Hofmann, C; Kuhn, S; Reitzenstein, S; Keldysh, LV; Kulakovskii, VD; Reinecke, TL; Forchel, A			Strong coupling in a single quantum dot-semiconductor microcavity system	NATURE			English	Article							INHIBITED SPONTANEOUS EMISSION; ATOMS; ELECTRODYNAMICS; PHOTONS; REGIME; DEVICE; BOXES	Cavity quantum electrodynamics, a central research field in optics and solid-state physics(1-3), addresses properties of atom-like emitters in cavities and can be divided into a weak and a strong coupling regime. For weak coupling, the spontaneous emission can be enhanced or reduced compared with its vacuum level by tuning discrete cavity modes in and out of resonance with the emitter(2,4-13). However, the most striking change of emission properties occurs when the conditions for strong coupling are fulfilled. In this case there is a change from the usual irreversible spontaneous emission to a reversible exchange of energy between the emitter and the cavity mode. This coherent coupling may provide a basis for future applications in quantum information processing or schemes for coherent control. Until now, strong coupling of individual two-level systems has been observed only for atoms in large cavities(14-17). Here we report the observation of strong coupling of a single two-level solid-state system with a photon, as realized by a single quantum dot in a semiconductor microcavity. The strong coupling is manifest in photoluminescence data that display anti-crossings between the quantum dot exciton and cavity-mode dispersion relations, characterized by a vacuum Rabi splitting of about 140 mueV.	Univ Wurzburg, D-97074 Wurzburg, Germany; Russian Acad Sci, PN Lebedev Phys Inst, Moscow 119991, Russia; Russian Acad Sci, Inst Solid State Phys, Chernogolovka 142432, Russia; USN, Res Lab, Washington, DC 20375 USA; Wroclaw Tech Univ, Inst Phys, PL-50370 Wroclaw, Poland	University of Wurzburg; Russian Academy of Sciences; Russian Academy of Science Lebedev Physical Institute; Russian Academy of Sciences; Osipyan Institute of Solid State Physics RAS; United States Department of Defense; United States Navy; Naval Research Laboratory; Wroclaw University of Science & Technology	Forchel, A (corresponding author), Univ Wurzburg, D-97074 Wurzburg, Germany.	alfred.forchel@physik.uni-wuerzburg.de	Reithmaier, Johann P/G-8171-2012; Kulakovskii, Vladimir/AAM-9718-2020; Kulakovskii, Vladimir D/B-4282-2018; Reitzenstein, Stephan/AAG-5399-2019; Reitzenstein, Stephan/A-9184-2014	Reithmaier, Johann P/0000-0002-1974-8292; Reitzenstein, Stephan/0000-0002-1381-9838; Forchel, Alfred/0000-0002-9377-9935				Andreani LC, 1999, PHYS REV B, V60, P13276, DOI 10.1103/PhysRevB.60.13276; Bayer M, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.041308; Bayer M, 2001, PHYS REV LETT, V86, P3168, DOI 10.1103/PhysRevLett.86.3168; GABRIELSE G, 1985, PHYS REV LETT, V55, P67, DOI 10.1103/PhysRevLett.55.67; Gerard JM, 2001, PHYSICA E, V9, P131, DOI 10.1016/S1386-9477(00)00187-9; Gerard JM, 1998, PHYS REV LETT, V81, P1110, DOI 10.1103/PhysRevLett.81.1110; GOY P, 1983, PHYS REV LETT, V50, P1903, DOI 10.1103/PhysRevLett.50.1903; Guest JR, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.241310; Hood CJ, 1998, PHYS REV LETT, V80, P4157, DOI 10.1103/PhysRevLett.80.4157; HULET RG, 1985, PHYS REV LETT, V55, P2137, DOI 10.1103/PhysRevLett.55.2137; Imamoglu A, 1999, PHYS REV LETT, V83, P4204, DOI 10.1103/PhysRevLett.83.4204; Kiraz A, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.032305; KLEPPNER D, 1981, PHYS REV LETT, V47, P233, DOI 10.1103/PhysRevLett.47.233; Li XQ, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.205301; Mabuchi H, 2002, SCIENCE, V298, P1372, DOI 10.1126/science.1078446; McKeever J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.133602; McKeever J, 2003, NATURE, V425, P268, DOI 10.1038/nature01974; Michler P, 2000, SCIENCE, V290, P2282, DOI 10.1126/science.290.5500.2282; Pelton M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233602; PURCELL EM, 1946, PHYS REV, V69, P681; Rudin S, 1999, PHYS REV B, V59, P10227, DOI 10.1103/PhysRevB.59.10227; Shimizu Y, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.233001; Solomon GS, 2001, PHYS REV LETT, V86, P3903, DOI 10.1103/PhysRevLett.86.3903; Stievater TH, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.133603; Vahala KJ, 2003, NATURE, V424, P839, DOI 10.1038/nature01939; YAMAMOTO Y, 1993, PHYS TODAY, V46, P66, DOI 10.1063/1.881356	28	1595	1614	11	493	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					197	200		10.1038/nature02969	http://dx.doi.org/10.1038/nature02969			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538362				2022-12-28	WOS:000225020200039
J	Francis, CK				Francis, CK			Professionalism and the medical student	LANCET			English	Editorial Material									New York Acad Med, Off Hlth Dispar, New York, NY 10029 USA	New York Academy of Medicine	Francis, CK (corresponding author), New York Acad Med, Off Hlth Dispar, New York, NY 10029 USA.	cfrancis@nyam.org						Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012	1	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1647	1648		10.1016/S0140-6736(04)17370-4	http://dx.doi.org/10.1016/S0140-6736(04)17370-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530608				2022-12-28	WOS:000224921600007
J	Kotrikova, B; Muhling, J; Steiner, HH; Hahnel, S; Krempien, R; Hassfeld, S				Kotrikova, B; Muhling, J; Steiner, HH; Hahnel, S; Krempien, R; Hassfeld, S			Operative correction of conjoined twins fused at head	LANCET			English	Editorial Material									Univ Heidelberg, Dept Oral & Maxillofacial Surg, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neuroradiol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Clin Radiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kotrikova, B (corresponding author), Univ Heidelberg, Dept Oral & Maxillofacial Surg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	bibiana.kotrikova@med.uni-heidelberg.de							0	0	0	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1958	1958		10.1016/S0140-6736(04)17479-5	http://dx.doi.org/10.1016/S0140-6736(04)17479-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567012				2022-12-28	WOS:000225327000034
J	Wang, YQ; Dohlman, HG				Wang, YQ; Dohlman, HG			Pheromone signaling mechanisms in yeast: A prototypical sex machine	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE REQUIRES; G-PROTEIN; GLOBAL ANALYSIS; FACTOR RECEPTOR; GAMMA-SUBUNITS; UBIQUITINATION; TRANSDUCTION; KINASES; GENOME	The actions of many extracellular stimuli are elicited by complexes of cell surface receptors, heterotrimeric guanine nucleotide-binding proteins (G proteins), and mitogen-activated protein (MAP) kinase complexes. Analysis of haploid yeast cells and their response to peptide mating pheromones has produced important advances in our understanding of G,protein and MAP kinase signaling mechanisms. Many of the components, their interrelationships, and-their regulators were first identified in yeast. Current analysis of the pheromone response pathway (see the Connections Maps at Science's Signal Transduction Knowledge Environment) will benefit from new and powerful genomic, proteomic, and computational approaches that will likely reveal additional general principles that are applicable to more complex organisms.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.	hdohlman@med.unc.edu		Dohlman, Henrik/0000-0003-2443-0729				CHOI KY, 1994, CELL, V78, P499; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHLMAN HG, 2004, SCI STKE         NOV; Endy D, 2001, NATURE, V409, P391, DOI 10.1038/35053181; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Phizicky E, 2003, NATURE, V422, P208, DOI 10.1038/nature01512; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Truckses DM, 2004, SCIENCE, V306, P1509, DOI 10.1126/science.1104677; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Zeitlinger J, 2003, CELL, V113, P395, DOI 10.1016/S0092-8674(03)00301-5; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	19	73	76	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1508	1509		10.1126/science.1104568	http://dx.doi.org/10.1126/science.1104568			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567849				2022-12-28	WOS:000225442700043
J	Bengtson, S; Budd, G				Bengtson, S; Budd, G			Comment on "Small bilaterian fossils from 40 to 55 million years before the Cambrian"	SCIENCE			English	Editorial Material							EMBRYOS		Swedish Museum Nat Hist, Dept Palaeozool, SE-10405 Stockholm, Sweden; Dept Earth Sci, SE-75236 Uppsala, Sweden	Swedish Museum of Natural History	Bengtson, S (corresponding author), Swedish Museum Nat Hist, Dept Palaeozool, Box 50007, SE-10405 Stockholm, Sweden.	stefan.bengtson@nrm.se		Bengtson, Stefan/0000-0003-0206-5791				Bengston S., 2003, P289; BENGTSON S, 1976, Lethaia, V9, P185, DOI 10.1111/j.1502-3931.1976.tb00966.x; Bengtson S, 1997, SCIENCE, V277, P1645, DOI 10.1126/science.277.5332.1645; Chen JY, 2004, SCIENCE, V305, P218, DOI 10.1126/science.1099213; Xiao SH, 2000, P NATL ACAD SCI USA, V97, P13684, DOI 10.1073/pnas.250491697; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Yue Z., 1999, LETHAIA, V32, P181, DOI DOI 10.1111/J.1502-3931.1999.TB00538.X	7	67	69	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550644				2022-12-28	WOS:000225301600021
J	Dave, SS; Wright, G; Tan, B; Rosenwald, A; Gascoyne, RD; Chan, WC; Fisher, RI; Braziel, RM; Rimsza, LM; Grogan, TM; Miller, TP; LeBlanc, M; Greiner, TC; Weisenburger, DD; Lynch, JC; Vose, J; Armitage, JO; Smeland, EB; Kvaloy, S; Holte, H; Delabie, J; Connors, JM; Lansdorp, PM; Ouyang, Q; Lister, TA; Davies, AJ; Norton, AJ; Muller-Hermelink, HK; Ott, G; Campo, E; Montserrat, E; Wilson, WH; Jaffe, ES; Simon, R; Yang, LM; Powell, J; Zhao, H; Goldschmidt, N; Chiorazzi, M; Staudt, LM				Dave, SS; Wright, G; Tan, B; Rosenwald, A; Gascoyne, RD; Chan, WC; Fisher, RI; Braziel, RM; Rimsza, LM; Grogan, TM; Miller, TP; LeBlanc, M; Greiner, TC; Weisenburger, DD; Lynch, JC; Vose, J; Armitage, JO; Smeland, EB; Kvaloy, S; Holte, H; Delabie, J; Connors, JM; Lansdorp, PM; Ouyang, Q; Lister, TA; Davies, AJ; Norton, AJ; Muller-Hermelink, HK; Ott, G; Campo, E; Montserrat, E; Wilson, WH; Jaffe, ES; Simon, R; Yang, LM; Powell, J; Zhao, H; Goldschmidt, N; Chiorazzi, M; Staudt, LM			Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-CD20 MONOCLONAL-ANTIBODY; NON-HODGKINS-LYMPHOMAS; LOW-GRADE; EXPRESSION PATTERNS; PROGNOSTIC-FACTORS; DENDRITIC CELLS; RITUXIMAB; CLONING; CHEMOTHERAPY; VACCINATION	Background: Patients with follicular lymphoma may survive for periods of less than 1 year to more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy specimens obtained at diagnosis to develop a molecular predictor of the length of survival. Methods: Gene-expression profiling was performed on 191 biopsy specimens obtained from patients with untreated follicular lymphoma. Supervised methods were used to discover expression patterns associated with the length of survival in a training set of 95 specimens. A molecular predictor of survival was constructed from these genes and validated in an independent test set of 96 specimens. Results: Individual genes that predicted the length of survival were grouped into gene-expression signatures on the basis of their expression in the training set, and two such signatures were used to construct a survival predictor. The two signatures allowed patients with specimens in the test set to be divided into four quartiles with widely disparate median lengths of survival (13.6, 11.1, 10.8, and 3.9 years), independently of clinical prognostic variables. Flow cytometry showed that these signatures reflected gene expression by nonmalignant tumor-infiltrating immune cells. Conclusions: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.	NCI, NIH, Bethesda, MD 20892 USA; Ctr Informat Technol, Bethesda, MD USA; NHLBI, Bethesda, MD 20892 USA; British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ Nebraska, Med Ctr, Omaha, NE USA; SW Oncol Grp, San Antonio, TX USA; Univ Rochester, Sch Med, Rochester, NY USA; Oregon Hlth & Sci Univ, Portland, OR USA; Univ Arizona, Ctr Canc, Tucson, AZ USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Norwegian Radium Hosp, Oslo, Norway; St Bartholomews Hosp, Canc Res UK, London, England; Univ Wurzburg, Wurzburg, Germany; Univ Barcelona, Barcelona, Spain	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); British Columbia Cancer Agency; University of Nebraska System; University of Nebraska Medical Center; Southwest Oncology Group; University of Rochester; Oregon Health & Science University; University of Arizona; Fred Hutchinson Cancer Center; University of Oslo; Cancer Research UK; University of London; Queen Mary University London; University of Wurzburg; University of Barcelona	Staudt, LM (corresponding author), NCI, NIH, Bldg 10,Rm 4N114, Bethesda, MD 20892 USA.	lstaudt@mail.nih.gov	Wright, George W/M-1660-2017; Connors, Joseph/AAF-5284-2019; Campo, Elias/AAC-5593-2019; Smeland, Erlend/AAO-3214-2020; Jaffe, Elaine/G-8981-2014; Holte, Harald/AAO-5647-2020; Gascoyne, Randy D/A-6009-2013; Staudt, Louis/AAC-5324-2019	Connors, Joseph/0000-0002-1361-7531; Campo, Elias/0000-0001-9850-9793; Gascoyne, Randy D/0000-0002-2610-5690; Davies, Andrew/0000-0002-7517-6938; Delabie, Jan/0000-0001-5023-0689; Lansdorp, Peter/0000-0001-7435-1071	NCI NIH HHS [UO1-CA84967] Funding Source: Medline; CENTER FOR INFORMATION TECHNOLOGY [Z01CT000260, ZIACT000260] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U01CA084967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CENTER FOR INFORMATION TECHNOLOGY(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Center for Information Technology (CIT)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Czuczman MS, 1999, J CLIN ONCOL, V17, P268, DOI 10.1200/JCO.1999.17.1.268; Decaudin D, 1999, J CLIN ONCOL, V17, P2499, DOI 10.1200/JCO.1999.17.8.2499; DRAPNER NS, 1966, APPL REGRESSION ANAL; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Federico M, 2000, BLOOD, V95, P783; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; Horning SJ, 2000, ANN ONCOL, V11, P23, DOI 10.1023/A:1008385202953; JOHNSON PWM, 1995, J CLIN ONCOL, V13, P140, DOI 10.1200/JCO.1995.13.1.140; KWAK LW, 1992, NEW ENGL J MED, V327, P1209, DOI 10.1056/NEJM199210223271705; LOPEZGUILLERMO A, 1994, J CLIN ONCOL, V12, P1343, DOI 10.1200/JCO.1994.12.7.1343; Lossos IS, 2003, SEMIN CANCER BIOL, V13, P191, DOI 10.1016/S1044-579X(03)00015-4; Maloney DG, 1997, BLOOD, V90, P2188; Montoto S, 2002, ANN ONCOL, V13, P523, DOI 10.1093/annonc/mdf119; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Ni DTN, 2003, J BIOL CHEM, V278, P38980, DOI 10.1074/jbc.M305930200; Ransohoff DF, 2004, NAT REV CANCER, V4, P309, DOI 10.1038/nrc1322; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Shaffer AL, 2001, IMMUNITY, V15, P375, DOI 10.1016/S1074-7613(01)00194-7; Solal-Celigny P, 2004, BLOOD, V104, P1258, DOI 10.1182/blood-2003-12-4434; Sui LL, 2003, BIOCHEM BIOPH RES CO, V304, P393, DOI 10.1016/S0006-291X(03)00601-6; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076	30	1043	1077	2	36	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2159	2169		10.1056/NEJMoa041869	http://dx.doi.org/10.1056/NEJMoa041869			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548776				2022-12-28	WOS:000225160600006
J	Ioannidis, JPA; Evans, SJW; Gotzsche, PC; O'Neill, RT; Altman, DG; Schulz, K; Moher, D				Ioannidis, JPA; Evans, SJW; Gotzsche, PC; O'Neill, RT; Altman, DG; Schulz, K; Moher, D		CONSORT Grp	Better reporting of harms in randomized trials: An extension of the CONSORT statement	ANNALS OF INTERNAL MEDICINE			English	Article							ADVERSE DRUG-REACTIONS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CLINICAL-TRIALS; SAFETY DATA; OUTCOMES; QUALITY; RHEUMATOLOGY; DEFINITIONS; ARTHRITIS; NEED	In response to overwhelming evidence and the consequences of poor-quality reporting of randomized, controlled trials (RCTs), many medical journals and editorial groups have now endorsed the CONSORT (Consolidated Standards of Reporting Trials) statement, a 22-item checklist and flow diagram. Because CONSORT primarily aimed at improving the quality of reporting of efficacy, only 1 checklist item specifically addressed the reporting of safety. Considerable evidence suggests that reporting of harms-related data from RCTs also needs improvement. Members of the CONSORT Group, including journal editors and scientists, met in Montebello, Quebec, Canada, in May 2003 to address this problem. The result is the following document: the standard CONSORT checklist with 10 new recommendations about reporting harms-related issues, accompanying explanation, and examples to highlight specific aspects of proper reporting. We hope that this document, in conjunction with other CONSORT-related materials (www.consort-statement.org), will help authors improve their reporting of harms-related data from RCTs. Better reporting will help readers critically appraise and interpret trial results. Journals can support this goal by revising Instructions to Authors so that they refer authors to this document.	Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada; Univ Ioannina, Sch Med, GR-45110 Ioannina, Greece; London Sch Hyg & Trop Med, London WC1, England; Nord Cochrane Ctr, Copenhagen, Denmark; US FDA, Rockville, MD 20857 USA; Canc Res UK, Natl Hlth Serv, Ctr Stat Med, Oxford, England; Family Hlth Int, Res Triangle Pk, NC 27709 USA; Univ Ioannina, Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ioannina; University of London; London School of Hygiene & Tropical Medicine; US Food & Drug Administration (FDA); Cancer Research UK; NHS Blood & Transplant (NHSBT); University of Oxford; Foundation for Research & Technology - Hellas (FORTH); University of Ioannina	Moher, D (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	dmoher@uottawa.ca	Ioannidis, John P. A./G-9836-2011	Moher, David/0000-0003-2434-4206; Evans, Stephen/0000-0002-1474-2596				Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; [Anonymous], 1999, COMMON TOXICITY CRIT; Bonhoeffer J, 2002, VACCINE, V21, P298, DOI 10.1016/S0264-410X(02)00449-8; CASTLE W, 1993, BRIT MED J, V306, P1034, DOI 10.1136/bmj.306.6884.1034; Cato A, 1987, Drug Inf J, V21, P3; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Chuang-Stein C, 1998, CONTROL CLIN TRIALS, V19, P167, DOI 10.1016/S0197-2456(97)00123-2; Clarke M, 2002, JAMA-J AM MED ASSOC, V287, P2799, DOI 10.1001/jama.287.21.2799; CORSO DM, 1992, ANN PHARMACOTHER, V26, P890, DOI 10.1177/106002809202600704; Cuervo LG, 2003, BMJ-BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Derry S, 2001, BMC Med Res Methodol, V1, P7, DOI 10.1186/1471-2288-1-7; Division of AIDS, 1992, DIV AIDS GRAD SEV AD; Docherty M, 1999, BRIT MED J, V318, P1224; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Edwards JE, 1999, J PAIN SYMPTOM MANAG, V18, P427, DOI 10.1016/S0885-3924(99)00093-7; Gotzsche PC, 2000, BRIT MED J, V320, P1058, DOI 10.1136/bmj.320.7241.1058; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Hayashi K, 1996, CONTROL CLIN TRIALS, V17, P99, DOI 10.1016/S0197-2456(96)80001-8; Ioannidis JPA, 2002, DRUG SAFETY, V25, P77, DOI 10.2165/00002018-200225020-00002; Ioannidis JPA, 2002, J CLIN EPIDEMIOL, V55, P619, DOI 10.1016/S0895-4356(02)00393-1; Ioannidis JPA, 2001, JAMA-J AM MED ASSOC, V285, P437, DOI 10.1001/jama.285.4.437; Ioannidis JPA, 1998, LANCET, V352, P1752, DOI 10.1016/S0140-6736(05)79825-1; Jovanovic BD, 1997, ANN EMERG MED, V30, P301, DOI 10.1016/S0196-0644(97)70165-3; Kohl KS, 2003, PHARMACOEPIDEM DR S, V12, P335, DOI 10.1002/pds.851; LESKO SM, 1995, JAMA-J AM MED ASSOC, V273, P929, DOI 10.1001/jama.273.12.929; Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3; Marshall M, 2000, BRIT J PSYCHIAT, V176, P249, DOI 10.1192/bjp.176.3.249; Martin RCG, 2002, ANN SURG, V235, P803, DOI 10.1097/00000658-200206000-00007; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Mucklow JC, 2001, LANCET, V357, P1384, DOI 10.1016/S0140-6736(00)04619-5; MYERS MG, 1987, CLIN PHARMACOL THER, V42, P250, DOI 10.1038/clpt.1987.142; O'Neill RT, 2002, STAT MED, V21, P2831, DOI 10.1002/sim.1287; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; PELOSO PM, 1995, J RHEUMATOL, V22, P989; Rochon PA, 1999, J CLIN EPIDEMIOL, V52, P113, DOI 10.1016/S0895-4356(98)00149-8; Roehrborn CG, 2002, UROLOGY, V59, P811, DOI 10.1016/S0090-4295(02)01649-7; Sanders C, 1998, BRIT MED J, V317, P1191, DOI 10.1136/bmj.317.7167.1191; SMITH A, 1980, REPORT STAT PHARM IN; Stephens M. D., 1998, DETECTION NEW ADVERS; Thall PF, 2001, STAT MED, V20, P1023, DOI 10.1002/sim.717; Trotti A, 2004, J CLIN ONCOL, V22, P19, DOI 10.1200/JCO.2004.10.911; Vitiello B, 2003, J AM ACAD CHILD PSY, V42, P634, DOI 10.1097/01.CHI.0000046840.90931.36; Wahlbeck K, 2001, PSYCHOPHARMACOLOGY, V155, P230, DOI 10.1007/s002130100711; WALLIN J, 1981, CLIN THER, V3, P450; Whitehead J, 1999, STAT MED, V18, P3425, DOI 10.1002/(SICI)1097-0258(19991230)18:24<3425::AID-SIM369>3.0.CO;2-D; Woodworth TG, 2001, J RHEUMATOL, V28, P1163; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	49	1001	1024	3	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					781	788		10.7326/0003-4819-141-10-200411160-00009	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545678				2022-12-28	WOS:000225206900005
J	Adkins, JF; Pasquero, C				Adkins, JF; Pasquero, C			Deep ocean overturning - Then and now	SCIENCE			English	Editorial Material							THERMOHALINE CIRCULATION; LAST DEGLACIATION; RADIOCARBON AGE; CARBON-CYCLE; ENERGETICS		CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA	California Institute of Technology	Adkins, JF (corresponding author), CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA.	jess@gps.caltech.edu	Adkins, Jess/GYI-8778-2022					Adkins JF, 2002, SCIENCE, V298, P1769, DOI 10.1126/science.1076252; Broecker W, 2004, SCIENCE, V306, P1169, DOI 10.1126/science.1102293; Huang RX, 1999, J PHYS OCEANOGR, V29, P727, DOI 10.1175/1520-0485(1999)029<0727:MAEOTO>2.0.CO;2; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Hughen KA, 2000, SCIENCE, V290, P1951, DOI 10.1126/science.290.5498.1951; KEIGWIN L, IN PRESS PALEOCEANOG; Munk W, 1998, DEEP-SEA RES PT I, V45, P1977, DOI 10.1016/S0967-0637(98)00070-3; Muscheler R, 2004, EARTH PLANET SC LETT, V219, P325, DOI 10.1016/S0012-821X(03)00722-2; SHACKLETON NJ, 1988, NATURE, V335, P708, DOI 10.1038/335708a0; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; TOGGWEILER JR, 1995, DEEP-SEA RES PT I, V42, P477, DOI 10.1016/0967-0637(95)00012-U; Wunsch C, 2004, ANNU REV FLUID MECH, V36, P281, DOI 10.1146/annurev.fluid.36.050802.122121	12	5	7	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1143	1144		10.1126/science.1105531	http://dx.doi.org/10.1126/science.1105531			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539591				2022-12-28	WOS:000225193100034
J	Pham, CG; Bubici, C; Zazzeroni, F; Papa, S; Jones, J; Alvarez, K; Jayawardena, S; De Smaele, E; Cong, R; Beaumont, C; Torti, FM; Torti, SV; Franzoso, G				Pham, CG; Bubici, C; Zazzeroni, F; Papa, S; Jones, J; Alvarez, K; Jayawardena, S; De Smaele, E; Cong, R; Beaumont, C; Torti, FM; Torti, SV; Franzoso, G			Ferritin heavy chain upregulation by NF-kappa B inhibits TNF alpha-induced apoptosis by suppressing reactive oxygen species	CELL			English	Article							OXIDATIVE STRESS; SIGNAL-TRANSDUCTION; CELL-DEATH; JNK; ACTIVATION; IRON; TARGET; ROS; GADD45-BETA; INDUCTION	During inflammation, NF-kappaB transcription factors antagonize apoptosis induced by tumor necrosis factor (TNF)alpha. This antiapoptotic activity of NF-kappaB involves suppressing the accumulation of reactive oxygen species (ROS) and controlling the activation of the c-Jun N-terminal kinase (JNK) cascade. However, the mechanism(s) by which NF-kappaB inhibits ROS accumulation is unclear. We identify ferritin heavy chain (FHC)-the primary iron storage factor-as an essential mediator of the antioxidant and protective activities of NF-kappaB. FHC is induced downstream of NF-kappaB and is required to prevent sustained JNK activation and, thereby, apoptosis triggered by TNFalpha. FHC-mediated inhibition of JNK signaling depends on suppressing ROS accumulation and is achieved through iron sequestration. These findings establish a basis for the NF-kappaB-mediated control of ROS induction and identify a mechanism by which NF-kappaB suppresses proapoptotic JNK signaling. Our results suggest modulation of FHC or, more broadly, of iron metabolism as a potential approach for anti-inflammatory therapy.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; CHU Bichat, Serv Hematol & Immunol Biol, INSERM, U409, Paris, France; Wake Forest Univ, Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	University of Chicago; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Wake Forest University; Wake Forest University	Franzoso, G (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	gfranzos@midway.uchicago.edu	De Smaele, Enrico/C-1124-2013; Papa, Salvatore/J-9413-2012; Franzoso, Guido/GRR-8628-2022	De Smaele, Enrico/0000-0003-4524-4423; Papa, Salvatore/0000-0002-8369-6538; Zazzeroni, Francesca/0000-0002-4474-3274; Bubici, Concetta/0000-0002-8074-4661; Franzoso, Guido/0000-0002-0778-988X	NATIONAL CANCER INSTITUTE [R01CA084040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042412, R37DK042412] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA84040] Funding Source: Medline; NHLBI NIH HHS [HL07237] Funding Source: Medline; NIDDK NIH HHS [DK42412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bernard D, 2001, CANCER RES, V61, P2656; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cozzi A, 2003, FEBS LETT, V537, P187, DOI 10.1016/S0014-5793(03)00114-5; Cozzi A, 2004, BLOOD, V103, P2377, DOI 10.1182/blood-2003-06-1842; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Ferreira C, 2000, J BIOL CHEM, V275, P3021, DOI 10.1074/jbc.275.5.3021; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guo Z, 2003, J BIOL CHEM, V278, P23570, DOI 10.1074/jbc.M303431200; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Kakhlon O, 2001, BLOOD, V97, P2863, DOI 10.1182/blood.V97.9.2863; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Matsuzawa A, 2002, ANTIOXID REDOX SIGN, V4, P415, DOI 10.1089/15230860260196218; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Smirnov IM, 1999, AM J PHYSIOL-LUNG C, V277, pL257, DOI 10.1152/ajplung.1999.277.2.L257; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Vulcano M, 2000, INT J IMMUNOPHARMACO, V22, P635, DOI 10.1016/S0192-0561(00)00026-6; Weiss G, 2002, BLOOD REV, V16, P87, DOI 10.1054/blre.2002.0193; Yang DC, 2002, ANTICANCER RES, V22, P1513; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	39	501	521	0	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					529	542		10.1016/j.cell.2004.10.017	http://dx.doi.org/10.1016/j.cell.2004.10.017			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537542	Bronze			2022-12-28	WOS:000225183200011
J	Gregory, RI; Yan, KP; Amuthan, G; Chendrimada, T; Doratotaj, B; Cooch, N; Shiekhattar, R				Gregory, RI; Yan, KP; Amuthan, G; Chendrimada, T; Doratotaj, B; Cooch, N; Shiekhattar, R			The Microprocessor complex mediates the genesis of microRNAs	NATURE			English	Article							RNASE-III; EXPRESSION; BRCA1	MicroRNAs (miRNAs) are a growing family of small non-protein-coding regulatory genes that regulate the expression of homologous target-gene transcripts. They have been implicated in the control of cell death and proliferation in flies(1,2), haematopoietic lineage differentiation in mammals(3), neuronal patterning in nematodes(4) and leaf and flower development in plants(5-8). miRNAs are processed by the RNA-mediated interference machinery. Drosha is an RNase III enzyme that was recently implicated in miRNA processing. Here we show that human Drosha is a component of two multi-protein complexes. The larger complex contains multiple classes of RNA-associated proteins including RNA helicases, proteins that bind double-stranded RNA, novel heterogeneous nuclear ribonucleoproteins and the Ewing's sarcoma family of proteins. The smaller complex is composed of Drosha and the double-stranded-RNA-binding protein, DGCR8, the product of a gene deleted in DiGeorge syndrome. In vivo knock-down and in vitro reconstitution studies revealed that both components of this smaller complex, termed Microprocessor, are necessary and sufficient in mediating the genesis of miRNAs from the primary miRNA transcript.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.upenn.edu						Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen XM, 2004, SCIENCE, V303, P2022, DOI 10.1126/science.1088060; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Shiohama A, 2003, BIOCHEM BIOPH RES CO, V304, P184, DOI 10.1016/S0006-291X(03)00554-0; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yamagishi H, 2003, TRENDS MOL MED, V9, P383, DOI 10.1016/S1471-4914(03)00141-2; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100	23	1971	2110	3	188	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					235	240		10.1038/nature03120	http://dx.doi.org/10.1038/nature03120			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15531877				2022-12-28	WOS:000225020200050
J	Groopman, J				Groopman, J			Doctors and patients: A great case	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Groopman, J (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2043	2045		10.1056/NEJMp048032	http://dx.doi.org/10.1056/NEJMp048032			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537903				2022-12-28	WOS:000225007200004
J	Wyithe, JSB; Loeb, A				Wyithe, JSB; Loeb, A			A characteristic size of similar to 10 Mpc for the ionized bubbles at the end of cosmic reionization	NATURE			English	Article							GAMMA-RAY BURSTS; HYDROGEN; QUASARS; FLUCTUATIONS; EVOLUTION; REDSHIFT	The first galaxies to appear in the Universe at redshifts z>20 created ionized bubbles in the intergalactic medium of neutral hydrogen left over from the Big Bang. The ionized bubbles grew with time, surrounding clusters of dwarf galaxies(1,2) and eventually overlapped quickly throughout the Universe over a narrow redshift interval near zapproximate to6. This event signalled the end of the reionization epoch when the Universe was a billion years old. Measuring the size distribution of the bubbles at their final overlap phase is a focus of forthcoming programmes to observe highly redshifted radio emission from atomic hydrogen. Here we show that the combined constraints of cosmic variance and light travel time imply an observed bubble size at the end of the overlap epoch of similar to10 physical Mpc, and a scatter in the observed redshift of overlap along different lines-of-sight of similar to0.15. This scatter is consistent with observational constraints from recent spectroscopic data on the farthest known quasars. This implies that future radio experiments should be tuned to a characteristic angular scale of 0.5 degrees and have a minimum frequency bandwidth of similar to8 MHz for an optimal detection of 21-cm flux fluctuations near the end of reionization.	Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia; Harvard Univ, Dept Astron, Cambridge, MA 02138 USA	University of Melbourne; Harvard University	Wyithe, JSB (corresponding author), Univ Melbourne, Sch Phys, Parkville, Vic 3010, Australia.	swyithe@isis.ph.unimelb.edu.au; aloeb@cfa.harvard.edu		Wyithe, Stuart/0000-0001-7956-9758				Barkana R, 2004, ASTROPHYS J, V609, P474, DOI 10.1086/421079; Barkana R, 2004, ASTROPHYS J, V601, P64, DOI 10.1086/380435; BOND JR, 1991, ASTROPHYS J, V379, P440, DOI 10.1086/170520; Bromm V, 2002, ASTROPHYS J, V575, P111, DOI 10.1086/341189; FAN X, 2004, IN PRESS ASTRON J; Fan XH, 2002, ASTRON J, V123, P1247, DOI 10.1086/339030; FURLANETTO SR, 2004, UNPUB ASTROPHYS J; Gnedin NY, 2000, ASTROPHYS J, V535, P530, DOI 10.1086/308876; GUNN JE, 1965, ASTROPHYS J, V142, P1633, DOI 10.1086/148444; MESINGER A, 2004, IN PRESS ASTROPHYS J; Miralda-Escude J, 2003, ASTROPHYS J, V597, P66, DOI 10.1086/378286; MORALES MF, 2003, IN PRESS ASTROPHYS J; Pentericci L, 2002, ASTRON J, V123, P2151, DOI 10.1086/340077; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; White RL, 2003, ASTRON J, V126, P1, DOI 10.1086/375547; Wyithe JSB, 2004, NATURE, V427, P815, DOI 10.1038/nature02336; Yoshida N, 2003, ASTROPHYS J, V598, P73, DOI 10.1086/378852; ZALDARRIAGA M, 2003, UNPUB ASTROPHYS J	18	89	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					194	196		10.1038/nature03033	http://dx.doi.org/10.1038/nature03033			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538361	Green Submitted			2022-12-28	WOS:000225020200038
J	Ship, AN				Ship, AN			A 46-year-old man with anxiety and nightmares after a motor vehicle collision, 2 years later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Stein MB, 2002, JAMA-J AM MED ASSOC, V288, P1513, DOI 10.1001/jama.288.12.1513	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2262	2262		10.1001/jama.292.18.2262	http://dx.doi.org/10.1001/jama.292.18.2262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536114				2022-12-28	WOS:000225070000028
J	Gahrton, G				Gahrton, G			New therapeutic targets in multiple myeloma	LANCET			English	Editorial Material							STEM-CELL TRANSPLANTATION; MARROW TRANSPLANTATION; BONE-MARROW; LEUKEMIA; CHEMOTHERAPY		Karolinska Inst, Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden	Karolinska Institutet	Gahrton, G (corresponding author), Karolinska Inst, Huddinge Hosp, Dept Med, S-14186 Huddinge, Sweden.	Gosta.Gahrton@medhs.ki.se						Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Corradini P, 2003, BLOOD, V102, P1927, DOI 10.1182/blood-2003-01-0189; Gahrton G, 2001, BRIT J HAEMATOL, V113, P209, DOI 10.1046/j.1365-2141.2001.02726.x; Goldman JM, 2004, EXP HEMATOL, V32, P2, DOI 10.1016/j.exphem.2003.10.001; Guven H, 2003, LEUKEMIA, V17, P1973, DOI 10.1038/sj.leu.2403083; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Marijt WAE, 2003, P NATL ACAD SCI USA, V100, P2742, DOI 10.1073/pnas.0530192100; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Sirohi B, 2004, LANCET, V363, P875, DOI 10.1016/S0140-6736(04)15736-X; ABOUT MMRC	12	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1648	1649		10.1016/S0140-6736(04)17371-6	http://dx.doi.org/10.1016/S0140-6736(04)17371-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530610				2022-12-28	WOS:000224921600008
J	Daubin, V; Voran, NA				Daubin, V; Voran, NA			Comment on "The origins of genome complexity"	SCIENCE			English	Editorial Material							BACTERIAL GENOMES/; ESCHERICHIA-COLI; SUBSTITUTIONS; EVOLUTION; SEQUENCE; BUCHNERA; PROCHLOROCOCCUS; PSEUDOGENES; NUMBERS; APHIDS		Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Ecol & Evolutionary Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Daubin, V (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA.	daubin@email.arizona.edu; mnoran@email.arizona.cdu		Daubin, Vincent/0000-0001-8269-9430				Abbot P, 2002, MOL ECOL, V11, P2649, DOI 10.1046/j.1365-294X.2002.01646.x; Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Andersson JO, 2001, MOL BIOL EVOL, V18, P829, DOI 10.1093/oxfordjournals.molbev.a003864; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; Boyd EF, 1996, APPL ENVIRON MICROB, V62, P804, DOI 10.1128/AEM.62.3.804-808.1996; Comeron JM, 1995, J MOL EVOL, V41, P1152, DOI 10.1007/BF00173196; Dobrindt U, 2001, CURR OPIN MICROBIOL, V4, P550, DOI 10.1016/S1369-5274(00)00250-2; Drake JW, 1998, GENETICS, V148, P1667; Funk DJ, 2001, GENETICS, V157, P477; Ikeda H, 2003, NAT BIOTECHNOL, V21, P526, DOI 10.1038/nbt820; Konstantinidis KT, 2004, P NATL ACAD SCI USA, V101, P3160, DOI 10.1073/pnas.0308653100; Lawrence JG, 2001, TRENDS MICROBIOL, V9, P535, DOI 10.1016/S0966-842X(01)02198-9; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch M, 2003, SCIENCE, V302, P1401, DOI 10.1126/science.1089370; Mira A, 2001, TRENDS GENET, V17, P589, DOI 10.1016/S0168-9525(01)02447-7; Moran NA, 2002, CELL, V108, P583, DOI 10.1016/S0092-8674(02)00665-7; NEI M, 1986, MOL BIOL EVOL, V3, P418; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; Ochman H, 1999, P NATL ACAD SCI USA, V96, P12638, DOI 10.1073/pnas.96.22.12638; Ochman H, 2003, MOL BIOL EVOL, V20, P2091, DOI 10.1093/molbev/msg229; Parkhill J, 2003, NAT GENET, V35, P32, DOI 10.1038/ng1227; Rispe C, 2004, GENOME RES, V14, P44, DOI 10.1101/gr.1358104; Rocap G, 2003, NATURE, V424, P1042, DOI 10.1038/nature01947; Urbach E, 1998, J MOL EVOL, V46, P188, DOI 10.1007/PL00006294; Wang FS, 1997, J BACTERIOL, V179, P6551, DOI 10.1128/jb.179.21.6551-6559.1997; WHITTAM TS, 1983, P NATL ACAD SCI-BIOL, V80, P1751, DOI 10.1073/pnas.80.6.1751; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555	28	46	48	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528429				2022-12-28	WOS:000225001100022
J	Marlovits, TC; Kubori, T; Sukhan, A; Thomas, DR; Galan, JE; Unger, VM				Marlovits, TC; Kubori, T; Sukhan, A; Thomas, DR; Galan, JE; Unger, VM			Structural insights into the assembly of the type III secretion needle complex	SCIENCE			English	Article							PROTEINS	Type III secretion systems (TTSSs) mediate translocation of virulence factors into host cells. We report the 17-angstrom resolution structures of a central component of Salmonella typhimurium TTSS, the needle complex, and its assembly precursor, the bacterial envelope-anchored base. Both the base and the fully assembled needle complex adopted multiple oligomeric states in vivo, and needle assembly was accompanied by recruitment of the protein PrgJ as a structural component of the base. Moreover, conformational changes during needle assembly created scaffolds for anchoring both PrgJ and the needle substructure and may provide the basis for substrate-specificity switching during type III secretion.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Sect Microbial Pathogenet, New Haven, CT 06536 USA; Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Yale University; Yale University; Brandeis University	Unger, VM (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA.	vinzenz.unger@yale.edu	Kubori, Tomoko/AAH-3609-2019; Marlovits, Thomas/A-3568-2019	Kubori, Tomoko/0000-0003-1098-6021; Marlovits, Thomas/0000-0001-8106-4038	NCRR NIH HHS [P42 RR-01081] Funding Source: Medline; NIAID NIH HHS [AI30492] Funding Source: Medline; NIGMS NIH HHS [GM35433, R01 GM066145, GM66145] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030492, R37AI030492, R01AI030492] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035433, R01GM066145, R37GM035433] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blocker A, 2001, MOL MICROBIOL, V39, P652, DOI 10.1046/j.1365-2958.2001.02200.x; Collazo CM, 1996, INFECT IMMUN, V64, P3524, DOI 10.1128/IAI.64.9.3524-3531.1996; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; Galan JE, 2001, ANNU REV CELL DEV BI, V17, P53, DOI 10.1146/annurev.cellbio.17.1.53; Kimbrough TG, 2000, P NATL ACAD SCI USA, V97, P11008, DOI 10.1073/pnas.200209497; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Kubori T, 2000, P NATL ACAD SCI USA, V97, P10225, DOI 10.1073/pnas.170128997; MARLOVITS TC, UNPUB; Sukhan A, 2003, J BACTERIOL, V185, P3480, DOI 10.1128/JB.185.11.3480-3483.2003; Sukhan A, 2001, J BACTERIOL, V183, P1159, DOI 10.1128/JB.183.4.1159-1167.2001; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; Yang SX, 2002, J MOL BIOL, V321, P839, DOI 10.1016/S0022-2836(02)00711-8	14	300	306	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1040	1042		10.1126/science.1102610	http://dx.doi.org/10.1126/science.1102610			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528446	Green Accepted			2022-12-28	WOS:000225001100045
J	Gershengorn, MC; Hardikar, AA; Wei, CJ; Geras-Raaka, E; Marcus-Samuels, B; Raaka, BM				Gershengorn, MC; Hardikar, AA; Wei, CJ; Geras-Raaka, E; Marcus-Samuels, B; Raaka, BM			Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells	SCIENCE			English	Article							INSULIN-PRODUCING CELLS; PANCREATIC BETA-CELLS; ADULT-MOUSE PANCREAS; IN-VITRO; STEM-CELLS; DIABETES-MELLITUS; PROGENITOR CELLS; DIFFERENTIATION; GENE; LINEAGES	Insulin-expressing beta cells, found in pancreatic islets, are capable of generating more beta cells even in the adult. We show that fibroblast-like cells derived from adult human islets donated postmortem proliferate readily in vitro. These mesenchymal-type cells, which exhibit no hormone expression, can then be induced to differentiate into hormone-expressing islet-like cell aggregates, which reestablishes the epithelial character typical of islet cells. Immunohistochemistry, in situ hybridization, and messenger RNA measurements in single cells and cell populations establish the transition of epithelial. cells within islets to mesenchymal cells in culture and then to insulin-expressing epithelial, cells.	NIDDKD, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gershengorn, MC (corresponding author), NIDDKD, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA.	marving@intra.niddk.nih.gov	Hardikar, Anandwardhan/ACF-7730-2022	Wei, Chiju/0000-0003-1551-5931	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK011007, ZIADK011007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152; Beattie GM, 1999, DIABETES, V48, P1013, DOI 10.2337/diabetes.48.5.1013; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; Bouckenooghe T, 2003, CELL TRANSPLANT, V12, P799, DOI 10.3727/000000003108747271; Cornelius JG, 1997, HORM METAB RES, V29, P271, DOI 10.1055/s-2007-979036; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; GERSHENGORN MC, UNPUB; Hardikar AA, 2003, P NATL ACAD SCI USA, V100, P7117, DOI 10.1073/pnas.1232230100; Hay ED, 1995, ACTA ANAT, V154, P8; Herrera PL, 2002, INT J DEV BIOL, V46, P97; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Lechner A, 2003, AM J PHYSIOL-ENDOC M, V284, pE259, DOI 10.1152/ajpendo.00393.2002; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Rajagopal J, 2003, SCIENCE, V299, P363; Ramiya VK, 2000, NAT MED, V6, P278; Seaberg RM, 2004, NAT BIOTECHNOL, V22, P1115, DOI 10.1038/nbt1004; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Soria B, 2001, DIFFERENTIATION, V68, P205, DOI 10.1046/j.1432-0436.2001.680408.x; Suzuki S, 2004, DIABETES, V53, pA214, DOI 10.2337/diabetes.53.8.2143; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; WELSH M, 1985, J BIOL CHEM, V260, P3590; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521; Zwillich T, 2000, SCIENCE, V289, P531, DOI 10.1126/science.289.5479.531	27	347	406	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	2004	306	5705					2261	2264		10.1126/science.1101968	http://dx.doi.org/10.1126/science.1101968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	882PE	15564314	Green Published			2022-12-28	WOS:000225950000048
J	Swan, MC; Furniss, D; Cassell, OCS				Swan, MC; Furniss, D; Cassell, OCS			Surgical management of metastatic inguinal lymphadenopathy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SQUAMOUS-CELL CARCINOMA; LYMPH-NODE DISSECTION; MALIGNANT-MELANOMA; PENILE CANCER; OPERATIVE MORBIDITY; GROIN DISSECTION; BIOPSY; LYMPHADENECTOMY; COMPLICATIONS; DIAGNOSIS		Radcliffe Infirm, Dept Plast & Reconstruct Surg, Oxford OX2 6HE, England	Radcliffe Infirmary	Swan, MC (corresponding author), Radcliffe Infirm, Dept Plast & Reconstruct Surg, Oxford OX2 6HE, England.	marc.swan@surgery.oxford.ac.uk	Furniss, Dominic/AAH-4447-2019					Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; BARONOFSKY ID, 1948, SURGERY, V24, P555; Basler GC, 1997, J AM ACAD DERMATOL, V36, P403, DOI 10.1016/S0190-9622(97)80216-2; BEITSCH P, 1992, AM J SURG, V164, P462, DOI 10.1016/S0002-9610(05)81181-X; BLAND KI, 1981, ANN SURG, V193, P372, DOI 10.1097/00000658-198103000-00022; BURGERS JK, 1992, UROL CLIN N AM, V19, P247; Caliendo MV, 2001, J VASC INTERV RADIOL, V12, P73, DOI 10.1016/S1051-0443(07)61407-9; Cascinelli N, 2000, ANN SURG ONCOL, V7, P469, DOI 10.1007/s10434-000-0469-z; Cascinelli N, 1998, LANCET, V351, P793, DOI 10.1016/S0140-6736(97)08260-3; Chandrasekaran D, 2003, BJU INT, V91, P296, DOI 10.1046/j.1464-410X.2003.04028.x; FORTNER JG, 1964, SURGERY, V55, P485; Gaarenstroom KN, 2003, INT J GYNECOL CANCER, V13, P522, DOI 10.1046/j.1525-1438.2003.13304.x; Gipponi M, 2004, J SURG ONCOL, V85, P171, DOI 10.1002/jso.20031; GUARISCHI A, 1987, CANCER-AM CANCER SOC, V59, P572, DOI 10.1002/1097-0142(19870201)59:3<572::AID-CNCR2820590336>3.0.CO;2-3; HARRIS MN, 1973, SURG GYNECOL OBSTET, V136, P33; Hettiaratchy SP, 2000, BRIT J PLAST SURG, V53, P559, DOI 10.1054/bjps.2000.3409; Holthouse DJ, 2001, J ROY COLL SURG EDIN, V46, P244; Horenblas S, 2000, J UROLOGY, V163, P100, DOI 10.1016/S0022-5347(05)67982-7; JAMES JH, 1982, SCAND J PLAST RECONS, V16, P167, DOI 10.3109/02844318209006586; JOHNSON DE, 1984, UROLOGY, V24, P312, DOI 10.1016/0090-4295(84)90198-5; KARAKOUSIS CP, 1983, AM J SURG, V141, P299; Kretschmer L, 2004, EUR J CANCER, V40, P212, DOI 10.1016/j.ejca.2003.07.003; LUCIA MS, 1992, UROL CLIN N AM, V19, P227; Moore RG, 2003, GYNECOL ONCOL, V89, P475, DOI 10.1016/S0090-8258(03)00130-6; *OFF NAT STAT, 2003, CANC REG STAT ENGL 2; ORNELLAS AA, 1994, J UROLOGY, V151, P1244; Paley PJ, 1997, GYNECOL ONCOL, V64, P237, DOI 10.1006/gyno.1996.4557; Pecorelli S, 1999, INT J GYNECOL OBSTET, V65, P243, DOI 10.1016/S0020-7292(99)00070-3; Perera D, 2003, DIS COLON RECTUM, V46, P1027, DOI 10.1007/s10350-004-7276-8; Roberts DLL, 2002, BRIT J DERMATOL, V146, P7, DOI 10.1046/j.1365-2133.2001.04614.x; ROSES DF, 1982, ARCH SURG-CHICAGO, V117, P921; Spratt J, 2000, J SURG ONCOL, V73, P243, DOI 10.1002/(SICI)1096-9098(200004)73:4<243::AID-JSO13>3.0.CO;2-W; Tanis PJ, 2002, J UROLOGY, V168, P76, DOI 10.1016/S0022-5347(05)64835-5; Tonouchi H, 2004, SURG TODAY, V34, P413, DOI 10.1007/s00595-003-2738-5; URIST MM, 1983, CANCER, V51, P2152, DOI 10.1002/1097-0142(19830601)51:11<2152::AID-CNCR2820511134>3.0.CO;2-7; *US NAT CANC I, AN CANC TREATM OPT O; VANDERVELDEN J, 2004, COCHRANE LIB; VORDERMARK JS, 1985, BRIT J PLAST SURG, V38, P321, DOI 10.1016/0007-1226(85)90235-8; WOODHALL JP, 1953, SURGERY, V33, P886; Zhang SH, 2000, CANCER-AM CANCER SOC, V89, P1520, DOI 10.1002/1097-0142(20001001)89:7<1520::AID-CNCR15>3.3.CO;2-E	41	35	37	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2004	329	7477					1272	1276B		10.1136/bmj.329.7477.1272	http://dx.doi.org/10.1136/bmj.329.7477.1272			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15564260	Green Published			2022-12-28	WOS:000225480900021
J	Lytle, BW				Lytle, BW			Prolonging patency - Choosing coronary bypass grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lytle, BW (corresponding author), Cleveland Clin Fdn, Dept Thorac & Cardiovasc Surg, Cleveland, OH 44195 USA.								0	33	35	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2262	2264		10.1056/NEJMp048238	http://dx.doi.org/10.1056/NEJMp048238			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564542				2022-12-28	WOS:000225298100004
J	Mellars, P				Mellars, P			Neanderthals and the modern human colonization of Europe	NATURE			English	Review							MODERN HUMAN ORIGINS; AURIGNACIAN; CHRONOLOGY	The fate of the Neanderthal populations of Europe and western Asia has gripped the popular and scientific imaginations for the past century. Following at least 200,000 years of successful adaptation to the glacial climates of northwestern Eurasia, they disappeared abruptly between 30,000 and 40,000 years ago, to be replaced by populations all but identical to modern humans. Recent research suggests that the roots of this dramatic population replacement can be traced far back to events on another continent, with the appearance of distinctively modern human remains and artefacts in eastern and southern Africa.	Univ Cambridge, Dept Archaeol, Cambridge CB2 3DZ, England	University of Cambridge	Mellars, P (corresponding author), Univ Cambridge, Dept Archaeol, Downing St, Cambridge CB2 3DZ, England.	p.a.mellars@arch.cam.ac.uk						Aitken M. J., 1990, SCI BASED DATING ARC; Bar-Yosef O., 2000, GEOGRAPHY NEANDERTHA, V107, P1189; Churchill SE, 2000, YEARB PHYS ANTHROPOL, V43, P61; Conard NJ, 2004, NATURE, V430, P198, DOI 10.1038/nature02690; Conard NJ, 2003, J HUM EVOL, V44, P331, DOI 10.1016/S0047-2484(02)00202-6; Coolidge FL, 2004, J ANTHROPOL RES, V60, P55, DOI 10.1086/jar.60.1.3631008; D'Errico F, 2003, EVOL ANTHROPOL, V12, P188, DOI 10.1002/evan.10113; Davies W., 2001, P PREHIST SOC, V67, P195, DOI [10.1017/S0079497X00001663, DOI 10.1017/S0079497X00001663]; DERRICO F, 1998, CURR ANTHROPOL, V39, P1, DOI DOI 10.1086/204695; Donald M., 1991, ORIGINS MODERN MIND; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Forster P, 2004, PHILOS T R SOC B, V359, P255, DOI 10.1098/rstb.2003.1394; GAMBIER D, 1989, HUMAN REVOLUTION, P194; Haesaerts P., 2003, CHRONOLOGY AURIGNACI, V33, P133; Henry-Gambier D., 2002, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V14, P89; Henshilwood C, 2004, SCIENCE, V304, P404, DOI 10.1126/science.1095905; Henshilwood CS, 2002, SCIENCE, V295, P1278, DOI 10.1126/science.1067575; Hublin J. -J., 2000, GEOGRAPHY NEANDERTHA, V8, P157; Hublin JJ, 1996, NATURE, V381, P224, DOI 10.1038/381224a0; Klein RG, 2000, EVOL ANTHROPOL, V9, P17, DOI 10.1002/(SICI)1520-6505(2000)9:1<17::AID-EVAN3>3.0.CO;2-A; Kozlowski JK, 2000, J ANTHROPOL RES, V56, P513, DOI 10.1086/jar.56.4.3630929; Krings M, 2000, NAT GENET, V26, P144, DOI 10.1038/79855; Lahr MM, 1998, YEARB PHYS ANTHROPOL, V41, P137; LEBON F, 2002, AURIGNACIEN MER OCEA; Lewis-Williams D., 2002, MIND CAVE; McBrearty S, 2000, J HUM EVOL, V39, P453, DOI 10.1006/jhev.2000.0435; Mellars P, 1999, CURR ANTHROPOL, V40, P341, DOI 10.1086/200024; Mellars P, 2003, P BRIT ACAD, V106, P31; Mellars P, 1998, NEANDERTALS AND MODERN HUMANS IN WESTERN ASIA, P493; MELLARS P, 1989, ANTIQUITY, V63, P761, DOI 10.1017/S0003598X00076894; MELLARS P, 2004, EXPLAINING SOCIAL CH, P27; Mellars P. A., 2001, PEOPLING BRITAIN SHA, P39; MELLARS PA, 1992, PHILOS T ROY SOC B, V337, P225, DOI 10.1098/rstb.1992.0100; Mellars Paul A., 1996, NEANDERTHAL LEGACY A; Mithen S., 1996, PREHISTORY MIND; Monigal K., 2003, MORE MEETS EYE STUDI, P118; Ohnuma K., 1990, EMERGENCE MODERN HUM, P91; Pinker Steven, 1994, LANGUAGE INSTINCT; Ramsey CB, 2004, RADIOCARBON, V46, P155, DOI 10.1017/S0033822200039473; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Serre D, 2004, PLOS BIOL, V2, P313, DOI 10.1371/journal.pbio.0020057; Shackleton NJ, 2004, QUATERNARY SCI REV, V23, P1513, DOI 10.1016/j.quascirev.2004.03.006; SHERRY ST, 1994, HUM BIOL, V66, P761; Smith NP, 1999, COMPUT SCI ENG, V1, P96; Stringer C, 2002, PHILOS T R SOC B, V357, P563, DOI 10.1098/rstb.2001.1057; Stringer C., 1989, PALEORIENT, V15, P99, DOI DOI 10.3406/paleo.1989.4512; Svoboda JA, 2002, ANTIQUITY, V76, P957, DOI 10.1017/S0003598X00091754; Tattersall Ian, 2002, Proceedings of the British Academy, V106, P49; Trinkaus E, 2003, P NATL ACAD SCI USA, V100, P11231, DOI 10.1073/pnas.2035108100; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; White R., 2001, ATHENA REV, V2, P41, DOI DOI 10.1016/J.JHEVOL.2008.08.017; White TD, 2003, NATURE, V423, P742, DOI 10.1038/nature01669	52	230	239	1	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					461	465		10.1038/nature03103	http://dx.doi.org/10.1038/nature03103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	874AA	15565144				2022-12-28	WOS:000225322100036
J	Steinbrook, R				Steinbrook, R			The cord-blood-bank controversies	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ABELSON R, 2004, NY TIMES        1101, pA1; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; 2004, MED LETT DRUGS THER, V46, P21	3	48	55	1	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2255	2257		10.1056/NEJMp048283	http://dx.doi.org/10.1056/NEJMp048283			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564539				2022-12-28	WOS:000225298100001
J	Feng, L; Gell, DA; Zhou, SP; Gu, LC; Kong, Y; Li, JQ; Hu, M; Yan, N; Lee, C; Rich, AM; Armstrong, RS; Lay, PA; Gow, AJ; Weiss, MJ; Mackay, JP; Shi, YG				Feng, L; Gell, DA; Zhou, SP; Gu, LC; Kong, Y; Li, JQ; Hu, M; Yan, N; Lee, C; Rich, AM; Armstrong, RS; Lay, PA; Gow, AJ; Weiss, MJ; Mackay, JP; Shi, YG			Molecular mechanism of AHSP-mediated stabilization of alpha-hemoglobin	CELL			English	Article							CRYSTAL-STRUCTURE; CHEMICAL-SHIFT; NMR STRUCTURE; PROTEIN; CYTOGLOBIN; GLOBIN; OXIDATION; INSIGHTS; PROGRAM; BLOOD	Hemoglobin A (HbA), the oxygen delivery system in humans, comprises two a and two beta subunits. Free alpha-hemoglobin (alphaHb) is unstable, and its precipitation contributes to the pathophysiology of beta thalassemia. In erythrocytes, the alpha-hemoglobin stabilizing protein (AHSP) binds aft and inhibits its precipitation. The crystal structure of AHSP bound to Fe(II)-alphaHb reveals that AHSP specifically recognizes the G and H helices of alphaHb through a hydrophobic interface that largely recapitulates the alpha(1)-beta(1) interface of hemoglobin. The AHSP-alphaHb interactions are extensive but suboptimal, explaining why beta-hemoglobin can competitively displace AHSP to form HbA. Remarkably, the Fe(II)-heme group in AHSP bound aft is coordinated by the distal but not the proximal histidine. Importantly, binding to AHSP facilitates the conversion of oxy-alphaHb to a deoxygenated, oxidized [Fe(III)], nonreactive form in which all six coordinate positions are occupied. These observations reveal the molecular mechanisms by which AHSP stabilizes free alphaHb.	Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Sydney, Sch Chem, Ctr Heavy Met Res, Sydney, NSW 2006, Australia; Univ Sydney, Sch Chem, Ctr Struct Biol & Struct Chem, Sydney, NSW 2006, Australia	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Sydney; Princeton University; University of Sydney; University of Sydney	Weiss, MJ (corresponding author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	weissmi@email.chop.edu; j.mackay@mmb.usyd.edu.au; yshi@molbio.princeton.edu	Gow, Andrew/AAR-2309-2020; Lay, Peter A/B-4698-2014; Gow, Andrew/N-8566-2013; Weiss, Mitchell J/A-1245-2013; Weiss, Mitchell J/W-9814-2018; Mackay, Joel/D-6834-2011	Gow, Andrew/0000-0003-0876-5158; Lay, Peter A/0000-0002-3232-2720; Gow, Andrew/0000-0003-0876-5158; Weiss, Mitchell J/0000-0003-2460-3036; Mackay, Joel/0000-0001-7508-8033; Shi, Yigong/0000-0003-2030-168X; Gell, David/0000-0003-0382-1181	NIDDK NIH HHS [R01 DK061692] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061692] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; BAGLIONI C, 1967, EUR J BIOCHEM, V2, P480, DOI 10.1111/j.1432-1033.1967.tb00162.x; BAGLIONI C, 1966, BIBL HAEMATOL, V29, P1056; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUNN HF, 1987, BLOOD, V69, P1; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; de Sanctis D, 2004, J MOL BIOL, V336, P917, DOI 10.1016/j.jmb.2003.12.063; Deane H., 1902, RECORDS GEOLOGICAL S, V1, P15; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; FERMI G, 1981, ATLAS MOL STRUCTURE; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Gell D, 2002, J BIOL CHEM, V277, P40602, DOI 10.1074/jbc.M206084200; GODDARD TD, 2004, SPARKY 3 11 COMPUTER; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kihm AJ, 2002, NATURE, V417, P758, DOI 10.1038/nature00803; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Marley J, 2001, J BIOMOL NMR, V20, P71, DOI 10.1023/A:1011254402785; Naito NR, 2001, BIOCHEMISTRY-US, V40, P2060, DOI 10.1021/bi0021028; NATHAN DG, 1966, AM J MED, V41, P815, DOI 10.1016/0002-9343(66)90039-8; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olson JS, 1997, ARTIF CELL BLOOD SUB, V25, P227, DOI 10.3109/10731199709118912; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pesce A, 2002, EMBO REP, V3, P1146, DOI 10.1093/embo-reports/kvf248; Rachmilewitz EA, 2001, DISORDERS HEMOGLOBIN, P233; Robinson VL, 2003, BIOCHEMISTRY-US, V42, P10113, DOI 10.1021/bi030059t; Santiveri CM, 2004, J BIOL CHEM, V279, P34963, DOI 10.1074/jbc.M405016200; Schubert M, 2002, J BIOMOL NMR, V24, P149, DOI 10.1023/A:1020997118364; SCOTT MD, 1993, J CLIN INVEST, V91, P1706, DOI 10.1172/JCI116380; SPIRO TG, 1976, J AM CHEM SOC, V98, P5482, DOI 10.1021/ja00434a013; Sugimoto H, 2004, J MOL BIOL, V339, P873, DOI 10.1016/j.jmb.2004.04.024; Svistunenko DA, 2000, BIOCHEM J, V351, P595, DOI 10.1042/0264-6021:3510595; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Vitagliano L, 2004, EUR J BIOCHEM, V271, P1651, DOI 10.1111/j.1432-1033.2004.04054.x; VULSTER GW, 1993, J AM CHEM SOC, V115, P7772	38	125	132	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					629	640		10.1016/j.cell.2004.11.025	http://dx.doi.org/10.1016/j.cell.2004.11.025			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550245	Bronze			2022-12-28	WOS:000225389500009
J	Saito, H; Kubota, M; Roberts, RW; Chi, QY; Matsunami, H				Saito, H; Kubota, M; Roberts, RW; Chi, QY; Matsunami, H			RTP family members induce functional expression of mammalian odorant receptors	CELL			English	Article							PUTATIVE PHEROMONE RECEPTORS; HUMAN OLFACTORY RECEPTOR; TASTE RECEPTORS; ENDOPLASMIC-RETICULUM; SIGNAL-TRANSDUCTION; MULTIGENE FAMILY; BINDING PROTEIN; CELL-TYPE; MOUSE; IDENTIFICATION	Transport of G protein-coupled receptors (GPCRs) to the cell surface membrane is critical in order for the receptors to recognize their ligands. However, mammalian GPCR odorant receptors (ORs), when heterologously expressed in cells, are poorly expressed on the cell surface. Here we show that the transmembrane proteins RTP1 and RTP2 promote functional cell surface expression of ORs expressed in HEK293T cells. Genes encoding these proteins are expressed specifically in olfactory neurons. These proteins are associated with OR proteins and enhance the OR responses to odorants. Similar although weaker effects were seen with a third protein, REEP1. These findings suggest that RTP1 and RTP2 in particular play significant roles in the translocation of ORs to the plasma membrane as well as in the functioning of ORs. We have used this approach to identify active odorant ligands for ORs, providing a platform for screening the chemical selectivity of the large OR family.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Duke University	Matsunami, H (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Res Dr, Durham, NC 27710 USA.	hiroaki.matsunami@duke.edu			NIDCD NIH HHS [DC05782] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005782] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adler E, 2000, CELL, V100, P693, DOI 10.1016/S0092-8674(00)80705-9; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; AXEL R, 1995, SCI AM, V273, P154, DOI 10.1038/scientificamerican1095-154; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Barnea G, 2004, SCIENCE, V304, P1468, DOI 10.1126/science.1096146; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Bozza T, 2002, J NEUROSCI, V22, P3033, DOI 10.1523/JNEUROSCI.22-08-03033.2002; Brady AE, 2002, CELL SIGNAL, V14, P297, DOI 10.1016/S0898-6568(01)00239-X; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Calero M, 2001, J BIOL CHEM, V276, P12100, DOI 10.1074/jbc.M008439200; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Chen CN, 2002, PLANT MOL BIOL, V49, P633, DOI 10.1023/A:1015593715144; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Feinstein P, 2004, CELL, V117, P833, DOI 10.1016/j.cell.2004.05.013; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Firestein S, 2001, NATURE, V413, P211, DOI 10.1038/35093026; Gaillard I, 2002, EUR J NEUROSCI, V15, P409, DOI 10.1046/j.0953-816x.2001.01871.x; Gimelbrant AA, 2001, J BIOL CHEM, V276, P7285, DOI 10.1074/jbc.M005433200; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; GRIFF IC, 1995, CELL, V83, P407, DOI 10.1016/0092-8674(95)90118-3; Hague C, 2004, P NATL ACAD SCI USA, V101, P13672, DOI 10.1073/pnas.0403854101; Hatt H, 1999, CELL MOL BIOL, V45, P285; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; Hurt CM, 2000, J BIOL CHEM, V275, P35424, DOI 10.1074/jbc.M006241200; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Kajiya K, 2001, J NEUROSCI, V21, P6018, DOI 10.1523/JNEUROSCI.21-16-06018.2001; Katada S, 2003, BIOCHEM BIOPH RES CO, V305, P964, DOI 10.1016/S0006-291X(03)00863-5; Katada S, 2004, J NEUROCHEM, V90, P1453, DOI 10.1111/j.1471-4159.2004.02619.x; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Larsson MC, 2004, NEURON, V43, P703, DOI 10.1016/j.neuron.2004.08.019; Lewcock JW, 2004, P NATL ACAD SCI USA, V101, P1069, DOI 10.1073/pnas.0307986100; Loconto J, 2003, CELL, V112, P607, DOI 10.1016/S0092-8674(03)00153-3; Lu M, 2003, TRAFFIC, V4, P416, DOI 10.1034/j.1600-0854.2003.00097.x; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; Matsunami H, 2000, NATURE, V404, P601, DOI 10.1038/35007072; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; McClintock TS, 2003, NEUROREPORT, V14, P1547, DOI 10.1097/00001756-200308260-00001; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mombaerts P, 2004, NAT REV NEUROSCI, V5, P263, DOI 10.1038/nrn1365; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Murrell JR, 1999, J NEUROSCI, V19, P8260; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Serizawa S, 2003, SCIENCE, V302, P2088, DOI 10.1126/science.1089122; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; Spehr M, 2003, SCIENCE, V299, P2054, DOI 10.1126/science.1080376; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WATANABE S, 1995, BIOCHEM BIOPH RES CO, V213, P130, DOI 10.1006/bbrc.1995.2107; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Yu R, 1997, MOL PHARMACOL, V51, P785, DOI 10.1124/mol.51.5.785; Zawistowski JS, 2002, HUM MOL GENET, V11, P389, DOI 10.1093/hmg/11.4.389; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Zozulya S, 2001, GENOME BIOL, V2	65	429	477	4	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					679	691		10.1016/j.cell.2004.11.021	http://dx.doi.org/10.1016/j.cell.2004.11.021			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550249	Bronze			2022-12-28	WOS:000225389500013
J	Reyburn, H; Mbatia, R; Drakeley, C; Carneiro, I; Mwakasungula, E; Mwerinde, O; Saganda, K; Shao, J; Kitua, A; Olomi, R; Greenwood, BM; Whitty, CJM				Reyburn, H; Mbatia, R; Drakeley, C; Carneiro, I; Mwakasungula, E; Mwerinde, O; Saganda, K; Shao, J; Kitua, A; Olomi, R; Greenwood, BM; Whitty, CJM			Overdiagnosis of malaria in patients with severe febrile illness in Tanzania: a prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL MALARIA; AFRICAN CHILDREN; TRANSMISSION; INDICATORS; DIAGNOSIS; MORTALITY; ADMISSION; FEATURES; AREA; CARE	Objective To study the diagnosis and outcomes in people admitted to hospital with a diagnosis of severe malaria in areas with differing intensities of malaria transmission. Design Prospective observational study of children and adults over the course a year. Setting 10 hospitals in north east Tanzania. Participants 17 313 patients were admitted to hospital; of these 4474 (2851 children aged under 5 years) fulfilled criteria for severe disease. Main outcome measure Details of the treatment given and outcome. Altitudes of residence (a proxy for transmission intensity) measured with a global positioning system. Results Blood film microscopy showed that 2062 (46.1%) of people treated for malaria had Plasmodium falciparum (slide positive). The proportion of slide positive cases fell with increasing age and increasing altitude of residence. Among 1086 patients aged greater than or equal to 5 years who lived above 600 metres only 338 (31.1%) were slide positive, while in children < 5 years living in areas of intense transmission (< 600 metres) most (958/1392,68.8%) were slide positive. Among 2375 people who were slide negative, 1571 (66.1%) were not treated with antibiotics and, of those, 120 (7.6%) died. The case fatality in slide negative patients was higher (292/2412, 12.1%) than for slide positive patients (142/2062, 6.9%) (P <0.001). Respiratory distress and altered consciousness were the strongest predictors of mortality in slide positive and slide negative patients and in adults as well as children. Conclusions In Tanzania, malaria is commonly overdiagnosed in people presenting with severe febrile illness, especially in those living in areas with low to moderate transmission and in adults. This is associated with a failure to treat alternative causes of severe infection. Diagnosis needs to be improved and syndromic treatment considered. Routine hospital data may overestimate mortality from malaria by over twofold.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Kilimanjaro Christian Med Ctr, Moshi, Tanzania; Natl Inst Med Res, Dar Es Salaam, Tanzania; Mawenzi Hosp, Moshi, Kilimanjaro, Tanzania	University of London; London School of Hygiene & Tropical Medicine; Kilimanjaro Christian Medical Centre; National Institute of Medical Research	Reyburn, H (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.	hugh.reyburn@lshtm.ac.uk	Whitty, Christopher/C-7740-2012	Whitty, Christopher/0000-0002-6076-5027				[Anonymous], 2003, AFR MAL REP 2003; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Bodker R, 2003, J MED ENTOMOL, V40, P706, DOI 10.1603/0022-2585-40.5.706; BODKER R, 2000, VARIATIONS MALARIA R, P56; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; English M, 2003, B WORLD HEALTH ORGAN, V81, P166; JONKMAN A, 1995, B WORLD HEALTH ORGAN, V73, P223; Makani J, 2003, QJM-INT J MED, V96, P355, DOI 10.1093/qjmed/hcg059; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Ministry of Health, 2002, HLTH STAT ABSTR 2002, V1; MOLYNEUX ME, 1989, Q J MED, V71, P441; Mundy C, 2000, T ROY SOC TROP MED H, V94, P583, DOI 10.1016/S0035-9203(00)90098-1; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Planche T, 2003, CLIN INFECT DIS, V37, P890, DOI 10.1086/377536; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; SMITH T, 1994, STAT MED, V13, P2345, DOI 10.1002/sim.4780132206; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; *WHO, 2000, MAN CHILD SEV INF SE; *WHO, IN MAN CHILDH ILLN; WHO UNICEF. WHO/CDS/MAL/, 2003, WHOCDSMAL2003, P1093	21	460	462	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1212	1215		10.1136/bmj.38251.658229.55	http://dx.doi.org/10.1136/bmj.38251.658229.55			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15542534	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000225335700017
J	Forget, F				Forget, F			Atien weather at the poles of Mars	SCIENCE			English	Editorial Material							CLOUDS; SIMULATION; CAP		Univ Paris 06, Inst Pierre Simon Laplace, Meteorol Dynam Lab, Paris 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	Forget, F (corresponding author), Univ Paris 06, Inst Pierre Simon Laplace, Meteorol Dynam Lab, Paris 5, France.	forget@lmd.jussieu.fr						Bibring JP, 2004, NATURE, V428, P627, DOI 10.1038/nature02461; Colaprete A, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2003JE002053; Forget F, 1998, ICARUS, V131, P302, DOI 10.1006/icar.1997.5874; FORGET F, 1995, J GEOPHYS RES-PLANET, V100, P21219, DOI 10.1029/95JE02378; HESS SL, 1979, J GEOPHYS RES, V84, P2969, DOI 10.1029/JB084iB06p02969; Kieffer H.H, 2003, 6 INT C MARS, P3158; Kieffer HH, 2000, J GEOPHYS RES-PLANET, V105, P9653, DOI 10.1029/1999JE001136; Pettengill GH, 2000, GEOPHYS RES LETT, V27, P609, DOI 10.1029/1999GL010896; Piqueux S, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002007; Sprague AL, 2004, SCIENCE, V306, P1364, DOI 10.1126/science.1098496; Tobie G, 2003, ICARUS, V164, P33, DOI 10.1016/S0019-1035(03)00131-3	11	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1298	1299		10.1126/science.1105669	http://dx.doi.org/10.1126/science.1105669			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550647				2022-12-28	WOS:000225301600026
J	Kortzinger, A; Schimanski, J; Send, U; Wallace, D				Kortzinger, A; Schimanski, J; Send, U; Wallace, D			The ocean takes a deep breath	SCIENCE			English	Article							OXYGEN		Leibniz Inst Meereswissensch, D-24105 Kiel, Germany	Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel	Kortzinger, A (corresponding author), Leibniz Inst Meereswissensch, D-24105 Kiel, Germany.	akoertzinger@ifm-geomar.de	Körtzinger, Arne/A-4141-2014	Körtzinger, Arne/0000-0002-8181-3593				Bopp L, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001445; Curry RG, 2001, J PHYS OCEANOGR, V31, P3374, DOI 10.1175/1520-0485(2001)031<3374:OGCCAW>2.0.CO;2; Garcia HE, 2001, J GEOPHYS RES-OCEANS, V106, P31155, DOI 10.1029/1999JC000200; Keeling RF, 1996, NATURE, V381, P218, DOI 10.1038/381218a0; Keeling RF, 2002, P NATL ACAD SCI USA, V99, P7848, DOI 10.1073/pnas.122154899; KORTZINGER A, IN PRESS J ATMOS OCE; McKinley GA, 2000, GEOPHYS RES LETT, V27, P2933, DOI 10.1029/2000GL011492	7	80	84	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1337	1337		10.1126/science.1102557	http://dx.doi.org/10.1126/science.1102557			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550662				2022-12-28	WOS:000225301600041
J	Bornebroek, M; Kumar-Singh, S				Bornebroek, M; Kumar-Singh, S			A novel drug target in Alzheimer's disease	LANCET			English	Editorial Material							BETA-SECRETASE ACTIVITY; THERAPEUTICS; BACE		Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Antwerp VIB, Dept Mol Genet, Antwerp, Belgium	Erasmus University Rotterdam; Erasmus MC; Flanders Institute for Biotechnology (VIB); University of Antwerp	Bornebroek, M (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands.	m.bornebroek@erasmusmc.nl	Kumar-Singh, Samir/G-6280-2012	Kumar-Singh, Samir/0000-0001-9466-6732				Citron M, 2004, NAT REV NEUROSCI, V5, P677, DOI 10.1038/nrn1495; Cruts M, 2001, NEUROSCI LETT, V313, P105, DOI 10.1016/S0304-3940(01)02234-0; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Kumar-Singh S, 2002, AM J PATHOL, V161, P507, DOI 10.1016/S0002-9440(10)64207-1; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Lobo A, 2000, NEUROLOGY, V54, pS4; Oertle T, 2003, TRENDS CELL BIOL, V13, P187, DOI 10.1016/S0962-8924(03)00035-7; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5	12	5	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1738	1739		10.1016/S0140-6736(04)17415-1	http://dx.doi.org/10.1016/S0140-6736(04)17415-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541434				2022-12-28	WOS:000225070600008
J	Hoffman, HM; Rosengren, S; Boyle, DL; Cho, JY; Nayar, J; Mueller, JL; Anderson, JP; Wanderer, AA; Firestein, GS				Hoffman, HM; Rosengren, S; Boyle, DL; Cho, JY; Nayar, J; Mueller, JL; Anderson, JP; Wanderer, AA; Firestein, GS			Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist	LANCET			English	Article							NF-KAPPA-B; PYRIN; GENE; MUTATIONS; CIAS1; FEVER; ACTIVATION; PHENOTYPE; URTICARIA; DEAFNESS	Background Familial cold autoinflammatory syndrome (FCAS) is an autosomal dominant disorder characterised by recurrent episodes of rash, arthralgia, and fever after cold exposure. The genetic basis of this disease has been elucidated. Cryopyrin, the protein that is altered in FCAS, is one of the adaptor proteins that activate caspase 1, resulting in release of interleukin 1. Methods An experimental cold challenge protocol was developed to study the acute inflammatory mechanisms occurring after a general cold exposure in FCAS patients and to investigate the effects of pretreatment with an antagonist of interleukin 1 receptor (IL-1Ra). ELISA, real-time PCR, and immunohistochemistry were used to measure cytokine responses. Findings After cold challenge, untreated patients with FCAS developed rash, fever, and arthralgias within 1-4 h. Significant increases in serum concentrations of interleukin 6 and white-blood-cell counts were seen 4-8 h after cold challenge. Serum concentrations of interleukin 1 and cytokine mRNA in peripheral-blood leucocytes were not raised, but amounts of interleukin 1 protein and mRNA were high in affected skin. IL-1Ra administered before cold challenge blocked symptoms and increases in white-blood-cell counts and serum interleukin 6. Interpretation The ability of IL-1Ra to prevent the clinical features and haematological and biochemical changes in patients with FCAS indicates a central role for interleukin 1beta in this disorder. Involvement of cryopyrin in activation of caspase 1 and NF-kappaB signalling suggests that it might have a role in many chronic inflammatory diseases. Relevance to practice These findings support a new therapy for a disorder with no previously known acceptable treatment. They also offer insights into the role of interleukin 1beta in more common inflammatory diseases.	Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Sch Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, UCSD Clin Invest Inst, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat & Allergy, Denver, CO USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hoffman, HM (corresponding author), Univ Calif San Diego, Div Rheumatol Allergy & Immunol, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	hahoffman@ucsd.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR047360] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000827, M01 RR00827] Funding Source: Medline; NIAID NIH HHS [R01 AI52430, R01 AI052430] Funding Source: Medline; NIAMS NIH HHS [P30 AR047360, 5 P30 AR47360] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aganna E, 2002, ARTHRITIS RHEUM-US, V46, P2445, DOI 10.1002/art.10509; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Bertin J, 2000, CELL DEATH DIFFER, V7, P1273, DOI 10.1038/sj.cdd.4400774; Boyle DL, 2003, ARTHRITIS RES THER, V5, pR352, DOI 10.1186/ar1004; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dode C, 2002, AM J HUM GENET, V70, P1498, DOI 10.1086/340786; Dowds TA, 2003, BIOCHEM BIOPH RES CO, V302, P575, DOI 10.1016/S0006-291X(03)00221-3; Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Hawkins PN, 2003, NEW ENGL J MED, V348, P2583, DOI 10.1056/NEJM200306193482523; HAWKINS PN, 2000, ARTHRITIS RHEUM, V50, P607; Hoffman HM, 2003, HUM GENET, V112, P209, DOI 10.1007/s00439-002-0860-x; Hoffman HM, 2001, J ALLERGY CLIN IMMUN, V108, P615, DOI 10.1067/mai.2001.118790; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Johnstone RF, 2003, ANN ALLERG ASTHMA IM, V90, P233, DOI 10.1016/S1081-1206(10)62147-3; Luheshi GN, 1998, ANN NY ACAD SCI, V856, P83, DOI 10.1111/j.1749-6632.1998.tb08316.x; Manji GA, 2002, J BIOL CHEM, V277, P11570, DOI 10.1074/jbc.M112208200; MUCKLE TJ, 1962, Q J MED, V31, P235; O'Connor W, 2003, J IMMUNOL, V171, P6329, DOI 10.4049/jimmunol.171.12.6329; OGOSTINI L, 2004, IMMUNITY, V20, P319; RICHARDS N, 2001, J BIOL CHEM, V9, P9; Rosengren S, 2005, ANN RHEUM DIS, V64, P708, DOI 10.1136/ard.2004.025577; Taylor PC, 2003, CURR PHARM DESIGN, V9, P1095, DOI 10.2174/1381612033454991	26	408	434	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1779	1785		10.1016/S0140-6736(04)17401-1	http://dx.doi.org/10.1016/S0140-6736(04)17401-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541451	Green Accepted			2022-12-28	WOS:000225070600031
J	Priebe, S; Badesconyi, A; Fioritti, A; Hansson, L; Kilian, RT; Torres-Gonzales, F; Turner, T; Wiersma, D				Priebe, S; Badesconyi, A; Fioritti, A; Hansson, L; Kilian, RT; Torres-Gonzales, F; Turner, T; Wiersma, D			Reinstitutionalisation in mental-health care: comparison of data on service provision from six European countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEOPLE; HOMICIDES; ILLNESS	Objective To establish whether reinstitutionalisation is occurring in mental health care mid, if so, with What variations between Western European countries. Design Comparison of data on changes in service provision. Setting Six European countries with different traditions of mental health care that have all experienced deinstitutionalisation since the 1970s - England, Germany, Italy, the Netherlands, Spain, mid Sweden. Outcome measures Changes in die number of forensic hospital beds, involuntary hospital admissions, places in supported housing, general psychiatric hospital beds, and general prison population between 1990-1 mid 2002-3. Results Forensic beds and places in supported housing have increased in all countries, whereas changes in it involuntary hospital admissions have been inconsistent. The number of psychiatric hospital beds h is been reduced in five countries, but only in two countries does this reduction outweigh the number of additional places in forensic institutions and supported housing The general prison population has substantially increased in all countries. Conclusions Reinstitutionalisation is taking place in European countries with different, traditions of health care, although with significant variation between the six countries studied. The precise reasons for the phenomenon remain unclear. General attitudes to risk containment in a society, as indicated by the size of the prison population, may be more Important than changing morbidity and new methods of mental healthcare delivery.	Queen Mary Univ London, Newham Ctr Mental Hlth, Social & Community Psychiat Unit, London E13 SSP, England; AUSL Rimini, I-47900 Rimini, Italy; Lund Univ, Dept Nursing, S-22100 Lund, Sweden; Univ Ulm, Dept Psychiat 2, D-89312 Gunzburg, Germany; Univ Granada, Dept Psychiat, E-18071 Granada, Spain; Univ Groningen Hosp, Dept Psychiat, NL-9700 RB Groningen, Netherlands	University of London; Queen Mary University London; Lund University; Ulm University; University of Granada; University of Groningen	Priebe, S (corresponding author), Queen Mary Univ London, Newham Ctr Mental Hlth, Social & Community Psychiat Unit, London E13 SSP, England.	s.priebe@qmul.ac.uk		Priebe, Stefan/0000-0001-9864-3394				Becker T, 2001, ACTA PSYCHIAT SCAND, V104, P8, DOI 10.1034/j.1600-0447.2001.1040s2008.x; Department of Health, 2001, SAF 1 5 YEAR REP NAT; Fakhoury W, 2002, CURR OPIN PSYCHIATR, V15, P187, DOI 10.1097/00001504-200203000-00011; Fazel S, 2002, LANCET, V359, P545, DOI 10.1016/S0140-6736(02)07740-1; FREEMAN H, 1999, CENTURY PSYCHIAT, P213; JONES K, 1993, ASYLUMS AFTER; LEFF J, 2004, PSYCHIAT B, V24, P165; LEVY C, 2002, 3 POST WAR ERAS COMP; Munro E, 2000, BRIT J PSYCHIAT, V176, P116, DOI 10.1192/bjp.176.2.116; Priebe S, 2004, ACTA PSYCHIAT SCAND, V110, P81, DOI 10.1111/j.1600-0047.2004.00386.x; Priebe S, 2003, BRIT MED J, V326, P175, DOI 10.1136/bmj.326.7382.175; Shaw J, 2004, BRIT MED J, V328, P734, DOI 10.1136/bmj.328.7442.734; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9	13	337	343	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2005	330	7483					123	126		10.1136/bmj.38296.611215.AE	http://dx.doi.org/10.1136/bmj.38296.611215.AE			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	889PM	15567803	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000226454900017
J	McGuire, W; Clerihew, L; Fowlie, PW				McGuire, W; Clerihew, L; Fowlie, PW			ABC of preterm birth - Infection in the preterm infant	BRITISH MEDICAL JOURNAL			English	Review							INTENSIVE-CARE-UNIT; WEIGHT INFANTS; ONSET SEPSIS; RISK-FACTORS		Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Neonatal Intens Care Unit, Dundee DD1 9SY, Scotland; Perth Royal Infirm, Perth, Scotland	University of Dundee; University of Dundee	McGuire, W (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 4HN, Scotland.			McGuire, William/0000-0001-8572-3467				Adams-Chapman I, 2002, CURR OPIN PEDIATR, V14, P157, DOI 10.1097/00008480-200204000-00003; Fanaroff AA, 1998, PEDIATR INFECT DIS J, V17, P593, DOI 10.1097/00006454-199807000-00004; Saiman L, 2000, PEDIATR INFECT DIS J, V19, P319, DOI 10.1097/00006454-200004000-00011; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Stoll BJ, 2002, NEW ENGL J MED, V347, P240, DOI 10.1056/NEJMoa012657	5	22	27	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 27	2004	329	7477					1277	1280		10.1136/bmj.329.7477.1277	http://dx.doi.org/10.1136/bmj.329.7477.1277			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15564261	Green Published			2022-12-28	WOS:000225480900022
J	Richardson, JE; Melosh, HJ; Greenberg, R				Richardson, JE; Melosh, HJ; Greenberg, R			Impact-induced seismic activity on asteroid 433 Eros: A surface modification process	SCIENCE			English	Article							EROS; HISTORY; FEATURES	High-resolution images of the surface of asteroid 433 Eros revealed evidence of downslope movement of a loose regolith layer, as well as the degradation and erasure of small impact craters (less than similar to100 meters in diameter). One hypothesis to explain these observations is seismic reverberation after impact events. We used a combination of seismic and geomorphic modeling to analyze the response of regolith-covered topography, particularly craters, to impact-induced seismic shaking. Applying these results to a stochastic cratering model for the surface of Eros produced good agreement with the observed size-frequency distribution of craters, including the paucity of small craters.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA	University of Arizona	Richardson, JE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.	jrich@lpl.arizona.edu						[Anonymous], SOIL MECH; Benz W, 1999, ICARUS, V142, P5, DOI 10.1006/icar.1999.6204; BOTTKE WF, 1994, ICARUS, V107, P255, DOI 10.1006/icar.1994.1021; Chapman CR, 2002, ICARUS, V155, P104, DOI 10.1006/icar.2001.6744; Cheng AF, 2002, METEORIT PLANET SCI, V37, P1095, DOI 10.1111/j.1945-5100.2002.tb00880.x; CINTALA MJ, 1978, P LUNAR PLANET SCI C, V9, P3803; Collins GS, 2002, ICARUS, V157, P24, DOI 10.1006/icar.2002.6822; CULLING WEH, 1960, J GEOL, V68, P336, DOI 10.1086/626663; Dainty A. M., 1974, Moon, V9, P11, DOI 10.1007/BF00565388; DUENNEBIER F, 1974, J GEOPHYS RES, V7929, P4365; GREENBERG R, 1994, ICARUS, V107, P84, DOI 10.1006/icar.1994.1008; Greenberg R, 1996, ICARUS, V120, P106, DOI 10.1006/icar.1996.0040; HOUSTON N, 1973, P LUNAR PLANET SCI C, V4, P2425; KANAMORI H, 1983, GEOPHYS RES LETT, V10, P373, DOI 10.1029/GL010i005p00373; MELOSH HJ, 1989, IMPACT CRATERING GEO, P154; Michel P, 1998, ASTRON J, V116, P2023, DOI 10.1086/300562; O'Brien D.P., 2004, THESIS U ARIZONA; Press W. H., 1992, NUMERICAL RECIPES FO, V77, P266; Prockter L, 2002, ICARUS, V155, P75, DOI 10.1006/icar.2001.6770; RICHARDSON DC, 2002, ASTEROIDS, V3, P501; Robinson MS, 2002, METEORIT PLANET SCI, V37, P1651, DOI 10.1111/j.1945-5100.2002.tb01157.x; Roering JJ, 1999, WATER RESOUR RES, V35, P853, DOI 10.1029/1998WR900090; SCHULTZ PH, 1975, MOON PLANETS, V12, P159, DOI 10.1007/BF00577875; Thomas PC, 2002, ICARUS, V155, P18, DOI 10.1006/icar.2001.6755; Veverka J, 2001, SCIENCE, V292, P484, DOI 10.1126/science.1058651; WORONOW A, 1979, ICARUS, V37, P467	27	121	122	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1526	1529		10.1126/science.1104731	http://dx.doi.org/10.1126/science.1104731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567856				2022-12-28	WOS:000225442700050
J	Stradner, A; Sedgwick, H; Cardinaux, F; Poon, WCK; Egelhaaf, SU; Schurtenberger, P				Stradner, A; Sedgwick, H; Cardinaux, F; Poon, WCK; Egelhaaf, SU; Schurtenberger, P			Equilibrium cluster formation in concentrated protein solutions and colloids	NATURE			English	Article							PHASE-TRANSITIONS; MODEL; SEPARATION; GELATION; LIQUID; STATES	Controlling interparticle interactions, aggregation and cluster formation is of central importance in a number of areas, ranging from cluster formation in various disease processes to protein crystallography and the production of photonic crystals. Recent developments in the description of the interaction of colloidal particles with short-range attractive potentials have led to interesting findings including metastable liquid-liquid phase separation and the formation of dynamically arrested states (such as the existence of attractive and repulsive glasses, and transient gels)(1-7). The emerging glass paradigm has been successfully applied to complex soft-matter systems, such as colloid polymer systems(8) and concentrated protein solutions(9). However, intriguing problems like the frequent occurrence of cluster phases remain(10-13). Here we report small-angle scattering and confocal microscopy investigations of two model systems: protein solutions and colloid-polymer mixtures. We demonstrate that in both systems, a combination of short-range attraction and long-range repulsion results in the formation of small equilibrium clusters. We discuss the relevance of this finding for nucleation processes during protein crystallization, protein or DNA self-assembly and the previously observed formation of cluster and gel phases in colloidal suspensions(12-17).	Univ Fribourg, Dept Phys, CH-1700 Fribourg, Switzerland; Univ Edinburgh, Sch Phys, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Edinburgh, COSMIC, Edinburgh EH9 3JZ, Midlothian, Scotland; Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Fribourg; University of Edinburgh; University of Edinburgh; University of Edinburgh	Schurtenberger, P (corresponding author), Univ Fribourg, Dept Phys, Chemin Musee 3, CH-1700 Fribourg, Switzerland.	peter.schurtenberger@unifr.ch	Stradner, Anna/B-5195-2015; Poon, Wilson C K/B-5960-2013; Poon, Wilson/V-3495-2019; Schurtenberger, Peter/K-1777-2013	Stradner, Anna/0000-0003-3310-3412; Poon, Wilson C K/0000-0003-0760-7940; Poon, Wilson/0000-0003-0760-7940; Schurtenberger, Peter/0000-0002-2790-8831; Egelhaaf, Stefan U./0000-0002-2574-3498	Engineering and Physical Sciences Research Council [GR/S10377/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Bergenholtz J, 2003, LANGMUIR, V19, P4493, DOI 10.1021/la0340089; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Dawson KA, 2002, CURR OPIN COLLOID IN, V7, P218, DOI 10.1016/S1359-0294(02)00052-3; Eckert T, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.125701; Foffi G, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031407; Groenewold J, 2001, J PHYS CHEM B, V105, P11702, DOI 10.1021/jp011646w; Guillot S, 2003, LANGMUIR, V19, P230, DOI 10.1021/la0206561; Kulkarni AM, 2003, FARADAY DISCUSS, V123, P37, DOI 10.1039/b204453f; Malfois M, 1996, J CHEM PHYS, V105, P3290, DOI 10.1063/1.471843; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; PEDERSEN JS, 1994, EUR BIOPHYS J BIOPHY, V22, P379, DOI 10.1007/BF00180159; Pham KN, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.011503; Pham KN, 2002, SCIENCE, V296, P104, DOI 10.1126/science.1068238; Piazza R, 2000, CURR OPIN COLLOID IN, V5, P38, DOI 10.1016/S1359-0294(00)00034-0; Poon WCK, 2002, J PHYS-CONDENS MAT, V14, pR859, DOI 10.1088/0953-8984/14/33/201; Puertas AM, 2004, J CHEM PHYS, V121, P2813, DOI 10.1063/1.1768936; Rojas LF, 2002, EUROPHYS LETT, V60, P802, DOI 10.1209/epl/i2002-00380-5; SCHURTENBERGER P, 1989, PHYS REV LETT, V63, P2064, DOI 10.1103/PhysRevLett.63.2064; Sciortino F, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.055701; Sciortino F, 2002, NAT MATER, V1, P145, DOI 10.1038/nmat752; Segre PN, 2001, PHYS REV LETT, V86, P6042, DOI 10.1103/PhysRevLett.86.6042; TANFORD C, 1972, BIOCHEMISTRY-US, V11, P2192, DOI 10.1021/bi00761a029; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Yethiraj A, 2003, NATURE, V421, P513, DOI 10.1038/nature01328	25	879	883	7	409	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					492	495		10.1038/nature03109	http://dx.doi.org/10.1038/nature03109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565151	Green Submitted			2022-12-28	WOS:000225322100043
J	Coast, J				Coast, J			Is economic evaluation in touch with society's health values?	BRITISH MEDICAL JOURNAL			English	Article							CARE DECISION-MAKING; BENEFITS		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Coast, J (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	jo.coast@bristol.ac.uk		Coast, Joanna/0000-0002-3537-5166				Allen D, 1989, Int J Health Plann Manage, V4, P261, DOI 10.1002/hpm.4740040403; Birch S, 2003, SOC SCI MED, V56, P1121, DOI 10.1016/S0277-9536(02)00101-6; Brouwer WBF, 2000, J HEALTH ECON, V19, P439, DOI 10.1016/S0167-6296(99)00038-7; Culyer AJ, 1989, QUALITY LIFE PERSPEC, P9; Dolan P, 2000, HEALTH POLICY, V51, P19, DOI 10.1016/S0168-8510(99)00079-2; Drummond M, 2003, VALUE HEALTH, V6, P407, DOI 10.1046/j.1524-4733.2003.64245.x; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; Hoffmann C, 2000, HEALTH POLICY, V52, P179, DOI 10.1016/S0168-8510(00)00076-2; Jacklin PB, 2003, BRIT MED J, V327, P84, DOI 10.1136/bmj.327.7406.84; *KINGS FUND OFF HL, 2002, COST EFF THRESH EC E; KLEVIT HD, 1991, ARCH INTERN MED, V151, P912, DOI 10.1001/archinte.151.5.912; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; McGuire A, 2001, EC EVALUATION HLTH C, P172; New B., 1999, GOOD ENOUGH SERVICE; NORD E, 1995, SOC SCI MED, V41, P1429, DOI 10.1016/0277-9536(95)00121-M; Richards Suzanne, 2003, J Health Serv Res Policy, V8, P171, DOI 10.1258/135581903322029539; Sen AK, 1993, LA CALIDAD DE VIDA; Sugden R., 1978, PRINCIPLES PRACTICAL; TSUCHIYA A, 2004, EC EVALUATION HLTH C, P22	19	184	186	1	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 20	2004	329	7476					1233	1236		10.1136/bmj.329.7476.1233	http://dx.doi.org/10.1136/bmj.329.7476.1233			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874FG	15550430	Green Published			2022-12-28	WOS:000225335700023
J	Horton, R				Horton, R			The war in Iraq: civilian casualties, political responsibilities	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Horton, R (corresponding author), Lancet, London NW1 7BY, England.								0	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1831	1831		10.1016/S0140-6736(04)17451-5	http://dx.doi.org/10.1016/S0140-6736(04)17451-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555648				2022-12-28	WOS:000225269300003
J	Ando, R; Mizuno, H; Miyawaki, A				Ando, R; Mizuno, H; Miyawaki, A			Regulated fast nucleocytoplasmic shuttling observed by reversible protein highlighting	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; CELLS; KINASE	The observation of the regulation of fast protein dynamics in a cellular context requires the development of reliable technologies. Here, a signal regulation cascade reliant on the stimulus-dependent acceleration of the bidirectional flow of mitogen-activated protein kinase (extracellular signal-regulated kinase) across the nuclear envelope was visualized by reversible protein highlighting. Light-induced conversion between the bright and dark states of a monomeric fluorescent protein engineered from a novel coral protein was employed. Because of its photochromic properties, the protein could be highlighted, erased, and highlighted again in a nondestructive manner, allowing direct observation of regulated fast nucleocytoplasmic shuttling of key signaling molecules.	RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Adv Technol Dev Grp, Wako, Saitama 3510198, Japan	RIKEN	Miyawaki, A (corresponding author), RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Adv Technol Dev Grp, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsushi@brain.riken.jp	Mizuno, Hideaki/AAH-5737-2021; Miyawaki, Atsushi/K-3569-2014	Mizuno, Hideaki/0000-0002-6983-5255; Miyawaki, Atsushi/0000-0002-2329-3235				Ando R, 2002, P NATL ACAD SCI USA, V99, P12651, DOI 10.1073/pnas.202320599; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chudakov DM, 2003, NAT BIOTECHNOL, V21, P191, DOI 10.1038/nbt778; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073; Furuno T, 2001, J IMMUNOL, V166, P4416, DOI 10.4049/jimmunol.166.7.4416; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Irie M, 2002, NATURE, V420, P759, DOI 10.1038/420759a; Labas YA, 2002, P NATL ACAD SCI USA, V99, P4256, DOI 10.1073/pnas.062552299; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liang YC, 2003, P NATL ACAD SCI USA, V100, P8109, DOI 10.1073/pnas.0832270100; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Verkhusha VV, 2004, NAT BIOTECHNOL, V22, P289, DOI 10.1038/nbt943; Volmat V, 2001, J CELL SCI, V114, P3433; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331; Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976	20	625	648	7	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1370	1373		10.1126/science.1102506	http://dx.doi.org/10.1126/science.1102506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550670				2022-12-28	WOS:000225301600051
J	Roche, D; Paillard, D; Cortijo, E				Roche, D; Paillard, D; Cortijo, E			Constraints on the duration and freshwater release of Heinrich event 4 through isotope modelling	NATURE			English	Article							NORTH-ATLANTIC SEDIMENTS; COUPLED CLIMATE MODEL; LAST GLACIAL MAXIMUM; GREENLAND ICE; THERMOHALINE CIRCULATION; INTERMEDIATE COMPLEXITY; ICEBERG DISCHARGES; SYSTEM MODEL; OCEAN; PATTERNS	Heinrich events(1)-abrupt climate cooling events due to ice-sheet instability that occurred during the last glacial period-are recorded in sediment cores throughout the North Atlantic Ocean(2,3). Modelling studies have described likely physical mechanisms(4-6) for these events, but the quantitative characteristics of Heinrich events are less well known. Here we use a climate model of intermediate complexity(7) that explicitly calculates the distribution of oxygen isotopes in the oceans to simulate Heinrich event 4 at about 40,000 yr ago. We compare an ensemble of scenarios for this Heinrich event with oxygen isotope data measured in foraminiferal calcite of a comprehensive set of sediment cores(8,9). From this comparison, we obtain a duration of 250 +/- 150 yr and an ice release of 2 +/- 1 m sea-level equivalent for Heinrich event 4, significantly reducing the uncertainties in both values compared to earlier estimates(5,10-14) of up to 2,000 yr and 15 m of sea-level equivalent ice release, respectively. Our results indicate that the consequences of Heinrich events may have been less severe than previously assumed, at least with respect to Greenland climate and sea level.	CEA, CNRS, IPSL Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS)	Roche, D (corresponding author), CEA, CNRS, IPSL Lab Sci Climat & Environm, F-91191 Gif Sur Yvette, France.	roche@lsce.saclay.cea.fr	Paillard, Didier/G-4776-2012; Roche, Didier M./C-9875-2010	Paillard, Didier/0000-0002-9995-2794; Roche, Didier M./0000-0001-6272-9428				BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; BOND GC, 1995, SCIENCE, V267, P1005, DOI 10.1126/science.267.5200.1005; Broecker W, 1992, CLIM DYNAM, V6, P265, DOI 10.1007/BF00193540; Calov R, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL016078; Cortijo E. L., 1997, EARTH PLANET SC LETT, V146, P129; DOWDESWELL JA, 1995, GEOLOGY, V23, P301, DOI 10.1130/0091-7613(1995)023<0297:IPDRAT>2.3.CO;2; Elliot M, 1998, PALEOCEANOGRAPHY, V13, P433, DOI 10.1029/98PA01792; Elliot M, 2001, EARTH PLANET SC LETT, V194, P151, DOI 10.1016/S0012-821X(01)00561-1; Fanning AF, 1997, PALEOCEANOGRAPHY, V12, P307, DOI 10.1029/96PA03726; FRANCOIS R, 1994, DEEP-SEA RES PT I, V41, P315, DOI 10.1016/0967-0637(94)90006-X; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Grousett F., 2001, QUATERNAIRE, V12, P203; GROUSSET FE, 1993, PALEOCEANOGRAPHY, V8, P175, DOI 10.1029/92PA02923; Grousset FE, 2001, PALEOCEANOGRAPHY, V16, P240, DOI 10.1029/2000PA000559; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Johnsen SJ, 1997, J GEOPHYS RES-OCEANS, V102, P26397, DOI 10.1029/97JC00167; JOUZEL J, 1994, J GEOPHYS RES-ATMOS, V99, P25791, DOI 10.1029/94JD01819; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P767, DOI 10.1029/93PA02201; MANABE S, 1995, NATURE, V378, P165, DOI 10.1038/378165a0; PAILLARD D, 1994, NATURE, V372, P162, DOI 10.1038/372162a0; Petoukhov V, 2000, CLIM DYNAM, V16, P1, DOI 10.1007/PL00007919; RAHMSTORF S, 1995, NATURE, V378, P145, DOI 10.1038/378145a0; Roche D, 2004, EARTH PLANET SC LETT, V218, P317, DOI 10.1016/S0012-821X(03)00700-3; RUDDIMAN WF, 1977, GEOL SOC AM BULL, V88, P1813, DOI 10.1130/0016-7606(1977)88<1813:LQDOIS>2.0.CO;2; Seidov D, 1996, J GEOPHYS RES-OCEANS, V101, P16305, DOI 10.1029/96JC01079; Stocker TF, 1998, RADIOCARBON, V40, P359; Vidal L, 1997, EARTH PLANET SC LETT, V146, P129; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002	29	95	96	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					379	382		10.1038/nature03059	http://dx.doi.org/10.1038/nature03059			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549102				2022-12-28	WOS:000225161400052
J	Hogerzeil, HV				Hogerzeil, HV			The concept of essential medicines: lessons for rich countries	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL GUIDELINES		WHO, Drugs & Med Policy, CH-1211 Geneva, Switzerland	World Health Organization	Hogerzeil, HV (corresponding author), WHO, Drugs & Med Policy, CH-1211 Geneva, Switzerland.	hogerzeilh@who.int						*COMM DEP HLTH AG, 2000, NAT MED POL; *DEP HLTH, 1999, PHIL NAT DRUG POL; *DEP HLTH, 2003, STAND TREATM GUID ES; DRUMMOND MF, 1992, HEALTH AFFAIR, V11, P191, DOI 10.1377/hlthaff.11.4.191; GOLD MR, 1995, NEW ENGL J MED, V333, P1678, DOI 10.1056/NEJM199512213332505; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Kafuko J, 1994, IMPACT NATL STANDARD; Laing RO, 2001, HEALTH POLICY PLANN, V16, P13, DOI 10.1093/heapol/16.1.13; Lipton HL, 2000, HEALTH AFFAIR, V19, P42, DOI 10.1377/hlthaff.19.2.42; *MIN HLTH CHILD WE, 2000, EDLIZ 4 ESS DRUGS LI; *MIN SAUD, 1981, GUIA TER; Minister of Health, 1996, NAT DRUG POL S AFR; Ministerio de Salud, 1972, VAD OFF MED BAS SECT; *PAP NEW GUIN, 1974, STAND TREATM COMM IL; SHARMA S, 2002, STANDARD TREATMENT G; *THER GUID, 2003, THER GUID ANT VERS 1; *UN C TRAD DEV, 1980, UNCTADTT33; Van Amelsvoort V, 1970, STANDARD NOTES TANZA; Walley T, 2000, BRIT MED J, V321, P1523, DOI 10.1136/bmj.321.7275.1523; WHO, 2004, WHO MED STRAT 2004 2; WHO, 2003, TECHN REP SER WHO, V914, P15; *WHO, 2003, TECHN REP SER WHO, V914; *WHO, 2001, EST IMPL NAT DRUG PO; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; 1978, LANCET, V1, P977	25	86	93	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1169	1172		10.1136/bmj.329.7475.1169	http://dx.doi.org/10.1136/bmj.329.7475.1169			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539676	Green Published			2022-12-28	WOS:000225169600029
J	Hill, MT; Dorren, HJS; de Vries, T; Leijtens, XJM; den Besten, JH; Smalbrugge, B; Oei, YS; Binsma, H; Khoe, GD; Smit, MK				Hill, MT; Dorren, HJS; de Vries, T; Leijtens, XJM; den Besten, JH; Smalbrugge, B; Oei, YS; Binsma, H; Khoe, GD; Smit, MK			A fast low-power optical memory based on coupled micro-ring lasers	NATURE			English	Article							WHISPERING-GALLERY-MODE; ROOM-TEMPERATURE; MICROCAVITY; RESONATORS; SILICON; DEFECT; CELL	The increasing speed of fibre-optic-based telecommunications has focused attention on high-speed optical processing of digital information(1). Complex optical processing requires a high-density, high-speed, low-power optical memory that can be integrated with planar semiconductor technology for buffering of decisions and telecommunication data(2). Recently, ring lasers with extremely small size and low operating power have been made(3-7), and we demonstrate here a memory element constructed by interconnecting these microscopic lasers. Our device occupies an area of 18x40 mum(2) on an InP/InGaAsP photonic integrated circuit, and switches within 20 ps with 5.5 fJ optical switching energy. Simulations show that the element has the potential for much smaller dimensions and switching times. Large numbers of such memory elements can be densely integrated and interconnected on a photonic integrated circuit: fast digital optical information processing systems employing large-scale integration should now be viable.	Tech Univ Eindhoven, COBRA Res Inst, NL-5600 MB Eindhoven, Netherlands; JDS Uniphase, NL-5656 AA Eindhoven, Netherlands	Eindhoven University of Technology	Hill, MT (corresponding author), Tech Univ Eindhoven, COBRA Res Inst, Postbus 513, NL-5600 MB Eindhoven, Netherlands.	m.t.hill@tue.nl	Leijtens, Xaveer J.M./F-3302-2010	Leijtens, Xaveer J.M./0000-0001-7794-8236				Baba T, 2003, IEEE J SEL TOP QUANT, V9, P1340, DOI 10.1109/JSTQE.2003.819464; BUCZEK CJ, 1971, J APPL PHYS, V42, P3133, DOI 10.1063/1.1660695; Chuang S. L, 2009, PHYS PHOTONIC DEVICE, V2nd; Cotter D, 1999, SCIENCE, V286, P1523, DOI 10.1126/science.286.5444.1523; den Besten JH, 2002, IEEE PHOTONIC TECH L, V14, P753, DOI 10.1109/LPT.2002.1003082; Fujita M, 2000, ELECTRON LETT, V36, P790, DOI 10.1049/el:20000609; Hagness SC, 1997, J LIGHTWAVE TECHNOL, V15, P2154, DOI 10.1109/50.641537; HARDER C, 1983, APPL PHYS LETT, V42, P328, DOI 10.1063/1.93921; Kawaguchi H., 1994, BISTABILITIES NONLIN; Keyes RW, 2001, P IEEE, V89, P227, DOI 10.1109/5.915372; Ledentsov NN, 2000, IEEE J SEL TOP QUANT, V6, P439, DOI 10.1109/2944.865099; LEVI AFJ, 1993, ELECTRON LETT, V29, P1666, DOI 10.1049/el:19931109; Noda S, 2000, NATURE, V407, P608, DOI 10.1038/35036532; Painter O, 1999, SCIENCE, V284, P1819, DOI 10.1126/science.284.5421.1819; Polman A, 2004, APPL PHYS LETT, V84, P1037, DOI 10.1063/1.1646748; Ryu HY, 2002, APPL PHYS LETT, V80, P3883, DOI 10.1063/1.1480103; Sakai A, 1999, J LIGHTWAVE TECHNOL, V17, P1493, DOI 10.1109/50.779175; SMITH SD, 1987, NATURE, V325, P27, DOI 10.1038/325027a0; Spillane SM, 2002, NATURE, V415, P621, DOI 10.1038/415621a; Van V, 2002, IEEE J SEL TOP QUANT, V8, P705, DOI 10.1109/JSTQE.2002.1016376; Yanik MF, 2003, APPL PHYS LETT, V83, P2739, DOI 10.1063/1.1615835; Zimmermann S, 1999, SCIENCE, V283, P1292, DOI 10.1126/science.283.5406.1292	22	491	501	8	147	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					206	209		10.1038/nature03045	http://dx.doi.org/10.1038/nature03045			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538365				2022-12-28	WOS:000225020200042
J	Mower, JP; Stefanovic, S; Young, GJ; Palmer, JD				Mower, JP; Stefanovic, S; Young, GJ; Palmer, JD			Plant genetics - Gene transfer from parasitic to host plants	NATURE			English	Editorial Material							FLOWERING PLANTS; TRANSMISSION		Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Mower, JP (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	jpalmer@bio.indiana.edu	Palmer, Jeffrey/P-6747-2014; Mower, Jeff/B-7875-2008; Mower, Jeff/P-5893-2019	Palmer, Jeffrey/0000-0002-4626-2220; Mower, Jeff/0000-0002-1501-5809; Mower, Jeff/0000-0002-1501-5809				Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Davis CC, 2004, SCIENCE, V305, P676, DOI 10.1126/science.1100671; Haupt S, 2001, J EXP BOT, V52, P173, DOI 10.1093/jexbot/52.354.173; HOSFORD RM, 1967, BOT REV, V33, P387, DOI 10.1007/BF02858742; Luteyn JL, 1999, PARAMOS CHECKLIST PL; Marcone C, 1999, J PHYTOPATHOL, V147, P187, DOI 10.1111/j.1439-0434.1999.tb03827.x; Molau U., 1990, OPERA BOT, V102, P1; Nickrent Daniel L., 1998, P211; Ronsted N, 2002, BOT J LINN SOC, V139, P323, DOI 10.1046/j.1095-8339.2002.00070.x; TESSENE MF, 1969, MICH BOT, V8, P72; Won H, 2003, P NATL ACAD SCI USA, V100, P10824, DOI 10.1073/pnas.1833775100; YUNCKER TG, 1932, MEM TORREY BOT CLUB, V18, P111	12	158	167	6	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					165	166		10.1038/432165b	http://dx.doi.org/10.1038/432165b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538356				2022-12-28	WOS:000225020200031
J	Slack, WV				Slack, WV			A 67-year-old man who e-mails his physician	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL INFORMATION-SYSTEM; MEDICAL-RECORDS; ELECTRONIC COMMUNICATION; CONTROLLED TRIAL; PATIENT; COMPUTER; CARE; HEALTH; TRANSITION; PROVIDERS		Beth Israel Deaconess Med Ctr, Div Clin Comp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Slack, WV (corresponding author), Beth Israel Deaconess Med Ctr, Div Clin Comp, Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	wslack@bidmc.harvard.edu						ALTMAN JH, 1980, NEW ENGL J MED, V302, P169, DOI 10.1056/NEJM198001173020310; *AM AC FAM PHYS, 2004, RUR HLTH CAR; *AM COLL PHYS, 1996, CHANG FAC AMB MED RE; *AM MED ASS, 2002, YPS GUID PHYS PAT EL; *AM MED ASS, 2004, CAT 3 COD CPT CAT 3; Bachman JW, 2003, MAYO CLIN PROC, V78, P67, DOI 10.4065/78.1.67; Baker L, 2003, JAMA-J AM MED ASSOC, V289, P2400, DOI 10.1001/jama.289.18.2400; BAKKER AR, 1990, M D COMPUT, V7, P91; Bergus GR, 1998, J FAM PRACTICE, V47, P357; BERNADT M, 1991, BMJ-BRIT MED J, V300, P967; BLEICH H, 1988, MEDINFO 98; BLEICH HL, 1985, NEW ENGL J MED, V312, P756, DOI 10.1056/NEJM198503213121205; Bodenheimer T, 2003, JAMA-J AM MED ASSOC, V290, P259, DOI 10.1001/jama.290.2.259; BRANGER PJ, 1992, BRIT MED J, V305, P1068, DOI 10.1136/bmj.305.6861.1068; CARD W I, 1974, International Journal of Bio-Medical Computing, V5, P175, DOI 10.1016/0020-7101(74)90028-2; COWIE JF, 1985, BRIT MED J, V291, P1439, DOI 10.1136/bmj.291.6506.1439; Delbanco T, 2004, NEW ENGL J MED, V350, P1705, DOI 10.1056/NEJMp038209; *DEP VET AFF, MY HEALTHEVET; Earnest MA, 2004, J AM MED INFORM ASSN, V11, P410, DOI 10.1197/jamia.M1479; ELBOURNE D, 1987, BRIT J OBSTET GYNAEC, V94, P612, DOI 10.1111/j.1471-0528.1987.tb03165.x; FISCHBACH RL, 1980, PATIENT COUNS HEALTH, V2, P1, DOI 10.1016/S0738-3991(80)80022-X; FISHER LA, 1977, AM J PUBLIC HEALTH, V67, P640, DOI 10.2105/AJPH.67.7.640; GARDNER RM, 1994, M D COMPUT, V11, P10; Gaster B, 2003, J GEN INTERN MED, V18, P385, DOI 10.1046/j.1525-1497.2003.20627.x; Gray JE, 2000, PEDIATRICS, V106, P1318, DOI 10.1542/peds.106.6.1318; GREENES RA, 1969, COMPUT BIOMED RES, V2, P469, DOI 10.1016/0010-4809(69)90012-3; Harris Interactive, 2002, HLTH CARE NEWS; HASTINGS GE, 1979, MED CARE, V17, P1238, DOI 10.1097/00005650-197912000-00007; HENDRICKSON G, 1992, M D COMPUT, V9, P35; Hobbs J, 2003, INT J MED INFORM, V70, P1, DOI 10.1016/S1386-5056(03)00007-8; Homer CSE, 1999, AUST NZ J OBSTET GYN, V39, P54, DOI 10.1111/j.1479-828X.1999.tb03445.x; HOROWITZ GL, 1981, NEW ENGL J MED, V305, P924, DOI 10.1056/NEJM198110153051605; Kane B, 1998, J AM MED INFORM ASSN, V5, P104, DOI 10.1136/jamia.1998.0050104; Katz SJ, 2003, J GEN INTERN MED, V18, P736, DOI 10.1046/j.1525-1497.2003.20756.x; Kleiner KD, 2002, PEDIATRICS, V109, P740, DOI 10.1542/peds.109.5.740; KOWALCZYK L, 2004, BOSTON GLOBE    1017, pA1; Liederman EM, 2003, J AM MED INFORM ASSN, V10, P260, DOI 10.1197/jamia.M1259; LILFORD RJ, 1982, MED INFORM, V7, P315, DOI 10.3109/14639238209010729; Lindberg DAB, 1968, COMPUTER MED CARE; Lovell A, 1987, Paediatr Perinat Epidemiol, V1, P57, DOI 10.1111/j.1365-3016.1987.tb00090.x; Mandl KD, 1998, ANN INTERN MED, V129, P495, DOI 10.7326/0003-4819-129-6-199809150-00012; MAYNE JG, 1968, MAYO CLIN PROC, V43, P1; MCDONALD CJ, 1992, M D COMPUT, V9, P206; METCALFE D, 1986, BRIT MED J, V292, P577, DOI 10.1136/bmj.292.6520.577; Moyer CA, 2002, AM J MANAG CARE, V8, P427; Moyer CA, 1999, AM J MANAG CARE, V5, P1513; Neill R A, 1994, Arch Fam Med, V3, P268, DOI 10.1001/archfami.3.3.268; POOL ID, 1983, SCIENCE, V221, P609, DOI 10.1126/science.221.4611.609; *RELAYHEALTH CORP, 2004, REL HLTH; Rhodes KV, 2001, ANN EMERG MED, V37, P284, DOI 10.1067/mem.2001.110818; RISSE GB, 1992, SOC HIST MED, V5, P183, DOI 10.1093/shm/5.2.183; ROSS AP, 1986, BRIT MED J, V292, P578, DOI 10.1136/bmj.292.6520.578; Ross SE, 2003, J AM MED INFORM ASSN, V10, P129, DOI 10.1197/jamia.M1147; SAFRAN C, 1989, M D COMPUT, V6, P141; SAFRAN C, 1991, M D COMPUT, V8, P291; Sands DZ, 2004, HLTH INFORMAT SER, P20; SANDS DZ, 1993, P ANN S COMPUT APPL, V17, P306; SCHERRER JR, 1990, M D COMPUT, V7, P81; SHAW B, 1975, DOCTORS DILEMMA TRAG; SHENKIN BN, 1973, NEW ENGL J MED, V289, P688, DOI 10.1056/NEJM197309272891311; Sittig DF, 2001, INT J MED INFORM, V61, P71, DOI 10.1016/S1386-5056(00)00134-9; Slack W V, 2000, Yearb Med Inform, P71; Slack WV, 1999, INT J MED INFORM, V54, P183, DOI 10.1016/S1386-5056(99)00006-4; Slack WV, 1997, M D COMPUT, V14, P83; Slack WV, 1997, M D COMPUT, V14, P8; SLACK WV, 1989, M D COMPUT, V6, P320; SLACK WV, 1977, LANCET, V2, P240; SLACK WV, 1966, NEW ENGL J MED, V274, P194, DOI 10.1056/NEJM196601272740406; SLACK WV, 1995, M D COMPUT, V12, P25; Slack WV, 2001, CYBERMEDICINE COMPUT, P38; Slack WV, 1972, COMPUTER DIAGNOSIS D, P3; SPIOTTA VL, 2003, JONAS HEALTHC LAW ET, V5, P53, DOI DOI 10.1097/00128488-200309000-00003; Stead WW, 1996, J AM MED INFORM ASSN, V3, P308, DOI 10.1136/jamia.1996.97035022; STEAD WW, 1993, M D COMPUT, V10, P225; TANG P, 2003, P AM MED INF ASS ANN, P649; Wald JS, 2001, J AM MED INFORM ASSN, P731; Wang SJ, 2003, AM J MED, V114, P397, DOI 10.1016/S0002-9343(03)00057-3; WEED LL, 1968, NEW ENGL J MED, V278, P652, DOI 10.1056/NEJM196803212781204; WEED LL, 1968, NEW ENGL J MED, V278, P593, DOI 10.1056/NEJM196803142781105; White CB, 2004, J AM MED INFORM ASSN, V11, P260, DOI 10.1197/jamia.M1445; WYSOCKI B, 2004, WALL STREET J   0721; 2002, FED REG, V45; [No title captured]	83	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2255	2261		10.1001/jama.292.18.2255	http://dx.doi.org/10.1001/jama.292.18.2255			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536113				2022-12-28	WOS:000225070000027
J	Villareal, DT; Holloszy, JO				Villareal, DT; Holloszy, JO			Effect of DHEA on abdominal fat and insulin action in elderly women and men - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVATED RECEPTOR-ALPHA; DEHYDROEPIANDROSTERONE-SULFATE CONCENTRATIONS; REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; BODY-COMPOSITION; GENE-EXPRESSION; VISCERAL FAT; OBESITY; RESISTANCE; RATS	Context Dehydroepiandrosterone (DHEA) administration has been shown to reduce accumulation of abdominal visceral fat and protect against insulin resistance in laboratory animals, but it is not known whether DHEA decreases abdominal obesity in humans. DHEA is widely available as a dietary supplement without a prescription. Objective To determine whether DHEA replacement therapy decreases abdominal fat and improves insulin action in elderly persons. Design and Setting Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from June 2001 to February 2004. Participants Fifty-six elderly persons (28 women and 28 men aged 71 [range, 65-78] years) with age-related decrease in DHEA level. Intervention Participants were randomly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months. Main Outcome Measures The primary outcome measures were 6-month change in visceral and subcutaneous abdominal fat measured by magnetic resonance imaging and glucose and insulin responses to an oral glucose tolerance test (OGTT). Results Of the 56 men and women enrolled, 52 underwent follow-up evaluations. Compliance with the intervention was 97% in the DHEA group and 95% in the placebo group. Based on intention-to-treat analyses, DHEA therapy compared with placebo induced significant decreases in visceral fat area (-13 cm(2) vs +3 cm(2), respectively; P=.001) and subcutaneous fat (-13 cm(2) vs +2 cm(2), P=.003). The insulin area under the curve (AUC) during the OGTT was significantly reduced after 6 months of DHEA therapy compared with placebo (-1119 muU/mL per 2 hours vs +818 muU/mL per 2 hours, P=.007). Despite the lower insulin levels, the glucose AUC was unchanged, resulting in a significant increase in an insulin sensitivity index in response to DHEA compared with placebo (+1.4 vs -0.7, P=.005). Conclusion DHEA replacement could play a role in prevention and treatment of the metabolic syndrome associated with abdominal obesity.	Washington Univ, Sch Med, Dept Med, Div Geriatr & Nutr Sci, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Div Geriatr & Nutr Sci, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jho1losz@im.wustl.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020579, P30DK056341, P60DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020076, P60AG013629] Funding Source: NIH RePORTER; NCRR NIH HHS [K23RR16191, RR00036] Funding Source: Medline; NIA NIH HHS [AG20076, AG13629] Funding Source: Medline; NIDDK NIH HHS [DK56341, DK20579] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AER CTR, 1997, MED SCI SPORT EXER S, V6, P10; ALLISON DB, 1995, DIABETES CARE, V18, P245, DOI 10.2337/diacare.18.2.245; Arlt W, 2001, J CLIN ENDOCR METAB, V86, P4686, DOI 10.1210/jc.86.10.4686; Arlt W, 1999, J CLIN ENDOCR METAB, V84, P2170, DOI 10.1210/jc.84.6.2170; BarrettConnor E, 1996, J CLIN ENDOCR METAB, V81, P59, DOI 10.1210/jc.81.1.59; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; CEFALU WT, 1995, METABOLISM, V44, P954, DOI 10.1016/0026-0495(95)90251-1; Chou CJ, 2002, J BIOL CHEM, V277, P24484, DOI 10.1074/jbc.M202449200; CLEARY MP, 1986, INT J OBESITY, V10, P193; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; DAUGHADAY WH, 1980, J CLIN ENDOCR METAB, V51, P781, DOI 10.1210/jcem-51-4-781; Diamond P, 1996, J ENDOCRINOL, V150, pS43; Ferrannini E, 1997, HYPERTENSION, V30, P1144, DOI 10.1161/01.HYP.30.5.1144; Flynn MA, 1999, J CLIN ENDOCR METAB, V84, P1527, DOI 10.1210/jc.84.5.1527; Friedman L.M., 1980, FUNDAMENTALS CLIN TR; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAARBO J, 1991, METABOLISM, V40, P1323, DOI 10.1016/0026-0495(91)90037-W; HAFFNER SM, 1994, METABOLISM, V43, P599, DOI 10.1016/0026-0495(94)90202-X; HAFFNER SM, 1993, INT J OBESITY, V17, P643; Han DH, 1998, J GERONTOL A-BIOL, V53, pB19, DOI 10.1093/gerona/53A.1.B19; Hansen PA, 1997, AM J PHYSIOL-REG I, V273, pR1704, DOI 10.1152/ajpregu.1997.273.5.R1704; Jedrzejuk D, 2003, Aging Male, V6, P151, DOI 10.1080/713604785; Kawano H, 2003, J CLIN ENDOCR METAB, V88, P3190, DOI 10.1210/jc.2002-021603; KHORRAM O, 1997, J GERONTOL A-BIOL, V52, P1; Kim H, 2003, DIABETES, V52, P1770, DOI 10.2337/diabetes.52.7.1770; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; MOHAN PF, 1990, J NUTR, V120, P1103, DOI 10.1093/jn/120.9.1103; Morales AJ, 1998, CLIN ENDOCRINOL, V49, P421, DOI 10.1046/j.1365-2265.1998.00507.x; MORALES AJ, 1995, J CLIN ENDOCR METAB, V80, P2799; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Munzer T, 2001, J CLIN ENDOCR METAB, V86, P3604, DOI 10.1210/jc.86.8.3604; ORENTREICH N, 1984, J CLIN ENDOCR METAB, V59, P551, DOI 10.1210/jcem-59-3-551; Peters JM, 1996, MOL PHARMACOL, V50, P67; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Schoonjans K, 1996, J LIPID RES, V37, P907; SHIMOKATA H, 1989, J GERONTOL, V44, P66; Tenenbaum A, 2004, CIRCULATION, V109, P2197, DOI 10.1161/01.CIR.0000126824.12785.B6; Villareal D, 2000, J AM GERIATR SOC, V48, pS24; Villareal DT, 2000, CLIN ENDOCRINOL, V53, P561, DOI 10.1046/j.1365-2265.2000.01131.x; YEN TT, 1977, LIPIDS, V12, P409, DOI 10.1007/BF02533624	44	181	199	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2243	2248		10.1001/jama.292.18.2243	http://dx.doi.org/10.1001/jama.292.18.2243			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536111	Bronze			2022-12-28	WOS:000225070000025
J	Aggarwal, R; Ranjan, P				Aggarwal, R; Ranjan, P			Preventing and treating hepatitis B infection	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TERM-FOLLOW-UP; NATURAL-HISTORY; LAMIVUDINE TREATMENT; ADEFOVIR DIPIVOXIL; INTERFERON-ALPHA; VIRUS-INFECTION; TRIAL		Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow 226014, Uttar Pradesh, India	Sanjay Gandhi Postgraduate Institute of Medical Sciences	Aggarwal, R (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Gastroenterol, Lucknow 226014, Uttar Pradesh, India.	rakesh@sgpgi.ac.in	Aggarwal, Rakesh/D-1583-2009	Aggarwal, Rakesh/0000-0001-9689-494X				Aggarwal R, 2003, J HEPATOL, V38, P215, DOI 10.1016/S0168-8278(02)00382-3; Banatvala J, 2000, LANCET, V355, P561, DOI 10.1016/S0140-6736(99)07239-6; Benhamou Y, 2004, CLIN INFECT DIS, V38, pS98, DOI 10.1086/381451; Chen HL, 1996, JAMA-J AM MED ASSOC, V276, P906, DOI 10.1001/jama.276.11.906; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Dienstag JL, 1999, NEW ENGL J MED, V341, P1256, DOI 10.1056/NEJM199910213411702; EASL International Consensus Conference on Hepatitis B, 2002, J HEPATOL, V38, P533; Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087; Hadziyannis SJ, 2000, HEPATOLOGY, V32, P847, DOI 10.1053/jhep.2000.17915; Hadziyannis SJ, 2003, NEW ENGL J MED, V348, P800, DOI 10.1056/NEJMoa021812; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Leung NWY, 2001, HEPATOLOGY, V33, P1527, DOI 10.1053/jhep.2001.25084; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; Liaw YF, 2003, J GASTROEN HEPATOL, V18, P239, DOI 10.1046/j.1440-1746.2003.03037.x; Lok ASF, 2001, HEPATOLOGY, V34, P1225, DOI 10.1053/jhep.2001.29401; Maddrey WC, 2000, J MED VIROL, V61, P362, DOI 10.1002/1096-9071(200007)61:3&lt;362::AID-JMV14&gt;3.0.CO;2-I; Manesis EK, 2001, GASTROENTEROLOGY, V121, P101, DOI 10.1053/gast.2001.25524; Marcellin P, 2003, NEW ENGL J MED, V348, P808, DOI 10.1056/NEJMoa020681; MCMAHON BJ, 1985, J INFECT DIS, V151, P599, DOI 10.1093/infdis/151.4.599; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Perrillo RP, 2002, HEPATOLOGY, V36, P186, DOI 10.1053/jhep.2002.34294; Perrillo RP, 2001, HEPATOLOGY, V33, P424, DOI 10.1053/jhep.2001.21554; Peters MG, 2004, GASTROENTEROLOGY, V126, P91, DOI 10.1053/j.gastro.2003.10.051; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; TASSOPOULOS NC, 1987, GASTROENTEROLOGY, V92, P1844, DOI 10.1016/0016-5085(87)90614-7; Thio CL, 2003, SEMIN LIVER DIS, V23, P125; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011; Wun YT, 2003, COCHRANE DATABASE SY	31	33	40	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1080	1086		10.1136/bmj.329.7474.1080	http://dx.doi.org/10.1136/bmj.329.7474.1080			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528620	Green Published			2022-12-28	WOS:000225070300023
J	Helms, E				Helms, E			A lesson from the third year	LANCET			English	Article									Mt Area Hlth Educ Ctr, Dept Obstet & Gynaecol, Asheville, NC 28801 USA		Helms, E (corresponding author), Mt Area Hlth Educ Ctr, Dept Obstet & Gynaecol, 93 Victoria Rd, Asheville, NC 28801 USA.	EHelms@mtn.ncahec.org							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1727	1727		10.1016/S0140-6736(04)17361-3	http://dx.doi.org/10.1016/S0140-6736(04)17361-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530635				2022-12-28	WOS:000224921600037
J	Landskron, K; Ozin, GA				Landskron, K; Ozin, GA			Periodic mesoporous dendrisilicas	SCIENCE			English	Article								We report the synthesis of a new class of materials called periodic mesoporous dendrisilicas. They are prepared from dendrimers with trialkoxysilyl groups at the outmost shell. Dendrimers of various cores and numbers of shells are used. The dendrisilica synthesis is based on acid- or base-catalyzed hydrolysis of the trialkoxysilyl groups and subsequent template-directed condensation of the dendrimers into an ordered template-dendrisilica nanocomposite. The template can be removed with organic solvents, producing a periodic mesoporous dendrisilica whose pore wails consist of interconnected dendrimer building blocks.	Univ Toronto, Dept Chem, Mat Chem Res Grp, Toronto, ON M5S 3H6, Canada	University of Toronto	Ozin, GA (corresponding author), Univ Toronto, Dept Chem, Mat Chem Res Grp, 80 St George St, Toronto, ON M5S 3H6, Canada.	gozin@chem.utoronto.ca						Fischer M, 1999, ANGEW CHEM INT EDIT, V38, P885, DOI 10.1002/(SICI)1521-3773(19990401)38:7<884::AID-ANIE884>3.0.CO;2-K; Hamley IW, 2003, ANGEW CHEM INT EDIT, V42, P1692, DOI 10.1002/anie.200200546; Inagaki S, 1999, J AM CHEM SOC, V121, P9611, DOI 10.1021/ja9916658; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Michalczyk MJ, 1996, J ORGANOMET CHEM, V521, P261, DOI 10.1016/0022-328X(96)06352-8; Newkome GR, 1999, CHEM REV, V99, P1689, DOI 10.1021/cr9800659; SEYFERTH D, 1994, ORGANOMETALLICS, V13, P2682, DOI 10.1021/om00019a026; Soler-illia GJD, 2002, CHEM REV, V102, P4093, DOI 10.1021/cr0200062; VANDERMADE AW, 1992, J CHEM SOC CHEM COMM, P1400, DOI 10.1039/c39920001400	9	124	128	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1529	1532		10.1126/science.1104555	http://dx.doi.org/10.1126/science.1104555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	875ST	15567857				2022-12-28	WOS:000225442700051
J	Michalakis, Y; Roze, D				Michalakis, Y; Roze, D			Epistasis in RNA viruses	SCIENCE			English	Editorial Material							EVOLUTION; RECOMBINATION; ROBUSTNESS; FITNESS		CNRS, UMR 2724, IRD, Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Michalakis, Y (corresponding author), CNRS, UMR 2724, IRD, Montpellier 5, France.	yannis.michatakis@mpl.ird.fr; denis.roze@mpl.ird.fr		Michalakis, Yannis/0000-0003-1929-0848				BARTON NH, 1995, GENET RES, V65, P123, DOI 10.1017/S0016672300033140; Bonhoeffer S, 2004, SCIENCE, V306, P1547, DOI 10.1126/science.1101786; de Visser JAGM, 2003, EVOLUTION, V57, P1959, DOI 10.1554/02-750R; Gavrilets S, 2004, FITNESS LANDSCAPES O; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P15376, DOI 10.1073/pnas.0404125101; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P8396, DOI 10.1073/pnas.0400146101; SCHUSTER P, 1988, B MATH BIOL, V50, P635, DOI 10.1016/S0092-8240(88)80059-4; SZATHMARY E, 1993, GENETICS, V133, P127; Wilke CO, 2003, MUTAT RES-FUND MOL M, V522, P3, DOI 10.1016/S0027-5107(02)00307-X; Wilke CO, 2001, NATURE, V412, P331, DOI 10.1038/35085569; Wolf J. B., 2000, EPISTASIS EVOLUTIONA; WRIGHT S, 1978, J ANIM SCI, V46, P1192, DOI 10.2527/jas1978.4651192x; You LC, 2002, GENETICS, V160, P1273	14	24	24	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1492	1493		10.1126/science.1106677	http://dx.doi.org/10.1126/science.1106677			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567846				2022-12-28	WOS:000225442700040
J	Hakimian, R; Korn, D				Hakimian, R; Korn, D			Ownership and use of tissue specimens for research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Academic and industrial scientists have sharply increased their demand for properly prepared and clinically annotated tissue samples that yield valuable insights into the origins and expressions of human disease. Historically, research on human tissue samples has been relatively unencumbered by federal regulations and occurred without delineation of ownership rights to the specimens, patient data, or research products. As regulations have become increasingly restrictive, and because clear ownership interests have never been established, the presumed right of researchers and institutions to collect, use, and dispose of specimens and their associated patient data has remained undefined and occasionally contentious. Recent examination of these issues by a US federal court resulted in a ruling that individuals do not retain rights of ownership or control of biological materials contributed for research, regardless of whether commercial benefit accrues. This article examines the legal, regulatory, and ethical framework within which human tissue research is currently conducted. We contend that because the benefits of medical knowledge derived from tissue research potentially accrue to all individuals and future generations (rather than a single recipient), society may justify an expansive use of these valuable resources for future studies.	Assoc Amer Med Coll, Div Biomed & Hlth Sci Res, Washington, DC 20037 USA	Association of American Medical Colleges	Korn, D (corresponding author), Assoc Amer Med Coll, Div Biomed & Hlth Sci Res, 2450 N St NW, Washington, DC 20037 USA.	dkorn@aamc.org						[Anonymous], 1979, ETH PRINC GUID PROT; *ASS AM MED COLL, PROT SUBJ PRES TRUST; *ASS AM U, REP IND I FIN CONFL; Association of American Medical Colleges, PROT SUBJ PRES TRUST; BARKER A, 2004, M ADV PAN RES PRES A; BARNES M, 2004, MED RES LAW POLICY, V3, P440; Eiseman E., 1999, HDB HUMAN TISSUE SOU; Gostin L O, 1999, Jurimetrics, P21; HAKIMIAN R, IN PRESS 50 STATE SU; JACK LA, 2003, BRIT MED J, V327, P262; Kass NE, 2003, J LAW MED ETHICS, V31, P429, DOI 10.1111/j.1748-720X.2003.tb00105.x; Korn D, 2000, ACAD MED, V75, P963, DOI 10.1097/00001888-200010000-00007; KORN D, 2000, RES INVOLVING HUMAN, V2; KORN D, 1999, GENETIC TESTING USE; MURRAY TH, 1997, GENETIC SECRETS PROT, P60; *NAT C STAT LEG, TABL STAT GEN PRIV L; *NIH NAT HUM GEN R, REP JOINT NIH DOE CO; *US DEP HHS OFF HU, EXC LANG INF CONS DO; *US DEP HHS OFF HU, ISS CONS RES US STOR; *US DEP HHS OFF HU, FIN REL INT RES INV; *US FDA, GUID I REV BOARDS CL; *US OFF TECHN ASS, 1987, PUBL OTA BA; Winickoff DE, 2003, NEW ENGL J MED, V349, P1180, DOI 10.1056/NEJMsb030036	23	51	51	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2500	2505		10.1001/jama.292.20.2500	http://dx.doi.org/10.1001/jama.292.20.2500			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562130				2022-12-28	WOS:000225303000026
J	Wang, TJ; Parise, H; Levy, D; Dagostino, RB; Wolf, PA; Vasan, RS; Benjamin, EJ				Wang, TJ; Parise, H; Levy, D; Dagostino, RB; Wolf, PA; Vasan, RS; Benjamin, EJ			Obesity and the risk of new-onset atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR HYPERTROPHY; CORONARY-HEART-DISEASE; NATURAL-HISTORY; FRAMINGHAM; HYPERTENSION; SIZE; PREVALENCE; POPULATION; ECHOCARDIOGRAPHY; PREDICTORS	Context Obesity is associated with atrial enlargement and ventricular diastolic dysfunction, both known predictors of atrial fibrillation (AF). However, it is unclear whether obesity is a risk factor for AF. Objective. To examine the association between body mass index (BMI) and the risk of developing AF. Design, Setting, and Participants Prospective, community-based observational cohort in Framingham, Mass. We studied 5282 participants (mean age, 57 [SD, 13] years; 2898 women [55%]) without baseline AF (electrocardiographic AF or arterial flutter). Body mass index (calculated as weight in kilograms divided by square of height in meters) was evaluated as both a continuous and a categorical variable (normal defined as <25.0; overweight, 25.0 to <30.0; and obese, greater than or equal to30.0). In addition to adjusting for clinical confounders by multivariable techniques, we also examined models including echocardiographic left atrial diameter to examine whether the influence of obesity was mediated by changes in left atrial dimensions. Main Outcome Measure Association between BMI or BMI category and risk of developing new-onset AF. Results During a mean follow-up of 13.7 years, 526 participants (234 women) developed AF. Age-adjusted incidence rates for AF increased across the 3 BMI categories in men (9.7,10.7, and 14.3 per 1000 person-years) and women (5.1, 8.6, and 9.9 per 1000 person-years). In multivariable models adjusted for cardiovascular risk factors and interim myocardial infarction or heart failure, a 4% increase in AF risk per 1-unit increase in BMI was observed in men (95% confidence interval [Cl], 1 %-7%; P=.02) and in women (95% Cl, 1%-7%; P=.009). Adjusted hazard ratios for AF associated with obesity were 1.52 (95% Cl, 1.09-2.13; P=.02) and 1.46 (95% Cl, 1.03-2.07; P=.03) for men and women, respectively, compared with individuals with normal BMI. After adjustment for echocardiographic left atrial diameter in addition to clinical risk factors, BMI was no longer associated with AF risk (adjusted hazard ratios per 1-unit increase in BMI, 1.00 [95% Cl, 0.97-1.04], P=.84 in men; 0.99 [95% Cl, 0.96-1.02], P=.56 in women). Conclusions Obesity is an important, potentially modifiable risk factor for AF. The excess risk of AF associated with obesity appears to be mediated by left atrial dilatation. These prospective data raise the possibility that interventions to promote normal weight may reduce the population. burden of AF.	Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA; Boston Univ, Dept Math, Boston, MA 02215 USA; NHLBI, Bethesda, MD 20892 USA; Boston Univ, Sch Med, Boston Med Ctr, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston Med Ctr, Cardiol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston Med Ctr, Prevent Med Sect, Boston, MA 02118 USA	Framingham Heart Study; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston Medical Center; Boston University; Boston Medical Center; Boston University; Boston Medical Center; Boston University	Benjamin, EJ (corresponding author), Framingham Heart Dis Epidemiol Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	emelia@bu.edu	Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021; Ramachandran, Vasan/Y-2527-2019; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Ramachandran, Vasan/0000-0001-7357-5970; Benjamin, Emelia/0000-0003-4076-2336; Parise, Helen/0000-0001-7761-4973; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [K23-HL074077-01, K24-HL-04334, N01-HC-25195] Funding Source: Medline; NINDS NIH HHS [6R01-NS-17950] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334, K23HL074077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAUDDIN A, 1990, SURGERY, V108, P809; Allessie M, 2002, CARDIOVASC RES, V54, P230, DOI 10.1016/S0008-6363(02)00258-4; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BENJAMIN EJ, 1994, JAMA-J AM MED ASSOC, V271, P840, DOI 10.1001/jama.271.11.840; COX DR, 1972, J R STAT SOC B, V34, P187; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Engeli S, 2001, J MOL MED, V79, P21, DOI 10.1007/s001090000144; Fox CS, 2004, JAMA-J AM MED ASSOC, V291, P2851, DOI 10.1001/jama.291.23.2851; Gerdts E, 2002, HYPERTENSION, V39, P739, DOI 10.1161/hy0302.105683; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Halligan SC, 2004, ANN INTERN MED, V140, P265, DOI 10.7326/0003-4819-140-4-200402170-00008; Iacobellis G, 2002, OBES RES, V10, P767, DOI 10.1038/oby.2002.104; Kanagala R, 2003, CIRCULATION, V107, P2589, DOI 10.1161/01.CIR.0000068337.25994.21; Kannel W., 1987, FRAMINGHAM HEART STU; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNER AD, 1981, J BEHAV MED, V1, P1; Kistler PM, 2004, J AM COLL CARDIOL, V44, P109, DOI 10.1016/j.jacc.2004.03.044; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; LAUER MS, 1991, JAMA-J AM MED ASSOC, V266, P231, DOI 10.1001/jama.266.2.231; MESSERLI FH, 1982, CIRCULATION, V66, P55, DOI 10.1161/01.CIR.66.1.55; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Pelat M, 1999, HYPERTENSION, V34, P1066, DOI 10.1161/01.HYP.34.5.1066; Pritchett AM, 2003, J AM COLL CARDIOL, V41, P1036, DOI 10.1016/S0735-1097(02)02981-9; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Ruigomez A, 2002, J CLIN EPIDEMIOL, V55, P358, DOI 10.1016/S0895-4356(01)00478-4; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAVAGE DD, 1987, HYPERTENSION, V9, P40; VAZIRI SM, 1994, CIRCULATION, V89, P724, DOI 10.1161/01.CIR.89.2.724; VAZIRI SM, 1995, HYPERTENSION, V25, P1155, DOI 10.1161/01.HYP.25.6.1155; Vincent HK, 1999, INT J OBESITY, V23, P67, DOI 10.1038/sj.ijo.0800761; Wilhelmsen L, 2001, J INTERN MED, V250, P382, DOI 10.1046/j.1365-2796.2001.00902.x; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784	35	918	956	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2471	2477		10.1001/jama.292.20.2471	http://dx.doi.org/10.1001/jama.292.20.2471			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562125	Bronze			2022-12-28	WOS:000225303000021
J	MacLennan, C; Solomon, T				MacLennan, C; Solomon, T			Potential neurovirulence of common cold virus	LANCET			English	Editorial Material							INTERCELLULAR-ADHESION MOLECULE-1; COMPLEMENT REGULATORS; ENTEROVIRUS-71; POLIOMYELITIS		Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 3, Malawi; Univ Birmingham, MRC, Ctr Immune Regulat, Birmingham, W Midlands, England; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England	University of Malawi; University of Birmingham; University of Liverpool; University of Liverpool	MacLennan, C (corresponding author), Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, POB 30096, Blantyre 3, Malawi.	cmaclennan@mlw.medcol.mw	MacLennan, Calman A/L-9343-2014	MacLennan, Calman A/0000-0001-9694-0846; Solomon, Tom/0000-0001-7266-6547				Brown B, 2003, J VIROL, V77, P8973, DOI 10.1128/JVI.77.16.8973-8984.2003; DELATORRE JC, 1992, P NATL ACAD SCI USA, V89, P2531, DOI 10.1073/pnas.89.7.2531; Dufresne AT, 2004, P NATL ACAD SCI USA, V101, P13636, DOI 10.1073/pnas.0403998101; ENDERS JF, 1949, SCIENCE, V109, P85, DOI 10.1126/science.109.2822.85; Gromeier M, 1998, J VIROL, V72, P5056, DOI 10.1128/JVI.72.6.5056-5060.1998; Kaminski HJ, 2004, EXP NEUROL, V189, P333, DOI 10.1016/j.expneurol.2004.06.005; McMinn PC, 2002, FEMS MICROBIOL REV, V26, P91, DOI 10.1111/j.1574-6976.2002.tb00601.x; PULLI T, 1995, VIROLOGY, V212, P30, DOI 10.1006/viro.1995.1450; Rieder E, 2001, Dev Biol (Basel), V105, P111; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Singhrao SK, 1999, LAB INVEST, V79, P1247; Solomon T, 2003, CURR OPIN INFECT DIS, V16, P375, DOI 10.1097/00001432-200310000-00002; Wen YY, 2003, J MED VIROL, V70, P109, DOI 10.1002/jmv.10366	13	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	2004	364	9448					1839	1840		10.1016/S0140-6736(04)17456-4	http://dx.doi.org/10.1016/S0140-6736(04)17456-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555652	Green Submitted			2022-12-28	WOS:000225269300008
J	Lehtinen, M; Paavonen, J				Lehtinen, M; Paavonen, J			Vaccination against human papillomaviruses shows great promise	LANCET			English	Editorial Material							CERVICAL-CARCINOMA; VOLUNTEERS; INFECTION; TYPE-16; TRIAL; RISK; L1		Natl Publ Hlth Inst, Dept Infect Dis Epidemiol, Helsinki 00300, Finland; Univ Helsinki, Dept Obstet & Gynaecol, Helsinki, Finland	Finland National Institute for Health & Welfare; University of Helsinki	Lehtinen, M (corresponding author), Natl Publ Hlth Inst, Dept Infect Dis Epidemiol, Helsinki 00300, Finland.	Matti.Lehtinen@uta.fi		Paavonen, Jorma/0000-0003-4775-606X; lehtinen, matti/0000-0002-9481-0535				Bjorge T, 2002, BRIT J CANCER, V87, P61, DOI 10.1038/sj.bjc.6600350; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Garnett GP, 2000, J CLIN VIROL, V19, P101, DOI 10.1016/S1386-6532(00)00129-3; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lehtinen M, 2003, INT J STD AIDS, V14, P787, DOI 10.1258/095646203322556084; Lehtinen M, 1996, BMJ-BRIT MED J, V312, P537, DOI 10.1136/bmj.312.7030.537; Mork J, 2001, NEW ENGL J MED, V344, P1125, DOI 10.1056/NEJM200104123441503; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Pinto LA, 2003, J INFECT DIS, V188, P327, DOI 10.1086/376505; zur Hausen H, 1975, Bibl Haematol, P569	11	30	31	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1731	1732		10.1016/S0140-6736(04)17410-2	http://dx.doi.org/10.1016/S0140-6736(04)17410-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541429				2022-12-28	WOS:000225070600003
J	Goldenberg, SJ; Cascio, TC; Shumway, SD; Garbutt, KC; Liu, JD; Xiong, Y; Zheng, N				Goldenberg, SJ; Cascio, TC; Shumway, SD; Garbutt, KC; Liu, JD; Xiong, Y; Zheng, N			Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases	CELL			English	Article							I-KAPPA-B; F-BOX PROTEINS; CYCLIN-E; NEDD8 MODIFICATION; COP9 SIGNALOSOME; MEDIATED DEGRADATION; CONJUGATION PATHWAY; SCF; MOTIF; CUL1	The SCF ubiquitin ligase complex regulates diverse cellular functions by ubiquitinating numerous protein substrates. Cand1, a 120 kDa HEAT repeat protein, forms a tight complex with the Cul1-Roc1 SCF catalytic core, inhibiting the assembly of the multisubunit E3 complex. The crystal structure of the Cand1-Cul1-Roc1 complex shows that Cand1 adopts a highly sinuous superhelical structure, clamping around the elongated SCF scaffold protein Cull. At one end, a Cand1 beta hairpin protrusion partially occupies the adaptor binding site on Cul1, inhibiting its interactions with the Skp1 adaptor and the substrate-recruiting F box protein subunits. At the other end, two Cand1 HEAT repeats pack against a conserved Cul1 surface cleft and bury a Cul1 lysine residue, whose modification by the ubiquitin-like protein, Nedd8, is able to block Cand1-Cul1 association. Together with biochemical evidence, these structural results elucidate the mechanisms by which Cand1 and Nedd8 regulate the assembly-disassembly cycles of SCIF and other cullin-dependent E3 complexes.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	Zheng, N (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	nzheng@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA107134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NCI NIH HHS [CA107134] Funding Source: Medline; NIGMS NIH HHS [2 T32 GM07270-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; del Pozo JC, 2002, PLANT CELL, V14, P421, DOI 10.1105/tpc.010282; DeLano WL, 2002, PYMOL USERS MANUAL; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dharmasiri S, 2003, EMBO J, V22, P1762, DOI 10.1093/emboj/cdg190; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Fan MY, 2003, MOL ENDOCRINOL, V17, P356, DOI 10.1210/me.2002-0323; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Furukawa M, 2003, NAT CELL BIOL, V5, P1001, DOI 10.1038/ncb1056; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Geyer R, 2003, MOL CELL, V12, P783, DOI 10.1016/S1097-2765(03)00341-1; Gray WM, 1999, GENE DEV, V13, P1678, DOI 10.1101/gad.13.13.1678; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; Grima B, 2002, NATURE, V420, P178, DOI 10.1038/nature01122; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Guo HW, 2003, CELL, V115, P667, DOI 10.1016/S0092-8674(03)00969-3; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Hwang JW, 2003, FEBS LETT, V541, P102, DOI 10.1016/S0014-5793(03)00321-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kumar A, 1998, P NATL ACAD SCI USA, V95, P2417, DOI 10.1073/pnas.95.5.2417; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Min KW, 2003, J BIOL CHEM, V278, P15905, DOI 10.1074/jbc.M213070200; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Oshikawa K, 2003, BIOCHEM BIOPH RES CO, V303, P1209, DOI 10.1016/S0006-291X(03)00501-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Patton EE, 2000, EMBO J, V19, P1613, DOI 10.1093/emboj/19.7.1613; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pintard L, 2003, NATURE, V425, P311, DOI 10.1038/nature01959; Podust VN, 2000, P NATL ACAD SCI USA, V97, P4579, DOI 10.1073/pnas.090465597; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Sasaki A, 2003, SCIENCE, V299, P1896, DOI 10.1126/science.1081077; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Walden H, 2003, NATURE, V422, P330, DOI 10.1038/nature01456; Wang XP, 2003, PLANT CELL, V15, P1071, DOI 10.1105/tpc.009936; Wang YQ, 2003, J BIOL CHEM, V278, P22284, DOI 10.1074/jbc.M301272200; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xu L, 2003, NATURE, V425, P316, DOI 10.1038/nature01985; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yogosawa S, 1996, BIOCHEM BIOPH RES CO, V229, P612, DOI 10.1006/bbrc.1996.1852; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	85	208	215	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					517	528		10.1016/j.cell.2004.10.019	http://dx.doi.org/10.1016/j.cell.2004.10.019			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537541	Bronze, Green Published			2022-12-28	WOS:000225183200010
J	Hug, BA				Hug, BA			HDAC4: A corepressor controlling bone development	CELL			English	Editorial Material							OSTEOBLAST DIFFERENTIATION; CBFA1; RUNX2; INTERACTS; PROMOTER		Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Hug, BA (corresponding author), Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.							Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Schroeder TM, 2004, J BIOL CHEM, V279, P41998, DOI 10.1074/jbc.M403702200; SMITH N, 2004, IN PRESS J CELL PHYS; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Westendorf JJ, 2002, MOL CELL BIOL, V22, P7982, DOI 10.1128/MCB.22.22.7982-7992.2002; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	9	19	22	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	2004	119	4					448	449		10.1016/j.cell.2004.10.023	http://dx.doi.org/10.1016/j.cell.2004.10.023			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537533	Bronze			2022-12-28	WOS:000225183200002
J	Matheus, P; Burns, J; Weinstock, J; Hofreiter, M				Matheus, P; Burns, J; Weinstock, J; Hofreiter, M			Pleistocene brown bears in the mid-continent of North America	SCIENCE			English	Article							LAURENTIDE		Univ Alaska Fairbanks, Alaska Quaternary Ctr, Fairbanks, AK 99775 USA; Prov Museum Alberta, Edmonton, AB, Canada; Univ Oxford, Henry Wellcome Ancient Biomol Ctr, Oxford, England; Max Planck Evolutionary Anthropol, Leipzig, Germany	University of Alaska System; University of Alaska Fairbanks; University of Oxford; Max Planck Society	Matheus, P (corresponding author), Univ Alaska Fairbanks, Alaska Quaternary Ctr, Fairbanks, AK 99775 USA.	ffpem1@uaf.edu	Hofreiter, Michael/A-3996-2017	Hofreiter, Michael/0000-0003-0441-4705				Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; Burns JA, 1996, QUATERN INT, V32, P107, DOI 10.1016/1040-6182(95)00057-7; Dyke AS, 2002, QUATERNARY SCI REV, V21, P9, DOI 10.1016/S0277-3791(01)00095-6; Kurten B., 1980, PLEISTOCENE MAMMALS; Leonard JA, 2000, P NATL ACAD SCI USA, V97, P1651, DOI 10.1073/pnas.040453097; YOUNG RR, 1994, GEOLOGY, V22, P683, DOI 10.1130/0091-7613(1994)022<0683:ASLWLG>2.3.CO;2	6	18	19	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1150	1150		10.1126/science.1101495	http://dx.doi.org/10.1126/science.1101495			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539594	Green Submitted			2022-12-28	WOS:000225193100037
J	Nelson, KD; Mao, ZQ; Maeno, Y; Liu, Y				Nelson, KD; Mao, ZQ; Maeno, Y; Liu, Y			Odd-parity superconductivity in Sr2RuO4	SCIENCE			English	Article							HIGH-TEMPERATURE SUPERCONDUCTORS; PAIRING STATE; KNIGHT-SHIFT; SYMMETRY	Phase-sensitive measurements were made on Sr2RuO4 to establish unambiguously the odd-parity pairing in this material. The critical current of Au0.5In0.5-Sr2RuO4 superconducting quantum interference devices prepared on Sr2RuO4 single crystals was found to be a maximum for devices with junctions on the same side of the crystal and a minimum for devices with junctions on opposite sides, in the limit of zero magnetic flux; these findings indicate that the phase of the superconducting order parameter in Sr2RuO4 changes by it under inversion. This result verifies the odd-parity pairing symmetry and the formation of spin-triplet Cooper pairs in Sr2RuO4.	Penn State Univ, Dept Phys, University Pk, PA 16802 USA; Kyoto Univ, Dept Phys, Kyoto 6068502, Japan; Kyoto Univ, Int Innovat Ctr, Kyoto 6068501, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Kyoto University; Kyoto University	Liu, Y (corresponding author), Penn State Univ, Dept Phys, 104 Davey Lab, University Pk, PA 16802 USA.	liu@phys.psu.edu						ANDERSON PW, 1959, PHYS REV LETT, V3, P325, DOI 10.1103/PhysRevLett.3.325; BARRETT SE, 1990, PHYS REV B, V41, P6283, DOI 10.1103/PhysRevB.41.6283; Baskaran G, 1996, PHYSICA B, V223-24, P490, DOI 10.1016/0921-4526(96)00155-X; Bergeret FS, 2000, PHYS REV B, V62, P11872, DOI 10.1103/PhysRevB.62.11872; Duffy JA, 2000, PHYS REV LETT, V85, P5412, DOI 10.1103/PhysRevLett.85.5412; GESHKENBEIN VB, 1986, JETP LETT+, V43, P395; GESHKENBEIN VB, 1987, PHYS REV B, V36, P235, DOI 10.1103/PhysRevB.36.235; Ishida K, 1998, NATURE, V396, P658, DOI 10.1038/25315; Ishii K, 2001, EUR J NEUROL, V8, P507, DOI 10.1046/j.1468-1331.2001.00276.x; Jin R, 2000, EUROPHYS LETT, V51, P341, DOI 10.1209/epl/i2000-00358-9; Leggett AJ, 1996, PHILOS MAG B, V74, P509, DOI 10.1080/01418639608240353; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; Maeno Y, 1998, PHYS REV LETT, V81, P3765, DOI 10.1103/PhysRevLett.81.3765; MAENO Y, 1994, NATURE, V372, P532, DOI 10.1038/372532a0; MILLIS A, 1988, PHYS REV B, V38, P4504, DOI 10.1103/PhysRevB.38.4504; NOER RJ, 1964, REV MOD PHYS, V36, P177, DOI 10.1103/RevModPhys.36.177; RICE TM, 1995, J PHYS-CONDENS MAT, V7, pL643, DOI 10.1088/0953-8984/7/47/002; RUDDLESDEN SN, 1957, ACTA CRYSTALLOGR, V10, P538, DOI 10.1107/S0365110X57001929; Schulz RR, 2000, APPL PHYS LETT, V76, P912, DOI 10.1063/1.125627; VANHARLINGEN DJ, 1995, REV MOD PHYS, V67, P515, DOI 10.1103/RevModPhys.67.515; Volovik G. E., 1985, Soviet Physics - JETP, V61, P843; WOLLMAN DA, 1993, PHYS REV LETT, V71, P2134, DOI 10.1103/PhysRevLett.71.2134; Zurbuchen MA, 2001, APPL PHYS LETT, V78, P2351, DOI 10.1063/1.1364659; [No title captured]	25	302	307	1	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1151	1154		10.1126/science.1103881	http://dx.doi.org/10.1126/science.1103881			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539595				2022-12-28	WOS:000225193100038
J	Raffaelli, D				Raffaelli, D			How extinction patterns affect ecosystems	SCIENCE			English	Editorial Material									Univ York, Dept Environm, York YO10 5DD, N Yorkshire, England	University of York - UK	Raffaelli, D (corresponding author), Univ York, Dept Environm, York YO10 5DD, N Yorkshire, England.	dr3@york.ac.uk						Loreau M, 2001, SCIENCE, V294, P804, DOI 10.1126/science.1064088; Loreau M., 2002, BIODIVERSITY ECOSYST, P294; Ruesink JL, 2001, OIKOS, V93, P221, DOI 10.1034/j.1600-0706.2001.930206.x; Solan M, 2004, SCIENCE, V306, P1177, DOI 10.1126/science.1103960; Zavaleta ES, 2004, SCIENCE, V306, P1175, DOI 10.1126/science.1102643	5	86	90	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1141	1142		10.1126/science.1106365	http://dx.doi.org/10.1126/science.1106365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539589				2022-12-28	WOS:000225193100032
J	Le Mee, L; Girardeau, J; Monnier, C				Le Mee, L; Girardeau, J; Monnier, C			Mantle segmentation along the Oman ophiolite fossil mid-ocean ridge	NATURE			English	Article							SPREADING CENTER; REDOX STATE; PERIDOTITES; BENEATH; OCEAN; ABYSSAL; SPINEL; GEOCHEMISTRY; ORIGIN; INDICATORS	It has been difficult to relate the segmentation of mid-ocean ridges to processes occurring in the Earth's underlying mantle, as the mantle is rarely sampled directly and chemical variations observed in lavas at the surface are heavily influenced by details of their production as melt extracted from the mantle. Our understanding of such mantle processes has therefore relied on the analysis of pieces of fossil oceanic lithosphere now exposed at the Earth's surface, known as ophiolites. Here we present the phase chemistry and whole-rock major- and trace-element contents of 174 samples of the mantle collected along over 400 km of the Oman Sultanate ophiolite. We show that, when analysed along the fossil ridge, variations of elemental ratios sensitive to the melting process define a three-dimensional geometry of mantle upwellings, which can be related to the segmentation observed in modern mid-ocean ridge environments.	Univ Nantes, Lab Planetol & Geodynam, CNRS, UMR 6112, F-44322 Nantes 3, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); Nantes Universite	Le Mee, L (corresponding author), Univ Nantes, Lab Planetol & Geodynam, CNRS, UMR 6112, 2 Rue Houssiniere,BP 92208, F-44322 Nantes 3, France.	Laurent.Lemee@chimie.univ-nantes.fr						ALABASTER T, 1982, CONTRIB MINERAL PETR, V81, P168, DOI 10.1007/BF00371294; Amri I, 1996, EARTH PLANET SC LETT, V139, P177, DOI 10.1016/0012-821X(95)00233-3; BALLHAUS C, 1990, NATURE, V348, P437, DOI 10.1038/348437a0; Barnes SJ, 2001, J PETROL, V42, P2279, DOI 10.1093/petrology/42.12.2279; Batanova VG, 1998, GEOCHIM COSMOCHIM AC, V62, P853, DOI 10.1016/S0016-7037(97)00384-0; BODINIER JL, 1990, J PETROL, V31, P597, DOI 10.1093/petrology/31.3.597; BONATTI E, 1989, EARTH PLANET SC LETT, V91, P297, DOI 10.1016/0012-821X(89)90005-8; BRYNDZIA LT, 1990, AM J SCI, V290, P1093, DOI 10.2475/ajs.290.10.1093; Cannat M, 1996, J GEOPHYS RES-SOL EA, V101, P2847, DOI 10.1029/95JB03116; CEULENEER G, 1988, TECTONOPHYSICS, V151, P1, DOI 10.1016/0040-1951(88)90238-7; CEULENEER G, 1986, THESIS U NANTES, P338; Choblet G, 2001, EARTH PLANET SC LETT, V184, P589, DOI 10.1016/S0012-821X(00)00330-7; DICK HJB, 1984, CONTRIB MINERAL PETR, V86, P54, DOI 10.1007/BF00373711; ERNEWEIN M, 1988, TECTONOPHYSICS, V151, P247, DOI 10.1016/0040-1951(88)90248-X; Girardeau J, 2002, MAR GEOPHYS RES, V23, P43, DOI 10.1023/A:1021297614067; GIRARDEAU J, 2002, GEOCHEM GEOPHY GEOSY, V3, P1; Godard M, 2000, EARTH PLANET SC LETT, V180, P133, DOI 10.1016/S0012-821X(00)00149-7; GODARD M, 1995, EARTH PLANET SC LETT, V133, P449, DOI 10.1016/0012-821X(95)00104-K; Gruau G, 1998, GEOCHIM COSMOCHIM AC, V62, P3545, DOI 10.1016/S0016-7037(98)00250-6; Hellebrand E, 2002, CHEM GEOL, V182, P227, DOI 10.1016/S0009-2541(01)00291-1; Hellebrand E, 2001, NATURE, V410, P677, DOI 10.1038/35070546; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; ISHII T, 1992, P OC DRILL PROGR SCI, V0125; JOHNSON KTM, 1990, J GEOPHYS RES-SOLID, V95, P2661, DOI 10.1029/JB095iB03p02661; JUTEAU T, 1988, TECTONOPHYSICS, V151, P167, DOI 10.1016/0040-1951(88)90245-4; KELEMEN PB, 1992, NATURE, V358, P635, DOI 10.1038/358635a0; KLEIN EM, 1987, J GEOPHYS RES-SOLID, V92, P8089, DOI 10.1029/JB092iB08p08089; LANGMUIR CH, 1992, GEOPH MONOG SERIES, V71, P183; MACDONALD KC, 1988, NATURE, V335, P217, DOI 10.1038/335217a0; MACLEOD CJ, 1992, GEOL SOC SPEC PUBL L, V60, P39, DOI DOI 10.1144/GSL.SP.1992.060.01.03; Meibom A, 2004, EARTH PLANET SC LETT, V217, P123, DOI 10.1016/S0012-821X(03)00573-9; MERCIER JCC, 1975, J PETROL, V16, P454; MONNIER C, 1995, GEOLOGY, V23, P851, DOI 10.1130/0091-7613(1995)023<0851:BABOFT>2.3.CO;2; Nicolas A, 2000, GEOL SOC AM SPEC PAP, P67; Nicolas A, 2000, MAR GEOPHYS RES, V21, P147, DOI 10.1023/A:1026769727917; NICOLAS A, 1988, TECTONOPHYSICS, V151, P27, DOI 10.1016/0040-1951(88)90239-9; Niu YL, 1997, J PETROL, V38, P1047, DOI 10.1093/petrology/38.8.1047; Niu YL, 1997, EARTH PLANET SC LETT, V146, P243, DOI 10.1016/S0012-821X(96)00218-X; Niu YL, 2001, EARTH PLANET SC LETT, V186, P383, DOI 10.1016/S0012-821X(01)00255-2; Parkinson IJ, 1999, CHEM GEOL, V160, P409, DOI 10.1016/S0009-2541(99)00110-2; Pearce JA, 2000, CONTRIB MINERAL PETR, V139, P36, DOI 10.1007/s004100050572; Python M, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000354; REUBER I, 1988, TECTONOPHYSICS, V151, P137, DOI 10.1016/0040-1951(88)90244-2; SACK RO, 1991, AM MINERAL, V76, P827; SEMPERE JC, 1987, REV GEOPHYS, V25, P1313, DOI 10.1029/RG025i006p01313; SINTON JM, 1991, J GEOPHYS RES-SOLID, V96, P6133, DOI 10.1029/90JB02454; SMEWING JD, 1981, J GEOPHYS RES, V86, P2645, DOI 10.1029/JB086iB04p02645; Sun S.-S., 1989, GEOLOGICAL SOC LONDO, V42, P323, DOI [10.1144/GSL.SP.1989.042.01.19, DOI 10.1144/GSL.SP.1989.042.01.19]; Takazawa E, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2001GC000232; Vernieres J, 1997, J GEOPHYS RES-SOL EA, V102, P24771, DOI 10.1029/97JB01946	50	72	72	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					167	172		10.1038/nature03075	http://dx.doi.org/10.1038/nature03075			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538358				2022-12-28	WOS:000225020200034
J	Luciani, LG; Luciani, L				Luciani, LG; Luciani, L			Staghorn renal-cell carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Santa Chiara Hosp, I-38100 Trento, Italy	Santa Chiara Hospital	Luciani, LG (corresponding author), Santa Chiara Hosp, I-38100 Trento, Italy.			Luciani, Lorenzo/0000-0002-0200-895X					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2101	2101		10.1056/NEJMicm040541	http://dx.doi.org/10.1056/NEJMicm040541			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537908				2022-12-28	WOS:000225007200011
J	Fletcher, AE; Price, GM; Ng, ESW; Stirling, SL; Bulpitt, C; Breeze, E; Nunes, M; Jones, DA; Latif, A; Fasey, NM; Vickers, MR; Tulloch, AJ				Fletcher, AE; Price, GM; Ng, ESW; Stirling, SL; Bulpitt, C; Breeze, E; Nunes, M; Jones, DA; Latif, A; Fasey, NM; Vickers, MR; Tulloch, AJ			Population-based multidimensional assessment of older people in UK general practice: a cluster-randomised factorial trial	LANCET			English	Article							COMPREHENSIVE GERIATRIC ASSESSMENT; ELDERLY-PEOPLE; HOME VISITS; CLINICAL-TRIAL; COMMUNITY; INTERVENTION; VALIDATION	Background The benefit of multidimensional assessment and management of older people remains controversial. Most trials have been too small to produce adequate evidence to inform policy. We aimed to measure the effects of different approaches to assessment and management of older people. Methods We undertook a cluster-randomised factorial trial in 106 general practices (43 219 eligible patients aged 75 years and older, 78% participation), comparing (1) universal versus targeted assessment and (2) subsequent management by hospital outpatient geriatric team versus the primary-care team. All participants received a brief multidimensional assessment followed by a nurse-led in-depth assessment in the universal group, whereas in the targeted group the in-depth assessment was offered only to those with problems established at the brief assessment, Referrals to the randomised team (geriatric management or primary care), other medical or social services, health. care workers, or agencies, and emergency referrals to the general practitioner were based on a standard protocol at the in-depth assessment. The primary endpoints were mortality, admissions to hospital and institution, and quality of life. Analysis was by intention to treat and per protocol. This trial has been assigned the International Standardised Randomised Controlled Trial Number ISRCTN23494848. Findings Mortality and hospital or institutional admissions did not differ between groups. During 3 years' follow-up, significant improvements in quality of life resulted from universal versus targeted assessment in terms of homecare and from management by geriatric team versus primary-care team, in terms of mobility, social interaction, an morale. However, only the result for social interaction was consistent with a small but important effect. Interpretation The different forms of multidimensional assessment offered almost no differences in patient outcome.	Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1E 7HT, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Sect Care Elderly, London, England; Llandough Hosp, Univ Dept Geriatr Med, Cardiff, S Glam, Wales; MRC, Clin Trials Unit, Gen Practice Res Framework, London, England; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Medical Research Council Clinical Trials Unit; University of Oxford	Fletcher, AE (corresponding author), Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, Keppel St, London WC1E 7HT, England.	astrid.fletcher@lshtm.ac.uk	Ng, Edmond/G-8788-2011; Breeze, Elizabeth/AAK-4927-2021; Unemo, Magnus/ABD-6653-2021; Ng, Edmond/L-5871-2019					BARBER JH, 1985, J R COLL GEN PRACT, V35, P288; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boult C, 2001, J AM GERIATR SOC, V49, P351, DOI 10.1046/j.1532-5415.2001.49076.x; BOWNS I, 1991, BRIT J GEN PRACT, V41, P100; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; *DEP HLTH, 1989, HOSP IN PAT ENQ SER, V29; *DEP HLTH, 1989, TERMS SERV DOCT GEN; Elkan R, 2001, BMJ-BRIT MED J, V323, P719, DOI 10.1136/bmj.323.7315.719; Engelhardt JB, 1996, J AM GERIATR SOC, V44, P847, DOI 10.1111/j.1532-5415.1996.tb03747.x; Fletcher A, 1998, BRIT MED BULL, V54, P945; Fletcher AE, 2002, BMC HEALTH SERV RES, V2, DOI 10.1186/1472-6963-2-21; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; HSIEH FY, 1988, STAT MED, V7, P1195, DOI 10.1002/sim.4780071113; ILLIFFE S, 1997, EVALUATION 75S CHECK; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; *LAING BUISS, 1999, CAR HOM HOSP INF CD; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; MCGRAW PV, 1993, OPHTHAL PHYSL OPT, V13, P400, DOI 10.1111/j.1475-1313.1993.tb00499.x; *OFF POP CENS SURV, 1991, MORT STAT AR SER, V10; PATHY MSJ, 1992, LANCET, V340, P890, DOI 10.1016/0140-6736(92)93294-W; Patrick D.L., 1989, DISABLEMENT COMMUNIT; POWELLLAWTON M, 1975, J GERONTOL, V30, P85; Reuben DB, 1999, J AM GERIATR SOC, V47, P269, DOI 10.1111/j.1532-5415.1999.tb02988.x; Rockwood K, 2003, J CLIN EPIDEMIOL, V56, P736, DOI 10.1016/S0895-4356(03)00132-X; Rockwood K, 2000, J AM GERIATR SOC, V48, P1080, DOI 10.1111/j.1532-5415.2000.tb04783.x; Samsa G, 1999, PHARMACOECONOMICS, V15, P141, DOI 10.2165/00019053-199915020-00003; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; SHIPLEY MJ, 1989, INT J EPIDEMIOL, V18, P457, DOI 10.1093/ije/18.2.457; SILVERMAN M, 1995, J AM GERIATR SOC, V43, P733, DOI 10.1111/j.1532-5415.1995.tb07041.x; SMEETH L, 2001, BMJ-BRIT MED J, V323, P1; *STAT CORP, 2001, STATACORP STAT STAT; Stuck AE, 2000, ARCH INTERN MED, V160, P977, DOI 10.1001/archinte.160.7.977; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; TAYLOR RC, 1987, 35 ROYAL COLL GEN PR; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; Williams EI, 1993, 59 ROYAL COLL GEN PR	43	113	116	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1667	1677		10.1016/S0140-6736(04)17353-4	http://dx.doi.org/10.1016/S0140-6736(04)17353-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530627				2022-12-28	WOS:000224921600029
J	Nakagawa, I; Amano, A; Mizushima, N; Yamamoto, A; Yamaguchi, H; Kamimoto, T; Nara, J; Funao, J; Nakata, M; Tsuda, K; Hamada, S; Yoshimori, T				Nakagawa, I; Amano, A; Mizushima, N; Yamamoto, A; Yamaguchi, H; Kamimoto, T; Nara, J; Funao, J; Nakata, M; Tsuda, K; Hamada, S; Yoshimori, T			Autophagy defends cells against invading group a Streptococcus	SCIENCE			English	Article							PYOGENES; VIRULENCE; INVASION	We found that the autophagic machinery could effectively eliminate pathogenic group A Streptococcus (GAS) within nonphagocytic cells. After escaping from endosomes into the cytoplasm, GAS became enveloped by autophagosome-like compartments and were killed upon fusion of these compartments with lysosomes. In autophagy-deficient Atg5(-/-) cells, GAS survived, multiplied, and were released from the cells. Thus, the autophagic machinery can act as an innate defense system against invading pathogens.	Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Dent, Dept Oral Frontier Biol, Suita, Osaka 5650871, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi, Saitama 3320012, Japan; Tokyo Metropolitan Inst Med Sci, Dept Bioregulat & Metab, Bunkyo Ku, Tokyo 1138613, Japan; Nagahama Inst Biosci & Technol, Fac Biosci, Dept Cell Biol, Nagahama, Shiga 5260829, Japan; Natl Inst Genet, SOKENDAI, Dept Cell Genet, Mishima, Shizuoka 4118540, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Graduate University for Advanced Studies - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Nakagawa, I (corresponding author), Osaka Univ, Grad Sch Dent, Dept Oral & Mol Microbiol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	ichiro@dent.osaka-u.ac.jp; tamyoshi@lab.nig.ac.jp	Mizushima, Noboru/C-3635-2009	Mizushima, Noboru/0000-0002-6258-6444; Nara, Atsuki/0000-0002-4115-3017; Nakata, Masanobu/0000-0003-1686-5415				Bisno AL, 2003, LANCET INFECT DIS, V3, P191, DOI 10.1016/S1473-3099(03)00576-0; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Dorn BR, 2001, INFECT IMMUN, V69, P5698, DOI 10.1128/IAI.69.9.5698-5708.2001; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Molinari G, 2000, CELL MICROBIOL, V2, P145, DOI 10.1046/j.1462-5822.2000.00040.x; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; Nyberg P, 2004, EMBO J, V23, P2166, DOI 10.1038/sj.emboj.7600214; Pizarro-Cerda J, 1998, INFECT IMMUN, V66, P2387; Polishchuk R, 2004, NAT CELL BIOL, V6, P297, DOI 10.1038/ncb1109; Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x; Schrager HM, 1996, J CLIN INVEST, V98, P1954, DOI 10.1172/JCI118998; Sturgill-Koszycki S, 2000, J EXP MED, V192, P1261, DOI 10.1084/jem.192.9.1261; TWETEN RK, 1995, VIRULENCE MECHANISMS OF BACTERIAL PATHOGENS, 2ND EDITION, P207; Walker DH, 1997, LAB INVEST, V76, P129; Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023	20	898	930	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1037	1040		10.1126/science.1103966	http://dx.doi.org/10.1126/science.1103966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528445				2022-12-28	WOS:000225001100044
J	Hankins, C				Hankins, C			From a vicious circle to a virtuous circle: reinforcing strategies of risk, vulnerability, and impact reduction for HIV prevention	LANCET			English	Editorial Material									UNAIDS Joint UN Programme HIV AIDS, Social Mobilisat & Strateg Informat Dept, CH-1211 Geneva 27, Switzerland	UNAIDS	Hankins, C (corresponding author), UNAIDS Joint UN Programme HIV AIDS, Social Mobilisat & Strateg Informat Dept, CH-1211 Geneva 27, Switzerland.	hankinsc@unaids.org		Hankins, Catherine/0000-0002-1642-8592				Halperin DT, 2004, LANCET, V364, P1913, DOI 10.1016/S0140-6736(04)17487-4; *UNAIDS, 2001, GLOB STRAT FRAM HIV; UNAIDS, 2004, 4 UNAIDS; *UNAIDS, 2004, GLOB COAL WOM AIDS; UNAIDS/WHO, 2004, AIDS EP UPD	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1915	1916		10.1016/S0140-6736(04)17488-6	http://dx.doi.org/10.1016/S0140-6736(04)17488-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566990				2022-12-28	WOS:000225327000004
J	Oransky, I				Oransky, I			Katharina Dorothea Dalton - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 30	2004	364	9445					1576	1576		10.1016/S0140-6736(04)17300-5	http://dx.doi.org/10.1016/S0140-6736(04)17300-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	866IQ	15536676				2022-12-28	WOS:000224767600012
J	Losos, JB; Schoener, TW; Spiller, DA				Losos, JB; Schoener, TW; Spiller, DA			Predator-induced behaviour shifts and natural selection in field-experimental lizard populations	NATURE			English	Article							ANOLIS LIZARDS; DRIVE	The role of behaviour in evolutionary change has long been debated. On the one hand, behavioural changes may expose individuals to new selective pressures by altering the way that organisms interact with the environment, thus driving evolutionary divergence(1-3). Alternatively, behaviour can act to retard evolutionary change(4-6): by altering behavioural patterns in the face of new environmental conditions, organisms can minimize exposure to new selective pressures. This constraining influence of behaviour has been put forward as an explanation for evolutionary stasis within lineages(4,7-9) and niche conservatism within clades(10,11). Nonetheless, the hypothesis that behavioural change prevents natural selection from operating in new environments has never been experimentally tested. We conducted a controlled and replicated experimental study of selection in entirely natural populations; we demonstrate that lizards alter their habitat use in the presence of an introduced predator, but that these behavioural shifts do not prevent patterns of natural selection from changing in experimental populations.	Washington Univ, Dept Biol, St Louis, MO 63130 USA; Univ Calif Davis, Sect Ecol & Evolut, Davis, CA 95616 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	Washington University (WUSTL); University of California System; University of California Davis; University of California System; University of California Davis	Losos, JB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.	losos@biology.wustl.edu						Bolnick DI, 2004, EVOLUTION, V58, P608, DOI 10.1111/j.0014-3820.2004.tb01683.x; Brandon R.N., 1988, P51; BRODIE ED, 1995, TRENDS ECOL EVOL, V10, P313, DOI 10.1016/S0169-5347(00)89117-X; Coope G. R., 1995, P55; DeWitt TJ, 2003, J SEA RES, V49, P143, DOI 10.1016/S1385-1101(02)00220-4; ELDREDGE N, 1989, MACROEVOLUTIONARY DY; Garland Theodore Jr., 1994, P240; Harvey P.H., 1991, COMP METHOD EVOLUTIO; Huey RB, 2003, AM NAT, V161, P357, DOI 10.1086/346135; HURLBERT SH, 1984, ECOL MONOGR, V54, P187, DOI 10.2307/1942661; Irschick DJ, 1999, AM NAT, V154, P293, DOI 10.1086/303239; Janzen FJ, 1998, EVOLUTION, V52, P1564, DOI 10.1111/j.1558-5646.1998.tb02237.x; LANDE R, 1983, EVOLUTION, V37, P1210, DOI 10.2307/2408842; LEVITON JS, 2001, PALEONTOLOGY MACROEV; LITTELL RC, 1999, SAS SYSTEM LINEAR MO; LOSOS JB, 1994, ANNU REV ECOL SYST, V25, P467, DOI 10.1146/annurev.es.25.110194.002343; Losos JB, 1999, ECOLOGY, V80, P252, DOI 10.1890/0012-9658(1999)080[0252:DCSAAI]2.0.CO;2; PACALA SW, 1985, ECOLOGY, V66, P129, DOI 10.2307/1941313; Rundle HD, 2003, P NATL ACAD SCI USA, V100, P14943, DOI 10.1073/pnas.2036360100; SCHOENER TW, 1975, ECOL MONOGR, V45, P233, DOI 10.2307/1942423; Schoener TW, 2002, ECOL MONOGR, V72, P383, DOI 10.1890/0012-9615(2002)072[0383:POACAL]2.0.CO;2; SCHOENER TW, 1982, OECOLOGIA, V53, P160, DOI 10.1007/BF00545659; Schoener TW, 2001, NATURE, V412, P183, DOI 10.1038/35084071; SCHOENER TW, 1982, OIKOS, V39, P1, DOI 10.2307/3544525; WAKE DB, 1983, J THEOR BIOL, V101, P211, DOI 10.1016/0022-5193(83)90335-1; WCISLO WT, 1989, ANNU REV ECOL SYST, V20, P137, DOI 10.1146/annurev.es.20.110189.001033; Webb CO, 2002, ANNU REV ECOL SYST, V33, P475, DOI 10.1146/annurev.ecolsys.33.010802.150448; WESTEBERHARD MJ, 1989, ANNU REV ECOL SYST, V20, P249, DOI 10.1146/annurev.es.20.110189.001341; Williams E.E., 1983, LIZARD ECOLOGY STUDI, P326, DOI DOI 10.4159/HARVARD.9780674183384.C18; WYLES JS, 1983, P NATL ACAD SCI-BIOL, V80, P4394, DOI 10.1073/pnas.80.14.4394	30	190	193	0	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					505	508		10.1038/nature03039	http://dx.doi.org/10.1038/nature03039			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565155				2022-12-28	WOS:000225322100047
J	Pandolfi, PP				Pandolfi, PP			Breast cancer - Loss of PTEN predicts resistance to treatment	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ERBB2		Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA.							Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972	5	127	144	1	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2337	2338		10.1056/NEJMcibr043143	http://dx.doi.org/10.1056/NEJMcibr043143			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564551				2022-12-28	WOS:000225298100017
J	Rodwin, VG; Le Pen, C				Rodwin, VG; Le Pen, C			Health care reform in France - The birth of state-led managed care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10003 USA; Int Longev Ctr USA, World Cities Project, New York, NY USA; Univ Paris 09, Paris, France	New York University; UDICE-French Research Universities; PSL Research University Paris; Universite Paris-Dauphine	Rodwin, VG (corresponding author), NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10003 USA.							DEKERVASDOUE J, 1999, REVOLUTION REFORME; FRAGONARD B, 2003, RAPPORT HAUT CONSEIL; LEPEN C, 1999, HABITS NEUFS HIPPOCR; Rodwin VG, 2003, AM J PUBLIC HEALTH, V93, P31, DOI 10.2105/AJPH.93.1.31; The world health report, 2000, HLTH SYST IMPR PERF	5	18	18	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2259	2262		10.1056/NEJMp048210	http://dx.doi.org/10.1056/NEJMp048210			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564541				2022-12-28	WOS:000225298100003
J	Teixeira, A; Tahiri-Alaoui, A; West, S; Thomas, B; Ramadass, A; Martianov, I; Dye, M; James, W; Proudfoot, NJ; Akoulitchev, A				Teixeira, A; Tahiri-Alaoui, A; West, S; Thomas, B; Ramadass, A; Martianov, I; Dye, M; James, W; Proudfoot, NJ; Akoulitchev, A			Autocatalytic RNA cleavage in the human beta-globin pre-mRNA promotes transcription termination	NATURE			English	Article							SELF-SPLICING RNA; IN-VIVO; CATALYSIS; TETRAHYMENA; EXPRESSION; INTRON	New evidence indicates that termination of transcription is an important regulatory step, closely related to transcriptional interference(1) and even transcriptional initiation(2). However, how this occurs is poorly understood. Recently, in vivo analysis of transcriptional termination for the human beta-globin gene revealed a new phenomenon-co-transcriptional cleavage (CoTC)(3). This primary cleavage event within beta-globin pre-messenger RNA, downstream of the poly(A) site, is critical for efficient transcriptional termination by RNA polymerase II3. Here we show that the CoTC process in the human beta-globin gene involves an RNA self-cleaving activity. We characterize the autocatalytic core of the CoTC ribozyme and show its functional role in efficient termination in vivo. The identified core CoTC is highly conserved in the 3' flanking regions of other primate beta-globin genes. Functionally, it resembles the 3' processive, self-cleaving ribozymes described for the protein-encoding genes from the myxomycetes Didymium iridis and Physarum polycephalum, indicating evolutionary conservation of this molecular process. We predict that regulated autocatalytic cleavage elements within pre-mRNAs may be a general phenomenon and that functionally it may provide the entry point for exonucleases involved in mRNA maturation, turnover and, in particular, transcriptional termination.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	University of Oxford; Wellcome Trust Sanger Institute	Akoulitchev, A (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	alexandre.akoulitchev@path.ox.ac.uk	Teixeira, Alexandre/N-9654-2013; james, william/H-4289-2013; West, Steven/AAG-4009-2019	Teixeira, Alexandre/0000-0001-8899-9514; james, william/0000-0002-2506-1198; West, Steven/0000-0002-7622-9050; Martiyanov, Igor/0000-0001-6108-2036; Proudfoot, Nicholas/0000-0001-8646-3222				ADAMS SE, 1988, NUCLEIC ACIDS RES, V16, P4287, DOI 10.1093/nar/16.10.4287; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Doherty EA, 2000, ANNU REV BIOCHEM, V69, P597, DOI 10.1146/annurev.biochem.69.1.597; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Dye MJ, 2001, CELL, V105, P669, DOI 10.1016/S0092-8674(01)00372-5; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; Emilsson GM, 2003, RNA, V9, P907, DOI 10.1261/rna.5680603; Greger IH, 2000, P NATL ACAD SCI USA, V97, P8415, DOI 10.1073/pnas.140217697; Krishnamurthy S, 2004, MOL CELL, V14, P387, DOI 10.1016/S1097-2765(04)00235-7; Kwek KY, 2002, NAT STRUCT BIOL, V9, P800, DOI 10.1038/nsb862; Lee JM, 1997, J BIOL CHEM, V272, P10990; Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p; Lilley DMJ, 2003, TRENDS BIOCHEM SCI, V28, P495, DOI 10.1016/S0968-0004(03)00191-9; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; ROCHELEAU GA, 1994, NUCLEIC ACIDS RES, V22, P4315, DOI 10.1093/nar/22.20.4315; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; Stage-Zimmermann TK, 1998, RNA, V4, P875, DOI 10.1017/S1355838298980876; TAHIRIALAOUI A, 2002, NUCLEIC ACIDS RES, V30, P1; Vader A, 1999, EMBO J, V18, P1003, DOI 10.1093/emboj/18.4.1003; van Hoof A, 2002, CURR BIOL, V12, pR285, DOI 10.1016/S0960-9822(02)00802-3; Winkler WC, 2003, CHEMBIOCHEM, V4, P1024, DOI 10.1002/cbic.200300685; Winkler WC, 2004, NATURE, V428, P281, DOI 10.1038/nature02362; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	29	81	88	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					526	530		10.1038/nature03032	http://dx.doi.org/10.1038/nature03032			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565159				2022-12-28	WOS:000225322100052
J	Yekeler, E; Akyol, Y				Yekeler, E; Akyol, Y			Cholelithiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Istanbul Fac Med, TR-34390 Istanbul, Turkey	Istanbul University	Yekeler, E (corresponding author), Istanbul Fac Med, TR-34390 Istanbul, Turkey.								0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2318	2318		10.1056/NEJMicm030898	http://dx.doi.org/10.1056/NEJMicm030898			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564547				2022-12-28	WOS:000225298100011
J	Haber, P; DeStefano, F; Angulo, FJ; Iskander, J; Shadomy, SV; Weintraub, E; Chen, RT				Haber, P; DeStefano, F; Angulo, FJ; Iskander, J; Shadomy, SV; Weintraub, E; Chen, RT			Guillain-Barre syndrome following influenza vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EVENT-REPORTING-SYSTEM; CAMPYLOBACTER-JEJUNI; UNITED-STATES; ASSOCIATION; INFECTION; VACCINES; SAFETY; VAERS	Context An unexplained increase in the risk of Guillain-Barre syndrome (GBS) occurred among recipients of the swine influenza vaccine in 1976-1977. Guillain-Barre syndrome remains the most frequent neurological condition reported after influenza vaccination to the Vaccine Adverse Events Reporting System (VAERS) since its inception in 1990. Objective to evaluate trends of reports to VAERS of GBS following influenza vaccination in adults. Design, Setting, and Participants VAERS is the US national spontaneous reporting system for adverse events following vaccination. Reports of GBS in persons 18 years or older following influenza vaccination were evaluated for each influenza season from July 1, 1990, through June 30, 2003. The number of people vaccinated was estimated from the National Health Interview Survey and US census data. Beginning in 1994, active follow-up was conducted to verify GBS diagnosis and obtain other clinical details. Main Outcome Measure Reporting rates of GBS following influenza vaccination over time. Results From July 1990 through June 2003, VAERS received 501 reports of GBS following influenza vaccination in adults. The median onset interval (13 days) was longer than that of non-GBS reports of adverse events after influenza vaccine (1 day) (P<.001). The annual reporting rate decreased 4-fold from a high of 0.17 per 100 000 vaccinees in 1993-1994 to 0.04 in 2002-2003 (P<.001). A GBS diagnosis was confirmed in 82% of reports. Preceding illness within 4 weeks of vaccination was identified in 24% of reported cases. Conclusions From 1990 to 2003, VAERS reporting rates of GBS after influenza vaccination decreased. The long onset interval and low prevalence of other preexisting illnesses are consistent with a possible causal association between GBS and influenza vaccine. These findings require additional research, which can lead to a fuller understanding of the causes of GBS and its possible relationship with influenza vaccine.	Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Haber, P (corresponding author), Ctr Dis Control & Prevent, Immunizat Safety Branch, Epidemiol & Surveillance Div, Natl Immunizat Program, 1600 Clifton Rd NE,Mail Stop E-61, Atlanta, GA 30333 USA.	PHaber@cdc.gov	Chen, Robert T/AIA-8164-2022; Shadomy, Sean/ABA-1234-2020	Chen, Robert T/0000-0002-3094-8367; 				BREMAN JG, 1984, AM J EPIDEMIOL, V119, P880, DOI 10.1093/oxfordjournals.aje.a113810; *CDCP, 1976, MMWR-MORBID MORTAL W, V25, P401; Chen R, 1992, POST MARKETING SURVE, V6, P5; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Ellenberg SS, 1997, PUBLIC HEALTH REP, V112, P10; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; HURWITZ ES, 1981, NEW ENGL J MED, V304, P1557, DOI 10.1056/NEJM198106253042601; Institute of Medicine, 2003, IMM SAF REV INFL VAC; KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698; LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; MARKS JS, 1980, JAMA-J AM MED ASSOC, V243, P2490, DOI 10.1001/jama.243.24.2490; MASSEY J, 1989, VITAL HLTH STAT 2, V110; MISHU B, 1993, CLIN INFECT DIS, V17, P104, DOI 10.1093/clinids/17.1.104; O'Mara D, 2003, INFECT MED, V20, P548; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; ROSCELLI JD, 1991, AM J EPIDEMIOL, V133, P952, DOI 10.1093/oxfordjournals.aje.a115974; Rosenthal S, 1995, AM J PUBLIC HEALTH, V85, P1706, DOI 10.2105/AJPH.85.12.1706; SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795; Singleton JA, 1999, VACCINE, V17, P2908, DOI 10.1016/S0264-410X(99)00132-2; Steiner Claudia, 2002, Eff Clin Pract, V5, P143; Teutsch S.M., 2000, PRINCIPLES PRACTICE; *US GOV, 2002, US GOV CENS REP; Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002; Vugia D., 2004, Morbidity and Mortality Weekly Report, V53, P340; ZHOU W, 2003, MMWR-MORBID MORTAL W, P1	27	179	193	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2478	2481		10.1001/jama.292.20.2478	http://dx.doi.org/10.1001/jama.292.20.2478			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562126				2022-12-28	WOS:000225303000022
J	Nolan, MF; Malleret, G; Dudman, JT; Buhl, DL; Santoro, B; Gibbs, E; Vronskaya, S; Buzsaki, G; Siegelbaum, SA; Kandel, ER; Morozov, A				Nolan, MF; Malleret, G; Dudman, JT; Buhl, DL; Santoro, B; Gibbs, E; Vronskaya, S; Buzsaki, G; Siegelbaum, SA; Kandel, ER; Morozov, A			A behavioral role for dendritic integration: HCN1 channels constrain spatial inputs to distal dendrites memory and plasticity at of CA1 pyramidal neurons	CELL			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL GAMMA OSCILLATIONS; CURRENT I-H; SYNAPTIC MODIFICATIONS; PACEMAKER CHANNELS; THETA OSCILLATIONS; CATION CURRENTS; MICE LACKING; CELLS; MOUSE	The importance of long-term synaptic plasticity as a cellular substrate for learning and memory is well established. By contrast, little is known about how learning and memory are regulated by voltage-gated ion channels that integrate synaptic information. We investigated this question using mice with general or forebrain-restricted knockout of the HCN1 gene, which we find encodes a major component of the hyperpolarization-activated inward current (I-h) and is an important determinant of dendritic integration in hippocampal CA1 pyramidal cells. Deletion of HCN1 from forebrain neurons enhances hippocampal-dependent learning and memory, augments the power of theta oscillations, and enhances long-term potentiation (LTP) at the direct perforant path input to the distal dendrites of CA1 pyramidal neurons, but has little effect on LTP at the more proximal Schaffer collateral inputs. We suggest that HCN1 channels constrain learning and memory by regulating dendritic integration of distal synaptic inputs to pyramidal cells.	Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ, Dept Physiol, New York, NY 10032 USA; Columbia Univ, Dept Biochem & Biophys, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Kavli Inst Brain Sci, New York, NY 10032 USA; NIMH, Hlth Behav Genet, Bethesda, MD 20892 USA	Columbia University; Rutgers State University Newark; Rutgers State University New Brunswick; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kandel, ER (corresponding author), Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA.	erk5@columbia.edu	Nolan, Matthew/A-1356-2009; Buhl, Derek/AAV-3911-2021	Nolan, Matthew/0000-0003-1062-6501; Buzsaki, Gyorgy/0000-0002-3100-4800; Santoro, Bina/0000-0002-4277-1992; Buhl, Derek/0000-0003-4433-7150	NIMH NIH HHS [MH045923, MH54671] Funding Source: Medline; NINDS NIH HHS [NS34994, NS36658] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036658, R01NS034994] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; Berger T, 2001, J NEUROPHYSIOL, V85, P855, DOI 10.1152/jn.2001.85.2.855; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; Bliss TVP, 2003, PHILOS T ROY SOC B, V358, P607, DOI 10.1098/rstb.2003.1282; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Buhl DL, 2003, J NEUROSCI, V23, P1013; Buzsaki G, 2003, NEUROSCIENCE, V116, P201, DOI 10.1016/S0306-4522(02)00669-3; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; COLBERT CM, 1993, BRAIN RES, V606, P87, DOI 10.1016/0006-8993(93)91573-B; Czurko A, 1999, EUR J NEUROSCI, V11, P344, DOI 10.1046/j.1460-9568.1999.00446.x; Fisahn A, 2002, NEURON, V33, P615, DOI 10.1016/S0896-6273(02)00587-1; Gasparini S, 1997, PFLUG ARCH EUR J PHY, V435, P99, DOI 10.1007/s004240050488; Golding NL, 2002, NATURE, V418, P326, DOI 10.1038/nature00854; Hu H, 2002, J PHYSIOL-LONDON, V545, P783, DOI 10.1113/jphysiol.2002.029249; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; Kamondi A, 1998, HIPPOCAMPUS, V8, P244, DOI 10.1002/(SICI)1098-1063(1998)8:3<244::AID-HIPO7>3.0.CO;2-J; Kubota M, 2001, BIOCHEM BIOPH RES CO, V282, P242, DOI 10.1006/bbrc.2001.4572; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Lorincz A, 2002, NAT NEUROSCI, V5, P1185, DOI 10.1038/nn962; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Lupica CR, 2001, J NEUROPHYSIOL, V86, P261, DOI 10.1152/jn.2001.86.1.261; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; Magee JC, 1998, J NEUROSCI, V18, P7613; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Malleret G, 1999, J NEUROSCI, V19, P6157, DOI 10.1523/JNEUROSCI.19-14-06157.1999; Malleret G, 2001, CELL, V104, P675, DOI 10.1016/S0092-8674(01)00264-1; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Meiri N, 1997, P NATL ACAD SCI USA, V94, P4430, DOI 10.1073/pnas.94.9.4430; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Nolan MF, 2003, CELL, V115, P551, DOI 10.1016/S0092-8674(03)00884-5; Notomi T, 2004, J COMP NEUROL, V471, P241, DOI 10.1002/cne.11039; Otmakhova NA, 2004, J NEUROPHYSIOL, V92, P2027, DOI 10.1152/jn.00427.2004; Otmakhova NA, 2002, J NEUROSCI, V22, P1199, DOI 10.1523/JNEUROSCI.22-04-01199.2002; Pike FG, 2000, J PHYSIOL-LONDON, V529, P205, DOI 10.1111/j.1469-7793.2000.00205.x; Remondes M, 2002, NATURE, V416, P736, DOI 10.1038/416736a; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Routtenberg A, 2000, P NATL ACAD SCI USA, V97, P7657, DOI 10.1073/pnas.97.13.7657; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; STROHMANN B, 1994, J NEUROPHYSIOL, V71, P1361, DOI 10.1152/jn.1994.71.4.1361; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Wang ZR, 2003, NEURON, V37, P463, DOI 10.1016/S0896-6273(02)01189-3; Williams SR, 2000, J NEUROPHYSIOL, V83, P3177, DOI 10.1152/jn.2000.83.5.3177; Williams SR, 2003, J NEUROSCI, V23, P7358; Witter MP, 2000, ANN NY ACAD SCI, V911, P1; Xu CQ, 2004, EUR J NEUROSCI, V19, P2299, DOI 10.1111/j.0953-816X.2004.03316.x	52	365	375	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					719	732		10.1016/S0092-8674(04)01055-4	http://dx.doi.org/10.1016/S0092-8674(04)01055-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550252	Bronze			2022-12-28	WOS:000225389500016
J	Amexo, M; Tolhurst, R; Barnish, G; Bates, I				Amexo, M; Tolhurst, R; Barnish, G; Bates, I			Malaria misdiagnosis: effects on the poor and vulnerable	LANCET			English	Review							PNEUMONIA; OVERLAP; BURDEN; CARE; COST; PAY	Context Effective and affordable treatment is recommended for all cases of malaria within 24 h of the onset of illness. Most cases of "malaria" (ie, fever) are self-diagnosed and most treatments, and deaths, occur at home. The most ethical and cost-effective policy is to ensure that newer drug combinations are only used for true cases of malaria. Although it is cost effective to improve the accuracy of malaria diagnosis, simple, accurate, and inexpensive methods are not widely available, particularly in poor communities where they are most needed. Starting point In a recent study in Uganda, Karin Kallander and colleagues emphasise the difficulty in making a presumptive diagnosis of malaria, and highlight the urgent need for improved diagnostic tools that can be used at community and primary-care level, especially in poorer populations (Acta Trap 2004; 90: 211-14). Where next? Health systems need strengthening at referral and community level, so that rapid accurate diagnosis and effective treatment is available for those who are least able to withstand the consequences of illness. Indirect evidence strongly suggests that misdiagnosis of malaria contributes to a vicious cycle of increasing ill-health and deepening poverty. Much better direct evidence is needed about why and how misdiagnosis affects the poor and vulnerable.	Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England	Liverpool School of Tropical Medicine; University of Liverpool	Bates, I (corresponding author), Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England.	ibates@liv.ac.uk		bates, imelda/0000-0002-0862-8199; Tolhurst, Rachel/0000-0002-3005-6641				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; AsensoOkyere WK, 1997, SOC SCI MED, V45, P659, DOI 10.1016/S0277-9536(96)00383-8; ASENSOOKYERE WK, 1994, WORLD HEALTH FORUM, V15, P265; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Breman JG, 2004, AM J TROP MED HYG, V71, P1; Chandramohan D, 2002, TROP MED INT HEALTH, V7, P45, DOI 10.1046/j.1365-3156.2002.00827.x; Duffy PE, 2004, LANCET, V363, P3, DOI 10.1016/S0140-6736(03)15230-0; El-Nageh M M, 1996, World Health Forum, V17, P200; FOSU GB, 1981, SOC SCI MED-MED ANTH, V15, P471, DOI 10.1016/0160-7987(81)90021-1; Goodman CA, 2001, HEALTH ECON, V10, P731, DOI 10.1002/hec.621; Hien TT, 2004, LANCET, V363, P18, DOI 10.1016/S0140-6736(03)15163-X; Kallander K, 2004, ACTA TROP, V90, P211, DOI 10.1016/j.actatropica.2003.11.013; McCombie SC, 2002, HEALTH POLICY PLANN, V17, P333, DOI 10.1093/heapol/17.4.333; Murray CK, 2003, TROP MED INT HEALTH, V8, P876, DOI 10.1046/j.1365-3156.2003.01115.x; Narayan D., 2000, VOICES POOR CRYING O; ODEMPSEY TJD, 1993, T ROY SOC TROP MED H, V87, P662, DOI 10.1016/0035-9203(93)90279-Y; Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7; Russell S, 1996, HEALTH POLICY PLANN, V11, P219, DOI 10.1093/heapol/11.3.219; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; Waddington C., 1990, International Journal of Health Planning and Management, V5, P287, DOI 10.1002/hpm.4740050405; *WHO, 2003, EC COST MAL, P10; YODER RA, 1989, SOC SCI MED, V29, P35, DOI 10.1016/0277-9536(89)90125-1	22	337	340	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1896	1898		10.1016/S0140-6736(04)17446-1	http://dx.doi.org/10.1016/S0140-6736(04)17446-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555670				2022-12-28	WOS:000225269300031
J	Gidwani, S; Fairbank, A				Gidwani, S; Fairbank, A			The orthopaedic approach to managing osteoarthritis of the knee	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SURVIVAL ANALYSIS; DOUBLE-BLIND; ARTHROPLASTY; REPLACEMENT; INJECTIONS; HYALURONAN; PLACEBO; HIP		Kingston Gen Hosp, Dept Orthopaed, Surrey KT2 7QB, England; Univ London St Georges Hosp, Dept Orthopaed, London SW17 0QT, England	St Georges University London	Gidwani, S (corresponding author), Kingston Gen Hosp, Dept Orthopaed, Surrey KT2 7QB, England.	samgidwani@yahoo.com						ACKROYD CE, 2003, J BONE JOINT SURG S, V2, P162; Billings A, 2000, J BONE JOINT SURG AM, V82A, P70, DOI 10.2106/00004623-200001000-00009; Brandt KD, 2000, ARTHRITIS RHEUM-US, V43, P1192, DOI 10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L; Brown A, 2001, Issues Emerg Health Technol, P1; BUECHEL FF, 2002, CLIN ORTHOP RELAT R, V404, P40; CALLAHAN CM, 1994, JAMA-J AM MED ASSOC, V271, P1349, DOI 10.1001/jama.271.17.1349; Deshmukh RV, 2001, CLIN ORTHOP RELAT R, P272; Dieppe P, 2003, RHEUM DIS CLIN N AM, V29, P687, DOI 10.1016/S0889-857X(03)00054-1; Dixon T, 2004, ANN RHEUM DIS, V63, P825, DOI 10.1136/ard.2003.012724; FELSON DT, 1988, EPIDEMIOL REV, V10, P1; Fond J, 2002, ARTHROSCOPY, V18, P829, DOI 10.1053/jars.2002.36225; Gidwani S, 2003, J ARTHROPLASTY, V18, P199, DOI 10.1054/arth.2003.50021; Gill G S, 2001, Am J Knee Surg, V14, P209; Gill GS, 2003, J BONE JOINT SURG AM, V85A, P432, DOI 10.2106/00004623-200303000-00005; Hanssen A D, 2001, Instr Course Lect, V50, P499; HUANG CH, 2003, CLIN ORTHOP RELAT R, V416, P265; Jacobs W, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003130.PUB2; Kane R.L., 2003, TOTAL KNEE REPLACEME; Karlsson J, 2002, RHEUMATOLOGY, V41, P1240, DOI 10.1093/rheumatology/41.11.1240; Kennedy LG, 2003, KNEE, V10, P161, DOI 10.1016/S0968-0160(02)00138-2; Khaw FM, 2001, J ARTHROPLASTY, V16, P161, DOI 10.1054/arth.2001.20254; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; Leopold SS, 2003, J BONE JOINT SURG AM, V85A, P1197, DOI 10.2106/00004623-200307000-00003; *MED SERV ADV COMM, 2003, INTR ART VISC TREATM, P88; Mont MA, 2002, J BONE JOINT SURG AM, V84A, P1977, DOI 10.2106/00004623-200211000-00011; Mont Michael A, 2003, Instr Course Lect, V52, P397; Moseley JB, 2002, NEW ENGL J MED, V347, P81, DOI 10.1056/NEJMoa013259; Moynihan R, 2002, BMJ-BRIT MED J, V324, P859, DOI 10.1136/bmj.324.7342.859; Murray DW, 1998, J BONE JOINT SURG BR, V80B, P983, DOI 10.1302/0301-620X.80B6.8177; Naudie D, 1999, CLIN ORTHOP RELAT R, P18; Raynauld JP, 2003, ARTHRITIS RHEUM, V48, P370, DOI 10.1002/art.10777; Ritter MA, 2001, CLIN ORTHOP RELAT R, P51; Robertsson O, 2001, ACTA ORTHOP SCAND, V72, P503, DOI 10.1080/000164701753532853; Smith AM, 2002, KNEE, V9, P27, DOI 10.1016/S0968-0160(01)00127-2; Svard UCG, 2001, J BONE JOINT SURG BR, V83B, P191, DOI 10.1302/0301-620X.83B2.10966; Tauro B, 2002, J BONE JOINT SURG BR, V84B, P308; TRIA AJ, 2003, CLIN ORTHOP RELAT R, V416, P185; Walker-Bone K, 2000, BMJ-BRIT MED J, V321, P936, DOI 10.1136/bmj.321.7266.936	38	33	36	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1220	1224A		10.1136/bmj.329.7476.1220	http://dx.doi.org/10.1136/bmj.329.7476.1220			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15550426	Green Published			2022-12-28	WOS:000225335700019
J	Wickens, M; Gonzalez, TN				Wickens, M; Gonzalez, TN			Knives, accomplices, and RNA	SCIENCE			English	Editorial Material							POLYADENYLATION; CLEAVAGE; COMPLEX; PROTEINS; TRANSCRIPTION; ENDONUCLEASE; COMPONENT; MECHANISM; ENZYMES; SNORNA		Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Wickens, M (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.	wickens@biochem.wisc.edu						Abelson J, 1998, J BIOL CHEM, V273, P12685, DOI 10.1074/jbc.273.21.12685; Aravind L, 1999, In Silico Biol, V1, P69; Bai CY, 1996, MOL CELL BIOL, V16, P6661; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; de Vries H, 2000, EMBO J, V19, P5895, DOI 10.1093/emboj/19.21.5895; Dheur S, 2003, EMBO J, V22, P2831, DOI 10.1093/emboj/cdg253; Edmonds M, 2002, PROG NUCLEIC ACID RE, V71, P285, DOI 10.1016/S0079-6603(02)71046-5; MAIZELS N, 1999, RNA WORLD, P79; Minvielle-Sebastia L, 1999, CURR OPIN CELL BIOL, V11, P352, DOI 10.1016/S0955-0674(99)80049-0; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; MOORE CL, 1986, EMBO J, V5, P1929, DOI 10.1002/j.1460-2075.1986.tb04446.x; Morlando M, 2002, MOL CELL BIOL, V22, P1379, DOI 10.1128/MCB.22.5.1379-1389.2002; OCONNOR JP, 1992, MOL CELL BIOL, V12, P3843, DOI 10.1128/MCB.12.9.3843; Paushkin SV, 2004, CELL, V117, P311, DOI 10.1016/S0092-8674(04)00342-3; Ryan K, 2004, RNA, V10, P565, DOI 10.1261/rna.5214404; Schiffer S, 2002, EMBO J, V21, P2769, DOI 10.1093/emboj/21.11.2769; SHEETS MD, 1987, MOL CELL BIOL, V7, P1518, DOI 10.1128/MCB.7.4.1518; Steinmetz EJ, 2003, MOL CELL BIOL, V23, P6339, DOI 10.1128/MCB.23.18.6339-6349.2003; Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999; Zhao J, 1999, MOL CELL BIOL, V19, P7733	24	17	17	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1299	1300		10.1126/science.1100137	http://dx.doi.org/10.1126/science.1100137			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550648				2022-12-28	WOS:000225301600027
J	Rajagopalan, H; Lengauer, C				Rajagopalan, H; Lengauer, C			Aneuploidy and cancer	NATURE			English	Article							CENTROSOME AMPLIFICATION; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; GENETIC INSTABILITY; EVOLUTION; INACTIVATION; DEFECTS; TUMORS; CELLS; HCDC4	In contrast to normal cells, aneuploidy - alterations in the number of chromosomes - is consistently observed in virtually all cancers. A growing body of evidence suggests that aneuploidy is often caused by a particular type of genetic instability, called chromosomal instability, which may reflect defects in mitotic segregation in cancer cells. A better understanding of the molecular mechanisms leading to aneuploidy holds promise for the development of cancer drugs that target this process.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Rajagopalan, H (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St, Baltimore, MD 21231 USA.	lengauer@jhmi.edu						Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Boveri T, 1914, FRAGE ENTSTEHUNG MAL; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; der-Sarkissian H, 2004, ONCOGENE, V23, P1221, DOI 10.1038/sj.onc.1207152; Duesberg P, 1999, ANTICANCER RES, V19, P4887; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fukagawa T, 2004, EXP CELL RES, V296, P21, DOI 10.1016/j.yexcr.2004.03.004; Gisselsson D, 2002, BRIT J CANCER, V87, P202, DOI 10.1038/sj.bjc.6600438; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; HEIM S, 1995, CANC CYTOGENETICS, P369; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEVINE DS, 1991, GASTROENTEROLOGY, V101, P1198, DOI 10.1016/0016-5085(91)90068-V; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; Pihan GA, 1998, CANCER RES, V58, P3974; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; REID BJ, 1987, GASTROENTEROLOGY, V93, P1; Risques RA, 2003, CANCER RES, V63, P7206; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sawyers CL, 2001, SCIENCE, V294, P1834; SPENCER F, 1990, GENETICS, V124, P237; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Yamamoto H, 2002, J GASTROENTEROL, V37, P153, DOI 10.1007/s005350200015; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou W, 2002, LANCET, V359, P219, DOI 10.1016/S0140-6736(02)07448-2; 王志强, 1989, Acta Mathematica Sinica. New Series, V5, P101	49	521	557	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					338	341		10.1038/nature03099	http://dx.doi.org/10.1038/nature03099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549096				2022-12-28	WOS:000225161400044
J	DeWitt, J; Devereaux, B; Chriswell, M; McGreevy, K; Howard, T; Imperiale, TF; Ciaccia, D; Lane, KA; Maglinte, D; Kopecky, K; LeBlanc, J; McHenry, L; Madura, J; Aisen, A; Cramer, H; Cummings, O; Sherman, S				DeWitt, J; Devereaux, B; Chriswell, M; McGreevy, K; Howard, T; Imperiale, TF; Ciaccia, D; Lane, KA; Maglinte, D; Kopecky, K; LeBlanc, J; McHenry, L; Madura, J; Aisen, A; Cramer, H; Cummings, O; Sherman, S			Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							PHASE HELICAL CT; DUCTAL ADENOCARCINOMA; DETERMINING RESECTABILITY; AMPULLARY CARCINOMA; VASCULAR INVASION; HEAD; EUS; ULTRASOUND; DIAGNOSIS; SURVIVAL	Background: Accurate preoperative detection and staging of pancreatic cancer may identify patients with locoregional disease that is amenable to surgical resection. Objective: To compare endoscopic ultrasonography and multidetector computed tomography (CT) for the detection, staging, and resectability of known or suspected locoregional pancreatic cancer. Design: Prospective, observational, cohort study. Setting: Single, tertiary referral hospital in Indianapolis, Indiana. Patients: 120 participants with known or suspected locoregional pancreatic cancer. Interventions: Endoscopic ultrasonography followed by multidetector CT was performed in all patients. Patients with known or suspected pancreatic cancer deemed potentially resectable by 1 or both tests were considered for surgery. Measurements: Detection, staging, and resectability of pancreatic cancer. Surgically resected pancreatic cancer with negative microscopic histologic margins was considered resectable. Results: Of 120 patients enrolled, 104 (87%) underwent endoscopic ultrasonography and CT. Of the 80 patients with pancreatic cancer, 27 (34%) were managed nonoperatively, and 53 (66%) treated surgically had resectable (n = 25) or unresectable (n = 28) cancer. For the 80 patients with cancer, the sensitivity of endoscopic ultrasonography (98% [95% CI, 91% to 100%]) for detecting a pancreatic mass was greater than that of CT (86% [CI, 77% to 93%]; P = 0.012). For the 53 surgical patients, endoscopic ultrasonography was superior to CT for tumor staging accuracy (67% vs. 41%; P < 0.001) but equivalent for nodal staging accuracy (44% vs. 47%; P > 0.2). Of the 25 resectable pancreatic tumors in patients recommended for surgery, endoscopic ultrasonography and CT correctly identified 88% and 92%, respectively, as resectable. Of the 28 unresectable pancreatic tumors in patients recommended for surgery, endoscopic ultrasonography and CT correctly identified 68% and 64%, respectively, as unresectable. Limitations: Radiologists who read the scans and endosonographers were not blinded to previous radiographic information. Because of the modest sample size, CIs of the sensitivity estimates were sometimes wide. Conclusion: Compared with multidetector CT, endoscopic ultrasonography is superior for tumor detection and staging but similar for nodal staging and resectability of preoperatively suspected nonmetastatic pancreatic cancer.	Indiana Univ, Med Ctr, Dept Med,Roudebush Vet Affairs Med Ctr, Div Gastroenterol, Indianapolis, IN 46202 USA; Regenstrief Inst Inc, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	DeWitt, J (corresponding author), Indiana Univ, Med Ctr, Dept Med,Roudebush Vet Affairs Med Ctr, Div Gastroenterol, 550 N Univ Blvd,UH 4100, Indianapolis, IN 46202 USA.	jodewitt@iupui.edu	DeWitt, John/AAP-3977-2020; Devereaux, Benedict/C-9440-2013	Imperiale, Thomas/0000-0001-7586-1073	NIDDK NIH HHS [K24 DK02756] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002756] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRESTI A, 1992, STAT SCI, V7, P131, DOI DOI 10.1214/SS/1177011454; Ahmad NA, 2000, GASTROINTEST ENDOSC, V52, P463, DOI 10.1067/mge.2000.107725; Akahoshi K, 1998, BRIT J RADIOL, V71, P492, DOI 10.1259/bjr.71.845.9691893; *AM GASTR ASS, 1999, GASTROENTEROLOGY, V117, P1463; Benassai G, 2000, J SURG ONCOL, V73, P212; Boland GW, 1999, AM J ROENTGENOL, V172, P605, DOI 10.2214/ajr.172.3.10063844; Buscail L, 1999, GASTROINTEST ENDOSC, V50, P34, DOI 10.1016/S0016-5107(99)70341-X; Choi BI, 1997, ABDOM IMAGING, V22, P199, DOI 10.1007/s002619900172; CONNOLLY MM, 1987, ANN SURG, V206, P366, DOI 10.1097/00000658-198709000-00015; Diehl SJ, 1998, RADIOLOGY, V206, P373, DOI 10.1148/radiology.206.2.9457188; ELASHOFF JD, 2002, NQUERY ADVISOR VERSI; Foley WD, 2002, RADIOGRAPHICS, V22, P701, DOI 10.1148/radiographics.22.3.g02ma28701; GREENE FL, 1997, AJCC CANC STAGING MA, P121; GREENE FL, 2003, AM JOINT COMMITTEE C, P179; Gress FG, 1999, GASTROINTEST ENDOSC, V50, P786, DOI 10.1016/S0016-5107(99)70159-8; GRIMM H, 1990, BAILLIERE CLIN GASTR, V4, P869, DOI 10.1016/0950-3528(90)90024-B; Hawass NED, 1997, BRIT J RADIOL, V70, P360, DOI 10.1259/bjr.70.832.9166071; Horton KM, 2002, J GASTROINTEST SURG, V6, P126, DOI 10.1016/S1091-255X(01)00055-5; Howard TJ, 1997, AM J SURG, V174, P237, DOI 10.1016/S0002-9610(97)00132-3; Hu H, 2000, RADIOLOGY, V215, P55, DOI 10.1148/radiology.215.1.r00ap3755; Hunt GC, 2002, GASTROINTEST ENDOSC, V55, P232, DOI 10.1067/mge.2002.121342; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Legmann P, 1998, AM J ROENTGENOL, V170, P1315, DOI 10.2214/ajr.170.5.9574609; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Mertz HR, 2000, GASTROINTEST ENDOSC, V52, P367, DOI 10.1067/mge.2000.107727; Midwinter MJ, 1999, BRIT J SURG, V86, P189, DOI 10.1046/j.1365-2168.1999.01042.x; MULLER MF, 1994, RADIOLOGY, V190, P745; O'Malley ME, 1999, AM J ROENTGENOL, V173, P1513, DOI 10.2214/ajr.173.6.10584794; Richter A, 2003, WORLD J SURG, V27, P324, DOI 10.1007/s00268-002-6659-z; Roche CJ, 2003, AM J ROENTGENOL, V180, P475, DOI 10.2214/ajr.180.2.1800475; Rosch T, 2000, GASTROINTEST ENDOSC, V52, P469, DOI 10.1067/mge.2000.106682; ROSCH T, 1991, GASTROINTEST ENDOSC, V37, P347, DOI 10.1016/S0016-5107(91)70729-3; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; ROSENBERG JM, 1985, J SURG ONCOL, V28, P217, DOI 10.1002/jso.2930280315; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Tabuchi T, 1999, AM J ROENTGENOL, V173, P375, DOI 10.2214/ajr.173.2.10430140; Tierney WM, 2001, GASTROINTEST ENDOSC, V53, P182, DOI 10.1067/mge.2001.111776; TIO TL, 1990, RADIOLOGY, V175, P455, DOI 10.1148/radiology.175.2.2183284; TREDE M, 1990, ANN SURG, V211, P447, DOI 10.1097/00000658-199004000-00011; YASUDA K, 1988, GASTROINTEST ENDOSC, V34, P1, DOI 10.1016/S0016-5107(88)71220-1; Yeo CJ, 1997, ANN SURG, V226, P248, DOI 10.1097/00000658-199709000-00004; Zeman RK, 1997, AM J ROENTGENOL, V169, P459, DOI 10.2214/ajr.169.2.9242754	42	345	362	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					753	763		10.7326/0003-4819-141-10-200411160-00006	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545675				2022-12-28	WOS:000225206900002
J	Peabody, JW; Luck, J; Glassman, P; Jain, S; Hansen, J; Spell, M; Lee, M				Peabody, JW; Luck, J; Glassman, P; Jain, S; Hansen, J; Spell, M; Lee, M			Measuring the quality of physician practice by using clinical vignettes: A prospective validation study	ANNALS OF INTERNAL MEDICINE			English	Article							STANDARDIZED PATIENTS; GENERAL-PRACTITIONERS; CHART ABSTRACTION; CARE; ILL; INFORMATION; DIAGNOSIS; ATTITUDES; CHILDREN; RISK	Background: worldwide efforts are under way to improve the quality of clinical practice. Most quality measurements, however, are poorly validated, expensive, and difficult to compare among sites. Objective: To validate whether vignettes accurately measure the quality of clinical practice by using a comparison with standardized patients (the gold standard method), and to determine whether vignettes are a more or less accurate method than medical record abstraction. Design: Prospective, multisite study. Setting: Outpatient primary care clinics in 2 Veterans Affairs medical centers and 2 large, private medical centers. Participants: 144 of 163 eligible physicians agreed to participate, and, of these, 116 were randomly selected to see standardized patients, to complete vignettes, or both. Measurements: Scores, expressed as the percentage of explicit quality criteria correctly completed, were obtained by using 3 methods. Results: Among all physicians, the quality of clinical practice as measured by the standardized patients was 73% correct (95% CI, 72.1% to 73.4%). By using exactly the same criteria, physicians scored 68% (CI, 67.9% to 68.9%) when measured by the vignettes but only 63% (CI, 62.7% to 64.0%) when assessed by medical record abstraction. These findings were consistent across all diseases and were independent of case complexity or physician training level. Vignettes also accurately measured unnecessary care. Finally, vignettes seem to capture the range in the quality of clinical practice among physicians within a site. Limitations: Despite finding variation in the quality of clinical practice, we did not determine whether poorer quality translated into worse health status for patients. In addition, the quality scores are based on measurements from 1 patient-provider interaction. As with all other scoring criteria, vignette criteria must be regularly updated. Conclusions: Vignettes are a valid tool for measuring the quality of clinical practice. They can be used for diverse clinical settings, diseases, physician types, and situations in which case-mix variation is a concern. They are inexpensive and easy to use. Vignettes are particularly useful for comparing quality among and within sites and may be useful for longitudinal evaluations of interventions intended to change clinical practice.	Univ Calif San Francisco, Inst Global Hlth, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94105 USA; Calif Pacific Med Ctr, San Francisco, CA USA; Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; RAND Corp, Santa Monica, CA USA; Vet Affairs Ctr Study Healthcare Provider Behav, Sepulveda, CA USA; So Calif Permanente Med Grp, Los Angeles, CA 90027 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; California Pacific Medical Center; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; RAND Corporation; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups	Peabody, JW (corresponding author), Univ Calif San Francisco, Inst Global Hlth, San Francisco Vet Affairs Med Ctr, 74 New Montgomery,Suite 508, San Francisco, CA 94105 USA.	peabody@psg.ucsf.edu						Aboff BM, 2002, JAMA-J AM MED ASSOC, V288, P381, DOI 10.1001/jama.288.3.381; Aitken ME, 1998, ARCH PEDIAT ADOL MED, V152, P1176; ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; Badger L W, 1995, Fam Med, V27, P126; BASKETT SJ, 1978, SOUTHERN MED J, V71, P1507, DOI 10.1097/00007611-197812000-00018; Brann P, 2001, AUST NZ J PSYCHIAT, V35, P370, DOI 10.1046/j.1440-1614.2001.00890.x; Cacciola JS, 1997, J SUBST ABUSE TREAT, V14, P439, DOI 10.1016/S0740-5472(97)00123-2; Carney P A, 1998, Nurse Pract, V23, P56; CHAPPEL JN, 1991, J PSYCHOACTIVE DRUGS, V23, P359, DOI 10.1080/02791072.1991.10471607; Cornfeld M, 2001, J CANCER EDUC, V16, P193; Dickson RA, 2000, J CLIN PSYCHIAT, V61, P10; Dresselhaus TR, 2000, J GEN INTERN MED, V15, P782, DOI 10.1046/j.1525-1497.2000.91007.x; Englund L, 2000, SCAND J PRIM HEALTH, V18, P48; Epstein SA, 2001, PSYCHOSOMATICS, V42, P482, DOI 10.1176/appi.psy.42.6.482; EVERITT DE, 1990, AM J MED, V89, P357, DOI 10.1016/0002-9343(90)90349-I; Fihn SD, 2000, JAMA-J AM MED ASSOC, V283, P1740, DOI 10.1001/jama.283.13.1740; Fowers BJ, 1996, J PSYCHOL, V130, P159, DOI 10.1080/00223980.1996.9914998; Friedmann PD, 1996, ANN INTERN MED, V124, P414, DOI 10.7326/0003-4819-124-4-199602150-00005; Furth SL, 2001, JAMA-J AM MED ASSOC, V285, P1027, DOI 10.1001/jama.285.8.1027; Glassman P A, 2000, Jt Comm J Qual Improv, V26, P644; Gorter K, 2001, FAM PRACT, V18, P569, DOI 10.1093/fampra/18.6.569; Gould D, 1996, J CLIN NURS, V5, P207, DOI 10.1111/j.1365-2702.1996.tb00253.x; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; Gutkind D, 2001, PSYCHIAT RES, V101, P269, DOI 10.1016/S0165-1781(01)00223-2; Hazelett Susan, 2002, Pain Manag Nurs, V3, P28, DOI 10.1053/jpmn.2002.29012; Hughes R, 2002, J ADV NURS, V37, P382, DOI 10.1046/j.1365-2648.2002.02100.x; Hugo M, 2001, J Psychiatr Ment Health Nurs, V8, P419, DOI 10.1046/j.1351-0126.2001.00430.x; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kalf AJH, 1996, SOC SCI MED, V42, P705, DOI 10.1016/0277-9536(95)00201-4; Kelly WF, 2002, CHEST, V121, P957, DOI 10.1378/chest.121.3.957; Kleinke JD, 1998, HEALTH AFFAIR, V17, P23, DOI 10.1377/hlthaff.17.6.23; Lawthers A G, 1995, J Ambul Care Manage, V18, P56; LLOYD SS, 1985, JAMA-J AM MED ASSOC, V254, P1330, DOI 10.1001/jama.254.10.1330; Luck J, 2000, AM J MED, V108, P642, DOI 10.1016/S0002-9343(00)00363-6; Luck J, 2002, BMJ-BRIT MED J, V325, P679, DOI 10.1136/bmj.325.7366.679; Mackel J V, 1995, Medinfo, V8 Pt 2, P1687; Malcolm L, 2000, NEW ZEAL MED J, V113, P79; Martin Carmel, 2002, Aust Fam Physician, V31, P55; McGlynn EA, 2004, HEALTH AFFAIR, V23, P100, DOI 10.1377/hlthaff.23.3.100; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Morita T, 2002, J CLIN ONCOL, V20, P758, DOI 10.1200/JCO.2002.20.3.758; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Nordyke RJ, 2002, HEALTH POLICY, V60, P67, DOI 10.1016/S0168-8510(01)00192-0; OConnor DW, 1996, NEUROLOGY, V47, P1194, DOI 10.1212/WNL.47.5.1194; Peabody JW, 2004, MED CARE, V42, P1066, DOI 10.1097/00005650-200411000-00005; Peabody JW, 2000, JAMA-J AM MED ASSOC, V283, P1715, DOI 10.1001/jama.283.13.1715; Peabody JW, 2004, HEALTH SERV RES, V39, P1951, DOI 10.1111/j.1475-6773.2004.00327.x; PEABODY JW, 2004, IN PRESS MEC CARE, V42; Poses RM, 1998, MED DECIS MAKING, V18, P131, DOI 10.1177/0272989X9801800201; Quinn T, 1998, Intensive Crit Care Nurs, V14, P219, DOI 10.1016/S0964-3397(98)80614-9; Ram P, 1999, ACAD MED, V74, P62, DOI 10.1097/00001888-199901000-00020; RETHANS JJ, 1991, BRIT MED J, V303, P1377, DOI 10.1136/bmj.303.6814.1377; RETHANS JJ, 1994, BRIT J GEN PRACT, V44, P153; ROSEN AK, 1995, J CLIN EPIDEMIOL, V48, P631, DOI 10.1016/0895-4356(94)00165-M; Rothera I, 2002, INT J GERIATR PSYCH, V17, P354, DOI 10.1002/gps.603; Sandvik H, 1995, Fam Med, V27, P388; Shekelle PG, 2000, HEALTH SERV RES, V34, P1429; Shields L, 2001, J Pediatr Nurs, V16, P137, DOI 10.1053/jpdn.2001.23466; Skaner Y, 1998, SCAND J PRIM HEALTH, V16, P95; Stillman AE, 1998, WESTERN J MED, V169, P162; Williams RG, 1999, ACAD MED, V74, P1118, DOI 10.1097/00001888-199910000-00015	61	499	502	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					771	780		10.7326/0003-4819-141-10-200411160-00008	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545677				2022-12-28	WOS:000225206900004
J	McKee, M; McPake, B				McKee, M; McPake, B			Commentary: the devil is in the detail	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, London WC1E 7HT, England; Univ London London Sch Hyg & Trop Med, Hlth Syst Dev Programme, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	McKee, M (corresponding author), Univ London London Sch Hyg & Trop Med, European Ctr Hlth Soc Transit, Keppel St, London WC1E 7HT, England.	Martin.McKee@lshtm.ac.uk	McPake, Barbara/AAE-8655-2021; McKee, Marc D/E-2187-2011; McKee, Martin/E-6673-2018	McPake, Barbara/0000-0002-9904-1077; McKee, Marc D/0000-0001-8349-965X; McKee, Martin/0000-0002-0121-9683				HAWKINS L, 2003, INNOVATIONS HLTH SER, P169; Healy J, 2002, HEALTH POLICY, V61, P1, DOI 10.1016/S0168-8510(01)00213-5; MCPAKE B, 1994, HEALTH POLICY PLANN, V9, P25, DOI 10.1093/heapol/9.1.25; McPake BI, 1996, HEALTH POLICY, V35, P155, DOI 10.1016/0168-8510(95)00778-4; Okuonzi SA, 2004, BMJ-BRIT MED J, V329, P1173, DOI 10.1136/bmj.329.7475.1173; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5	6	2	2	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1175	1176		10.1136/bmj.329.7475.1175	http://dx.doi.org/10.1136/bmj.329.7475.1175			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539679	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000225169600032
J	Perico, N; Cattaneo, D; Sayegh, MH; Remuzzi, G				Perico, N; Cattaneo, D; Sayegh, MH; Remuzzi, G			Delayed graft function in kidney transplantation	LANCET			English	Review							ISCHEMIA-REPERFUSION INJURY; CADAVERIC RENAL-TRANSPLANTATION; INTERCELLULAR-ADHESION MOLECULE-1; ATRIAL-NATRIURETIC-PEPTIDE; UNIVERSITY-OF-WISCONSIN; COLD ISCHEMIA/REPERFUSION INJURY; RANDOMIZED MULTICENTER TRIAL; COLONY-STIMULATING FACTOR; PLACEBO-CONTROLLED TRIAL; ACUTE TUBULAR-NECROSIS	Delayed graft function is a form of acute renal failure resulting in post-transplantation oliguria, increased allograft immunogenicity and risk of acute rejection episodes, and decreased long-term survival. Factors related to the donor and prerenal, renal, or postrenal transplant factors related to the recipient can contribute to this condition. From experimental studies, we have learnt that both ischaemia and reinstitution of blood flow in ischaemically damaged kidneys after hypothermic preservation activate a complex sequence of events that sustain renal injury and play a pivotal part in the development of delayed graft function. Elucidation of the pathophysiology of renal ischaemia and reperfusion injury has contributed to the development of strategies to decrease the rate of delayed graft function, focusing on donor management, organ procurement and preservation techniques, recipient fluid management, and pharmacological agents (vasodilators, antioxidants, anti-inflammatory agents). Several new drugs show promise in animal studies in preventing or ameliorating ischaemia-reperfusion injury and possibly delayed graft function, but definitive clinical trials are lacking. The goal of monotherapy for the prevention or treatment of is perhaps unattainable, and multidrug approaches or single drug targeting multiple signals will be the next step to reduce post-transplantation injury and delayed graft function.	Osped Riuniti Bergamo, Mario Negri Inst Pharmacol Res, Dept Med & Transplantat, I-24100 Bergamo, Italy; Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Ospedali Riuniti di Bergamo; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School	Perico, N (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.	perico@marionegri.it	Cattaneo, Dario/J-9265-2016; Perico, Norberto/ABH-3222-2020; Remuzzi, Giuseppe/V-9766-2017	Perico, Norberto/0000-0002-3147-4327; Sayegh, Mohamed/0000-0002-2847-588X; Remuzzi, Giuseppe/0000-0002-6194-3446				Abramowicz D, 1996, KIDNEY INT, V49, pS39; Ahlenstiel T, 2003, KIDNEY INT, V63, P554, DOI 10.1046/j.1523-1755.2003.00774.x; ALEJANDRO V, 1995, J CLIN INVEST, V95, P820, DOI 10.1172/JCI117732; ALEJANDRO VSJ, 1995, KIDNEY INT, V48, P1308, DOI 10.1038/ki.1995.415; Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; Angelescu M, 2003, TRANSPLANTATION, V75, P1190, DOI 10.1097/01.TP.0000061600.74982.0D; [Anonymous], ORGAN PROCUREMENT TR; Arumugam TV, 2002, J SURG RES, V103, P260, DOI 10.1006/jsre.2002.6369; Azuma H, 1997, TRANSPLANTATION, V64, P190, DOI 10.1097/00007890-199707270-00002; Ben-Ari Z, 2002, TRANSPLANTATION, V73, P1875, DOI 10.1097/00007890-200206270-00004; Benigni A, 2001, J AM SOC NEPHROL, V12, P941, DOI 10.1681/ASN.V125941; BENSON EM, 1985, J IMMUNOL, V134, P7; Bonventre J V, 1996, Curr Opin Nephrol Hypertens, V5, P254, DOI 10.1097/00041552-199605000-00011; BONVENTRE JV, 1991, CELL REGUL, V2, P251, DOI 10.1091/mbc.2.3.251; Brennan DC, 1999, TRANSPLANTATION, V67, P1011, DOI 10.1097/00007890-199904150-00013; BRENNAN DC, 2003, AM J TRANSPLANT, V3, P1121; BRENNER BM, 1992, J AM SOC NEPHROL, V3, P162; BREZIS M, 1991, J CLIN INVEST, V88, P390, DOI 10.1172/JCI115316; Canadian Multicentre Transplant Study Group, 1986, N Engl J Med, V314, P1219; Castaneda MP, 2003, TRANSPLANTATION, V76, P50, DOI 10.1097/01.TP.0000069835.95442.9F; Chandraker A, 1997, KIDNEY INT, V52, P1678, DOI 10.1038/ki.1997.502; Chandrasekar B, 2001, CIRCULATION, V103, P2296; Chatterjee PK, 2003, KIDNEY INT, V63, P853, DOI 10.1046/j.1523-1755.2003.00802.x; CLOZEL M, 1991, J CARDIOVASC PHARM, V17, pS313, DOI 10.1097/00005344-199100177-00089; CONGER JD, 1989, KIDNEY INT, V35, P1126, DOI 10.1038/ki.1989.100; Cosio FG, 1997, TRANSPLANTATION, V63, P1611, DOI 10.1097/00007890-199706150-00013; DAVIES SJ, 1995, EXP NEPHROL, V3, P348; DAWIDSON IJA, 1992, TRANSPLANTATION, V53, P774, DOI 10.1097/00007890-199204000-00014; de Boer J, 1999, TRANSPLANT INT, V12, P447, DOI 10.1007/s001470050256; De Perrot M, 2002, AM J RESP CRIT CARE, V165, P211, DOI 10.1164/ajrccm.165.2.2011151; de Vries B, 2003, J IMMUNOL, V170, P3883, DOI 10.4049/jimmunol.170.7.3883; De Vries B, 2003, TRANSPLANTATION, V75, P375, DOI 10.1097/01.TP.0000044455.05584.2A; DeVries ME, 2003, SEMIN IMMUNOL, V15, P33, DOI 10.1016/S1044-5323(02)00126-4; DIJOSEPH JF, 1992, TRANSPLANTATION, V53, P507, DOI 10.1097/00007890-199203000-00002; DiMari J, 1997, AM J PHYSIOL-RENAL, V272, pF292, DOI 10.1152/ajprenal.1997.272.3.F292; Donckier V, 2003, TRANSPLANTATION, V75, P902, DOI 10.1097/01.TP.0000056633.50445.AC; Dragun D, 1998, KIDNEY INT, V54, P2113, DOI 10.1046/j.1523-1755.1998.00189.x; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; EMAMI A, 1991, AM J PHYSIOL, V260, pF479, DOI 10.1152/ajprenal.1991.260.4.F479; Faenza A, 2001, TRANSPLANTATION, V72, P1274, DOI 10.1097/00007890-200110150-00016; FARHOOD A, 1995, J LEUKOCYTE BIOL, V57, P368, DOI 10.1002/jlb.57.3.368; FINN WF, 1987, KIDNEY INT, V32, P479, DOI 10.1038/ki.1987.235; Furuichi K, 2003, J AM SOC NEPHROL, V14, P1066, DOI 10.1097/01.ASN.0000059339.14780.E4; Gaber LW, 1996, CLIN TRANSPLANT, V10, P629; Giral-Classe M, 1998, KIDNEY INT, V54, P972, DOI 10.1046/j.1523-1755.1998.00071.x; Gjertson D W, 2000, Clin Transpl, P467; GOES N, 1995, TRANSPLANTATION, V59, P565; Goggins WC, 2003, TRANSPLANTATION, V76, P798, DOI 10.1097/01.TP.0000081042.67285.91; Gonwa TA, 2002, TRANSPLANTATION, V74, P1560, DOI 10.1097/00007890-200212150-00013; GREEN CJ, 1989, FREE RADICAL RES COM, V7, P255, DOI 10.3109/10715768909087950; Halloran PF, 2001, AM J TRANSPLANT, V1, P1, DOI 10.1034/j.1600-6143.2001.010101.x; HALLORAN PF, 1988, TRANSPLANTATION, V46, P223, DOI 10.1097/00007890-198808000-00007; Harada H, 2002, TRANSPLANTATION, V74, P1434, DOI 10.1097/00007890-200211270-00016; Hauet T, 2000, J AM SOC NEPHROL, V11, P138, DOI 10.1681/ASN.V111138; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; Haugen E, 1999, BLOOD PURIFICAT, V17, P58, DOI 10.1159/000014377; Heidenreich S, 2003, J AM SOC NEPHROL, V14, P234, DOI 10.1097/01.ASN.0000039567.22063.9D; Hernandez A, 1999, TRANSPLANTATION, V67, P200, DOI 10.1097/00007890-199901270-00003; Hirschberg R, 1999, KIDNEY INT, V55, P2423, DOI 10.1046/j.1523-1755.1999.00463.x; Hladunewich MA, 2003, KIDNEY INT, V64, P593, DOI 10.1046/j.1523-1755.2003.00100.x; Hocher B, 2002, THROMB HAEMOSTASIS, V87, P194; Hoffmann SC, 2002, TRANSPLANTATION, V74, P916, DOI 10.1097/00007890-200210150-00003; Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0; Hourmant M, 1996, TRANSPLANTATION, V62, P1565, DOI 10.1097/00007890-199612150-00006; HOWARD RJ, 1993, TRANSPLANT P, V25, P884; Huang CL, 2002, NEPHROL DIAL TRANSPL, V17, P1578, DOI 10.1093/ndt/17.9.1578; Inman SR, 2003, TRANSPLANTATION, V75, P1655, DOI 10.1097/01.TP.0000063127.02261.E4; Jacobs SC, 2004, J UROLOGY, V171, P47, DOI 10.1097/01.ju.0000100221.20410.4a; Ke BB, 2003, TRANSPLANTATION, V75, P1118, DOI 10.1097/01.TP.0000062861.80771.D5; KELLY KJ, 1994, P NATL ACAD SCI USA, V91, P812, DOI 10.1073/pnas.91.2.812; Koning OHJ, 1997, TRANSPLANTATION, V63, P1620, DOI 10.1097/00007890-199706150-00015; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; LACHANCE SL, 1985, J UROLOGY, V133, P950, DOI 10.1016/S0022-5347(17)49326-8; LAUZURICA R, 1992, TRANSPLANT P, V24, P46; Lemos FBC, 2003, J AM SOC NEPHROL, V14, P3278, DOI 10.1097/01.ASN.0000098683.92538.66; Lin FM, 2003, J AM SOC NEPHROL, V14, P1188, DOI 10.1097/01.ASN.0000061595.28546.A0; Ling H, 1999, AM J PHYSIOL-RENAL, V277, pF383; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Lu CY, 1999, KIDNEY INT, V55, P2157, DOI 10.1046/j.1523-1755.1999.00491.x; Maeshima A, 2003, J AM SOC NEPHROL, V14, P3138, DOI 10.1097/01.ASN.0000098685.43700.28; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Marshall R, 1996, SURGERY, V120, P663, DOI 10.1016/S0039-6060(96)80014-6; McCormick BB, 2004, NEPHROL DIAL TRANSPL, V19, P714, DOI 10.1093/ndt/gfg582; McIntyre JA, 2003, LUPUS, V12, P555, DOI 10.1191/0961203303lu401oa; McLaren AJ, 1999, CLIN TRANSPLANT, V13, P266, DOI 10.1034/j.1399-0012.1999.130308.x; McTaggart RA, 2003, AM J TRANSPLANT, V3, P416, DOI 10.1034/j.1600-6143.2003.00078.x; Meguro M, 2003, TRANSPLANTATION, V75, P703, DOI 10.1097/01.TP.0000053400.42842.5C; MERION RM, 1990, TRANSPLANTATION, V50, P230, DOI 10.1097/00007890-199008000-00011; MERKUS JWS, 1991, NEPHROL DIAL TRANSPL, V6, P881, DOI 10.1093/ndt/6.11.881; Mister M, 2002, KIDNEY INT, V61, P1064, DOI 10.1046/j.1523-1755.2002.00212.x; Miura M, 2001, AM J PATHOL, V159, P2137, DOI 10.1016/S0002-9440(10)63065-9; Monteiro F, 1997, TRANSPLANTATION, V63, P542, DOI 10.1097/00007890-199702270-00010; Nashan B, 1997, LANCET, V350, P1193, DOI 10.1016/S0140-6736(97)09278-7; NEUMAYER HH, 1992, KIDNEY INT, V41, pS87; Nicholson ML, 1996, TRANSPL INT, V9, P415, DOI 10.1111/j.1432-2277.1996.tb00901.x; NIGAM S, 2000, AM J PHYSIOL, V2279, pF3; Noiri E, 1996, J CLIN INVEST, V97, P2377, DOI 10.1172/JCI118681; NOVICK AC, 1986, TRANSPLANTATION, V42, P154, DOI 10.1097/00007890-198608000-00010; Ojo AO, 1997, TRANSPLANTATION, V63, P968, DOI 10.1097/00007890-199704150-00011; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; Perico N, 2003, AM J NEPHROL, V23, P245, DOI 10.1159/000072055; PLOEG RJ, 1992, LANCET, V340, P129, DOI 10.1016/0140-6736(92)93212-6; Pratt JR, 2002, NAT MED, V8, P582, DOI 10.1038/nm0602-582; Pratt JR, 2000, AM J PATHOL, V157, P825, DOI 10.1016/S0002-9440(10)64596-8; Prommool S, 2000, J AM SOC NEPHROL, V11, P565, DOI 10.1681/ASN.V113565; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; Ramao JE, 1999, NEPHROL DIAL TRANSPL, V14, P709, DOI 10.1093/ndt/14.3.709; Ratner LE, 1997, J AM COLL SURGEONS, V185, P437, DOI 10.1016/S1072-7515(01)00954-1; RENNKE HG, 1989, AM J KIDNEY DIS, V13, P443, DOI 10.1016/S0272-6386(89)80001-0; Salmela K, 1999, TRANSPLANTATION, V67, P729, DOI 10.1097/00007890-199903150-00015; SANFILIPPO F, 1984, TRANSPLANTATION, V38, P643, DOI 10.1097/00007890-198412000-00019; Sayegh MH, 1999, KIDNEY INT, V56, P1967, DOI 10.1046/j.1523-1755.1999.00751.x; Schilling M, 1996, TRANSPLANT P, V28, P304; Sehirli AO, 2003, J NEPHROL, V16, P75; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Senel FM, 1998, RENAL FAILURE, V20, P589, DOI 10.3109/08860229809045151; SHAW SG, 1987, J CLIN INVEST, V80, P1232, DOI 10.1172/JCI113197; Shoskes DA, 2001, UROL CLIN N AM, V28, P721, DOI 10.1016/S0094-0143(01)80028-8; Shoskes DA, 1998, TRANSPLANTATION, V66, P1697, DOI 10.1097/00007890-199812270-00022; Shoskes DA, 1996, J UROLOGY, V155, P1831, DOI 10.1016/S0022-5347(01)66023-3; Shoskes DA, 1997, TRANSPLANTATION, V63, P495, DOI 10.1097/00007890-199702270-00002; Smith KD, 2003, J AM SOC NEPHROL, V14, P1037, DOI 10.1097/01.ASN.0000057542.86377.5A; Snyder JJ, 2002, KIDNEY INT, V62, P1423, DOI 10.1111/j.1523-1755.2002.kid563.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stallone G, 2004, J AM SOC NEPHROL, V15, P228, DOI 10.1097/01.ASN.0000102469.32182.8C; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Stegall MD, 2002, TRANSPLANTATION, V74, P924, DOI 10.1097/00007890-200210150-00004; Supavekin S, 2003, KIDNEY INT, V63, P1714, DOI 10.1046/j.1523-1755.2003.00928.x; SUTHANTHIRAN M, 1993, TRANSPLANTATION, V55, P1008, DOI 10.1097/00007890-199305000-00011; Szczech LA, 1997, J AM SOC NEPHROL, V8, P1771; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TANNER GA, 1973, KIDNEY INT, V4, P377, DOI 10.1038/ki.1973.134; Thadhani R, 1996, NEW ENGL J MED, V334, P1448, DOI 10.1056/NEJM199605303342207; Thomas MC, 2003, TRANSPLANTATION, V75, P1989, DOI 10.1097/01.TP.0000058747.47027.44; TORRAS J, 1993, TRANSPLANT INT, V6, P236, DOI 10.1007/BF00337106; Troppmann C, 1999, TRANSPLANT P, V31, P1290, DOI 10.1016/S0041-1345(98)02001-6; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; Wagenknecht DR, 1999, TRANSPLANTATION, V68, P241, DOI 10.1097/00007890-199907270-00014; Wagner M, 2003, KIDNEY INT, V63, P1564, DOI 10.1046/j.1523-1755.2003.00897.x; Walker LM, 2000, J PHARMACOL EXP THER, V295, P417; WHJTTAKER JR, 1973, SURG GYNECOL OBSTET, V136, P919; Wilhelm SM, 1999, KIDNEY INT, V55, P1011, DOI 10.1046/j.1523-1755.1999.0550031011.x; Woo YM, 1999, KIDNEY INT, V55, P692, DOI 10.1046/j.1523-1755.1999.00294.x; Woo YM, 2002, CLIN NEPHROL, V57, P38; Yokota N, 2003, AM J NEPHROL, V23, P13, DOI 10.1159/000066301; YOKOYAMA I, 1994, CLIN TRANSPLANT, V8, P101; Yoshida T, 2002, KIDNEY INT, V61, P1646, DOI 10.1046/j.1523-1755.2002.00341.x	149	725	773	3	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1814	1827		10.1016/S0140-6736(04)17406-0	http://dx.doi.org/10.1016/S0140-6736(04)17406-0			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541456				2022-12-28	WOS:000225070600036
J	Saitoh, E; Miyajima, H; Yamaoka, T; Tatara, G				Saitoh, E; Miyajima, H; Yamaoka, T; Tatara, G			Current-induced resonance and mass determination of a single magnetic domain wall	NATURE			English	Article							ELECTRIC-CURRENT; PERMALLOY-FILMS; PULSED-CURRENT; FORCE	A magnetic domain wall (DW) is a spatially localized change of magnetization configuration in a magnet. This topological object has been predicted to behave at low energy as a composite particle with finite mass(1). This particle will couple directly with electric currents as well as magnetic fields, and its manipulation using electric currents(2-8) is of particular interest with regard to the development of high-density magnetic memories(9). The DW mass sets the ultimate operation speed of these devices, but has yet to be determined experimentally. Here we report the direct observation of the dynamics of a single DW in a ferromagnetic nanowire, which demonstrates that such a topological particle has a very small but finite mass of 6.6x10(-23) kg. This measurement was realized by preparing a tunable DW potential in the nanowire, and detecting the resonance motion of the DW induced by an oscillating current. The resonance also allows low-current operation, which is crucial in device applications; a DW displacement of 10 mum was induced by a current density of 10(10) A m(-2).	Keio Univ, Dept Phys, Yokohama, Kanagawa 2238522, Japan; SII NanoTechnol Inc, Matsudo, Chiba 2702222, Japan; Osaka Univ, Dept Earth & Space Sci, Osaka 5600043, Japan	Keio University; Osaka University	Saitoh, E (corresponding author), Keio Univ, Dept Phys, Yokohama, Kanagawa 2238522, Japan.	eizi@phys.keio.ac.jp	Saitoh, Eiji/C-1004-2011; Tatara, Gen/I-8676-2012	Saitoh, Eiji/0000-0003-2675-0718; Tatara, Gen/0000-0003-0642-8609				BERGER L, 1978, J APPL PHYS, V49, P2156, DOI 10.1063/1.324716; BERGER L, 1984, J APPL PHYS, V55, P1954, DOI 10.1063/1.333530; Chikazumi S., 1997, PHYS FERROMAGNETISM, P559; DONAHUE MJ, 1998, OBJECT ORIENTED MICR; DORING W, 1948, Z NATURFORSCH A, V3, P373, DOI 10.1515/zna-1948-0701; FREITAS PP, 1985, J APPL PHYS, V57, P1266, DOI 10.1063/1.334524; Gan L, 2000, IEEE T MAGN, V36, P3047, DOI 10.1109/20.908674; Grollier J, 2003, APPL PHYS LETT, V83, P509, DOI 10.1063/1.1594841; HUNG CY, 1988, J APPL PHYS, V63, P4276, DOI 10.1063/1.340201; Koo H, 2002, APPL PHYS LETT, V81, P862, DOI 10.1063/1.1495883; Lim CK, 2004, APPL PHYS LETT, V84, P2820, DOI 10.1063/1.1711168; RADO GT, 1952, PHYS REV, V88, P909, DOI 10.1103/PhysRev.88.909; Tatara G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086601; Yamanouchi M, 2004, NATURE, V428, P539, DOI 10.1038/nature02441	15	341	349	1	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					203	206		10.1038/nature03009	http://dx.doi.org/10.1038/nature03009			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538364				2022-12-28	WOS:000225020200041
J	Schmittner, J; Schroeder, JR; Epstein, DH; Preston, KL				Schmittner, J; Schroeder, JR; Epstein, DH; Preston, KL			QT interval increased after single dose of lofexidine	BMJ-BRITISH MEDICAL JOURNAL			English	Article									NIDA, NIH, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Schmittner, J (corresponding author), NIDA, NIH, Intramural Res Program, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	jschmitt@intra.nida.nih.gov	Preston, Kenzie L/J-5830-2013	Preston, Kenzie L/0000-0003-0603-2479	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000175, ZIADA000175] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BEDNAR MM, 2001, PROG CARDIOVASC D S1, V43, pS1; Roden DM, 2004, NEW ENGL J MED, V350, P1013, DOI 10.1056/NEJMra032426; TSATI TH, 1982, ARZNEIMITTEL-FORSCH, V32, P955; WILKINS LH, 1981, CLIN PHARMACOL THER, V30, P752, DOI 10.1038/clpt.1981.234	4	8	8	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1075	1075		10.1136/bmj.329.7474.1075	http://dx.doi.org/10.1136/bmj.329.7474.1075			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528619	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000225070300021
J	Carvalho, AB; Clark, AG				Carvalho, AB; Clark, AG			Y chromosome of D-pseudoobscura is not homologous to the ancestral Drosophila Y	SCIENCE			English	Article							OBSCURA GROUP; EVOLUTION; MELANOGASTER; FERTILITY; SEQUENCES; PATTERNS; GENOME; GENES	We report a genome-wide search of Y-linked genes in Drosophila pseudoobscura. All six identifiable orthologs of the D. melanogaster, Y-linked genes have autosomal inheritance in D. pseudoobscura. Four-orthologs were investigated in detail and proved to be Y-linked in D. guanche and D. bifasciata, which shows that less than 18 million years ago the ancestral Drosophila Y chromosome was translocated to an autosome in the D. pseudoobscura lineage. We found 15 genes and pseudogenes in the current Y of D. pseudoobscura, and none are shared with the D. melanogaster Y. Hence, the Y chromosome in the D. pseudoobscura lineage appears to have arisen de novo and is not homologous to the D. melanogaster Y.	Univ Fed Rio de Janeiro, Dept Genet, BR-21944970 Rio De Janeiro, Brazil; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Universidade Federal do Rio de Janeiro; Cornell University	Carvalho, AB (corresponding author), Univ Fed Rio de Janeiro, Dept Genet, Caixa Postal 68011, BR-21944970 Rio De Janeiro, Brazil.	bernardo@biologia.ufrj.br	Carvalho, Antonio/D-5402-2013	Carvalho, Antonio/0000-0001-8959-6469; Clark, Andrew/0000-0001-7159-8511	FOGARTY INTERNATIONAL CENTER [R03TW005673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064590] Funding Source: NIH RePORTER; FIC NIH HHS [TW005673] Funding Source: Medline; NIGMS NIH HHS [GM64590] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bachtrog D, 2003, NAT GENET, V34, P215, DOI 10.1038/ng1164; Baffi MA, 2002, BIOCHEM GENET, V40, P411, DOI 10.1023/A:1020729612672; Bull J.J., 1983, EVOLUTION SEX DETERM; BUNEMANN H, COMMUNICATION; Carvalho AB, 2003, GENETICA, V117, P227, DOI 10.1023/A:1022900313650; Carvalho AB, 2002, CURR OPIN GENET DEV, V12, P664, DOI 10.1016/S0959-437X(02)00356-8; Carvalho AB, 2001, P NATL ACAD SCI USA, V98, P13225, DOI 10.1073/pnas.231484998; Charlesworth B, 2000, PHILOS T R SOC B, V355, P1563, DOI 10.1098/rstb.2000.0717; COOPER KW, 1946, GENETICS, V31, P181; GATTI M, 1983, CHROMOSOMA, V88, P349, DOI 10.1007/BF00285858; GODDARD K, 1990, EVOLUTION, V44, P1656, DOI 10.1111/j.1558-5646.1990.tb03854.x; Hackstein JHP, 1996, BIOESSAYS, V18, P317, DOI 10.1002/bies.950180410; Kalmykova AI, 1997, P NATL ACAD SCI USA, V94, P6297, DOI 10.1073/pnas.94.12.6297; Kurek R, 2000, GENETICA, V109, P113, DOI 10.1023/A:1026552604229; O'Grady PM, 1999, MOL PHYLOGENET EVOL, V12, P124, DOI 10.1006/mpev.1998.0598; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; RICHARDS S, IN PRESS GENOME RES; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; STEINEMANN M, 1984, CHROMOSOMA, V91, P46, DOI 10.1007/BF00286484; STEINEMANN M, 1993, P NATL ACAD SCI USA, V90, P5737, DOI 10.1073/pnas.90.12.5737; Tamura K, 2004, MOL BIOL EVOL, V21, P36, DOI 10.1093/molbev/msg236; VOELKER RA, 1971, EVOLUTION, V25, P119, DOI 10.1111/j.1558-5646.1971.tb01865.x; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; Yu YC, 1999, HEREDITY, V83, P39, DOI 10.1038/sj.hdy.6885470	24	118	119	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	2005	307	5706					108	110		10.1126/science.1101675	http://dx.doi.org/10.1126/science.1101675			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	886GG	15528405				2022-12-28	WOS:000226214300048
J	Miller, ER; Pastor-Barriuso, R; Dalal, D; Riemersma, RA; Appel, LJ; Guallar, E				Miller, ER; Pastor-Barriuso, R; Dalal, D; Riemersma, RA; Appel, LJ; Guallar, E			Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality	ANNALS OF INTERNAL MEDICINE			English	Review							TOCOPHEROL-MEDIATED PEROXIDATION; NUTRITION INTERVENTION TRIALS; DISEASE-SPECIFIC MORTALITY; RANDOMIZED CLINICAL-TRIAL; ALPHA-TOCOPHEROL; DOUBLE-BLIND; ANTIOXIDANT VITAMINS; CARDIOVASCULAR-DISEASE; MINERAL SUPPLEMENTATION; LOGISTIC-REGRESSION	Background: Experimental models and observational studies suggest that vitamin E supplementation may prevent cardiovascular disease and cancer. However, several trials of high-dosage vitamin E supplementation showed non-statistically significant increases in total mortality. Purpose: To perform a meta-analysis of the dose-response relationship between vitamin E supplementation and total mortality by using data from randomized, controlled trials. Patients: 135 967 participants in 19 clinical trials. Of these trials, 9 tested vitamin E alone and 10 tested vitamin E combined with other vitamins or minerals. The dosages of vitamin E ranged from 16.5 to 2000 IU/d (median, 400 IU/d). Data Sources: PubMed search from 1966 through August 2004, complemented by a search of the Cochrane Clinical Trials Database and review of citations of published reviews and meta-analyses. No language restrictions were applied. Data Extraction: 3 investigators independently abstracted study reports. The investigators of the original publications were contacted if required information was not available. Data Synthesis: 9 of 11 trials testing high-dosage vitamin E ( :400 IU/d) showed increased risk (risk difference > 0) for all-cause mortality in comparisons of vitamin E versus control. The pooled all-cause mortality risk difference in high-dosage vitamin E trials was 39 per 10 000 persons (95% CI, 3 to 74 per 10 000 persons; P = 0.035). For low-dosage vitamin E trials, the risk difference was -16 per 10 000 persons (CI, -41 to 10 per 10 000 persons; P > 0.2). A dose-response analysis showed a statistically significant relationship between vitamin E dosage and all-cause mortality, with increased risk of dosages greater than 150 IU/d. Limitations: High-dosage (>= 400 IU/d) trials were often small and were performed in patients with chronic diseases. The generalizability of the findings to healthy adults is uncertain. Precise estimation of the threshold at which risk increases is difficult. Conclusion: High-dosage (>= 400 IU/d) vitamin E supplements may increase all-cause mortality and should be avoided.	Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, John Hopkins Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, John Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; Inst Salud Carlos III, Natl Ctr Epidemiol, Madrid, Spain; Univ Edinburgh, Edinburgh, Midlothian, Scotland; Univ Tromso, Tromso, Norway	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Medicine; Instituto de Salud Carlos III; University of Edinburgh; UiT The Arctic University of Tromso	Miller, ER (corresponding author), Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-624, Baltimore, MD 21205 USA.	ermiller@jhmi.edu	Pastor-Barriuso, Roberto/AAA-6746-2019; Appel, Larry/GLT-2608-2022; Guallar, Eliseo/D-3807-2014	Pastor-Barriuso, Roberto/0000-0002-7325-3960; Guallar, Eliseo/0000-0002-4471-9565				Abudu N, 2004, CLIN CHIM ACTA, V339, P11, DOI 10.1016/j.cccn.2003.09.018; Adler LA, 1999, ARCH GEN PSYCHIAT, V56, P836, DOI 10.1001/archpsyc.56.9.836; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ANDERSON TW, 1974, AM J CLIN NUTR, V27, P1174, DOI 10.1093/ajcn/27.8.1174; Balluz LS, 2000, ARCH FAM MED, V9, P258, DOI 10.1001/archfami.9.3.258; BENDICH A, 1988, AM J CLIN NUTR, V48, P612, DOI 10.1093/ajcn/48.3.612; Bendich A, 2001, DIETARY REFERENCE IN, DOI [10.1016/s0899-9007(00)00596-7, DOI 10.1016/S0899-9007(00)00596-7]; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BIERI JG, 1973, AM J CLIN NUTR, V26, P382, DOI 10.1093/ajcn/26.4.382; BIERI JG, 1981, AM J CLIN NUTR, V34, P289, DOI 10.1093/ajcn/34.2.289; Bjelakovic G, 2004, LANCET, V364, P1219, DOI 10.1016/S0140-6736(04)17138-9; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Boaz M, 2000, LANCET, V356, P1213, DOI 10.1016/S0140-6736(00)02783-5; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; de Waart FG, 2001, ATHEROSCLEROSIS, V158, P227, DOI 10.1016/S0021-9150(01)00420-8; DECOSSE JJ, 1989, JNCI-J NATL CANCER I, V81, P1290, DOI 10.1093/jnci/81.17.1290; Desnuelle C, 2001, AMYOTROPH LATERAL SC, V2, P9, DOI 10.1080/146608201300079364; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; DOWD P, 1995, P NATL ACAD SCI USA, V92, P8171, DOI 10.1073/pnas.92.18.8171; Eidelman RS, 2004, ARCH INTERN MED, V164, P1552, DOI 10.1001/archinte.164.14.1552; Forman D, 2004, LANCET, V364, P1193, DOI 10.1016/S0140-6736(04)17153-5; Girodon F, 1999, ARCH INTERN MED, V159, P748, DOI 10.1001/archinte.159.7.748; GOETGHEBEUR EJT, 1995, J ROY STAT SOC A STA, V158, P107, DOI 10.2307/2983406; Graat JM, 2002, JAMA-J AM MED ASSOC, V288, P715, DOI 10.1001/jama.288.6.715; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; Hofstad B, 1998, DIGESTION, V59, P148, DOI 10.1159/000007480; Huang HY, 2003, J NUTR, V133, P3137, DOI 10.1093/jn/133.10.3137; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; LI JY, 1993, J NATL CANCER I, V85, P1492, DOI 10.1093/jnci/85.18.1492; MCKEOWNEYSSEN G, 1988, CANCER RES, V48, P4701; McNeil JJ, 2004, OPHTHALMOLOGY, V111, P75, DOI 10.1016/j.ophtha.2003.04.009; Mitchinson MJ, 1999, LANCET, V353, P381, DOI 10.1016/S0140-6736(05)74955-2; Morris CD, 2003, ANN INTERN MED, V139, P56, DOI 10.7326/0003-4819-139-1-200307010-00014; Muntwyler J, 2002, ARCH INTERN MED, V162, P1472, DOI 10.1001/archinte.162.13.1472; Olmedilla B, 2003, NUTRITION, V19, P21, DOI 10.1016/S0899-9007(02)00861-4; OMDAHL G, 1994, J INTERN MED, V235, P205; Pasantes-Morales H, 2002, METAB BRAIN DIS, V17, P183, DOI 10.1023/A:1019926122125; Pastor R, 1998, AM J EPIDEMIOL, V148, P631, DOI 10.1093/aje/148.7.631; RABINS P, 2004, PRACTICE GUIDELINE T; Raudenbush S.W., 2001, HLM 5 HIERARCHICAL L, V2nd ed.; Raudenbush SW, 2002, HIERARCHICAL LINEAR; Richer S, 1996, J Am Optom Assoc, V67, P30; ROBERTS HJ, 1981, JAMA-J AM MED ASSOC, V246, P129, DOI 10.1001/jama.246.2.129; RONCUCCI L, 1993, DIS COLON RECTUM, V36, P227, DOI 10.1007/BF02053502; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Satia-Abouta J, 2003, AM J PREV MED, V24, P43, DOI 10.1016/S0749-3797(02)00571-8; Shekelle PG, 2004, J GEN INTERN MED, V19, P380, DOI 10.1111/j.1525-1497.2004.30090.x; Shoulson I, 1998, ANN NEUROL, V43, P318; STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; TAKAMATSU S, 1995, J INT MED RES, V23, P342, DOI 10.1177/030006059502300504; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Tribble DL, 1999, CIRCULATION, V99, P591, DOI 10.1161/01.CIR.99.4.591; Valagussa F, 1999, LANCET, V354, P447, DOI 10.1016/S0140-6736(99)07072-5; van Haaften RIM, 2003, TOXICOL IN VITRO, V17, P245, DOI 10.1016/S0887-2333(03)00038-9; Virtamo J, 2003, JAMA-J AM MED ASSOC, V290, P476, DOI 10.1001/jama.290.4.476; Vivekananthan DP, 2003, LANCET, V361, P2017, DOI 10.1016/S0140-6736(03)13637-9; Waters DD, 2002, JAMA-J AM MED ASSOC, V288, P2432, DOI 10.1001/jama.288.19.2432; Wluka A, 2002, J RHEUMATOL, V29, P2585; WONG GY, 1985, J AM STAT ASSOC, V80, P513, DOI 10.2307/2288464; You WC, 2001, EUR J CANCER PREV, V10, P257, DOI 10.1097/00008469-200106000-00009; Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302; Zaridze D, 1993, Ann Epidemiol, V3, P225; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; Zureik M, 2004, ARTERIOSCL THROM VAS, V24, P1485, DOI 10.1161/01.ATV.0000136648.62973.c8; [No title captured]	70	1746	1814	4	155	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 4	2005	142	1					37	46		10.7326/0003-4819-142-1-200501040-00110	http://dx.doi.org/10.7326/0003-4819-142-1-200501040-00110			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	916DS	15537682				2022-12-28	WOS:000228366200004
J	Panchanathan, K; Boyd, R				Panchanathan, K; Boyd, R			Indirect reciprocity can stabilize cooperation without the second-order free rider problem	NATURE			English	Article							GROUP SELECTION; EVOLUTION; NORMS; PUNISHMENT; DEFECTORS	Models of large-scale human cooperation take two forms. 'Indirect reciprocity'(1) occurs when individuals help others in order to uphold a reputation and so be included in future cooperation. In 'collective action'(2), individuals engage in costly behaviour that benefits the group as a whole. Although the evolution of indirect reciprocity is theoretically plausible(3-6), there is no consensus about how collective action evolves. Evidence suggests that punishing free riders can maintain cooperation(7-9), but why individuals should engage in costly punishment is unclear. Solutions to this 'second-order free rider problem' include meta-punishment(10), mutation(11), conformism(12), signalling(13-15) and group-selection(16-18). The threat of exclusion from indirect reciprocity can sustain collective action in the laboratory(19). Here, we show that such exclusion is evolutionarily stable, providing an incentive to engage in costly cooperation, while avoiding the second-order free rider problem because punishers can withhold help from free riders without damaging their reputations. However, we also show that such a strategy cannot invade a population in which indirect reciprocity is not linked to collective action arises.	Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Panchanathan, K (corresponding author), Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90095 USA.	buddha@ucla.edu						Alexander R., 1987, BIOL MORAL SYSTEMS; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Bowles S, 2004, ROUNDTABLE SER BEHAV, P1; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; BOYD R, 1990, J THEOR BIOL, V145, P331, DOI 10.1016/S0022-5193(05)80113-4; BOYD R, 1992, ETHOL SOCIOBIOL, V13, P171, DOI 10.1016/0162-3095(92)90032-Y; Boyd R, 2002, J THEOR BIOL, V215, P287, DOI 10.1006/jtbi.2001.2515; ELLISON G, 1993, ECONOMETRICA, V61, P1047, DOI 10.2307/2951493; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Gintis H, 2001, J THEOR BIOL, V213, P103, DOI 10.1006/jtbi.2001.2406; Gintis H, 2000, J THEOR BIOL, V206, P169, DOI 10.1006/jtbi.2000.2111; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Henrich J, 2001, J THEOR BIOL, V208, P79, DOI 10.1006/jtbi.2000.2202; KANDORI M, 1993, ECONOMETRICA, V61, P29, DOI 10.2307/2951777; LEIMAR O, 2001, P ROY SOC LOND B BIO, V268, P2495; Maynard Smith J., 1982, pi; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Nowak MA, 1998, J THEOR BIOL, V194, P561, DOI 10.1006/jtbi.1998.0775; OLSON M., 1971, LOGIC COLLECTIVE ACT; OSTROM E, 1992, AM POLIT SCI REV, V86, P404, DOI 10.2307/1964229; Panchanathan K, 2003, J THEOR BIOL, V224, P115, DOI 10.1016/S0022-5193(03)00154-1; Roberts G, 1998, P ROY SOC B-BIOL SCI, V265, P427, DOI 10.1098/rspb.1998.0312; Samuelson L., 1997, EVOLUTIONARY GAMES E; Sethi R, 1996, AM ECON REV, V86, P766; Smith EA, 2000, EVOL HUM BEHAV, V21, P245, DOI 10.1016/S1090-5138(00)00031-3; Sober E., 1999, OTHERS EVOLUTION PSY; SOLTIS J, 1995, CURR ANTHROPOL, V36, P473, DOI 10.1086/204381; Sugden R, 1986, EC RIGHTS COOPERATIO; YAMAGISHI T, 1986, J PERS SOC PSYCHOL, V51, P110, DOI 10.1037/0022-3514.51.1.110; YOUNG HP, 1993, ECONOMETRICA, V61, P57, DOI 10.2307/2951778	30	528	541	5	113	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					499	502		10.1038/nature02978	http://dx.doi.org/10.1038/nature02978			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565153				2022-12-28	WOS:000225322100045
J	Carrozza, JP; Sellke, FW				Carrozza, JP; Sellke, FW			A 69-year-old woman with left main coronary artery disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SIROLIMUS-ELUTING STENTS; RANDOMIZED CONTROLLED-TRIAL; BALLOON-EXPANDABLE-STENT; BYPASS GRAFT-SURGERY; FOLLOW-UP; MULTIVESSEL DISEASE; ELECTIVE PROCEDURES; STABLE ANGINA; TERM OUTCOMES; MODERN-ERA		Beth Israel Deaconess Med Ctr, Sect Intervent Cardiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Carrozza, JP (corresponding author), Beth Israel Deaconess Med Ctr, Sect Intervent Cardiol, 330 Brookline Ave, Boston, MA 02215 USA.	jcarrozz@bidmc.harvard.edu						Alderman EL, 1996, NEW ENGL J MED, V335, P217; Ascione R, 2002, ANN THORAC SURG, V74, P474, DOI 10.1016/S0003-4975(02)03727-X; Bergh C, 2002, ANN THORAC SURG, V74, P689, DOI 10.1016/S0003-4975(02)03723-2; Black A, 2001, J AM COLL CARDIOL, V37, P832, DOI 10.1016/S0735-1097(00)01176-1; Brener SJ, 2002, J AM COLL CARDIOL, V40, P1961, DOI 10.1016/S0735-1097(02)02538-X; CARACCIOLO EA, 1995, CIRCULATION, V91, P2325, DOI 10.1161/01.CIR.91.9.2325; Cohen DJ, 2004, CIRCULATION, V110, P508, DOI 10.1161/01.CIR.0000136821.99814.43; COHEN MV, 1975, CIRCULATION, V52, P275, DOI 10.1161/01.CIR.52.2.275; CONLEY MJ, 1978, CIRCULATION, V57, P947, DOI 10.1161/01.CIR.57.5.947; CUTLIP D, DATE PATIENT INFORMA; Cutlip DE, 2001, CIRCULATION, V103, P1967; de Lezo JS, 2003, CIRCULATION, V108, P408; DETRE KM, 1984, NEW ENGL J MED, V311, P1333; Ellis SG, 1997, CIRCULATION, V96, P3867; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9; GRUNTZIG A, 1978, LANCET, V1, P263, DOI 10.1016/s0140-6736(78)90500-7; Hannan EL, 2000, J AM COLL CARDIOL, V36, P395, DOI 10.1016/S0735-1097(00)00752-X; Jeremias A, 2004, CIRCULATION, V109, P1930, DOI 10.1161/01.CIR.0000127105.99982.21; John R, 2000, ANN THORAC SURG, V69, P30, DOI 10.1016/S0003-4975(99)01309-0; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; Leavitt BJ, 2001, CIRCULATION, V103, P507, DOI 10.1161/01.CIR.103.4.507; LOOP FD, 1986, NEW ENGL J MED, V314, P1, DOI 10.1056/NEJM198601023140101; Mehilli J, 2000, JAMA-J AM MED ASSOC, V284, P1799, DOI 10.1001/jama.284.14.1799; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Moses JW, 2003, NEW ENGL J MED, V349, P1315, DOI 10.1056/NEJMoa035071; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; OKEEFE JH, 1989, AM J CARDIOL, V64, P144, DOI 10.1016/0002-9149(89)90447-5; Park SJ, 2003, AM J CARDIOL, V91, P12, DOI 10.1016/S0002-9149(02)02990-9; POCOCK SJ, 1995, LANCET, V346, P1184, DOI 10.1016/S0140-6736(95)92897-9; Rodriguez A, 2001, J AM COLL CARDIOL, V37, P51, DOI 10.1016/S0735-1097(00)01052-4; RYAN TJ, 1988, CIRCULATION, V78, P486, DOI 10.1161/01.CIR.78.2.486; Schofer J, 2003, LANCET, V362, P1093, DOI 10.1016/S0140-6736(03)14462-5; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Sigwart U, 2002, LANCET, V360, P965; Silvestri M, 2000, J AM COLL CARDIOL, V35, P1543, DOI 10.1016/S0735-1097(00)00588-X; SIMES PA, 1996, J AM COLL CARDIOL, V28, P1444; Steuer J, 2002, EUR HEART J, V23, P1219, DOI 10.1053/euhj.2002.3171; Taggart DP, 1999, J THORAC CARDIOV SUR, V118, P414, DOI 10.1016/S0022-5223(99)70177-7; Takagi T, 2002, CIRCULATION, V106, P698, DOI 10.1161/01.CIR.0000024983.34728.5D; Tatoulis J, 1999, ANN THORAC SURG, V68, P2093, DOI 10.1016/S0003-4975(99)01150-9; Van Dijk D, 2002, JAMA-J AM MED ASSOC, V287, P1405, DOI 10.1001/jama.287.11.1405; VARNAUSKAS E, 1982, LANCET, V2, P1173; VARNAUSKAS E, 1988, NEW ENGL J MED, V319, P332, DOI 10.1056/NEJM198808113190603; Versaci F, 1997, NEW ENGL J MED, V336, P817, DOI 10.1056/NEJM199703203361201; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	47	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2506	2514		10.1001/jama.292.20.2506	http://dx.doi.org/10.1001/jama.292.20.2506			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562131				2022-12-28	WOS:000225303000027
J	Tannen, T				Tannen, T			Lawrence Z Freedman	LANCET			English	Biographical-Item												asalea@sbcglobal.net							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1850	1850		10.1016/S0140-6736(04)17427-8	http://dx.doi.org/10.1016/S0140-6736(04)17427-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15568211	Bronze			2022-12-28	WOS:000225269300012
J	Flowers, J				Flowers, J			The route to atomic and quantum standards	SCIENCE			English	Review							FINE-STRUCTURE CONSTANT; REALIZATION; FREQUENCY; JOSEPHSON; KILOGRAM	Over the past half-century, there has been a shift away from standards based on particular artifacts toward those based on physical effects, the most stable being based on quantum properties of systems. This change was proposed at the end of the 19th century but is still not complete at the start of the 21st. We discuss how this vision has been implemented through recent advances in science and metrology and how these may soon lead to an SI system finally free from artifact standards, with a consistency based on fundamental constants.	Natl Phys Lab, Teddington TW11 0LW, Middx, England	National Physical Laboratory - UK	Flowers, J (corresponding author), Natl Phys Lab, Teddington TW11 0LW, Middx, England.	jeff.flowers@npl.co.uk						Ashworth WJ, 2004, SCIENCE, V306, P1314, DOI 10.1126/science.1102551; Avron JE, 2003, PHYS TODAY, V56, P38, DOI 10.1063/1.1611351; Becker P, 2001, REP PROG PHYS, V64, P1945, DOI 10.1088/0034-4885/64/12/206; Bize S, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.150802; *BUR INT POIDS MES, 2000, INT SYST UN SI; Bureau International des Poids et Mesures, 1998, INT SYST UN SI; CLOTHIER WK, 1989, METROLOGIA, V26, P9, DOI 10.1088/0026-1394/26/1/003; Diddams SA, 2004, SCIENCE, V306, P1318, DOI 10.1126/science.1102330; Eichenberger A, 2003, METROLOGIA, V40, P356, DOI 10.1088/0026-1394/40/6/007; ESSEN L, 1955, NATURE, V176, P281; Fischer M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.230802; Flowers JL, 2004, CONTEMP PHYS, V45, P123, DOI 10.1080/00107510410001647562; FUNCK T, 1991, IEEE T INSTRUM MEAS, V40, P158, DOI 10.1109/TIM.1990.1032905; Giacomo P, 1984, METROLOGIA, V20, P25, DOI [10.1088/0026-1394/17/2/007, DOI 10.1088/0026-1394/17/2/007]; Glaser M, 2003, METROLOGIA, V40, P376, DOI 10.1088/0026-1394/40/6/009; JOSEPHSON BD, 1962, PHYS LETT, V1, P251, DOI 10.1016/0031-9163(62)91369-0; Keller MW, 1999, SCIENCE, V285, P1706, DOI 10.1126/science.285.5434.1706; KIBBLE B. P, 1976, ATOMIC MASSES FUNDAM, V5, P545; KIBBLE BP, 1990, METROLOGIA, V27, P173, DOI 10.1088/0026-1394/27/4/002; MARTIN JE, 1985, METROLOGIA, V21, P147, DOI 10.1088/0026-1394/21/3/007; MOHR PJ, 2003, IN PRESS REV MOD PHY; Murphy MT, 2003, MON NOT R ASTRON SOC, V345, P609, DOI 10.1046/j.1365-8711.2003.06970.x; NIETO MM, 1984, PHYS REV A, V29, P3413, DOI 10.1103/PhysRevA.29.3413; Pereverzev SV, 1997, NATURE, V388, P449, DOI 10.1038/41277; PETLEY BW, 1983, NATURE, V303, P373, DOI 10.1038/303373a0; Piquemal F, 2000, METROLOGIA, V37, P207, DOI 10.1088/0026-1394/37/3/4; Rusby RL, 1996, METROLOGIA, V33, P409, DOI 10.1088/0026-1394/33/4/17; Simmonds RW, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.035301; Spietz L, 2003, SCIENCE, V300, P1929, DOI 10.1126/science.1084647; Srianand R, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.121302; Sukhatme K, 2001, NATURE, V411, P280, DOI 10.1038/35077024; TAYLOR BN, 1989, METROLOGIA, V26, P47, DOI 10.1088/0026-1394/26/1/004; TERRIEN J, 1968, METROLOGIA, V4, P41, DOI 10.1088/0026-1394/4/1/006; THOMPSON AM, 1956, NATURE, V177, P888, DOI 10.1038/177888a0; VANDYCK RS, 1987, PHYS REV LETT, V59, P26, DOI 10.1103/PhysRevLett.59.26; VONKLITZING K, 1980, PHYS REV LETT, V45, P494, DOI 10.1103/PhysRevLett.45.494	36	49	50	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1324	1330		10.1126/science.1102156	http://dx.doi.org/10.1126/science.1102156			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550660				2022-12-28	WOS:000225301600039
J	Zhang, M; Atkinson, KR; Baughman, RH				Zhang, M; Atkinson, KR; Baughman, RH			Multifunctional carbon nanotube yarns by downsizing an ancient technology	SCIENCE			English	Article							FIBERS; ARRAYS; KNOT	By introducing twist during spinning of multiwalled carbon nanotubes from nanotube forests to make multi-ply, torque-stabilized yarns, we achieve yarn strengths greater than 460 megapascals. These yarns deform hysteretically over large strain ranges, reversibly providing up to 48% energy damping, and are nearly as tough as fibers used for bulletproof vests. Unlike ordinary fibers and yarns, these nanotube yarns are not degraded in strength by overhand knotting. They also retain their strength and flexibility after heating in air at 450degreesC for an hour or when immersed in liquid nitrogen. High creep resistance and high electrical conductivity are observed and are retained after polymer infiltration, which substantially increases yarn strength.	Univ Texas, NanoTech Inst, Richardson, TX 75083 USA; Univ Texas, Dept Chem, Richardson, TX 75083 USA; CSIRO Text & Fibre Technol, Belmont, Vic 3216, Australia	University of Texas System; University of Texas Dallas; University of Texas System; University of Texas Dallas; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Baughman, RH (corresponding author), Univ Texas, NanoTech Inst, Richardson, TX 75083 USA.	ray.baughman@utdallas.edu	Atkinson, Ken R/B-9931-2008; Baughman, Ray/A-8628-2018	Baughman, Ray/0000-0001-5845-5137				Arai Y, 1999, NATURE, V399, P446, DOI 10.1038/20894; Barber E. J. W., 1992, PREHISTORIC TEXTILES; Baughman RH, 1998, SCIENCE, V279, P1522, DOI 10.1126/science.279.5356.1522; Baughman RH, 2002, SCIENCE, V297, P787, DOI 10.1126/science.1060928; Dalton AB, 2003, NATURE, V423, P703, DOI 10.1038/423703a; Donnet J.-B., 1998, CARBON FIBERS; Ericson LM, 2004, SCIENCE, V305, P1447, DOI 10.1126/science.1101398; Fan SS, 1999, SCIENCE, V283, P512, DOI 10.1126/science.283.5401.512; Hearle J. W. S., 1969, STRUCTURAL MECH FIBE, V1; HEARLE JWS, 1967, J POLYM SCI C, V20, P215; Jiang KL, 2002, NATURE, V419, P801, DOI 10.1038/419801a; Kumar S, 2002, MACROMOLECULES, V35, P9039, DOI 10.1021/ma0205055; Li YL, 2004, SCIENCE, V304, P276, DOI 10.1126/science.1094982; Pipes RB, 2002, COMPOS SCI TECHNOL, V62, P419, DOI 10.1016/S0266-3538(02)00002-7; Qian D, 2003, COMPOS SCI TECHNOL, V63, P1561, DOI 10.1016/S0266-3538(03)00064-2; Ren ZF, 1998, SCIENCE, V282, P1105, DOI 10.1126/science.282.5391.1105; Saitta AM, 1999, NATURE, V399, P46, DOI 10.1038/19935; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331	18	1347	1430	21	669	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1358	1361		10.1126/science.1104276	http://dx.doi.org/10.1126/science.1104276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550667				2022-12-28	WOS:000225301600047
J	Costello, A; Osrin, D; Manandhar, D				Costello, A; Osrin, D; Manandhar, D			Reducing maternal and neonatal mortality in the poorest communities	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEVELOPING-COUNTRIES; RANDOMIZED-TRIAL; SAFE MOTHERHOOD; 3RD STAGE; CARE; MANAGEMENT; METAANALYSIS; MISOPROSTOL; PREGNANCY; OUTCOMES		UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England	University of London; University College London	Costello, A (corresponding author), UCL, Inst Child Hlth, Int Perinatal Care Unit, London WC1N 1EH, England.	ipu@ich.ucl.ac.uk		Osrin, David/0000-0001-9691-9684				AbouZahr C, 2003, BRIT MED BULL, V67, P1, DOI 10.1093/bmb/ldg015; Austveg B, 2004, BJOG-INT J OBSTET GY, V111, P397, DOI 10.1111/j.1471-0528.2004.00111.x; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; *BOARD GLOB HLTH C, 2003, IMPR BIRTH OUTC M CH; De Brouwere V, 1998, TROP MED INT HEALTH, V3, P771, DOI 10.1046/j.1365-3156.1998.00310.x; Donnay F, 2000, INT J GYNECOL OBSTET, V70, P89, DOI 10.1016/S0020-7292(00)00236-8; ElRefaey H, 1996, LANCET, V347, P1257, DOI 10.1016/S0140-6736(96)90771-0; Graham WJ, 2004, LANCET, V363, P23, DOI 10.1016/S0140-6736(03)15165-3; Gulmezoglu AM, 2001, LANCET, V358, P689, DOI 10.1016/S0140-6736(01)05835-4; GWATKIN D, 2004, LOOKING GLOBAL CHILD; Haines A, 2004, BMJ-BRIT MED J, V329, P394, DOI 10.1136/bmj.329.7462.394; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; Koblinsky MA, 1999, B WORLD HEALTH ORGAN, V77, P399; Maine D, 1999, AM J PUBLIC HEALTH, V89, P480, DOI 10.2105/AJPH.89.4.480; Maine D, 2001, INT J GYNECOL OBSTET, V74, P99, DOI 10.1016/S0020-7292(01)00428-3; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; MESKO N, 2003, BMC INT HLTH HUM RIG, V3; Pallikadavath S, 2004, SOC SCI MED, V59, P1147, DOI 10.1016/j.socscimed.2003.11.045; Sazawal S, 2003, LANCET INFECT DIS, V3, P547, DOI 10.1016/S1473-3099(03)00737-0; Shy CM, 1997, AM J EPIDEMIOL, V145, P479; Sibley L, 2004, MIDWIFERY, V20, P51, DOI 10.1016/S0266-6138(03)00053-6; Tew M., 1990, SAFER CHILDBIRTH CRI; Tsu VD, 2004, INT J GYNECOL OBSTET, V85, pS42, DOI 10.1016/j.ijgo.2004.02.009; *UN, 2004, MILL IND; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; *WHO, 2004, GLOB ACT SKILL ATT P	26	66	69	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1166	1168		10.1136/bmj.329.7475.1166	http://dx.doi.org/10.1136/bmj.329.7475.1166			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539675	Green Published			2022-12-28	WOS:000225169600028
J	Flaherty, G; Bell, M; O'Keeffe, D; Crowley, J; O'Brien, T				Flaherty, G; Bell, M; O'Keeffe, D; Crowley, J; O'Brien, T			When head rules heart	LANCET			English	Editorial Material							GROWTH-HORMONE		Univ Coll Hosp Galway, Dept Endocrinol, Galway, Ireland; Univ Coll Hosp Galway, Dept Radiol, Galway, Ireland; Univ Coll Hosp Galway, Dept Cardiol, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	O'Brien, T (corresponding author), Univ Coll Hosp Galway, Dept Endocrinol, Galway, Ireland.	timothy.obrien@nuigalway.ie	O'Brien, Timothy/N-7112-2014; Flaherty, Gerard/F-1797-2015	O'Brien, Timothy/0000-0001-9028-5481; Flaherty, Gerard/0000-0002-5987-1658				BATES AS, 1993, Q J MED, V86, P293; CHANSON P, 1990, ANN INTERN MED, V113, P921, DOI 10.7326/0003-4819-113-12-921; Lombardi G, 1997, HORM RES, V48, P38, DOI 10.1159/000191311; SACCA L, 1994, ENDOCR REV, V15, P555, DOI 10.1210/er.15.5.555	4	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1828	1828		10.1016/S0140-6736(04)17407-2	http://dx.doi.org/10.1016/S0140-6736(04)17407-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541457				2022-12-28	WOS:000225070600037
J	Niessing, D; Huttelmaier, S; Zenklusen, D; Singer, RH; Burley, SK				Niessing, D; Huttelmaier, S; Zenklusen, D; Singer, RH; Burley, SK			She2p is a novel RNA binding protein with a basic helical hairpin motif	CELL			English	Article							ASH1 MESSENGER-RNA; BUDDING YEAST DEPENDS; STRUCTURAL ELEMENTS; MYOSIN MYO4P; LOCALIZATION; FUMARASE; MOTOR; ASSOCIATION; TRANSLATION; DETERMINANT	Selective transport of mRNAs in ribonucleoprotein particles (mRNP) ensures asymmetric distribution of information within and among eukaryotic cells. Actin-dependent transport of ASH1 mRNA in yeast represents one of the best-characterized examples of mRNP translocation. Formation of the ASH1 mRNP requires recognition of zip code elements by the RNA binding protein She2p. We determined the X-ray structure of She2p at 1.95 A resolution. She2p is a member of a previously unknown class of nucleic acid binding proteins, composed of a single globular domain with a five alpha helix bundle that forms asymmetric homodimer. After demonstrating potent, dimer-dependent RNA binding in vitro, we mapped the RNA binding surface of She2p to a basic helical hairpin in vitro and in vivo and present a mechanism for mRNA-dependent initiation of ASH1 mRNP complex assembly.	Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10461 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine	Burley, SK (corresponding author), Struct Genomix Inc, 10505 Roselle St, San Diego, CA 92121 USA.	sburley@stromix.com	Niessing, Dierk/AAE-4936-2022; Niessing, Dierk/M-4619-2014; Hüttelmaier, Stefan/AAQ-1203-2021; Zenklusen, Daniel/C-4503-2008	Niessing, Dierk/0000-0002-5589-369X; Niessing, Dierk/0000-0002-5589-369X; Zenklusen, Daniel/0000-0002-0067-0093; Burley, Stephen K./0000-0002-2487-9713	NIGMS NIH HHS [GM61262, GM57071] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057071, R01GM061262] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Chartrand P, 1999, CURR BIOL, V9, P333, DOI 10.1016/S0960-9822(99)80144-4; Chartrand P, 2002, MOL CELL, V10, P1319, DOI 10.1016/S1097-2765(02)00694-9; Chartrand P, 2001, ANNU REV CELL DEV BI, V17, P297, DOI 10.1146/annurev.cellbio.17.1.297; Cohen SL, 2001, ANNU REV BIOPH BIOM, V30, P67, DOI 10.1146/annurev.biophys.30.1.67; Darzacq X, 2003, CURR OPIN MICROBIOL, V6, P614, DOI 10.1016/j.mib.2003.10.005; Dasgupta S, 1997, PROTEINS, V28, P494, DOI 10.1002/(SICI)1097-0134(199708)28:4<494::AID-PROT4>3.0.CO;2-A; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Ding B, 2003, CURR OPIN PLANT BIOL, V6, P596, DOI 10.1016/j.pbi.2003.09.010; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Estevez M, 2002, PROTEIN SCI, V11, P1552, DOI 10.1110/ps.0201502; Farina KL, 2002, TRENDS CELL BIOL, V12, P466, DOI 10.1016/S0962-8924(02)02357-7; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; FerreDAmare AR, 1997, METHOD ENZYMOL, V276, P157, DOI 10.1016/S0076-6879(97)76056-7; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Gonsalvez GB, 2003, RNA, V9, P1383, DOI 10.1261/rna.5120803; Gonzalez I, 1999, CURR BIOL, V9, P337, DOI 10.1016/S0960-9822(99)80145-6; Gu W, 2004, GENE DEV, V18, P1452, DOI 10.1101/gad.1189004; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Ke HM, 1997, METHOD ENZYMOL, V276, P448, DOI 10.1016/S0076-6879(97)76071-3; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kloc M, 2002, CELL, V108, P533, DOI 10.1016/S0092-8674(02)00651-7; Kruse C, 2002, J CELL BIOL, V159, P971, DOI 10.1083/jcb.200207101; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; Long RM, 2000, EMBO J, V19, P6592, DOI 10.1093/emboj/19.23.6592; Mohr E, 2001, INT J BIOCHEM CELL B, V33, P669, DOI 10.1016/S1357-2725(01)00047-4; Munchow S, 1999, J CELL SCI, V112, P1511; Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pieper U, 2004, NUCLEIC ACIDS RES, V32, pD217, DOI 10.1093/nar/gkh095; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; Steward O, 2001, Results Probl Cell Differ, V34, P1; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Takizawa PA, 2000, P NATL ACAD SCI USA, V97, P5273, DOI 10.1073/pnas.080585897; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Tekotte H, 2002, TRENDS GENET, V18, P636, DOI 10.1016/S0168-9525(02)02819-6; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TYSON CB, 1979, J BACTERIOL, V138, P92, DOI 10.1128/JB.138.1.92-98.1979; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Wickens M, 2000, COLD SPRING HARBOR M, V39, P295; WOODS SA, 1986, BIOCHEM J, V237, P547, DOI 10.1042/bj2370547; ZUCKER M, 1989, SCIENCE, V244, P48	59	60	62	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					491	502		10.1016/j.cell.2004.10.018	http://dx.doi.org/10.1016/j.cell.2004.10.018			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537539	Bronze			2022-12-28	WOS:000225183200008
J	Vega, RB; Matsuda, K; Oh, J; Barbosa, AC; Yang, XL; Meadows, E; McAnally, J; Pomajzl, C; Shelton, JM; Richardson, JA; Karsenty, G; Olson, EN				Vega, RB; Matsuda, K; Oh, J; Barbosa, AC; Yang, XL; Meadows, E; McAnally, J; Pomajzl, C; Shelton, JM; Richardson, JA; Karsenty, G; Olson, EN			Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis	CELL			English	Article							INDIAN HEDGEHOG; BONE-FORMATION; DIFFERENTIATION; EXPRESSION; CARTILAGE; CBFA1; TRANSCRIPTION; COLLAGEN; ENHANCER; PATHWAY	Histone deacetylases (HDACs) modulate cell growth and differentiation by governing chromatin structure and repressing the activity of specific transcription factors. We showed previously that HDAC9 acts as a negative regulator of cardiomyocyte hypertrophy and skeletal muscle differentiation. Here we report that HDAC4, which is expressed in prehypertrophic chondrocytes, regulates chondrocyte hypertrophy and endochondral bone formation by interacting with and inhibiting the activity of Runx2, a transcription factor necessary for chondrocyte hypertrophy. HDAC4-null mice display premature ossification of developing bones due to ectopic and early onset chondrocyte hypertrophy, mimicking the phenotype that results from constitutive Runx2 expression in chondrocytes. Conversely, overexpression of HDAC4 in proliferating chondrocytes in vivo inhibits chondrocyte hypertrophy and differentiation, mimicking a Runx2 loss-of-function phenotype. These results establish HDAC4 as a central regulator of chondrocyte hypertrophy an skeletogenesis and suggest general roles for class II HDACs in the control of cellular hypertrophy.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Baylor Coll Med, Dept Mol & Human Genet, Bone Dis Program Texas, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	eric.olson@utsouthwestern.edu	Matsuda, Koichi/D-4597-2011	Matsuda, Koichi/0000-0001-7292-2686				Akiyama H, 1999, BIOCHEM BIOPH RES CO, V257, P814, DOI 10.1006/bbrc.1999.0494; Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467-8476.2004; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Shelton JM, 2000, J LIPID RES, V41, P532; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stott NS, 1997, J CELL SCI, V110, P2691; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zhang CL, 2001, P NATL ACAD SCI USA, V98, P7354, DOI 10.1073/pnas.131198498; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	35	611	651	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					555	566		10.1016/j.cell.2004.10.024	http://dx.doi.org/10.1016/j.cell.2004.10.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537544	Bronze			2022-12-28	WOS:000225183200013
J	Kangas, AT; Evans, AR; Thesleff, I; Jernvall, J				Kangas, AT; Evans, AR; Thesleff, I; Jernvall, J			Nonindependence of mammalian dental characters	NATURE			English	Article							MORPHOLOGICAL EVIDENCE; MOLECULAR-DATA; ECTODYSPLASIN; GENE; PHENOTYPE; EVOLUTION; RECEPTOR; TEETH; MOUSE; EDAR	Studies of mammalian evolution frequently use data derived from the dentition(1-4). Dental characters are particularly central for inferring phylogenetic relationships of fossil taxa(1-4), of which teeth are often the only recovered part. The use of different aspects of dental morphology as phylogenetic signals implies the independence of dental characters from each other. Here we report, however, that, at least developmentally, most dental characters may be nonindependent. We investigated how three different levels of the cell signalling protein ectodysplasin (Eda)(5) changed dental characters in mouse. We found that with increasing expression levels of this one gene, the number of cusps increases, cusp shapes and positions change, longitudinal crests form, and number of teeth increases. The consistent modification of characters related to lateral placement of cusps can be traced to a small difference in the formation of an early signalling centre at the onset of tooth crown formation. Our results suggest that most aspects of tooth shape have the developmental potential for correlated changes during evolution which may, if not taken into account, obscure phylogenetic history.	Univ Helsinki, Inst Biotechnol, Dev Biol Program, FIN-00014 Helsinki, Finland	University of Helsinki	Jernvall, J (corresponding author), Univ Helsinki, Inst Biotechnol, Dev Biol Program, POB 56, FIN-00014 Helsinki, Finland.	jernvall@fastmail.fm	Evans, Alistair R/D-4239-2011; Self, Casey J/B-6871-2011	Evans, Alistair R/0000-0002-4078-4693; 				Archibald JD, 2003, MOL PHYLOGENET EVOL, V28, P350, DOI 10.1016/S1055-7903(03)00034-4; Bateson W., 1894, MAT STUDY VARIATION; Beard KC, 1996, SCIENCE, V272, P82, DOI 10.1126/science.272.5258.82; BUTLER PM, 1956, BIOL REV, V31, P30, DOI 10.1111/j.1469-185X.1956.tb01551.x; Dawson Mary R., 1998, Bulletin of Carnegie Museum of Natural History, V34, P278; Evans AR, 2001, J MICROSC-OXFORD, V204, P108, DOI 10.1046/j.1365-2818.2001.00939.x; Flynn JJ, 1999, NATURE, V401, P57, DOI 10.1038/43420; Flynn L.J., 1985, NATO ASI (Advanced Science Institutes) Series Series A Life Sciences, V92, P589; Geisler JH, 2003, J VERTEBR PALEONTOL, V23, P991, DOI 10.1671/32; Goodwin HT, 1998, J MAMMAL, V79, P1161, DOI 10.2307/1383007; Hlusko LJ, 2004, P NATL ACAD SCI USA, V101, P2653, DOI 10.1073/pnas.0307678101; Jernvall J, 2000, P NATL ACAD SCI USA, V97, P14444, DOI 10.1073/pnas.97.26.14444; JERNVALL J, 1999, PALAEONTOL ELECT, V2; Laurikkala J, 2001, DEV BIOL, V229, P443, DOI 10.1006/dbio.2000.9955; Luo ZX, 2001, NATURE, V409, P53, DOI 10.1038/35051023; Meng J, 2003, B AM MUS NAT HIST, P1; Mikkola ML, 2003, CYTOKINE GROWTH F R, V14, P211, DOI 10.1016/S1359-6101(03)00020-0; Mustonen T, 2003, DEV BIOL, V259, P123, DOI 10.1016/S0012-1606(03)00157-X; Naylor GJP, 2001, SYST BIOL, V50, P444, DOI 10.1080/106351501300318030; Nowak RM, 1991, WALKERS MAMMALS WORL; O'Leary MA, 2003, SYST BIOL, V52, P853, DOI 10.1080/10635150390252279; Pispa J, 2004, DEV DYNAM, V231, P432, DOI 10.1002/dvdy.20138; Salazar-Ciudad I, 2002, P NATL ACAD SCI USA, V99, P8116, DOI 10.1073/pnas.132069499; Seiffert ER, 2003, NATURE, V422, P421, DOI 10.1038/nature01489; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Tucker AS, 2004, DEV BIOL, V268, P185, DOI 10.1016/j.ydbio.2003.12.019; VANVALEN L, 1970, DEV BIOL, V23, P456, DOI 10.1016/0012-1606(70)90110-7; Viriot L, 2002, CONNECT TISSUE RES, V43, P129, DOI 10.1080/03008200290001168; Weiss KM, 1998, CRIT REV ORAL BIOL M, V9, P369, DOI 10.1177/10454411980090040101; Woodburne MO, 2003, MOL PHYLOGENET EVOL, V28, P360, DOI 10.1016/S1055-7903(03)00113-1	30	226	235	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					211	214		10.1038/nature02927	http://dx.doi.org/10.1038/nature02927			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538367				2022-12-28	WOS:000225020200044
J	Baris, E; Ezzati, M				Baris, E; Ezzati, M			Should interventions to reduce respirable pollutants be linked to tuberculosis control programmes?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMOKING; MORTALITY; CHINA; DEATHS; DOTS		Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Ezzati, M (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	mezzati@hsph.harvard.edu			NIA NIH HHS [P01-AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Chen XY, 2004, LANCET, V364, P417; Dye C, 2003, TUBERCULOSIS, V83, P35, DOI 10.1016/S1472-9792(02)00056-2; Dye C, 2002, B WORLD HEALTH ORGAN, V80, P437; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Florig HK, 1997, ENVIRON SCI TECHNOL, V31, pA274, DOI 10.1021/es972315t; Frieden TR, 2003, LANCET, V362, P887, DOI 10.1016/S0140-6736(03)14333-4; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964; Lam TH, 2001, BRIT MED J, V323, P361, DOI 10.1136/bmj.323.7309.361; Leung CC, 2003, INT J TUBERC LUNG D, V7, P980; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2; Perez-Padilla R, 2001, INT J TUBERC LUNG D, V5, P441; Raviglione MC, 1997, LANCET, V350, P624, DOI 10.1016/S0140-6736(97)04146-9; Raviglione MC, 2002, LANCET, V359, P775, DOI 10.1016/S0140-6736(02)07880-7; SMITH KR, 1993, WORLD DEV, V21, P941, DOI 10.1016/0305-750X(93)90053-C; Squire SB, 2004, LANCET, V364, P391, DOI 10.1016/S0140-6736(04)16777-9; Squire SB, 1997, BMJ-BRIT MED J, V315, P1395, DOI 10.1136/bmj.315.7120.1395; Thomas P, 1999, AIR POLLUTION HLTH; WHO, 2002, RED RISKS PROM HLTH	20	13	13	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 6	2004	329	7474					1090	1093		10.1136/bmj.329.7474.1090	http://dx.doi.org/10.1136/bmj.329.7474.1090			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528622	Green Published			2022-12-28	WOS:000225070300025
J	Wolfson, W				Wolfson, W			Profile - Staffan Hildebrand: film maker who charts the spread of AIDS	LANCET			English	Biographical-Item												wendywolfson@comcast.net							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1931	1931		10.1016/S0140-6736(04)17499-0	http://dx.doi.org/10.1016/S0140-6736(04)17499-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15570696				2022-12-28	WOS:000225327000015
J	Anderson, TM; Neiwert, WA; Kirk, ML; Piccoli, PMB; Schultz, AJ; Koetzle, TF; Musaev, DG; Morokuma, K; Cao, R; Hill, CL				Anderson, TM; Neiwert, WA; Kirk, ML; Piccoli, PMB; Schultz, AJ; Koetzle, TF; Musaev, DG; Morokuma, K; Cao, R; Hill, CL			A late-transition metal oxo complex: K7Na9[O=Pt-IV(H2O)L-2]. L = [PW9O34](9-)	SCIENCE			English	Article							METHANE MONOOXYGENASE; RIBONUCLEOTIDE REDUCTASE; ENZYMES; ACTIVATION; REACTIVITY; CONVERSION; CHEMISTRY	Terminal mono-oxo complexes of the late transition metal elements have long been considered too unstable to synthesize because of repulsion between the oxygen electrons and the mostly fitted metal d orbitals. A platinum(IV)-oxo compound flanked by two polytungstate ligands, K7Na9[O=Pt(H2O)L-2], L = [PW9O34](9-), has now been prepared and isolated at room temperature as air-stable brown crystals. X-ray and neutron diffraction at 30 kelvin revealed a very short [1.720(18) angstrom] Pt-O bond and no evidence of a hydrogen atom at the terminal oxygen, ruling out a better precedented Pt-OH complex. Density functional theory and spectroscopic data account for the stability of the Pt(IV)-oxo unit by electron withdrawal into delocalized orbitals of the polytungstates.	Emory Univ, Dept Chem, Atlanta, GA 30322 USA; Univ New Mexico, Dept Chem, Albuquerque, NM 87131 USA; Argonne Natl Lab, Intense Pulsed Neutron Source, Argonne, IL 60439 USA	Emory University; University of New Mexico; United States Department of Energy (DOE); Argonne National Laboratory	Hill, CL (corresponding author), Emory Univ, Dept Chem, 1515 Pierce Dr, Atlanta, GA 30322 USA.	chill@emory.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057378] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-057378] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 2004, COMPREHENSIVE COORDA, DOI DOI 10.1016/B0-08-043748-6/03035-8; Appleby A. J., 1993, FUEL CELL HDB; Basch H, 1999, J AM CHEM SOC, V121, P7249, DOI 10.1021/ja9906296; BORRASALMENAR JJ, 2003, POLYOXOMETALATE MOL, V98; CARDUCCI MD, 1994, J AM CHEM SOC, V116, P11856, DOI 10.1021/ja00105a028; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Decker A, 2004, J AM CHEM SOC, V126, P5378, DOI 10.1021/ja0498033; Domaille PJ., 1990, INORG SYNTH, V27, P96; Gherman BF, 2004, J AM CHEM SOC, V126, P2978, DOI 10.1021/ja036506+; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Hill C.L, 2003, COMPREHENSIVE COORDI, V4, P679, DOI DOI 10.1016/B0-08-043748-6/03036-X; Inscore FE, 1999, INORG CHEM, V38, P1401, DOI 10.1021/ic981126o; Jones R, 1998, INORG CHEM, V37, P2842, DOI 10.1021/ic970790m; JORRIS TL, 1987, J AM CHEM SOC, V109, P7402, DOI 10.1021/ja00258a025; MacBeth CE, 2000, SCIENCE, V289, P938, DOI 10.1126/science.289.5481.938; NUGENT WA, 1988, METAL LIAND MULTIPLE; Parkin G, 1998, PROG INORG CHEM, V47, P1; POPE MT, 1991, ANGEW CHEM INT EDIT, V30, P34, DOI 10.1002/anie.199100341; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; RONG CY, 1992, J AM CHEM SOC, V114, P2932, DOI 10.1021/ja00034a027; SCHEIDT WR, 2000, SYSTEMATICS STEREOCH, V3; SHELEF M, 1995, CHEM REV, V95, P209, DOI 10.1021/cr00033a008; Sintchak MD, 2002, NAT STRUCT BIOL, V9, P293, DOI 10.1038/nsb774; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Somorjai G.A., 2010, INTRO SURFACE CHEM C; SPALTENSTEIN E, 1989, J AM CHEM SOC, V111, P8741, DOI 10.1021/ja00205a038; Torrent M, 2002, J AM CHEM SOC, V124, P192, DOI 10.1021/ja016589z; TOURNE CM, 1988, J CHEM SOC DALTON, P2411, DOI 10.1039/dt9880002411; Tshuva EY, 2004, CHEM REV, V104, P987, DOI 10.1021/cr020622y	29	124	128	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2004	306	5704					2074	2077		10.1126/science.1104696	http://dx.doi.org/10.1126/science.1104696			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881CM	15564312				2022-12-28	WOS:000225841000057
J	Frohling, S; Dohner, H				Frohling, S; Dohner, H			Disruption of C/EBP alpha function in acute myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany	Ulm University	Frohling, S (corresponding author), Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.		Döhner, Hartmut/C-8933-2016	Döhner, Hartmut/0000-0003-2116-5536				Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989	4	18	20	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2370	2372		10.1056/NEJMp048241	http://dx.doi.org/10.1056/NEJMp048241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575052				2022-12-28	WOS:000225429000005
J	Strom, BL				Strom, BL			Potential for conflict of interest in the evaluation of suspected adverse drug reactions - A counterpoint	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							REPORTING ODDS RATIO; CLINICAL JUDGMENT; COMMON-SENSE; CERIVASTATIN		Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol,Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med,Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Pharmacol,Ctr Educ & Res Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Strom, BL (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol,Ctr Educ & Res Therapeut, 824 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	bstrom@cceb.med.upenn.edu						Califf RM, 2002, PHARMACOEPIDEM DR S, V11, P319, DOI 10.1002/pds.699; Fischer MA, 2004, PHARMACOEPIDEM DR S, V13, P207, DOI 10.1002/pds.872; GRAHAM DJ, 2004, PHARMACOEPIDEMIOL S1, V13, pS250; Graham DJ., 2000, PHARMACOEPIDEM DR S, P109, DOI [10.1002/0470842555.ch8, DOI 10.1002/0470842555.CH8]; Heeley E, 2001, LANCET, V358, P1872, DOI 10.1016/S0140-6736(01)06898-2; Hennessy S, 2004, PHARMACOEPIDEM DR S, V13, P503, DOI 10.1002/pds.995; Iglehart JK, 2004, NEW ENGL J MED, V350, P826, DOI 10.1056/NEJMhpr045002; *JOINT COMM PRESCR, 1980, REP JOINT COMM PRESC; Kennedy D, 2000, PHARMACOEPIDEM DR S, P151; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Mann RD, 2004, PHARMACOEPIDEM DR S, V13, P501, DOI 10.1002/pds.994; *PHARM RES MAN AM, 2004, PHARM IND PROF 2004; Psaty BM, 2004, JAMA-J AM MED ASSOC, V292, P2622, DOI 10.1001/jama.292.21.2622; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P527, DOI 10.1002/pds.1003; Rothman KJ, 2004, PHARMACOEPIDEM DR S, V13, P519, DOI 10.1002/pds.1001; Shapiro S, 2004, PHARMACOEPIDEM DR S, V13, P511, DOI 10.1002/pds.999; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Strom BL, 2003, PHARMACOEPIDEM DR S, V12, P653, DOI 10.1002/pds.859; Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P3; *US GEN ACC OFF, 1990, US GEN ACC OFF PUBL, P24; Waller P, 2004, PHARMACOEPIDEM DR S, V13, P525, DOI 10.1002/pds.1002; YUISENBERG KS, 2002, PHARMACOEPIDEMIOL S1, V11, pS180; Zhou WG, 2004, PHARMACOEPIDEM DR S, V13, P515, DOI 10.1002/pds.1000; Zhou WG, 2004, PHARMACOEPIDEM DR S, V13, P505, DOI 10.1002/pds.998	25	41	43	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2643	2646		10.1001/jama.292.21.2643	http://dx.doi.org/10.1001/jama.292.21.2643			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572722				2022-12-28	WOS:000225409100027
J	Guttmacher, AE; Collins, FS; Carmona, RH				Guttmacher, AE; Collins, FS; Carmona, RH			The family history - More important than ever	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CANCER; BREAST; RISK		NHGRI, NIH, Bethesda, MD 20892 USA; Dept Hlth & Human Serv, Off Surg Gen, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Guttmacher, AE (corresponding author), NHGRI, NIH, Bldg 31,Rm 4B09, Bethesda, MD 20892 USA.							Acheson LS, 2000, GENET MED, V2, P180, DOI 10.1097/00125817-200005000-00004; Acheson LS, 2002, AM J HUM GENET, V71, P182; *AM MED ASS, AD FAM HIST FORM; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Brandi ML, 2001, ARTHRITIS RES, V3, P270, DOI 10.1186/ar316; Guttmacher AE, 2004, GENOMIC MED ARTICLES; Harrison TA, 2003, AM J PREV MED, V24, P152, DOI 10.1016/S0749-3797(02)00588-3; Johns LE, 2001, AM J GASTROENTEROL, V96, P2992, DOI 10.1111/j.1572-0241.2001.04677.x; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Pharoah PDP, 2002, BEST PRACT RES CL OB, V16, P449, DOI 10.1053/beog.2002.0296; Rich EC, 2004, J GEN INTERN MED, V19, P273, DOI 10.1111/j.1525-1497.2004.30401.x; Runeson B, 2003, AM J PSYCHIAT, V160, P1525, DOI 10.1176/appi.ajp.160.8.1525; Scheuner MT, 1997, AM J MED GENET, V71, P315, DOI 10.1002/(SICI)1096-8628(19970822)71:3<315::AID-AJMG12>3.0.CO;2-N; Sifri Randa D, 2002, J Fam Pract, V51, P856; Suther S, 2003, GENET MED, V5, P70, DOI 10.1097/01.GIM.0000055201.16487.61; Williams RR, 2001, AM J CARDIOL, V87, P129, DOI 10.1016/S0002-9149(00)01303-5; YOON P, 2004, FAMILY HIST PUBLIC H, P39; 2004, N ENGL J MED, V351, P2319	19	358	367	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					2333	2336		10.1056/NEJMsb042979	http://dx.doi.org/10.1056/NEJMsb042979			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564550				2022-12-28	WOS:000225298100016
J	Antonny, B				Antonny, B			SNARE filtering by dynamin	CELL			English	Editorial Material							VACUOLE FUSION; CONSTRICTION; ENDOCYTOSIS; ORGANELLE	Fission and fusion are the two elementary steps of membrane traffic. The mechanoenzyme dynamin acts at the fission step, but, in this issue of Cell, Peters et al. (2004) suggest an additional role of dynamin in preparing membranes for fusion.	Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Antonny, B (corresponding author), Univ Nice, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France.		Antonny, Bruno/ABH-7434-2020	Antonny, Bruno/0000-0002-9166-8668				Chen YJ, 2004, NAT STRUCT MOL BIOL, V11, P574, DOI 10.1038/nsmb762; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; Danino D, 2004, J STRUCT BIOL, V147, P259, DOI 10.1016/j.jsb.2004.04.005; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Mossessova E, 2003, CELL, V114, P483, DOI 10.1016/S0092-8674(03)00608-1; Song BD, 2004, J BIOL CHEM, V279, P40431, DOI 10.1074/jbc.M407007200; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247	9	11	12	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	2004	119	5					581	582		10.1016/j.cell.2004.11.026	http://dx.doi.org/10.1016/j.cell.2004.11.026			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550238	Bronze			2022-12-28	WOS:000225389500002
J	Haslam, N; Campbell, GC; Duggan, JE				Haslam, N; Campbell, GC; Duggan, JE			Lesson of the week - Gastric rupture associated with use of the laryngeal mask airway during cardiopulmonary resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review							POSITIVE-PRESSURE VENTILATION; RESPIRATORY MECHANICS; INSUFFLATION; STRATEGIES; MANAGEMENT; STOMACH; SYSTEM		Wansbeck Gen Hosp, Ashington NE63 9JJ, England; James Cook Univ Hosp, Middlesbrough TS4 3BW, Cleveland, England	James Cook University Hospital	Haslam, N (corresponding author), Wansbeck Gen Hosp, Ashington NE63 9JJ, England.	nhaslam@doctors.org.uk						Brimacombe JR, 1997, J CLIN ANESTH, V9, P113, DOI 10.1016/S0952-8180(97)00233-X; BRIMACOMBE JR, 1999, INSTRUCTION MANUAL U; de Latorre F, 2001, RESUSCITATION, V48, P211, DOI 10.1016/S0300-9572(00)00379-8; DEVITT JH, 1994, ANESTHESIOLOGY, V80, P550, DOI 10.1097/00000542-199403000-00011; Dorges V, 2001, EMERG MED J, V18, P90, DOI 10.1136/emj.18.2.90; Ho-Tai LM, 1998, CAN J ANAESTH, V45, P206, DOI 10.1007/BF03012903; IDRIS AH, 1995, CIRCULATION, V92, P3653; MELKER RJ, 1985, ANN EMERG MED, V14, P397, DOI 10.1016/S0196-0644(85)80280-8; Miller JS, 1997, ANN EMERG MED, V30, P343, DOI 10.1016/S0196-0644(97)70173-2; PENNANT JH, 1992, ANESTH ANALG, V74, P531; RABL W, 1995, AM J FOREN MED PATH, V16, P135, DOI 10.1097/00000433-199506000-00011; *RES COUNC UK, 2000 GUID; Smally AJ, 2002, J EMERG MED, V22, P27, DOI 10.1016/S0736-4679(01)00433-4; Weiler N, 1997, ANESTH ANALG, V84, P1025, DOI 10.1097/00000539-199705000-00013; Wenzel V, 2001, RESUSCITATION, V49, P123, DOI 10.1016/S0300-9572(00)00349-X; Wenzel V, 1998, RESUSCITATION, V38, P113, DOI 10.1016/S0300-9572(98)00095-1	16	16	16	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	2004	329	7476					1225	1226		10.1136/bmj.329.7476.1225	http://dx.doi.org/10.1136/bmj.329.7476.1225			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874FG	15550427	Green Published			2022-12-28	WOS:000225335700020
J	Young, H; Borrel, A; Holland, D; Salama, P				Young, H; Borrel, A; Holland, D; Salama, P			Public nutrition in complex emergencies	LANCET			English	Review							SEVERELY MALNOURISHED CHILDREN; UPPER-ARM CIRCUMFERENCE; SUPPLEMENTARY FEEDING PROGRAMS; SEVERE MALNUTRITION; EASTERN SUDAN; FOOD CRISIS; FAMINE; MORTALITY; REFUGEES; LESSONS	Public nutrition is a broad-based, problem-solving approach to addressing malnutrition in complex emergencies that combines analysis of nutritional risk and vulnerability with action-oriented strategies, including policies, programmes, and capacity development. This paper focuses on six broad areas: nutritional assessment, distribution of a general food ration, prevention and treatment of moderate malnutrition, treatment of severe malnutrition in children and adults, prevention and treatment of micronutrient deficiency diseases, and nutritional support for at-risk groups, including infants, pregnant and lactating women, elderly people, and people living with HIV. Learning and documenting good practice from previous emergencies, the promotion of good practice in current emergencies, and adherence to international standards and guidelines have contributed to establishing the field of public nutrition. However, many practical challenges reduce the effectiveness of nutritional interventions in complex emergencies, and important research and programmatic questions remain.	Tufts Univ, Friedman Sch Nutr Sci & Policy, Medford, MA 02155 USA; UNICEF, Kabul, Afghanistan	Tufts University	Young, H (corresponding author), 126 Curtis St, Medford, MA 02155 USA.	helen.young@tufts.edu						*ACC SUBC NUTR UN, 1993, REP NUTR SIT REF DIS; Aklilu Y, 2001, LIVESTOCK LIVELIHOOD; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; [Anonymous], 1995, PHYS STAT US INT ANT; APPLETON J, 2000, NUTR REF DISPL POP, pCH5; Ashworth A, 1998, NUTRITION, V14, P244, DOI 10.1016/S0899-9007(97)00433-4; Ashworth A, 1997, HEALTH POLICY PLANN, V12, P115, DOI 10.1093/heapol/12.2.115; AYALEW W, 1999, REDUCING VITAMIN A D; BAQUET S, 2000, FIELD EXCHANGE, V10, P6; BEATON GH, 1982, AM J CLIN NUTR, V35, P864, DOI 10.1093/ajcn/35.4.864; BEATON GH, 1996, FORTIFICATION FOODS; BERN C, 1995, LANCET, V345, P631, DOI 10.1016/S0140-6736(95)90527-8; BINKIN N, 1992, DISASTERS, V16, P97, DOI 10.1111/j.1467-7717.1992.tb00383.x; Black Maggie, 1992, CAUSE OUR TIMES OXFA; Borrel A, 2001, DISASTERS, V25, P149, DOI 10.1111/1467-7717.00167; BORREL A, 2000, ADDRESSING NUTR NEED; BORREL A, 1997, REP WORKSH SEL FEED; BRIEND A, 1995, LANCET, V345, P1119; BRIEND A, 1989, EUR J CLIN NUTR, V43, P715; Charlton KE, 2001, J NUTR, V131, p2424S, DOI 10.1093/jn/131.9.2424S; Cheung Edith, 2003, Food and Nutrition Bulletin, V24, P247; Clay DC, 1999, FOOD POLICY, V24, P391, DOI 10.1016/S0306-9192(99)00030-5; *COD AL COMM, 1991, GUID FORM S FOODS OL; Collins S, 2002, LANCET, V360, P1824, DOI 10.1016/S0140-6736(02)11770-3; Collins S, 1998, AM J CLIN NUTR, V68, P193, DOI 10.1093/ajcn/68.1.193; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6; Collins S, 1996, JAMA-J AM MED ASSOC, V276, P391, DOI 10.1001/jama.276.5.391; COLLINS S, 1995, NAT MED, V1, P810, DOI 10.1038/nm0895-810; Collins S, 2000, ADULTS ASSESSMENT NU; COTTON MF, 1992, S AFR MED J, V81, P87; CURDY A, 1994, WORKSH IMPR NUTR REF; DAVIS LE, 1971, AM J CLIN NUTR, V24, P358; de Ville de Goyet C., 1978, MANAGEMENT NUTR EMER; de Waal A, 2003, LANCET, V362, P1234, DOI 10.1016/S0140-6736(03)14548-5; deOnis M, 1996, AM J CLIN NUTR, V64, P650, DOI 10.1093/ajcn/64.4.650; DICK B, 1986, DISASTERS, V10, P53, DOI 10.1111/j.1467-7717.1986.tb00568.x; Diop EHI, 2003, AM J CLIN NUTR, V78, P302, DOI 10.1093/ajcn/78.2.302; DOWELL SF, 1995, JAMA-J AM MED ASSOC, V273, P1802, DOI 10.1001/jama.273.22.1802; *EM NUTR COORD UN, 2002, NAT NUTR SURV GUID; *ETH NUTR I, 1974, GUID EM FEED; *FANTA, 2000, POT US FOOD AID SUPP; *FANTA, 2002, P STAND MON ASS REL; Food and Nutrition Technical Assistance (FANTA), 2001, HIV AIDS GUID NUTR C, P24; FRIEDLAND IR, 1992, ANN TROP PAEDIATR, V12, P433, DOI 10.1080/02724936.1992.11747610; GIBB C, 1986, DISASTERS, V10, P17, DOI 10.1111/j.1467-7717.1986.tb00563.x; Golden BE, 2000, T ROY SOC TROP MED H, V94, P12, DOI 10.1016/S0035-9203(00)90420-6; GOLDEN MHN, 1996, SEVERE MALNUTRITION; GOLDEN MHN, 2002, P STAND MON ASS REL; Henry CJK, 1992, J REFUG STUD, V5, P359; Hilderbrand K, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79169-8; Hussein K., 1995, Journal of Refugee Studies, V8, P26, DOI 10.1093/jrs/8.1.26; INGHAM R, GM FOOD ROW CLOUDS F; *INT REG INF NETW, ZAMB GOVT COMPL GM G; ISAACK H, 1992, E AFR MED J, V69, P433; Jaspars S, 1999, DISASTERS, V23, P359, DOI 10.1111/1467-7717.00125; JASPARS S, 1989, RESPONDING CRISIS CO; KELLY M, 1993, DISASTERS, V17, P110, DOI 10.1111/j.1467-7717.1993.tb01138.x; KHANUM S, 1994, LANCET, V344, P1728; Lautze S., 2003, RISK VULNERABILITY E; LEYENAAR J, IN PRESS DISASTERS; MACRAE J, 2003, 14 OV DEV I HUM POL; MACRAE J, 2002, 11 OV DEV I HUM POL; MALFAIT P, 1993, INT J EPIDEMIOL, V22, P504, DOI 10.1093/ije/22.3.504; MARDEL S, 1995, EUR J CLIN NUTR, V49, pS46; MASON F, 2002, SCN NEWS, V24, P21; Mason JB, 2002, J NUTR, V132, p2096S, DOI 10.1093/jn/132.7.2096S; Mears C., 1998, ACCEPTABILITY USE CE; *MED SANS FRONT, 2002, NUTR GUID REV DRAFT; Medecins Sans Frontieres, 1995, NUTR GUID; Mei ZG, 1998, ARCH PEDIAT ADOL MED, V152, P471; MICHAELSEN KF, 1987, LANCET, V1, P1421; Munro LT, 2002, DISASTERS, V26, P242, DOI 10.1111/1467-7717.00203; Nabeth P, 1997, LANCET, V349, P59, DOI 10.1016/S0140-6736(05)62198-8; NIEBURG P, 1988, B WORLD HEALTH ORGAN, V66, P689; Peachey K, 1999, DISASTERS, V23, P350, DOI 10.1111/1467-7717.00124; PEEL S, 1977, 4 OXF; PELLETIER DL, 1995, FOOD POLICY, V20, P279, DOI 10.1016/0306-9192(95)00026-7; PELLETIER DL, 1995, B WORLD HEALTH ORGAN, V73, P443; PHELPS L, 1999, INFANT FEEDING PRACT, P7; Pieterse S, 2003, DISASTERS, V27, P16, DOI 10.1111/1467-7717.00217; Prinzo ZW, 2002, P NUTR SOC, V61, P251, DOI 10.1079/PNS2002151; *PROT CAL ADV GROU, 1977, GUID FOOD HLTH REL O; Prudhon C, 1997, EUR J CLIN NUTR, V51, P771, DOI 10.1038/sj.ejcn.1600483; PRUDHON C, 2002, ASSESSMENT TREATMENT; Reed BA, 1998, LANCET, V351, P128, DOI 10.1016/S0140-6736(97)06329-0; RIVERS JPW, 1976, ANN SOC BELG MED TR, V56, P345; Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563; SALAMA P, 2000, ENN FIELD EXCHANGE, P18; Schofield EC, 1996, DISASTERS, V20, P248, DOI 10.1111/j.1467-7717.1996.tb01037.x; Seal A, 2001, DISASTERS, V25, P136, DOI 10.1111/1467-7717.00166; SEAMAN J, 1975, P NUTR SOC, V34, pA114; SEAMAN J, 1988, J ROY STAT SOC A STA, V151, P464, DOI 10.2307/2982994; SHOHAM J, 1995, GOOD PRACTICE REV 2; Sklaver B, 2003, DISASTERS, V27, P259, DOI 10.1111/1467-7717.00232; *SPHER PROJ, IN PRESS NUTR MIN ST; *SPHERE PROJ, 2001, SPHER HUM CHART MIN; Spiegel PB, 2004, JAMA-J AM MED ASSOC, V292, P613, DOI 10.1001/jama.292.5.613; STEFANAK MA, 1989, J TROP PEDIATRICS, V35, P214, DOI 10.1093/tropej/35.5.214; The Sphere Project, 2004, HUM CHART MIN STAND; Toole M. J., 1992, Journal of Refugee Studies, V5, P313, DOI 10.1093/jrs/5.3-4.313; TOOLE MJ, 1988, J TROP PEDIATRICS, V34, P218, DOI 10.1093/tropej/34.5.218; *UNAIDS WHO, 2002, AIDS EP UPD, P17; *UNFPA UNICEF WHO, 2000, NEW DAT PREV MOTH CH; Unhcr Unicef Wfp Who, 2002, FOOD NUTR NEEDS EM; *UNHCR WFP, 1999, UNHCR WFP GUID SEL F; *UNICEF, 2002, INF FEED MOTH CHILD; UNICEF, 1990, STRAT IMPR NUTR CHIL; United Nations Children's Fund, 2000, STAT WORLDS CHILDR 2; *US AG INT DEV, 1989, NUTR TIM DIS REP INT; *US AG INT DEV, AM FOOD AID PLEDG TO; Vautier F, 1999, TROP MED INT HEALTH, V4, P875, DOI 10.1046/j.1365-3156.1999.00495.x; VERVERS MT, 1997, NUTR INTERVENTIONS P, P7; VESPA J, 1995, BRIT MED J, V311, P652, DOI 10.1136/bmj.311.7006.652; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; *WHA, 54 WORLD HLTH ASS A5; *WHA, 1994, 47 WORLD HLTH ASS; *WHO, 2002, 55 WORLD HLTH ASS A5; *WHO, 2003, REP TECHN CONS; WHO, 1995, FIELD GUID RAP NUTR; *WHO, 2000, GUID PRINC FEED INF; *WHO, HIV INF FEED FRAM PR; WHO-UNICEF, 1998, WKLY EPIDEMIOL REC, V73, P25; WOODRUFF BA, 2000, ADOLESCENTS ASSESSME; *WORLD FOOD PROGR, 2000, FOOD NUTR HDB; World Health Organization, 2000, MAN NUTR MAJ EM; World Health Organization, 1981, INT COD MARK BREASTM; World Health Organization, 1999, MAN SEV MALN MAN PHY; YIP R, 1994, J NUTR, V124, pS2043; YOUNG H, 1995, DISASTERS, V19, P26, DOI 10.1111/j.1467-7717.1995.tb00330.x; Young H, 1999, DISASTERS, V23, P277, DOI 10.1111/1467-7717.00118; YOUNG H, 1995, NUTR MATTERS PEOPL F; Young Helen, 1995, GEN FOOD DISTRIBUTIO, V3; 2002, LANCET, V360, P1261; 1998, WKLY EPIDEMIOL REC, V73, P139; 1998, WKLY EPIDEMIOL REC, V73, P91	135	74	75	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1899	1909		10.1016/S0140-6736(04)17447-3	http://dx.doi.org/10.1016/S0140-6736(04)17447-3			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555671				2022-12-28	WOS:000225269300032
J	MacKinnon, R				MacKinnon, R			Voltage sensor meets lipid membrane	SCIENCE			English	Editorial Material							DEPENDENT K+ CHANNEL; ION CHANNELS; CHARGE MOVEMENT; GATING CHARGE; S4 SEGMENT; PERSPECTIVE; GATE		Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	mackinn@rockefeller.edu						Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; Bezanilla F, 2003, ADV PROTEIN CHEM, V63, P211; Bezanilla F, 2002, J GEN PHYSIOL, V120, P465, DOI 10.1085/jgp.20028660; Cuello LG, 2004, SCIENCE, V306, P491, DOI 10.1126/science.1101373; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Horn R, 2002, J GEN PHYSIOL, V120, P449, DOI 10.1085/jgp.20028658; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Jiang QX, 2004, NATURE, V430, P806, DOI 10.1038/nature02735; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Larsson HP, 2002, J GEN PHYSIOL, V120, P475, DOI 10.1085/jgp.20028657; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894	15	29	32	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1304	1305		10.1126/science.1105528	http://dx.doi.org/10.1126/science.1105528			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550651				2022-12-28	WOS:000225301600030
J	Chuine, I; Yiou, P; Viovy, N; Seguin, B; Daux, V; Ladurie, EL				Chuine, I; Yiou, P; Viovy, N; Seguin, B; Daux, V; Ladurie, EL			Historical phenology: Grape ripening as a past climate indicator	NATURE			English	Editorial Material							TEMPERATURE VARIABILITY		CNRS, CEFE, F-34293 Montpellier, France; CE Saclay Orme Merisiers, CNRS, CEA, LSCE, F-91191 Gif Sur Yvette, France; INRA Site Agroparc, F-84914 Avignon 9, France; Coll France, F-75231 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; PSL Research University Paris; College de France	Chuine, I (corresponding author), CNRS, CEFE, 1919 Route Mende, F-34293 Montpellier, France.	pascal.yiou@cea.fr	Viovy, Nicolas/S-2631-2018; Daux, Valérie/H-5639-2011	Viovy, Nicolas/0000-0002-9197-6417; Daux, Valérie/0000-0002-8643-260X				Bohm R, 2001, INT J CLIMATOL, V21, P1779, DOI 10.1002/joc.689; BRIFFA KR, 1988, QUATERNARY RES, V30, P36, DOI 10.1016/0033-5894(88)90086-5; Jones PD, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000143; Le Roy Ladurie E., 1983, HIST CLIMAT DEPUIS A; Luterbacher J, 2004, SCIENCE, V303, P1499, DOI 10.1126/science.1093877; MANLEY G, 1974, Q J ROY METEOR SOC, V100, P389, DOI 10.1002/qj.49710042511; Pfister C, 1999, WETTERNACHHERSAGE 50; RENOU E, 1887, ANN BUR CTR METEOR B, P195; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Webb A D, OXFORD COMPANION WIN	10	295	317	8	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					289	290		10.1038/432289a	http://dx.doi.org/10.1038/432289a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549085				2022-12-28	WOS:000225161400030
J	LeRoy, BJ; Lemay, SG; Kong, J; Dekker, C				LeRoy, BJ; Lemay, SG; Kong, J; Dekker, C			Electrical generation and absorption of phonons in carbon nanotubes	NATURE			English	Article							SPECTROSCOPY; MICROSCOPY	The interplay between discrete vibrational and electronic degrees of freedom directly influences the chemical and physical properties of molecular systems. This coupling is typically studied through optical methods such as fluorescence, absorption and Raman spectroscopy. Molecular electronic devices provide new opportunities for exploring vibration-electronic interactions at the single molecule level(1-6). For example, electrons injected from a scanning tunnelling microscope tip into a metal can excite vibrational excitations of a molecule situated in the gap between tip and metal(7). Here we show how current directly injected into a freely suspended individual single-wall carbon nanotube can be used to excite, detect and control a specific vibrational mode of the molecule. Electrons tunnelling inelastically into the nanotube cause a non-equilibrium occupation of the radial breathing mode, leading to both stimulated emission and absorption of phonons by successive electron tunnelling events. We exploit this effect to measure a phonon lifetime of the order of 10 ns, corresponding to a quality factor of well over 10,000 for this nanomechanical oscillator.	Delft Univ Technol, Kavli Inst Nanosci, NL-2628 CJ Delft, Netherlands	Delft University of Technology	Dekker, C (corresponding author), Delft Univ Technol, Kavli Inst Nanosci, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.	dekker@mb.tn.tudelft.nl	LeRoy, Brian J/J-9112-2012; Lemay, Serge G./AAZ-9887-2021	LeRoy, Brian J/0000-0003-1610-5424; Lemay, Serge G./0000-0002-0404-3169; Dekker, Cees/0000-0001-6273-071X				Cleland A. N., 2003, FDN NANOMECHANICS; Cobden DH, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.046803; Dresselhaus MS, 2000, ADV PHYS, V49, P705, DOI 10.1080/000187300413184; GRABERT H, 1992, SINGLE CHARGE TUNNEL; HANNA AE, 1991, PHYS REV B, V44, P5919, DOI 10.1103/PhysRevB.44.5919; Iliev MN, 2000, CHEM PHYS LETT, V316, P217, DOI 10.1016/S0009-2614(99)01293-2; LeRoy BJ, 2004, APPL PHYS LETT, V84, P4280, DOI 10.1063/1.1748836; Liang WJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.126801; Park H, 2000, NATURE, V407, P57, DOI 10.1038/35024031; Park J, 2002, NATURE, V417, P722, DOI 10.1038/nature00791; PASUPATHY AN, 2003, CONDMAT0311150; Reulet B, 2000, PHYS REV LETT, V85, P2829, DOI 10.1103/PhysRevLett.85.2829; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; TIEN PK, 1963, PHYS REV, V129, P647, DOI 10.1103/PhysRev.129.647; Venema LC, 2000, PHYS REV B, V61, P2991, DOI 10.1103/PhysRevB.61.2991; Vitali L, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.136103; Weig EM, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.046804; Zhitenev NB, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.226801	18	285	289	0	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					371	374		10.1038/nature03046	http://dx.doi.org/10.1038/nature03046			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549099	Green Submitted			2022-12-28	WOS:000225161400049
J	Schanz, S; Fierlbeck, G				Schanz, S; Fierlbeck, G			Scleromyxedema	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Tubingen, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schanz, S (corresponding author), Univ Tubingen, D-72076 Tubingen, Germany.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2218	2218		10.1056/NEJMicm040158	http://dx.doi.org/10.1056/NEJMicm040158			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548782				2022-12-28	WOS:000225160600012
J	Wang, KL; Mittleman, DM				Wang, KL; Mittleman, DM			Metal wires for terahertz wave guiding	NATURE			English	Article							PROPAGATION; PULSES; INTERCONNECT; FIBER	Sources and systems for far-infrared or terahertz (1 THz = 10(12) Hz) radiation have received extensive attention in recent years, with applications in sensing, imaging and spectroscopy(1-10). Terahertz radiation bridges the gap between the microwave and optical regimes, and offers significant scientific and technological potential in many fields. However, waveguiding in this intermediate spectral region still remains a challenge. Neither conventional metal waveguides for microwave radiation, nor dielectric fibres for visible and near-infrared radiation can be used to guide terahertz waves over a long distance, owing to the high loss from the finite conductivity of metals or the high absorption coefficient of dielectric materials in this spectral range. Furthermore, the extensive use of broadband pulses in the terahertz regime imposes an additional constraint of low dispersion, which is necessary for compatibility with spectroscopic applications. Here we show how a simple waveguide, namely a bare metal wire, can be used to transport terahertz pulses with virtually no dispersion, low attenuation, and with remarkable structural simplicity. As an example of this new waveguiding structure, we demonstrate an endoscope for terahertz pulses.	Rice Univ, Dept Elect & Comp Engn, Houston, TX 77251 USA	Rice University	Mittleman, DM (corresponding author), Rice Univ, Dept Elect & Comp Engn, MS 366, Houston, TX 77251 USA.	daniel@rice.edu		Mittleman, Daniel/0000-0003-4277-7419				Coleman S, 2004, APPL PHYS LETT, V84, P654, DOI 10.1063/1.1644923; Coleman S, 2003, APPL PHYS LETT, V83, P3656, DOI 10.1063/1.1624474; Crawley D, 2003, J BIOMED OPT, V8, P303, DOI 10.1117/1.1559059; Gallot G, 2000, J OPT SOC AM B, V17, P851, DOI 10.1364/JOSAB.17.000851; Goto M, 2004, JPN J APPL PHYS 2, V43, pL317, DOI 10.1143/JJAP.43.L317; Han H, 2002, APPL PHYS LETT, V80, P2634, DOI 10.1063/1.1468897; Jacobsen RH, 1996, OPT LETT, V21, P2011, DOI 10.1364/OL.21.002011; Jamison SP, 2000, APPL PHYS LETT, V76, P1987, DOI 10.1063/1.126231; Jepsen PU, 1996, J OPT SOC AM B, V13, P2424, DOI 10.1364/JOSAB.13.002424; Kawase K, 2003, OPT EXPRESS, V11, P2549, DOI 10.1364/OE.11.002549; Marcuvitz N., 1951, WAVEGUIDE HDB; McGowan RW, 1999, OPT LETT, V24, P1431, DOI 10.1364/OL.24.001431; Mendis R, 2000, J APPL PHYS, V88, P4449, DOI 10.1063/1.1310179; Mendis R, 2001, IEEE MICROW WIREL CO, V11, P444, DOI 10.1109/7260.966036; Mendis R, 2001, OPT LETT, V26, P846, DOI 10.1364/OL.26.000846; Mittleman D., 2002, SENSING TERAHERTZ RA; Mittleman DM, 1996, IEEE J SEL TOP QUANT, V2, P679, DOI 10.1109/2944.571768; Quabis S, 2000, OPT COMMUN, V179, P1, DOI 10.1016/S0030-4018(99)00729-4; Rudd JV, 2000, PROC SPIE, V3934, P27, DOI 10.1117/12.386344; SMITH PR, 1988, IEEE J QUANTUM ELECT, V24, P255, DOI 10.1109/3.121; VANEXTER M, 1990, IEEE T MICROW THEORY, V38, P1684, DOI 10.1109/22.60016; Wang KL, 2004, APPL PHYS LETT, V84, P305, DOI 10.1063/1.1640473; Wang S, 2004, J PHYS D APPL PHYS, V37, pR1, DOI 10.1088/0022-3727/37/4/R01; Woodward RM, 2003, J BIOL PHYS, V29, P257, DOI 10.1023/A:1024409329416	24	894	921	21	369	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					376	379		10.1038/nature03040	http://dx.doi.org/10.1038/nature03040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549101				2022-12-28	WOS:000225161400051
J	Smalligan, R; Cole, J; Brito, N; Laing, GD; Mertz, BL; Manock, S; Maudlin, J; Quist, B; Holland, G; Nelson, S; Lalloo, DG; Rivadeneira, G; Barragan, ME; Dolley, D; Eddleston, M; Warrell, DA; Theakston, RDG				Smalligan, R; Cole, J; Brito, N; Laing, GD; Mertz, BL; Manock, S; Maudlin, J; Quist, B; Holland, G; Nelson, S; Lalloo, DG; Rivadeneira, G; Barragan, ME; Dolley, D; Eddleston, M; Warrell, DA; Theakston, RDG			Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BOTHROPS-JARARACA; PATIENTS BITTEN; CLINICAL-TRIAL; SAO-PAULO; VENOM; BRAZIL; COLOMBIA	Objective To compare the efficacy and safety of three polyspecific antivenoms for bites from pit vipers. Design Randomised double blind comparative trial of three antivenoms. Setting Shell, Pastaza, southeastern Ecuador. Participants 210 patients with incoagulable blood were recruited from 221 consecutive patients, admitted with snake bite between January 1997 and December 2001. Intervention One of three antivenoms manufactured in Brazil, Colombia, and Ecuador, chosen for their preclinical potency against Ecuadorian venoms. Main outcome measures Permanent restoration of blood coagulability after 6 and 24 hours. Results The snakes responsible for the bites were identified in 187 cases: 109 patients (58%) were bitten by Bothrops atrox, 68 (36%) by B bilineatus, and 10 (5%) by B taeniatus, B brazili, or Lachesis muta. Eighty seven patients (41%) received Colombian antivenom, 82 (39%) received Brazilian antivenom, but only 41 (20%) received Ecuadorian antivenom because the supply was exhausted. Two patients died; and 10 developed local necrosis. All antivenoms achieved the primary end point of permanently restoring blood coagulability by 6 or 24 hours after the start of treatment in >40% of patients. Colombian antivenom, however, was the most effective after initial doses of 20 ml (two vials), < 70 ml, and any initial dose at both 6 and 24 hours. An initial dose of 20 ml of Colombian antivenom permanently restored blood coagulability in 64% (46/72) of patients after 6 hours (P = 0.054 compared with the other two antivenoms) and an initial dose of < 70 ml was effective at 6 hours (65%, P = 0.045) and 24 hours (99%, P = 0.06). Early anaphylactoid reactions were common (53%,73%, and 19%, respectively, for Brazilian, Colombian, and Ecuadorian antivenoms, P < 0.0001) but only three reactions were severe and none was fatal. Conclusions All three antivenoms can be recommended for the treatment of snakebites in this region, though the reactogenicity of Brazilian and Colombian antivenoms is a cause for concern.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Hosp Vozandes Oriente, Shell, Pastaza, Ecuador; Univ Liverpool, Liverpool Sch Trop Med, Alistair Reid Venom Res Unit, Liverpool L3 5QA, Merseyside, England; Minist Hlth, Guayaquil, Ecuador; Fdn Herpetol Gustavo Orces, Quito, Ecuador	University of Oxford; Royal Dutch Shell; Liverpool School of Tropical Medicine; University of Liverpool	Warrell, DA (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	david.warrell@clinical-medicine.oxford.ac.uk		Lalloo, David/0000-0001-7680-2200				Ariaratnam CA, 2001, T ROY SOC TROP MED H, V95, P74, DOI 10.1016/S0035-9203(01)90339-6; AUDEBERT F, 1992, TOXICON, V30, P599, DOI 10.1016/0041-0101(92)90854-X; Bucher B, 1997, T ROY SOC TROP MED H, V91, P186, DOI 10.1016/S0035-9203(97)90219-4; Campbell J. A., 2004, VENOMOUS REPTILES W; CARDOSO JLC, 1993, Q J MED, V86, P315; CHAVES F, 1995, TOXICON, V33, P31, DOI 10.1016/0041-0101(94)00135-U; Fan HW, 1999, BRIT MED J, V318, P1451, DOI 10.1136/bmj.318.7196.1451; Farsky SHP, 1997, TOXICON, V35, P185, DOI 10.1016/S0041-0101(96)00135-3; Franca FOS, 2003, T ROY SOC TROP MED H, V97, P312, DOI 10.1016/S0035-9203(03)90158-1; JORGE MT, 1995, T ROY SOC TROP MED H, V89, P111, DOI 10.1016/0035-9203(95)90678-9; KERRIGAN KR, 1991, AM J TROP MED HYG, V44, P93, DOI 10.4269/ajtmh.1991.44.93; Laing GD, 2003, EUR J IMMUNOL, V33, P3458, DOI 10.1002/eji.200324475; MALASIT P, 1986, BRIT MED J, V292, P17, DOI 10.1136/bmj.292.6512.17; Otero R, 1996, T ROY SOC TROP MED H, V90, P696, DOI 10.1016/S0035-9203(96)90442-3; Otero-Patino R, 1998, AM J TROP MED HYG, V58, P183, DOI 10.4269/ajtmh.1998.58.183; Pardal PPD, 2004, T ROY SOC TROP MED H, V98, P28, DOI 10.1016/S0035-9203(03)00005-1; PHILLIPS RE, 1988, Q J MED, V68, P691; REID HA, 1978, MEDICINE, V3, P341; SANOMARTINS IS, 1994, TOXICON, V32, P1045, DOI 10.1016/0041-0101(94)90388-3; SILVAHAAD JJ, 1982, COMANDO UNIFICADO AM, V82, P45; SWAROOP S, 1954, Bull World Health Organ, V10, P35; THEAKSTON RDG, 1991, TOXICON, V29, P1419, DOI 10.1016/0041-0101(91)90002-9; THEAKSTON RDG, 1992, AM J TROP MED HYG, V47, P593, DOI 10.4269/ajtmh.1992.47.593; THEAKSTON RDG, 1995, T ROY SOC TROP MED H, V89, P550, DOI 10.1016/0035-9203(95)90105-1; TOUZET JM, 1986, PUBLICACIONES MUSEO, V5, P163; TREBIEN HA, 1989, AGENTS ACTIONS, V26, P292, DOI 10.1007/BF01967293; TUNPE, 1991, T ROY SOC TROP MED H, V85, P804, DOI 10.1016/0035-9203(91)90464-A; Warrell D.A., 2004, VENOMOUS REPTILES W, P709; WARRELL DA, 1977, Q J MED, V46, P33; WARRELL DA, 1986, AM J TROP MED HYG, V35, P1235, DOI 10.4269/ajtmh.1986.35.1235	30	79	81	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1129	1133		10.1136/bmj.329.7475.1129	http://dx.doi.org/10.1136/bmj.329.7475.1129			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539665	Green Published, Bronze, Green Submitted, Green Accepted			2022-12-28	WOS:000225169600016
J	McGuire, W; McEwan, P; Fowlie, PW				McGuire, W; McEwan, P; Fowlie, PW			ABC of preterm birth - Care in the early newborn period	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland	University of Dundee	McGuire, W (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.			McGuire, William/0000-0001-8572-3467				Cornblath M, 2000, PEDIATRICS, V105, P1141, DOI 10.1542/peds.105.5.1141; EVANS NJ, PRACTICAL ECHOCARDIO; Flenady VJ, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000435, DOI 10.1002/14651858.CD000435]; FOWLIE PW, 2003, COCHRANE DB SYST REV; Malviya M., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003951.PUB2; Rabe H., 2012, COCHRANE DATABASE SY	6	3	3	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 6	2004	329	7474					1087	1089		10.1136/bmj.329.7474.1087	http://dx.doi.org/10.1136/bmj.329.7474.1087			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PN	15528621	Green Published			2022-12-28	WOS:000225070300024
J	Rewers, M; Zimmet, P				Rewers, M; Zimmet, P			The rising tide of childhood type 1 diabetes - what is the elusive environmental trigger?	LANCET			English	Editorial Material							EXPOSURE; RISK		Int Diabet Inst, Caulfield 3162, Australia; Barbara Davis Ctr, Denver, CO USA		Zimmet, P (corresponding author), Int Diabet Inst, Caulfield 3162, Australia.	pzimmet@idi.org.au	Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776				Hermann R, 2003, DIABETOLOGIA, V46, P420, DOI 10.1007/s00125-003-1045-4; Hettiarachchi KD, 2004, J AUTOIMMUN, V22, P287, DOI 10.1016/j.jaut.2004.02.004; Hyoty H, 2004, ENDOCRIN METAB CLIN, V33, P27, DOI 10.1016/j.ecl.2003.12.004; KONTIAINEN S, 1988, LANCET, V2, P219; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Pitkaniemi J, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-5; PORTUESE E, 1995, DIABETES AM; REWERS A, 2003, AM DIAB ASS ANN M NE; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; STONE RA, 1990, DIABETES, V39, P858; SVEJGAARD A, 1986, TISSUE ANTIGENS, V28, P237; Ziegler AG, 2003, JAMA-J AM MED ASSOC, V290, P1721, DOI 10.1001/jama.290.13.1721	12	22	23	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1645	1647		10.1016/S0140-6736(04)17368-6	http://dx.doi.org/10.1016/S0140-6736(04)17368-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530607				2022-12-28	WOS:000224921600006
J	Andrew, P; Barnes, WL				Andrew, P; Barnes, WL			Energy transfer across a metal film mediated by surface plasmon polaritons	SCIENCE			English	Article							ENHANCED RAMAN-SCATTERING; MOLECULES; MICROCAVITIES; FLUORESCENCE; OPTICS; WAVES	Coupled surface plasmon polaritons (SPPs) are shown to provide effective transfer of excitation energy from donor molecules to acceptor molecules on opposite sides of metal films up to 120 nanometers thick. This variant of radiative transfer should allow directional control over the flow of excitation energy with the use of suitably designed metallic nanostructures, with SPPs mediating transfer over length scales of 10(-7) to 10(-4) meters. In the emerging field of nanophotonics, such a prospect could allow subwavelength-scale manipulation of light and provide an interface to the outside world.	Univ Exeter, Sch Phys, Exeter EX4 4QL, Devon, England	University of Exeter	Andrew, P (corresponding author), Univ Exeter, Sch Phys, Stocker Rd, Exeter EX4 4QL, Devon, England.	w.l.barnes@exeter.ac.uk	Andrew, Piers/F-8188-2013; Barnes, William L/J-7111-2013	Andrew, Piers/0000-0001-5601-5322; Barnes, William L/0000-0002-9474-5534				Andrew P, 2000, SCIENCE, V290, P785, DOI 10.1126/science.290.5492.785; Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Barnes WL, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.107401; Barnes WL, 1998, J MOD OPTIC, V45, P661, DOI 10.1080/09500349808230614; Bozhevolnyi SI, 2001, OPT LETT, V26, P734, DOI 10.1364/OL.26.000734; Charbonneau R, 2000, OPT LETT, V25, P844, DOI 10.1364/OL.25.000844; DEXTER DL, 1953, J CHEM PHYS, V21, P836, DOI 10.1063/1.1699044; Ditlbacher H, 2002, APPL PHYS LETT, V81, P1762, DOI 10.1063/1.1506018; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Finlayson CE, 2001, CHEM PHYS LETT, V338, P83, DOI 10.1016/S0009-2614(01)00247-0; FORD GW, 1984, PHYS REP, V113, P195, DOI 10.1016/0370-1573(84)90098-X; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; FORSTER T, 1959, DISCUSS FARADAY SOC, P7; Gifford DK, 2002, APPL PHYS LETT, V81, P4315, DOI 10.1063/1.1525882; GRUHLKE RW, 1986, PHYS REV LETT, V56, P2838, DOI 10.1103/PhysRevLett.56.2838; HARRIS JB, 1995, J OPT SOC AM A, V12, P1965, DOI 10.1364/JOSAA.12.001965; Hopmeier M, 1999, PHYS REV LETT, V82, P4118, DOI 10.1103/PhysRevLett.82.4118; Meier M, 1999, APPL PHYS LETT, V74, P7, DOI 10.1063/1.123116; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; Oppenheimer J. R., 1941, PHYS REV, V60, P158; Salt MG, 1999, OPT COMMUN, V166, P151, DOI 10.1016/S0030-4018(99)00248-5; SARID D, 1981, PHYS REV LETT, V47, P1927, DOI 10.1103/PhysRevLett.47.1927; WEBER WH, 1979, OPT LETT, V4, P236, DOI 10.1364/OL.4.000236; Wedge S, 2004, APPL PHYS LETT, V85, P182, DOI 10.1063/1.1772516; Weeber JC, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.045411; Xu HX, 1999, PHYS REV LETT, V83, P4357, DOI 10.1103/PhysRevLett.83.4357	26	403	420	4	231	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1002	1005		10.1126/science.1102992	http://dx.doi.org/10.1126/science.1102992			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528438				2022-12-28	WOS:000225001100034
J	Hewlett, S; Kirwan, J; Pollock, J; Mitchell, K; Hehir, M; Blair, PS; Memel, D; Perry, MG				Hewlett, S; Kirwan, J; Pollock, J; Mitchell, K; Hehir, M; Blair, PS; Memel, D; Perry, MG			Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine whether direct access to hospital review initiated by patients with rheumatoid arthritis would result in improved clinical mid psychological outcome, reduced overall use of healthcare resources, and greater satisfaction with care than seen in patients receiving regular review initiated by a rheumatologist. Design two year randomised controlled trial extended to six years. Setting Rheumatology outpatient department in teaching hospital. Participants 209 consecutive patients with rheumatoid arthritis for over two years; 68 (65%) in the direct access group and 52 (50%) in the control group completed the study (P = 0.04). Main outcome measures Clinical outcome: pain, disease activity, early morning stiffness, inflammatory indices, disability, grip strength, range of movement in joints, and bone erosion. Psychological status: anxiety, depression, helplessness, self efficacy, satisfaction, and confidence in die system. Number of visits to hospital physician mid general,practitioner for arthritis. Results Participants were well matched at baseline. After six years there was only one significant difference between the two groups for the 14 clinical outcomes measured (deterioration in range of movement in elbow was less in direct access patients). There were no significant differences between groups for median change in psychological status. Satisfaction and confidence in the system were significantly higher in the direct access group at two, four, and six years: confidence 9.8 v 8.4, 9.4 v 8, 8.7 v 6.9; satisfaction 9.3 v 8.3, 9.3 v 7.7, 8.9 v 7.1 (All P < 0.02). Patients in the direct access go-roup had 38% fewer hospital appointments (median 8 v 13, P < 0.0001). years rheumatoid Conclusions Over six years, patients with rheumatoid arthritis who initiated their reviews through direct access were clinically and psychologically at least as well as patients having traditional reviews initiated by a physician. The), requested fewer appointments, found direct access more acceptable, mid had more than a third fewer medical appointments. This radical responsive management could be tested in other chronic diseases.	Univ Bristol Acad, Rheumatol Unit, Bristol Royal Infirm, Bristol BS2 8HW, Avon, England; Univ W England, Fac Hlth & Social Care, Bristol BS16 1DD, Avon, England; Univ Bristol, Inst Child Hlth, UBHT Educ Ctr, Bristol Royal Infirm, Bristol, Avon, England; Air Balloon Surg, Bristol BS5 7PD, Avon, England	Bristol Royal Infirmary; University of Bristol; University of West England; Bristol Royal Infirmary; University of Bristol	Hewlett, S (corresponding author), Univ Bristol Acad, Rheumatol Unit, Bristol Royal Infirm, Bristol BS2 8HW, Avon, England.	Sarah.Hewlett@bristol.ac.uk	Blair, Peter S/C-1213-2009	Blair, Peter/0000-0002-7832-8087; Kirwan, John/0000-0002-6617-3217				Bellamy N., 1993, MUSCULOSKELETAL CLIN; Department of Health, 2001, EXP PAT NEW APPR CHR; Dickson DJ, 1996, BRIT J RHEUMATOL, V35, P920; Dolan SA, 1995, J EPIDEMIOL COMMUN H, V49, pS30, DOI 10.1136/jech.49.Suppl_2.S30; FAULKNER A, 1993, EVALUATION DELIVERY, V48, P54; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Hehir M, 2001, RHEUMATOLOGY, V40, P146; Hewlett S, 2000, RHEUMATOLOGY, V39, P990, DOI 10.1093/rheumatology/39.9.990; Kirwan JR, 1997, BRIT J RHEUMATOL, V36, P481; Kirwan JR, 2003, RHEUMATOLOGY, V42, P422, DOI 10.1093/rheumatology/keg130; KIRWAN JR, 1991, BRIT J RHEUMATOL, V30, P285; Kirwan JR, 2000, J RHEUMATOL, V27, P264; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Memel D., 2003, PRIM HEALTH CARE RES, V4, P29, DOI DOI 10.1191/1463423603pc120oa; MOWAT AG, 1980, ANN RHEUM DIS, V39, P12, DOI 10.1136/ard.39.1.12; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; Reeve H, 1997, FAM PRACT, V14, P24, DOI 10.1093/fampra/14.1.24; Robinson A, 2001, LANCET, V358, P976, DOI 10.1016/S0140-6736(01)06105-0; Schulpen G J.C., 2003, Eur J Intern Med, V14, P158, DOI 10.1016/S0953-6205(03)00031-1; STEIN MJ, 1988, J RHEUMATOL, V15, P427; SYMMONS D, 2002, HLTH CARE NEEDS ASSE; VANDAMME R, 1994, BRIT J GEN PRACT, V44, P9; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Williams JG, 2000, BRIT MED J, V320, P544, DOI 10.1136/bmj.320.7234.544; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	26	87	87	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2005	330	7484					171	175		10.1136/bmj.38265.493773.8F	http://dx.doi.org/10.1136/bmj.38265.493773.8F			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	891OQ	15546895	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000226590800016
J	Manca, A				Manca, A		UK BEAM Trial Team	United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACCEPTABILITY; PHYSIOTHERAPY; PACKAGE	Objective To assess the cost effectiveness of adding spinal manipulation, exercise classes, or manipulation followed by exercise ("combined treatment") to "best care in general practice for patients consulting with low back pain. Design Stochastic cost utility analysis alongside pragmatic randomised trial with factorial design. Setting 181 general practices and 63 community settings for physical treatments around 14 centres across the United Kingdom. Participants 1287 (96%) of 1334 trial participants. Main outcome measures Healthcare costs, quality adjusted life years (QALYs), and cost per QALY over 12 months. Results Over one year, mean treatment costs relative to "best care" were 1195 ($360; (sic)279; 95% credibility interval pound85 to pound308) for manipulation, pound140 (pound3 to pound278) for exercise, and pound125 (pound21 to pound228) for combined treatment. All three active treatments increased participants' average QALYs compared with best care alone. Each extra QALY that combined treatment yielded relative to best care cost pound3800; in economic terms it had an "incremental cost effectiveness ratio" of pound3800. Manipulation alone had a ratio of 5:8700 relative to combined treatment If the NHS was prepared to pay at least pound10 000 for each extra QALY (lower than previous recommendations in the United Kingdom), manipulation alone would probably be the best strategy. If manipulation was not available, exercise would have an incremental cost effectiveness ratio of pound8300 relative to best care. Conclusions Spinal manipulation is a cost effective addition to "best care" for back pain in general practice. Manipulation alone probably gives better value for money than manipulation followed by exercise.	Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England	University of York - UK	Manca, A (corresponding author), Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.	am126@york.ac.uk	Russell, Ian T/H-1181-2012; Underwood, Martin/D-6364-2015	Coulton, Simon/0000-0002-7704-3274; Torgerson, David/0000-0002-1667-4275; Farrin, Amanda/0000-0002-2876-0584; Underwood, Martin/0000-0002-0309-1708; Burton, Kim/0000-0002-9462-2227				Baldwin M L, 2001, Spine J, V1, P138, DOI 10.1016/S1529-9430(01)00016-X; *BUPA HOSP UK, MUCH WILL IT COST; *CHART I PUBL FIN, 2002, HLTH SERV DAT 2002; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Gold MR, 1996, COST EFFECTIVENESS H; Harvey E, 2003, MANUAL THER, V8, P46, DOI 10.1054/math.2002.0472; KIND P, 1999, 172 U YORK CTR HLTH; Kind P, 1996, QUALITY LIFE PHARMAC; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; Maetzel A, 2002, BEST PRACT RES CL RH, V16, P23, DOI 10.1053/berh.2001.0204; MALMIVAARA A, 1995, NEW ENGL J MED, V332, P351, DOI 10.1056/NEJM199502093320602; MANCA A, 2004, HLTH EC         1020; MANCA A, 2004, HLTH EC         0614; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; Moffett JK, 1999, BRIT MED J, V319, P279, DOI 10.1136/bmj.319.7205.279; MOFFETT JK, 2000, PHYSIOTHERAPY, V85, P295; NETTEN A, 2002, UNIT COSTS HLTH SOCI; Raftery J, 2001, BRIT MED J, V323, P1300, DOI 10.1136/bmj.323.7324.1300; RASBACH J, 2000, USERS GUIDE MLWIN VE; RASBASH J, 2000, USERS GUIDE MLWIN VE; Roland M, 2000, BACK BOOK; Skargren EI, 1998, SPINE, V23, P1875, DOI 10.1097/00007632-199809010-00016; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; Underwood M, 2002, FAM PRACT, V19, P511, DOI 10.1093/fampra/19.5.511	27	134	137	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1381	1385		10.1136/bmj.38282.607859.AE	http://dx.doi.org/10.1136/bmj.38282.607859.AE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15556954	Green Published, Green Accepted, Green Submitted, Bronze			2022-12-28	WOS:000225785000021
J	Shekelle, PG				Shekelle, PG			Commentary: Socioeconomic inequalities in indicator scores for A diabetes: poor quality or poor measures?	BRITISH MEDICAL JOURNAL			English	Editorial Material							DISPARITIES; CARE		W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Shekelle, PG (corresponding author), W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	shekelle@rand.org						BAKER D, DOESP RIMARY CARE RE; Epstein AM, 2001, NEW ENGL J MED, V344, P1471, DOI 10.1056/NEJM200105103441911; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Hippisley-Cox J, 2004, BRIT MED J, V329, P1267, DOI 10.1136/bmj.38279.588125.7C; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832	5	3	3	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 27	2004	329	7477					1269	1270		10.1136/bmj.38285.603692.7C	http://dx.doi.org/10.1136/bmj.38285.603692.7C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15548560	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000225480900017
J	Bonhoeffer, S; Chappey, C; Parkin, NT; Whitcomb, JM; Petropoulos, CJ				Bonhoeffer, S; Chappey, C; Parkin, NT; Whitcomb, JM; Petropoulos, CJ			Evidence for positive epistasis in HIV-1	SCIENCE			English	Article							DELETERIOUS MUTATIONS; RNA VIRUS; RECOMBINATION; EVOLUTION; FITNESS; SEX; HYPOTHESES; CELLS	Reproductive strategies such as sexual reproduction and recombination that involve the shuffling of parental genomes for the production of offspring are ubiquitous in nature. However, their evolutionary benefit remains unclear. Many theories have identified potential benefits, but progress is hampered by the scarcity of relevant data. One class of theories is based on the assumption that mutations affecting fitness exhibit negative epistasis. Retroviruses recombine frequently and thus provide a unique opportunity to test these theories. Using amino acid sequence data and fitness values from 9466 human immunodeficiency virus 1 (HIV-1) isolates, we find in contrast to these theories strong statistical evidence for a predominance of positive epistasis in HIV-1.	ETH Zentrum NW, ETH Zurich, CH-8092 Zurich, Switzerland; ViroLogic, San Francisco, CA 94080 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich	Bonhoeffer, S (corresponding author), ETH Zentrum NW, ETH Zurich, CH-8092 Zurich, Switzerland.	seb@env.ethz.ch	Parkin, Neil/P-2724-2019; Bonhoeffer, Sebastian/A-2735-2008	Bonhoeffer, Sebastian/0000-0001-8052-3925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI050321, R43AI057068] Funding Source: NIH RePORTER; NIAID NIH HHS [R43 AI050321, R43 AI057068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARTON NH, 1995, GENET RES, V65, P123, DOI 10.1017/S0016672300033140; Barton NH, 1998, SCIENCE, V281, P1986, DOI 10.1126/science.281.5385.1986; Bretscher MT, 2004, BIOESSAYS, V26, P180, DOI 10.1002/bies.10386; Burch CL, 2004, GENETICS, V167, P559, DOI 10.1534/genetics.103.021196; Burch CL, 2003, J EVOLUTION BIOL, V16, P1223, DOI 10.1046/j.1420-9101.2003.00632.x; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; de la Pena M, 2000, EVOLUTION, V54, P686; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Elena SF, 1999, J MOL EVOL, V49, P703, DOI 10.1007/PL00000082; FELDMAN MW, 1980, P NATL ACAD SCI-BIOL, V77, P4838, DOI 10.1073/pnas.77.8.4838; Iles MM, 2003, GENETICS, V165, P2249; Jung A, 2002, NATURE, V418, P144, DOI 10.1038/418144a; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; Levy DN, 2004, P NATL ACAD SCI USA, V101, P4204, DOI 10.1073/pnas.0306764101; Maynard Smith J, 1976, EVOLUTION SEX; Michod R. E., 1988, THE EVOLUTION OF SEX; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; Otto SP, 2002, NAT REV GENET, V3, P252, DOI 10.1038/nrg761; Peters AD, 2000, GENETICS, V156, P1635; Rice WR, 2002, NAT REV GENET, V3, P241, DOI 10.1038/nrg760; Rivero A, 2003, EVOLUTION, V57, P1698, DOI 10.1111/j.0014-3820.2003.tb00375.x; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P15376, DOI 10.1073/pnas.0404125101; SZATHMARY E, 1993, GENETICS, V133, P127; TEMIN HM, 1991, TRENDS GENET, V7, P71, DOI 10.1016/0168-9525(91)90048-U; Whitlock MC, 2000, EVOLUTION, V54, P1654, DOI 10.1111/j.0014-3820.2000.tb00709.x; Wloch DM, 2001, GENETICS, V159, P441	27	186	188	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1547	1550		10.1126/science.1101786	http://dx.doi.org/10.1126/science.1101786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567861				2022-12-28	WOS:000225442700056
J	Sanders, SL; Portoso, M; Mata, J; Bahler, J; Allshire, RC; Kouzarides, T				Sanders, SL; Portoso, M; Mata, J; Bahler, J; Allshire, RC; Kouzarides, T			Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage	CELL			English	Article							NUCLEOSOME CORE PARTICLE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; REPLICATION CHECKPOINT; PURIFICATION; GENE; METHYLTRANSFERASE; CHROMATIN; PROTEIN; PHOSPHORYLATION	Histone lysine methylation is a key regulator of gene expression and heterochromatin function, but little is known as to how this modification impinges on other chromatin activities. Here we demonstrate that a previously uncharacterized SET domain protein, Set9, is responsible for H4-K20 methylation in the fission yeast Schizosaccharomyces pombe. Surprisingly, H4-K20 methylation does not have any apparent role in the regulation of gene expression or heterochromatin function. Rather, we find the modification has a role in DNA damage response. Loss of Set9 activity or mutation of H4-K20 markedly impairs cell survival after genotoxic challenge and compromises the ability of cells to maintain checkpoint mediated cell cycle arrest. Genetic experiments link Set9 to Crb2, a homolog of the mammalian checkpoint protein 53BP1, and the enzyme is required for Crb2 localization to sites of DNA damage. These results argue that H4-K20 methylation functions as a "histone mark" required for the recruitment of the checkpoint protein Crb2.	Wellcome Trust Canc Res UK, Gurdon Inst, Cambridge CB2 1QN, England; Wellcome Trust Canc Res UK, Dept Pathol, Cambridge CB2 1QN, England; Univ Edinburgh, Sch Biol Sci, Inst Cell Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Cancer Research UK; Cancer Research UK; University of Edinburgh; Wellcome Trust Sanger Institute	Kouzarides, T (corresponding author), Wellcome Trust Canc Res UK, Gurdon Inst, Tennis Court Rd, Cambridge CB2 1QN, England.	tk106@mole.bio.cam.ac.uk	Bahler, Jurg/B-4572-2009	Bahler, Jurg/0000-0003-4036-1532; Kouzarides, Tony/0000-0002-8918-4162; Mata, Juan/0000-0002-5514-3653; Allshire, Robin/0000-0002-8005-3625	Cancer Research UK [A6517] Funding Source: Medline; Wellcome Trust [077118] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Allshire R, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P149; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Bjerling P, 2002, MOL CELL BIOL, V22, P2170, DOI 10.1128/MCB.22.7.2170-2181.2002; Carr AM, 2003, MOLECULAR BIOLOGY OF SCHIZOSACCHAROMYCES POMBE, P41; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 2002, GENE DEV, V16, P1195, DOI 10.1101/gad.221402; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Du LL, 2003, MOL CELL BIOL, V23, P6150, DOI 10.1128/MCB.23.17.6150-6158.2003; Edwards RJ, 1997, METHOD ENZYMOL, V283, P471; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fernandez-Capetillo O, 2004, P NATL ACAD SCI USA, V101, P1427, DOI 10.1073/pnas.0307342101; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hughes-Davies L, 2003, CELL, V115, P523, DOI 10.1016/S0092-8674(03)00930-9; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Logie C, 1999, METHOD ENZYMOL, V304, P726; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marmorstein R, 2003, TRENDS BIOCHEM SCI, V28, P59, DOI 10.1016/S0968-0004(03)00007-0; Mata J, 2002, NAT GENET, V32, P143, DOI 10.1038/ng951; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mellone BG, 2003, CURR BIOL, V13, P1748, DOI 10.1016/j.cub.2003.09.031; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tasto JJ, 2001, YEAST, V18, P657, DOI 10.1002/yea.713; Watson A, 2004, MOL BIOL CELL, V15, P851, DOI 10.1091/mbc.E03-08-0569; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Willson J, 1997, NUCLEIC ACIDS RES, V25, P2138, DOI 10.1093/nar/25.11.2138; Xiao B, 2003, NATURE, V421, P652, DOI 10.1038/nature01378	42	430	450	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					603	614		10.1016/j.cell.2004.11.009	http://dx.doi.org/10.1016/j.cell.2004.11.009			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550243	Bronze			2022-12-28	WOS:000225389500007
J	De Yoreo, JJ; Dove, PM				De Yoreo, JJ; Dove, PM			Shaping crystals with biorriolecules	SCIENCE			English	Editorial Material							ATOMIC-FORCE MICROSCOPY; ABALONE SHELL PROTEINS; CALCITE; GROWTH; MORPHOLOGY; CRYSTALLIZATION; IONS; CITRATE; STEPS		Lawrence Livermore Natl Lab, Chem & Mat Sci Directorate, Livermore, CA 94551 USA; Virginia Polytech Inst & State Univ, Dept Geosci, Blacksburg, VA 24061 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Virginia Polytechnic Institute & State University	De Yoreo, JJ (corresponding author), Lawrence Livermore Natl Lab, Chem & Mat Sci Directorate, Livermore, CA 94551 USA.	deyoreo1@llnl.gov; dove@vt.edu	Dove, Patricia M/A-7911-2010					ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; Becker U, 2001, PHYS CHEM MINER, V28, P545, DOI 10.1007/s002690100188; Beniash E, 1997, P ROY SOC B-BIOL SCI, V264, P461, DOI 10.1098/rspb.1997.0066; BURTON WK, 1951, PHILOS T R SOC S-A, V243, P299, DOI 10.1098/rsta.1951.0006; Davis KJ, 2004, AM MINERAL, V89, P714; Elderfield H, 2000, NATURE, V405, P442, DOI 10.1038/35013033; FU G, UNPUB; Gower LB, 2000, J CRYST GROWTH, V210, P719, DOI 10.1016/S0022-0248(99)00749-6; Guo SW, 2002, LANGMUIR, V18, P4284, DOI 10.1021/la011754+; Han YJ, 2003, J AM CHEM SOC, V125, P4032, DOI 10.1021/ja034094z; MANN S, 1993, SCIENCE, V261, P1286, DOI 10.1126/science.261.5126.1286; Orme CA, 2001, NATURE, V411, P775, DOI 10.1038/35081034; Qiu SR, 2004, P NATL ACAD SCI USA, V101, P1811, DOI 10.1073/pnas.0307900100; Raz S, 2000, ADV MATER, V12, P38, DOI 10.1002/(SICI)1521-4095(200001)12:1<38::AID-ADMA38>3.0.CO;2-I; Rohl AL, 2003, CURR OPIN SOLID ST M, V7, P21, DOI 10.1016/S1359-0286(03)00019-6; SHIRANE Y, 1993, J UROLOGY, V150, P1980, DOI 10.1016/S0022-5347(17)35950-5; Thomas TN, 2004, LANGMUIR, V20, P7643, DOI 10.1021/la049546f; Thompson JB, 2000, BIOPHYS J, V79, P3307, DOI 10.1016/S0006-3495(00)76562-3; Touryan LA, 2004, NAT MATER, V3, P239, DOI 10.1038/nmat1096; Walters DA, 1997, BIOPHYS J, V72, P1425, DOI 10.1016/S0006-3495(97)78789-7; WILLIAMS ED, 1991, SCIENCE, V251, P393, DOI 10.1126/science.251.4992.393	21	147	152	4	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1301	1302		10.1126/science.1100889	http://dx.doi.org/10.1126/science.1100889			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550649				2022-12-28	WOS:000225301600028
J	Bramble, DM; Lieberman, DE				Bramble, DM; Lieberman, DE			Endurance running and the evolution of Homo	NATURE			English	Article							ENERGY-COST; STRIDE LENGTH; BODY-SIZE; SPEED; WALKING; ENERGETICS; BRAIN; MASS; DIMENSIONS; LOCOMOTION	Striding bipedalism is a key derived behaviour of hominids that possibly originated soon after the divergence of the chimpanzee and human lineages. Although bipedal gaits include walking and running, running is generally considered to have played no major role in human evolution because humans, like apes, are poor sprinters compared to most quadrupeds. Here we assess how well humans perform at sustained long-distance running, and review the physiological and anatomical bases of endurance running capabilities in humans and other mammals. Judged by several criteria, humans perform remarkably well at endurance running, thanks to a diverse array of features, many of which leave traces in the skeleton. The fossil evidence of these features suggests that endurance running is a derived capability of the genus Homo, originating about 2 million years ago, and may have been instrumental in the evolution of the human body form.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Harvard Univ, Peabody Museum, Cambridge, MA 02138 USA	Utah System of Higher Education; University of Utah; Harvard University	Bramble, DM (corresponding author), Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA.	bramble@bioscience.utah.edu; danlieb@fas.harvard.edu						Aiello L, 1990, INTRO HUMAN EVOLUTIO; AIELLO LC, 1995, CURR ANTHROPOL, V36, P199, DOI 10.1086/204350; ALEXANDER RM, 1991, J EXP BIOL, V160, P55; ALEXANDER RM, 1980, J ZOOL, V190, P155, DOI 10.1111/j.1469-7998.1980.tb07765.x; ALEXANDER RM, 1980, J ZOOL, V192, P97, DOI 10.1111/j.1469-7998.1980.tb04222.x; BIANCHI M, 1989, ANAT ANZEIGER, V169, P53; BIEWENER AA, 1986, J EXP BIOL, V123, P383; CABANAC M, 1979, J PHYSIOL-LONDON, V286, P255, DOI 10.1113/jphysiol.1979.sp012617; CARRIER DR, 1984, CURR ANTHROPOL, V25, P483, DOI 10.1086/203165; CAVAGNA GA, 1976, J PHYSIOL-LONDON, V262, P639, DOI 10.1113/jphysiol.1976.sp011613; CAVANAGH PR, 1989, MED SCI SPORT EXER, V21, P467; CLARKE RJ, 1995, SCIENCE, V269, P521, DOI 10.1126/science.7624772; Dillman C J, 1975, Exerc Sport Sci Rev, V3, P193; FALK D, 1990, BEHAV BRAIN SCI, V13, P333, DOI 10.1017/S0140525X00078973; FARLEY CT, 1993, J EXP BIOL, V185, P71; Galik K, 2004, SCIENCE, V305, P1450, DOI 10.1126/science.1098807; GARLAND T, 1983, J ZOOL, V199, P157, DOI 10.1111/j.1469-7998.1983.tb02087.x; Haeusler M, 2004, J HUM EVOL, V46, P433, DOI 10.1016/j.jhevol.2004.01.004; Haile-Selassie Y, 2001, NATURE, V412, P178, DOI 10.1038/35084063; Harcourt-Smith WE, 2002, FORM FUNCTION HOMINO; HEGLUND NC, 1988, J EXP BIOL, V138, P301; Heinrich Bernd, 2002, WHY WE RUN NATURAL H; Hinrichs R.N., 1990, BIOMECHANICS DISTANC, P107; Holekamp KE, 2000, ON THE MOVE: HOW AND WHY ANIMALS TRAVEL IN GROUPS, P587; HOYT DF, 1981, NATURE, V292, P239, DOI 10.1038/292239a0; HUNT KD, 1991, AM J PHYS ANTHROPOL, V86, P521, DOI 10.1002/ajpa.1330860408; Isbell LA, 1998, AM J PHYS ANTHROPOL, V105, P199, DOI 10.1002/(SICI)1096-8644(199802)105:2<199::AID-AJPA7>3.0.CO;2-Q; Jellema Lyman M., 1993, P294; JUNGERS WL, 1988, J HUM EVOL, V17, P247, DOI 10.1016/0047-2484(88)90056-5; Keller TS, 1996, CLIN BIOMECH, V11, P253, DOI 10.1016/0268-0033(95)00068-2; KER RF, 1987, NATURE, V325, P147, DOI 10.1038/325147a0; KRAM R, 1990, NATURE, V346, P265, DOI 10.1038/346265a0; LATIMER B, 1989, AM J PHYS ANTHROPOL, V78, P369, DOI 10.1002/ajpa.1330780306; Lewis O.J., 1989, FUNCTIONAL MORPHOLOG; LOVEJOY CO, 1988, SCI AM, V259, P118, DOI 10.1038/scientificamerican1188-118; MARGARIA R, 1963, J APPL PHYSIOL, V18, P367, DOI 10.1152/jappl.1963.18.2.367; McClay I, 1990, BIOMECHANICS DISTANC, P165; Mero A, 1991, J SPORT SCI, V9, P161, DOI 10.1080/02640419108729877; Minetti AE, 2003, NATURE, V426, P785, DOI 10.1038/426785a; MUYBRIDGE E, 1985, HUMAN FIGURE MOTION; MYERS MJ, 1985, J EXP BIOL, V116, P363; Nabokov Peter, 1987, INDIAN RUNNING NATIV; *NAT CTR CHRON DIS, 1998, PART PHYS ACT AD AG; NIINIMAA V, 1981, RESP PHYSIOL, V43, P69, DOI 10.1016/0034-5687(81)90089-X; OCONNELL JF, 1988, CURR ANTHROPOL, V29, P356, DOI 10.1086/203648; PENNYCUICK CJ, 1979, SERENGETI DYNAMICS E, P164; REYNOLDS TR, 1987, AM J PHYS ANTHROPOL, V72, P101, DOI 10.1002/ajpa.1330720113; Rose M.D., 1991, P37; ROSE MD, 1984, AM J PHYS ANTHROPOL, V63, P371, DOI 10.1002/ajpa.1330630404; Ruff C, 1998, PRIMATE LOCOMOTION, P449; RUFF CB, 1991, J HUM EVOL, V21, P81, DOI 10.1016/0047-2484(91)90001-C; Sanders WJ, 1998, J HUM EVOL, V34, P249, DOI 10.1006/jhev.1997.0193; Semaw S, 2003, J HUM EVOL, V45, P169, DOI 10.1016/S0047-2484(03)00093-9; SPOOR F, 1994, NATURE, V369, P645, DOI 10.1038/369645a0; STERN JT, 1983, AM J PHYS ANTHROPOL, V60, P279, DOI 10.1002/ajpa.1330600302; SUSMAN RL, 1984, FOLIA PRIMATOL, V43, P113, DOI 10.1159/000156176; Swindler D.R., 1973, ATLAS PRIMATE GROSS; TAYLOR CR, 1973, SCIENCE, V179, P186, DOI 10.1126/science.179.4069.186; TAYLOR CR, 1982, J EXP BIOL, V97, P1; Thorpe SKS, 1999, AM J PHYS ANTHROPOL, V110, P179, DOI 10.1002/(SICI)1096-8644(199910)110:2<179::AID-AJPA5>3.0.CO;2-Z; WALKER A, 1993, NARIOKOTOME HOMO ER; Ward CV, 2002, YEARB PHYS ANTHROPOL, V45, P185, DOI 10.1002/ajpa.10185; WHEELER PE, 1991, J HUM EVOL, V21, P107, DOI 10.1016/0047-2484(91)90002-D; Wood B, 1999, SCIENCE, V284, P65, DOI 10.1126/science.284.5411.65; Wrangham RW, 1999, CURR ANTHROPOL, V40, P567, DOI 10.1086/300083; Yang N, 2003, AM J HUM GENET, V73, P627, DOI 10.1086/377590; Zihlman A., 1979, YEARB PHYS ANTHROPOL, V22, P132	67	935	955	16	581	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					345	352		10.1038/nature03052	http://dx.doi.org/10.1038/nature03052			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549097				2022-12-28	WOS:000225161400045
J	Fischer, MA; Schneeweiss, S; Avorn, J; Solomon, DH				Fischer, MA; Schneeweiss, S; Avorn, J; Solomon, DH			Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; REGIONAL-VARIATIONS; ROFECOXIB; TRIAL; EFFICACY; OUTCOMES	Background: Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for a growing proportion of prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs). To control these expenses, many state Medicaid programs have implemented prior-authorization requirements before coxibs can be prescribed. We evaluated the effect of such programs on the use of coxibs by Medicaid beneficiaries. Methods: We surveyed state Medicaid agencies to determine whether prescription of coxibs required prior authorization and, if so, the criteria for authorization. For each program, we compared these criteria with evidence-based recommendations for prescribing of coxibs. Using data for all filled prescriptions in 50 state Medicaid programs from 1999 through the end of 2003, we calculated the proportion of defined daily doses of NSAIDs accounted for by coxibs. Time-series analyses were used to measure the changes in prescription patterns after the implementation of each prior-authorization program. Results: By 2001, coxibs accounted for half of all NSAID doses covered by Medicaid. This proportion varied widely according to the state in 2003, from a low of 11 percent to a high of 70 percent of all NSAID doses. Twenty-two states implemented prior-authorization programs for coxibs during the study period. Overall, the implementation of such programs reduced the proportion of NSAID doses made up by coxibs by 15.0 percent (95 percent confidence interval, 10.9 to 19.2 percent), corresponding to a decrease of $10.28 (95 percent confidence interval, $7.56 to $13.00) in spending per NSAID prescription. The effect of such programs was not influenced by the degree to which a prior-authorization program incorporated evidence-based prescribing recommendations. Conclusions: The use of coxibs and spending on NSAIDs varies widely by state and declined substantially after the implementation of prior-authorization programs. Determining whether these reductions are clinically appropriate will have important implications for the development of rational drug-reimbursement policies.	Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Brigham & Womens Hosp, Dept Med, Div Rheumatol, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Fischer, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	mfischer@partners.org	Schneeweiss, Sebastian/C-2125-2013	Schneeweiss, Sebastian/0000-0003-2575-467X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010881] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K23AR048616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015507] Funding Source: NIH RePORTER; AHRQ HHS [HS-010881] Funding Source: Medline; NIAMS NIH HHS [AR-48616] Funding Source: Medline; NIDA NIH HHS [DA-15507] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905; [Anonymous], 2004, PHARM BEN STAT MED A; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Avorn J, 2004, POWERFUL MED BENEFIT; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; *CTR MED MED SERV, 2003, MED ENR BEN SEL FISC; *CTR MED MED SERV, 2004, MSIS STAT REP FED FI; Day R, 2000, ARCH INTERN MED, V160, P1781, DOI 10.1001/archinte.160.12.1781; Dubois RW, 2004, ALIMENT PHARM THER, V19, P197, DOI 10.1111/j.0269-2813.2004.01834.x; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; *HLTH CAR FIN ADM, 2000, STAT DRUG UT DAT; Huskamp HA, 2003, NEW ENGL J MED, V349, P2224, DOI 10.1056/NEJMsa030954; *IMS HLTH IMS NAT, 2004, LEAD 20 THER CLASS U; JENKINS CL, 2004, WASHINGTON POST 0303, pB1; KAYE N, 2002, AFFORDING PRESCRIPTI; Lanza FL, 1998, AM J GASTROENTEROL, V93, P2037; LaPensee Kenneth T, 2003, J Manag Care Pharm, V9, P36; Mello MM, 2004, NEW ENGL J MED, V350, P608, DOI 10.1056/NEJMlim035683; Momani AA, 2002, ANN PHARMACOTHER, V36, P1686; Motheral B, 2001, MED CARE, V39, P1293, DOI 10.1097/00005650-200112000-00005; *NAT I CLIN EXC, 2001, GUID US CYCL COX 2 S; PEAR R, 2004, NY TIMES        0130, pA1; Saag K, 2000, ARCH FAM MED, V9, P1124, DOI 10.1001/archfami.9.10.1124; Schneeweiss S, 2002, NEW ENGL J MED, V346, P822, DOI 10.1056/NEJMsa003087; Smalley W, 2002, ARTHRITIS RHEUM, V46, P2195, DOI 10.1002/art.10425; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; Solomon DH, 2003, AM J MED, V115, P715, DOI 10.1016/j.amjmed.2003.08.025; SOMERS S, 2003, MODEL PRESCRIPTION D; STACY J, 2004, J MANAGE CARE PHARM, V10, P87; Stacy Jane, 2003, J Manag Care Pharm, V9, P327; Statacorp, 2001, STAT STAT SOFTW REL; STEIN C, 2004, BOSTON GLOBE    0217, pC1; STEIN C, 2004, BOSTON GLOBE    0217, pC4; *THOMS PDR, 2004, DRUG TOP RED BOOK; TILLY J, 2003, PRIOR AUTHORIZATION; Veney JE, 1991, EVALUATION DECISION; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; *WHO COLL CTR DRUG, 2004, ATC DDD IND 2004	41	104	105	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2187	2194		10.1056/NEJMsa042770	http://dx.doi.org/10.1056/NEJMsa042770			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548779				2022-12-28	WOS:000225160600009
J	Finch, L				Finch, L			Fighting for food aid - the struggle to assist groups affected by HIV/AIDS	LANCET			English	Editorial Material									Ndi Moyo, Salima, Malawi		Finch, L (corresponding author), Ndi Moyo, POB 84, Salima, Malawi.	tfinch@mw.celtelplus.com						Food and Nutrition Technical Assistance (FANTA), 2001, HIV AIDS GUID NUTR C, P24; *UNICEF, 2003, REV LINK HIV AIDS NU; Uys L., 2003, HOME BASED HIV AIDS	3	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1650	1651		10.1016/S0140-6736(04)17372-8	http://dx.doi.org/10.1016/S0140-6736(04)17372-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530611				2022-12-28	WOS:000224921600009
J	Gazzani, S; Lawrenson, T; Woodward, C; Headon, D; Sablowski, R				Gazzani, S; Lawrenson, T; Woodward, C; Headon, D; Sablowski, R			A link between rnRNA turnover and RNA interference in Arabidopsis	SCIENCE			English	Article							MESSENGER-RNA; C-ELEGANS; GERM-LINE; GENE; POLYMERASE; TRANSGENE; PROTEIN; REQUIRES; WUSCHEL; TARGETS	In RNA interference (RNAi), double-stranded RNA (dsRNA) triggers degradation of homologous messenger RNA. In many organisms, RNA-dependent RNA polymerase (RdRp) is required to initiate or amplify RNAi, but the substrate for dsRNA synthesis in vivo is not known. Here, we show that RdRp-dependent transgene silencing in Arabidopsis was caused by mutation of XRN4, which is a ribonuclease (RNase) implicated in mRNA turnover by means of decapping and 5'-3' exonucteotysis. When both XRN4 and the RdRp were mutated, the plants accumulated decapped transgene mRNA. We propose that mRNAs lacking a cap structure become exposed to RdRp to initiate or maintain RNAi.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England; Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Washington; University of Washington Seattle; University of Manchester	Sablowski, R (corresponding author), John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England.	robert.sablowski@bbsrc.ac.uk		Sablowski, Robert/0000-0002-1732-2909	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000594] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Beclin C, 2002, CURR BIOL, V12, P684, DOI 10.1016/S0960-9822(02)00792-3; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dernburg AF, 2000, GENE DEV, V14, P1578; Foster TM, 2002, PLANT CELL, V14, P1497, DOI 10.1105/tpc.001685; Gallois JL, 2002, DEVELOPMENT, V129, P3207; GAZZI S, UNPUB; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Ito T, 2004, NATURE, V430, P356, DOI 10.1038/nature02733; Kastenmayer JP, 2000, P NATL ACAD SCI USA, V97, P13985, DOI 10.1073/pnas.97.25.13985; Kennedy S, 2004, NATURE, V427, P645, DOI 10.1038/nature02302; Klahre U, 2002, P NATL ACAD SCI USA, V99, P11981, DOI 10.1073/pnas.182204199; LAWRENSON T, UNPUB; Lechtenberg B, 2003, PLANT J, V34, P507, DOI 10.1046/j.1365-313X.2003.01746.x; Lenhard M, 2002, DEVELOPMENT, V129, P3195; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; Lynn K, 1999, DEVELOPMENT, V126, P469; Makeyev EV, 2002, MOL CELL, V10, P1417, DOI 10.1016/S1097-2765(02)00780-3; Martens H, 2002, MOL BIOL CELL, V13, P445, DOI 10.1091/mbc.01-04-0211; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Newbury S, 2004, RNA, V10, P59, DOI 10.1261/rna.2195504; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; SCHIEBEL W, 1993, J BIOL CHEM, V268, P11858; Sijen T, 2001, CELL, V107, P465, DOI 10.1016/S0092-8674(01)00576-1; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Souret FF, 2004, MOL CELL, V15, P173, DOI 10.1016/j.molcel.2004.06.006; Stevens A, 2001, METHOD ENZYMOL, V342, P251, DOI 10.1016/S0076-6879(01)42549-3	29	251	263	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1046	1048		10.1126/science.1101092	http://dx.doi.org/10.1126/science.1101092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528448				2022-12-28	WOS:000225001100047
J	Judd, A; Hickman, M; Jones, S; McDonald, T; Parry, JV; Stimson, GV; Hall, AJ				Judd, A; Hickman, M; Jones, S; McDonald, T; Parry, JV; Stimson, GV; Hall, AJ			Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASSAY		Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, Ctr Res Drugs & Hlth Behav, London W6 8RP, England; Hlth Protect Agcy London, Sexually Transmitted & Blood Borne Virus Lab, London, England; London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, London WC1, England	Imperial College London; Health Protection Agency; University of London; London School of Hygiene & Tropical Medicine	Judd, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, Ctr Res Drugs & Hlth Behav, London W6 8RP, England.	a.judd@imperial.ac.uk	Hickman, Matthew/Y-2400-2019; Judd, Ali/B-5132-2009	Hickman, Matthew/0000-0001-9864-459X; Judd, Ali/0000-0003-3176-5295				CONNELL JA, 1993, J MED VIROL, V41, P159, DOI 10.1002/jmv.1890410212; Hickman M, 2004, J EPIDEMIOL COMMUN H, V58, P766, DOI 10.1136/jech.2003.015164; *HLTH PROT AG SCOT, 2003, SHOOT INF INJ DRUG U; Judd A, 2003, J MED VIROL, V71, P49, DOI 10.1002/jmv.10463; Murphy G, 2004, AIDS, V18, P265, DOI 10.1097/00002030-200401230-00016	5	127	129	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					24	25		10.1136/bmj.38286.841227.7C	http://dx.doi.org/10.1136/bmj.38286.841227.7C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15533854	Green Published, Green Submitted, Green Accepted, Bronze			2022-12-28	WOS:000226176700015
J	Steer, PJ; Little, MP; Kold-Jensen, T; Chapple, J; Elliott, P				Steer, PJ; Little, MP; Kold-Jensen, T; Chapple, J; Elliott, P			Maternal blood pressure in pregnancy, birth weight, and perinatal. mortality in first births: prospective study	BRITISH MEDICAL JOURNAL			English	Article							CHRONIC-FATIGUE-SYNDROME; MEAN ARTERIAL-PRESSURE; HYPERTENSIVE DISORDERS; HYPOTENSION; FETAL; PREECLAMPSIA; DEFINITION; CLASSIFICATION; POPULATION	Objective To investigate the relation of diastolic blood pressure in pregnancy with birth weight and perinatal mortality. Design Prospective study. Setting 15 maternity units in one London health region, 1988-2000. Participants 210 814 first singleton births of babies weighing more than 200 g among mothers with no hypertension before 20 weeks' gestation and without proteinuria, delivering between 24 and 43 weeks' gestation. Main outcome measures' Birth weight and perinatal mortality. Results The mean (SD) birth weight of babies born to mothers with no hypertension before 20 weeks' gestation or proteinuria was 3282 g (545 g) and there were 1335 perinatal deaths, compared with 94 perinatal deaths among women with proteinuria or a history of hypertension. Diastolic blood pressure at booking for antenatal checks was progressively higher from weeks 34 to 40 of gestation. The birth weight of babies being delivered after 34 weeks was highest for highest recorded maternal diastolic blood pressures of between 70 and 80 turn Hg and lower for blood pressures outside this range. Both low and high diastolic blood pressures were associated with statistically significantly higher perinatal mortality. Using a linear quadratic model, 94 of 825 (11.4%) perinatal deaths could be attributed to mothers having blood pressure differing from the optimal blood pressure (82.7 turn Hg) predicted by the fitted model. Most of these excess deaths occurred with blood pressures below the optimal value. Conclusion Both low and high diastolic blood pressures in women during pregnancy are associated with small babies and high perinatal mortality.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Chelsea & Westminster Hosp, Acad Dept Obstet & Gynaecol, London SW10 9NH, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England	Imperial College London; Imperial College London	Steer, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Chelsea & Westminster Hosp, Acad Dept Obstet & Gynaecol, London SW10 9NH, England.	p.steer@imperial.ac.uk		Little, Mark/0000-0003-0980-7567; Jensen, Tina Kold/0000-0003-2311-5778				American College of Obstetricians and Gynecologists, 1996, HYP PREGN; Biswas A, 1997, ACTA OBSTET GYN SCAN, V76, P829, DOI 10.3109/00016349709024360; Brown MA, 1998, AM J OBSTET GYNECOL, V178, P836, DOI 10.1016/S0002-9378(98)70501-0; Carstairs V., 1991, DEPRIVATION HLTH SCO; *CESDI, 1998, CONF ENQ STILLB DEAT; CLAPP JF, 1988, AM J OBSTET GYNECOL, V159, P1456, DOI 10.1016/0002-9378(88)90574-1; CLEARY R, 1994, BRIT J OBSTET GYNAEC, V101, P1042, DOI 10.1111/j.1471-0528.1994.tb13579.x; COGSWELL ME, 1995, SEMIN PERINATOL, V19, P222, DOI 10.1016/S0146-0005(05)80028-X; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; Davison AC, 1997, BOOTSTRAP METHODS TH; DESWIET M, 1991, BRIT J OBSTET GYNAEC, V98, P239; deSwiet M, 1996, BRIT J OBSTET GYNAEC, V103, P862; Easterling TR, 1999, OBSTET GYNECOL, V93, P725, DOI 10.1016/S0029-7844(98)00522-5; FRIEDMAN EA, 1978, JAMA-J AM MED ASSOC, V239, P2249; GRUNBERGER W, 1979, GYNECOL OBSTET INVES, V10, P32; HALLIGAN A, 1993, J HYPERTENS, V11, P869, DOI 10.1097/00004872-199308000-00014; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; JOHENNING AR, 1992, AM J OBSTET GYNECOL, V167, P577, DOI 10.1016/S0002-9378(11)91552-X; Lenfant C, 2001, J Clin Hypertens (Greenwich), V3, P75; MACGILLIVRAY I, 1969, CLIN SCI, V37, P395; MARGULIES M, 1987, AM J OBSTET GYNECOL, V156, P1105, DOI 10.1016/0002-9378(87)90119-0; Mathias CJ, 2001, LANCET, V357, P348, DOI 10.1016/S0140-6736(00)03642-4; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; MOUTQUIN JM, 1985, AM J OBSTET GYNECOL, V151, P191, DOI 10.1016/0002-9378(85)90010-9; NG PH, 1992, AUST NZ J OBSTET GYN, V32, P14, DOI 10.1111/j.1479-828X.1992.tb01888.x; Owens PE, 2000, J HUM HYPERTENS, V14, P243, DOI 10.1038/sj.jhh.1000973; PAGE EW, 1976, AM J OBSTET GYNECOL, V125, P740, DOI 10.1016/0002-9378(76)90839-5; PERRY IJ, 1991, BRIT J OBSTET GYNAEC, V98, P241, DOI 10.1111/j.1471-0528.1991.tb13386.x; PILGRIM JA, 1992, BRIT MED J, V304, P75, DOI 10.1136/bmj.304.6819.75; *PROSP STUD COLL, 2004, LANCET, V360, P1903; REDMAN CWG, 1988, LANCET, V1, P809; REISS RE, 1987, AM J OBSTET GYNECOL, V156, P894, DOI 10.1016/0002-9378(87)90347-4; Rowe PC, 2002, J PEDIATR-US, V140, P387, DOI 10.1067/mpd.2002.124318; Shennan A, 1996, LANCET, V347, P139, DOI 10.1016/S0140-6736(96)90338-4; Steer PJ, 1999, BRIT J OBSTET GYNAEC, V106, P753, DOI 10.1111/j.1471-0528.1999.tb08394.x; Streeten DHP, 2000, AM J MED SCI, V320, P1, DOI 10.1097/00000441-200007000-00001; von Dadelszen P, 2000, LANCET, V355, P87, DOI 10.1016/S0140-6736(98)08049-0; 1998, REPORT CONFIDENTIAL	38	99	101	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 4	2004	329	7478					1312	1314B		10.1136/bmj.38258.566262.7C	http://dx.doi.org/10.1136/bmj.38258.566262.7C			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15561733	Green Submitted, Green Published			2022-12-28	WOS:000225657800016
J	Lee, TH				Lee, TH			Rationing influenza vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*COMM MA, 2004, REV ORD EST RUL PRIO; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905	2	12	12	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2365	2366		10.1056/NEJMp048328	http://dx.doi.org/10.1056/NEJMp048328			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575049				2022-12-28	WOS:000225429000002
J	Davis, S; Kopecky, KJ; Hamilton, TE; Onstad, L				Davis, S; Kopecky, KJ; Hamilton, TE; Onstad, L		Hanford Thyroid Dis Study Team	Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the Hanford Nuclear Site	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINE-NEEDLE-ASPIRATION; ATOMIC-BOMB SURVIVORS; POPULATION-BASED COHORT; FOLLOW-UP; CHILDHOOD IRRADIATION; RETROSPECTIVE COHORT; FOLLICULAR NEOPLASIA; RISK-FACTORS; CANCER RISK; SERUM TSH	Context Approximately 740000 Ci (2.73 X 10(16) Bq) of iodine 131 (I-131) were released to the atmosphere from the Hanford Nuclear Site in Washington State from 1944 through 1957. The risk of thyroid disease resulting from prolonged environmental I-131 exposure is poorly understood. Objective The Hanford Thyroid Disease Study (HTDS) was conducted to determine if thyroid disease is increased among persons exposed as children to atmospheric releases of I-131 from Hanford. Design Retrospective cohort study. Exposure could have occurred from December 1944 through 1957. Follow-up occurred until the time of the HTDS examination (December 1992-September 1997). Participants' thyroid radiation doses from Hanford's 1111 releases were estimated from interview data regarding residence and dietary histories. Setting The cohort included a sample of all births from 1940 through 1946 to mothers with usual residence in 1 of 7 counties in eastern Washington State. Participants Of 5199 individuals identified, 4350 were located alive and 3440 were evaluable; ie, had sufficient data for dose estimation and received an HTDS evaluation for thyroid disease, including a thyroid ultrasound, physical examination, and fine needle biopsy if required to evaluate thyroid nodularity. Main Outcome Measures Thyroid cancer, benign thyroid nodules, total neoplasia, any thyroid nodules, autoimmune thyroiditis, and hypothyroidism. Results There was no evidence of a relationship between Hanford radiation dose and the cumulative incidence of any of the outcomes. These results remained unchanged after taking into account several factors that might confound the relationship between radiation do, se and the outcomes of interest. Conclusion These results do not support the hypothesis that exposure during infancy and childhood to 131 1 at the dose levels (median, 97 mGy; mean, 174 mGy) and exposure circumstances experienced by our study participants increases the risk of the forms of thyroid disease evaluated in this study.	Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Canc Prevent, Seattle, WA 98109 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Sch Med, Div Endocrinol & Metab, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Davis, S (corresponding author), Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Epidemiol, 1100 Fairview Ave N,M4-B874,POB 19024, Seattle, WA 98109 USA.	sdavis@fhcrc.org	Hamilton, Thomas Edward/GQB-4837-2022					AKIYAMA M, 1995, INT J RADIAT BIOL, V68, P497, DOI 10.1080/09553009514551491; amashita S., 1997, P 5 CHERN SAS MED CO; Astakhova LN, 1998, RADIAT RES, V150, P349, DOI 10.2307/3579983; BEACH SA, 1962, PHYS MED BIOL, V6, P538; BOOK SA, 1980, RADIAT RES, V81, P254, DOI 10.2307/3575401; CHRISTOV K, 1978, RADIAT RES, V73, P330, DOI 10.2307/3574824; CLARK DE, 1955, JAMA-J AM MED ASSOC, V159, P1007, DOI 10.1001/jama.1955.02960270027007; CONARD RA, 1980, US DEP ENERGY PUBLIC, P51; DAVIS S, 2004, RADIAT RES, V62, P241; Davis S., 2002, HANFORD THYROID DIS; DEGROOT LJ, 1983, AM J MED, V74, P852, DOI 10.1016/0002-9343(83)91077-X; Dickman PW, 2003, INT J CANCER, V106, P580, DOI 10.1002/ijc.11258; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; Eheman CR, 2003, THYROID, V13, P453, DOI 10.1089/105072503322021115; Farris WT, 1996, HEALTH PHYS, V71, P588, DOI 10.1097/00004032-199610000-00016; Franklyn JA, 1999, LANCET, V353, P2111, DOI 10.1016/S0140-6736(98)12295-X; GEUL KW, 1993, CLIN ENDOCRINOL, V39, P275, DOI 10.1111/j.1365-2265.1993.tb02366.x; Hahn K, 2001, RADIAT RES, V156, P61, DOI 10.1667/0033-7587(2001)156[0061:TCADAO]2.0.CO;2; Hall P, 1996, RADIAT RES, V145, P86, DOI 10.2307/3579200; HAMILTON TE, 1987, JAMA-J AM MED ASSOC, V258, P629, DOI 10.1001/jama.258.5.629; HANCOCK SL, 1991, NEW ENGL J MED, V325, P599, DOI 10.1056/NEJM199108293250902; *HANF ENV DOS REC, 1990, PNL7412 HEDR BATT PA; Heeb CM, 1996, HEALTH PHYS, V71, P545, DOI 10.1097/00004032-199610000-00012; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; HOLM LE, 1980, J NATL CANCER I, V65, P1221; HOLM LE, 1980, J NATL CANCER I, V64, P1055; HOLM LE, 1980, NEW ENGL J MED, V303, P188, DOI 10.1056/NEJM198007243030404; HOLM LE, 1984, RAD CARCINOGENESIS E, P263; JAMES RA, 1964, US DEP ENERGY PUBLIC; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KAPLAN MM, 1983, AM J MED, V74, P272, DOI 10.1016/0002-9343(83)90626-5; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; Kopecky KJ, 2004, HEALTH PHYS, V87, P15, DOI 10.1097/00004032-200407000-00003; LARSEN PR, 1982, JAMA-J AM MED ASSOC, V247, P1571, DOI 10.1001/jama.247.11.1571; LESSARD E, 1985, US DEP ENERGY PUBLIC; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; NAGATAKI S, 1994, JAMA-J AM MED ASSOC, V272, P364, DOI 10.1001/jama.272.5.364; Napier BA, 2002, HEALTH PHYS, V83, P204, DOI 10.1097/00004032-200208000-00006; *NAT COUNC RAD PRO, 1985, 80 NAT COUNC RAD PRO; *NCI, 1997, EST EXP THYR REC AM; Pacini F, 1998, LANCET, V352, P763, DOI 10.1016/S0140-6736(97)11397-6; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; Prentice R L, 1982, Natl Cancer Inst Monogr, V62, P207; Raber W, 2000, THYROID, V10, P709, DOI 10.1089/10507250050137806; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; RON E, 1995, RADIAT RES, V141, P259, DOI 10.2307/3579003; Ron E., 1984, RAD CARCINOGENESIS E, P139; SAFA AM, 1975, NEW ENGL J MED, V292, P167, DOI 10.1056/NEJM197501232920401; Schlinkert RT, 1997, MAYO CLIN PROC, V72, P913, DOI 10.1016/S0025-6196(11)63360-0; SCHNEIDER AB, 1986, ANN INTERN MED, V105, P405, DOI 10.7326/0003-4819-105-3-405; SCHNEIDER AB, 1993, J CLIN ENDOCR METAB, V77, P362, DOI 10.1210/jc.77.2.362; SCHNEIDER AB, 1985, MEDICINE, V64, P1; SEVENS W, 1992, NN01CO23917 NCI; Shipler DB, 1996, HEALTH PHYS, V71, P532, DOI 10.1097/00004032-199610000-00011; SHORE RE, 1976, ARCH ENVIRON HEALTH, V31, P21, DOI 10.1080/00039896.1976.10667184; SHORE RE, 1993, RADIAT RES, V134, P217, DOI 10.2307/3578462; SHORE RE, 1984, RAD CARCINOGENESIS E, P131; SIKOV MR, 1969, RADIAT RES, V38, P449, DOI 10.2307/3572786; SIMPSON CL, 1955, RADIOLOGY, V64, P840, DOI 10.1148/64.6.840; THOMPSON DE, 1994, RAD RES S, V137, P17; Tomer Y, 1997, CLIN IMMUNOL IMMUNOP, V82, P3, DOI 10.1006/clin.1996.4243; Tuttle RM, 1998, THYROID, V8, P377, DOI 10.1089/thy.1998.8.377; *UN SCI COMM EFF A, 2000, SOURC EFF IONZ RAD, V2; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Vermiglio F, 1999, THYROID, V9, P781, DOI 10.1089/thy.1999.9.781; World Health Organization, 1977, INT CLASS DIS; YOSHIMOTO Y, 1995, RADIAT RES, V141, P278, DOI 10.2307/3579004	71	89	93	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2600	2613		10.1001/jama.292.21.2600	http://dx.doi.org/10.1001/jama.292.21.2600			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572718	Bronze			2022-12-28	WOS:000225409100023
J	Psaty, BM; Furberg, CD; Ray, WA; Weiss, NS				Psaty, BM; Furberg, CD; Ray, WA; Weiss, NS			Potential for conflict of interest in the evaluation of suspected adverse drug reactions - Use of cerivastatin and risk of rhabdomyolysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY EVENTS; CLINICAL-TRIALS; PRAVASTATIN; PREVENTION; AVERAGE; SAFETY; LOVASTATIN; MEDICINES; OUTCOMES; DISEASE	Context In recent years, US patients have increasingly been the first to receive new medications, some of which are subsequently discovered to have suspected adverse drug reactions (SADRs). As a result, the challenge of early detection has largely shifted to the US postmarketing systems. Objective To review the association between the use of cerivastatin sodium and the risk of rhabdomyolysis in an effort to illustrate the operation and limitations of the current US postmarketing safety-surveillance system. Data Sources and Selection For the published literature, we used previous reviews and MEDLINE searches from all years through 2003. For the unpublished literature, we used internal company documents that have become part of the public record during a trial in Nueces County, Texas. Data Synthesis In the published literature, cerivastatin was associated with much larger risks of rhabdomyolysis than other statins. Although only a small percentage of cerivastatin users also took gemfibrozil, approximately half of the case reports of rhabdomyolysis occurred in users of this combination therapy, and a cerivastatin-gemfibrozil interaction was supported by the results of a 3-day pharmacokinetic study. In internal company documents, multiple case reports suggested a drug-drug interaction within approximately 100 days of the launch in 1998; however, the company did not add a contraindication about the concomitant use of cerivastatin and gemfibrozil to the package insert for more than 18 months. Unpublished data available in July 1999 also suggested an increased risk of rhabdomyolysis associated with high doses of cerivastatin monotherapy. In late 1999 and early 2000, company scientists conducted high-quality analyses of the US Food and Drug Administration adverse event reporting system data. These analyses suggested that compared with atorvastatin calcium, cerivastatin monotherapy substantially increased the risk of rhabdomyolysis. To our knowledge, these findings were not disseminated or published. The company continued to conduct safety studies, some of them inadequately designed to assess the risk of rhabdomyolysis, until cerivastatin was removed from the market in August 2001. Conclusions Despite limitations of the available data, the asymmetry between the information available to the company and the information available to patients and physicians seems striking. A subjective element is present in the effort to infer whether or not the occurrence of untoward outcomes in users of a particular drug was actually the consequence of the use of that drug, and, under the current system, a pharmaceutical company's appraisal of SADRs may be influenced by economic considerations. Such an appraisal would best be made by an independent group. The US Congress should mandate and provide adequate support for independent reviews and analysis of postmarketing data.	Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; Vanderbilt Univ, Ctr Geriatr Res Educ & Clin, Nashville Vet Adm Med Ctr, Nashville, TN 37212 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Wake Forest Baptist Medical Center; Vanderbilt University; Geriatric Research Education & Clinical Center; Vanderbilt University	Psaty, BM (corresponding author), Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Suite 1360,1730 Minor Ave, Seattle, WA 98101 USA.	psaty@u.washington.edu						*AM MED ASS, FUND EL PAT PHYS REL; American Medical Association, 2001, PRINC MED ETH; Antes G, 2003, LANCET, V361, P978, DOI 10.1016/S0140-6736(03)12838-3; Backman JT, 2002, CLIN PHARMACOL THER, V72, P685, DOI 10.1067/mcp.2002.128469; Bate A, 2002, EUR J CLIN PHARMACOL, V58, P483, DOI 10.1007/s00228-002-0484-x; Berwick D, 2001, BRIT MED J, V323, P616, DOI 10.1136/bmj.323.7313.616; Brennan T, 2002, LANCET, V359, P520, DOI 10.1016/s0140-6736(02)07684-5; CADA DJ, 2002, DRUG FACTS COMPARISO; *CDCP, 1999, JAMA-J AM MED ASSOC, V282, P2113; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Ehresman K, 1999, JAMA-J AM MED ASSOC, V282, P520; *FDA, 2003, CAL HEALTHL; FISHER C, 2001, HRB PUBLICATION, V1588; *FOOD DRUG ADM, 1997, FED REGISTER, V62, P52237; *FOOD DRUG ADM, 2003, FED REGISTER, V68, P12406; *FOOD DRUG ADM, 2002, CDER 2001 REP NAT IM; *FOOD DRUG ADM MED, 20740S008S013 FOOD D; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Horton R, 2000, LANCET, V356, P959; Hyman DJ, 2002, ANN INTERN MED, V137, P74, DOI 10.7326/0003-4819-137-1-200207020-00028; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Meadows Michelle, 2002, FDA Consum, V36, P19; Meadows Michelle, 2002, FDA Consum, V36, P11; Moore TJ, 1998, JAMA-J AM MED ASSOC, V279, P1571, DOI 10.1001/jama.279.19.1571; Muck W, 1998, DRUGS, V56, P15; Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804; PEDERSEN TR, 1994, LANCET, V344, P1383; Pfeffer MA, 2002, CIRCULATION, V105, P2341, DOI 10.1161/01.CIR.0000017634.00171.24; Pich J, 2003, LANCET, V361, P1015, DOI 10.1016/S0140-6736(03)12799-7; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; Pierfitte C, 1999, BRIT J CLIN PHARMACO, V47, P329, DOI 10.1046/j.1365-2125.1999.00881.x; Pogson GW, 1999, AM J CARDIOL, V83, P1146, DOI 10.1016/S0002-9149(99)00034-X; Psaty BM, 1999, JAMA-J AM MED ASSOC, V282, P786, DOI 10.1001/jama.282.8.786; Relman AS, 2000, NEW REPUBLIC, P27; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172; Temple R, 1999, JAMA-J AM MED ASSOC, V281, P841, DOI 10.1001/jama.281.9.841; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; *US DEP HHS, 2003, FDAS REV PROC NEW DR; Williams D, 2002, CLIN PHARMACOKINET, V41, P343, DOI 10.2165/00003088-200241050-00003; Wood AJJ, 1998, NEW ENGL J MED, V339, P1851, DOI 10.1056/NEJM199812173392512	50	122	125	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2622	2631		10.1001/jama.292.21.2622	http://dx.doi.org/10.1001/jama.292.21.2622			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572720				2022-12-28	WOS:000225409100025
J	Gfeller, A; Farmer, EE				Gfeller, A; Farmer, EE			Keeping the leaves green above us	SCIENCE			English	Article							TRANSCRIPTION FACTOR; PLANT DEFENSE; JASMONATE; ARABIDOPSIS; RESPONSES; CORONATINE-INSENSITIVE1; SIGNALS; ENCODES; TOMATO	The-plant immune system relies to a great extent on the highly regulated expression of hundreds of defense genes encoding antimicrobial proteins, such as defensins, and antiherbivore proteins, such as lectins. The expression of many of these genes is controlled by a family of mediators known as jasmonates;these cyclic oxygenated fatty acid derivatives are reminiscent of prostaglandins. The roles of jasmonates also extend to the control of reproductive development. How are these complex events regulated? Nearly 20 members of the jasmonate family have been characterized. Some, like jasmonic acid, exist in unmodified forms, whereas others are conjugated to other lipids or to hydrophobic amino acids. Why do so many chemically different forms of these mediators exist, and do individual jasmonates have unique signaling properties or are they made to facilitate transport within and between cells? Key features of the jasmonate signal pathway have been identified and include the specific activation of E3-type ubiquitin ligases thought to target as-yet-undescribed transcriptional repressors for modification or destruction. Several classes of transcription factor are known to function in the jasmonate pathway, and, in some cases, these proteins provide nodes that integrate this network with other important defensive and developmental pathways. Progress in jasmonate research is now rapid, but large gaps in our knowledge exist. Aimed to keep pace with progress, the ensemble of jasmonate Connections Maps at the Signal Transduction Knowledge Environment describe (i) the canonical signaling pathway, (ii) the Arabidopsis signaling pathway, and (iii) the biogenesis and structures of the jasmonates themselves.	Univ Lausanne, Gene Express Lab, CH-1015 Lausanne, Switzerland	University of Lausanne	Farmer, EE (corresponding author), Univ Lausanne, Gene Express Lab, Biol Bldg, CH-1015 Lausanne, Switzerland.	edward.farmer@unil.ch	Farmer, Edward E/H-1635-2011					Boter M, 2004, GENE DEV, V18, P1577, DOI 10.1101/gad.297704; Devoto A, 2002, PLANT J, V32, P457, DOI 10.1046/j.1365-313X.2002.01432.x; Evans NH, 2003, PLANT PHYSIOL, V131, P8, DOI 10.1104/pp.014266; Hara-Nishimura I, 2003, CURR OPIN PLANT BIOL, V6, P583, DOI 10.1016/j.pbi.2003.09.015; Heil M, 2004, J ECOL, V92, P527, DOI 10.1111/j.0022-0477.2004.00890.x; Kessler A, 2004, SCIENCE, V305, P665, DOI 10.1126/science.1096931; Li J, 2004, PLANT CELL, V16, P319, DOI 10.1105/tpc.016980; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; LIECHTI R, 2004, SCI STKE         NOV; Lorenzo O, 2004, PLANT CELL, V16, P1938, DOI 10.1105/tpc.022319; Lorenzo O, 2003, PLANT CELL, V15, P165, DOI 10.1105/tpc.007468; Mengiste T, 2003, PLANT CELL, V15, P2551, DOI 10.1105/tpc.014167; Reymond P, 2004, PLANT CELL, V16, P3132, DOI 10.1105/tpc.104.026120; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Thaler JS, 2004, PLANT PHYSIOL, V135, P530, DOI 10.1104/pp.104.041566; Xiao S, 2004, PLANT CELL, V16, P1132, DOI 10.1105/tpc.020370	16	20	26	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1515	1516		10.1126/science.1104352	http://dx.doi.org/10.1126/science.1104352			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567853				2022-12-28	WOS:000225442700047
J	Hernandez, JV; Kay, ER; Leigh, DA				Hernandez, JV; Kay, ER; Leigh, DA			A reversible synthetic rotary molecular motor	SCIENCE			English	Article							BROWNIAN MOTORS; UNIDIRECTIONAL ROTATION; MOTION; RATCHETS; TRANSPORT; ACCELERATION; SPEED; ROTOR	The circumrotation of a submolecular fragment in either direction in a synthetic molecular structure is described. The movement of a small ring around a larger one occurs through positional displacements arising from biased Brownian motion that are kinetically captured and then directionally released. The sense of rotation is governed solely by the order in which a series of orthogonal chemical transformations is performed. The minimalist nature of the [2]catenane flashing ratchet design permits certain mechanistic comparisons with the Smoluchowski-Feynman ratchet and pawl. Even when no work has to be done against an opposing force and no net energy is used to power the motion, a finite conversion of energy is intrinsically required for the molecular motor to undergo directional rotation. Nondirectional rotation has no such, requirement.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Edinburgh	Leigh, DA (corresponding author), Univ Edinburgh, Sch Chem, Kings Bldg,W Mains Rd, Edinburgh EH9 3JJ, Midlothian, Scotland.	David.Leigh@ed.ac.uk	Kay, Euan R/G-4473-2011; Leigh, David/K-5965-2015	Kay, Euan R/0000-0001-8177-6393; Leigh, David/0000-0002-1202-4507				Altieri A, 2003, ANGEW CHEM INT EDIT, V42, P2296, DOI 10.1002/anie.200250745; Astumian RD, 1998, EUR BIOPHYS J BIOPHY, V27, P474, DOI 10.1007/s002490050158; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 2002, PHYS TODAY, V55, P33, DOI 10.1063/1.1535005; Bader JS, 1999, P NATL ACAD SCI USA, V96, P13165, DOI 10.1073/pnas.96.23.13165; Balzani V, 2000, ANGEW CHEM INT EDIT, V39, P3348, DOI 10.1002/1521-3773(20001002)39:19<3348::AID-ANIE3348>3.0.CO;2-X; Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; Davis AP, 1998, ANGEW CHEM INT EDIT, V37, P909, DOI 10.1002/(SICI)1521-3773(19980420)37:7<909::AID-ANIE909>3.0.CO;2-X; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; Feynman R.P., 1963, FEYNMAN LECT PHYS; Gatti FG, 2003, P NATL ACAD SCI USA, V100, P10, DOI 10.1073/pnas.0134757100; Hawthorne MF, 2004, SCIENCE, V303, P1849, DOI 10.1126/science.1093846; Kelly TR, 2000, J AM CHEM SOC, V122, P6935, DOI 10.1021/ja001048f; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Kelly TR, 1997, ANGEW CHEM INT EDIT, V36, P1866, DOI 10.1002/anie.199718661; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Koumura N, 2002, J AM CHEM SOC, V124, P5037, DOI 10.1021/ja012499i; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; Linke H, 2002, APPL PHYS A-MATER, V75, P167, DOI 10.1007/s003390201401; Magnasco MO, 1998, J STAT PHYS, V93, P615, DOI 10.1023/B:JOSS.0000033245.43421.14; Mandl CP, 2004, ANGEW CHEM INT EDIT, V43, P1622, DOI 10.1002/anie.200301697; Matthias S, 2003, NATURE, V424, P53, DOI 10.1038/nature01736; Onsager L, 1931, PHYS REV, V37, P405, DOI 10.1103/PhysRev.37.405; Oster G, 2003, TRENDS CELL BIOL, V13, P114, DOI 10.1016/S0962-8924(03)00004-7; Parrondo JMR, 2004, CONTEMP PHYS, V45, P147, DOI 10.1080/00107510310001644836; Parrondo JMR, 1996, AM J PHYS, V64, P1125, DOI 10.1119/1.18393; PURCELL EM, 1977, AM J PHYS, V45, P3, DOI 10.1119/1.10903; Reimann P, 2002, PHYS REP, V361, P57, DOI 10.1016/S0370-1573(01)00081-3; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; SCHLIWA M, 2003, MOL MOTORS; ter Wiel MKJ, 2003, J AM CHEM SOC, V125, P15076, DOI 10.1021/ja036782o; van Delden RA, 2004, ORG BIOMOL CHEM, V2, P1531, DOI 10.1039/b402222j; von Smoluchowski M, 1912, PHYS Z, V13, P1069	33	471	471	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1532	1537		10.1126/science.1103949	http://dx.doi.org/10.1126/science.1103949			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	875ST	15567858	Green Submitted			2022-12-28	WOS:000225442700052
J	Zioutas, K; Hoffmann, DHH; Dennerl, K; Papaevangelou, T				Zioutas, K; Hoffmann, DHH; Dennerl, K; Papaevangelou, T			What is dark matter made of?	SCIENCE			English	Editorial Material							X-RAY-EMISSION; PARTICLE PHYSICS; CP CONSERVATION; CLUSTERS; ASTROPHYSICS; SIGNATURE; GALAXY		Univ Thessaloniki, Dept Phys, Thessaloniki 52114, Greece; CERN, CH-1211 Geneva 23, Switzerland; Tech Univ Darmstadt, Inst Kernphys, D-64289 Darmstadt, Germany; Max Planck Inst Extraterr Phys, D-85748 Garching, Germany	Aristotle University of Thessaloniki; European Organization for Nuclear Research (CERN); Technical University of Darmstadt; Max Planck Society	Zioutas, K (corresponding author), Univ Thessaloniki, Dept Phys, Thessaloniki 52114, Greece.	hoffmann@physik.tu-darmstadt.de	Papaevangelou, Thomas/G-2482-2016; Zioutas, Konstantin/L-3554-2017; Hoffmann, Dieter H.H./A-5265-2008	Papaevangelou, Thomas/0000-0003-2829-9158; 				Aharonian F, 2004, ASTRON ASTROPHYS, V425, pL13, DOI 10.1051/0004-6361:200400055; Bradley R, 2003, REV MOD PHYS, V75, P777, DOI 10.1103/RevModPhys.75.777; Cho A, 2004, SCIENCE, V304, P1092; Day C, 2003, PHYS TODAY, V56, P16, DOI 10.1063/1.1564333; Di Lella L, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.125011; DiLella L, 2003, ASTROPART PHYS, V19, P145, DOI 10.1016/S0927-6505(02)00186-X; Ebisawa K, 2001, SCIENCE, V293, P1633, DOI 10.1126/science.1063529; Irion R, 2004, SCIENCE, V305, P763; Jean P, 2003, ASTRON ASTROPHYS, V407, pL55, DOI 10.1051/0004-6361:20031056; McCarthy IG, 2003, ASTROPHYS J, V591, P515, DOI 10.1086/375486; McCarthy IG, 2003, ASTROPHYS J, V591, P526, DOI 10.1086/375487; Muno MP, 2004, ASTROPHYS J, V613, P326, DOI 10.1086/422865; Oh SP, 2004, MON NOT R ASTRON SOC, V353, P468, DOI 10.1111/j.1365-2966.2004.08081.x; PECCEI RD, 1977, PHYS REV D, V16, P1791, DOI 10.1103/PhysRevD.16.1791; PECCEI RD, 1977, PHYS REV LETT, V38, P1440, DOI 10.1103/PhysRevLett.38.1440; Raffelt GG, 1999, ANNU REV NUCL PART S, V49, P163, DOI 10.1146/annurev.nucl.49.1.163; Raffelt GG, 2000, PHYS REP, V333, P593, DOI 10.1016/S0370-1573(00)00039-9; Zioutas K, 2004, ASTROPHYS J, V607, P575, DOI 10.1086/383301	18	19	19	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1485	+		10.1126/science.1102823	http://dx.doi.org/10.1126/science.1102823			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567843				2022-12-28	WOS:000225442700037
J	Horwich, AL				Horwich, AL			Chaperoned protein disaggregation - The ClpB ring uses its central channel	CELL			English	Editorial Material								In this issue of Cell, Weibezahn et al. (2004) exploit a clever manipulation of the Hsp100 ring chaperone, ClpB, to gain some mechanistic and physiologic understanding of the action of this chaperone in mediating ATP-dependent disaggregation of protein aggregates that accumulate in the bacterial cytoplasm under severe heat shock conditions.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Yale University; Yale University; Scripps Research Institute	Horwich, AL (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06536 USA.							Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Lee S, 2003, CELL, V115, P229, DOI 10.1016/S0092-8674(03)00807-9; Lum R, 2004, J BIOL CHEM, V279, P29139, DOI 10.1074/jbc.M403777200; Mancini EJ, 2004, CELL, V118, P743, DOI 10.1016/j.cell.2004.09.007; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Weibezahn J, 2004, CELL, V119, P653, DOI 10.1016/j.cell.2004.11.027	8	8	8	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					579	581		10.1016/j.cell.2004.11.018	http://dx.doi.org/10.1016/j.cell.2004.11.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550237	Bronze			2022-12-28	WOS:000225389500001
J	Tsunoda, A; Kanazawa, H; Ishige, T; Kishimoto, S				Tsunoda, A; Kanazawa, H; Ishige, T; Kishimoto, S			A missing denture	LANCET			English	Editorial Material									Tokyo Med & Dent Univ, Sch Med, Dept Head & Neck Surg, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Tsunoda, A (corresponding author), Tokyo Med & Dent Univ, Sch Med, Dept Head & Neck Surg, Bunkyo Ku, Yushima 1-5-45, Tokyo 1138519, Japan.	at.hns@tmd.ac-jp							0	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1884	1884		10.1016/S0140-6736(04)17444-8	http://dx.doi.org/10.1016/S0140-6736(04)17444-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555668	Bronze			2022-12-28	WOS:000225269300029
J	Cuk, T; Shen, ZL; Gromko, AD; Sun, Z; Dessau, DS				Cuk, T; Shen, ZL; Gromko, AD; Sun, Z; Dessau, DS			Copper oxide superconductors - Sharp-mode coupling in high-T-c superconductors	NATURE			English	Letter							RENORMALIZATION		Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94305 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA	Stanford University; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of Colorado System; University of Colorado Boulder	Cuk, T (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	tanjacuk@stanford.edu	Sun, Zhe/AAU-6242-2020; Sun, Zhe/AAA-9363-2021					Abanov A, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.177002; Cuk T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117003; Devereaux TP, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.117004; Gromko AD, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.174520; Hwang J, 2004, NATURE, V427, P714, DOI 10.1038/nature02347; Kaminski A, 2001, PHYS REV LETT, V86, P1070, DOI 10.1103/PhysRevLett.86.1070; Sato T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.157003	7	5	5	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015								10.1038/nature03163	http://dx.doi.org/10.1038/nature03163			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15568212	Bronze			2022-12-28	WOS:000225161400034
J	Okin, PM; Devereux, RB; Jern, S; Kjeldsen, SE; Julius, S; Nieminen, MS; Snapinn, S; Harris, KE; Aurup, P; Edelman, JM; Wedel, H; Dahlof, B				Okin, PM; Devereux, RB; Jern, S; Kjeldsen, SE; Julius, S; Nieminen, MS; Snapinn, S; Harris, KE; Aurup, P; Edelman, JM; Wedel, H; Dahlof, B		LIFE Study Investigators	Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							END-POINT REDUCTION; LOSARTAN INTERVENTION; HYPERTENSIVE PATIENTS; PROGNOSTIC-SIGNIFICANCE; BLOOD-PRESSURE; SERIAL CHANGES; MASS; CRITERIA; RISK; MORTALITY	Context Electrocardiographic left ventricular hypertrophy (LVH) is a strong predictor of cardiovascular (CV) morbidity and mortality. However, the predictive value of changes in the magnitude of electrocardiographic LVH criteria during antihypertensive therapy remains unclear. Objective To test the hypothesis that lesser severity of electrocardiographic LVH during anti hypertensive treatment is associated with decreased CV morbidity and mortality; independent of blood pressure levels and reduction and treatment modality. Design, Setting, and Participants Double-blind, randomized, parallel-group study conducted in 1995-2001 among 9193 men and women with hypertension aged 55 through 80 years (mean, 67 years), with electrocardiographic LVH by Cornell voltage-duration product or Sokolow-Lyon voltage criteria and enrolled in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. Interventions Losartan- or atenolol-based treatment regimens, with follow-up assessments for at least 4 (mean, 4.8 [SD, 0.9]) years. Main Outcome Measure Composite end point of CV death, myocardial infarction (MI), or stroke in relation to severity of electrocardiographic LVH determined at baseline and on subsequent electrocardiograms obtained at 1 or more annual revisits. Results Cardiovascular death, nonfatal MI, or stroke occurred in 1096 patients (11.9%). In Cox regression models controlling for treatment type, baseline Framingham risk score, baseline and in-treatment blood pressure, and severity of baseline electrocardiographic LVH by Cornell product and Sokolow-Lyon voltage, less-severe in-treatment LVH by Cornell product and Sokolow-Lyon voltage were associated with 14% and 17% lower rates, respectively, of the composite CV end point (adjusted hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.82-0.90; P<.001 for every 1050-mm x ms [1-SD] decrease in Cornell product; and HR, 0.83; 95% CI, 0.78-0.88; P<.001 for every 10.5-mm [1-SD] decrease in Sokolow-Lyon voltage). In parallel analyses, lower Cornell product and Sokolow-Lyon voltage were each independently associated with lower risks of CV mortality (HR, 0.78; 95% CI 0.73-0.83; P<.001; and HR, 0.80; 95% CI 0.73-0.87; P<.001, respectively), MI (HR 0.90; 95% CI, 0.82-0.98; P=.01; and HR, 0.90; 95% CI, 0.81-1.00; P=.04), and stroke (HR, 0.90; 95% CI, 0.840.96; P=.002; and HR, 0.81; 95% CI, 0.75-0.89; P<.001). Conclusions Less-severe electrocardiographic LVH by Cornell product and Sokolow- Lyon voltage criteria during antihypertensive therapy is associated with lower likelihoods of CV morbidity and mortality independent of blood pressure lowering and treatment modality in persons with essential hypertension. Antihypertensive therapy targeted at regression or prevention of electrocardiographic LVH may improve prognosis.	Cornell Univ, Med Ctr, Div Cardiol, Dept Med, New York, NY 10021 USA; Sahlgrens Univ Hosp, Gothenburg, Sweden; Ullevaal Univ Hosp, Oslo, Norway; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Univ Helsinki, Cent Hosp, Dept Med, Div Cardiol, Helsinki, Finland; Amgen Inc, Thousand Oaks, CA 91320 USA; Merck Res Labs, West Point, PA USA; Merck & Co Inc, Whitehouse Stn, NJ USA; Nord Sch Publ Hlth, Gothenburg, Sweden; Umea Univ, Umea, Sweden	Cornell University; Sahlgrenska University Hospital; University of Oslo; University of Michigan System; University of Michigan; University of Helsinki; Helsinki University Central Hospital; Amgen; Merck & Company; Merck & Company; Umea University	Okin, PM (corresponding author), Cornell Univ, Med Ctr, Div Cardiol, Dept Med, 525 E 68th St, New York, NY 10021 USA.	pokin@mail.med.cornell.edu						ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; [Anonymous], 1980, LANCET, V1, P1261; CASALE PN, 1987, CIRCULATION, V75, P565, DOI 10.1161/01.CIR.75.3.565; CASALE PN, 1985, J AM COLL CARDIOL, V6, P572, DOI 10.1016/S0735-1097(85)80115-7; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER JA, 1989, HYPERTENSION S1, V13, P36; Dahlof B, 1997, AM J HYPERTENS, V10, P705; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 1998, HYPERTENSION, V32, P989, DOI 10.1161/01.HYP.32.6.989; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVIS CE, 1976, AM J EPIDEMIOL, V104, P493, DOI 10.1093/oxfordjournals.aje.a112321; Devereux RB, 2004, JAMA-J AM MED ASSOC, V292, P2350, DOI 10.1001/jama.292.19.2350; Devereux RB, 2002, J HYPERTENS, V20, P1445, DOI 10.1097/00004872-200207000-00033; Devereux RB, 2001, BLOOD PRESSURE, V10, P74, DOI 10.1080/08037050152112050; FARB A, 1990, J AM COLL CARDIOL, V15, P618, DOI 10.1016/0735-1097(90)90636-4; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Hoieggen A, 2004, KIDNEY INT, V65, P1041, DOI 10.1111/j.1523-1755.2004.00484.x; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kjeldsen SE, 2000, AM J HYPERTENS, V13, P899, DOI 10.1016/S0895-7061(00)00280-6; KOREN MJ, 1991, ANN INTERN MED, V114, P345, DOI 10.7326/0003-4819-114-5-345; Kumpusalo E, 2001, J HUM HYPERTENS, V15, P255, DOI 10.1038/sj.jhh.1001166; LEVY D, 1994, CIRCULATION, V90, P1786, DOI 10.1161/01.CIR.90.4.1786; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LIAO YL, 1995, JAMA-J AM MED ASSOC, V273, P1592, DOI 10.1001/jama.273.20.1592; MACHIN D, 1988, BRIT MED J, V296, P1369, DOI 10.1136/bmj.296.6633.1369; Mathew J, 2001, CIRCULATION, V104, P1615, DOI 10.1161/hc3901.096700; MOLLOY TJ, 1992, J AM COLL CARDIOL, V20, P1180, DOI 10.1016/0735-1097(92)90376-X; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; NORMAN JE, 1995, J AM COLL CARDIOL, V26, P1022, DOI 10.1016/0735-1097(95)00269-5; Oikarinen L, 2004, HYPERTENSION, V43, P1029, DOI 10.1161/01.HYP.0000125230.46080.c6; Okin PM, 2004, J HUM HYPERTENS, V18, P403, DOI 10.1038/sj.jhh.1001707; OKIN PM, 1995, J AM COLL CARDIOL, V25, P417, DOI 10.1016/0735-1097(94)00371-V; Okin PM, 1998, HYPERTENSION, V31, P937, DOI 10.1161/01.HYP.31.4.937; Prineas RJ, 2001, J ELECTROCARDIOL, V34, P91, DOI 10.1054/jelc.2001.23360; SCHILLACI G, 1994, AM J CARDIOL, V74, P714, DOI 10.1016/0002-9149(94)90316-6; Schillaci G, 2000, HYPERTENSION, V35, P580, DOI 10.1161/01.HYP.35.2.580; Schlaich MP, 1998, AM J HYPERTENS, V11, P1394, DOI 10.1016/S0895-7061(98)00149-6; SOKOLOW M, 1949, AM HEART J, V37, P161, DOI 10.1016/0002-8703(49)90562-1; Verdecchia P, 1998, J AM COLL CARDIOL, V31, P383, DOI 10.1016/S0735-1097(97)00493-2; Verdecchia P, 1998, CIRCULATION, V97, P48, DOI 10.1161/01.CIR.97.1.48; WILLEMS JL, 1972, CIRCULATION, V45, P1057, DOI 10.1161/01.CIR.45.5.1057; ZHOU SH, 1993, J ELECTROCARDIOL, V26, P108; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1985, HYPERTENSION, V7, P105	47	489	504	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2343	2349		10.1001/jama.292.19.2343	http://dx.doi.org/10.1001/jama.292.19.2343			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547161				2022-12-28	WOS:000225070100022
J	West, JB				West, JB			The physiologic basis of high-altitude diseases	ANNALS OF INTERNAL MEDICINE			English	Review							ACUTE MOUNTAIN-SICKNESS; BLOOD-GAS BARRIER; OBSTRUCTIVE PULMONARY-DISEASE; OPERATION EVEREST-II; STRESS FAILURE; EXTREME ALTITUDES; VENTILATORY DRIVE; CEREBRAL EDEMA; HEART-FAILURE; MT EVEREST		Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	West, JB (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr,0623A, La Jolla, CA 92093 USA.	jwest@ucsd.edu			NHLBI NIH HHS [R01 HL 60698] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAND IS, 1990, LANCET, V335, P561, DOI 10.1016/0140-6736(90)90348-9; [Anonymous], 1980, Ann Intern Med, V93, P391; Antezana G, 1982, HIGH ALTITUDE PHYSL, P232; Barcroft J, 1920, J PHYSIOL-LONDON, V53, P450, DOI 10.1113/jphysiol.1920.sp001892; Bartsch P, 2004, HIGH ALT MED BIOL, V5, P110, DOI 10.1089/1527029041352108; Bartsch P, 2003, SWISS MED WKLY, V133, P377; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; Bartsch P., 1990, HYPOXIA ADAPTATIONS, P241; Beall CM, 1998, AM J PHYS ANTHROPOL, V106, P385, DOI 10.1002/(SICI)1096-8644(199807)106:3<385::AID-AJPA10>3.3.CO;2-6; BIGLANDRITCHIE R, 1988, HYPOXIA TOLERABLE LI, P315; BORGSTROM L, 1975, ACTA PHYSIOL SCAND, V93, P423, DOI 10.1111/j.1748-1716.1975.tb05832.x; CERETELLI P, 1980, PULMONARY GAS EXCHAN, P97; CLARKE C, 1976, BRIT MED J, V2, P495, DOI 10.1136/bmj.2.6034.495; DICKINSON J, 1983, THORAX, V38, P646, DOI 10.1136/thx.38.9.646; Dumont L, 2000, BRIT MED J, V321, P267, DOI 10.1136/bmj.321.7256.267; ELLIOTT AR, 1992, J APPL PHYSIOL, V73, P1150, DOI 10.1152/jappl.1992.73.3.1150; FERRAZZINI G, 1987, BRIT MED J, V294, P1380, DOI 10.1136/bmj.294.6584.1380; GRANT I, 1987, ARCH GEN PSYCHIAT, V44, P999; HACKETT PH, 1986, JAMA-J AM MED ASSOC, V256, P36; HACKETT PH, 1980, NEW ENGL J MED, V302, P1070, DOI 10.1056/NEJM198005083021907; Hackett PH, 1998, JAMA-J AM MED ASSOC, V280, P1920, DOI 10.1001/jama.280.22.1920; Hackett PH, 2001, NEW ENGL J MED, V345, P107, DOI 10.1056/NEJM200107123450206; Hackett PH, 2004, HIGH ALT MED BIOL, V5, P136, DOI 10.1089/1527029041352054; HADDAD GG, 1993, PROG NEUROBIOL, V40, P277, DOI 10.1016/0301-0082(93)90014-J; HARPER AM, 1965, J NEUROL NEUROSUR PS, V28, P449, DOI 10.1136/jnnp.28.5.449; HEATON RK, 1983, ARCH INTERN MED, V143, P1941, DOI 10.1001/archinte.143.10.1941; HECHT HH, 1962, AM J MED, V32, P171, DOI 10.1016/0002-9343(62)90288-7; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; HOUSTON CS, 1960, NEW ENGL J MED, V263, P478, DOI 10.1056/NEJM196009082631003; HOUSTON CS, 1975, LANCET, V2, P758; HOUSTON CS, 1987, J APPL PHYSIOL, V63, P877, DOI 10.1152/jappl.1987.63.2.877; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; HULTGREN HN, 1964, CIRCULATION, V29, P393, DOI 10.1161/01.CIR.29.3.393; Hurtado A, 1942, J AMER MED ASSOC, V120, P1278, DOI 10.1001/jama.1942.02830510016004; KRYGER M, 1978, AM REV RESPIR DIS, V118, P659, DOI 10.1164/arrd.1978.118.4.659; LAHIRI S, 1983, RESP PHYSIOL, V52, P281, DOI 10.1016/0034-5687(83)90086-5; MCFARLAND RA, 1972, PHYSL ADAPTATIONS DE, P157; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Moore LG, 1998, YEARB PHYS ANTHROPOL, V41, P25; Nakayama H, 2002, AM J RESP CRIT CARE, V165, P1251, DOI 10.1164/rccm.2110041; OELZ O, 1989, LANCET, V2, P1241; Peacock AJ, 1997, EUR RESPIR J, V10, P1439, DOI 10.1183/09031936.97.10071439; PENALOZA D, 1969, AM J CARDIOL, V23, P369, DOI 10.1016/0002-9149(69)90517-7; Pugh L., 1984, HDB PHYSL ADAPTATION, P861; PUGH LGC, 1964, J PHYSIOL-LONDON, V170, P344, DOI 10.1113/jphysiol.1964.sp007335; RAHN H, 1949, AM J PHYSIOL, V157, P445, DOI 10.1152/ajplegacy.1949.157.3.445; Richalet JP, 2002, HIGH ALT MED BIOL, V3, P159, DOI 10.1089/15270290260131894; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; Schneider M, 2002, MED SCI SPORT EXER, V34, P1886, DOI 10.1097/00005768-200212000-00005; Schoene RB, 2004, HIGH ALT MED BIOL, V5, P125, DOI 10.1089/1527029041352063; SCHOENE RB, 1986, JAMA-J AM MED ASSOC, V256, P63, DOI 10.1001/jama.256.1.63; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; Siesjo B.K., 1978, BRAIN ENERGY METABOL; SINGH I, 1965, LANCET, V1, P229; SINGH I, 1969, NEW ENGL J MED, V280, P175, DOI 10.1056/NEJM196901232800402; SINGH MV, 1990, INT J BIOMETEOROL, V34, P93, DOI 10.1007/BF01093454; SMITH CA, 2001, HIGH ALTITUDE, P139; SUAREZ J, 1987, AM J CARDIOL, V60, P137, DOI 10.1016/0002-9149(87)91000-9; SUI GJ, 1988, J PATHOL, V155, P161, DOI 10.1002/path.1711550213; Swenson ER, 2002, JAMA-J AM MED ASSOC, V287, P2228, DOI 10.1001/jama.287.17.2228; SWENSON ER, 2001, HIGH ALTITUDE EXPLOR, P525; TORRICELLI E, 1981, HIGH A LTITUDE PHYSL, P60; TOZZI CA, 1989, J CLIN INVEST, V84, P1005, DOI 10.1172/JCI114221; TSUKIMOTO K, 1991, J APPL PHYSIOL, V71, P573, DOI 10.1152/jappl.1991.71.2.573; Weil JV, 2004, HIGH ALT MED BIOL, V5, P180, DOI 10.1089/1527029041352162; WEST JB, 1992, RESP PHYSIOL, V88, P141, DOI 10.1016/0034-5687(92)90035-U; WEST JB, 1983, J APPL PHYSIOL, V55, P678, DOI 10.1152/jappl.1983.55.3.678; WEST JB, 1984, SCIENCE, V223, P784, DOI 10.1126/science.6364351; West JB, 1999, ANNU REV PHYSIOL, V61, P543, DOI 10.1146/annurev.physiol.61.1.543; West JB, 2004, OBSERVATORY, V124, P1; West JB, 2003, AM J PHYSIOL-LUNG C, V285, pL501, DOI 10.1152/ajplung.00117.2003; WEST JB, 1980, RESP PHYSIOL, V42, P1, DOI 10.1016/0034-5687(80)90100-0; WEST JB, 1983, J APPL PHYSIOL, V54, P1188, DOI 10.1152/jappl.1983.54.5.1188; WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731; WEST JB, 1995, RESP PHYSIOL, V99, P225, DOI 10.1016/0034-5687(94)00094-G; WEST JB, 1992, INT J SPORTS MED, V13, pS54, DOI 10.1055/s-2007-1024594; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117; 1964, MANUAL ICAO STANDARD	79	224	242	3	45	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					789	800		10.7326/0003-4819-141-10-200411160-00010	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545679				2022-12-28	WOS:000225206900006
J	Ruiz-Pelaez, JG; Charpak, N; Cuervo, LG				Ruiz-Pelaez, JG; Charpak, N; Cuervo, LG			Kangaroo Mother Care, an example to follow from developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; RANDOMIZED CONTROLLED-TRIAL; TRADITIONAL CARE; PRETERM INFANTS; DEPRESSION; ANXIETY	Caring for low birthweight infants imposes a heavy burden on poor countries. An effective healthcare technique developed in 1978 may offer a solution to this problem and additionally be of use in wealthy countries too.	Kangaroo Fdn, Bogota, Colombia; Kangaroo Mother Care Program, Bogota, Colombia; BMJ Knowledge, London WC1H 9JR, England; Javeriana Univ, Sch Med, Clin Epidemiol & Biostat Unit, Bogota, Colombia	Pontificia Universidad Javeriana	Charpak, N (corresponding author), Kangaroo Fdn, Bogota, Colombia.	herchar5@colomsat.net.co	Cuervo, Luis Gabriel/A-9464-2009; Ruiz, Juan Gabriel/AAZ-5882-2021	Cuervo, Luis Gabriel/0000-0003-2732-5019; Ruiz, Juan Gabriel/0000-0003-3088-5834; charpak, nathalie/0000-0001-6697-5837				Affonso D, 1993, Neonatal Netw, V12, P25; [Anonymous], 2003, KANG MOTH CAR PRACT; BROOTEN D, 1988, NURS RES, V37, P213; Cattaneo A, 1998, J TROP PEDIATRICS, V44, P279, DOI 10.1093/tropej/44.5.279; Cattaneo A, 1998, ACTA PAEDIATR, V87, P976, DOI 10.1080/080352598750031653; Charpak N, 2000, ACTA PAEDIATR, V89, P501, DOI 10.1080/713794578; Charpak N, 1997, PEDIATRICS, V100, P682, DOI 10.1542/peds.100.4.682; CHARPAK N, 1994, PEDIATRICS, V94, P804; Charpak N, 2001, PEDIATRICS, V108, P1072, DOI 10.1542/peds.108.5.1072; Charpak Nathalie, 1996, Current Opinion in Pediatrics, V8, P108, DOI 10.1097/00008480-199604000-00004; CONDEAGUDELO A, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002771; de Onis M, 1998, EUR J CLIN NUTR, V52, pS5; *DEP REPR HLTH RES, THERM PROT NEWB PRAC; Engler Arthur J, 2002, MCN Am J Matern Child Nurs, V27, P146, DOI 10.1097/00005721-200205000-00004; Feldman R, 2003, J FAM PSYCHOL, V17, P94, DOI 10.1037/0893-3200.17.1.94; Feldman R, 2002, PEDIATRICS, V110, P16, DOI 10.1542/peds.110.1.16; GENNARO S, 1988, NURS RES, V37, P82; *INK FDN CANG BOG, INT NETW KANG MOTH C; Kambarami RA, 1998, ANN TROP PAEDIATR, V18, P81, DOI 10.1080/02724936.1998.11747932; Kambarami RA, 2002, TROP DOCT, V32, P131, DOI 10.1177/004947550203200303; Lincetto O, 2000, J TROP PEDIATRICS, V46, P293, DOI 10.1093/tropej/46.5.293; Ludington-Hoe SM, 1998, ACTA PAEDIATR, V87, P711, DOI 10.1080/080352598750014201; Ludington-Hoe SM, 2003, JOGNN-J OBST GYN NEO, V32, P579, DOI 10.1177/0884217503257618; Martinez, 1983, MANEJO RACIONAL NINO; Mew Andea Morawski, 2003, Neonatal Netw, V22, P51; Moore ER, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003519.pub2; Quasem Iftekhar, 2003, J Perinatol, V23, P646, DOI 10.1038/sj.jp.7210999; Ruiz JG, 2002, ACTA PAEDIATR, V91, P1130, DOI 10.1080/080352502760311665; SLOAN NL, 1994, LANCET, V344, P782, DOI 10.1016/S0140-6736(94)92341-8; Sontheimer D, 2004, PEDIATRICS, V113, P920, DOI 10.1542/peds.113.4.920; Swinth Joan Y, 2003, Neonatal Netw, V22, P33; Tessier R, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.2.e17; Tessier R, 2003, INFANT BEHAV DEV, V26, P384, DOI 10.1016/S0163-6383(03)00037-7; Ukpong D I, 2003, East Afr Med J, V80, P289	34	58	70	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1179	1181		10.1136/bmj.329.7475.1179	http://dx.doi.org/10.1136/bmj.329.7475.1179			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539681	Green Published			2022-12-28	WOS:000225169600034
J	Nissen, SE; Tuzcu, EM; Libby, P; Thompson, PD; Ghali, M; Garza, D; Berman, L; Shi, H; Buebendorf, E; Topol, EJ				Nissen, SE; Tuzcu, EM; Libby, P; Thompson, PD; Ghali, M; Garza, D; Berman, L; Shi, H; Buebendorf, E; Topol, EJ		CAMELOT Investigators	Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure the CAMELOT study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMLODIPINE; ATHEROSCLEROSIS; PROGRESSION; REDUCTION; MORTALITY	Context The effect of anti hypertensive drugs on cardiovascular events in patients with coronary artery disease (CAD) and normal blood pressure remains uncertain. Objective To compare the effects of amlodipine or enalapril vs placebo on cardiovascular events in patients with CAD. Design, Setting, and Participants Double-blind, randomized, multicenter, 24-month trial (enrollment April 1999-April 2002) comparing amlodipine or enalapril with placebo in 1991 patients with angiographically documented CAD (>20% stenosis by coronary angiography) and diastolic blood pressure <100 mm Hg. A substudy of 274 patients measured atherosclerosis progression by intravascular ultrasound (IVUS). Interventions Patients were randomized to receive amlodipine, 10 mg; enalapril, 20 mg; or placebo. IVUS was performed at baseline and study completion. Main Outcome Measures The primary efficacy parameter was incidence of cardiovascular events for amlodipine vs placebo. Other outcomes included comparisons of amlodipine vs enalapril and enalapril vs placebo. Events included cardiovascular death, nonfatal myocardial infarction, resuscitated cardiac arrest, coronary revascularization, hospitalization for angina pectoris, hospitalization for congestive heart failure, fatal or nonfatal stroke or transient ischemic attack, and new diagnosis of peripheral vascular disease. The IVUS end point was change in percent atheroma volume. Results Baseline blood pressure averaged 129/78 mm Hg for all patients; it increased by 0.7/0.6 mm Hg in the placebo group and decreased by 4.8/2.5 mm Hg and 4.9/2.4 mm Hg in the amlodipine and enalapril groups, respectively (P<.001 for both vs placebo). Cardiovascular events occurred in 151 (23.1%) placebo-treated patients, in 110 (16.6%) amlodipine-treated patients (hazard ratio [HR], 0.69; 95% CI, 0.54-0.88 [P=.003]), and in 136 (20.2%) enalapril-treated patients (HR, 0.85; 95% CI, 0.67-1.07 [P=.16]. Primary end point comparison for enalapril vs amlodipine was not significant (HR,0.81;95% CI, 0.63-1.04 [P=.10]). The IVUS substudy showed a trend toward less progression of atherosclerosis in the amlodipine group vs placebo (P=.12), with significantly less progression in the subgroup with systolic blood pressures greater than the mean (P=.02). Compared with baseline, IVUS showed progression in the placebo group (P<.001), a trend toward progression in the enalapril group (P=.08), and no progression in the amlodipine group (P=.31). For the amlodipine group, correlation between blood pressure reduction and progression was r=0.19, P=.07. Conclusions Administration of amlodipine to patients with CAD and normal blood pressure resulted in reduced adverse cardiovascular events. Directionally similar, but smaller and nonsignificant, treatment effects were observed with enalapril. For amlodipine, IVUS showed evidence of slowing of atherosclerosis progression.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Hartford Hosp, Dept Cardiol, Hartford, CT USA; Iowa Heart Ctr, Dept Cardiol, Des Moines, IA USA; Pfizer Inc, New York, NY USA	Cleveland Clinic Foundation; Harvard University; Brigham & Women's Hospital; Hartford Hospital; Pfizer	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org	Libby, Peter/AAY-6404-2021	Libby, Peter/0000-0002-1502-502X; Topol, Eric/0000-0002-1478-4729				*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2998, DOI DOI 10.1016/S1062-1458(03)00049-7; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; Chambers J. M., 1983, GRAPHICAL METHODS DA; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Fox KM, 2003, LANCET, V362, P782; Jorgensen B, 2000, J AM COLL CARDIOL, V35, P592, DOI 10.1016/S0735-1097(99)00599-9; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; MACFADYEN RJ, 1993, CLIN PHARMACOKINET, V25, P274, DOI 10.2165/00003088-199325040-00003; Mason RP, 2002, ATHEROSCLEROSIS, V165, P191, DOI 10.1016/S0021-9150(01)00729-8; Neal B, 2000, LANCET, V356, P1955; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; Nissen SE, 2003, JAMA-J AM MED ASSOC, V290, P2292, DOI 10.1001/jama.290.17.2292; Pitt B, 2000, CIRCULATION, V102, P1503, DOI 10.1161/01.CIR.102.13.1503; Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Veterans Administration Cooperative Study Group on Antihypertensive Agents, 1967, JAMA-J AM MED ASSOC, V202, P116, DOI DOI 10.1001/JAMA.1967.03130150084015; Yusuf S, 2000, NEW ENGL J MED, V342, P145	18	886	984	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2217	2226		10.1001/jama.292.18.2217	http://dx.doi.org/10.1001/jama.292.18.2217			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536108	Bronze			2022-12-28	WOS:000225070000022
J	Gillespie, KM; Bain, SC; Barnett, AH; Bingley, PJ; Christie, MR; Gill, GV; Gale, EAM				Gillespie, KM; Bain, SC; Barnett, AH; Bingley, PJ; Christie, MR; Gill, GV; Gale, EAM			The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes	LANCET			English	Article								The incidence of childhood type 1 diabetes has risen over the past 50 years. We compared the frequency of HLA class II haplotypes in 194 patients diagnosed more than 50 years ago and 582 age-matched and sex-matched individuals diagnosed between 1985 and 2002. The proportion of high-risk susceptibility genotypes was increased in the earlier cohort (p=0.003), especially in those diagnosed at age 5 years or younger, which is consistent with the hypothesis that the rise of type 1 diabetes is due to a major environmental effect.	Univ Bristol, Diabet & Metab Div Med, Bristol, Avon, England; Univ Birmingham, Birmingham, W Midlands, England; Birmingham Heartlands & Solihull NHS Trust, Birmingham, W Midlands, England; Univ Liverpool, Univ Hosp Aintree, Dept Med, Liverpool L69 3BX, Merseyside, England; Guys Kings & St Thomas Sch Med, Dept Med, London, England	University of Bristol; University of Birmingham; University of Liverpool; University of London; King's College London	Gale, EAM (corresponding author), Southmead Gen Hosp, Med Sch Unit, Bristol BS10 5NB, Avon, England.	Edwin.Gale@bristol.ac.uk		Christie, Michael/0000-0001-5192-3196				Bain SC, 2003, DIABETIC MED, V20, P808, DOI 10.1046/j.1464-5491.2003.01029.x; Chowdhury TA, 1999, DIABETOLOGIA, V42, P1017, DOI 10.1007/s001250051262; FALCONER DS, 1964, INTRO QUANTITATIVE G, P301; Gale EAM, 2002, DIABETES, V51, P3353, DOI 10.2337/diabetes.51.12.3353; Gardner SG, 1997, BRIT MED J, V315, P713, DOI 10.1136/bmj.315.7110.713; Gillespie KM, 2000, TISSUE ANTIGENS, V56, P530, DOI 10.1034/j.1399-0039.2000.560607.x; Hermann R, 2003, DIABETOLOGIA, V46, P420, DOI 10.1007/s00125-003-1045-4	7	212	216	1	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1699	1700		10.1016/S0140-6736(04)17357-1	http://dx.doi.org/10.1016/S0140-6736(04)17357-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530631				2022-12-28	WOS:000224921600033
J	Marian, A; Stowe, MC; Lawall, JR; Felinto, D; Ye, J				Marian, A; Stowe, MC; Lawall, JR; Felinto, D; Ye, J			United time-frequency spectroscopy for dynamics and global structure	SCIENCE			English	Article							MODE-LOCKED LASER; 2-PHOTON SPECTROSCOPY; PULSES; TRANSITIONS; EXCITATION; STATE; TRAIN	Ultrashort laser pulses have thus far been used in two distinct modes. In the time domain, the pulses have allowed probing and manipulation of dynamics on a subpicosecond time scale. More recently, phase stabilization has produced optical frequency combs with absolute frequency reference across a broad bandwidth. Here we combine these two applications in a spectroscopic study of rubidium atoms. A wide-bandwidth, phase-stabilized femto-second laser is used to monitor the real-time dynamic evolution of population transfer. Coherent pulse accumulation and quantum interference effects are observed and well modeled by theory. At the same time, the narrow line-width of individual comb lines permits a precise and efficient determination of the global energy-level structure, providing a direct connection among the optical, terahertz, and radio-frequency domains. The mechanical action of the optical frequency comb on the atomic sample is explored and controlled, leading to precision spectroscopy with an appreciable reduction in systematic errors.	Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA; Univ Colorado, Dept Phys, Boulder, CO 80309 USA; NIST, Atom Phys Div, Gaithersburg, MD 20899 USA	National Institute of Standards & Technology (NIST) - USA; University of Colorado System; University of Colorado Boulder; National Institute of Standards & Technology (NIST) - USA	Ye, J (corresponding author), Natl Inst Stand & Technol, Joint Inst Lab Astrophys, Boulder, CO 80309 USA.	ye@jila.colorado.edu	Felinto, Daniel/M-8756-2014; Ye, Jun/C-3312-2011	Felinto, Daniel/0000-0001-9078-7756; Ye, Jun/0000-0003-0076-2112; Marian, Adela/0000-0002-9159-5227; Lawall, John/0000-0003-3368-4253				BARWOOD GP, 1991, APPL PHYS B-PHOTO, V53, P142, DOI 10.1007/BF00330229; BJORKHOLM JE, 1974, PHYS REV LETT, V33, P128, DOI 10.1103/PhysRevLett.33.128; BREWER RG, 1975, PHYS REV A, V11, P1641, DOI 10.1103/PhysRevA.11.1641; Chen LS, 2003, CHEM PHYS LETT, V381, P777, DOI 10.1016/j.cplett.2003.10.052; Cundiff ST, 2003, REV MOD PHYS, V75, P325, DOI 10.1103/RevModPhys.75.325; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; Dudovich N, 2001, PHYS REV LETT, V86, P47, DOI 10.1103/PhysRevLett.86.47; Felinto D, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.043403; Felinto D, 2003, OPT COMMUN, V215, P69, DOI 10.1016/S0030-4018(02)02230-7; Holman KW, 2003, OPT LETT, V28, P2405, DOI 10.1364/OL.28.002405; Jones DJ, 2000, SCIENCE, V288, P635, DOI 10.1126/science.288.5466.635; Jones RJ, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.051803; KIELPINSKI D, 2003, QUANTPH0306099; MARIAN A, UNPUB; NEZ F, 1993, OPT COMMUN, V102, P432, DOI 10.1016/0030-4018(93)90417-4; POULSEN O, 1981, PHYS REV LETT, V47, P1522, DOI 10.1103/PhysRevLett.47.1522; Shelton RK, 2001, SCIENCE, V293, P1286, DOI 10.1126/science.1061754; Snadden MJ, 1996, OPT COMMUN, V125, P70, DOI 10.1016/0030-4018(95)00711-3; TEETS R, 1977, PHYS REV LETT, V38, P760, DOI 10.1103/PhysRevLett.38.760; Udem T, 1999, OPT LETT, V24, P881, DOI 10.1364/OL.24.000881; Udem T, 1999, PHYS REV LETT, V82, P3568, DOI 10.1103/PhysRevLett.82.3568; VITANOV NV, 1995, PHYS REV A, V52, P2245, DOI 10.1103/PhysRevA.52.2245; Weinacht TC, 1999, NATURE, V397, P233, DOI 10.1038/16654; Wilpers G, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.230801; Ye J, 1996, OPT LETT, V21, P1280, DOI 10.1364/OL.21.001280; Ye J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.270801; Yoon TH, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.011402; Zewail AH, 2000, ANGEW CHEM INT EDIT, V39, P2587	28	225	227	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2004	306	5704					2063	2068		10.1126/science.1105660	http://dx.doi.org/10.1126/science.1105660			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881CM	15550622				2022-12-28	WOS:000225841000054
J	Morbidelli, A				Morbidelli, A			How Neptune pushed, the boundaries of our solar system	SCIENCE			English	Editorial Material							KUIPER-BELT; INCLINATION DISTRIBUTION; PLANETARY MIGRATION; ORIGIN		Observ Cote Azur, F-06034 Nice 4, France	UDICE-French Research Universities; Universite Cote d'Azur; Observatoire de la Cote d'Azur	Morbidelli, A (corresponding author), Observ Cote Azur, BP 4229, F-06034 Nice 4, France.	morby@obs-nice.fr						Adams FC, 2004, ASTROPHYS J, V611, P360, DOI 10.1086/421989; Brown ME, 2001, ASTRON J, V121, P2804, DOI 10.1086/320391; Fernandez JA, 1996, PLANET SPACE SCI, V44, P431, DOI 10.1016/0032-0633(95)00142-5; Gomes RS, 2000, ASTRON J, V120, P2695, DOI 10.1086/316816; Gomes RS, 2004, ICARUS, V170, P492, DOI 10.1016/j.icarus.2004.03.011; Gomes RS, 2003, ICARUS, V161, P404, DOI 10.1016/S0019-1035(02)00056-8; Hartmann W. K., 2000, ORIGIN EARTH MOON, P493; Ida S, 2000, ASTROPHYS J, V528, P351, DOI 10.1086/308179; Levison HF, 2003, NATURE, V426, P419, DOI 10.1038/nature02120; Levison HF, 2001, ICARUS, V151, P286, DOI 10.1006/icar.2001.6608; Levison HF, 2001, ASTRON J, V121, P1730, DOI 10.1086/319420; MALHOTRA R, 1995, ASTRON J, V110, P420, DOI 10.1086/117532; STONE JM, 1998, PROTOSTARS PLANETS, V4, P589; Trujillo CA, 2002, ASTROPHYS J, V566, pL125, DOI 10.1086/339437; Trujillo CA, 2001, ASTROPHYS J, V554, pL95, DOI 10.1086/320917; WEIDENSCHILLING S, IN PRESS COMETS, V2; Youdin AN, 2002, ASTROPHYS J, V580, P494, DOI 10.1086/343109	17	10	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1302	1304		10.1126/science.1099114	http://dx.doi.org/10.1126/science.1099114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550650				2022-12-28	WOS:000225301600029
J	DeFelice, LJ				DeFelice, LJ			Going against the flow	NATURE			English	Editorial Material									Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	DeFelice, LJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.			De Felice, Louis/0000-0002-4594-3171				DeFelice LJ, 2004, TRENDS NEUROSCI, V27, P352, DOI 10.1016/j.tins.2004.04.007; Hodgkin A. L., 1992, CHANCE DESIGN; Lauger P., 1991, ELECTROGENIC ION PUM; Stein W., 1990, CHANNELS CARRIERS PU	4	5	5	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					279	279		10.1038/432279a	http://dx.doi.org/10.1038/432279a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549077	Bronze			2022-12-28	WOS:000225161400024
J	Bell, ML; McDermott, A; Zeger, SL; Samet, JM; Dominici, F				Bell, ML; McDermott, A; Zeger, SL; Samet, JM; Dominici, F			Ozone and short-term mortality in 95 US urban communities, 1987-2000	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARTICULATE AIR-POLLUTION; TIME-SERIES; EXPOSURE; CITIES; HEALTH; MATTER; ASSOCIATIONS; METAANALYSIS; POLLUTANTS; PARTICLES	Context Ozone has been associated with various adverse health effects, including increased rates of hospital admissions and exacerbation of respiratory illnesses. Although numerous time-series studies have estimated associations between day-today variation in ozone levels and mortality counts, results have been inconclusive. Objective To investigate whether short-term (daily and weekly) exposure to ambient ozone is associated with mortality in the United States. Design and Setting Using analytical methods and databases developed for the National Morbidity, Mortality, and Air Pollution Study, we estimated a national average relative rate of mortality associated with short-term exposure to ambient ozone for 95 large US urban communities from 1987-2000. We used distributed-lag models for estimating community-specific relative rates of mortality adjusted for time-varying confounders (particulate matter, weather, seasonality, and long-term trends) and hierarchical models for combining relative rates across communities to estimate a national average relative rate, taking into account spatial heterogeneity. Main Outcome Measure Daily counts of total non-injury-related mortality and cardiovascular and respiratory mortality in 95 large US communities during a 14-year period. Results A 10-ppb increase in the previous week's ozone was associated with a 0.52% increase in daily mortality (95% posterior interval [PI], 0.27%-0.77%) and a 0.64% increase in cardiovascular and respiratory mortality (95% PI, 0.31%-0.98%). Effect estimates for aggregate ozone during the previous week were larger than for models considering only a single day's exposure. Results were robust to adjustment for particulate matter, weather, seasonality, and long-term trends. Conclusions These results indicate a statistically significant association between short-term changes in ozone and mortality on average for 95 large US urban communities, which include about 40% of the total US population. The findings indicate that this widespread pollutant adversely affects public health.	Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Yale University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Bell, ML (corresponding author), Yale Univ, Sch Forestry & Environm Studies, 205 Prospect St, New Haven, CT 06511 USA.	michelle.bell@yale.edu	Bell, Michelle/Y-4608-2018	Bell, Michelle/0000-0002-3965-1359; Zeger, Scott/0000-0001-8907-1603	NIEHS NIH HHS [R01 ES012054, P30 ES 03819, ES012054-01, P30 ES003819] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819, R01ES012054] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Anderson H.R., 2004, METAANALYSIS TIME SE; Anderson HR, 2001, OCCUP ENVIRON MED, V58, P504, DOI 10.1136/oem.58.8.504; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477, DOI 10.1164/ajrccm.153.2.8564086; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3, DOI 10.1164/ajrccm.153.1.8542133; BorjaAburto VH, 1997, AM J EPIDEMIOL, V145, P258, DOI 10.1093/oxfordjournals.aje.a009099; Braga ALF, 2001, EPIDEMIOLOGY, V12, P662; Braga ALF, 2001, J OCCUP ENVIRON MED, V43, P927; CARLIN BP, 2000, C&H TEXT STAT SCI, P1; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2003, ENVIRON HEALTH PERSP, V111, P39, DOI 10.1289/ehp.5181; Dominici F, 2002, AM J EPIDEMIOL, V156, P193, DOI 10.1093/aje/kwf062; Dominici F, 2002, J AM STAT ASSOC, V97, P100, DOI 10.1198/016214502753479266; DUMOUCHEL WH, 1983, J AM STAT ASSOC, V78, P293, DOI 10.2307/2288631; EVERSON P, 2000, 2 LEVEL NORMAL INDEP; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98, DOI 10.1164/ajrccm.149.1.8111607; Frank R, 2001, AM J RESP CRIT CARE, V164, P1253, DOI 10.1164/ajrccm.164.7.2010043; Gelman A., 2003, BAYESIAN DATA ANAL; Goldberg MS, 2001, AM J EPIDEMIOL, V154, P817, DOI 10.1093/aje/154.9.817; Goodman PG, 2004, ENVIRON HEALTH PERSP, V112, P179, DOI 10.1289/ehp.6451; HAAGENSMIT AJ, 1952, IND ENG CHEM, V44, P1342, DOI 10.1021/ie50510a045; HEI (Health Effects Institute), 2003, REV AN TIM SER STUD; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455, DOI 10.1080/00039899709602224; Hong YC, 1999, ENVIRON HEALTH PERSP, V107, P873, DOI 10.2307/3454474; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; Ito K, 1996, J EXPO ANAL ENV EPID, V6, P79; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Le Tertre A, 2002, ARCH ENVIRON HEALTH, V57, P311, DOI 10.1080/00039890209601414; Lee JT, 2000, ENVIRON RES, V84, P247, DOI 10.1006/enrs.2000.4096; Levy JI, 2001, ENVIRON HEALTH PERSP, V109, P1215, DOI 10.2307/3454743; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; LIPPMANN M, 1993, J EXPO ANAL ENV EPID, V3, P103; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; *NAT CLIM DAT CTR, NCDC SURF AIRW; Prescott GJ, 1998, OCCUP ENVIRON MED, V55, P697, DOI 10.1136/oem.55.10.697; Saez M, 2002, ENVIRON HEALTH PERSP, V110, P221, DOI 10.1289/ehp.02110221; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samet JM, 2000, NATL MORBIDITY MORTA; SAMET JM, 2000, NATL MORBIDITY MOR 1; Schwartz J., 2003, MORBIDITY MORTALITY, V20, P25; Schwarz N, 2002, PSYCHOL INQ, V13, P87; Seinfeld J. H., 1998, ATMOSPHERIC CHEM PHY; Stieb DM, 2002, J AIR WASTE MANAGE, V52, P470, DOI 10.1080/10473289.2002.10470794; Stieb DM, 2003, J AIR WASTE MANAGE, V53, P258, DOI 10.1080/10473289.2003.10466149; Thurston G.D., 1999, AIR POLLUT HLTH, P485, DOI DOI 10.1016/B978-012352335-8/50097-1; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177, DOI 10.1093/oxfordjournals.aje.a009249; U.S. EPA, GREEN BOOK NON AR CR; *US EPA, 2003, 454K03001 EPA US EPA; Zanobetti A, 2003, ENVIRON HEALTH PERSP, V111, P1188, DOI 10.1289/ehp.5712; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279; 1997, FED REG, V62, P38855	53	826	852	12	200	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2372	2378		10.1001/jama.292.19.2372	http://dx.doi.org/10.1001/jama.292.19.2372			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547165	Bronze, Green Accepted			2022-12-28	WOS:000225070100026
J	Battersby, MW				Battersby, MW			Commentary: Community models of mental care warrant more governmental support	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Flinders Univ S Australia, Flinders Human Behav & Hlth Res Unit, Bedford Pk, SA 5042, Australia	Flinders University South Australia	Battersby, MW (corresponding author), Flinders Univ S Australia, Flinders Human Behav & Hlth Res Unit, Bedford Pk, SA 5042, Australia.	malcolm.battersby@flinders.edu.au		Battersby, Malcolm/0000-0001-7306-5591				ASCH SM, 2003, AC HLTH AN RES M NAS; Department of Health, 2001, EXP PAT NEW APPR CHR; Gordon PR, 1996, ACAD MED, V71, P973, DOI 10.1097/00001888-199609000-00012; Institute for Healthcare Improvement, 2003, BREAKTHR SER IHIS CO; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Lynn J, 2000, Jt Comm J Qual Improv, V26, P254; McKenzie K, 2004, BRIT MED J, V329, P1138, DOI 10.1136/bmj.329.7475.1138; *NAT PRIM CAR DEV, HLTH COMM COLL WAV I; Richards A, 2003, BRIT J GEN PRACT, V53, P764; Richards D., 2002, PRIM HEALTH CARE RES, V3, P159, DOI DOI 10.1191/1463423602PC103OA; SCHONLAU M, EVALUATION ADULT AST; Urakalo M, 2004, NOARLUNGA CHRONIC DI; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; *WHO, HELP PEOPL MENT ILLN	14	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1140	1141		10.1136/bmj.329.7475.1140	http://dx.doi.org/10.1136/bmj.329.7475.1140			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539668	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225169600019
J	Harper, DM; Franco, EL; Wheeler, C; Ferris, DG; Jenkins, D; Schuind, A; Zahaf, T; Innis, B; Naud, P; De Carvalho, NS; Roteli-Martins, CM; Teixeira, J; Blatter, MM; Korn, AP; Quint, W; Dubin, G				Harper, DM; Franco, EL; Wheeler, C; Ferris, DG; Jenkins, D; Schuind, A; Zahaf, T; Innis, B; Naud, P; De Carvalho, NS; Roteli-Martins, CM; Teixeira, J; Blatter, MM; Korn, AP; Quint, W; Dubin, G		GlaxoSmithKline HPV Vaccine Study	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial	LANCET			English	Article							CERVICAL-CANCER; NATURAL-HISTORY; PCR; ASSAY; EPIDEMIOLOGY; WORLDWIDE; SPECIMENS; ADJUVANT	Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesions. Methods We randomised 1113 women between 15-25 years of age to receive three doses of either the vaccine formulated with AS04 adjuvant or placebo on a 0 month, 1 month, and 6 month schedule in North America and Brazil. Women were assessed for HPV infection by cervical cytology and self-obtained cervicovaginal samples for up to 27 months, and for vaccine safety and immunogenicity. Findings In the according-to-protocol analyses, vaccine efficacy was 91.6% (95% CI 64.5-98.0) against incident infection and 100% against persistent infection (47.0-100) with HPV-16/18. In the intention-to-treat analyses, vaccine efficacy was 95.1% (63.5-99.3) against persistent cervical infection with HPV-16/18 and 92.9% (70.0-98.3) against cytological abnormalities associated with HPV-16/18 infection. The vaccine was generally safe, well tolerated, and highly immunogenic. Interpretation The bivalent HPV vaccine was efficacious in prevention of incident and persistent cervical infections with HPV-16 and HPV-18, and associated cytological abnormalities and lesions. Vaccination against such infections could substantially reduce incidence of cervical cancer.	Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Gynecol Canc Prevent Res Grp, Lebanon, NH 03756 USA; McGill Univ, Dept Oncol & Epidemiol, Montreal, PQ, Canada; Univ New Mexico, Hlth Sci Ctr, Dept Mol Genet & Microbiol, Albuquerque, NM USA; Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM USA; Med Coll Georgia, Dept Family Med & Obstet & Gynecol, Augusta, GA USA; GlaxoSmithKline Biol, Rixensart, Belgium; GlaxoSmithKline Biol, King Of Prussia, PA USA; Univ Fed Rio Grande do Sul, Porto Alegre Clin Res Ctr, Ctr Vaccine Study, Porto Alegre, RS, Brazil; Univ Parana, Ginecol Obstet Infect Dis Sector, Dept Gynecol & Obstet, Curitiba, Parana, Brazil; LM Barros Hosp, Sao Paulo, Brazil; Univ Estadual Campinas, CAISM, Div Oncol, Dept Gynecol, Campinas, Brazil; Primary Phys Res, Pittsburgh, PA USA; Univ Calif San Francisco, Dept Gynecol, San Francisco, CA USA; Delft Diagnost Lab, Delft, Netherlands	Dartmouth College; Norris Cotton Cancer Center; McGill University; University of New Mexico; University of New Mexico's Health Sciences Center; University of New Mexico; University of New Mexico's Health Sciences Center; University System of Georgia; Augusta University; GlaxoSmithKline; GlaxoSmithKline; Universidade Federal do Rio Grande do Sul; Universidade Estadual de Campinas; University of California System; University of California San Francisco	Harper, DM (corresponding author), Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Gynecol Canc Prevent Res Grp, 1 Med Ctr Dr,Rubin 880, Lebanon, NH 03756 USA.	diane.m.harper@dartmouth.edu	de carvalho, newton/G-5045-2013; Teixeira, Julio Cesar/H-3151-2013; Harper, Diane M./I-2180-2014; Franco, Eduardo/C-6445-2014	Teixeira, Julio Cesar/0000-0002-0979-376X; Harper, Diane M./0000-0001-7648-883X; Innis, Bruce/0000-0002-1753-7248; Franco, Eduardo/0000-0002-4409-8084				Baay MFD, 1996, J CLIN MICROBIOL, V34, P745, DOI 10.1128/JCM.34.3.745-747.1996; Bosch F Xavier, 2003, J Natl Cancer Inst Monogr, P3; Bosch F Xavier, 2002, Curr Oncol Rep, V4, P175, DOI 10.1007/s11912-002-0079-y; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Clifford GM, 2003, BRIT J CANCER, V89, P101, DOI 10.1038/sj.bjc.6601024; Clifford GM, 2003, BRIT J CANCER, V88, P63, DOI 10.1038/sj.bjc.6600688; *DEP HLTH HUM SERV, PREV GEN HPV INF SEQ; Franco EL, 2001, CAN MED ASSOC J, V164, P1017; Galloway DA, 2003, LANCET INFECT DIS, V3, P469, DOI 10.1016/S1473-3099(03)00720-5; Goldie SJ, 2003, INT J CANCER, V106, P896, DOI 10.1002/ijc.11334; Harper Diane M, 2003, Ann Fam Med, V1, P221, DOI 10.1370/afm.90; Harper DM, 2002, AM J OBSTET GYNECOL, V186, P365, DOI 10.1067/mob.2002.121076; Harro CD, 2001, JNCI-J NATL CANCER I, V93, P284, DOI 10.1093/jnci/93.4.284; Jansen KU, 2004, ANNU REV MED, V55, P319, DOI 10.1146/annurev.med.55.091902.103520; Kleter B, 1998, AM J PATHOL, V153, P1731, DOI 10.1016/S0002-9440(10)65688-X; Kleter B, 1999, J CLIN MICROBIOL, V37, P2508, DOI 10.1128/JCM.37.8.2508-2517.1999; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lowy Douglas R, 2003, J Natl Cancer Inst Monogr, P111; Mandic A, 2004, ANN ONCOL, V15, P197, DOI 10.1093/annonc/mdh043; Moscicki AB, 2004, J INFECT DIS, V190, P37, DOI 10.1086/421467; Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Quint WGV, 2001, J PATHOL, V194, P51, DOI 10.1002/path.855; Richardson H, 2003, CANCER EPIDEM BIOMAR, V12, P485; Schiffman M, 2003, ARCH PATHOL LAB MED, V127, P930; Schiller J T, 2001, J Natl Cancer Inst Monogr, P50; Schlecht NF, 2003, AM J EPIDEMIOL, V158, P878, DOI 10.1093/aje/kwg235; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; Ulrich J T, 1995, Pharm Biotechnol, V6, P495; van Doorn LJ, 2002, J CLIN MICROBIOL, V40, P979, DOI 10.1128/JCM.40.3.979-983.2002; Vogel FR, 2000, CLIN INFECT DIS, V30, pS266, DOI 10.1086/313883; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wheeler CM, 1996, OBSTET GYNECOL, V88, P261, DOI 10.1016/0029-7844(96)00120-2; Woodman CBJ, 2003, LANCET, V361, P40, DOI 10.1016/S0140-6736(03)12120-4; Yang BH, 2004, INT J CANCER, V109, P418, DOI 10.1002/ijc.11719	38	1175	1284	6	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1757	1765		10.1016/S0140-6736(04)17398-4	http://dx.doi.org/10.1016/S0140-6736(04)17398-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541448				2022-12-28	WOS:000225070600028
J	Harries, AD; Libamba, E; Schouten, EJ; Mwansambo, A; Salaniponi, FM; Mpazanje, R				Harries, AD; Libamba, E; Schouten, EJ; Mwansambo, A; Salaniponi, FM; Mpazanje, R			Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Minist Hlth, HIV AIDS Unit, Lilongwe, Malawi; Minist Hlth, Natl TB Control Programme, Lilongwe, Malawi; Minist Hlth, Dept Clin Serv, Lilongwe, Malawi; Natl AIDS Commiss, Lilongwe, Malawi		Harries, AD (corresponding author), Minist Hlth, HIV AIDS Unit, POB 30377, Lilongwe, Malawi.	adharries@malawi.net						Banerjee A, 2000, INT J TUBERC LUNG D, V4, P333; Chimzizi R, 2004, REPORT COUNTRY WIDE; Harries AD, 2001, LANCET, V358, P410, DOI 10.1016/S0140-6736(01)05551-9; Lee JW, 2003, LANCET, V362, P2083, DOI 10.1016/S0140-6736(03)15107-0; Liechty CA, 2003, AIDS, V17, P1383, DOI 10.1097/00002030-200306130-00013; Manders AJE, 2001, INT J TUBERC LUNG D, V5, P838; *MIN HLTH POP, 2002, MAN NAT TUB CONTR PR; *MIN HLTH POP, 2001, MAL NAT HLTH ACC BRO; Mitty JA, 2002, CLIN INFECT DIS, V34, P984, DOI 10.1086/339447; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; *NAT AIDS COMM, 2003, NAT EST HIV AIDS MAL; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Stevens W, 2004, BMJ-BRIT MED J, V328, P280, DOI 10.1136/bmj.328.7434.280; *UNAIDS WHO, 2003, AIDS EP UPD; Warndorff DK, 2000, INT J TUBERC LUNG D, V4, P752; *WHO, 2004, WHOHTMTB2004331; World Health Organization, 2003, TREATM TUB GUID NAT; World Health Organization, 2003, SCAL ANT THER RES LT	18	38	38	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1163	1166		10.1136/bmj.329.7475.1163	http://dx.doi.org/10.1136/bmj.329.7475.1163			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539674	Green Accepted, Green Published			2022-12-28	WOS:000225169600027
J	Pal, U; Li, X; Wang, T; Montgomery, RR; Ramamoorthi, N; deSilva, AM; Bao, FK; Yang, XF; Pypaert, M; Pradhan, D; Kantor, FS; Telford, S; Anderson, JF; Fikrig, E				Pal, U; Li, X; Wang, T; Montgomery, RR; Ramamoorthi, N; deSilva, AM; Bao, FK; Yang, XF; Pypaert, M; Pradhan, D; Kantor, FS; Telford, S; Anderson, JF; Fikrig, E			TROSPA, an Ixodues scapularis receptor for Borrelia burgdorferi	CELL			English	Article							LYME-DISEASE SPIROCHETE; SURFACE PROTEIN-A; TICKS; INFECTION; PATHOGENS	The Lyme disease agent Borrelia burgdorferi naturally persists in a cycle that primarily involves ticks and mammals. We have now identified a tick receptor (TROSPA) that is required for spirochetal colonization of Ixodes scapularis. B. burgdorferi outer surface protein A, which is abundantly expressed on spirochetes within the arthropod and essential for pathogen adherence to the vector, specifically bound to TROSPA. TROSPA mRNA levels in ticks increased following spirochete infestation and decreased in response to engorgement, events that are temporally linked to B. burgdorferi entry into and egress from the vector. The blockade of TROSPA by TROSPA antisera or by the repression of TROSPA expression via RNA interference reduced B. burgdorferi adherence to the L scapularis gut in vivo, thereby preventing efficient colonization of the vector and subsequently reducing pathogen transmission to the mammalian host. Identification of an I. scapularis receptor for B. burgdorferi is the first step toward elucidating arthropod ligands that are required for survival of spirochetes in nature.	Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, Sect Allergy & Immunol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA; Harvard Univ, Sch Publ Hlth, Dept Trop Publ Hlth, Boston, MA 02115 USA; Connecticut Agr Expt Stn, Dept Entomol, New Haven, CT 06504 USA	Yale University; Yale University; Yale University; Yale University; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Harvard T.H. Chan School of Public Health; Connecticut Agricultural Experiment Station	Fikrig, E (corresponding author), Yale Univ, Sch Med, Rheumatol Sect, New Haven, CT 06520 USA.	erol.fikrig@yale.edu	Pradhan, Debabrata/W-5476-2019; Yang, X. Frank/F-3266-2010; desilva, Aravinda/ABE-6260-2020; Pal, Utpal/I-5265-2015; Li, Xin/E-3505-2011	Pradhan, Debabrata/0000-0003-4995-6882; desilva, Aravinda/0000-0003-3317-5950; Li, Xin/0000-0002-7270-3480; Montgomery, Ruth/0000-0002-8661-4454				Das S, 2001, J INFECT DIS, V184, P1056, DOI 10.1086/323351; DESILVA AM, 1995, AM J TROP MED HYG, V53, P397, DOI 10.4269/ajtmh.1995.53.397; deSilva AM, 1996, J EXP MED, V183, P271, DOI 10.1084/jem.183.1.271; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Grimm D, 2004, P NATL ACAD SCI USA, V101, P3142, DOI 10.1073/pnas.0306845101; Guo BP, 1998, MOL MICROBIOL, V30, P711, DOI 10.1046/j.1365-2958.1998.01103.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MALAWISTA SE, 2000, ARTHRITIS ALLIED CON, P2321; MUNDERLOH UG, 1995, ANNU REV ENTOMOL, V40, P221, DOI 10.1146/annurev.en.40.010195.001253; Nadelman RB, 1998, LANCET, V352, P557, DOI 10.1016/S0140-6736(98)01146-5; Narasimhan S, 2004, P NATL ACAD SCI USA, V101, P1141, DOI 10.1073/pnas.0307669100; Ohnishi J, 2001, P NATL ACAD SCI USA, V98, P670, DOI 10.1073/pnas.98.2.670; Pal U, 2000, J CLIN INVEST, V106, P561, DOI 10.1172/JCI9427; Pal U, 2004, J CLIN INVEST, V113, P220, DOI 10.1172/JCI200419894; Pal U, 2001, J IMMUNOL, V166, P7398, DOI 10.4049/jimmunol.166.12.7398; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Sauer J.R.a.H., 1986, MORPHOLOGY PHYSL BIO, V1; Schwan TG, 2000, J CLIN MICROBIOL, V38, P382; Sonenshine D.E, 1993, BIOL TICKS, V1; Steere AC, 2004, J CLIN INVEST, V113, P1093, DOI [10.1172/JCI200421681, 10.1172/JCI21681]; Steere AC, 2001, NEW ENGL J MED, V345, P115, DOI 10.1056/NEJM200107123450207; Yang XFF, 2004, J EXP MED, V199, P641, DOI 10.1084/jem.20031960	23	302	317	2	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					457	468		10.1016/j.cell.2004.10.027	http://dx.doi.org/10.1016/j.cell.2004.10.027			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537536	Bronze			2022-12-28	WOS:000225183200005
J	Tibbetts, EA; Dale, J				Tibbetts, EA; Dale, J			A socially enforced signal of quality in a paper wasp	NATURE			English	Article							INDIVIDUAL IDENTITY; PLUMAGE VARIABILITY; SPARROWS; SIZE; BADGES; COST	Organisms use signals of quality to communicate information about aspects of their relative phenotypic and genetic constitution(1-4). Badges of status(5-7) are a subset of signals of quality that reveal information about an individual's size and dominance. In general, signals of quality require high and differential costs to remain honest(1,2) (that is, prevent low-quality cheaters from exploiting any fitness benefits associated with communicating high quality). The theoretically required costs for badges of status remain controversial because the development (or 'production') of such signals often seems to be relatively cost-free(5,6,8). One important hypothesis is that such signals impose social (or 'maintenance') costs incurred through repeated agonistic interactions with other individuals(9-12). However, convincing empirical evidence for social costs remains elusive(6,7). Here we report social costs in a previously undescribed badge of status: the highly variable black facial patterns of female paper wasps, Polistes dominulus. Facial patterns strongly predict body size and social dominance. Moreover, in staged contests between pairs of unfamiliar wasps, subordinate wasps with experimentally altered facial features ('cheaters') received considerably more aggression from the dominant than did sham controls, indicating that facial patterns are signals and that dishonest signalling imposes social costs.	Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA; Univ Arizona, Ctr Insect Sci, Tucson, AZ 85721 USA; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Simon Fraser Univ, Dept Biol Sci, Burnaby, BC V5A 1S6, Canada	Cornell University; University of Arizona; University of Arizona; Simon Fraser University	Tibbetts, EA (corresponding author), Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA.	eat11@email.arizona.edu	Dale, James/E-7203-2011	Dale, James/0000-0001-5950-5829; Tibbetts, Elizabeth/0000-0002-5625-892X				Andersson Malte, 1994; BALPH MH, 1979, AUK, V96, P78; CLUTTONBROCK TH, 1995, NATURE, V373, P209, DOI 10.1038/373209a0; COLE BJ, 1986, BEHAV ECOL SOCIOBIOL, V18, P165, DOI 10.1007/BF00290820; Dale J, 2001, AM NAT, V158, P75, DOI 10.1086/320861; EICKWORT KR, 1969, EVOLUTION, V23, P391, DOI 10.1111/j.1558-5646.1969.tb03523.x; Gobin B, 2003, J INSECT PHYSIOL, V49, P747, DOI 10.1016/S0022-1910(03)00111-2; GRAFEN A, 1990, J THEOR BIOL, V144, P517, DOI 10.1016/S0022-5193(05)80088-8; HOLBERTON RL, 1989, ANIM BEHAV, V37, P681, DOI 10.1016/0003-3472(89)90047-X; HORRIDGE GA, 1995, J INSECT PHYSIOL, V41, P681, DOI 10.1016/0022-1910(95)00021-L; JOHNSTONE RA, 1993, BEHAV ECOL SOCIOBIOL, V32, P127, DOI 10.1007/BF00164045; McGraw KJ, 2003, BEHAV ECOL SOCIOBIOL, V53, P116, DOI 10.1007/s00265-002-0558-z; OWENS IPF, 1991, AM NAT, V138, P1187, DOI 10.1086/285277; Part T, 1997, ANIM BEHAV, V54, P893, DOI 10.1006/anbe.1997.0514; Pereboom JJM, 2003, OECOLOGIA, V137, P42, DOI 10.1007/s00442-003-1324-2; Pryke SR, 2003, BEHAV ECOL SOCIOBIOL, V53, P393, DOI 10.1007/s00265-003-0587-2; Reeve H.K., 1991, P99; ROHWER S, 1975, EVOLUTION, V29, P593, DOI 10.1111/j.1558-5646.1975.tb00853.x; ROHWER S, 1978, ANIM BEHAV, V26, P1012, DOI 10.1016/0003-3472(78)90090-8; Roseler P.-F., 1991, P309; Senar JC., 1999, P INT ORNITHOLOGICAL, V22, P1669; SHIELDS WM, 1977, EVOLUTION, V31, P905, DOI 10.1111/j.1558-5646.1977.tb01086.x; Sledge MF, 2001, BEHAV ECOL SOCIOBIOL, V49, P401, DOI 10.1007/s002650000311; SMITH JM, 1988, PHILOS T ROY SOC B, V319, P557, DOI 10.1098/rstb.1988.0065; Strassmann Joan E., 1996, P190; Tibbetts EA, 2002, P ROY SOC B-BIOL SCI, V269, P1423, DOI 10.1098/rspb.2002.2031; WATT DJ, 1986, ANIM BEHAV, V34, P1, DOI 10.1016/0003-3472(86)90001-1; WHITFIELD DP, 1987, TRENDS ECOL EVOL, V2, P13; Whiting MJ, 2003, LIZARD SOCIAL BEHAVIOR, P47; ZAHAVI A, 1975, J THEOR BIOL, V53, P205, DOI 10.1016/0022-5193(75)90111-3	30	301	309	3	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					218	222		10.1038/nature02949	http://dx.doi.org/10.1038/nature02949			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538369				2022-12-28	WOS:000225020200046
J	Grandi, P; Palumb, GGC				Grandi, P; Palumb, GGC			Jet and accretion-disk emission untangled in 3C 273	SCIENCE			English	Article							X-RAY-SPECTRA; ACTIVE GALACTIC NUCLEI; QUASI-SIMULTANEOUS OBSERVATIONS; COMPTON REFLECTION; CONTINUUM EMISSION; BEPPOSAX; 3C-273; GALAXIES; ROSAT; 3C273	A long-term spectral variability study of 3C 273 on data obtained by BeppoSAX allows us to decouple the beamed nonthermal (jet) and unbeamed thermal (accretion flow) radiation produced in the inner region of a radio-loud active galactic nucleus. jet power, when compared with unbeamed radiation, increases with energy. The thermal component is generally overwhelmed by the nonthermal radiation, by a factor of 1.2 to 3 in the 2- to 10-keV range and up to a factor of 7 above 20 keV. In only one case, the accretion flow overcomes the jet, allowing the Kalpha iron line to emerge clearly over the continuum.	Ist Astrofis Spaziale & Fis Cosm, Consiglio Nazl Ric, Ist Nazl Astrofis, Sez Bologna, I-40129 Bologna, Italy; Univ Bologna, Dipartimento Astron, I-40127 Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Bologna	Grandi, P (corresponding author), Ist Astrofis Spaziale & Fis Cosm, Consiglio Nazl Ric, Ist Nazl Astrofis, Sez Bologna, Via Gobetti 101, I-40129 Bologna, Italy.	grandi@bo.iasf.cnr.it		Grandi, Paola/0000-0003-1848-6013				Arnaud KA, 1996, ASTR SOC P, V101, P17; Boella G, 1997, ASTRON ASTROPHYS SUP, V122, P299, DOI 10.1051/aas:1997136; BUHLER P, 1995, ASTRON ASTROPHYS, V295, P309; Cappi M, 1998, PUBL ASTRON SOC JPN, V50, P213, DOI 10.1093/pasj/50.2.213; COURVOISIER TJL, 1987, ASTRON ASTROPHYS, V176, P197; Dovciak M, 2004, MON NOT R ASTRON SOC, V350, P745, DOI 10.1111/j.1365-2966.2004.07683.x; Fiore F., 1999, COOKBOOK BEPPOSAX NF; Grandi P, 1997, ASTRON ASTROPHYS, V325, pL17; GRANDI P, 1990, 3C 273 BEPPOSAX ASCA; HAARDT F, 1993, ASTROPHYS J, V413, P507, DOI 10.1086/173020; Haardt F, 1998, ASTRON ASTROPHYS, V340, P35; Kataoka J, 2002, MON NOT R ASTRON SOC, V336, P932, DOI 10.1046/j.1365-8711.2002.05845.x; Lawson AJ, 1997, MON NOT R ASTRON SOC, V288, P920, DOI 10.1093/mnras/288.4.920; LEACH CM, 1995, MON NOT R ASTRON SOC, V272, P221, DOI 10.1093/mnras/272.1.221; LICHTI GG, 1995, ASTRON ASTROPHYS, V298, P711; MAGDZIARZ P, 1995, MON NOT R ASTRON SOC, V273, P837, DOI 10.1093/mnras/273.3.837; Maraschi L, 1991, APJ, V380, P51, DOI DOI 10.1086/186171; MASNOU JL, 1992, ASTRON ASTROPHYS, V253, P35; Orr A, 1998, ASTRON ASTROPHYS, V337, P685; Page KL, 2004, MON NOT R ASTRON SOC, V349, P57, DOI 10.1111/j.1365-2966.2004.07499.x; Perola GC, 2002, ASTRON ASTROPHYS, V389, P802, DOI 10.1051/0004-6361:20020658; Poutanen J, 1996, ASTROPHYS J, V470, P249, DOI 10.1086/177865; Reeves JN, 2000, MON NOT R ASTRON SOC, V316, P234, DOI 10.1046/j.1365-8711.2000.03510.x; SHAKURA NI, 1973, ASTRON ASTROPHYS, V24, P337; TURNER MJL, 1990, MON NOT R ASTRON SOC, V244, P310; TURNER TJ, 1991, ASTROPHYS J, V381, P85, DOI 10.1086/170631; ULRICH MH, 1988, ASTRON ASTROPHYS, V204, P21; WALTER R, 1994, ASTRON ASTROPHYS, V285, P119; WILKES BJ, 1987, ASTROPHYS J, V323, P243, DOI 10.1086/165822; WILLIAMS OR, 1992, ASTROPHYS J, V389, P157, DOI 10.1086/171194; Yaqoob T, 2000, ASTROPHYS J, V544, pL95, DOI 10.1086/317318	32	82	82	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2004	306	5698					998	1002		10.1126/science.1101787	http://dx.doi.org/10.1126/science.1101787			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528437				2022-12-28	WOS:000225001100033
J	Kusch, T; Florens, L; MacDonald, WH; Swanson, SK; Glaser, RL; Yates, JR; Abmayr, SM; Washburn, MP; Workman, JL				Kusch, T; Florens, L; MacDonald, WH; Swanson, SK; Glaser, RL; Yates, JR; Abmayr, SM; Washburn, MP; Workman, JL			Acetylation by Tip60 is required for selective histone variant exchange at DNA lesions	SCIENCE			English	Article							ACETYLTRANSFERASE COMPLEX; REPAIR; CHROMATIN; DAMAGE; NUCLEOSOME; H2A; APOPTOSIS; YEAST	Phosphorylation of the human histone variant H2A.X and H2Av, its homolog in Drosophila melanogaster, occurs rapidly at sites of DNA double-strand breaks. Little is known about the function of this phosphorylation or its removal during DNA repair. Here, we demonstrate that the Drosophila Tip60 (dTip60) chromatin-remodeling complex acetylates nucleosomal phospho-H2Av and exchanges it with an unmodified H2Av. Both the histone a cetyltransfe rase dTip60 as well as the adenosine triphosphatase Domino/p400 catalyze the exchange of phospho-H2Av. Thus, these data reveal a previously unknown mechanism for selective histone exchange that uses the concerted action of two distinct chromatin-remodeling enzymes within the same multiprotein complex.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	Stowers Institute for Medical Research; Scripps Research Institute; State University of New York (SUNY) System; Wadsworth Center	Kusch, T (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	tnk@stowers-institute.org; jlw@stowers-institute.org		Washburn, Michael/0000-0001-7568-2585; Florens, Laurence/0000-0002-9310-6650				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Allard S, 2004, BBA-GENE STRUCT EXPR, V1677, P158, DOI 10.1016/j.bbaexp.2003.10.016; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Choy JS, 2002, MOL CELL BIOL, V22, P8215, DOI 10.1128/MCB.22.23.8215-8225.2002; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Fernandez-Capetillo O, 2003, CELL CYCLE, V2, P426, DOI 10.4161/cc.2.5.509; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Kusch T, 2003, MOL CELL BIOL, V23, P3305, DOI 10.1128/MCB.23.9.3305-3319.2003; KUSCH T, UNPUB; Langst G, 2004, BBA-GENE STRUCT EXPR, V1677, P58, DOI 10.1016/j.bbaexp.2003.10.011; Lusser A, 2003, BIOESSAYS, V25, P1192, DOI 10.1002/bies.10359; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Malik HS, 2003, NAT STRUCT BIOL, V10, P882, DOI 10.1038/nsb996; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Redon C, 2003, EMBO REP, V4, P678, DOI 10.1038/sj.embor.embor871; Scherthan H, 2003, CYTOGENET GENOME RES, V103, P235, DOI 10.1159/000076809; Sedelnikova OA, 2003, CANCER BIOL THER, V2, P233; Wang Yanming, 2004, Novartis Found Symp, V259, P3	28	519	544	5	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2004	306	5704					2084	2087		10.1126/science.1103455	http://dx.doi.org/10.1126/science.1103455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881CM	15528408				2022-12-28	WOS:000225841000060
J	Flo, TH; Smith, KD; Sato, S; Rodriguez, DJ; Holmes, MA; Strong, RK; Akira, S; Aderem, A				Flo, TH; Smith, KD; Sato, S; Rodriguez, DJ; Holmes, MA; Strong, RK; Akira, S; Aderem, A			Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron	NATURE			English	Article							HUMAN NEUTROPHIL GELATINASE; ACUTE-PHASE PROTEIN; TOLL-LIKE RECEPTORS; PATTERN-RECOGNITION; MOUSE; ACQUISITION; UTEROCALIN; NGAL	Although iron is required to sustain life, its free concentration and metabolism have to be tightly regulated(1). This is achieved through a variety of iron-binding proteins including transferrin and ferritin(2). During infection, bacteria acquire much of their iron from the host by synthesizing siderophores that scavenge iron and transport it into the pathogen(3,4). We recently demonstrated that enterochelin, a bacterial catecholate siderophore, binds to the host protein lipocalin 2 (ref. 5). Here, we show that this event is pivotal in the innate immune response to bacterial infection. Upon encountering invading bacteria the Toll-like receptors on immune cells stimulate the transcription, translation and secretion of lipocalin 2; secreted lipocalin 2 then limits bacterial growth by sequestrating the iron-laden siderophore. Our finding represents a new component of the innate immune system and the acute phase response to infection.	Inst Syst Biol, Seattle, WA 98103 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Med, N-7489 Trondheim, Norway; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Japan Sci & Technol Corp, ERATO, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Host Def, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Institute for Systems Biology (ISB); Norwegian University of Science & Technology (NTNU); University of Washington; University of Washington Seattle; Japan Science & Technology Agency (JST); Osaka University; Fred Hutchinson Cancer Center	Aderem, A (corresponding author), Inst Syst Biol, Seattle, WA 98103 USA.	aaderem@systemsbiology.org	Akira, Shizuo/C-3134-2009; Flo, Trude Helen/E-1311-2013	Flo, Trude Helen/0000-0002-2569-0381; Sato, Shintaro/0000-0001-5156-3354				Andrews NC, 2000, NAT REV GENET, V1, P208, DOI 10.1038/35042073; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; Goetz DH, 2002, MOL CELL, V10, P1033, DOI 10.1016/S1097-2765(02)00708-6; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hou ZG, 1997, INORG CHIM ACTA, V263, P341, DOI 10.1016/S0020-1693(97)05664-8; Kjeldsen L, 2000, BBA-PROTEIN STRUCT M, V1482, P272, DOI 10.1016/S0167-4838(00)00152-7; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Liu QS, 1997, MOL REPROD DEV, V46, P507, DOI 10.1002/(SICI)1098-2795(199704)46:4&lt;507::AID-MRD9&gt;3.0.CO;2-S; LIU QS, 1995, J BIOL CHEM, V270, P22565, DOI 10.1074/jbc.270.38.22565; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Suire S, 2001, BIOCHEM J, V356, P369, DOI 10.1042/0264-6021:3560369; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; TRIEBEL S, 1992, FEBS LETT, V314, P386, DOI 10.1016/0014-5793(92)81511-J; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; Winkelmann G, 2002, BIOCHEM SOC T, V30, P691, DOI 10.1042/BST0300691; Xu SY, 2000, BBA-PROTEIN STRUCT M, V1482, P298, DOI 10.1016/S0167-4838(00)00163-1; Yang J, 2002, MOL CELL, V10, P1045, DOI 10.1016/S1097-2765(02)00710-4	24	1278	1330	5	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	2004	432	7019					917	921		10.1038/nature03104	http://dx.doi.org/10.1038/nature03104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	879QY	15531878				2022-12-28	WOS:000225733500057
J	Egan, KM; Lawson, JA; Fries, S; Koller, B; Rader, DJ; Smyth, EM; FitzGerald, GA				Egan, KM; Lawson, JA; Fries, S; Koller, B; Rader, DJ; Smyth, EM; FitzGerald, GA			COX-2-derived prostacyclin confers atheroprotection on female mice	SCIENCE			English	Article							NITRIC-OXIDE; IN-VIVO; ATHEROSCLEROSIS; DEFICIENT; ROLES; 17-BETA-ESTRADIOL; CYCLOOXYGENASE-2; SUPEROXIDE; LACKING	Female gender affords relative protection from cardiovascular disease until the menopause. We report that estrogen acts on estrogen receptor subtype alpha to up-regulate the production of atheroprotective prostacyclin, PGI(2), by activation of cyclooxygenase 2 (COX-2). This mechanism restrained both oxidant stress and platelet activation that contribute to atherogenesis in female mice. Deletion of the PGI(2) receptor removed the atheroprotective effect of estrogen in ovariectomized female mice. This suggests that chronic treatment of patients with selective inhibitors of COX-2 could undermine protection from cardiovascular disease in premenopausal females.	Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of Pennsylvania; Pennsylvania Medicine; University of North Carolina; University of North Carolina Chapel Hill	FitzGerald, GA (corresponding author), Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	FitzGerald, Garret A/A-4222-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, P50HL070128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62250, HL70128] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akarasereenont P, 2000, INFLAMM RES, V49, P460, DOI 10.1007/s000110050617; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GRYGLEWSKI RJ, 1995, ANN NY ACAD SCI, V748, P194; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; Kobayashi T, 2004, J CLIN INVEST, V114, P784, DOI 10.1172/JCI200421446; KOWALA MC, 1993, ARTERIOSCLER THROMB, V13, P435, DOI 10.1161/01.ATV.13.3.435; Malamas MS, 2004, J MED CHEM, V47, P5021, DOI 10.1021/jm049719y; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Munzel T, 2002, ARTERIOSCL THROM VAS, V22, P1761, DOI 10.1161/01.ATV.0000034022.11764.EC; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; SINZINGER H, 1979, THROMB HAEMOSTASIS, V42, P803; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Xiao CY, 2001, CIRCULATION, V104, P2210, DOI 10.1161/hc4301.098058; ZHONGHUA Q, 2002, J CLIN INVEST, V110, P61; ZHONGHUA Q, 2002, J CLIN INVEST, V110, P1	22	337	370	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2004	306	5703					1954	1957		10.1126/science.1103333	http://dx.doi.org/10.1126/science.1103333			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	879DC	15550624				2022-12-28	WOS:000225695600050
J	Schlessinger, J				Schlessinger, J			Common and distinct elements in cellular signaling via EGF and FGF receptors	SCIENCE			English	Article							DOCKING-PROTEIN FRS2-ALPHA; FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASES; MECHANISM; PATHWAYS; BINDING	Signaling pathways that are activated by epidermal growth factor (EGF) or fibroblast growth factor (FGF) receptors have been identified and compared (detailed Connections Maps are available at Science's Signal Transduction Knowledge Environment). Both receptors stimulate a similar complement of intracellular signaling pathways. However, whereas activated EGF receptors (EGFRs) function as the main platform for recruitment of signaling proteins, signaling through the FGF receptors (FGFRs) is mediated primarily by assembly of a multidocking protein complex. Moreover, FGFR signaling is subject to additional intracellular and extracellular control mechanisms that do not affect EGFR signaling. The differential circuitry of the intracellular networks that are activated by EGFR and FGFR may affect signal specificity and physiological responses.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Schlessinger, J (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	joseph.schlessinger@yale.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051448] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR051448-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; COCHET C, 1984, J BIOL CHEM, V259, P2553; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Lamothe B, 2004, MOL CELL BIOL, V24, P5657, DOI 10.1128/MCB.24.13.5657-5666.2004; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SCHLESSINGER J, 2004, SCI STKE         NOV; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wong A, 2002, P NATL ACAD SCI USA, V99, P6684, DOI 10.1073/pnas.052138899	21	345	363	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1506	1507		10.1126/science.1105396	http://dx.doi.org/10.1126/science.1105396			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567848				2022-12-28	WOS:000225442700042
J	Nomura, K; Ohta, H; Takagi, A; Kamiya, T; Hirano, M; Hosono, H				Nomura, K; Ohta, H; Takagi, A; Kamiya, T; Hirano, M; Hosono, H			Room-temperature fabrication of transparent flexible thin-film transistors using amorphous oxide semiconductors	NATURE			English	Article								Transparent electronic devices formed on flexible substrates are expected to meet emerging technological demands where silicon-based electronics cannot provide a solution. Examples of active flexible applications include paper displays and wearable computers(1). So far, mainly flexible devices based on hydrogenated amorphous silicon (a-Si:H)(2-5) and organic semiconductors(2,6-10) have been investigated. However, the performance of these devices has been insufficient for use as transistors in practical computers and current-driven organic light-emitting diode displays. Fabricating high-performance devices is challenging, owing to a trade-off between processing temperature and device performance. Here, we propose to solve this problem by using a novel semiconducting material-namely, a transparent amorphous oxide semiconductor from the In-Ga-Zn-O system (a-IGZO)-for the active channel in transparent thin-film transistors (TTFTs). The a-IGZO is deposited on polyethylene terephthalate at room temperature and exhibits Hall effect mobilities exceeding 10 cm(2) V-1 s(-1), which is an order of magnitude larger than for hydrogenated amorphous silicon. TTFTs fabricated on polyethylene terephthalate sheets exhibit saturation mobilities of 6-9 cm(2) V-1 s(-1), and device characteristics are stable during repetitive bending of the TTFT sheet.	Tokyo Inst Technol, ERATO, SORST, JST,Frontier Collaborat Res Ctr,Midori Ku, Yokohama, Kanagawa, Japan; Tokyo Inst Technol, Mat & Struct Lab, Midori Ku, Yokohama, Kanagawa 2268503, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Tokyo Institute of Technology	Hosono, H (corresponding author), Tokyo Inst Technol, ERATO, SORST, JST,Frontier Collaborat Res Ctr,Midori Ku, Mail Box S2-13,4259 Nagatsuta, Yokohama, Kanagawa, Japan.	hosono@msl.titech.ac.jp	Hosono, HIdeo/J-3489-2013; Hosono, Hideo/T-1845-2019; Kamiya, Toshio/E-8615-2014; Ohta, Hiromichi/ABB-7878-2021; 太田, 裕道/AAK-4915-2020; Ohta, Hiromichi/H-4468-2012	Hosono, HIdeo/0000-0001-9260-6728; Kamiya, Toshio/0000-0002-8358-240X; Ohta, Hiromichi/0000-0001-7013-0343; Ohta, Hiromichi/0000-0001-7013-0343				Carey PG, 1999, J VAC SCI TECHNOL A, V17, P1946, DOI 10.1116/1.581708; Choi HY, 2004, ADV MATER, V16, P732, DOI 10.1002/adma.200306244; Dimitrakopoulos CD, 2001, IBM J RES DEV, V45, P11, DOI 10.1147/rd.451.0011; Dimitrakopoulos CD, 2002, ADV MATER, V14, P99, DOI 10.1002/1521-4095(20020116)14:2<99::AID-ADMA99>3.0.CO;2-9; Hosono H, 2004, INT J APPL CERAM TEC, V1, P106; Hosono H, 1996, J NON-CRYST SOLIDS, V200, P165, DOI 10.1016/0022-3093(96)80019-6; Huitema HEA, 2001, NATURE, V414, P599, DOI 10.1038/414599a; Kawazoe H, 1997, NATURE, V389, P939, DOI 10.1038/40087; KUO Y, 2004, THIN FILM TRANSISTOR; Kwo J, 2001, J APPL PHYS, V89, P3920, DOI 10.1063/1.1352688; Lee JH, 2003, SYNTHETIC MET, V139, P445, DOI 10.1016/S0379-6779(03)00197-8; Madelung O., 2000, TECHNOLOGY APPL AMOR; Mitzi DB, 2003, THIN-FILM TRANSISTORS, P475; MOTT NF, 1977, ADV PHYS, V26, P363, DOI 10.1080/00018737700101413; Narushima S, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.035203; Narushima S, 2003, ADV MATER, V15, P1409, DOI 10.1002/adma.200304947; Nomura K, 2004, APPL PHYS LETT, V85, P1993, DOI 10.1063/1.1788897; Nomura K, 2003, SCIENCE, V300, P1269, DOI 10.1126/science.1083212; Ohta H, 2004, MATER TODAY, V7, P42, DOI 10.1016/S1369-7021(04)00288-3; Orita M, 2001, PHILOS MAG B, V81, P501, DOI 10.1080/13642810110045923; Shaw JM, 2001, IBM J RES DEV, V45, P3, DOI 10.1147/rd.451.0003; TAUT Y, 1988, FUNDAMENTALS MODERN; Thomas G, 1997, NATURE, V389, P907, DOI 10.1038/39999; Wager JF, 2003, SCIENCE, V300, P1245, DOI 10.1126/science.1085276; Wang SC, 2003, JPN J APPL PHYS 2, V42, pL1044, DOI 10.1143/JJAP.42.L1044; Yang CS, 2000, J VAC SCI TECHNOL B, V18, P683, DOI 10.1116/1.591259	26	5521	6643	111	3119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					488	492		10.1038/nature03090	http://dx.doi.org/10.1038/nature03090			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565150				2022-12-28	WOS:000225322100042
J	De Wals, P; Deceuninck, G; Boulianne, N; De Serres, G				De Wals, P; Deceuninck, G; Boulianne, N; De Serres, G			Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	11th International Congress on Infectious Diseases	MAR 04-07, 2004	Cancun, MEXICO				DISEASE	Context Meningococcal polysaccharide vaccines are of limited effectiveness. New protein-polysaccharide conjugate vaccines have yet to be evaluated in field conditions. Objective To assess the effectiveness of a serogroup C conjugate meningococcal vaccine in an outbreak setting. Design, Setting, and Participants Population-based observational study of cases of invasive serogroup C meningococcal disease from 1996 through 2002 in Quebec identified from the provincial registry of notifiable diseases and from the provincial reference laboratory. In 2001, a mass immunization campaign with a conjugate vaccine was conducted to control an emerging epidemic. The number of vaccinated individuals was extracted from meningococcal immunization registries. Main Outcome Measures Incidence of invasive meningococcal disease before and 1 year after the campaign in vaccinated and unvaccinated individuals. Results Vaccination coverage of those 2 months to 20 years was 82.1%. After the campaign, the number of cases of serogroup C disease decreased from 58 in 2001 to 27 in 2002, and the incidence from 7.8 per million to 3.6 per million. Vaccine effectiveness was found to be 96.8% (95% confidence interval, 75.0%-99.9%). There was no observed increase in the incidence of the other serogroups. Conclusion The new conjugate vaccine was effective in controlling an emerging epidemic of serogroup C meningococcal disease, as well as providing short-term protection across a wide age range.	Univ Laval, Dept Prevent & Social Med, Quebec City, PQ G1K 7P4, Canada; Univ Laval, Quebec Natl Publ Hlth Inst, Quebec City, PQ G1K 7P4, Canada; Univ Quebec, Ctr Hosp, Publ Hlth Res Unit, Quebec City, PQ, Canada	Laval University; Institut national de sante publique du Quebec (INSPQ); Laval University; Laval University; University of Quebec	De Wals, P (corresponding author), Univ Laval, Dept Prevent & Social Med, Pavillon Est,2180 Chemin St Foy, Quebec City, PQ G1K 7P4, Canada.	Philippe.De.Wals@ssss.gouv.qc.ca						ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; Borrow R, 2001, INFECT IMMUN, V69, P1568, DOI 10.1128/IAI.69.3.1568-1573.2001; Bose A, 2003, LANCET, V361, P675, DOI 10.1016/S0140-6736(03)12563-9; *CYTEL SOFTW CORP, 1999, STATXACT 4 WIND; De Wals P, 2001, JAMA-J AM MED ASSOC, V285, P177, DOI 10.1001/jama.285.2.177; DeWals P, 1996, B WORLD HEALTH ORGAN, V74, P407; DEWALS P, 2004, P 44 INT C ANT AG CH; FARRINGTON P, 2001, MENINGOCOCCAL VACCIN; Lavigne P, 1992, Can Commun Dis Rep, V18, P113; Miller E, 2001, VACCINE, V20, pS58, DOI 10.1016/S0264-410X(01)00299-7; *MIN SANT SERV SOC, 1994, PROT IINT INF MEN; *NAT ADV COMM IMM, 2001, CAN COMMUN DIS REP, V27, P2; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Rivest D, 1999, CAN J PUBLIC HEALTH, V90, P250, DOI 10.1007/BF03404126; Squires S G, 2004, Can Commun Dis Rep, V30, P17; Trotter CL, 2004, LANCET, V364, P365, DOI 10.1016/S0140-6736(04)16725-1; Tsang RSW, 2003, CAN J MICROBIOL, V49, P633, DOI 10.1139/W03-074	17	71	73	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2491	2494		10.1001/jama.292.20.2491	http://dx.doi.org/10.1001/jama.292.20.2491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	873TD	15562128	Bronze			2022-12-28	WOS:000225303000024
J	Fox, CS; Coady, S; Sorlie, PD; Levy, D; Meigs, JB; D'Agostino, RB; Wilson, PWF; Savage, PJ				Fox, CS; Coady, S; Sorlie, PD; Levy, D; Meigs, JB; D'Agostino, RB; Wilson, PWF; Savage, PJ			Trends in cardiovascular complications of diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; ACUTE MYOCARDIAL-INFARCTION; UNITED-STATES; DEATH CERTIFICATES; TEMPORAL TRENDS; SEX-DIFFERENCES; MEDICAL-CARE; EVENT RATES; US ADULTS; MORTALITY	Context Despite reductions in cardiovascular disease (CVD) mortality over the past few decades, it is unclear whether adults with and without diabetes have experienced similar declines in CVD risk. Objective To determine whether adults with and without diabetes experienced similar declines in incident CVD in 1950-1995. Design, Setting, and Participants Participants aged 45-64 years from the Framingham Heart Study original and offspring cohorts who attended examinations in 1950-1966 ("earlier" time period; 4118 participants, 113 with diabetes) and 1977-1995 ("later" time period; 4063 participants, 317 with diabetes). Incidence rates of CVD among those with and without diabetes were compared between the earlier and later periods. Main Outcome Measures Myocardial infarction, coronary heart disease death, and stroke. Results Among participants with diabetes, the age- and sex-adjusted CVD incidence rate was 286.4 per 10000 person-years in the earlier period and 146.9 per 10000 in the later period, a 49.3% (95% confidence interval [Cl], 16.7%-69.4%) decline. Among participants without diabetes, the age- and sex-adjusted incidence rate was 84.6 per 10000 person-years in the earlier period and 54.3 per 10000 person-years in the later period, a 35.4% (95% Cl, 25.3%-45.4%) decline. Hazard ratios for diabetes as a predictor of incident CVD were not different in the earlier vs later periods. Conclusions We report a 50% reduction in the rate of incident CVD events among adults with diabetes, although the absolute risk of CVD is 2-fold greater than among persons without diabetes. Adults with and without diabetes have benefited similarly during the decline in CVD rates over the last several decades. More aggressive treatment of CVD risk factors and further research on diabetes-specific factors contributing to CVD, risk are needed to further reduce the high absolute risk of CVD still experienced by persons with diabetes.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; NHLBI, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Endocrinol Diabet & Hypertens, Boston, MA USA; Massachusetts Gen Hosp, Dept Med, Div Gen Med, Boston, MA 02114 USA; Boston Univ, Dept Math, Boston, MA 02215 USA; Med Univ S Carolina, Dept Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Boston University; Medical University of South Carolina	Fox, CS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	foxca@nhlbi.nih.gov	Meigs, James/P-3927-2019; Wilson, Peter W.F./J-2455-2016; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Meigs, James/0000-0002-2439-2657; Levy, Daniel/0000-0003-1843-8724	NHLBI NIH HHS [N01-HC-25195] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDRESEN EM, 1993, AM J PUBLIC HEALTH, V83, P1021, DOI 10.2105/AJPH.83.7.1021; [Anonymous], 2001, SAS STAT US GUID VER; BILD DE, 1992, J CLIN EPIDEMIOL, V45, P275, DOI 10.1016/0895-4356(92)90087-4; Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CUPPLES LA, 1987, NIH PUBLICATION; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Gaede P, 2003, NEW ENGL J MED, V348, P383, DOI 10.1056/NEJMoa021778; Gerstein HC, 2000, LANCET, V355, P253; GILLUM RF, 1983, NEW ENGL J MED, V309, P1353, DOI 10.1056/NEJM198312013092203; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Gu K, 1999, JAMA-J AM MED ASSOC, V281, P1291, DOI 10.1001/jama.281.14.1291; Guidry UC, 1999, CIRCULATION, V100, P2054, DOI 10.1161/01.CIR.100.20.2054; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hu FB, 2001, ARCH INTERN MED, V161, P1717, DOI 10.1001/archinte.161.14.1717; Kannel W B, 1979, Diabetes Care, V2, P120, DOI 10.2337/diacare.2.2.120; LIAO YL, 1993, DIABETES CARE, V16, P708, DOI 10.2337/diacare.16.5.708; Liu J, 2004, JAMA-J AM MED ASSOC, V291, P2591, DOI 10.1001/jama.291.21.2591; Lloyd-Jones DM, 1998, ANN INTERN MED, V129, P1020, DOI 10.7326/0003-4819-129-12-199812150-00005; Lotufo PA, 2001, ARCH INTERN MED, V161, P242, DOI 10.1001/archinte.161.2.242; Lundberg V, 1997, J INTERN MED, V241, P485; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; McGovern PG, 2001, CIRCULATION, V104, P19, DOI 10.1161/01.CIR.104.1.19; Miettinen H, 1998, DIABETES CARE, V21, P69, DOI 10.2337/diacare.21.1.69; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Mokdad AH, 2000, DIABETES CARE, V23, P1278, DOI 10.2337/diacare.23.9.1278; Mokdad AH, 2001, DIABETES CARE, V24, P412, DOI 10.2337/diacare.24.2.412; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Saaddine JB, 2002, ANN INTERN MED, V136, P565, DOI 10.7326/0003-4819-136-8-200204160-00005; Salomaa V, 1996, CIRCULATION, V94, P3130, DOI 10.1161/01.CIR.94.12.3130; SHURTLEFF D, 1973, DHEW PUBLICATION NIH; Sievers ML, 1996, DIABETES CARE, V19, P107, DOI 10.2337/diacare.19.2.107; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stovring H, 2003, LANCET, V362, P537, DOI 10.1016/S0140-6736(03)14116-5; Thomas RJ, 2003, ARCH INTERN MED, V163, P445, DOI 10.1001/archinte.163.4.445; Tunstall-Pedoe H, 2000, LANCET, V355, P688, DOI 10.1016/S0140-6736(99)11181-4; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254; 1992, MMWR MORB MORTAL WKL, V41, P556; 1997, MMWR MORB MORTAL WKL, V46, P146; 2003, MMWR MORB MORTAL WKL, V52, P1065; 1992, MMWR MORB MORTAL WKL, V41, P548	45	416	440	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2495	2499		10.1001/jama.292.20.2495	http://dx.doi.org/10.1001/jama.292.20.2495			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562129				2022-12-28	WOS:000225303000025
J	Pereira, MA; Swain, J; Goldfine, AB; Rifai, N; Ludwig, DS				Pereira, MA; Swain, J; Goldfine, AB; Rifai, N; Ludwig, DS			Effects of a low-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METABOLIC-RATE; INSULIN-RESISTANCE; LOW-CALORIE; NEUROENDOCRINE; PROTEIN; OBESITY; PLASMA; INDEX; HOMEOSTASIS; STARVATION	Context Weight loss elicits physiological adaptations relating to energy intake and expenditure that antagonize ongoing weight loss. Objective To test whether dietary composition affects the physiological adaptations to weight loss, as assessed by resting energy expenditure. Design, Study, and Participants A randomized parallel-design study of 39 overweight or obese young adults aged 18 to 40 years who received an energy-restricted diet, either low-glycemic load or low-fat. Participants were studied in the General Clinical Research Centers of the Brigham and Women's Hospital and the Children's Hospital, Boston, Mass, before and after 10% weight loss. The study was conducted from January 4, 2001, to May 6, 2003. Main Outcome Measures Resting energy expenditure measured in the fasting state by indirect calorimetry, body composition by dual-energy x-ray absorptiometry, cardiovascular disease risk factors, and self-reported hunger. Results Resting energy expenditure decreased less with the low-glycemic load diet than with the low-fat diet, expressed in absolute terms (mean [SE], 96 [24] vs 176 [27] kcal/d; P=.04) or as a proportion (5.9% [1.5%] vs 10.6% [1.7%]; P=.05). Participants receiving the low-glycemic load diet reported less hunger than those receiving the low-fat diet (P=.04). Insulin resistance (P=.01), serum triglycerides (P=.01), C-reactive protein (P=.03), and blood pressure (P=.07 for both systolic and diastolic) improved more with the low-glycemic load diet. Changes in body composition (fat and lean mass) in both groups were very similar (P=.85 and P=.45, respectively). Conclusions Changes in dietary composition within prevailing norms can affect physiological adaptations that defend body weight. Reduction in glycemic load may aid in the prevention or treatment of obesity, cardiovascular disease, and diabetes mellitus.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Gen Clin Res Ctr, Boston, MA 02115 USA; Joslin Diabet Ctr, Boston, MA 02215 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Joslin Diabetes Center, Inc.	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu	Biguzzi, Felipe A/E-4724-2015	Ludwig, David/0000-0003-3307-8544; Pereira, Mark/0000-0002-6704-5276	NCRR NIH HHS [M01 RR02172, M01 RR02635] Funding Source: Medline; NIDDK NIH HHS [R01 DK59240] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635, M01RR002172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus MSD, 2000, AM J CLIN NUTR, V71, P901; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Astrup A, 1999, AM J CLIN NUTR, V69, P1117; Brand-Miller JC, 2003, J NUTR, V133, P2728, DOI 10.1093/jn/133.9.2728; Chan JL, 2003, J CLIN INVEST, V111, P1409, DOI 10.1172/JCI200317490; DURRANT ML, 1980, BRIT J NUTR, V44, P275, DOI 10.1079/BJN19800042; Ebbeling C B, 2001, Adv Pediatr, V48, P179; ELLIOT DL, 1989, AM J CLIN NUTR, V49, P93, DOI 10.1093/ajcn/49.1.93; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fruehwald-Schultes B, 2000, METABOLISM, V49, P794, DOI 10.1053/meta.2000.6262; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Harris J. A., 1919, BIOMETRIC STUDY BASA, P279; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; Hirsch J, 1998, AM J CLIN NUTR, V67, p551S, DOI 10.1093/ajcn/67.3.551S; LAIRD N, 1983, AM STAT, V37, P329, DOI 10.2307/2682785; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; Ludwig DS, 2003, J NUTR, V133, P2695, DOI 10.1093/jn/133.9.2695; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; Luscombe ND, 2003, INT J OBESITY, V27, P582, DOI 10.1038/sj.ijo.0802270; Luscombe ND, 2002, DIABETES CARE, V25, P652, DOI 10.2337/diacare.25.4.652; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Pawlak D B, 2002, Obes Rev, V3, P235, DOI 10.1046/j.1467-789X.2002.00079.x; Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7; Pereira M A, 1997, Med Sci Sports Exerc, V29, pS1; Raben A, 2002, Obes Rev, V3, P245, DOI 10.1046/j.1467-789X.2002.00080.x; RATTAN S, 1989, INT J OBESITY, V13, P189; Ravussin E, 1999, INT J OBESITY, V23, P37, DOI 10.1038/sj.ijo.0800793; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Schwartz MW, 1997, NEW ENGL J MED, V336, P1802, DOI 10.1056/NEJM199706193362507; SOARES MJ, 1988, BRIT J NUTR, V60, P425, DOI 10.1079/BJN19880114; Weinsier RL, 2003, OBES RES, V11, P937, DOI 10.1038/oby.2003.129; Weinsier RL, 2000, AM J CLIN NUTR, V72, P1088; Westerterp KR, 1999, INT J OBESITY, V23, P287, DOI 10.1038/sj.ijo.0800810; YOSHIDA T, 1994, INT J OBESITY, V18, P345	39	222	232	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2004	292	20					2482	2490		10.1001/jama.292.20.2482	http://dx.doi.org/10.1001/jama.292.20.2482			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873TD	15562127	Bronze			2022-12-28	WOS:000225303000023
J	Chintu, C; Bhat, GJ; Walker, AS; Mulenga, V; Sinyinza, F; Lishimpi, K; Farrelly, L; Kaganson, N; Zumla, A; Gillespie, SH; Nunn, AJ; Gibb, DM				Chintu, C; Bhat, GJ; Walker, AS; Mulenga, V; Sinyinza, F; Lishimpi, K; Farrelly, L; Kaganson, N; Zumla, A; Gillespie, SH; Nunn, AJ; Gibb, DM		CHAP Trial Team	Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controled trial	LANCET			English	Article							PNEUMOCYSTIS-CARINII-PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; COTE-DIVOIRE; ABIDJAN; RESISTANCE; DISEASE; BURDEN	Background No trials of co-trimoxazole (trimethoprim-sulfamethoxazole) prophylaxis for HIV-infected adults or children have been done in areas with high levels of bacterial resistance to this antibiotic. We aimed to assess the efficacy of daily co-trimoxazole in such an area. Methods We did a double-blind randomised placebo-controlled trial in children aged 1-14 years with clinical features of HIV infection in Zambia. Primary outcomes were mortality and adverse events possibly related to treatment. Analysis was by intention to treat. Findings In October, 2003, the data and safety monitoring committee recommended early stopping of the trial. 541 children had been randomly assigned; seven were subsequently identified as HIV negative and excluded. After median follow-up of 19 months, 74 (28%) children in the co-trimoxazole group and 112 (42%) in the placebo group had died (hazard ratio [HR] 0.57 [95% Cl 0.43-0.77], p=0.0002). This benefit applied in children followed up beyond 12 months (n=320, HR 0.48 [0.27-0.84], test for heterogeneity p=0.60) and across all ages (test for heterogeneity p=0.82) and baseline CD4 counts (test for heterogeneity p=0.36). 16 (6%) children in the co-trimoxazole group had grade 3 or 4 adverse events compared with 18 (7%) in the placebo group. These events included rash (one placebo), and a neutrophil count on one occasion less than 0 . 5 X 10(9)/L (16 [6%] co-trimoxazole vs seven [3%] placebo, p=0.06). Pneumocystis carinii was identified by immunofluorescence in only one (placebo) of 73 nasopharyngeal aspirates from children with pneumonia. Interpretation Our results suggest that children of all ages with clinical features of HIV infection should receive cotrimoxazole prophylaxis in resource-poor settings, irrespective of local resistance to this drug.	MRC, Clin Trials Unit, London NW1 2DA, England; Univ Teaching Hosp, Lusaka, Zambia; UCL Royal Free & Univ Coll Med Sch, London, England	Medical Research Council Clinical Trials Unit; University of Zambia; University of London; University College London; UCL Medical School	Gibb, DM (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	d.gibb@ctu.mrc.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735; Gibb, Diana/0000-0002-9738-5490; Nunn, Andrew/0000-0002-9158-4595				Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; ANSARI NA, 1999, INT J TUBERC LUNG S1, V3, pS201; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Bortolotti W, 2002, AIDS, V16, P1309, DOI 10.1097/00002030-200207050-00002; Chintu C, 2002, LANCET, V360, P985, DOI 10.1016/S0140-6736(02)11082-8; FELKIN DR, 2000, J INFECT DIS, V181, P1501; FREEMAN JV, 1995, ARCH DIS CHILD, V73, P17, DOI 10.1136/adc.73.1.17; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Graham SM, 2000, LANCET, V355, P369, DOI 10.1016/S0140-6736(98)11074-7; Graham SM, 2002, LANCET, V360, P1966, DOI 10.1016/S0140-6736(02)11921-0; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; JONES JL, 1992, MMWR-MORBID MORTAL W, V48, P1; Lishimpi K, 2002, AIDS, V16, P932, DOI 10.1097/00002030-200204120-00017; Lucas SB, 1996, BRIT MED J, V312, P335, DOI 10.1136/bmj.312.7027.335; Madhi SA, 2000, CLIN INFECT DIS, V31, P170, DOI 10.1086/313925; MOFENSON LM, 1991, NEW ENGL J MED, V325, P73, DOI 10.1056/NEJM199107113250201; Mwansa J, 2002, EMERG INFECT DIS, V8, P92, DOI 10.3201/eid0801.010018; Nathoo KJ, 2001, T ROY SOC TROP MED H, V95, P37, DOI 10.1016/S0035-9203(01)90325-6; Ndhlovua Z, 2004, J TROP PEDIATRICS, V50, P94, DOI 10.1093/tropej/50.2.94; Olliaro PL, 1995, B WORLD HEALTH ORGAN, V73, P735; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POCOCK SJ, 1982, CLIN TRIALS PRACTICA, P213; Ruffini DD, 2002, AIDS, V16, P105, DOI 10.1097/00002030-200201040-00013; WADE AM, 1994, STAT MED, V13, P2359, DOI 10.1002/sim.4780132207; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization/UNAIDS, 2001, AFR HEALTH SCI, V1, P30; Zar HJ, 2000, PEDIATR INFECT DIS J, V19, P603, DOI 10.1097/00006454-200007000-00004	28	260	268	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1865	1871		10.1016/S0140-6736(04)17442-4	http://dx.doi.org/10.1016/S0140-6736(04)17442-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555666				2022-12-28	WOS:000225269300027
J	Braine, J; Herpin, F				Braine, J; Herpin, F			Molecular hydrogen beyond the optical edge of an isolated spiral galaxy	NATURE			English	Article							MILKY-WAY; GAS; CLOUDS; NGC-4414; ANATOMY; REGIONS; DUST; DISK; M31	Knowledge about the outermost portions of galaxies is limited owing to the small amount of light coming from them. It is known that in many cases atomic hydrogen (H I) extends well beyond the optical radius(1). In the centres of galaxies, however, molecular hydrogen (H-2) usually dominates by a large factor(2-4), raising the question of whether H-2 is also abundant in the outer regions. Here we report the detection of emission from carbon monoxide (CO), the most abundant tracer of H-2, beyond the optical radius of the nearby galaxy NGC 4414. The host molecular clouds probably formed in the regions of relatively high H I column density and in the absence of spiral density waves. The relative strength of the lines from the two lowest rotational levels indicates that both the temperature and density of the H-2 are quite low compared to conditions closer to the centre. The inferred surface density of the molecular material continues the monotonic decrease from the inner regions. We conclude that although molecular clouds can form in the outer region of this galaxy, there is little mass associated with them.	Observ Bordeaux, CNRS, UMR 5804, INSU, F-33270 Floirac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universite de Bordeaux	Braine, J (corresponding author), Observ Bordeaux, CNRS, UMR 5804, INSU, BP 89, F-33270 Floirac, France.	braine@obs.u-bordeaux1.fr						Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; BRAINE J, 1993, ASTRON ASTROPHYS SUP, V97, P887; BRAINE J, 1993, ASTRON ASTROPHYS, V280, P451; Braine J, 1997, ASTRON ASTROPHYS, V318, P19; Braun R, 1997, ASTROPHYS J, V484, P637, DOI 10.1086/304346; CASERTANO S, 1991, ASTRON J, V101, P1231, DOI 10.1086/115759; COMBES F, 1991, ANNU REV ASTRON ASTR, V29, P195, DOI 10.1146/annurev.aa.29.090191.001211; Cuillandre JC, 2001, ASTROPHYS J, V554, P190, DOI 10.1086/321358; DICKEY JM, 1993, ASTROPHYS J, V405, P153, DOI 10.1086/172348; DICKMAN RL, 1986, ASTROPHYS J, V309, P326, DOI 10.1086/164604; DIGEL S, 1994, ASTROPHYS J, V422, P92, DOI 10.1086/173706; Engargiola G, 2003, ASTROPHYS J SUPPL S, V149, P343, DOI 10.1086/379165; Heyer MH, 1998, ASTROPHYS J, V502, P265, DOI 10.1086/305881; PFENNIGER D, 1994, ASTRON ASTROPHYS, V285, P94; POGGE RW, 1989, ASTROPHYS J SUPPL S, V71, P433, DOI 10.1086/191381; Sodroski TJ, 1997, ASTROPHYS J, V480, P173, DOI 10.1086/303961; Spitzer L., 1978, PHYS PROCESSES INTER, V333; Thornley MD, 1996, ASTROPHYS J, V469, pL45, DOI 10.1086/310250; van Zee L, 1998, ASTRON J, V116, P2805, DOI 10.1086/300647; YOUNG JS, 1991, ANNU REV ASTRON ASTR, V29, P581, DOI 10.1146/annurev.aa.29.090191.003053	20	27	27	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					369	371		10.1038/nature03054	http://dx.doi.org/10.1038/nature03054			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549098				2022-12-28	WOS:000225161400048
J	Guerin, C; Gaillard, S; Lemasson, S; Ayzac, L; Girard, R; Beuret, P; Palmier, B; Le, QV; Sirodot, M; Rosselli, S; Cadiergue, V; Sainty, JM; Barbe, P; Combourieu, E; Debatty, D; Rouffineau, J; Ezingeard, E; Millet, O; Guelon, D; Rodriguez, L; Martin, O; Renault, A; Sibille, JP; Kaidomar, M				Guerin, C; Gaillard, S; Lemasson, S; Ayzac, L; Girard, R; Beuret, P; Palmier, B; Le, QV; Sirodot, M; Rosselli, S; Cadiergue, V; Sainty, JM; Barbe, P; Combourieu, E; Debatty, D; Rouffineau, J; Ezingeard, E; Millet, O; Guelon, D; Rodriguez, L; Martin, O; Renault, A; Sibille, JP; Kaidomar, M			Effect of systematic prone positioning in hypoxemic acute respiratory failure - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISTRESS-SYNDROME; ORGAN FAILURE; GAS-EXCHANGE; LUNG INJURY; DEFINITIONS; OXYGENATION; VENTILATION; DISEASE; MODEL; ARDS	Context A recent trial showed that placing patients with acute lung injury in the prone position did not increase survival; however, whether those results hold true for patients with hypoxemic acute respiratory failure (ARF) is unclear. Objective To determine whether prone positioning improves mortality in ARF patients. Design, Setting, and Patients Prospective, unblinded, multicenter controlled trial of 791 ARF patients in 21 general intensive care units in France using concealed randomization conducted from December 14, 1998, through December 31, 2002. To be included, patients had to be at least 18 years, hemodynamically stable, receiving mechanical ventilation, and intubated and had to have a partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FIO2) ratio of 300 or less and no contraindications to lying prone. Interventions Patients were randomly assigned to prone position placement (n = 413), applied as early as possible for at least 8 hours per day on standard beds, or to supine position placement (n = 378). Main Outcome Measures The primary end point was 28-day mortality; secondary end points were 90-day mortality, duration of mechanical ventilation, incidence of ventilator-associated pneumonia (VAP), and oxygenation. Results The 2 groups were comparable at randomization. The 28-day mortality rate was 32.4% for the prone group and 31.5% for the supine group (relative risk [RR], 0.97; 95% confidence interval [CI], 0.79-1.19; P=.77). Ninety-day mortality for the prone group was 43.3% vs 42.2% for the supine group (RR, 0.98; 95% CI, 0.84-1.13; P=.74). The mean (SD) duration of mechanical ventilation was 13.7 (7.8) days for the prone group vs 14.1 (8.6) days for the supine group (P=.93) and the VAP incidence was 1.66 vs 2.14 episodes per 100-patients days of intubation, respectively (P=.045). The PaO2/FIO2 ratio was significantly higher in the prone group during the 28-day follow-up. However, pressure sores, selective intubation; and endotracheal tube obstruction incidences were higher in the prone group. Conclusions This trial demonstrated no beneficial outcomes and some safety concerns associated with prone positioning. For patients with hypoxemic ARF, prone position placement may lower the incidence of VAP.	Hop Croix Rousse, Serv Reanimat Med, F-69004 Lyon, France; Ctr Hosp Lyon Sud, C Clin Sud Est, F-69310 Pierre Benite, France; Ctr Hosp Lyon Sud, Serv Hyg & Epidemiol, F-69310 Pierre Benite, France; Serv Reanimat Polyvalente, Roanne, France; Hop Instruct Armees St Anne, Serv Reanimat, F-83800 Toulon, France; Serv Reanimat Polyvalente, Chalon Sur Saone, France; Serv Reanimat Polyvalente, Annecy, France; Ctr Hosp St Joseph, Serv Reanimat Med, Lyon, France; Ctr Hosp Lyon Sud, Serv Reanimat Med, Lyon, France; Hop St Marguerite, Serv Reanimat Med, Marseille, France; Serv Reanimat Polyvalente, Chambery, France; Hop Instruct Armees, Serv Reanimat, Lyon, France; Serv Reanimat Polyvalente, Macon, France; CHU La Miletrie, Serv Reanimat Med, Poitiers, France; Clin Mutualiste, Serv Reanimat, St Etienne, France; Serv Reanimat, Lons Le Saunier, France; CHU Gabriel Montpied, Serv Reanimat Chirurg, Clermont Ferrand, France; Serv Reanimat Polyvalente, Aix En Provence, France; Hop Edouard Herriot, Serv Reanimat Med, Lyon, France; CHU Brest, Serv Reanimat Med, F-29285 Brest, France; Serv Reanimat Polyvalente, Briancon, France; Serv Reanimat Polyvalente, Frejus, France	CHU Lyon; CHU Lyon; CHU Lyon; Hospital Instruction Of Armees Sainte-Anne; CHU Lyon; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Val-de-Grace Hospital; CHU Poitiers; Universite de Poitiers; CHU Clermont Ferrand; CHU Lyon; CHU Brest	Guerin, C (corresponding author), Hop Croix Rousse, Serv Reanimat Med, 103 Grande Rue Crooix Rousse, F-69004 Lyon, France.	claude.guerin@chu-lyon.fr	Millet, Oscar/F-9696-2011; guerin, claude/H-5692-2014	Millet, Oscar/0000-0001-8748-4105; guerin, claude/0000-0003-4700-6672				Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Beuret P, 2002, INTENS CARE MED, V28, P564, DOI 10.1007/s00134-002-1266-x; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BRYAN AC, 1974, AM REV RESPIR DIS, V110, P143; Chatte G, 1997, AM J RESP CRIT CARE, V155, P473, DOI 10.1164/ajrccm.155.2.9032181; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteve J, 1994, DESCRIPTIVE EPIDEMIO; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; GAUSSORGUES P, 1987, PRESSE MED, V16, P1200; Guerin C, 1999, INTENS CARE MED, V25, P1222, DOI 10.1007/s001340051050; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Leonet S, 2002, INTENS CARE MED, V28, P576, DOI 10.1007/s00134-002-1274-x; Mancebo J, 2003, INTENS CARE MED, V29, pS64; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; McCormick J, 2001, Intensive Crit Care Nurs, V17, P331, DOI 10.1054/iccn.2001.1611; Mentzelopoulos SD, 2003, ANESTH ANALG, V96, P1756, DOI 10.1213/01.ANE.0000064282.79068.1E; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; MUTOH T, 1992, AM REV RESPIR DIS, V146, P300, DOI 10.1164/ajrccm/146.2.300; Nakos G, 2000, AM J RESP CRIT CARE, V161, P360, DOI 10.1164/ajrccm.161.2.9810037; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Rello J, 2003, CRIT CARE MED, V31, P2544, DOI 10.1097/01.CCM.0000089928.84326.D2; Richard JC, 2002, J APPL PHYSIOL, V93, P2181, DOI 10.1152/japplphysiol.00313.2002; Roupie E, 1999, INTENS CARE MED, V25, P920, DOI 10.1007/s001340050983; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC	31	364	397	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2379	2387		10.1001/jama.292.19.2379	http://dx.doi.org/10.1001/jama.292.19.2379			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547166	Bronze			2022-12-28	WOS:000225070100027
J	Murray, AJ; Anderson, RE; Watson, GC; Radda, GK; Clarke, K				Murray, AJ; Anderson, RE; Watson, GC; Radda, GK; Clarke, K			Uncoupling proteins in human heart	LANCET			English	Article								Abnormal energetic activity in heart failure correlates inversely with plasma free-fatty-acid concentrations. However, the link between energetic and metabolic abnormalities is unknown. To investigate this association, we obtained blood samples from 39 patients undergoing coronary artery bypass graft surgery. Patients fasted overnight before samples were taken. When plasma free-fatty-acid concentrations were raised, cardiac mitochondrial uncoupling proteins (UCP) increased (isoform UCP2, p<0.0001; isoform UCP3, p=0.0036) and those of glucose transporter (GLUT4) protein decreased (cardiac, p=0.0001; skeletal muscle, p=0.0006). Consequently, energy deficiency in heart failure might result from increased mitochondrial UCPs (ie, less efficient ATP synthesis) and depleted GLUT4 (ie, reduced glucose uptake). New treatment to correct these energy defects would be to simultaneously lower plasma free fatty acids and provide an alternative energy source.	Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Karolinska Hosp, Dept Cardiothorac Anesthesia & Intens Care, S-10401 Stockholm, Sweden	University of Oxford; Karolinska Institutet; Karolinska University Hospital	Clarke, K (corresponding author), Univ Oxford, Physiol Lab, Parks Rd, Oxford OX1 3PT, England.	Kieran.Clarke@physiol.ox.ac.uk	Murray, Andrew/B-3130-2010	Murray, Andrew/0000-0002-0929-9315	British Heart Foundation [PS/02/002/14893] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		Boehm EA, 2001, AM J PHYSIOL-HEART C, V280, pH977, DOI 10.1152/ajpheart.2001.280.3.H977; Neubauer S, 1997, CIRCULATION, V96, P2190; Scheuermann-Freestone M, 2003, CIRCULATION, V107, P3040, DOI 10.1161/01.CIR.0000072789.89096.10; Stanley William C, 2002, Heart Fail Rev, V7, P115, DOI 10.1023/A:1015320423577; van Bilsen M, 2002, MOL CELL BIOCHEM, V239, P131, DOI 10.1023/A:1020553428294	5	227	237	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1786	1788		10.1016/S0140-6736(04)17402-3	http://dx.doi.org/10.1016/S0140-6736(04)17402-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541452				2022-12-28	WOS:000225070600032
J	Driskell, AC; Ane, C; Burleigh, JG; McMahon, MM; O'Meara, BC; Sanderson, MJ				Driskell, AC; Ane, C; Burleigh, JG; McMahon, MM; O'Meara, BC; Sanderson, MJ			Prospects for building the tree of life from large sequence databases	SCIENCE			English	Article							GENE TREES; MISSING DATA; MITOCHONDRIAL; PHYLOGENY	We assess the phylogenetic potential of similar to300,000 protein sequences sampled from Swiss-Prot and GenBank. Although only a small subset of these data was potentially phylogenetically informative, this subset retained a substantial fraction of the original taxonomic diversity. Sampling biases in the databases necessitate building phylogenetic data sets that have large numbers of missing entries. However, an analysis of two "supermatrices" suggests that even data sets with as much as 92% missing data can provide insights into broad sections of the tree of life.	Univ Calif Davis, Sect Evolut & Ecol, Davis, CA 95616 USA; Univ Calif Davis, Ctr Populat Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Driskell, AC (corresponding author), Univ Calif Davis, Sect Evolut & Ecol, 1 Shields Ave, Davis, CA 95616 USA.	acdriskell@ucdavis.edu		O'Meara, Brian/0000-0002-0337-5997; Ane, Cecile/0000-0002-4702-8217				ALEXE G, 2002, 200252 DIMACS; Arvestad L, 2003, BIOINFORMATICS, V19, pi7, DOI 10.1093/bioinformatics/btg1000; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; Bininda-Emonds O R, 2001, Pac Symp Biocomput, P547; DErchia AM, 1996, NATURE, V381, P597, DOI 10.1038/381597a0; DONDOSHANSKY I, 2002, BLASTCLUST VERS 6 1; Duvall MR, 2004, MOL PHYLOGENET EVOL, V30, P97, DOI 10.1016/S1055-7903(03)00187-8; Erdos PL, 1999, RANDOM STRUCT ALGOR, V14, P153, DOI 10.1002/(SICI)1098-2418(199903)14:2<153::AID-RSA3>3.0.CO;2-R; FELSENSTEIN J, 1981, BIOL J LINN SOC, V16, P183, DOI 10.1111/j.1095-8312.1981.tb01847.x; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; Kim J, 2001, Pac Symp Biocomput, P571; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; Lerat E, 2003, PLOS BIOL, V1, P101, DOI 10.1371/journal.pbio.0000019; Page RDM, 2000, MOL PHYLOGENET EVOL, V14, P89, DOI 10.1006/mpev.1999.0676; Philippe H, 2004, MOL BIOL EVOL, V21, P1740, DOI 10.1093/molbev/msh182; Phillips MJ, 2003, MOL PHYLOGENET EVOL, V28, P171, DOI 10.1016/S1055-7903(03)00057-5; Rokas A, 2003, NATURE, V425, P798, DOI 10.1038/nature02053; Sanderson MJ, 2003, TRENDS PLANT SCI, V8, P374, DOI 10.1016/S1360-1385(03)00165-1; Sanderson MJ, 2003, MOL BIOL EVOL, V20, P1036, DOI 10.1093/molbev/msg115; Sanderson MJ, 1998, TRENDS ECOL EVOL, V13, P105, DOI 10.1016/S0169-5347(97)01242-1; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; Wiens JJ, 2003, SYST BIOL, V52, P528, DOI 10.1080/10635150390218330; Yang ZH, 1998, SYST BIOL, V47, P125, DOI 10.1080/106351598261067; Zardoya R, 1998, MOL BIOL EVOL, V15, P506, DOI 10.1093/oxfordjournals.molbev.a025950	24	199	206	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1172	1174		10.1126/science.1102036	http://dx.doi.org/10.1126/science.1102036			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539599				2022-12-28	WOS:000225193100045
J	Braunwald, E; Pfeffer, MA; Domanski, M; Fowler, S; Rice, M; Rosenberg, Y; Dunlap, M; Flaker, G; Geller, N; Gersh, B; Goldberg, A; Hsia, J; Limacher, M; Maggioni, A; Mills, P; Rouleau, J; Warnica, J; Wasserman, A; Domanski, M; Rosenberg, Y; Geller, N; Mills, P; Fowler, S; Cleary, P; Close, N; Davey, T; Green, J; Hsia, J; Jablonski, K; Mason, D; Pakalapati, S; Rice, M; Verter, J; Wasserman, A; Weir, J; Yalamanchili, V; Maggioni, A; Fabbri, G; Gorini, M; Lorimer, A; Lucci, D; Sarti, L; Hsia, J; Clemenza, F; Cuddy, T; Goldberg, A; Huynh, T; Maggioni, A; Starling, M; Title, L; Zabalgoitia, M; Fye, C; Gagne, W; Steffes, M; Bucksa, J; Rynders, G; Frye, R; Cooper, E; Davis, C; Grimes, C; Nanda, N; Pellegrino, E; Stokes, L; Dunlap, M; Ortiz, J; Fleegle, R; Armstrong, A; Jafri, S; Goldberg, A; Frank, D; Piotrowski, K; Kotlewski, A; Mahrer, P; Browning, R; Sharma, A; Nediratta, S; Ely, G; Allen, V; Goodfield, P; Tredinnick, K; Hundley, R; Mabry, V; Sparrow, T; Cunningham, P; Owens, S; Nelson, D; Lewis, S; Kelley, D; Starling, M; Majors, C; Flaker, G; Belew, K; Rodeheffer, R; Anderson, P; Dodin, E; Vold, D; Wertheimer, J; McKinney, V; Ouyang, P; Wingo, J; Erenrich, N; Grumbach, C; Serfas, D; Oskins, D; Denny, D; VanVactor, B; Chaitman, B; Aubuchon, S; Brachfeld, C; McKinster, B; Logemann, T; Joyce, D; Smith, E; Pacheco, R; Limacher, M; Bryant, B; Wolinsky, D; Westlake-Hicks, L; Lopez, M; Schenks, R; Graham, S; Jackson, J; Durr, S; De Raad, R; Solomon, S; Mercier, R; Lader, E; Meyer, M; Wickemeyer, W; Young, N; Omar, B; Clark, L; Reddy, P; Norwood, T; Perry, J; Romero, T; Eastburn, T; Hicks, K; Jain, A; Limon, L; Vetrovec, G; Damico, K; Liang, CS; Perkins, E; Katz, R; Arevalo, J; Thadani, U; Thresher, M; Weiss, R; Brennan, B; Ackell, P; Noble, M; Kahl, F; Soots, S; Marzo, K; Hodnett, P; Seaworth, J; Farris, S; Jiang, L; Duquette, M; Ziperman, D; Greene-Nashold, J; Timmis, G; Clark, C; Colfer, H; Ronquist, M; Wagner, S; Olliges, M; Mohiuddin, S; Rasmussen, L; Sheikh, K; Hengerer-Yates, T; Palmeri, S; Casazza, L; Leimbach, W; Ritter, D; Zabalgoitia, M; Paredes, A; Golden, J; McCaskill, B; Duvernoy, W; Cunningham, D; Goldman, S; Ohm, J; McBride, J; Foster, B; Rosenson, R; Dahle, K; Schmidt, P; Ness, C; Patton, J; Davison, C; Riba, A; Draus, C; Herzog, E; Tormey, D; Keller, A; Obeid, M; Hendrix, G; Schulz, M; Larry, J; Homan, J; Kutscher, A; Calhoon, W; Medici, S; Amidi, M; Bell, M; Khadra, S; Bax, J; Wool, K; Parker, J; Smith, M; Feick, P; Schulman, P; Folger, J; Shanes, J; Guard, K; Solomon, S; English, M; Ellis, J; Kelly, D; Menapace, F; Kleman, M; Fitzpatrick, P; Sass, A; Gillespie, J; Cohen, L; Kowey, P; Heaney, S; Kussmaul, W; Mark, L; Bugni, W; Sweeney, S; Kereiakes, D; Ibanez, K; Slater, W; Guerra, B; Brown, E; Valeria, A; Fifer, M; Benard, P; Feicht, C; Crist, K; Capone, R; Omorogbe, T; Desai, V; Pierre-Louis, J; Jutzy, K; Bishop, V; Dadkhah, S; Fisch, A; Costantino, T; Basilious, M; Smitherman, T; Rosenfelder, D; Canaday, D; Baxter, J; DeWood, M; Chapman, D; Olson, W; Lamas, G; Hussein, S; Stein, R; Varvatsas, J; Smith, E; Davison, C; Kazmierski, J; O'Mara, K; Smith, J; Cromer, C; DiCola, J; Dolan, S; Martin, W; Manns, H; Kipperman, R; Zhang, Y; Grossman, D; Morrison, B; Chiaramida, A; Gaven, R; DeQuattro, V; Song, Z; Bergin, P; Masengil, J; Ely, D; Reynolds, F; Dennish, G; Horton, N; Bates, E; Luciano, A; Moloo, J; Kaminski, M; Geltman, E; Flanagan, J; Hayden, CT; Felicetta, J; Beckner, L; Kaushik, V; Mueco, A; Lee, R; Metcalf, A; Fowles, R; Summers, K; Heerema, M; Jacobson, M; Diggs, P; Roeske, M; Rosenstein, R; Dawley, D; Dorst, D; Warnica, J; Smith, B; Walker, L; Scarcelli, D; Tam, J; Cuddy, T; Courcelles, P; Miller, N; Gosselin, G; Ducharme, A; Marquis, J; Lamy, M; Title, L; Johnstone, D; Francis, M; Cossett, J; Dion, D; St-Hilaire, R; Morissette, A; Poulin, F; Arnold, M; Krupa, M; Boulianne, M; Campeau, J; Ouimet, F; Roberge, B; Huynh, T; Finkenbine, S; St Jacques, B; Boudreault, C; Borts, D; Bonafede, N; Burtcher, J; Edwards, C; Baigrie, R; Gee, F; Judge, J; Reilly, K; Bernstein, V; MacDonald, K; Mooney, S; Rouleau, J; Vienneau, R; Mayer, JP; Mitges, S; Nawaz, S; Dhaliwal, R; Talbot, P; Talbot, M; Sussex, B; Newman, S; Baird, M; Fraser, M; Guimond, C; Leboeuf, J; Moe, G; Day, D; Rajakumar, G; Kroeger, B; Khouri, M; Zello, N; Lee, H; Barban, K; Kostuk, W; Powell, AM; Smilovitch, M; Toyota, V; Phaneuf, D; Duclos, R; Goulet, G; Primeau, L; Machel, T; Morash, J; Gossard, D; Boutin, L; Vizel, S; Fox, B; Stanton, E; Lawrence, M; Sullivan, H; Paterson, R; Hoag, G; Ilott, K; Dufton, J; Sweeney, R; Garcia-Palmieri, M; Banchs, H; Gonzalez, M; Perez, M; Colon, P; Vazquez, N; Schweiger, C; Frisinghelli, A; Galati, A; Palma, P; Di Pasquale, P; Clemenza, F; Filorizzo, G; Petacchi, R; Cogo, R; Ferrari, M; Battaglia, A; Mancino, F; D'Alessandro, B; Truncellito, L; Maina, M; Romanzi, S; Chieffo, C; Cardillo, A; De Lorenzi, E; Bergarno, A; Boccalatte, A; Gaeta, G; Neri, G; Masaro, G; Perticone, F; Maio, R; De Biase, M; Carrone, M; Scrutinio, D; La Gioia, R; Leonzio, L; Tullio, D; Santarone, M; Tagliagambe, L; Zonzin, P; Capanna, M; Di Giovanni, N; Fiore, I; Gavazzi, A; Mazzoleni, D; Pinelli, G; Ribani, M; Mangiameli, S; Rubino, V; Viecca, M; Sala, R; Porcu, M; Salis, S; Amici, R; Patteri, G; Bortolini, F; Turelli, A; Maresta, A; Dalla Valle, G; Braschi, G; Abrignani, M; Terrosu, P; Castellaccio, M; Boccanelli, A; Morosetti, P; Tartarini, G; Levantesi, D; Grieco, A; Cazzaniga, A; Poggio, G; Giani, S; Ferrari, G; Belluschi, R; Del Citerna, F; Balli, E; Maiolino, P; Pedon, L; Mininni, N; Monda, V				Braunwald, E; Pfeffer, MA; Domanski, M; Fowler, S; Rice, M; Rosenberg, Y; Dunlap, M; Flaker, G; Geller, N; Gersh, B; Goldberg, A; Hsia, J; Limacher, M; Maggioni, A; Mills, P; Rouleau, J; Warnica, J; Wasserman, A; Domanski, M; Rosenberg, Y; Geller, N; Mills, P; Fowler, S; Cleary, P; Close, N; Davey, T; Green, J; Hsia, J; Jablonski, K; Mason, D; Pakalapati, S; Rice, M; Verter, J; Wasserman, A; Weir, J; Yalamanchili, V; Maggioni, A; Fabbri, G; Gorini, M; Lorimer, A; Lucci, D; Sarti, L; Hsia, J; Clemenza, F; Cuddy, T; Goldberg, A; Huynh, T; Maggioni, A; Starling, M; Title, L; Zabalgoitia, M; Fye, C; Gagne, W; Steffes, M; Bucksa, J; Rynders, G; Frye, R; Cooper, E; Davis, C; Grimes, C; Nanda, N; Pellegrino, E; Stokes, L; Dunlap, M; Ortiz, J; Fleegle, R; Armstrong, A; Jafri, S; Goldberg, A; Frank, D; Piotrowski, K; Kotlewski, A; Mahrer, P; Browning, R; Sharma, A; Nediratta, S; Ely, G; Allen, V; Goodfield, P; Tredinnick, K; Hundley, R; Mabry, V; Sparrow, T; Cunningham, P; Owens, S; Nelson, D; Lewis, S; Kelley, D; Starling, M; Majors, C; Flaker, G; Belew, K; Rodeheffer, R; Anderson, P; Dodin, E; Vold, D; Wertheimer, J; McKinney, V; Ouyang, P; Wingo, J; Erenrich, N; Grumbach, C; Serfas, D; Oskins, D; Denny, D; VanVactor, B; Chaitman, B; Aubuchon, S; Brachfeld, C; McKinster, B; Logemann, T; Joyce, D; Smith, E; Pacheco, R; Limacher, M; Bryant, B; Wolinsky, D; Westlake-Hicks, L; Lopez, M; Schenks, R; Graham, S; Jackson, J; Durr, S; De Raad, R; Solomon, S; Mercier, R; Lader, E; Meyer, M; Wickemeyer, W; Young, N; Omar, B; Clark, L; Reddy, P; Norwood, T; Perry, J; Romero, T; Eastburn, T; Hicks, K; Jain, A; Limon, L; Vetrovec, G; Damico, K; Liang, CS; Perkins, E; Katz, R; Arevalo, J; Thadani, U; Thresher, M; Weiss, R; Brennan, B; Ackell, P; Noble, M; Kahl, F; Soots, S; Marzo, K; Hodnett, P; Seaworth, J; Farris, S; Jiang, L; Duquette, M; Ziperman, D; Greene-Nashold, J; Timmis, G; Clark, C; Colfer, H; Ronquist, M; Wagner, S; Olliges, M; Mohiuddin, S; Rasmussen, L; Sheikh, K; Hengerer-Yates, T; Palmeri, S; Casazza, L; Leimbach, W; Ritter, D; Zabalgoitia, M; Paredes, A; Golden, J; McCaskill, B; Duvernoy, W; Cunningham, D; Goldman, S; Ohm, J; McBride, J; Foster, B; Rosenson, R; Dahle, K; Schmidt, P; Ness, C; Patton, J; Davison, C; Riba, A; Draus, C; Herzog, E; Tormey, D; Keller, A; Obeid, M; Hendrix, G; Schulz, M; Larry, J; Homan, J; Kutscher, A; Calhoon, W; Medici, S; Amidi, M; Bell, M; Khadra, S; Bax, J; Wool, K; Parker, J; Smith, M; Feick, P; Schulman, P; Folger, J; Shanes, J; Guard, K; Solomon, S; English, M; Ellis, J; Kelly, D; Menapace, F; Kleman, M; Fitzpatrick, P; Sass, A; Gillespie, J; Cohen, L; Kowey, P; Heaney, S; Kussmaul, W; Mark, L; Bugni, W; Sweeney, S; Kereiakes, D; Ibanez, K; Slater, W; Guerra, B; Brown, E; Valeria, A; Fifer, M; Benard, P; Feicht, C; Crist, K; Capone, R; Omorogbe, T; Desai, V; Pierre-Louis, J; Jutzy, K; Bishop, V; Dadkhah, S; Fisch, A; Costantino, T; Basilious, M; Smitherman, T; Rosenfelder, D; Canaday, D; Baxter, J; DeWood, M; Chapman, D; Olson, W; Lamas, G; Hussein, S; Stein, R; Varvatsas, J; Smith, E; Davison, C; Kazmierski, J; O'Mara, K; Smith, J; Cromer, C; DiCola, J; Dolan, S; Martin, W; Manns, H; Kipperman, R; Zhang, Y; Grossman, D; Morrison, B; Chiaramida, A; Gaven, R; DeQuattro, V; Song, Z; Bergin, P; Masengil, J; Ely, D; Reynolds, F; Dennish, G; Horton, N; Bates, E; Luciano, A; Moloo, J; Kaminski, M; Geltman, E; Flanagan, J; Hayden, CT; Felicetta, J; Beckner, L; Kaushik, V; Mueco, A; Lee, R; Metcalf, A; Fowles, R; Summers, K; Heerema, M; Jacobson, M; Diggs, P; Roeske, M; Rosenstein, R; Dawley, D; Dorst, D; Warnica, J; Smith, B; Walker, L; Scarcelli, D; Tam, J; Cuddy, T; Courcelles, P; Miller, N; Gosselin, G; Ducharme, A; Marquis, J; Lamy, M; Title, L; Johnstone, D; Francis, M; Cossett, J; Dion, D; St-Hilaire, R; Morissette, A; Poulin, F; Arnold, M; Krupa, M; Boulianne, M; Campeau, J; Ouimet, F; Roberge, B; Huynh, T; Finkenbine, S; St Jacques, B; Boudreault, C; Borts, D; Bonafede, N; Burtcher, J; Edwards, C; Baigrie, R; Gee, F; Judge, J; Reilly, K; Bernstein, V; MacDonald, K; Mooney, S; Rouleau, J; Vienneau, R; Mayer, JP; Mitges, S; Nawaz, S; Dhaliwal, R; Talbot, P; Talbot, M; Sussex, B; Newman, S; Baird, M; Fraser, M; Guimond, C; Leboeuf, J; Moe, G; Day, D; Rajakumar, G; Kroeger, B; Khouri, M; Zello, N; Lee, H; Barban, K; Kostuk, W; Powell, AM; Smilovitch, M; Toyota, V; Phaneuf, D; Duclos, R; Goulet, G; Primeau, L; Machel, T; Morash, J; Gossard, D; Boutin, L; Vizel, S; Fox, B; Stanton, E; Lawrence, M; Sullivan, H; Paterson, R; Hoag, G; Ilott, K; Dufton, J; Sweeney, R; Garcia-Palmieri, M; Banchs, H; Gonzalez, M; Perez, M; Colon, P; Vazquez, N; Schweiger, C; Frisinghelli, A; Galati, A; Palma, P; Di Pasquale, P; Clemenza, F; Filorizzo, G; Petacchi, R; Cogo, R; Ferrari, M; Battaglia, A; Mancino, F; D'Alessandro, B; Truncellito, L; Maina, M; Romanzi, S; Chieffo, C; Cardillo, A; De Lorenzi, E; Bergarno, A; Boccalatte, A; Gaeta, G; Neri, G; Masaro, G; Perticone, F; Maio, R; De Biase, M; Carrone, M; Scrutinio, D; La Gioia, R; Leonzio, L; Tullio, D; Santarone, M; Tagliagambe, L; Zonzin, P; Capanna, M; Di Giovanni, N; Fiore, I; Gavazzi, A; Mazzoleni, D; Pinelli, G; Ribani, M; Mangiameli, S; Rubino, V; Viecca, M; Sala, R; Porcu, M; Salis, S; Amici, R; Patteri, G; Bortolini, F; Turelli, A; Maresta, A; Dalla Valle, G; Braschi, G; Abrignani, M; Terrosu, P; Castellaccio, M; Boccanelli, A; Morosetti, P; Tartarini, G; Levantesi, D; Grieco, A; Cazzaniga, A; Poggio, G; Giani, S; Ferrari, G; Belluschi, R; Del Citerna, F; Balli, E; Maiolino, P; Pedon, L; Mininni, N; Monda, V		PEACE Trial Investigators	Angiotensin-converting-enzyme inhibition in stable coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; CHRONIC HEART-FAILURE; MYOCARDIAL-INFARCTION; AMERICAN-COLLEGE; TASK-FORCE; GUIDELINES; SURVIVAL; EVENTS; ASSOCIATION; ENALAPRIL	Background: Angiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure. Methods: In the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial, we tested the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy. The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients). Results: The mean (+/-SD) age of the patients was 64+/-8 years, the mean blood pressure 133+/-17/78+/-10 mm Hg, and the mean left ventricular ejection fraction 58+/-9 percent. The patients received intensive treatment, with 72 percent having previously undergone coronary revascularization and 70 percent receiving lipid-lowering drugs. The incidence of the primary end point -- death from cardiovascular causes, myocardial infarction, or coronary revascularization -- was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval, 0.88 to 1.06; P=0.43) over a median follow-up period of 4.8 years. Conclusions: In patients with stable coronary heart disease and preserved left ventricular function who are receiving ``current standard'' therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization.	Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; George Washington Univ, Rockville, MD USA; Mayo Clin Fdn, Rochester, MN USA; George Washington Univ, Washington, DC USA; Univ Montreal, Montreal, PQ, Canada	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); George Washington University; Mayo Clinic; George Washington University; Universite de Montreal	Braunwald, E (corresponding author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA.		Abrignani, Maurizio G/J-5105-2016; Jafri, Wasim/AAE-5085-2020; LAGIOIA, ROCCO/E-4582-2019; Scrutinio, Domenico/E-8074-2019; Ducharme, Anique/AAC-5946-2020	Abrignani, Maurizio G/0000-0002-0237-7157; LAGIOIA, ROCCO/0000-0002-2036-1634; Scrutinio, Domenico/0000-0002-8535-3264; Ducharme, Anique/0000-0003-1681-9187	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC065149] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01 HC065149, N01 HC065149-12] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; Amer Diabet Assoc, 2002, DIABETES CARE, V25, P213; Anderson Robert N, 2003, Natl Vital Stat Rep, V52, P1; BALL SG, 1993, LANCET, V342, P821; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COX DR, 1972, J R STAT SOC B, V34, P187; De Giorgio L, 2000, NEW ENGL J MED, V342, P1376; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Fox KM, 2003, LANCET, V362, P782; Guay DRP, 2003, CLIN THER, V25, P713, DOI 10.1016/S0149-2918(03)80107-8; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; LAN KKG, 1990, BIOMETRICS, V46, P759, DOI 10.2307/2532094; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lewis EJ, 2001, NEW ENGL J MED, V345, P851, DOI 10.1056/NEJMoa011303; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 1998, AM J CARDIOL, V82, p25H; Remme WJ, 2002, EUR J HEART FAIL, V4, P11, DOI 10.1016/S1388-9842(01)00231-8; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; Shih JH, 1995, CONTROL CLIN TRIALS, V16, P395, DOI 10.1016/S0197-2456(95)00132-8; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N; Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S., 1992, NEW ENGL J MED, V327, P685, DOI [DOI 10.1056/NEJM199209033271003, 10.1056/NEJM199209033271003.Erratumin]	29	883	924	1	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2058	2068						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15531767				2022-12-28	WOS:000225007200007
J	Moscicki, AB; Shiboski, S; Hills, NK; Powell, KJ; Jay, N; Hanson, EN; Miller, S; Canjura-Clayton, LK; Farhat, S; Broering, JM; Darragh, TM				Moscicki, AB; Shiboski, S; Hills, NK; Powell, KJ; Jay, N; Hanson, EN; Miller, S; Canjura-Clayton, LK; Farhat, S; Broering, JM; Darragh, TM			Regression of low-grade squamous intra-epithelial lesions in young women	LANCET			English	Article							HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL DYSPLASIA; NATURAL-HISTORY; SEXUAL FACTORS; NEOPLASIA; COHORT; RISK; ADOLESCENT; DISEASE; AGE	Background The aim of this study was to assess the probability of low-grade squamous intra-epithelial lesion (LSIL) regression in young women, and to examine the factors associated with this regression. Methods In a longitudinal study of human papilloma virus (HPV) infection, female adolescents aged 13-22 years were examined every 4 months by cytology, colposcopy, and HPV DNA status. Both prevalent and incident LSIL cases were included in the analysis, with regression defined as at least three consecutive normal Pap smears. Findings Median follow-up time from baseline (defined as the time of first LSIL diagnosis) for the 187 women with LSIL was 61 months (IQR 34-80). Median time they had been sexually active at diagnosis was 3.2 years (2.6-6.5). Probability of regression for the entire cohort was 61% (95% Cl 53-70) at 12 months and 91% (84-99) at 36 months of follow-up. No associations were found between LSIL regression and HPV status at baseline, sexual behaviour, contraceptive use, substance or cigarette use, incident sexually transmitted infection, or biopsy. Multivariate analysis showed that only HPV status at the current visit was associated with rate of regression, whether infection was caused by one or more viral types (relative hazard=0.3 [95% Cl 0.21-0.42], and 0.14 [0.08-0.25], respectively). Interpretation The high rate of regression recorded in this study lends support to observation by cytology in the management of LSIL in female adolescents. Negative HPV status was associated with regression, suggesting that HPV testing could be helpful in monitoring LSIL.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moscicki, AB (corresponding author), 3333 Calif St,Suite 245, San Francisco, CA 94118 USA.	annam@itsa.ucsf.edu	Moscicki, Anna-Barbara/AAP-3806-2021	Broering, Jeanette/0000-0002-7580-8931	NCI NIH HHS [R01CA51323, R01CA54053, R01 CA051323, R37 CA051323] Funding Source: Medline; NCRR NIH HHS [M01 RR001271, M01 RR01271] Funding Source: Medline; PHS HHS [MCJ000978, P01A121912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA051323, R01CA054053, R01CA051323] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BACCHETTI P, 1991, BIOMETRICS, V47, P947, DOI 10.2307/2532651; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; DEVET HCW, 1993, INT J EPIDEMIOL, V22, P798, DOI 10.1093/ije/22.5.798; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; Franco ELF, 1996, OBSTET GYN CLIN N AM, V23, P597; Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; HOLMES KK, 1981, SCAND J INFECT DIS, P110; Joly P, 1998, BIOMETRICS, V54, P185, DOI 10.2307/2534006; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Kurman RJ, 1994, BETHESDA SYSTEM REPO; LAVECCHIA C, 1986, CANCER, V58, P935, DOI 10.1002/1097-0142(19860815)58:4<935::AID-CNCR2820580422>3.0.CO;2-O; MOSCICKI AB, 1993, OBSTET GYNECOL, V82, P578; Moscicki AB, 2001, JAMA-J AM MED ASSOC, V285, P2995, DOI 10.1001/jama.285.23.2995; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; Mount SL, 1999, PEDIATRICS, V103, P539, DOI 10.1542/peds.103.3.539; NASH JD, 1987, OBSTET GYNECOL, V69, P160; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; OLSEN AO, 1995, INT J CANCER, V61, P312, DOI 10.1002/ijc.2910610306; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; Ries LA, 2002, SEER CANC STAT REV 1; Schlecht NF, 2003, JNCI-J NATL CANCER I, V95, P1336, DOI 10.1093/jnci/djg037; Scott M, 2001, CLIN DIAGN LAB IMMUN, V8, P209, DOI 10.1128/CDLI.8.2.209-220.2001; Smith PJ, 1997, STAT MED, V16, P485, DOI 10.1002/(SICI)1097-0258(19970315)16:5&lt;485::AID-SIM422&gt;3.0.CO;2-#; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; WRIGHT VC, 1984, AM J OBSTET GYNECOL, V149, P824, DOI 10.1016/0002-9378(84)90598-2	28	285	299	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1678	1683		10.1016/S0140-6736(04)17354-6	http://dx.doi.org/10.1016/S0140-6736(04)17354-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530628				2022-12-28	WOS:000224921600030
J	Choi, KJ; Biegalski, M; Li, YL; Sharan, A; Schubert, J; Uecker, R; Reiche, P; Chen, YB; Pan, XQ; Gopalan, V; Chen, LQ; Schlom, DG; Eom, CB				Choi, KJ; Biegalski, M; Li, YL; Sharan, A; Schubert, J; Uecker, R; Reiche, P; Chen, YB; Pan, XQ; Gopalan, V; Chen, LQ; Schlom, DG; Eom, CB			Enhancement of ferroelectricity in strained BaTiO3 thin films	SCIENCE			English	Article							ELECTRICAL-PROPERTIES; THICKNESS DEPENDENCE; HETEROSTRUCTURES; SUPERLATTICES; POLARIZATION; MULTILAYERS; TEMPERATURE; TRANSITION; DEFECTS	Biaxial compressive strain has been used to markedly enhance the ferroelectric properties of BaTiO3 thin films. This strain, imposed by coherent epitaxy, can result in a ferroelectric transition temperature nearly 500degreesC higher and a remanent polarization at least 250% higher than bulk BaTiO3 single crystals. This work demonstrates a route to a lead-free ferroelectric for nonvolatile memories and electro-optic devices.	Univ Wisconsin, Dept Mat Sci & Engn, Madison, WI 53706 USA; Penn State Univ, Dept Mat Sci & Engn, University Pk, PA 16802 USA; Forschungszentrum Julich, Inst Schichten & Grenzflachen ISG1IT, D-52425 Julich, Germany; Inst Crystal Growth, Berlin, Germany; Univ Michigan, Dept Mat Sci & Engn, Ann Arbor, MI 48109 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Helmholtz Association; Research Center Julich; Leibniz Institut fur Kristallzuchtung (IKZ); University of Michigan System; University of Michigan	Eom, CB (corresponding author), Univ Wisconsin, Dept Mat Sci & Engn, 1509 Univ Ave, Madison, WI 53706 USA.	eom@engr.wisc.edu	Schubert, Jürgen/K-9543-2013; Eom, Chang-Beom/I-5567-2014; Choi, Kyoung Jin/N-4662-2013; Li, Yulan/F-8929-2018; Pan, Xiaoqing/ABF-4088-2020; Schlom, Darrell G/J-2412-2013; Choi, Kyoung Jin/D-6941-2013; Chen, LongQing/I-7536-2012	Schubert, Jürgen/0000-0003-0185-6794; Li, Yulan/0000-0002-2431-5408; Pan, Xiaoqing/0000-0002-0965-8568; Schlom, Darrell G/0000-0003-2493-6113; Chen, LongQing/0000-0003-3359-3781				Ahn CH, 2004, SCIENCE, V303, P488, DOI 10.1126/science.1092508; BEACH RS, 1993, PHYS REV LETT, V70, P3502, DOI 10.1103/PhysRevLett.70.3502; BIEGALSKI MD, UNPUB; Bozovic I, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.107001; DEVONSHIRE AF, 1951, PHILOS MAG, V42, P1065; EOM CB, 1992, SCIENCE, V258, P1766, DOI 10.1126/science.258.5089.1766; EOM CB, 1993, APPL PHYS LETT, V63, P2570, DOI 10.1063/1.110436; FOX GR, 1990, MATER LETT, V9, P284, DOI 10.1016/0167-577X(90)90062-Q; Gan Q, 1998, APPL PHYS LETT, V72, P978, DOI 10.1063/1.120603; Haeni JH, 2004, NATURE, V430, P758, DOI 10.1038/nature02773; HELLWEGE KH, 1981, LANDOLTBORNSTEIN A, V16, P67; Jaffe Jr B., 1971, PIEZOELECTRIC CERAMI, P78; Junquera J, 2003, NATURE, V422, P506, DOI 10.1038/nature01501; Li YL, 2001, APPL PHYS LETT, V78, P3878, DOI 10.1063/1.1377855; MATTHEWS JW, 1974, J CRYST GROWTH, V27, P118, DOI 10.1016/S0022-0248(74)80055-2; Nagarajan V, 1999, J APPL PHYS, V86, P595, DOI 10.1063/1.370772; Neaton JB, 2003, APPL PHYS LETT, V82, P1586, DOI 10.1063/1.1559651; NIX WD, 1989, METALL TRANS A, V20, P2217, DOI 10.1007/BF02666659; Nix WD, 1999, J MATER RES, V14, P3467, DOI 10.1557/JMR.1999.0468; Pertsev NA, 1998, PHYS REV LETT, V80, P1988, DOI 10.1103/PhysRevLett.80.1988; RAMESH R, 1992, APPL PHYS LETT, V61, P1537, DOI 10.1063/1.107488; Sato H, 1997, PHYSICA C, V274, P221, DOI 10.1016/S0921-4534(96)00675-2; Schubert J, 2003, APPL PHYS LETT, V82, P3460, DOI 10.1063/1.1575935; *SEM IND ASS, 2003, INT TECHN ROADM SEM, P50; Sepliarsky M, 2002, J APPL PHYS, V91, P3165, DOI 10.1063/1.1435826; Sharan A, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.214109; Specht ED, 1998, PHYS REV LETT, V80, P4317, DOI 10.1103/PhysRevLett.80.4317; SPECK JS, 1995, J APPL PHYS, V78, P1696, DOI 10.1063/1.360267; Streiffer SK, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.067601; Wang J, 2003, SCIENCE, V299, P1719, DOI 10.1126/science.1080615; Yanase N, 1999, JPN J APPL PHYS 1, V38, P5305, DOI 10.1143/JJAP.38.5305	32	1486	1531	58	1161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 5	2004	306	5698					1005	1009		10.1126/science.1103218	http://dx.doi.org/10.1126/science.1103218			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528439				2022-12-28	WOS:000225001100035
J	Kamhawi, S; Ramalho-Ortigao, M; Pham, VM; Kumar, S; Lawyer, PG; Turco, SJ; Barillas-Mury, C; Sacks, DL; Valenzuela, JG				Kamhawi, S; Ramalho-Ortigao, M; Pham, VM; Kumar, S; Lawyer, PG; Turco, SJ; Barillas-Mury, C; Sacks, DL; Valenzuela, JG			A role for insect galectins in parasite survival	CELL			English	Article							LEISHMANIA-MAJOR PROMASTIGOTES; DEVELOPMENTAL MODIFICATION; VECTORIAL COMPETENCE; RHODNIUS-PROLIXUS; LIPOPHOSPHOGLYCAN; LECTIN; IDENTIFICATION; GENES; RECOGNITION; INFECTION	Insect galectins are associated with embryonic development or immunity against pathogens. Here, we show that they can be exploited by parasites for survival in their insect hosts. PpGalec, a tandem repeat galectin expressed in the midgut of the sand fly Phlebotomus papatasi, is used by Leishmania major as a receptor for mediating specific binding to the insect midgut, an event crucial for parasite survival, and accounts for species-specific vector competence. PpGalec is thus identified as a key molecule controlling vector competence for the most widely distributed form of cutaneous leishmaniasis in the Old World. In addition, these studies demonstrate the feasibility of using midgut receptors for parasite ligands as target antigens for transmission-blocking vaccines.	NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; NIAID, Mosquito Immun & Vector Competence Unit, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Univ Kentucky, Med Ctr, Dept Mol & Cellular Biochem, Lexington, KY 40502 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Kentucky	Valenzuela, JG (corresponding author), NIAID, Vector Mol Biol Unit, Lab Malaria & Vector Res, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	jvalenzuela@niaid.nih.gov	Ramalho-Ortigao, Marcelo/E-8225-2011	Kumar, Sanjeev/0000-0003-3866-4593; Ramalho-Ortigao, Marcelo/0000-0002-1490-4946	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020941, Z01AI000256, R37AI020941, Z01AI000947] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20941] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arata Y, 2001, J BIOL CHEM, V276, P3068, DOI 10.1074/jbc.M008602200; Basseri HR, 2002, EXP PARASITOL, V100, P226, DOI 10.1016/S0014-4894(02)00026-7; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BLANCHET MA, 2000, PROTEINS, V40, P378; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; Dillon RJ, 1999, PARASITOLOGY, V118, P27, DOI 10.1017/S0031182098003588; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dobson DE, 2003, J BIOL CHEM, V278, P28840, DOI 10.1074/jbc.M302728200; Hughes RC, 2001, BIOCHIMIE, V83, P667; Joshi PB, 1998, MOL MICROBIOL, V27, P519, DOI 10.1046/j.1365-2958.1998.00689.x; Kamhawi S, 2000, PARASITOLOGY, V121, P25, DOI 10.1017/S0031182099006125; Kamhawi S, 2002, WORLD CL PARASITES, V4, P59; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; MCCONVILLE MJ, 1995, BIOCHEM J, V310, P807, DOI 10.1042/bj3100807; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; Mello CB, 1999, EXP PARASITOL, V91, P289, DOI 10.1006/expr.1998.4385; Moody TN, 2000, FEBS LETT, V470, P305, DOI 10.1016/S0014-5793(00)01347-8; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; Pace KE, 2002, GLYCOCONJUGATE J, V19, P607, DOI 10.1023/B:GLYC.0000014092.86763.2f; Pace KE, 2002, J BIOL CHEM, V277, P13091, DOI 10.1074/jbc.M112105200; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Pelletier I, 2003, J BIOL CHEM, V278, P22223, DOI 10.1074/jbc.M302693200; Pelletier I, 2002, J BIOL CHEM, V277, P17663, DOI 10.1074/jbc.M201562200; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9; Sacks D, 2001, ANNU REV MICROBIOL, V55, P453, DOI 10.1146/annurev.micro.55.1.453; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Sujatha MS, 2004, PROTEINS, V55, P44, DOI 10.1002/prot.10612; SVODODOVA M, 1996, ANN TROP MED PARASIT, V90, P329; TESH RB, 1983, J MED ENTOMOL, V20, P199, DOI 10.1093/jmedent/20.2.199; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Valenzuela JG, 2002, J EXP BIOL, V205, P2843; Valenzuela JG, 2002, INSECT BIOCHEM MOLEC, V32, P1101, DOI 10.1016/S0965-1748(02)00047-4; Volf P, 1998, MED VET ENTOMOL, V12, P151, DOI 10.1046/j.1365-2915.1998.00089.x; Volf P, 2002, EUR J BIOCHEM, V269, P6294, DOI 10.1046/j.1432-1033.2002.03349.x; WALLBANKS KR, 1986, TROP MED PARASITOL, V37, P409; Yang RY, 2003, CELL MOL LIFE SCI, V60, P267, DOI 10.1007/s000180300022; Young AR, 2002, GLYCOCONJUGATE J, V19, P601, DOI 10.1023/B:GLYC.0000014091.00844.0a	51	195	205	1	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 29	2004	119	3					329	341		10.1016/j.cell.2004.10.009	http://dx.doi.org/10.1016/j.cell.2004.10.009			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	868IW	15543683	Bronze			2022-12-28	WOS:000224908300005
J	Boyd, PA; Armstrong, B; Dolk, H; Botting, B; Pattenden, S; Abramsky, L; Rankin, J; Vrijheid, M; Wellesley, D				Boyd, PA; Armstrong, B; Dolk, H; Botting, B; Pattenden, S; Abramsky, L; Rankin, J; Vrijheid, M; Wellesley, D			Congenital anomaly surveillance in England - ascertainment deficiencies in the national system	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NOTIFICATION	Objective Firstly, to assess the completeness of ascertainment in die National Congenital Anomaly System (NCAS), the basis for congenital anomaly surveillance in England and Wales, and its variation by defect geographical area, and socioeconomic deprivation. Secondly, to assess die impact of the lack of data on pregnancies terminated because of fetal anomaly. Design Comparison of the NCAS with four local congenital anomaly registers in England. Setting Four regions in England covering some 109 000 annual births. Participants Cases of congenital anomalies registered in the NCAS (live births and stillbirths) and independently registered in the four local registers (live births, stillbirths, fetal losses from 20 weeks' gestation, and pregnancies terminated after prenatal diagnosis of fetal anomaly). Main outcome measure The ratio of cases identified by the national register to those in local registry files, calculated for different specified anomalies, for whole registry areas, and for hospital catchment areas within registry boundaries. Results Ascertainment by the NCAS (compared with data from local registers, from which terminations of pregnancy were removed) was 40% (34% for chromosomal anomalies and 42% for non-chromosomal anomalies) and varied markedly by defect, by local register, and by hospital catchment area, but not by area deprivation. When terminations of pregnancy were included in the register data, ascertainment-by NCAS was 27% (19% for chromosomal anomalies and 31% for non-chromosomal anomalies),and the geographical variation was of a similar magnitude. Conclusion The surveillance of congenital anomalies in England is currently inadequate because ascertainment to the national register is low and non-uniform and because no data exist on termination of pregnancy resulting from prenatal diagnosis of fetal anomaly.	Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Ulster, Fac Life & Hlth Sci, Newtownabbey BT37 0QB, Antrim, North Ireland; Off Natl Stat, London SW1V 2QQ, England; Northwick Pk Hosp & Clin Res Ctr, N Thames Perinatal Publ Hlth Unit, Harrow HA1 3UJ, Middx, England; Newcastle Univ, Fac Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Int Agcy Res Canc, F-69372 Lyon 08, France; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England	University of Oxford; University of London; London School of Hygiene & Tropical Medicine; Ulster University; Imperial College London; Newcastle University - UK; World Health Organization; International Agency for Research on Cancer (IARC)	Boyd, PA (corresponding author), Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England.	patricia.boyd@perinat.ox.ac.uk	Vrijheid, Martine/H-2702-2014	Vrijheid, Martine/0000-0002-7090-1758; armstrong, benedict/0000-0003-4407-0409				ABRAMSKY I, 2003, N THAMES PERINATAL P; [Anonymous], 1992, Arch Dis Child, V67, P770; BOTTING B, 2000, HLTH STAT Q, V5, P7; BOYD PA, 2003, REPORT OXFORD CONGEN; Busby A, 1998, ARCH DIS CHILD-FETAL, V79, pF168, DOI 10.1136/fn.79.3.F168; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; Dolk H, 2003, STUDY GEOGRAPHICAL V; Elliott P, 2001, BRIT MED J, V323, P363, DOI 10.1136/bmj.323.7309.363; HEY K, 1994, ARCH DIS CHILD-FETAL, V71, pF198, DOI 10.1136/fn.71.3.F198; KNOX EG, 1984, J EPIDEMIOL COMMUN H, V38, P296, DOI 10.1136/jech.38.4.296; *NDSCR, 2003, NAT DOWN SYNDR CYT R; *OFF POP CENS SURV, 1995, 43 OPCS; PAYNE JN, 1992, PUBLIC HEALTH, V106, P437, DOI 10.1016/S0033-3506(05)80458-5; *STAT OFF, 1997, CONG MALF STAT N MB3; TAN KH, 1996, BRIT MED J, V313, P993; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; WELLESLEY D, 2003, WESSEX ANTENATALLY D	17	80	82	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 1	2005	330	7481					27	29		10.1136/bmj.38300.665301.3A	http://dx.doi.org/10.1136/bmj.38300.665301.3A			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	885SH	15561730	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000226176700017
J	Ratiu, PF; Talos, I				Ratiu, PF; Talos, I			The tale of Phineas Gage, digitally remastered	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Ratiu, PF (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	22	22	0	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					E21	E21		10.1056/NEJMicm031024	http://dx.doi.org/10.1056/NEJMicm031024			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575047				2022-12-28	WOS:000225429000013
J	Gussekloo, J; van Exel, E; de Craen, AJM; Meinders, AE; Frolich, M; Westendorp, RGJ				Gussekloo, J; van Exel, E; de Craen, AJM; Meinders, AE; Frolich, M; Westendorp, RGJ			Thyroid status, disability and cognitive function, and survival in old age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; L-THYROXINE THERAPY; SUBCLINICAL HYPOTHYROIDISM; DOUBLE-BLIND; LIFE-SPAN; HEART-DISEASE; DWARF MICE; ALL-CAUSE; DYSFUNCTION; HYPERTHYROIDISM	Context Despite the equivocal outcomes of randomized controlled trials, general clinical opinion favors screening and treatment of elderly individuals with subclinical thyroid disorders. Objectives To determine whether subclinical thyroid dysfunction should be treated in old age and the long-term impact of thyroid dysfunction on performance and survival in old age. Design, Setting, and Participants A prospective, observational, population-based follow-up study within the Leiden 85-Plus Study of 87% of a 2-year birth cohort (1912-1914) in the municipality of Leiden, the Netherlands. A total of 599 participants were followed up from age 85 years through age 89 years (mean [SD] follow-up, 3.7 [1.4] years). Main Outcome Measures Complete thyroid status at baseline; disability in daily life, depressive symptoms, cognitive function, and mortality from age 85 years through 89 years. Results Plasma levels of thyrotropin and free thyroxine were not associated with disability in daily life, depressive symptoms, and cognitive impairment at baseline or during follow-up. Increasing levels of thyrotropin were associated with a lower mortality rate that remained after adjustments were made for baseline disability and health status. The hazard ratio (HR) for mortality per SD increase of 2.71 mIU/L of thyrotropin was 0,77 (95% confidence interval [CI], 0.63-0.94; P=.009). The HR for mortality per SD increase of 0.21 ng/dL (2.67 pmol/L) of free thyroxine increased 1.16-fold (95% Cl, 1.04-1.30; P=.009). Conclusions In the general population of the oldest old, elderly individuals with abnormally, high levels of thyrotropin do not experience adverse effects and may have a prolonged life span. However, evidence for not treating elderly individuals can only come from a well-designed, randomized placebo-controlled clinical trial.	Leiden Univ, Med Ctr, Sect Gerontol & Geriatr, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Gussekloo, J (corresponding author), Leiden Univ, Med Ctr, Sect Gerontol & Geriatr, C-2-R Room 133,POB 9600, NL-2300 RC Leiden, Netherlands.	jgussekloo@lumc.nl	Gussekloo, Jacobijn/ABE-3879-2021	Gussekloo, Jacobijn/0000-0001-7186-8278; van Exel, Eric/0000-0002-5737-9600				Ayala AR, 2000, ENDOCRIN METAB CLIN, V29, P399, DOI 10.1016/S0889-8529(05)70139-0; Bartke A, 2001, EXP GERONTOL, V36, P21, DOI 10.1016/S0531-5565(00)00205-9; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Blanc S, 2003, J CLIN ENDOCR METAB, V88, P16, DOI 10.1210/jc.2002-020405; Bootsma-van der Wiel A, 2002, J CLIN EPIDEMIOL, V55, P1119, DOI 10.1016/S0895-4356(02)00505-X; Bootsma-van der Wiel A, 2001, J AM GERIATR SOC, V49, P909; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Caraccio N, 2002, J CLIN ENDOCR METAB, V87, P1533, DOI 10.1210/jc.87.4.1533; Cerillo AG, 2003, ANN THORAC SURG, V75, P82, DOI 10.1016/S0003-4975(02)03919-X; Chueire VB, 2003, ARCH GERONTOL GERIAT, V36, P281, DOI 10.1016/S0167-4943(02)00173-5; Col NF, 2004, JAMA-J AM MED ASSOC, V291, P239, DOI 10.1001/jama.291.2.239; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; Cooper DS, 2001, NEW ENGL J MED, V345, P260, DOI 10.1056/NEJM200107263450406; Danese MD, 1996, JAMA-J AM MED ASSOC, V276, P285, DOI 10.1001/jama.276.4.285; Davis Jennifer Duncan, 2003, Curr Psychiatry Rep, V5, P384, DOI 10.1007/s11920-003-0073-6; de Craen AJM, 2003, INT J GERIATR PSYCH, V18, P63, DOI 10.1002/gps.773; Dugbartey AT, 1998, ARCH INTERN MED, V158, P1413, DOI 10.1001/archinte.158.13.1413; Flurkey K, 2002, MECH AGEING DEV, V123, P121, DOI 10.1016/S0047-6374(01)00339-6; Gueorguieva R, 2004, ARCH GEN PSYCHIAT, V61, P310, DOI 10.1001/archpsyc.61.3.310; Helfand M, 2004, ANN INTERN MED, V140, P128, DOI 10.7326/0003-4819-140-2-200401200-00015; Houx PJ, 2002, J NEUROL NEUROSUR PS, V73, P385, DOI 10.1136/jnnp.73.4.385; Iervasi G, 2003, CIRCULATION, V107, P708, DOI 10.1161/01.CIR.0000048124.64204.3F; Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089; Jaeschke R, 1996, J GEN INTERN MED, V11, P744, DOI 10.1007/BF02598988; Kong WM, 2002, AM J MED, V112, P348, DOI 10.1016/S0002-9343(02)01022-7; Ladenson PW, 2000, ARCH INTERN MED, V160, P1573, DOI 10.1001/archinte.160.11.1573; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; McIver B, 1997, THYROID, V7, P125, DOI 10.1089/thy.1997.7.125; Meier C, 2001, J CLIN ENDOCR METAB, V86, P4860, DOI 10.1210/jc.86.10.4860; Mobbs CV, 2001, J GERONTOL A-BIOL, V56, P34, DOI 10.1093/gerona/56.suppl_1.34; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; OLSEN T, 1978, J CLIN ENDOCR METAB, V47, P1111, DOI 10.1210/jcem-47-5-1111; Omar RZ, 1999, STAT MED, V18, P1587, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1587::AID-SIM141>3.0.CO;2-Z; OOKA H, 1983, MECH AGEING DEV, V22, P113, DOI 10.1016/0047-6374(83)90104-5; OOKA H, 1986, MECH AGEING DEV, V33, P275, DOI 10.1016/0047-6374(86)90052-7; Parle JV, 2001, LANCET, V358, P861, DOI 10.1016/S0140-6736(01)06067-6; Pollock MA, 2001, BRIT MED J, V323, P891, DOI 10.1136/bmj.323.7318.891; ROBERTSON T. BRAILSFORD, 1928, AUSTRALIAN JOUR EXP BIOL MED SCI, V5, P69, DOI 10.1038/icb.1928.4; Speakman JR, 2002, J NUTR, V132, p1583S, DOI 10.1093/jn/132.6.1583S; Stathatos N, 2001, BEST PRACT RES CL EN, V15, P465, DOI 10.1053/beem.2001.0164; Surks MI, 2004, JAMA-J AM MED ASSOC, V291, P228, DOI 10.1001/jama.291.2.228; Toft AD, 2001, NEW ENGL J MED, V345, P512, DOI 10.1056/NEJMcp010145; von Faber M, 2001, ARCH INTERN MED, V161, P2694, DOI 10.1001/archinte.161.22.2694	45	605	638	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2591	2599		10.1001/jama.292.21.2591	http://dx.doi.org/10.1001/jama.292.21.2591			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572717				2022-12-28	WOS:000225409100022
J	Resneck, JS; Van Beek, M; Furmanski, L; Oyugi, J; LeBoit, PE; Katabira, E; Kambugu, F; Maurer, T; Berger, T; Pletcher, MJ; Machtinger, EL				Resneck, JS; Van Beek, M; Furmanski, L; Oyugi, J; LeBoit, PE; Katabira, E; Kambugu, F; Maurer, T; Berger, T; Pletcher, MJ; Machtinger, EL			Etiology of pruritic papular eruption with HIV infection in Uganda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE; EOSINOPHILIA; MECHANISMS; ANTIGENS; ZAMBIA; SHIFT; AIDS	Context A frequent cause of human immunodeficiency virus (HIV)-related morbidity in sub-Saharan Africa is a commonly occurring, intensely pruritic skin rash. The resulting scars are disfiguring and stigmatizing. Despite the substantial prevalence of pruritic papular eruption (PPE) among HIV-infected Africans, the cause has been elusive. Objective To determine the etiology of PPE occurring in HIV-infected individuals. Design, Setting, and Patients Cross-sectional study of HIV-infected patients with active PPE from clinics in Uganda conducted from May 19 through June 6, 2003. Enrollment occurred in the month preceding May 19. Each participant was clinically examined by 2 dermatologists, had laboratory studies performed, was administered an epidemiologic questionnaire, and had a skin biopsy of a new lesion evaluated by a dermatopathologist. Main Outcome Measures Histological characteristics of new pruritic lesions. Other assessments included CD4 cell count, eosinophil count, and physician-assessed rash severity. Results Of 109 patients meeting inclusion criteria, 102 (93.6%) completed the study. The CD4 cell counts in this study population were generally low (median, 46/muL) and inversely related to increasing rash severity (median CD4 cell counts: 122 for mild, 41 for moderate, and 9 for severe; P<.001 for trend). Eighty-six patients (84%; 95% confidence interval, 77%-91%) had biopsy findings characteristic of arthropod bites. Patients with arthropod bites on biopsy had significantly higher peripheral eosinophil counts (median, 330 vs 180/&mu;L; P=.02) and had a trend toward lower CD4 cell counts (median, 40 vs 99/&mu;L; P=.07) than those without histological evidence of arthropod bites. Conclusions Pruritic papular eruption occurring in HIV-infected individuals may be a reaction to arthropod bites. We hypothesize that this condition reflects an altered and exaggerated immune response to arthropod antigens in a subset of susceptible HIV-infected patients.	Univ Calif San Francisco, Sch Med, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Iowa, Dept Dermatol, Iowa City, IA USA; Univ Iowa, Dept Epidemiol, Iowa City, IA USA; Reach Out Mbuya Parish AIDS Initiat, Kampala, Uganda; Acad Alliance AIDS Care & Prevent Africa, Kampala, Uganda; Makerere Univ, Kampala, Uganda	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Iowa; University of Iowa; Makerere University	Resneck, JS (corresponding author), Univ Calif San Francisco, Sch Med, Dept Dermatol, Box 0363, San Francisco, CA 94143 USA.	resneck@itsa.ucsf.edu		Van Beek, Marta/0000-0003-2467-5830				ACKERMAN AB, 1997, HISTOLOGIC DIAGNOSIS, P202; Aires JM, 2000, INT J DERMATOL, V39, P903, DOI 10.1046/j.1365-4362.2000.00106.x; ALCOM K, 2004, AIDSMAP NEWS    0218; Barry SM, 2003, JAIDS-J ACQ IMM DEF, V34, P351, DOI 10.1097/00126334-200312010-00001; BASON MM, 1993, INT J DERMATOL, V32, P784, DOI 10.1111/j.1365-4362.1993.tb02762.x; Boonchai W, 1999, INT J DERMATOL, V38, P348, DOI 10.1046/j.1365-4362.1999.00694.x; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; COLEBUNDERS R, 1987, AIDS, V1, P117; ELGART ML, 1996, CUTANEOUS MED SURG I, P804; FEINGOLD BF, 1968, ANNU REV ENTOMOL, V13, P137, DOI 10.1146/annurev.en.13.010168.001033; GILLET JD, 1972, MOSQUITO ITS LIFE AC; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P451, DOI 10.1016/S0190-9622(88)70197-8; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P87; JASON J, 1995, J ACQ IMMUN DEF SYND, V10, P471, DOI 10.1097/00042560-199512000-00011; Klein SA, 1997, AIDS, V11, P1111, DOI 10.1097/00002030-199709000-00005; LIAUTAUD B, 1989, ARCH DERMATOL, V125, P629, DOI 10.1001/archderm.125.5.629; MAGNAN A, 1995, REV MAL RESPIR, V12, P177; Mahe A, 1996, J AM ACAD DERMATOL, V34, P1084, DOI 10.1016/S0190-9622(96)90295-9; Milazzo F, 1999, ALLERGY, V54, P266, DOI 10.1034/j.1398-9995.1999.00885.x; Muyinda H, 1997, HEALTH PLACE, V3, P143, DOI 10.1016/S1353-8292(97)00010-5; *NAT I ALL INF DIS, 2001, LESS BLOOD MEAL; Olumide YM, 1997, INT J DERMATOL, V36, P741, DOI 10.1046/j.1365-4362.1997.00338.x; PALLANGYO KJ, 1992, TROP DOCT, V22, P35, DOI 10.1177/00494755920220S107; Peng ZK, 2004, INT ARCH ALLERGY IMM, V133, P198, DOI 10.1159/000076787; PENNEYS NS, 1989, J AM ACAD DERMATOL, V21, P421, DOI 10.1016/S0190-9622(89)80051-9; Pirmohamed M, 2001, CURR OPIN ALLERGY CL, V1, P311, DOI 10.1097/00130832-200108000-00006; Pitche P, 1995, Sante, V5, P349; Rosatelli JB, 2001, ARCH DERMATOL, V137, P672; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P705, DOI 10.1016/S0091-6749(99)70348-9; Skiest DJ, 1997, AM J MED, V102, P449, DOI 10.1016/S0002-9343(97)00048-X; Smith KJ, 1997, CLIN EXP DERMATOL, V22, P118, DOI 10.1111/j.1365-2230.1997.tb01038.x	32	43	48	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2614	2621		10.1001/jama.292.21.2614	http://dx.doi.org/10.1001/jama.292.21.2614			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572719	Bronze			2022-12-28	WOS:000225409100024
J	Rehman, HU; Bajwa, TA				Rehman, HU; Bajwa, TA			10-minute consultation - Newly diagnosed hypothyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Broomfield Hosp, Chelmsford CM1 7ET, Essex, England; Figges Marsh Surg, Mitcham CR4 2AD, England	Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Rehman, HU (corresponding author), Broomfield Hosp, Chelmsford CM1 7ET, Essex, England.	habib786@aol.com						Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206	1	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2004	329	7477					1271	1271		10.1136/bmj.329.7477.1271	http://dx.doi.org/10.1136/bmj.329.7477.1271			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15564259	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000225480900020
J	Reichart, P; Datzmann, G; Hauptner, A; Hertenberger, R; Wild, C; Dollinger, G				Reichart, P; Datzmann, G; Hauptner, A; Hertenberger, R; Wild, C; Dollinger, G			Three-dimensional hydrogen microscopy in diamond	SCIENCE			English	Article							POLYCRYSTALLINE DIAMOND; SURFACE; GROWTH; TEMPERATURE; MOBILITY; ERDA	A microprobe of protons with an energy of 17 million electron volts is used to quantitatively image three-dimensional hydrogen distributions at a lateral resolution better than 1 micrometer with high sensitivity. Hydrogen images of a <110>-textured undoped potycrystalline diamond film show that most of the hydrogen is located at grain boundaries. The average amount of hydrogen atoms along the grain boundaries is (8.1 +/- 1.5) x 10(14) per square centimeter, corresponding to about a third of a monolayer. The hydrogen content within the grain is below the experimental sensitivity of 1.4 x 10(16) atoms per cubic centimeter (0.08 atomic parts per million). The data prove a low hydrogen content within chemical vapor deposition-grown diamond and the importance of hydrogen at grain boundaries, for example, with respect to electronic properties of polycrystalline diamond.	Tech Univ Munich, Phys Dept E12, D-85748 Garching, Germany; Univ Munich, Dept Phys, D-85748 Garching, Germany; Fraunhofer Inst Appl Solid State Phys, D-79108 Freiburg, Germany	Technical University of Munich; University of Munich; Fraunhofer Gesellschaft	Reichart, P (corresponding author), Univ Melbourne, Sch Phys, Microanalyt Res Ctr, Parkville, Vic 3010, Australia.	p.reichart@ph.unimetb.edu.au	Dollinger, Guenther/A-7590-2011					ANGUS JC, 1988, SCIENCE, V241, P913, DOI 10.1126/science.241.4868.913; Bergmaier A, 2001, SURF SCI, V481, pL433, DOI 10.1016/S0039-6028(01)01030-5; Bergonzo P, 2001, PHYS STATUS SOLIDI A, V185, P167, DOI 10.1002/1521-396X(200105)185:1<167::AID-PSSA167>3.0.CO;2-F; COHEN BL, 1972, J APPL PHYS, V43, P19, DOI 10.1063/1.1660806; Connell SH, 1998, DIAM RELAT MATER, V7, P1714, DOI 10.1016/S0925-9635(98)00266-0; Datzmann G, 2001, NUCL INSTRUM METH B, V181, P20, DOI 10.1016/S0168-583X(01)00549-3; DISCHLER B, 1993, PHYSICA B, V185, P217, DOI 10.1016/0921-4526(93)90240-7; DISCHLER B, 1998, SPRINGER SERIES MAT, V11; DOLLINGER G, 1995, DIAM RELAT MATER, V4, P591, DOI 10.1016/0925-9635(94)05274-3; Dujmic D, 1996, NUCL INSTRUM METH B, V111, P126, DOI 10.1016/0168-583X(95)01263-X; Feldman GJ, 1998, PHYS REV D, V57, P3873, DOI 10.1103/PhysRevD.57.3873; FUCHS F, 1995, APPL PHYS LETT, V66, P177, DOI 10.1063/1.113126; Glover C, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.185507; Hearne SM, 2004, APPL PHYS LETT, V84, P4493, DOI 10.1063/1.1756201; Isberg J, 2002, SCIENCE, V297, P1670, DOI 10.1126/science.1074374; Kawarada H, 1996, SURF SCI REP, V26, P205, DOI 10.1016/S0167-5729(97)80002-7; Kawarada H, 1997, J APPL PHYS, V81, P3490, DOI 10.1063/1.365047; Maclear RD, 1999, DIAM RELAT MATER, V8, P1615, DOI 10.1016/S0925-9635(99)00061-8; Maier F, 2000, PHYS REV LETT, V85, P3472, DOI 10.1103/PhysRevLett.85.3472; Maier F, 1999, SURF SCI, V443, P177, DOI 10.1016/S0039-6028(99)01010-9; Manfredotti C, 2001, NUCL INSTRUM METH A, V458, P360, DOI 10.1016/S0168-9002(00)00882-2; Nebel CE, 2001, APPL PHYS LETT, V79, P4541, DOI 10.1063/1.1429756; Reichart P, 2004, NUCL INSTRUM METH B, V219, P980, DOI 10.1016/j.nimb.2004.01.200; Reichart P, 2002, NUCL INSTRUM METH B, V197, P134, DOI 10.1016/S0168-583X(02)01479-9; Samlenski R, 2002, NUCL INSTRUM METH B, V190, P324, DOI 10.1016/S0168-583X(02)00454-8; Sjoland KA, 1997, NUCL INSTRUM METH B, V124, P639, DOI 10.1016/S0168-583X(97)00116-X; STONEHAM AM, 1992, PROPERTIES NATURAL S, P4; Talbot-Ponsonby DF, 1998, PHYS REV B, V57, P2264, DOI 10.1103/PhysRevB.57.2264; Vescan A, 1998, DIAM RELAT MATER, V7, P581, DOI 10.1016/S0925-9635(97)00200-8; WILD C, 1990, J APPL PHYS, V68, P973, DOI 10.1063/1.346663; Woerner E, 2001, DIAM RELAT MATER, V10, P557, DOI 10.1016/S0925-9635(00)00393-9; Yan CS, 2002, P NATL ACAD SCI USA, V99, P12523, DOI 10.1073/pnas.152464799	32	97	105	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1537	1540		10.1126/science.1102910	http://dx.doi.org/10.1126/science.1102910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567859				2022-12-28	WOS:000225442700053
J	Lotz, J; Macchiarini, P				Lotz, J; Macchiarini, P			Double aortic arch diagnosed by magnetic resonance imaging	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Hannover Med Sch, D-30625 Hannover, Germany; Klinikum Hannover Heidehaus, D-30419 Hannover, Germany	Hannover Medical School	Lotz, J (corresponding author), Hannover Med Sch, D-30625 Hannover, Germany.		Macchiarini, Paolo/E-6878-2013						0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	2004	351	22					E20	E20		10.1056/ENEJMicm030865	http://dx.doi.org/10.1056/ENEJMicm030865			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873RH	15564538				2022-12-28	WOS:000225298100012
J	West, S; Gromak, N; Proudfoot, NJ				West, S; Gromak, N; Proudfoot, NJ			Human 5 '-> 3 ' exonuclease Xrn2 promotes transcription termination at co-transcriptional cleavage sites	NATURE			English	Article							RNA-POLYMERASE-II; GENE; REQUIRES; PROTEIN; SIGNAL; END	Eukaryotic protein-encoding genes possess poly(A) signals that define the end of the messenger RNA and mediate downstream transcriptional termination by RNA polymerase II (Pol II)(1). Termination could occur through an 'anti-termination' mechanism whereby elongation factors dissociate when the poly(A) signal is encountered, producing termination-competent Pol II2,3. An alternative 'torpedo' model postulated that poly(A) site cleavage provides an unprotected RNA 5' end that is degraded by 5' --> 3' exonuclease activities ( torpedoes) and so	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	nicholas.proudfoot@path.ox.ac.uk	Gromak, Natalia/F-6475-2014; West, Steven/AAG-4009-2019	Gromak, Natalia/0000-0002-4158-3586; Proudfoot, Nicholas/0000-0001-8646-3222; West, Steven/0000-0002-7622-9050				ADAMS SE, 1988, NUCLEIC ACIDS RES, V16, P4287, DOI 10.1093/nar/16.10.4287; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; Bauren G, 1998, GENE DEV, V12, P2759, DOI 10.1101/gad.12.17.2759; Cerutti H, 2003, TRENDS GENET, V19, P39, DOI 10.1016/S0168-9525(02)00010-0; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dye MJ, 2001, CELL, V105, P669, DOI 10.1016/S0092-8674(01)00372-5; Dye MJ, 1999, MOL CELL, V3, P371, DOI 10.1016/S1097-2765(00)80464-5; Hammann C, 2002, CHEMBIOCHEM, V3, P691; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; Huertas P, 2003, MOL CELL, V12, P711, DOI 10.1016/j.molcel.2003.08.010; Kadener S, 2002, P NATL ACAD SCI USA, V99, P8185, DOI 10.1073/pnas.122246099; Lejeune F, 2003, MOL CELL, V12, P675, DOI 10.1016/S1097-2765(03)00349-6; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; Proudfoot N, 2004, CURR OPIN CELL BIOL, V16, P272, DOI 10.1016/j.ceb.2004.03.007; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Samarsky DA, 1999, P NATL ACAD SCI USA, V96, P6609, DOI 10.1073/pnas.96.12.6609; STEVENS A, 1995, J BIOL CHEM, V270, P16063, DOI 10.1074/jbc.270.27.16063; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Torchet C, 2002, MOL CELL, V9, P1285, DOI 10.1016/S1097-2765(02)00544-0; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Zhang M, 1999, GENOMICS, V59, P252, DOI 10.1006/geno.1999.5866	25	272	277	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					522	525		10.1038/nature03035	http://dx.doi.org/10.1038/nature03035			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565158				2022-12-28	WOS:000225322100051
J	Alessandri, G; Pagano, S; Bez, A; Benetti, A; Pozzi, S; Iannolo, G; Baronio, M; Invernici, G; Caruso, A; Muneretto, C; Bisleri, G; Parati, E				Alessandri, G; Pagano, S; Bez, A; Benetti, A; Pozzi, S; Iannolo, G; Baronio, M; Invernici, G; Caruso, A; Muneretto, C; Bisleri, G; Parati, E			Isolation and culture of human muscle-derived stem cells able to differentiate into myogenic and neurogenic cell lineages	LANCET			English	Article							BONE-MARROW; PROGENITOR CELLS; SATELLITE CELL; STEM/PROGENITOR CELLS; GENE-THERAPY; SPINAL-CORD; EXPRESSION; MULTIPOTENT; PLURIPOTENT; BLOOD	Background Skeletal-muscle-derived stem cells seem to be a distinct population of immature progenitors of satellite cells, but their functional properties remain unclear, especially in human adult tissue. We investigated their differentiation in samples of skeletal muscle obtained from adults undergoing cardiovascular surgery. Methods Samples were obtained from the brachioradialis muscle of 12 patients in whom the radial artery was the conduit for myocardial revascularisation. The stem cells were isolated by a procedure similar to that used for rat gastrocnemius and cultured in medium optimised for growth of neural stem cells. Cytometry was used for phenotypic characterisation and immunocytochemistry and RT-PCR to assess differentiation. Immunohistochemistry was used to examine engraftment of skeletal-muscle-derived stem cells into injured rat spinal cord. Findings The skeletal-muscle stem cells consisted of two distinct types: one with the typical spindle morphology of satellite cells, the other of rounded cells. Some cultures could be maintained for longer than 6 months. The cells were mainly positive for desmin and to a lesser extent CD105, vimentin, and AC133/CD133, but negative for FLK-1/KDR, CD34, CD31, CD45, von Willebrand factor, Ve-cadherins, and BCL2. After in-vitro differentiation, the cells were able to organise skeletal-muscle fibres and stained positively for striated-muscle actin, smooth-muscle actin, and desmin. Moreover, they differentiated into astrocytes and neurons, as confirmed by positive staining for characteristic proteins. Interpretation Adult human skeletal muscle includes a population of progenitor stem cells that can generate cells of the same lineage and cells with neurogenic properties. Muscle may therefore be a tissue source for the isolation of pluripotent stem cells for development of cell-based therapies for human myogenic and neurogenic diseases.	Ist Nazl Neurol Carlo Besta, Lab Neurobiol & Neuroregenerat, I-20131 Milan, Italy; Univ Brescia, Dept Pathol, Brescia, Italy; Univ Brescia, Microbiol Lab, Brescia, Italy; Univ Brescia, Sch Med, Osped Civile, Div Cardiac Surg, Brescia, Italy	IRCCS Istituto Neurologico Besta; University of Brescia; University of Brescia; Hospital Spedali Civili Brescia; University of Brescia	Alessandri, G (corresponding author), Ist Nazl Neurol Carlo Besta, Lab Neurobiol & Neuroregenerat, Via Celoria 11, I-20131 Milan, Italy.	neurofarmacologial@istituto-besta.it	Parati, Eugenio A/G-8765-2011; Bisleri, Gianluigi/AAE-9695-2020; Caruso, Arnaldo/H-7818-2014; Iannolo, Gioacchin/AAC-2375-2022; MUNERETTO, Claudio/ACB-5130-2022; Bisleri, Gianluigi/E-7971-2010; Parati, Eugenio Agostino/AAN-5893-2021	MUNERETTO, Claudio/0000-0003-2656-4544; Parati, Eugenio Agostino/0000-0001-5020-6523; iannolo, gioacchin/0000-0002-7710-4735; alessandri, giulio/0000-0002-1861-8461; CARUSO, Arnaldo/0000-0001-5178-566X; Bisleri, Gianluigi/0000-0002-9816-1480				Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; Blesch A, 2002, BRAIN RES BULL, V57, P833, DOI 10.1016/S0361-9230(01)00774-2; Bosch P, 2000, J ORTHOP RES, V18, P933, DOI 10.1002/jor.1100180613; BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chakravarthy MV, 2000, J APPL PHYSIOL, V89, P1365, DOI 10.1152/jappl.2000.89.4.1365; Clarke D, 2001, CURR OPIN GENET DEV, V11, P575, DOI 10.1016/S0959-437X(00)00235-5; Daley GQ, 2003, ANN NY ACAD SCI, V996, P122, DOI 10.1111/j.1749-6632.2003.tb03240.x; Deasy BM, 2002, CURR OPIN MOL THER, V4, P382; Emery AEH, 1998, BRIT MED J, V317, P991, DOI 10.1136/bmj.317.7164.991; Ferrari G, 2002, NEUROMUSCULAR DISORD, V12, pS7, DOI 10.1016/S0960-8966(02)00102-5; Gerlach M, 2002, J NEUROL S3, V249, piii33, DOI DOI 10.1007/S00415-002-1307-Y; GIBSON MC, 1983, MUSCLE NERVE, V6, P574, DOI 10.1002/mus.880060807; Gray JA, 2000, CELL TRANSPLANT, V9, P153, DOI 10.1177/096368970000900203; Grounds MD, 1998, ANN NY ACAD SCI, V854, P78, DOI 10.1111/j.1749-6632.1998.tb09894.x; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; Ishikawa F, 2003, ANN NY ACAD SCI, V996, P174, DOI 10.1111/j.1749-6632.2003.tb03245.x; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085; LUCAS PA, 1995, WOUND REPAIR REGEN, V3, P457; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; McKinney-Freeman SL, 2002, P NATL ACAD SCI USA, V99, P1341, DOI 10.1073/pnas.032438799; Menasche P, 2003, ANN THORAC SURG, V75, pS20, DOI 10.1016/S0003-4975(03)00462-4; Minasi MG, 2002, DEVELOPMENT, V129, P2773; Mizuno H, 2002, PLAST RECONSTR SURG, V109, P199, DOI 10.1097/00006534-200201000-00030; Orlic D, 2003, ANN NY ACAD SCI, V996, P152, DOI 10.1111/j.1749-6632.2003.tb03243.x; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; Peault B, 2003, ANN NY ACAD SCI, V996, P132, DOI 10.1111/j.1749-6632.2003.tb03241.x; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Pomyje J, 2003, EUR J HAEMATOL, V70, P143, DOI 10.1034/j.1600-0609.2003.00040.x; Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257; Ratajczak MZ, 2003, STEM CELLS, V21, P363, DOI 10.1634/stemcells.21-3-363; RAY C, 1995, ANN THORAC SURG, V60, P12; Reiss K, 2002, NEUROSCIENCE, V115, P295, DOI 10.1016/S0306-4522(02)00307-X; REMOND DE, 2002, NEUROSCIENTIST, V5, P457; Rivier F, 2002, CYTOTHERAPY, V4, P513, DOI 10.1080/146532402761624665; Romero-Ramos M, 2002, J NEUROSCI RES, V69, P894, DOI 10.1002/jnr.10374; Royer CL, 2002, IN VITRO CELL DEV-AN, V38, P512, DOI 10.1290/1071-2690(2002)038<0512:MCPCGR>2.0.CO;2; SCHULTZ E, 1985, MECH AGEING DEV, V30, P63, DOI 10.1016/0047-6374(85)90059-4; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Stewart JD, 2003, J CELL PHYSIOL, V196, P70, DOI 10.1002/jcp.10322; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Torrente Y, 2001, CELL TRANSPLANT, V11, P25; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Vourc'h P, 2004, BIOCHEM BIOPH RES CO, V317, P893, DOI 10.1016/j.bbrc.2004.03.121; Young HE, 2001, ANAT RECORD, V263, P350, DOI 10.1002/ar.1112; Young HE, 1999, P SOC EXP BIOL MED, V221, P63, DOI 10.1046/j.1525-1373.1999.d01-55.x; Yu Y, 2002, J BIOL CHEM, V277, P20711, DOI 10.1074/jbc.M202349200; Zammit PS, 2001, DIFFERENTIATION, V68, P193, DOI 10.1046/j.1432-0436.2001.680407.x; Zanjani ED, 2003, EXP HEMATOL, V31, P406, DOI 10.1016/S0301-472X(03)00051-1; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	60	155	177	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1872	1883		10.1016/S0140-6736(04)17443-6	http://dx.doi.org/10.1016/S0140-6736(04)17443-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555667				2022-12-28	WOS:000225269300028
J	Margolis, HS; Barwood, GP; Huang, G; Klein, HA; Lea, SN; Szymaniec, K; Gill, P				Margolis, HS; Barwood, GP; Huang, G; Klein, HA; Lea, SN; Szymaniec, K; Gill, P			Hertz-level measurement of the optical clock frequency in a single Sr-88(+) ion	SCIENCE			English	Article							FEMTOSECOND LASER; TRAPPED ION; HG-199(+); STANDARD; SHIFTS	The frequency of the 5S S-2(1/2)-4d D-2(5/2) electric quadrupole clock transition in a single, trapped, laser-cooled Sr-88(+) ion has been measured by using an optical frequency comb referenced to a cesium fountain primary frequency standard. The frequency of the transition is measured as 444,779,044,095,484.6 (1.5) hertz, with a fractional uncertainty within a factor of 3 of that of the cesium standard. Improvements' required to obtain a cesium-limited frequency measurement are described and are expected to lead to a Sr-88(+) optical clock with stability and reproducibility exceeding that of the primary cesium standard.	Natl Phys Lab, Teddington TW11 0LW, Middx, England	National Physical Laboratory - UK	Margolis, HS (corresponding author), Natl Phys Lab, Teddington TW11 0LW, Middx, England.	helen.margolis@npl.co.uk	Margolis, Helen/AAN-3253-2020	Margolis, Helen/0000-0002-8991-3855				Barwood GP, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.133001; Becker T, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.051802; Berkeland DJ, 1998, J APPL PHYS, V83, P5025, DOI 10.1063/1.367318; Bernard JE, 1998, OPT COMMUN, V150, P170, DOI 10.1016/S0030-4018(98)00121-7; Blythe PJ, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.020501; DEHMELT HG, 1982, IEEE T INSTRUM MEAS, V31, P83, DOI 10.1109/TIM.1982.6312526; Diddams SA, 2000, PHYS REV LETT, V84, P5102, DOI 10.1103/PhysRevLett.84.5102; Diddams SA, 2001, SCIENCE, V293, P825, DOI 10.1126/science.1061171; DREVER RWP, 1983, APPL PHYS B-PHOTO, V31, P97, DOI 10.1007/BF00702605; DUBE P, 2004, 2004 C PREC EL MEAS; Fischer M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.230802; GILL P, 2002, P 6 S FREQ STAND MET, P12703; Itano WM, 2000, J RES NATL INST STAN, V105, P829, DOI 10.6028/jres.105.065; Madej AA, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.012507; Margolis HS, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.032501; Peik E, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.170801; Rafac RJ, 2000, PHYS REV LETT, V85, P2462, DOI 10.1103/PhysRevLett.85.2462; SCHRAMA CA, 1993, OPT COMMUN, V101, P32, DOI 10.1016/0030-4018(93)90318-Y; SIEMERS I, 1992, EUROPHYS LETT, V18, P139, DOI 10.1209/0295-5075/18/2/009; Stenger J, 2001, OPT LETT, V26, P1589, DOI 10.1364/OL.26.001589; SZYMANIEC K, UNPUB; Udem T, 1999, OPT LETT, V24, P881, DOI 10.1364/OL.24.000881; Udem T, 2001, PHYS REV LETT, V86, P4996, DOI 10.1103/PhysRevLett.86.4996	23	258	266	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1355	1358		10.1126/science.1105497	http://dx.doi.org/10.1126/science.1105497			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550666				2022-12-28	WOS:000225301600046
J	Okuonzi, SA				Okuonzi, SA			Learning from failed health reform in Uganda	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Council Children, Kampala, Uganda		Okuonzi, SA (corresponding author), Natl Council Children, POB 21456, Kampala, Uganda.	sokuonzi@infocom.co.ug						Abel-Smith B., 1994, INTRO HLTH POLICY PL; ADETUNJI J, 2000, B WORLD HEALTH ORGAN, V78, P1002; Brown DC, 2002, HISTOPATHOLOGY, V40, P2, DOI 10.1046/j.1365-2559.2002.01343.x; CHEN S, 2004, HAVE POOREST FARED E; DEININGER K, 2004, EC WELFARE IMPACT AB; *GOV UG, 2004, POV ER ACT PLAN DRAF; *GOV UG, 2003, MIDT REV REP HLTH SE; *GOV UG, 2003, STAT EM OBST CAR EMO; *GOV UG, 2004, UG NAT HIV AIDS POL; Government of Uganda, 2004, BACKGR BUDG FIN YEAR; JITTA J, 1998, QUALITY CARE UGANDA, P35; KIYONGA C, 2001, UGANDA HLTH B, V7; LINDELOW M, 2004, SOMETIMES MORE EQUAL; OCOM F, 1997, THESIS MAKERERE U; Okuonzi SA, 2000, INT J HEALTH PLAN M, V15, P201; RAVALLION M, 2004, COMPETING CONCEPTS I; STIGLIZ JE, 2002, GLOBALIZATION ITS DI; Uganda Bureau of Statistics, 2001, UG DEM HLTH SURV 200; *WORLD BANK, 1994, STAFF APPR REP DISTR; World Bank, 1993, WORLD DEV REP INV HL	20	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1173	1175		10.1136/bmj.329.7475.1173	http://dx.doi.org/10.1136/bmj.329.7475.1173			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539678	Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000225169600031
J	Crandall, KA; Buhay, JE				Crandall, KA; Buhay, JE			Genomoc databases and the tree of life	SCIENCE			English	Editorial Material									Brigham Young Univ, Dept Integrat Biol, Provo, UT 84602 USA; Brigham Young Univ, Monte L Bean Life Sci Museum, Provo, UT 84602 USA; Brigham Young Univ, Dept Mol Biol & Microbiol, Provo, UT 84602 USA	Brigham Young University; Brigham Young University; Brigham Young University	Crandall, KA (corresponding author), Brigham Young Univ, Dept Integrat Biol, Provo, UT 84602 USA.	keith_crandalt@byu.edu	Crandall, Keith A./H-2789-2019	Crandall, Keith A./0000-0002-0836-3389				Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Driskell AC, 2004, SCIENCE, V306, P1172, DOI 10.1126/science.1102036; Hebert PDN, 2004, P NATL ACAD SCI USA, V101, P14812, DOI 10.1073/pnas.0406166101; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Rivera MC, 2004, NATURE, V431, P152, DOI 10.1038/nature02848; Sanderson MJ, 1998, TRENDS ECOL EVOL, V13, P105, DOI 10.1016/S0169-5347(97)01242-1; Thornton JW, 2000, ANNU REV GENOM HUM G, V1, P41, DOI 10.1146/annurev.genom.1.1.41; Wiens JJ, 2003, SYST BIOL, V52, P528, DOI 10.1080/10635150390218330; WILSON E O, 1992	9	22	22	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1144	1145		10.1126/science.1106198	http://dx.doi.org/10.1126/science.1106198			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539592				2022-12-28	WOS:000225193100035
J	O'Rand, MG; Widgren, EE; Sivashanmugam, P; Richardson, RT; Hall, SH; French, FS; VandeVoort, CA; Ramachandra, SG; Ramesh, V; Rao, AJ				O'Rand, MG; Widgren, EE; Sivashanmugam, P; Richardson, RT; Hall, SH; French, FS; VandeVoort, CA; Ramachandra, SG; Ramesh, V; Rao, AJ			Reversible Immunocontraception in mate monkeys immunized with Eppin	SCIENCE			English	Article							PROTEASE INHIBITORS; CONTRACEPTION	Various forms of birth control have been developed for women; however, there are currently few options for men. The development of mate contraceptives that are effective, safe, and reversible is desired for family planning throughout the world. We now report contraception of mate nonhuman primates (Macaca radiata) immunized with Eppin, a testis/epididymis-specific protein. Seven out of nine mates (78%) developed high titers to Eppin, and A of these high-titer monkeys were infertile. Five out of seven (71%) high-anti-Eppin titer mates recovered fertility when immunization was stopped. This study demonstrates that effective and reversible mate immunocontraception is an attainable goal. This method of immunocontraception may be extended to humans.	Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; Univ Calif Davis, Calif Natl Primate Res Ctr, Davis, CA 95616 USA; Indian Inst Sci, Dept Biochem, Primate Res Lab, Bangalore 560012, Karnataka, India	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis; Indian Institute of Science (IISC) - Bangalore	O'Rand, MG (corresponding author), Univ N Carolina, Reprod Biol Lab, Chapel Hill, NC 27599 USA.	morand@unc.edu	Addicam, Jagannadha Rao/E-2409-2012	Gudde, Ramachandra/0000-0002-0744-3627				Amory JK, 2000, TRENDS ENDOCRIN MET, V11, P61, DOI 10.1016/S1043-2760(99)00224-6; Holden C, 2002, SCIENCE, V296, P2172, DOI 10.1126/science.296.5576.2172; Kamischke A, 2004, TRENDS PHARMACOL SCI, V25, P49, DOI 10.1016/j.tips.2003.11.009; Lea IA, 1998, BIOL REPROD, V58, P794, DOI 10.1095/biolreprod58.3.794; Lea IA, 1998, BIOL REPROD, V59, P527, DOI 10.1095/biolreprod59.3.527; NASS S, 2004, NEW FRONTIERS CONTRA; O'Rand MG, 1997, J REPROD IMMUNOL, V36, P51, DOI 10.1016/S0165-0378(97)00052-1; PRIMAKOFF P, 1988, NATURE, V335, P543, DOI 10.1038/335543a0; Richardson RT, 2004, BIOL REPROD, P98; Richardson RT, 2001, GENE, V270, P93, DOI 10.1016/S0378-1119(01)00462-0; Sivashanmugam P, 2003, GENE, V312, P125, DOI 10.1016/S0378-1119(03)00608-5; TALWAR GP, 1994, P NATL ACAD SCI USA, V91, P8532, DOI 10.1073/pnas.91.18.8532; Zinkernagel RM, 2001, SCIENCE, V293, P251, DOI 10.1126/science.1063005	13	133	148	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1189	1190		10.1126/science.1099743	http://dx.doi.org/10.1126/science.1099743			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539605	Green Accepted			2022-12-28	WOS:000225193100051
J	Zavaleta, ES; Hulvey, KB				Zavaleta, ES; Hulvey, KB			Realistic species losses disproportionately reduce grassland resistance to biological invaders	SCIENCE			English	Article							ECOSYSTEM FUNCTION; DIVERSITY; BIODIVERSITY; RICHNESS; INVASION; PATTERNS; SUBSETS	Consequences of progressive biodiversity declines depend on the functional roles of individual species and the order in which species are lost. Most studies of the biodiversity-ecosystem functioning relation tackle only the first of these factors. We used observed variation in grassland diversity to design an experimental test of how realistic species losses affect invasion resistance. Because entire plant functional groups disappeared faster than expected by chance, resistance declined dramatically with progressive species losses. Realistic biodiversity losses, even of rare species, can thus affect ecosystem processes far more than indicated by randomized-loss experiments.	Univ Calif Santa Cruz, Dept Environm Studies, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Zavaleta, ES (corresponding author), Univ Calif Santa Cruz, Dept Environm Studies, Santa Cruz, CA 95064 USA.	zavaleta@ucsc.edu	hulvey, k/L-4227-2019; Hulvey, Kris/B-3730-2011	hulvey, k/0000-0001-9062-4113; 				Aarssen LW, 1997, OIKOS, V80, P183, DOI 10.2307/3546531; ATMAR W, 1995, NESTEDNESS TEMPERATU; Belyea LR, 1999, OIKOS, V86, P402, DOI 10.2307/3546646; Blockstein DE, 1998, SCIENCE, V279, P1831, DOI 10.1126/science.279.5358.1831c; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; Dukes JS, 2001, OECOLOGIA, V126, P563, DOI 10.1007/s004420000549; Estes JA, 1998, SCIENCE, V282, P473, DOI 10.1126/science.282.5388.473; Foster BL, 1998, ECOLOGY, V79, P2593, DOI 10.1890/0012-9658(1998)079[2593:SRIASG]2.0.CO;2; Fox BJ, 1987, EVOL ECOL, V1, P201, DOI 10.1007/BF02067551; GOLDBERG DE, 1990, ECOLOGY, V71, P213, DOI 10.2307/1940261; Hadly EA, 2001, EVOL ECOL RES, V3, P477; Henle K, 2004, BIODIVERS CONSERV, V13, P207, DOI 10.1023/B:BIOC.0000004319.91643.9e; HOBBS RJ, 1991, ECOLOGY, V72, P59, DOI 10.2307/1938902; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; HUENNEKE LF, 1990, ECOLOGY, V71, P478, DOI 10.2307/1940302; KADMON R, 1995, ECOLOGY, V76, P458, DOI 10.2307/1941204; Lawler SP, 2002, MG POP BIOL, V33, P294; Loreau M, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P79; Lyons KG, 2001, ECOL LETT, V4, P358, DOI 10.1046/j.1461-0248.2001.00235.x; Magurran A.E., 1988, ECOLOGICAL DIVERSITY; MCDONALD KA, 1992, CONSERV BIOL, V6, P409, DOI 10.1046/j.1523-1739.1992.06030409.x; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; NEWMAN EI, 1973, NATURE, V244, P310, DOI 10.1038/244310a0; Ostfeld RS, 2003, ECOLOGY, V84, P1421, DOI 10.1890/02-3125; PATTERSON BD, 1986, BIOL J LINN SOC, V28, P65, DOI 10.1111/j.1095-8312.1986.tb01749.x; PRESTON FW, 1962, ECOLOGY, V43, P185, DOI 10.2307/1931976; Purvis A, 2000, SCIENCE, V288, P328, DOI 10.1126/science.288.5464.328; Rabinowitz D., 1981, BIOL ASPECTS RARE PL, P205, DOI DOI 10.1177/004728702237415; Smith MD, 2003, ECOL LETT, V6, P509, DOI 10.1046/j.1461-0248.2003.00454.x; Stevens CJ, 2004, SCIENCE, V303, P1876, DOI 10.1126/science.1094678; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Vitousek PM, 1997, NEW ZEAL J ECOL, V21, P1; Watkinson AR, 2001, J APPL ECOL, V38, P233, DOI 10.1046/j.1365-2664.2001.00621.x; Weiher E, 2004, OIKOS, V106, P151, DOI 10.1111/j.0030-1299.2004.12545.x; Wright DH, 1998, OECOLOGIA, V113, P1, DOI 10.1007/s004420050348; WRIGHT DH, 1992, OECOLOGIA, V92, P416, DOI 10.1007/BF00317469	36	253	266	7	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1175	1177		10.1126/science.1102643	http://dx.doi.org/10.1126/science.1102643			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539600	Green Submitted			2022-12-28	WOS:000225193100046
J	Moller-Jensen, J; Gerdes, K				Moller-Jensen, J; Gerdes, K			Dynarnic instability of a bacterial engine	SCIENCE			English	Editorial Material							ESCHERICHIA-COLI; DNA SEGREGATION; BACILLUS-SUBTILIS; PLASMID R1; DIVISION; CELL; CYTOSKELETON; OSCILLATION; MECHANISM; FILAMENTS		MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	MRC Laboratory Molecular Biology; University of Southern Denmark	Moller-Jensen, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	kgerdes@bmb.sdu.dk	Møller-Jensen, Jakob/AAO-8480-2020; Gerdes, Kenn/AAS-5548-2021; Gerdes, Kenn/M-2420-2014	Møller-Jensen, Jakob/0000-0002-6008-3771; Gerdes, Kenn/0000-0002-7462-4612; Gerdes, Kenn/0000-0002-7462-4612				BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Carballido-Lopez R, 2003, DEV CELL, V4, P19, DOI 10.1016/S1534-5807(02)00403-3; Ebersbach G, 2004, MOL MICROBIOL, V52, P385, DOI 10.1111/j.1365-2958.2004.04002.x; Ebersbach G, 2001, P NATL ACAD SCI USA, V98, P15078, DOI 10.1073/pnas.261569598; Garner EC, 2004, SCIENCE, V306, P1021, DOI 10.1126/science.1101313; Gitai Z, 2004, P NATL ACAD SCI USA, V101, P8643, DOI 10.1073/pnas.0402638101; Jensen RB, 1998, P NATL ACAD SCI USA, V95, P8550, DOI 10.1073/pnas.95.15.8550; Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504; Lowe J, 2004, ANNU REV BIOPH BIOM, V33, P177, DOI 10.1146/annurev.biophys.33.110502.132647; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Soufo HJD, 2003, CURR BIOL, V13, P1916, DOI 10.1016/j.cub.2003.10.024; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7	18	1	1	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					987	+		10.1126/science.1105535	http://dx.doi.org/10.1126/science.1105535			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528434				2022-12-28	WOS:000225001100030
J	Van Duyne, RP				Van Duyne, RP			Molecular plasmonics	SCIENCE			English	Editorial Material							LIGHT		Northwestern Univ, Dept Chem, Evanston, IL 60208 USA	Northwestern University	Van Duyne, RP (corresponding author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL 60208 USA.	vanduyne@chem.northwestern.edu	Van Duyne, Richard/P-6045-2017					Andrew P, 2004, SCIENCE, V306, P1002, DOI 10.1126/science.1102992; Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Brockman JM, 2000, ANNU REV PHYS CHEM, V51, P41, DOI 10.1146/annurev.physchem.51.1.41; Haes AJ, 2004, ANAL BIOANAL CHEM, V379, P920, DOI 10.1007/s00216-004-2708-9; Haynes CL, 2003, J PHYS CHEM B, V107, P7337, DOI 10.1021/jp034234r; Haynes CL, 2003, NANO LETT, V3, P939, DOI 10.1021/nl0342287; Krasavin AV, 2004, APPL PHYS LETT, V84, P1416, DOI 10.1063/1.1650904; Kulzer F, 2004, ANNU REV PHYS CHEM, V55, P585, DOI 10.1146/annurev.physchem.54.011002.103816; Lezec HJ, 2002, SCIENCE, V297, P820, DOI 10.1126/science.1071895; Maier SA, 2003, NAT MATER, V2, P229, DOI 10.1038/nmat852; Pettinger B, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.096101; Schatz G.C., 2002, HDB VIBRATIONAL SPEC, P759, DOI DOI 10.1002/0470027320.S0601; Smith LH, 2004, APPL PHYS LETT, V84, P2986, DOI 10.1063/1.1712036; Srituravanich W, 2004, NANO LETT, V4, P1085, DOI 10.1021/nl049573q; Wedge S, 2004, APPL PHYS LETT, V85, P182, DOI 10.1063/1.1772516	15	90	95	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					985	986		10.1126/science.1104976	http://dx.doi.org/10.1126/science.1104976			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528432				2022-12-28	WOS:000225001100028
J	Williams, SEJ; Wootton, P; Mason, HS; Bould, J; Iles, DE; Riccardi, D; Peers, C; Kemp, PJ				Williams, SEJ; Wootton, P; Mason, HS; Bould, J; Iles, DE; Riccardi, D; Peers, C; Kemp, PJ			Hemoxygenase-2 is an oxygen sensor for a calcium-sensitive potassium channel	SCIENCE			English	Article							CA2+-ACTIVATED K+ CHANNELS; CAROTID-BODY; LARGE-CONDUCTANCE; CHEMORECEPTOR CELLS; CYTOSOLIC FACTORS; CARBON-MONOXIDE; CENTRAL NEURONS; CURRENTS; MECHANISM; HEME	Modulation of calcium-sensitive potassium (BK) channels by oxygen is important in several mammalian tissues, and in the carotid body it is crucial to respiratory control. However, the identity of the oxygen sensor remains unknown. We demonstrate that hemoxygenase-2 (HO-2) is part of the BK channel complex and enhances channel activity in normoxia. Knockdown of HO-2 expression reduced channel activity, and carbon monoxide, a product of HO-2 activity, rescued this loss of function. Inhibition of BK channels by hypoxia was dependent on HO-2 expression and was augmented by HO-2 stimulation. Furthermore, carotid body cells demonstrated HO-2-dependent hypoxic BK channel inhibition, which indicates that HO-2 is an oxygen sensor that controls channel activity during oxygen deprivation.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Chem, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Leeds, Sch Med, Leeds LS2 9JT, W Yorkshire, England; Univ Wales Coll Cardiff, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Leeds; University of Leeds; University of Leeds; University of Leeds; Cardiff University	Kemp, PJ (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	KempPJ@Cardiff.ac.uk	Bould, J/GRX-7488-2022; Riccardi, Daniela/A-4674-2010; Kemp, Paul/A-4634-2010; Bould, Jonathan/H-4536-2015	Riccardi, Daniela/0000-0002-7322-3163; Kemp, Paul/0000-0003-2773-973X; Bould, Jonathan/0000-0003-3615-1938; Peers, Chris/0000-0002-8354-346X				Ahring PK, 1997, FEBS LETT, V415, P67, DOI 10.1016/S0014-5793(97)01096-X; COMFIELD DN, 1996, P NATL ACAD SCI USA, V93, P8089; JIANG C, 1994, P NATL ACAD SCI USA, V91, P7198, DOI 10.1073/pnas.91.15.7198; JIANG C, 1994, J PHYSIOL-LONDON, V481, P15, DOI 10.1113/jphysiol.1994.sp020415; Lewis A, 2002, J PHYSIOL-LONDON, V540, P771, DOI 10.1113/jphysiol.2001.013888; Liu HJ, 1999, J CLIN INVEST, V104, P577, DOI 10.1172/JCI7291; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Peng W, 1999, AM J RESP CELL MOL, V20, P737, DOI 10.1165/ajrcmb.20.4.3390; PRABHAKAR NR, 1995, P NATL ACAD SCI USA, V92, P1994, DOI 10.1073/pnas.92.6.1994; Prabhakar NR, 1999, RESP PHYSIOL, V115, P161, DOI 10.1016/S0034-5687(99)00019-5; Riesco-Fagundo AM, 2001, CIRC RES, V89, P430, DOI 10.1161/hh1701.095632; Tang XD, 2003, NATURE, V425, P531, DOI 10.1038/nature02003; Thompson RJ, 1998, J PHYSIOL-LONDON, V512, P421, DOI 10.1111/j.1469-7793.1998.421be.x; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Williams SE, 2004, BIOCHEM BIOPH RES CO, V314, P63, DOI 10.1016/j.bbrc.2003.12.052; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295	19	370	379	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	2004	306	5704					2093	2097		10.1126/science.1105010	http://dx.doi.org/10.1126/science.1105010			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	881CM	15528406				2022-12-28	WOS:000225841000063
J	Underwood, M				Underwood, M		UK BEAM Trial Team	United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSIOTHERAPY; FRAMEWORK; BELIEFS; THERAPY; PACKAGE	Objective To estimate the effect of adding exercise classes, spinal manipulation delivered in NHS or private premises, or manipulation followed by exercise to "best care" in general practice for patients consulting with back pain. Design Pragmatic randomised trial with factorial design. Setting 181 general practices in Medical Research Council General Practice Research Framework; 63 community settings around 14 centres across the United Kingdom. Participants 1334 patients consulting their general practices about low back pain. Main outcome measures Scores on the Roland Morris disability questionnaire at three and 12 months, adjusted for centre and baseline scores. Results All groups improved over time. Exercise improved mean disability questionnaire scores at three months by 1.4 (95% confidence interval 0.6 to 2.1) more than "best care." For manipulation the additional improvement was 1.6 (0.8 to 2.3) at three months and 1.0 (0.2 to 1.8) at 12 months. For manipulation followed by exercise the additional improvement was 1.9 (1.2 to 2.6) at three months and 1.3 (0.5 to 2.1) at 12 months. No significant differences in Outcome occurred between manipulation in NHS premises and in private premises. No serious adverse events occur-red. Conclusions Relative to "best care" in general practice, manipulation followed by exercise achieved a moderate benefit at three months and a small benefit at 12 months; spinal manipulation achieved a small to moderate benefit at three months and a small benefit at 12 months; and exercise achieved a small benefit at three months but not at 12 months.	Queen Mary Univ London, Barts & London Queen Marys Sch Med & Dent, Inst Community Hlth Sci, Ctr Gen Practice & Primary Care, London E1 4NS, England	University of London; Queen Mary University London	Underwood, M (corresponding author), Queen Mary Univ London, Barts & London Queen Marys Sch Med & Dent, Inst Community Hlth Sci, Ctr Gen Practice & Primary Care, London E1 4NS, England.	m.undenvood@qmul.ac.uk	Russell, Ian T/H-1181-2012; Underwood, Martin/D-6364-2015	Underwood, Martin/0000-0002-0309-1708				Assendelft WJJ, 2003, ANN INTERN MED, V138, P871, DOI 10.7326/0003-4819-138-11-200306030-00008; ASSENDELFT WJJ, 1991, J MANIP PHYSIOL THER, V14, P281; Bombardier C, 2001, J RHEUMATOL, V28, P431; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Harvey E, 2003, MANUAL THER, V8, P46, DOI 10.1054/math.2002.0472; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; KNIPSCHILD P, 1991, J CLIN EPIDEMIOL, V44, P461, DOI 10.1016/0895-4356(91)90208-Q; Koes BW, 2001, SPINE, V26, P2504, DOI 10.1097/00007632-200111150-00022; Manca A, 2004, BMJ-BRIT MED J, V329, P1381, DOI 10.1136/bmj.38282.607859.AE; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MOFFETT JK, 2000, PHYSIOTHERAPY, V85, P295; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, BACK BOOK; Russell I, 2003, BMC HEALTH SERV RES, V3; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; Underwood M, 2002, FAM PRACT, V19, P511, DOI 10.1093/fampra/19.5.511; Underwood MR, 1999, SPINE, V24, P1104, DOI 10.1097/00007632-199906010-00010; van Tulder M, 2000, SPINE, V25, P2784, DOI 10.1097/00007632-200011010-00011; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Waddell G, 1999, LOW BACK PAIN EVIDEN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	24	275	277	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2004	329	7479					1377	1381		10.1136/bmj.38282.669225AE	http://dx.doi.org/10.1136/bmj.38282.669225AE			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	880JB	15556955				2022-12-28	WOS:000225785000020
J	Atkinson, HDE; Nicol, SG; Purkayastha, S; Paterson-Brown, S				Atkinson, HDE; Nicol, SG; Purkayastha, S; Paterson-Brown, S			Surgical management of inguinal hernia: retrospective cohort study in southeastern Scotland, 1985-2001	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REPAIR		Charing Cross Hosp, Dept Orthopaed & Trauma Surg, London W6 8RF, England; Bristol Royal Infirm & Gen Hosp, Dept Trauma & Orthopaed Surg, Bristol, Avon, England; St Marys Hosp, Dept Gen Surg, London, England; Univ Edinburgh, Royal Infirm Edinburgh, Dept Surg, Edinburgh EH3 9YW, Midlothian, Scotland	Imperial College London; Bristol Royal Infirmary; Imperial College London; Royal Infirmary of Edinburgh; University of Edinburgh	Atkinson, HDE (corresponding author), Charing Cross Hosp, Dept Orthopaed & Trauma Surg, London W6 8RF, England.	duscha@hotmail.com	Atkinson, Henry Dushan Edward/AAB-1735-2019	Atkinson, Henry Dushan Edward/0000-0001-6003-207X				Bay-Nielsen M, 2001, LANCET, V358, P1124, DOI 10.1016/S0140-6736(01)06251-1; Grant A, 2000, BRIT J SURG, V87, P854, DOI 10.1046/j.1365-2168.2000.01539.x; LICHTENSTEIN IL, 1989, AM J SURG, V157, P188, DOI 10.1016/0002-9610(89)90526-6; McCormack K, 2003, Cochrane Database Syst Rev, pCD001785, DOI 10.1002/14651858.CD001785; SCHUMPELICK V, 1994, LANCET, V344, P375	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	2004	329	7478					1315	1316		10.1136/bmj.38282.675556.F7	http://dx.doi.org/10.1136/bmj.38282.675556.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15546894	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000225657800017
J	Bjordal, JM; Ljunggren, AE; Klovning, A; Slordal, L				Bjordal, JM; Ljunggren, AE; Klovning, A; Slordal, L			Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							QUALITY-OF-LIFE; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; OSTEO-ARTHRITIS; ADVERSE EVENTS; OSTEOARTHRITIS; EFFICACY; SAFETY; NABUMETONE; CELECOXIB	Objective To estimate the analgesic efficacy of non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclo-oxygenase-2 inhibitors (coxibs), in patients with osteoarthritis of the knee. Design Systematic review and meta-analysis of randomised placebo controlled trials. Studies reviewed 23 trials including 10 845 patients, median age of 62.5 years. 7807 patients received adequate doses of NSAIDs and 3038 received placebo. The mean weighted baseline pain score was 64.2 mm on 100 turn visual analogue scale (VAS),and average duration of symptoms was 8.2 years. Main outcome measure Change in overall intensity of pain. Results Methodological quality of trials was acceptable, but 13 trials excluded patients before randomisation if they did not respond to NSAIDs. One trial provided long term data for pain that showed no significant effect of NSAIDs compared with placebo at one to four years. The pooled difference for pain on visual analogue scale in all included trials was 10.1 mm (95% confidence interval 7.4 to 12.8) or 15.6% better than placebo after 2-13 weeks. The results were heterogeneous, and the effect size for pain reduction was 0.32 (0.24 to 0.39) in a random effects model. In 10 trials that did not exclude non-responders to NSAID treatment the results were homogeneous, with an effect size for pain reduction of 0.23 (0.15 to 0.31). Conclusion NSAIDs can reduce short term pain in osteoarthritis of the knee slightly better than placebo, but the current analysis does not support long term use of NSAIDs for this condition. As serious adverse effects are associated with oral NSAIDs, only limited use can be recommended.	Univ Bergen, Dept Publ Hlth & Primary Hlth Care, N-5018 Bergen, Norway; Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, N-7489 Trondheim, Norway	University of Bergen; Norwegian University of Science & Technology (NTNU)	Bjordal, JM (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Hlth Care, N-5018 Bergen, Norway.	jmb@hib.no	Bjordal, Jan Magnus/T-7122-2019; Bannuru, Raveendhara/G-2601-2011	Bannuru, Raveendhara/0000-0002-8069-5783				ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Andrianakos A, 2003, J RHEUMATOL, V30, P1589; Angst F, 2002, J RHEUMATOL, V29, P131; BARDEN J, 2003, COCHRANE DATABASE SY; Barden J, 2003, COCHRANE DB SYST REV; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; Bensen WG, 1999, MAYO CLIN PROC, V74, P1095, DOI 10.4065/74.11.1095; Bleumink GS, 2003, DRUGS, V63, P525, DOI 10.2165/00003495-200363060-00001; Case JP, 2003, ARCH INTERN MED, V163, P169, DOI 10.1001/archinte.163.2.169; Cerezo JG, 2003, EUR J CLIN PHARMACOL, V59, P169, DOI 10.1007/s00228-003-0579-1; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Cowan SM, 2001, ARCH PHYS MED REHAB, V82, P183, DOI 10.1053/apmr.2001.19022; Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619; Dieppe PA, 2004, BRIT MED J, V329, P867, DOI 10.1136/bmj.329.7471.867; DORE R, 1995, CLIN THER, V17, P656, DOI 10.1016/0149-2918(95)80042-5; Eccles M, 1998, BRIT MED J, V317, P526; Ehrich EW, 2000, J RHEUMATOL, V27, P2635; Ehrich EW, 2001, AM J MANAG CARE, V7, P609; Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003-4819-133-8-200010170-00016; Fleischmann RM, 1997, CLIN THER, V19, P642, DOI 10.1016/S0149-2918(97)80090-2; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gibofsky A, 2003, ARTHRITIS RHEUM-US, V48, P3102, DOI 10.1002/art.11330; Gottesdiener K, 2002, RHEUMATOLOGY, V41, P1052, DOI 10.1093/rheumatology/41.9.1052; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; Johnson AG, 1997, DRUG SAFETY, V17, P277, DOI 10.2165/00002018-199717050-00001; Jordan KM, 2003, ANN RHEUM DIS, V62, P1145, DOI 10.1136/ard.2003.011742; Juni P, 2002, BRIT MED J, V324, P1287, DOI 10.1136/bmj.324.7349.1287; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kivitz A, 2002, J FAM PRACTICE, V51, P530; Kivitz AJ, 2004, J AM GERIATR SOC, V52, P666, DOI 10.1111/j.1532-5415.2004.52201.x; LEE P, 1985, J RHEUMATOL, V12, P544; Lund B, 1998, SCAND J RHEUMATOL, V27, P32; Makarowski W, 1996, CLIN THER, V18, P114, DOI 10.1016/S0149-2918(96)80184-6; McKenna F, 2001, SCAND J RHEUMATOL, V30, P11; McKenna F, 2001, JCR-J CLIN RHEUMATOL, V7, P151, DOI 10.1097/00124743-200106000-00004; Phelan KM, 2003, J CLIN PSYCHIAT, V64, P1328, DOI 10.4088/JCP.v64n1108; Radebold A, 2001, SPINE, V26, P724, DOI 10.1097/00007632-200104010-00004; Roos EM, 1999, SCAND J RHEUMATOL, V28, P210; Rowbotham MC, 2001, PAIN, V94, P131, DOI 10.1016/S0304-3959(01)00371-2; SCHNITZER TJ, 1995, CLIN THER, V17, P602, DOI 10.1016/0149-2918(95)80037-9; Scott DL, 2000, RHEUMATOLOGY, V39, P1095, DOI 10.1093/rheumatology/39.10.1095; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Speldewinde GC, 2001, MED J AUSTRALIA, V174, P174, DOI 10.5694/j.1326-5377.2001.tb143210.x; Steultjens MPM, 2000, RHEUMATOLOGY, V39, P955, DOI 10.1093/rheumatology/39.9.955; Sturkenboom MCJM, 2002, ARTHRIT RHEUM-ARTHR, V47, P132, DOI 10.1002/art.10268; Suenaga S, 2001, J COMPUT ASSIST TOMO, V25, P476, DOI 10.1097/00004728-200105000-00023; Tannenbaum H, 2004, ANN RHEUM DIS, V63, P1419, DOI 10.1136/ard.2003.015974; TANNENBAUM H, 2004, ANN RHEUM DIS; Tramer MR, 2000, PAIN, V85, P169, DOI 10.1016/S0304-3959(99)00267-5; Uzun H, 2001, ACTA ORTHOP SCAND, V72, P499, DOI 10.1080/000164701753532844; Vaatainen U, 1998, OSTEOARTHR CARTILAGE, V6, P115, DOI 10.1053/joca.1997.0101; WATSON MC, 2004, COCHRANE DATABASE SY; WEAVER A, 1995, CLIN THER, V17, P735, DOI 10.1016/0149-2918(95)80050-6; Wegman A, 2004, J RHEUMATOL, V31, P344; Whelton A., 1999, AM J MED, V106, p13S, DOI [10.1016/s0002-9343(99)00113-8, DOI 10.1016/S0002-9343(99)00113-8]; Williams GW, 2001, CLIN THER, V23, P213, DOI 10.1016/S0149-2918(01)80004-7; WILLIAMS PI, 1989, CURR MED RES OPIN, V11, P463, DOI 10.1185/03007998909115933; Wright JM, 2002, CAN MED ASSOC J, V167, P1131; Zabinski RA, 2001, PHARMACOECONOMICS, V19, P49, DOI 10.2165/00019053-200119001-00004; Zhang W, 2004, ANN RHEUM DIS, V63, P901, DOI 10.1136/ard.2003.018531; Zhao SZ, 1999, PHARMACOTHERAPY, V19, P1269, DOI 10.1592/phco.19.16.1269.30879	62	298	310	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	2004	329	7478					1317	1320D		10.1136/bmj.38273.626655.63	http://dx.doi.org/10.1136/bmj.38273.626655.63			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15561731	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225657800019
J	Vaugelade, J; Pinchinat, S; Guiella, G; Elguero, E; Simondon, F				Vaugelade, J; Pinchinat, S; Guiella, G; Elguero, E; Simondon, F			Non-specific effects of vaccination on child survival: prospective cohort study in Burkina Faso	BRITISH MEDICAL JOURNAL			English	Article							WEST-AFRICA; MORTALITY	Objective To study the effect of vaccination on mortality before 2 years of age in a developing country. Design Prospective cohort study. Setting Rural communities in Burkina Faso. Participants 9085 children born in the study area between 1985 and 1993. Main outcome measure Child death rate. Results Mortality before 2 years of age was lower in the group of children who had been vaccinated: those vaccinated with BCG only had significantly lower mortality (0.37, 95% confidence interval 0.29 to 0.48) as did those vaccinated with diphtheria, tetanus, and pertussis only (0.24, 0.13 to 0.43). The second dose of diphtheria, tetanus, and pertussis was not associated with lower mortality (0.80, 0.58 to 1.12). Conclusion Vaccination with diphtheria, tetanus, and pertussis as well as BCG is associated with better survival of children up to 2 years of age.	Inst Rech Dev, Lab Populat Environm & Dev, F-34394 Montpellier 5, France; Biostatem, F-30035 Nimes, France; Unite Etud & Rech Demog, Ouagadougou 03, Burkina Faso	UDICE-French Research Universities; Aix-Marseille Universite; Institut de Recherche pour le Developpement (IRD)	Vaugelade, J (corresponding author), Inst Rech Dev, Lab Populat Environm & Dev, BP 64501, F-34394 Montpellier 5, France.	vaugelad@ird.fr	Elguero, Eric/J-3014-2012	Simondon, Francois/0000-0003-0395-1314				AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Aaby P, 2003, LANCET, V361, P2183, DOI 10.1016/S0140-6736(03)13771-3; COX, 1972, J ROY STAT SOC B, P187; FINE P, 2000, BRIT MED J, V321, P1440; GARENNE M, 1991, AM J EPIDEMIOL, V338, P183; HULL HF, 1983, LANCET, V1, P972; JENSEN H, 2002, THESIS U COPENHAGEN; KOENIG MA, 1990, B WORLD HEALTH ORGAN, V68, P441; Kristensen I, 2000, BRIT MED J, V321, P1435, DOI 10.1136/bmj.321.7274.1435; VAUGELADE J, 1988, VARIATIONS MORTALITE; VAUGELADE J, 1997, DEMOGRAPHIC EVALUATI, P123; VAUGELADE J, 2000, PROBLEMATIQUE METHOD	12	73	73	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 4	2004	329	7478					1309	1311		10.1136/bmj.38261.496366.82	http://dx.doi.org/10.1136/bmj.38261.496366.82			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	878PC	15550402	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225657800015
J	Wadsworth, JDF; Asante, EA; Desbruslais, M; Linehan, JM; Joiner, S; Gowland, I; Welch, J; Stone, L; Lloyd, SE; Hill, AF; Brandner, S; Collinge, J				Wadsworth, JDF; Asante, EA; Desbruslais, M; Linehan, JM; Joiner, S; Gowland, I; Welch, J; Stone, L; Lloyd, SE; Hill, AF; Brandner, S; Collinge, J			Human prion protein with valine 129 prevents expression of variant CJD phenotype	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; BOVINE SPONGIFORM ENCEPHALOPATHY; BLOOD-TRANSFUSION; STRAIN VARIATION; SUSCEPTIBILITY; MICE; BSE; TRANSMISSION; GENOTYPE; VCJD	Variant Creutzfeldt-jpkob disease (vCJD) is a unique and highly distinctive clinicopathological and molecular phenotype of human prion disease associated with infection with bovine spongiform encephalopathy (BSE)-like prions. Here, we found that generation of this phenotype in transgenic mice required expression of human prion protein (PrP) with methionine 129. Expression of human PrP with valine 129 resulted in a distinct phenotype and, remarkably, persistence of a barrier to transmission of BSE-derived prions on subpassage. Polymorphic residue 129 of human PrP dictated propagation of distinct prion strains after BSE prion infection. Thus, primary and secondary human infection with BSE-derived prions may result in sporadic CJD-like or novel phenotypes in addition to vCJD, depending on the genotype of the prion source and the recipient.	UCL, MRC, Prion Unit, London WC1N 3BG, England; UCL, Dept Neurodegenerat Dis, Inst Neurol, London WC1N 3BG, England	University of London; University College London; University of London; University College London	Collinge, J (corresponding author), UCL, MRC, Prion Unit, Queen Sq, London WC1N 3BG, England.	j.collinge@prion.ucl.ac.uk	Brandner, Sebastian/J-4562-2014; Hill, Andrew F./GZL-4124-2022; Hill, Andrew F./AAH-2854-2020; Hill, Andrew F/B-4527-2009	Brandner, Sebastian/0000-0002-9821-0342; Hill, Andrew F./0000-0001-5581-2354; Hill, Andrew F/0000-0001-5581-2354; Wadsworth, Jonathan/0000-0002-4797-2259; Asante, Emmanuel A/0000-0003-3771-4843	Medical Research Council [MC_U123160653, MC_U123160655] Funding Source: Medline; MRC [MC_U123160655] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Asante EA, 2002, EMBO J, V21, P6358, DOI 10.1093/emboj/cdf653; ASANTE EA, UNPUB; BRUCE M, 1994, PHILOS T R SOC B, V343, P405, DOI 10.1098/rstb.1994.0036; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; COLLINGE J, 1995, NATURE, V378, P779, DOI 10.1038/378779a0; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hill AF, 2003, TRENDS MICROBIOL, V11, P578, DOI 10.1016/j.tim.2003.10.007; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Lasmezas CI, 2001, P NATL ACAD SCI USA, V98, P4142, DOI 10.1073/pnas.041490898; Lee HS, 2001, J INFECT DIS, V183, P192, DOI 10.1086/317935; Llewelyn CA, 2004, LANCET, V363, P417, DOI 10.1016/S0140-6736(04)15486-X; Mead S, 2003, SCIENCE, V300, P640, DOI 10.1126/science.1083320; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Wadsworth JDF, 1999, NAT CELL BIOL, V1, P55, DOI 10.1038/9030; Wadsworth JDF, 2001, LANCET, V358, P171, DOI 10.1016/S0140-6736(01)05403-4; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	21	203	207	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	2004	306	5702					1793	1796		10.1126/science.1103932	http://dx.doi.org/10.1126/science.1103932			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878FA	15539564				2022-12-28	WOS:000225630800058
J	Emerson, SU; Purcell, RH				Emerson, SU; Purcell, RH			Global health - Running like water - The omnipresence of hepatitis E	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NIAID, Mol Hepatitis Sect, NIH, Bethesda, MD 20892 USA; NIAID, Hepatitis Viruses Sect, Infect Dis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Emerson, SU (corresponding author), NIAID, Mol Hepatitis Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000311, ZIAAI000596, Z01AI000596, ZIAAI000311] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Xing L, 1999, VIROLOGY, V265, P35, DOI 10.1006/viro.1999.0005	1	64	71	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2367	2368		10.1056/NEJMp048285	http://dx.doi.org/10.1056/NEJMp048285			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575050				2022-12-28	WOS:000225429000003
J	Page, RL				Page, RL			Clinical practice - Newly diagnosed atrial fibrillation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; PULMONARY VEIN ISOLATION; QUALITY-OF-LIFE; CATHETER ABLATION; RHYTHM CONTROL; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; AMERICAN-COLLEGE; RISK-FACTORS; FOLLOW-UP	A 77-year-old woman with a history of hypertension treated with metoprolol presents for her annual examination. She reports no new symptoms. The examination is remarkable only for the finding of an irregular heart rate. Electrocardiographic testing reveals atrial fibrillation at an average rate of 75 beats per minute. She has no history of arrhythmia, coronary disease, valvular disease, diabetes, alcohol abuse, transient ischemic attack, or stroke. For the past several months, she has exercised on a treadmill without difficulty, although she notes that the machine does not always measure her heart rate. What should her physician advise?	Univ Washington, Sch Med, Div Cardiol, Dept Internal Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Page, RL (corresponding author), Univ Washington, Sch Med, Div Cardiol, Dept Internal Med, 1959 NE Pacific St,Rm AA510,Hlth Sci Bldg,Box 356, Seattle, WA 98195 USA.	rpage@u.washington.edu	Page, Richard L./L-5501-2014	Page, Richard L./0000-0001-5603-1330				Albers GW, 2003, LANCET, V362, P1691; Albers GW, 2001, CHEST, V119, p194S, DOI 10.1378/chest.119.1_suppl.194S; Alboni P, 2004, NEW ENGL J MED, V351, P2384, DOI 10.1056/NEJMoa041233; [Anonymous], 1994, ARCH INTERN MED, V154, P2254; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Bonow RO, 1998, J AM COLL CARDIOL, V32, P1486, DOI 10.1016/S0735-1097(98)00454-9; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; Chen MS, 2004, J AM COLL CARDIOL, V43, P1004, DOI 10.1016/j.jacc.2003.09.056; Clark DM, 1997, J AM COLL CARDIOL, V30, P1039, DOI 10.1016/S0735-1097(97)00254-4; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COX JL, 1991, J THORAC CARDIOV SUR, V101, P569, DOI 10.1016/s0022-5223(19)36684-x; Ellenbogen KA, 2003, J AM COLL CARDIOL, V42, P198, DOI 10.1016/S0735-1097(03)00583-7; ELLENBOGEN KA, 2003, ANN INTERN MED, V138, P634; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1993, NEW ENGL J MED, V328, P148; Farshi R, 1999, J AM COLL CARDIOL, V33, P304, DOI 10.1016/S0735-1097(98)00561-0; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hagens VE, 2004, J AM COLL CARDIOL, V43, P241, DOI 10.1016/j.jacc.2003.08.037; Haissaguerre M, 1998, NEW ENGL J MED, V339, P659, DOI 10.1056/NEJM199809033391003; HALPERIN JL, 1988, STROKE, V19, P937, DOI 10.1161/01.STR.19.8.937; Hart RG, 2000, J AM COLL CARDIOL, V35, P183, DOI 10.1016/S0735-1097(99)00489-1; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; HOHNLOSER SH, 1995, J CARDIOVASC ELECTR, V6, P920, DOI 10.1111/j.1540-8167.1995.tb00368.x; Hsu LF, 2004, NEW ENGL J MED, V351, P2373, DOI 10.1056/NEJMoa041018; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Israel CW, 2004, J AM COLL CARDIOL, V43, P47, DOI 10.1016/j.jacc.2003.08.027; Kanagala R, 2003, CIRCULATION, V107, P2589, DOI 10.1161/01.CIR.0000068337.25994.21; Kerr C, 1996, EUR HEART J, V17, P48, DOI 10.1093/eurheartj/17.suppl_C.48; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Klein AL, 2001, NEW ENGL J MED, V344, P1411, DOI 10.1056/NEJM200105103441901; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KRAHN AD, 1995, AM J MED, V98, P476, DOI 10.1016/S0002-9343(99)80348-9; Kuhlkamp V, 2000, J AM COLL CARDIOL, V36, P139, DOI 10.1016/S0735-1097(00)00693-8; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LEMERY R, 1987, AM J CARDIOL, V60, P1406, DOI 10.1016/0002-9149(87)90633-3; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; Oral H, 2002, CIRCULATION, V105, P1077, DOI 10.1161/hc0902.104712; PACKER DL, 1986, AM J CARDIOL, V57, P563, DOI 10.1016/0002-9149(86)90836-2; Page RL, 2003, CIRCULATION, V107, P1141, DOI 10.1161/01.CIR.0000051455.44919.73; PAGE RL, 1994, CIRCULATION, V89, P224, DOI 10.1161/01.CIR.89.1.224; Page RL, 2000, J AM COLL CARDIOL, V36, P147, DOI 10.1016/S0735-1097(00)00676-8; Pappone C, 2003, J AM COLL CARDIOL, V42, P185, DOI 10.1016/S0735-1097(03)00577-1; Pedersen OD, 1999, CIRCULATION, V100, P376, DOI 10.1161/01.CIR.100.4.376; PETERSEN P, 1989, LANCET, V1, P175; Purerfellner H, 2004, AM J CARDIOL, V93, P1428, DOI 10.1016/S0002-9149(04)00297-8; Rockson SG, 2004, J AM COLL CARDIOL, V43, P929, DOI 10.1016/j.jacc.2003.11.028; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Savelieva I, 2000, PACE, V23, P145, DOI 10.1111/j.1540-8159.2000.tb00794.x; Snow V, 2003, ANN INTERN MED, V139, P1009, DOI 10.7326/0003-4819-139-12-200312160-00011; Stein PD, 2001, CHEST, V119, p220S, DOI 10.1378/chest.119.1_suppl.220S; Stein PD, 2001, CHEST, V120, P1044; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Vasamreddy CR, 2004, HEART RHYTHM, V1, P78, DOI 10.1016/j.hrthm.2004.02.006; Vermes E, 2003, CIRCULATION, V107, P2926, DOI 10.1161/01.CIR.0000072793.81076.D4; WOLF PA, 1983, STROKE, V14, P664, DOI 10.1161/01.STR.14.5.664; Wolk R, 1996, INT J CARDIOL, V54, P207, DOI 10.1016/0167-5273(96)02631-9; Wyse DG, 2004, CIRCULATION, V109, P3089, DOI 10.1161/01.CIR.0000132611.01101.DC; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zabalgoitia M, 1998, ANN INTERN MED, V128, P639, DOI 10.7326/0003-4819-128-8-199804150-00005	64	73	77	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2004	351	23					2408	2416		10.1056/NEJMcp041956	http://dx.doi.org/10.1056/NEJMcp041956			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875OC	15575057				2022-12-28	WOS:000225429000010
J	Alonso, JM; Stepanova, AN				Alonso, JM; Stepanova, AN			The ethylene signaling pathway	SCIENCE			English	Article							RECEPTOR GENE FAMILY; RAF-LIKE KINASE; RESPONSE PATHWAY; ARABIDOPSIS-THALIANA; CTR1; TRANSDUCTION; ETR1; GAS; ETHYLENE-INSENSITIVE3; PERSPECTIVE	Plants use a structurally very simple gas molecule, the hydrocarbon ethylene, to modulate various developmental programs and coordinate responses to a multitude of external stress factors. How this simple molecule generates such a diverse array of effects has been the subject of intense research for the past two decades. A fascinating signaling pathway, with classical as well as novel plant-specific signaling elements, is emerging from these studies. We describe the four main modules that constitute this signaling pathway: a phosphotransfer relay, an EIN2-based unit, a ubiquitin-mediated protein degradation component, and a transcriptional cascade. The canonical and Arabidopsis ethylene signaling pathways in the Signal Transduction Knowledge Environment Connections Maps provide a complete panoramic view of these signaling events in plants.	N Carolina State Univ, Dept Genet, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Alonso, JM (corresponding author), N Carolina State Univ, Dept Genet, Box 7614, Raleigh, NC 27695 USA.	jmalonso@unity.ncsu.edu	Stepanova, Anna/P-9575-2019; Alonso, Jose M/K-6826-2014	Stepanova, Anna/0000-0003-1018-4758; Alonso, Jose M/0000-0001-7087-1571				Abeles F, 1992, ETHYLENE PLANT BIOL; Alonso JM, 1999, SCIENCE, V284, P2148, DOI 10.1126/science.284.5423.2148; Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391; Alonso JM, 2003, P NATL ACAD SCI USA, V100, P2992, DOI 10.1073/pnas.0438070100; Bleecker AB, 1999, TRENDS PLANT SCI, V4, P269, DOI 10.1016/S1360-1385(99)01427-2; Bleecker AB, 2000, ANNU REV CELL DEV BI, V16, P1, DOI 10.1146/annurev.cellbio.16.1.1; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; Clark KL, 1998, P NATL ACAD SCI USA, V95, P5401, DOI 10.1073/pnas.95.9.5401; Gagne JM, 2004, P NATL ACAD SCI USA, V101, P6803, DOI 10.1073/pnas.0401698101; Gao ZY, 2003, J BIOL CHEM, V278, P34725, DOI 10.1074/jbc.M305548200; Guo HW, 2003, CELL, V115, P667, DOI 10.1016/S0092-8674(03)00969-3; Guo HW, 2004, CURR OPIN PLANT BIOL, V7, P40, DOI 10.1016/j.pbi.2003.11.011; Hirayama T, 2000, PLANT CELL PHYSIOL, V41, P548, DOI 10.1093/pcp/41.5.548; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Huang YF, 2003, PLANT J, V33, P221, DOI 10.1046/j.1365-313X.2003.01620.x; Hyodo H., 1991, PLANT HORMONE ETHYLE; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Klee HJ, 2004, PLANT PHYSIOL, V135, P660, DOI 10.1104/pp.104.040998; Lorenzo O, 2003, PLANT CELL, V15, P165, DOI 10.1105/tpc.007468; MOUSSATCHE P, 2004, IN PRESS J BIOL 0909; Ouaked F, 2003, EMBO J, V22, P1282, DOI 10.1093/emboj/cdg131; Potuschak T, 2003, CELL, V115, P679, DOI 10.1016/S0092-8674(03)00968-1; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; STEPANOVA AN, 2004, SCI STKE         NOV; Wang KLC, 2002, PLANT CELL, V14, pS131, DOI 10.1105/tpc.001768; Wang WY, 2003, P NATL ACAD SCI USA, V100, P352, DOI 10.1073/pnas.0237085100	30	147	162	6	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1513	1515		10.1126/science.1104812	http://dx.doi.org/10.1126/science.1104812			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567852				2022-12-28	WOS:000225442700046
J	Dorigo, B; Schalch, T; Kulangara, A; Duda, S; Schroeder, RR; Richmond, TJ				Dorigo, B; Schalch, T; Kulangara, A; Duda, S; Schroeder, RR; Richmond, TJ			Nucleosome arrays reveal the two-start organization of the chromatin fiber	SCIENCE			English	Article							HIGHER-ORDER STRUCTURE; HISTONE H1; METAPHASE CHROMOSOMES; ANGSTROM RESOLUTION; LINKER HISTONES; CORE PARTICLE; IN-VIVO; LENGTH	Chromatin folding determines the accessibility of DNA constituting eukaryotic genomes and consequently is profoundly important in the mechanisms of nuclear processes such as gene regulation. Nucleosome arrays compact to form a 30-nanometer chromatin fiber of hitherto disputed structure. Two competing classes of models have been proposed in which nucleosomes are either arranged linearly in a one-start higher order helix or zigzag back and forth in a two-start helix. We analyzed compacted nucleosome arrays stabilized by introduction of disulfide cross-links and show that the chromatin fiber comprises two stacks of nucleosomes in accord with the two-start model.	ETH Honggerberg, ETH Zurich, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Max Planck Inst Med Res, Dept Biomed Mech, D-69120 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; Max Planck Society	Richmond, TJ (corresponding author), ETH Honggerberg, ETH Zurich, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland.	richmond@mot.biol.ethz.ch	Schalch, Thomas/E-7507-2010; Schröder, Rasmus R/S-6220-2016; Schalch, Thomas/A-6007-2014	Schalch, Thomas/0000-0002-0758-3013				Barra JL, 2000, MOL CELL BIOL, V20, P61, DOI 10.1128/MCB.20.1.61-69.2000; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; Davey CA, 2002, J MOL BIOL, V319, P1097, DOI 10.1016/S0022-2836(02)00386-8; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; DORIGO B, UNPUB; Fan YH, 2003, MOL CELL BIOL, V23, P4559, DOI 10.1128/MCB.23.13.4559-4572.2003; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; Patterton HG, 1998, J BIOL CHEM, V273, P7268, DOI 10.1074/jbc.273.13.7268; Ramon A, 2000, MOL MICROBIOL, V35, P223, DOI 10.1046/j.1365-2958.2000.01702.x; RATTNER JB, 1978, CHROMOSOMA, V69, P363, DOI 10.1007/BF00332139; Richmond TJ, 2000, CHROMATIN STRUCTURE, P1; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; Strukov YG, 2003, J CELL BIOL, V162, P23, DOI 10.1083/jcb.200303098; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; Van Holde KE, 1988, SPRINGER SERIES MOL; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WILLIAMS SP, 1986, BIOPHYS J, V49, P233, DOI 10.1016/S0006-3495(86)83637-2; WOODCOCK CLF, 1984, J CELL BIOL, V99, P42, DOI 10.1083/jcb.99.1.42; WORCEL A, 1981, P NATL ACAD SCI-BIOL, V78, P1461, DOI 10.1073/pnas.78.3.1461	22	412	426	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1571	1573		10.1126/science.1103124	http://dx.doi.org/10.1126/science.1103124			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567867				2022-12-28	WOS:000225442700064
J	Fiske, ST; Harris, LT; Cuddy, AJC				Fiske, ST; Harris, LT; Cuddy, AJC			Why ordinary people torture enemy prisoners	SCIENCE			English	Editorial Material							META-ANALYSIS; INTEGRATION; AGGRESSION; PREJUDICE; MODEL; METAANALYSIS; STRATEGIES; AMYGDALA; FOOT; DOOR		Princeton Univ, Princeton, NJ 08544 USA	Princeton University	Fiske, ST (corresponding author), Princeton Univ, Princeton, NJ 08544 USA.	sfiske@princeton.edu; tharris@princeton.edu; acuddy@princeton.edu		Harris, Lasana/0000-0002-8503-3201				Altemeyer B., 1988, ENEMIES FREEDOM UNDE; Anderson C.A., 1997, REV GEN PSYCHOL, V1, P19, DOI [DOI 10.1037/1089-2680.1.1.19, 10.1037//1089-2680.1.1.19, DOI 10.1037//1089-2680.1.1.19]; Bandura A, 1999, Pers Soc Psychol Rev, V3, P193, DOI 10.1207/s15327957pspr0303_3; BEAMAN AL, 1983, PERS SOC PSYCHOL B, V9, P181, DOI 10.1177/0146167283092002; Berkowitz L, 1999, Pers Soc Psychol Rev, V3, P246; Bettencourt BA, 1996, PSYCHOL BULL, V119, P422, DOI 10.1037/0033-2909.119.3.422; Blass T, 1999, J APPL SOC PSYCHOL, V29, P955, DOI 10.1111/j.1559-1816.1999.tb00134.x; Bond R, 1996, PSYCHOL BULL, V119, P111, DOI 10.1037/0033-2909.119.1.111; CARLSON M, 1988, SOCIOL SOC RES, V72, P155; CARLSON M, 1989, PERS SOC PSYCHOL B, V15, P377, DOI 10.1177/0146167289153008; CUDDY AJ, 2004, UNPUB BIAS MAP BEHAV; Darley J M, 1999, Pers Soc Psychol Rev, V3, P269, DOI 10.1207/s15327957pspr0303_9; DILLARD JP, 1984, HUM COMMUN RES, V10, P461, DOI 10.1111/j.1468-2958.1984.tb00028.x; Dovidio J. F., 1996, STEREOTYPES STEREOTY; Duckitt J., 2001, ADV EXPT SOCIAL PSYC; FERN EF, 1986, J MARKETING RES, V23, P144, DOI 10.2307/3151661; FISKE S, 2004, SOCIAL BEINGS; Fiske ST, 2002, J PERS SOC PSYCHOL, V82, P878, DOI 10.1037//0022-3514.82.6.878; Haney C. B., 1973, INT J CRIMINOLOGY PE, V1, P69, DOI DOI 10.1037/H0076835; HARRIS LT, UNPUB; Hart AJ, 2000, NEUROREPORT, V11, P2351, DOI 10.1097/00001756-200008030-00004; HELLER LJ, 2002, THESIS PRINCETON U; KELMAN HC, 1991, POLITICS PAIN TORTUR; Leyens JP, 2003, EUR J SOC PSYCHOL, V33, P703, DOI 10.1002/ejsp.170; MILGRAM S., 1974, OBEDIENCE AUTHORITY; Miller A G, 1999, Pers Soc Psychol Rev, V3, P254, DOI 10.1207/s15327957pspr0303_8; Miller A. G, 2004, SOCIAL PSYCHOL GOOD; MULLEN B, 1985, J EXP SOC PSYCHOL, V21, P262, DOI 10.1016/0022-1031(85)90020-4; MULLEN B, 1988, BRIT J SOC PSYCHOL, V27, P333, DOI 10.1111/j.2044-8309.1988.tb00836.x; MULLEN B, 1992, EUR J SOC PSYCHOL, V22, P103, DOI 10.1002/ejsp.2420220202; MULLEN B, 1990, BRIT J SOC PSYCHOL, V29, P11, DOI 10.1111/j.2044-8309.1990.tb00883.x; Phelps EA, 2000, J COGNITIVE NEUROSCI, V12, P729, DOI 10.1162/089892900562552; REICHER SD, 1984, EUR J SOC PSYCHOL, V14, P1, DOI 10.1002/ejsp.2420140102; Richard FD, 2003, REV GEN PSYCHOL, V7, P331, DOI 10.1037/1089-2680.7.4.331; SCHLESINGER JR, FINAL REPORT INDPEND; Schutz H, 1996, INT J INTERCULT REL, V20, P441, DOI 10.1016/0147-1767(96)00028-4; Sidanius J., 1999, SOCIAL DOMINANCE INT; Solomon S, 2000, CURR DIR PSYCHOL SCI, V9, P200, DOI 10.1111/1467-8721.00094; Staub E, 1999, Pers Soc Psychol Rev, V3, P179, DOI 10.1207/s15327957pspr0303_2; TALASKA C, 2004, UNPUB PREDICTING DIS; TANFORD S, 1984, PSYCHOL BULL, V95, P189, DOI 10.1037/0033-2909.95.2.189; Tata J, 1996, J SOC BEHAV PERS, V11, P739; Turner J. C, 1991, SOC INFLUENCE; WHEELER ME, IN PRESS PSYCHOL SCI	44	97	99	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1482	1483		10.1126/science.1103788	http://dx.doi.org/10.1126/science.1103788			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	875ST	15567841				2022-12-28	WOS:000225442700035
J	Shapiro, B; Drummond, AJ; Rambaut, A; Wilson, MC; Matheus, PE; Sher, AV; Pybus, OG; Gilbert, MTP; Barnes, I; Binladen, J; Willerslev, E; Hansen, AJ; Baryshnikov, GF; Burns, JA; Davydov, S; Driver, JC; Froese, DG; Harington, CR; Keddie, G; Kosintsev, P; Kunz, ML; Martin, LD; Stephenson, RO; Storer, J; Tedford, R; Zimov, S; Cooper, A				Shapiro, B; Drummond, AJ; Rambaut, A; Wilson, MC; Matheus, PE; Sher, AV; Pybus, OG; Gilbert, MTP; Barnes, I; Binladen, J; Willerslev, E; Hansen, AJ; Baryshnikov, GF; Burns, JA; Davydov, S; Driver, JC; Froese, DG; Harington, CR; Keddie, G; Kosintsev, P; Kunz, ML; Martin, LD; Stephenson, RO; Storer, J; Tedford, R; Zimov, S; Cooper, A			Rise and fall of the Beringian steppe bison	SCIENCE			English	Article							ICE-FREE CORRIDOR; EUROPEAN CATTLE; EXTINCTION; PALEOENVIRONMENTS; LAURENTIDE; OVERKILL; ORIGINS; HISTORY; MAMMALS; CANADA	The widespread extinctions of large mammals at the end of the Pleistocene epoch have often been attributed to the depredations of humans; here we present genetic evidence that questions this assumption. We used ancient DNA and Bayesian techniques to reconstruct a detailed genetic history of bison throughout the late Pleistocene and Holocene epochs. Our analyses depict a large diverse population living throughout Beringia until around 37,000 years before the present, when the population's genetic diversity began to decline dramatically. The timing of this decline correlates with environmental changes associated with the onset of the last glacial cycle, whereas archaeological evidence does, not support the presence of large populations of humans in Eastern Beringia until more than 15,000 years later.	Univ Oxford, Henry Wellcome Ancient Biomol Ctr, Oxford OX1 3PS, England; Univ Oxford, Dept Zool, Oxford OX1 3PS, England; Douglas Coll, Dept Geol, New Westminster, BC V3L 5B2, Canada; Douglas Coll, Dept Anthropol, New Westminster, BC V3L 5B2, Canada; Univ Alaska Fairbanks, Alaska Quaternary Ctr, Fairbanks, AK 99775 USA; Univ Alaska Fairbanks, Inst Arctic Biol, Fairbanks, AK 99775 USA; Russian Acad Sci, Severtsov Inst Ecol & Evolut, Moscow 119071, Russia; UCL, Dept Biol, Ctr Genet Anthropol, London WC1E 6BT, England; Univ Copenhagen, Inst Zool, Dept Evolutionary Biol, DK-2100 Copenhagen, Denmark; Russian Acad Sci, Inst Zool, St Petersburg 199034, Russia; Prov Museum Alberta, Edmonton, AB T5N 0M6, Canada; Russian Acad Sci, NE Sci Stn, Cherskii, Republic Sakha, Russia; Simon Fraser Univ, Dept Archaeol, Burnaby, BC V5A 1S6, Canada; Univ Alberta, Dept Earth & Atmospher Sci, Edmonton, AB T6G 2E3, Canada; Canadian Museum Nat Paleobiol, Ottawa, ON K1P 6P4, Canada; Royal British Columbia Museum, Dept Archaeol, Victoria, BC V8V 1X4, Canada; Russian Acad Sci, Inst Plant & Anim Ecol, Ekaterinburg 620144, Russia; Bur Land Management, Fairbanks, AK 99708 USA; Univ Kansas, Dept Ecol & Evolutionary Biol, Lawrence, KS 66045 USA; Alaska Dept Fish & Game, Fairbanks, AK 99701 USA; Yukon Dept Tourism & Culture, Heritage Resources, Whitehorse, YT Y1A 2C6, Canada; Amer Museum Nat Hist, Dept Paleontol, New York, NY 10024 USA	University of Oxford; University of Oxford; University of Alaska System; University of Alaska Fairbanks; University of Alaska System; University of Alaska Fairbanks; Russian Academy of Sciences; Saratov Scientific Center of the Russian Academy of Sciences; Severtsov Institute of Ecology & Evolution; University of London; University College London; University of Copenhagen; Russian Academy of Sciences; Zoological Institute of the Russian Academy of Sciences; Russian Academy of Sciences; Simon Fraser University; University of Alberta; Russian Academy of Sciences; Institute of Plant & Animal Ecology of the Russian Academy of Sciences; University of Kansas; Alaska Department of Fish & Game; American Museum of Natural History (AMNH)	Cooper, A (corresponding author), Univ Oxford, Henry Wellcome Ancient Biomol Ctr, S Parks Rd, Oxford OX1 3PS, England.	alan.cooper@zoo.ox.ac.uk	Froese, Duane G/B-6038-2009; Willerslev, Eske/AAA-5686-2019; Pybus, Oliver G/B-2640-2012; Rambaut, Andrew/B-2481-2009; Zimov, Sergey/K-3009-2018; Cooper, Alan/E-8171-2012; Barnes, Ian C/B-8081-2008; Willerslev, Eske/A-9619-2011; Davydov, Sergei P./S-9906-2018; Drummond, Alexei J/A-3209-2010; Cooper, Andrew/AAH-4251-2020; Baryshnikov, Gennady/AAE-1972-2020; Driver, Jonathan/D-1013-2009; Gilbert, Marcus TP/A-8936-2013; Hansen, Anders Johannes/A-5608-2013	Pybus, Oliver G/0000-0002-8797-2667; Rambaut, Andrew/0000-0003-4337-3707; Cooper, Alan/0000-0002-7738-7851; Barnes, Ian C/0000-0001-8322-6918; Willerslev, Eske/0000-0002-7081-6748; Drummond, Alexei J/0000-0003-4454-2576; Cooper, Andrew/0000-0003-4972-8812; Gilbert, Marcus TP/0000-0002-5805-7195; Hansen, Anders Johannes/0000-0002-1890-2702; Davydov, Sergei/0000-0003-0820-9426; Zimov, Sergey/0000-0002-0053-6599; Driver, Jonathan/0000-0002-9782-641X; Shapiro, Beth/0000-0002-2733-7776				Alroy J, 2001, SCIENCE, V292, P1893, DOI 10.1126/science.1059342; Anderson PH, 2001, QUATERNARY SCI REV, V20, P93, DOI 10.1016/S0277-3791(00)00129-3; Barnes I, 2002, SCIENCE, V295, P2267, DOI 10.1126/science.1067814; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; Brook BW, 2004, J BIOGEOGR, V31, P517, DOI 10.1046/j.1365-2699.2003.01028.x; Burns JA, 1996, QUATERN INT, V32, P107, DOI 10.1016/1040-6182(95)00057-7; Catto N, 1996, QUATERN INT, V32, P21, DOI 10.1016/S1040-6182(96)90012-9; DRIVER JC, 2001, BRIT ARCHAEOLOGICAL, V0944, P00013; Drummond AJ, 2002, GENETICS, V161, P1307; Dyke AS, 2002, QUATERNARY SCI REV, V21, P9, DOI 10.1016/S0277-3791(01)00095-6; Graham RW, 1996, SCIENCE, V272, P1601; Grayson DK, 2003, J ARCHAEOL SCI, V30, P585, DOI 10.1016/S0305-4403(02)00205-4; GRIFFITHS RC, 1994, PHILOS T ROY SOC B, V344, P403, DOI 10.1098/rstb.1994.0079; Guthrie R.D., 1990, FROZEN FAUNA MAMMOTH; Guthrie RD, 2003, NATURE, V426, P169, DOI 10.1038/nature02098; Halsey LA, 1998, CLIMATIC CHANGE, V40, P315, DOI 10.1023/A:1005425124749; Hewitt G, 2000, NATURE, V405, P907, DOI 10.1038/35016000; Lambert DM, 2002, SCIENCE, V295, P2270, DOI 10.1126/science.1068105; Mandryk CAS, 2001, QUATERNARY SCI REV, V20, P301, DOI 10.1016/S0277-3791(00)00115-3; McDonald JN, 1981, N AM BISON THEIR CLA; Morlan RE, 2003, QUATERNARY RES, V60, P123, DOI 10.1016/S0033-5894(03)00070-X; Pannell JR, 2003, EVOLUTION, V57, P949; Roe F. G., 1970, N AM BUFFALO; SKINNER MF, 1947, B AM MUS NAT HIST, V89, P126; STEPHENSON RO, 2001, BRIT ARCHAEOLOGICAL, V944, P125; Strimmer K, 2001, MOL BIOL EVOL, V18, P2298, DOI 10.1093/oxfordjournals.molbev.a003776; Troy CS, 2001, NATURE, V410, P1088, DOI 10.1038/35074088; Wilson MC, 1996, QUATERN INT, V32, P97, DOI 10.1016/S1040-6182(96)90017-8; Yesner DR, 2001, QUATERNARY SCI REV, V20, P315, DOI 10.1016/S0277-3791(00)00114-1; Zazula GD, 2003, NATURE, V423, P603, DOI 10.1038/423603a	30	514	531	1	230	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	2004	306	5701					1561	1565		10.1126/science.1101074	http://dx.doi.org/10.1126/science.1101074			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567864	Green Published			2022-12-28	WOS:000225442700061
J	Arbic, BK; Macayeal, DR; Mitrovica, JX; Milne, GA				Arbic, BK; Macayeal, DR; Mitrovica, JX; Milne, GA			Palaeoclimate - Ocean tides and Heinrich events	NATURE			English	Editorial Material									Princeton Univ, Program Atmospher & Ocean Sci, Princeton, NJ 08544 USA; Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA; Univ Toronto, Dept Phys, Toronto, ON M5S 1A7, Canada; Univ Durham, Sci Labs, Dept Earth Sci, Durham DH1 3LE, England	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; University of Chicago; University of Toronto; Durham University	Arbic, BK (corresponding author), Princeton Univ, Program Atmospher & Ocean Sci, POB CN710,Sayre Hall, Princeton, NJ 08544 USA.	arbic@splash.princeton.edu		MacAyeal, Douglas/0000-0003-0647-6176; Arbic, Brian K/0000-0002-7969-2294				ARBIC BK, IN PRESS DEEP SEA RE, V2; Bindschadler RA, 2003, SCIENCE, V301, P1087, DOI 10.1126/science.1087231; Doake CSM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014606; Egbert GD, 2004, J GEOPHYS RES-OCEANS, V109, DOI 10.1029/2003JC001973; EGBERT GD, 1994, J GEOPHYS RES-OCEANS, V99, P24821, DOI 10.1029/94JC01894; HEINRICH H, 1988, QUATERNARY RES, V29, P142, DOI 10.1016/0033-5894(88)90057-9; Hemming SR, 2004, REV GEOPHYS, V42, DOI 10.1029/2003RG000128; Hulbe CL, 2004, PALEOCEANOGRAPHY, V19, DOI 10.1029/2003PA000890; Lambeck K, 2002, QUATERNARY SCI REV, V21, P343, DOI 10.1016/S0277-3791(01)00071-3; MACAYEAL DR, 1993, PALEOCEANOGRAPHY, V8, P775, DOI 10.1029/93PA02200; Milne GA, 1999, GEOPHYS J INT, V139, P464, DOI 10.1046/j.1365-246x.1999.00971.x; PLATZMAN GW, 1981, J PHYS OCEANOGR, V11, P579, DOI 10.1175/1520-0485(1981)011<0579:NMOTWO>2.0.CO;2; Rahmstorf S, 2002, NATURE, V419, P207, DOI 10.1038/nature01090	13	52	54	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					460	460		10.1038/432460a	http://dx.doi.org/10.1038/432460a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565143	Green Submitted, Bronze			2022-12-28	WOS:000225322100032
J	Bock-Marquette, I; Saxena, A; White, MD; DiMaio, JM; Srivastava, D				Bock-Marquette, I; Saxena, A; White, MD; DiMaio, JM; Srivastava, D			Thymosin beta 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; BETA-THYMOSINS; ACTIN; PROTEINS; PEPTIDE; DOMAIN; B/AKT; SERUM	Heart disease is a leading cause of death in newborn children and in adults. Efforts to promote cardiac repair through the use of stem cells hold promise but typically involve isolation and introduction of progenitor cells. Here, we show that the G-actin sequestering peptide thymosin beta4 promotes myocardial and endothelial cell migration in the embryonic heart and retains this property in postnatal cardiomyocytes. Survival of embryonic and postnatal cardiomyocytes in culture was also enhanced by thymosin beta4. We found that thymosin beta4 formed a functional complex with PINCH and integrin-linked kinase (ILK), resulting in activation of the survival kinase Akt ( also known as protein kinase B). After coronary artery ligation in mice, thymosin beta4 treatment resulted in upregulation of ILK and Akt activity in the heart, enhanced early myocyte survival and improved cardiac function. These findings suggest that thymosin beta4 promotes cardiomyocyte migration, survival and repair and the pathway it regulates may be a new therapeutic target in the setting of acute myocardial damage.	Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cardiovasc & Thorac Surg, Dallas, TX 75390 USA; Childrens Med Ctr Dallas, Dallas, TX 75390 USA; Univ Pecs, Fac Med, Dept Med Genet & Child Dev, H-7624 Pecs, Hungary	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Pecs	Srivastava, D (corresponding author), Univ Texas, SW Med Ctr, Dept Pediat, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Deepak.Srivastava@UTSouthwestern.edu		Saxena, Ankur/0000-0001-8646-2887				*AM HEART ASS, 2004, HEART DIS STROK STAT, P11; Anversa P, 2002, NATURE, V415, P240, DOI 10.1038/415240a; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Depre C, 2004, CIRC RES, V95, P433, DOI 10.1161/01.RES.0000138301.42713.18; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Garner LB, 2003, AM J PHYSIOL-HEART C, V285, pH2500, DOI 10.1152/ajpheart.00432.2003; GomezMarquez J, 1996, BBA-GENE STRUCT EXPR, V1306, P187, DOI 10.1016/0167-4781(96)00003-6; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; Hertzog M, 2004, CELL, V117, P611, DOI 10.1016/S0092-8674(04)00403-9; Hoffman JIE, 2002, J AM COLL CARDIOL, V39, P1890, DOI 10.1016/S0735-1097(02)01886-7; Huang WQ, 2001, EXP HEMATOL, V29, P12, DOI 10.1016/S0301-472X(00)00634-2; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Kelly RG, 2002, TRENDS GENET, V18, P210, DOI 10.1016/S0168-9525(02)02642-2; LIN SC, 1990, J MOL NEUROSCI, V2, P35, DOI 10.1007/BF02896924; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Marinissen MJ, 2004, MOL CELL, V14, P29, DOI 10.1016/S1097-2765(04)00153-4; Mora CA, 1997, INT J IMMUNOPHARMACO, V19, P1, DOI 10.1016/S0192-0561(97)00005-2; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Olave IA, 2002, ANNU REV BIOCHEM, V71, P755, DOI 10.1146/annurev.biochem.71.110601.135507; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; RUNYAN RB, 1983, DEV BIOL, V95, P108, DOI 10.1016/0012-1606(83)90010-6; SAFER D, 1991, J BIOL CHEM, V266, P4029; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Sun HQ, 1996, J BIOL CHEM, V271, P9223, DOI 10.1074/jbc.271.16.9223; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; van den Hoff MJB, 1999, DEV BIOL, V212, P477, DOI 10.1006/dbio.1999.9366; Yamagishi H, 2003, GENE DEV, V17, P269, DOI 10.1101/gad.1048903; YU FX, 1993, J BIOL CHEM, V268, P502; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166	38	531	579	2	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					466	472		10.1038/nature03000	http://dx.doi.org/10.1038/nature03000			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565145				2022-12-28	WOS:000225322100037
J	Kim, M; Krogan, NJ; Vasiljeva, L; Rando, OJ; Nedea, E; Greenblatt, JF; Buratowski, S				Kim, M; Krogan, NJ; Vasiljeva, L; Rando, OJ; Nedea, E; Greenblatt, JF; Buratowski, S			The yeast Rat1 exonuclease promotes transcription termination by RNA polymerase II	NATURE			English	Article							SMALL NUCLEOLAR RNAS; KINASE CTDK-I; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; DOMAIN; GENOME; EXORIBONUCLEASE; IDENTIFICATION; COMPONENT; COMPLEXES	The carboxy-terminal domain (CTD) of the RNA polymerase II (RNApII) largest subunit consists of multiple heptapeptide repeats with the consensus sequence YSPTSPS. Different CTD phosphorylation patterns act as recognition sites for the binding of various messenger RNA processing factors, thereby coupling transcription and mRNA processing(1). Polyadenylation factors are co-transcriptionally recruited by phosphorylation of CTD serine 2 (ref. 2) and these factors are also required for transcription termination(3,4). RNApII transcribes past the poly(A) site, the RNA is cleaved by the polyadenylation machinery, and the RNA downstream of the cleavage site is degraded. Here we show that Rtt103 and the Rat1/Rai1 5' --> 3' exonuclease are localized at 3' ends of protein coding genes. In rat1-1 or rai1Delta cells, RNA 3' to polyadenylation sites is greatly stabilized and termination defects are seen at many genes. These findings support a model in which poly(A) site cleavage and subsequent degradation of the 3'-downstream RNA by Rat1 trigger transcription termination(5,6).	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; University of Toronto; Harvard University	Buratowski, S (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	steveb@hms.harvard.edu	Vasilieva, Lidia/AAU-1473-2020; NEDEA, EDUARD/D-5476-2009	Vasiljeva, Lidia/0000-0002-1244-8772; Rando, Oliver/0000-0003-1516-9397				Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; Bousquet-Antonelli C, 2000, CELL, V102, P765, DOI 10.1016/S0092-8674(00)00065-9; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; CONNELLY S, 1989, CELL, V57, P561, DOI 10.1016/0092-8674(89)90126-8; Das B, 2003, MOL CELL BIOL, V23, P5502, DOI 10.1128/MCB.23.16.5502-5515.2003; Dheur S, 2003, EMBO J, V22, P2831, DOI 10.1093/emboj/cdg253; Doerks T, 2002, GENOME RES, V12, P47, DOI 10.1101/gr.203201; Hammell CM, 2002, MOL CELL BIOL, V22, P6441, DOI 10.1128/MCB.22.18.6441-6457.2002; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kim M, 2004, EMBO J, V23, P354, DOI 10.1038/sj.emboj.7600053; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Lashkari DA, 1997, P NATL ACAD SCI USA, V94, P13057, DOI 10.1073/pnas.94.24.13057; Meinhart A, 2004, NATURE, V430, P223, DOI 10.1038/nature02679; Nedea E, 2003, J BIOL CHEM, V278, P33000, DOI 10.1074/jbc.M304454200; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; PROUDFOOT NJ, 1989, TRENDS BIOCHEM SCI, V14, P105, DOI 10.1016/0968-0004(89)90132-1; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Scholes DT, 2001, GENETICS, V159, P1449; Skaar DA, 2002, MOL CELL, V10, P1429, DOI 10.1016/S1097-2765(02)00731-1; Solinger JA, 1999, MOL CELL BIOL, V19, P5930; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Ujvari A, 2002, J BIOL CHEM, V277, P32527, DOI 10.1074/jbc.M201145200; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; Xue Y, 2000, MOL CELL BIOL, V20, P4006, DOI 10.1128/MCB.20.11.4006-4015.2000; Yonaha M, 2000, EMBO J, V19, P3770, DOI 10.1093/emboj/19.14.3770; Zhao J, 1999, MOL CELL BIOL, V19, P7733	29	366	374	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					517	522		10.1038/nature03041	http://dx.doi.org/10.1038/nature03041			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565157				2022-12-28	WOS:000225322100050
J	Al-Rubeyi, BI				Al-Rubeyi, BI			Mortality before and after the invasion of Iraq in 2003	LANCET			English	Editorial Material									Queen Elizabeth Hosp, London SE18 4QH, England		Al-Rubeyi, BI (corresponding author), Queen Elizabeth Hosp, London SE18 4QH, England.	br@doctors.org.uk						BOLLYN C, MEDIA COVERAGE IRAQ; EPSTEIN E, 2003, SAN FRANCISCO C 0503; JENABI A, 2004, ALJAZEERA       0902; MURALIDHARAM S, 2003, FRONTLINE       0224; PETERSON S, 2002, CHRISTIAN SCI M 1022; *REF INT HUM LAW, 2003, UK PARL SEL COMM INT; RITTER S, 2004, WAR IRAQ HAS MADE MO; *UNICEF, COUNTR CRIS; World Health Organization, 2003, POT IMP CONFL HLTH I; 2003, MEDACT EXECUTIVE SUM; 2004, BRIEFING PAPER HLTH	11	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1834	1835		10.1016/S0140-6736(04)17453-9	http://dx.doi.org/10.1016/S0140-6736(04)17453-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555649				2022-12-28	WOS:000225269300005
J	Linden, S; Enkrich, C; Wegener, M; Zhou, JF; Koschny, T; Soukoulis, CM				Linden, S; Enkrich, C; Wegener, M; Zhou, JF; Koschny, T; Soukoulis, CM			Magnetic response of metamaterials at 100 terahertz	SCIENCE			English	Article							REFRACTION; INDEX	An array of single nonmagnetic metallic split rings can be used to implement a magnetic resonance, which arises from an inductor-capacitor circuit (LC) resonance, at 100-terahertz frequency. The excitation of the LC resonance in the normal-incidence geometry used in our experiments occurs through the coupling of the electric field of the incident light to the capacitance. The measured optical spectra of, the nanofabricated gold structures come very close to the theoretical expectations. Additional numerical simulations show that our structures exhibit a frequency range with negative permeability for a beam configuration in which the magnetic field couples to the LC resonance. Together with an electric response that has negative permittivity, this can lead to materials with a negative index of refraction.	Iowa State Univ, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Phys & Astron, Ames, IA 50011 USA; Fdn Res & Technol Hellas, Inst Elect Struct & Laser, Iraklion 71110, Crete, Greece; Forschungszentrum Karlsruhe Helmholtz Gemeinschaf, Inst Nanotechnol, D-76021 Karlsruhe, Germany; Univ Karlsruhe TH, Inst Angew Phys, D-76131 Karlsruhe, Germany	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University; Foundation for Research & Technology - Hellas (FORTH); Helmholtz Association; Karlsruhe Institute of Technology; Helmholtz Association; Karlsruhe Institute of Technology	Soukoulis, CM (corresponding author), Iowa State Univ, Ames Lab, Ames, IA 50011 USA.	soukoulis@ameslab.gov	Wegener, Martin/S-5456-2016; Wegener, Martin/ABD-5353-2021; Soukoulis, Costas M./A-5295-2008; Zhou, Jiangfeng/D-4292-2009; Koschny, Thomas/AAZ-6273-2020	Wegener, Martin/0000-0002-9770-2441; Wegener, Martin/0000-0002-9770-2441; Zhou, Jiangfeng/0000-0002-6958-3342; Koschny, Thomas/0000-0003-4960-9266; Sanchez-Fernandez, Gregorio Esteban/0000-0002-6059-7182				Katsarakis N, 2004, APPL PHYS LETT, V84, P2943, DOI 10.1063/1.1695439; Koschny T, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.107402; Koschny T, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.065602; ORDAL MA, 1983, APPL OPTICS, V22, P1099, DOI 10.1364/AO.22.001099; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Sirtori C, 2002, NATURE, V417, P132, DOI 10.1038/417132b; Smith DR, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.195104; Smith DR, 2004, SCIENCE, V305, P788, DOI 10.1126/science.1096796; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Yen TJ, 2004, SCIENCE, V303, P1494, DOI 10.1126/science.1094025	12	1267	1326	19	522	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1351	1353		10.1126/science.1105371	http://dx.doi.org/10.1126/science.1105371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550664	Green Published			2022-12-28	WOS:000225301600044
J	Batey, RT; Gilbert, SD; Montange, RK				Batey, RT; Gilbert, SD; Montange, RK			Structure of a natural guanine-responsive riboswitch complexed with the metabolite hypoxanthine	NATURE			English	Article							RNA-PROTEIN RECOGNITION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; INDUCED FIT; BINDING; RIBOZYMES; SELECTION; SWITCHES; APTAMER; MOTIF	Riboswitches are genetic regulatory elements found in the 50 untranslated region of messenger RNA that act in the absence of protein cofactors(1,2). They are broadly distributed across bacteria and account for the regulation of more than 2% of all genes in Bacillus subtilis, underscoring their importance in the control of cellular metabolism(3). The 5' untranslated region of many mRNAs of genes involved in purine metabolism and transport contain a guanine-responsive riboswitch that directly binds guanine, hypoxanthine or xanthine to terminate transcription(3,4). Here we report the crystal structure at 1.95 Angstrom resolution of the purine-binding domain of the guanine riboswitch from the xpt-pbuX operon of B. subtilis bound to hypoxanthine, a prevalent metabolite in the bacterial purine salvage pathway. This structure reveals a complex RNA fold involving several phylogenetically conserved nucleotides that create a binding pocket that almost completely envelops the ligand. Hypoxanthine functions to stabilize this structure and to promote the formation of a downstream transcriptional terminator element, thereby providing a mechanism for directly repressing gene expression in response to an increase in intracellular concentrations of metabolite.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder	Batey, RT (corresponding author), Univ Colorado, Dept Chem & Biochem, 215 UCB, Boulder, CO 80309 USA.	robert.batey@colorado.edu	Batey, Robert/A-8265-2009	Batey, Robert/0000-0002-1384-6625	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008759] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM142607, T32 GM008759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baugh C, 2000, J MOL BIOL, V301, P117, DOI 10.1006/jmbi.2000.3951; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; Correll CC, 2003, NUCLEIC ACIDS RES, V31, P6806, DOI 10.1093/nar/gkg908; De la Pena M, 2003, EMBO J, V22, P5561, DOI 10.1093/emboj/cdg530; Doherty EA, 2001, NAT STRUCT BIOL, V8, P339, DOI 10.1038/86221; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Fan P, 1996, J MOL BIOL, V258, P480, DOI 10.1006/jmbi.1996.0263; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Johansen LE, 2003, J BACTERIOL, V185, P5200, DOI 10.1128/JB.185.17.5200-5209.2003; Khvorova A, 2003, NAT STRUCT BIOL, V10, P708, DOI 10.1038/nsb959; Kieft JS, 2004, RNA, V10, P988, DOI 10.1261/rna.7040604; Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Mandal M, 2004, NAT STRUCT MOL BIOL, V11, P29, DOI 10.1038/nsmb710; Mandal M, 2003, CELL, V113, P577, DOI 10.1016/S0092-8674(03)00391-X; Mandal M, 2004, NAT REV MOL CELL BIO, V5, P451, DOI 10.1038/nrm1403; MOLINARO M, 1995, NUCLEIC ACIDS RES, V23, P3056, DOI 10.1093/nar/23.15.3056; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723; Silverman SK, 2003, RNA, V9, P377, DOI 10.1261/rna.2200903; TERWILLIGER T, 2001, J SYNCHROTRON RADIAT, V11, P49; Vitreschak AG, 2004, TRENDS GENET, V20, P44, DOI 10.1016/j.tig.2003.11.008; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575; Zimmermann GR, 1997, NAT STRUCT BIOL, V4, P644, DOI 10.1038/nsb0897-644	28	394	429	1	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					411	415		10.1038/nature03037	http://dx.doi.org/10.1038/nature03037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549109				2022-12-28	WOS:000225161400060
J	Gershon, D				Gershon, D			Making connections	NATURE			English	Article																			0	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					243	+		10.1038/432243a	http://dx.doi.org/10.1038/432243a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538372	Bronze			2022-12-28	WOS:000225020200051
J	Fanos, V; Cataldi, L				Fanos, V; Cataldi, L			Antibiotics or surgery for vesicoureteric reflux in children	LANCET			English	Review							URINARY-TRACT-INFECTION; SURGICAL-TREATMENT; RANDOMIZED TRIAL; YOUNG-CHILDREN; INFANTS; HYDRONEPHROSIS; NEPHROPATHY; PREVENTION; MANAGEMENT; DIAGNOSIS	Context 1-2% of children have vesicoureteric reflux (VUR). VUR occurs in 25-40% of children with acute pyelonephritis. VUR can lead to renal scarring, hypertension, and end-stage renal disease. The best form of treatment for children with VUR is debated: no treatment, long-term antibiotic prophylaxis, surgery, or a combination of antibiotic prophylaxis and surgery. In children with recurrent urinary tract infections (UTIs) and progressive renal damage, despite antibiotic prophylaxis, surgical correction of VUR, especially high-grade VUR, is generally recommended. Starting point Danielle Wheeler and colleagues recently did a meta-analysis of ten randomised controlled trials (964 children) to evaluate whether any intervention for VUR is better than no treatment (Cochrane Database Syst Rev 2004; 3: CD001532). The main endpoints were incidence of UTIs, new or progressive renal damage, renal growth, hypertension, and glomerular filtration rate. They concluded that it is uncertain whether the identification of children with VUR is associated with clinically important benefit. The additional benefit of surgery over antibiotics is small. Where next? New strategies for management will require a tailored diagnostic and therapeutic approach, including noninvasive or less invasive diagnostic procedures, and a less aggressive therapeutic approach. Whether the common practice of cystourethrography as a first-fine investigation is warranted needs evaluation. The goal of paediatricians in the future, to prevent kidney damage, will probably be prevention of renal parenchymal injury and not necessarily the correction of ureterovesical junction anomalies. Because two main clinical pictures of VUR (diagnosed prenatally or postnatally with different age and sex distribution) can be identified, boys and girls will probably be managed differently. The factors responsible for congenital and acquired renal injury in children with VUR need to be studied.	Univ Cagliari, Neonatal Intens Care Unit, I-09124 Cagliari, Italy; Sacred Heart Univ Rome, Policlin A Gemelli, Div Neonatol, Rome, Italy	University of Cagliari; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Fanos, V (corresponding author), Univ Cagliari, Neonatal Intens Care Unit, I-09124 Cagliari, Italy.	vafanos@tiscali.it	Fanos, Vassilios/AHI-0685-2022	Fanos, Vassilios/0000-0003-2617-2890				[Anonymous], 1987, Br Med J (Clin Res Ed), V295, P237; Arant BS, 2001, J PEDIATR-US, V139, P620, DOI 10.1067/mpd.2001.119451; Bergman DA, 1999, PEDIATRICS, V103, P843; Bosio M, 1998, PEDIATR RADIOL, V28, P250, DOI 10.1007/s002470050343; Cataldi Luigi, 2002, Rays, V27, P93; Chand DH, 2003, J UROLOGY, V170, P1548, DOI 10.1097/01.ju.0000084299.55552.6c; Chertin B, 2003, J UROLOGY, V169, P1804, DOI 10.1097/01.ju.0000058428.00284.d5; Chertin B, 2002, EUR UROL, V42, P598, DOI 10.1016/S0302-2838(02)00447-5; Fanos V, 1999, DRUG SAFETY, V20, P245, DOI 10.2165/00002018-199920030-00005; Fanos V, 2000, ACTA PAEDIATR, V89, P900, DOI 10.1080/080352500750043305; Haszon I, 2002, PEDIATR NEPHROL, V17, P1027, DOI 10.1007/s00467-002-0968-1; Hellerstein S, 2000, CURR OPIN PEDIATR, V12, P125, DOI 10.1097/00008480-200004000-00007; Hoberman A, 2003, NEW ENGL J MED, V348, P195, DOI 10.1056/NEJMoa021698; Hollowell JG, 2002, J UROLOGY, V168, P2138, DOI 10.1016/S0022-5347(05)64337-6; Jantunen ME, 2002, J INFECT DIS, V185, P375, DOI 10.1086/338771; Jodal Ulf, 2004, J Pediatr, V144, P405; Kerr KG, 1999, LANCET, V353, P673, DOI 10.1016/S0140-6736(05)75468-4; Kobayashi H, 1997, EUR UROL, V31, P343; Konda R, 1997, J UROLOGY, V157, P2282, DOI 10.1016/S0022-5347(01)64763-3; Kontiokari T, 2001, BMJ-BRIT MED J, V322, P1571, DOI 10.1136/bmj.322.7302.1571; Lightner Deborah J, 2002, Curr Opin Urol, V12, P333, DOI 10.1097/00042307-200207000-00012; Marra G, 2004, J PEDIATR-US, V144, P677, DOI 10.1016/j.jpeds.2004.01.043; McKenna P H, 2000, Curr Opin Urol, V10, P599, DOI 10.1097/00042307-200011000-00011; Nakai H, 2003, J UROLOGY, V169, P309, DOI 10.1016/S0022-5347(05)64113-4; NOE HN, 1992, J UROLOGY, V148, P1869, DOI 10.1016/S0022-5347(17)37053-2; Phan V, 2003, PEDIATR NEPHROL, V18, P1224, DOI 10.1007/s00467-003-1287-x; Piepsz A, 1998, EUR J PEDIATR, V157, P753, DOI 10.1007/s004310050929; REDDY PP, 1997, P AAP PEDIAT S; ROSENBERG AR, 1992, J UROLOGY, V148, P1746, DOI 10.1016/S0022-5347(17)37019-2; Schwab CW, 2002, J UROLOGY, V168, P2594, DOI 10.1016/S0022-5347(05)64225-5; Smellie JM, 2001, LANCET, V357, P1329, DOI 10.1016/S0140-6736(00)04520-7; Smellie JM, 2001, J PEDIATR-US, V139, P656, DOI 10.1067/mpd.2001.117583; Vallee JP, 1999, UROLOGY, V53, P812, DOI 10.1016/S0090-4295(98)00587-1; Wennerstrom M, 1998, ARCH PEDIAT ADOL MED, V152, P879; Wheeler DM., 2004, COCHRANE DB SYST REV, V3, DOI [10.1002/14651858.CD001532.pub2, DOI 10.1002/14651858.CD001532.PUB2, DOI 10.1002/14651858.CD001532.pub2]; Williams G, 2001, J PEDIATR-US, V138, P868, DOI 10.1067/mpd.2001.113785; Yeung CK, 1997, BRIT J UROL, V80, P319, DOI 10.1046/j.1464-410X.1997.00309.x	37	76	81	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1720	1722		10.1016/S0140-6736(04)17359-5	http://dx.doi.org/10.1016/S0140-6736(04)17359-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530633				2022-12-28	WOS:000224921600035
J	Trohman, RG; Kim, MH; Pinski, SL				Trohman, RG; Kim, MH; Pinski, SL			Cardiac pacing: the state of the art	LANCET			English	Review							HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; CHRONIC ATRIAL-FIBRILLATION; CONGESTIVE-HEART-FAILURE; TERM-FOLLOW-UP; VASOVAGAL SYNCOPE; RESYNCHRONIZATION THERAPY; DOUBLE-BLIND; ATRIOVENTRICULAR JUNCTION; VENTRICULAR-TACHYCARDIA; RANDOMIZED-TRIAL	Permanent cardiac pacing remains the only effective treatment for chronic, symptomatic bradycardia. In recent years, the role of implantable pacing devices has expanded substantially. At the beginning of the 21st century, exciting developments in technology seem to happen at an exponential rate. Major advances have extended the use of pacing beyond the arrhythmia horizon. Such developments include dual-chamber pacers, rate-response algorithms, improved functionality of implantable cardioverter defibrillators, combinations of sensors for optimum physiological response, and advances in lead placement and extraction. Cardiac pacing is poised to help millions of patients worldwide to live better electrically. We review pacing studies of sick-sinus syndrome, neurocardiogenic syncope, hypertrophic obstructive cardiomyopathy, and cardiac resynchronisation therapy, which are common or controversial indications for cardiac pacing. We also look at the benefits and complications of implantation in specific arrhythmias, suitability of different pacing modes, and the role of permanent pacing in the management of patients with heart failure.	Rush Presbyterian St Lukes Med Ctr, Arrhythmia & Pacemaker Serv, Dept Med, Cardiol Sect, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA	Rush University; Rush University	Trohman, RG (corresponding author), Rush Presbyterian St Lukes Med Ctr, Arrhythmia & Pacemaker Serv, Sect Electrophysiol, Room 983 Jelke, Chicago, IL 60612 USA.	rtrohman@rush.edu		Kim, Michael/0000-0002-1458-8234				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; ABRAHAM WT, MEDTRONIC INSYNC ICD; Achilli A, 2003, J AM COLL CARDIOL, V42, P2117, DOI 10.1016/j.jacc.2003.08.024; Ammirati F, 2001, CIRCULATION, V104, P52, DOI 10.1161/hc2601.091708; Ammirati F, 1998, PACE, V21, P2178, DOI 10.1111/j.1540-8159.1998.tb01148.x; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Andersen HR, 1997, LANCET, V350, P1210, DOI 10.1016/S0140-6736(97)03425-9; Andersen HR, 1998, CIRCULATION, V98, P1315, DOI 10.1161/01.CIR.98.13.1315; Auricchio A, 2003, J AM COLL CARDIOL, V42, P2109, DOI 10.1016/j.jacc.2003.04.003; Bakker PF, 2000, J INTERV CARD ELECTR, V4, P395; Barold SS, 2001, AM J MED, V111, P224, DOI 10.1016/S0002-9343(01)00807-5; Barold SS, 2000, CHEST, V118, P1819, DOI 10.1378/chest.118.6.1819; BAROLD SS, 1992, HEART DIS TXB CARDIO; Baron-Esquivias G, 2002, EUR HEART J, V23, P483, DOI 10.1053/euhj.2001.2900; Bernstein AD, 2002, PACE, V25, P260, DOI 10.1046/j.1460-9592.2002.00260.x; Best PJM, 1999, PACE, V22, P79, DOI 10.1111/j.1540-8159.1999.tb00303.x; Bohm A, 1999, PACE, V22, P1557, DOI 10.1111/j.1540-8159.1999.tb00365.x; Bracke F, 2002, PACE, V25, P1037, DOI 10.1046/j.1460-9592.2002.01037.x; Bradley DJ, 2003, JAMA-J AM MED ASSOC, V289, P730, DOI 10.1001/jama.289.6.730; BRANDT J, 1992, J AM COLL CARDIOL, V20, P633, DOI 10.1016/0735-1097(92)90018-I; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; BRIGNOLE M, 1992, AM J CARDIOL, V69, P1039, DOI 10.1016/0002-9149(92)90860-2; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Byrd CL, 2002, PACE, V25, P804, DOI 10.1046/j.1460-9592.2002.t01-1-00804.x; BYRD CL, 2000, CLIN CARDIAC PACING; CALKINS H, 2001, HEART DIS TXB CARDIV; Carlson MD, 2003, J AM COLL CARDIOL, V42, P627, DOI 10.1016/S0735-1097(03)00780-0; Cazeau S, 2000, HEART, V84, P579, DOI 10.1136/heart.84.6.579; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Chua JD, 2000, ANN INTERN MED, V133, P604, DOI 10.7326/0003-4819-133-8-200010170-00011; CHUGH A, 2002, AM COLL CARDIOL CURR, V11, P77; COMAN JA, 1995, AM J CARDIOL, V76, P781, DOI 10.1016/S0002-9149(99)80226-4; Connolly SJ, 2003, JAMA-J AM MED ASSOC, V289, P2224, DOI 10.1001/jama.289.17.2224; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Connolly SJ, 2000, NEW ENGL J MED, V342, P1385, DOI 10.1056/NEJM200005113421902; COWELL R, 1993, PACE, V16, P1441, DOI 10.1111/j.1540-8159.1993.tb01742.x; DAOUD E, 2004, HEART RHYTHM, V1, P5; *DAVID TRIAL INV, 2002, JAMA-J AM MED ASSOC, V228, P1; de Voogt WG, 1999, AM J CARDIOL, V83, p187D; Ellenbogen KA, 2003, AM J CARDIOL, V92, P740, DOI 10.1016/S0002-9149(03)00844-0; Ellenbogen KA, 2000, AM J CARDIOL, V86, P59, DOI 10.1016/S0002-9149(00)00828-6; Ertas F, 2000, J ELECTROCARDIOL, V33, P253, DOI 10.1054/jelc.2000.8234; ETIENNE Y, 2000, PACING CLIN ELECTROP, V23, P596; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; Flevari P, 2002, J AM COLL CARDIOL, V40, P499, DOI 10.1016/S0735-1097(02)01974-5; Francis Gary S., 2001, Cardiology Clinics, V19, P541, DOI 10.1016/S0733-8651(05)70241-1; Furman S, 2002, PACE, V25, P1, DOI 10.1046/j.1460-9592.2002.00001.x; FURMAN S, 1993, PACE, V16, P953, DOI 10.1111/j.1540-8159.1993.tb04566.x; Garrigue S, 2000, PACE, V23, P1700, DOI 10.1046/j.1460-9592.2000.01700.x; Gillis AM, 1999, CIRCULATION, V99, P2553, DOI 10.1161/01.CIR.99.19.2553; Gillis AM, 2000, CIRCULATION, V102, P736, DOI 10.1161/01.CIR.102.7.736; GILLIS AM, 2000, CARDIOL CLIN, V18, P225; Gold MR, 2000, AM J CARDIOL, V85, P1106, DOI 10.1016/S0002-9149(00)00704-9; Gregoratos G, ACC AHA NASPE 2002 G; Gronefeld GC, 2002, PACE, V25, P1708, DOI 10.1046/j.1460-9592.2002.01708.x; GROSS JN, 1992, AM J CARDIOL, V70, P1507, DOI 10.1016/0002-9149(92)90313-N; Guyomar Y, 1999, PACE, V22, P1747, DOI 10.1111/j.1540-8159.1999.tb00406.x; HARDAGE ML, 1996, IMPLANTABLE CARDIVOE; HAYWOOD GA, 1990, PACE, V13, P2054, DOI 10.1111/j.1540-8159.1990.tb06941.x; HELGUERA ME, 1994, CLEV CLIN J MED, V61, P25, DOI 10.3949/ccjm.61.1.25; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Higgins SL, 1998, AM J CARDIOL, V81, P1360, DOI 10.1016/S0002-9149(98)00170-2; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JANOSIK DL, 2000, CLIN CARDIAC PACING; Jeanrenaud X, 1996, J INTERV CARDIOL, V9, P327, DOI 10.1111/j.1540-8183.1996.tb00638.x; Jeanrenaud X, 1997, PACE, V20, P1673, DOI 10.1111/j.1540-8159.1997.tb03538.x; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; Kappenberger L, 1997, EUR HEART J, V18, P1249; Kaushik V, 2000, CRIT CARE MED, V28, pN121, DOI 10.1097/00003246-200010001-00003; Kay GN, 2000, AM HEART J, V140, P821, DOI 10.1067/mhj.2000.110571; Kenny RA, 1999, EUROPACE, V1, P69, DOI 10.1053/eupc.1998.0016; Kenny RAM, 2001, J AM COLL CARDIOL, V38, P1491, DOI 10.1016/S0735-1097(01)01537-6; Kusumoto FM, 1996, NEW ENGL J MED, V334, P89, DOI 10.1056/NEJM199601113340206; Lamas GA, 2002, NEW ENGL J MED, V346, P1854, DOI 10.1056/NEJMoa013040; Lamas GA, 1998, NEW ENGL J MED, V338, P1097, DOI 10.1056/NEJM199804163381602; LAU CP, 1989, CLIN CARDIOL, V12, P505, DOI 10.1002/clc.4960120907; LAU CP, 1999, PACE, V22, P804; Leclercq C, 2000, HEART, V84, P125, DOI 10.1136/heart.84.2.125; Lee SH, 1998, J AM COLL CARDIOL, V31, P637, DOI 10.1016/S0735-1097(97)00530-5; Leon AR, 2002, J AM COLL CARDIOL, V39, P1258, DOI 10.1016/S0735-1097(02)01779-5; Leung Sum-Kin, 2000, Cardiology Clinics, V18, P113, DOI 10.1016/S0733-8651(05)70131-4; Linde C, 2000, HEART, V84, P123, DOI 10.1136/heart.84.2.123; LUKL J, 1994, PACE, V17, P1844, DOI 10.1111/j.1540-8159.1994.tb03760.x; MALONEY JD, 1988, CLEV CLIN J MED, V55, P542, DOI 10.3949/ccjm.55.6.542; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; Martinelli Filho Martino, 2002, Arq. Bras. Cardiol., V78, P110, DOI 10.1590/S0066-782X2002000100010; McAlister FA, 2004, ANN INTERN MED, V141, P381, DOI 10.7326/0003-4819-141-5-200409070-00101; Morady F, 1997, J AM COLL CARDIOL, V29, P113, DOI 10.1016/S0735-1097(96)00445-7; Naegeli B, 1996, PACE, V19, P455, DOI 10.1111/j.1540-8159.1996.tb06516.x; Nichol G, 2004, ANN INTERN MED, V141, P343, DOI 10.7326/0003-4819-141-5-200409070-00102; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; OMAHONY D, 1995, LANCET, V346, P950, DOI 10.1016/S0140-6736(95)91563-X; Pavia S, 2001, CURR OPIN CARDIOL, V16, P66, DOI 10.1097/00001573-200101000-00010; PETERS RW, 2001, CARDIOL CLIN, V18, P55; Pinski SL, 2003, JAMA-J AM MED ASSOC, V289, P754, DOI 10.1001/jama.289.6.754; Pinski SL, 2002, PACE, V25, P1612, DOI 10.1046/j.1460-9592.2002.01612.x; Pinski SL, 2000, PACE, V23, P1667, DOI 10.1046/j.1460-9592.2000.01667.x; PINSKI SL, 2002, TXB CARDIVOASCULAR M; PINSKI SL, 2001, EVIDENCIAS CARDIOLOG, P366; Qin JX, 2001, J AM COLL CARDIOL, V38, P1994; Raviele A, 2004, EUR HEART J, V25, P1741, DOI 10.1016/j.ehj.2004.06.031; Rosenheck S, 2000, EUROPACE, V2, P60, DOI 10.1053/eupc.1999.0062; Rosenheck S, 2000, PACE, V23, P1226, DOI 10.1111/j.1540-8159.2000.tb00935.x; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; Saksena S, 1998, J CARDIOVASC ELECTR, V9, pS155; Santini M, 2001, EUROPACE, V3, P324, DOI 10.1053/eupc.2001.0188; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; Sethi K K, 1992, Indian Heart J, V44, P145; SGARBOSSA EB, 1993, ANN INTERN MED, V119, P359, DOI 10.7326/0003-4819-119-5-199309010-00002; SGARBOSSA EB, 1994, AM J CARDIOL, V73, P693, DOI 10.1016/0002-9149(94)90936-9; SGARBOSSA EB, 1993, CIRCULATION, V88, P1045, DOI 10.1161/01.CIR.88.3.1045; Shaw FE, 2003, BRIT MED J, V326, P73, DOI 10.1136/bmj.326.7380.73; Skanes AC, 2001, J AM COLL CARDIOL, V38, P167, DOI 10.1016/S0735-1097(01)01326-2; Slade AKB, 1996, HEART, V75, P44, DOI 10.1136/hrt.75.1.44; SORAJJA P, 2000, CARDIOL CLIN, V18, P6779; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; STEIN K, 1999, PACING CLIN ELECTROP, V22, P824; Sutton R, 2000, CIRCULATION, V102, P294; Sweeney MO, 2002, PACE, V25, P1715, DOI 10.1046/j.1460-9592.2002.01715.x; Tang ASL, 2001, CIRCULATION, V103, P3081, DOI 10.1161/01.CIR.103.25.3081; TROHMAN RG, 1992, AM J CARDIOL, V70, P1438, DOI 10.1016/0002-9149(92)90296-B; TROHMAN RG, 1991, PACE, V14, P1448, DOI 10.1111/j.1540-8159.1991.tb04063.x; *UKPACE, 2003, LAT BREAK CLIN TRIAL; UNTEREKER DF, 2000, CLIN CARDIAC PACING; *US FDA, SUMM SAF EFF GUID CO; *US FDA, SUMM SAF EFF MEDTR I; Viskin S, 1996, J AM COLL CARDIOL, V28, P1262, DOI 10.1016/S0735-1097(96)00311-7; Viskin S, 2000, J CARDIOVASC ELECTR, V11, P593, DOI 10.1111/j.1540-8167.2000.tb00015.x; Walker S, 2000, AM J CARDIOL, V86, P231, DOI 10.1016/S0002-9149(00)00865-1; Warwick R, 1973, GRAYS ANATOMY; Wasmer K, 2001, CIRCULATION, V104, P784; Wathen MS, 2001, CIRCULATION, V104, P796, DOI 10.1161/hc3101.093906; Wiggins MJ, 2001, J BIOMED MATER RES, V58, P302; Wilkoff BL, 1999, J AM COLL CARDIOL, V33, P1671, DOI 10.1016/S0735-1097(99)00074-1; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; WISH M, 1987, AM J CARDIOL, V60, P566, DOI 10.1016/0002-9149(87)90306-7; Yildirir A, 2002, J CARDIOVASC ELECTR, V13, P290, DOI 10.1046/j.1540-8167.2002.00290.x; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Zagrodzky JD, 2001, AM J CARDIOL, V87, P1208, DOI 10.1016/S0002-9149(01)01498-9	141	67	73	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1701	1719		10.1016/S0140-6736(04)17358-3	http://dx.doi.org/10.1016/S0140-6736(04)17358-3			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530632				2022-12-28	WOS:000224921600034
J	Staedke, SG; Mpimbaza, A; Kamya, MR; Nzarubara, BK; Dorsey, G; Rosenthal, PJ				Staedke, SG; Mpimbaza, A; Kamya, MR; Nzarubara, BK; Dorsey, G; Rosenthal, PJ			Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial	LANCET			English	Article							SULFADOXINE-PYRIMETHAMINE; COMPARATIVE EFFICACY; TREATMENT FAILURE; AMODIAQUINE; ARTESUNATE; DRUG; RESISTANCE; CHILDREN; CHLOROQUINE; SULFADOXINE/PYRIMETHAMINE	Background Plasmodium falciparum resistance has rendered chloroquine monotherapy ineffective in much of Africa, but data on alternative regimens are limited. We compared chloroquine+sulfadoxine-pyrimethamine, amodiaquine+sulfadoxine-pyrimethamine, and amodiaquine+artesunate for treatment of uncomplicated malaria in Kampala, Uganda. Methods Of 1017 consecutive patients aged 6 months to 10 years with uncomplicated malaria who were screened, 418 were randomised to receive: chloroquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine (25 mg/kg sulfadoxine, 1.25 mg/kg pyrimethamine, single dose); amodiaquine (25 mg/kg over 3 days) and sulfadoxine-pyrimethamine; or amodiaquine and artesunate (4 mg/kg daily for 3 days). Primary efficacy outcomes were 28-day clinical failure risks, adjusted and unadjusted by genotyping to distinguish new infection and recrudescence. The primary safety endpoint was incidence of serious adverse events during follow-up. Analysis was intention to treat and per protocol. Findings 18 patients were excluded before enrolment. Of those enrolled, 384 of 400 (96%) were assigned an efficacy outcome and 396 (99%) were assessed for safety. Risk of 28-day clinical treatment failure was significantly higher with chloroquine+sulfadoxine-pyrimethamine (44/125 [35%]) than with amodiaquine+sulfadoxine-pyrimethamine (12/129 [9%]; risk difference 26% [95% CI 16-36]; p<0.0001) or amodiaquine+artesunate (3/130 [2%]; 33% [24-42]; p<0.0001). The greater risk of clinical treatment failure with amodiaquine+sulfadoxine-pyrimethamine was balanced by a lower risk of new infection, resulting in a similar need for retreatment over 28 days for amodiaquine+sulfadoxine-pyrimethamine (17/129 [13%]) and amodiaquine+artesunate (16/130 [12%]; p=0.854). Serious adverse events were uncommon with all regimens. Interpretation Risk of treatment failure with chloroquine+sulfadoxine-pyrimethamine was unacceptably high. Combinations of amodiaquine and sulfadoxine-pyrimethamine or artesunate were significantly more efficacious, and each regimen could be an appropriate alternative for treatment of uncomplicated malaria in Africa.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA USA; Makerere Univ, Sch Med, Kampala, Uganda	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Makerere University	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, Dept Med, Box 0811, San Francisco, CA 94143 USA.	rosnthl@itsa.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI043301, K23AI049212] Funding Source: NIH RePORTER; FIC NIH HHS [TW01506, TW00007] Funding Source: Medline; NIAID NIH HHS [AI43301, K23 AI49212] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; [Anonymous], 2003, ASS MON ANT DRUG EFF; Basco LK, 2002, B WORLD HEALTH ORGAN, V80, P538; Bloland PB, 1999, ANN TROP MED PARASIT, V93, P5, DOI 10.1080/00034989958753; BLOLAND PB, 2000, B WORLD HEALTH ORGAN, V78, P1374; Cattamanchi A, 2003, AM J TROP MED HYG, V68, P133, DOI 10.4269/ajtmh.2003.68.133; Dorsey G, 2003, J INFECT DIS, V188, P1231, DOI 10.1086/378523; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; Dorsey G, 2000, AM J TROP MED HYG, V62, P686, DOI 10.4269/ajtmh.2000.62.686; Gasasira AF, 2003, AM J TROP MED HYG, V68, P127, DOI 10.4269/ajtmh.2003.68.127; Goodman CA, 2001, HEALTH ECON, V10, P731, DOI 10.1002/hec.621; Ittarat W, 2003, AM J TROP MED HYG, V68, P147, DOI 10.4269/ajtmh.2003.68.147; Kamya MR, 2002, TROP MED INT HEALTH, V7, P1031, DOI 10.1046/j.1365-3156.2002.00974.x; Kamya MR, 2001, T ROY SOC TROP MED H, V95, P50, DOI 10.1016/S0035-9203(01)90331-1; MCINTOSH HM, 2000, COCHRANE LIB; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; OLLIARO P, 2003, COCHRANE LIB; PHILLIPSHOWARD PA, 1990, J ROY SOC MED, V83, P82, DOI 10.1177/014107689008300208; Rapuoda B, 2003, TROP MED INT HEALTH, V8, P860, DOI 10.1046/j.1360-2276.2003.01114.x; Ribeiro I R, 1998, Med Trop (Mars), V58, P50; Rwagacondo CE, 2003, AM J TROP MED HYG, V68, P743, DOI 10.4269/ajtmh.2003.68.743; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; Snow RW, 2003, TRENDS PARASITOL, V19, P363, DOI 10.1016/S1471-4922(03)00168-5; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; STURCHLER D, 1993, DRUG SAFETY, V8, P160; Trape JF, 2001, AM J TROP MED HYG, V64, P12, DOI 10.4269/ajtmh.2001.64.12; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; WATKINS WM, 1993, T ROY SOC TROP MED H, V87, P75, DOI 10.1016/0035-9203(93)90431-O; White NJ, 2002, TRENDS PARASITOL, V18, P458, DOI 10.1016/S1471-4922(02)02373-5; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301; *WHO, 2003, WHOCDSMAL20031094WHO; *WHO, 1996, ASS THER EFF ANT DRU	33	67	69	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1950	1957		10.1016/S0140-6736(04)17478-3	http://dx.doi.org/10.1016/S0140-6736(04)17478-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567011				2022-12-28	WOS:000225327000033
J	Gu, CH; Yoshida, Y; Livet, J; Reimert, DV; Mann, F; Merte, J; Henderson, CE; Jessell, TM; Kolodkin, AL; Ginty, DD				Gu, CH; Yoshida, Y; Livet, J; Reimert, DV; Mann, F; Merte, J; Henderson, CE; Jessell, TM; Kolodkin, AL; Ginty, DD			Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; RECEPTOR; CELLS; MORPHOGENESIS; COMPLEXES; GUIDANCE; BINDING	The development of a patterned vasculature is essential for normal organogenesis. We found that signaling by semaphorin 3E (Sema3E) and its receptor plexin-D1 controls endothelial cell positioning and the patterning of the developing vasculature in the mouse. Sema3E is highly expressed in developing somites, where it acts as a repulsive cue for plexin-D1-expressing endotheiial cells of adjacent intersomitic vessels. Sema3E-plexin-D1 signaling did not require neuropilins, which were previously presumed to be obligate Sema3 coreceptors. Moreover, genetic ablation of Sema3E or plexin-D1 but not neuropilin-mediated Sema3 signaling disrupted vascular patterning. These findings reveal an unexpected semaphorin signaling pathway and define a mechanism for controlling vascular patterning.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Dev Biol Inst Marseille, INSERM, UMR623, F-13288 Marseille, France	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Columbia University; Howard Hughes Medical Institute; Institut National de la Sante et de la Recherche Medicale (Inserm)	Kolodkin, AL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	kolodkin@jhmi.edu; dginty@jhmi.edu	Mann, Fanny/G-2786-2016; livet, jean/C-2766-2012	Mann, Fanny/0000-0003-4839-4347; livet, jean/0000-0003-3079-4908; Henderson, Christopher/0000-0002-9936-3279	NCI NIH HHS [CA23767-24] Funding Source: Medline; NIMH NIH HHS [MH59199-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Gitler AD, 2004, DEV CELL, V7, P107, DOI 10.1016/j.devcel.2004.06.002; GU C, UNPUB; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; He Zhigang, 2002, Sci STKE, V2002, pre1, DOI 10.1126/stke.2002.119.re1; Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Levine AJ, 2003, DEV BIOL, V254, P50, DOI 10.1016/S0012-1606(02)00029-5; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Miyazaki N, 1999, NEUROSCI RES, V33, P269, DOI 10.1016/S0168-0102(99)00015-2; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114; Torres-Vazquez J, 2004, DEV CELL, V7, P117, DOI 10.1016/j.devcel.2004.06.008; Toyofuku T, 2004, GENE DEV, V18, P435, DOI 10.1101/gad.1167304; Van Der Zwaag B, 2002, DEV DYNAM, V225, P336, DOI 10.1002/dvdy.10159; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8	21	383	406	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	2005	307	5707					265	268		10.1126/science.1105416	http://dx.doi.org/10.1126/science.1105416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	888GJ	15550623				2022-12-28	WOS:000226361900046
J	Bond, GL; Hu, WW; Bond, EE; Robins, H; Lutzker, SG; Arva, NC; Bargonetti, J; Bartel, F; Taubert, H; Wuerl, P; Onel, K; Yip, L; Hwang, SJ; Strong, LC; Lozano, G; Levine, AJ				Bond, GL; Hu, WW; Bond, EE; Robins, H; Lutzker, SG; Arva, NC; Bargonetti, J; Bartel, F; Taubert, H; Wuerl, P; Onel, K; Yip, L; Hwang, SJ; Strong, LC; Lozano, G; Levine, AJ			A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans	CELL			English	Article							SOFT-TISSUE SARCOMAS; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; BREAST-CANCER; EXPRESSION; GENE; AMPLIFICATION; ACTIVATION; MUTATIONS	The tumor suppressor p53 gene is mutated in minimally half of all cancers. It is therefore reasonable to assume that naturally occurring polymorphic genetic variants in the p53 stress response pathway might determine an individual's susceptibility to cancer. A central node in the p53 pathway is the MDM2 protein, a direct negative regulator of p53. In this report, a single nucleotide polymorphism (SNP309) is found in the MDM2 promoter and is shown to increase the affinity of the transcriptional activator Sp1, resulting in higher levels of MDM2 RNA and protein and the subsequent attenuation of the p53 pathway. In humans, SNP309 is shown to associate with accelerated tumor formation in both hereditary and sporadic cancers. A model is proposed whereby SNP309 serves as a rate-limiting event in carcinogenesis.	Inst Adv Study, Sch Nat Sci, Princeton, NJ 08540 USA; Univ Med & Dent New Jersey, Canc Inst New Jersey, New Brunswick, NJ 08903 USA; Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Houston, TX 77030 USA; Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle Saale, Germany; Univ Ulm, Surg Clin, D-89075 Ulm, Germany; Cornell Univ, Weill Coll Med, Dept Med, New York, NY 10021 USA; CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; CUNY, Grad Sch, New York, NY 10021 USA	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Texas System; UTMD Anderson Cancer Center; Martin Luther University Halle Wittenberg; Ulm University; Cornell University; City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System	Levine, AJ (corresponding author), Inst Adv Study, Sch Nat Sci, Olden Lane, Princeton, NJ 08540 USA.	alevine@ias.edu		Bargonetti, Jill/0000-0003-2692-0991; Taubert, Helge/0000-0002-9077-1727				BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; CORDONCARDO C, 1994, CANCER RES, V54, P794; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Freedman DA, 1999, CANCER RES, V59, P1; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hurtado J, 2002, Expert Opin Pharmacother, V3, P521; Hwang SJ, 2003, AM J HUM GENET, V72, P975, DOI 10.1086/374567; Jin SK, 2001, J CELL SCI, V114, P4139; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lain S, 2003, EUR J CANCER, V39, P1053, DOI 10.1016/S0959-8049(03)00063-7; Landers JE, 1997, CANCER RES, V57, P3562; LEACH FS, 1993, CANCER RES, V53, P2231; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; Lu WG, 2002, CANCER RES, V62, P1305; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Phelps M, 2003, CANCER RES, V63, P2616; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Taubert H, 2000, MOL MED, V6, P50, DOI 10.1007/BF03401934; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	30	1002	1039	1	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					591	602		10.1016/j.cell.2004.11.022	http://dx.doi.org/10.1016/j.cell.2004.11.022			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550242	Green Published, Bronze			2022-12-28	WOS:000225389500006
J	Hata, K; Futaba, DN; Mizuno, K; Namai, T; Yumura, M; Iijima, S				Hata, K; Futaba, DN; Mizuno, K; Namai, T; Yumura, M; Iijima, S			Water-Assisted Highly Efficient Synthesis of Impurity-Free Single-Walled Carbon Nanotubes	SCIENCE			English	Article							WALLED NANOTUBES; PURIFICATION; GROWTH	We demonstrate the efficient chemical vapor deposition synthesis of single-waited carbon nanotubes where the activity and lifetime of the catalysts are enhanced by water. Water-stimulated enhanced catalytic activity results in massive growth of superdense and vertically aligned nanotube forests with heights up to 2.5 millimeters that can be easily separated from the catalysts, providing nanotube material with carbon purity above 99.98%. Moreover, patterned, highly organized intrinsic nanotube structures were successfully fabricated. The water-assisted synthesis method addresses many critical problems that currently plague carbon nanotube synthesis.	AIST, Res Ctr Adv Carbon Mat, Tsukuba, Ibaraki 3058565, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Hata, K (corresponding author), AIST, Res Ctr Adv Carbon Mat, Tsukuba, Ibaraki 3058565, Japan.	kenji-hata@aist.go.jp	Futaba, Don N./C-8294-2009; Hata, Kenji/B-3262-2009	Futaba, Don N./0000-0002-7083-2772; Hata, Kenji/0000-0003-1623-391X				Cao A, 2001, J MATER RES, V16, P3107, DOI 10.1557/JMR.2001.0428; Chiang IW, 2001, J PHYS CHEM B, V105, P8297, DOI 10.1021/jp0114891; Choi HC, 2003, NANO LETT, V3, P157, DOI 10.1021/nl025876d; Cinke M, 2002, CHEM PHYS LETT, V365, P69, DOI 10.1016/S0009-2614(02)01420-3; Helveg S, 2004, NATURE, V427, P426, DOI 10.1038/nature02278; O'Connell MJ, 2002, SCIENCE, V297, P593, DOI 10.1126/science.1072631; Tohji K, 1996, NATURE, V383, P679, DOI 10.1038/383679a0; Tohji K, 1997, J PHYS CHEM B, V101, P1974, DOI 10.1021/jp962888c	8	2182	2281	21	938	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1362	1364		10.1126/science.1104962	http://dx.doi.org/10.1126/science.1104962			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550668				2022-12-28	WOS:000225301600048
J	Launay, P; Cheng, H; Srivatsan, S; Penner, R; Fleig, A; Kinet, JP				Launay, P; Cheng, H; Srivatsan, S; Penner, R; Fleig, A; Kinet, JP			TRPM4 regulates calcium oscillations after T cell activation	SCIENCE			English	Article							GENE-EXPRESSION; CHANNELS; LYMPHOCYTES; SYSTEM	TRPM4 has recently been described as a calcium-activated nonselective (CAN) cation channel that mediates membrane depolarization. However, the functional importance of TRPM4 in the context of calcium (Ca2+) signaling and its effect on cellular responses are not known. Here, the molecular inhibition of endogenous TRPM4 in T cells was shown to suppress TRPM4 currents, with a profound influence on receptor-mediated Ca2+ mobilization. Agonist-mediated oscillations in intracellutar Ca2+ concentration ([Ca2+](i)), which are driven by store-operated Ca2+ influx, were transformed into a sustained elevation in [Ca2+](i). This increase in Ca2+ influx enhanced interleukin-2 production. Thus, TRPM4-mediated depolarization modulates Ca2+ oscillations, with downstream effects on cytokine production in T lymphocytes.	Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Hawaii, Queens Med Ctr, Biomed Res Ctr, Lab Cell & Mol Signaling, Honolulu, HI 96813 USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96813 USA; Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA	Harvard University; Harvard Medical School; The Queen's Medical Center; University of Hawaii System; University of Hawaii System; Harvard University; Beth Israel Deaconess Medical Center	Kinet, JP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.	jkinet@bidmc.harvard.edu	Launay, Pierre/AAH-7076-2019	Fleig, Andrea/0000-0001-8396-7249; Penner, Reinhold/0000-0002-5366-1537	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050200, R01AI046734] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065360, R01GM063954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040927] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI46734, R01-AI50200] Funding Source: Medline; NIGMS NIH HHS [R01-GM63954, R01-GM65360] Funding Source: Medline; NINDS NIH HHS [R01-NS40927] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abraham RT, 2004, NAT REV IMMUNOL, V4, P301, DOI 10.1038/nri1330; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; DOLMETSCH RE, 1994, J GEN PHYSIOL, V103, P365, DOI 10.1085/jgp.103.3.365; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; HAROOTUNIAN AT, 1989, J BIOL CHEM, V264, P19458; Hofmann T, 2003, CURR BIOL, V13, P1153, DOI 10.1016/S0960-9822(03)00431-7; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MINTA A, 1989, J BIOL CHEM, V264, P19449; Murakami M, 2003, BIOCHEM BIOPH RES CO, V307, P522, DOI 10.1016/S0006-291X(03)01186-0; Nilius B, 2003, J BIOL CHEM, V278, P30813, DOI 10.1074/jbc.M305127200; Nilius B, 2003, ENDOTHELIUM-J ENDOTH, V10, P5, DOI 10.1080/10623320303356; Petersen OH, 2002, CURR BIOL, V12, pR520, DOI 10.1016/S0960-9822(02)01027-8; VERHEUGEN JAH, 1995, CELL CALCIUM, V17, P287, DOI 10.1016/0143-4160(95)90075-6; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198	19	240	252	3	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1374	1377		10.1126/science.1098845	http://dx.doi.org/10.1126/science.1098845			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550671				2022-12-28	WOS:000225301600052
J	Bhowmick, NA; Neilson, EG; Moses, HL				Bhowmick, NA; Neilson, EG; Moses, HL			Stromal fibroblasts in cancer initiation and progression	NATURE			English	Article							PREOPERATIVE PLASMA-LEVELS; KERATINOCYTE GROWTH-FACTOR; TGF-BETA; MATRIX METALLOPROTEINASES; TUMOR PROGRESSION; UROGENITAL SINUS; EPITHELIAL-CELLS; INVASIVE GROWTH; MAMMARY-GLAND; BREAST-CANCER	It is widely accepted that the development of carcinoma - the most common form of human cancer - is due to the accumulation of somatic mutations in epithelial cells. The behaviour of carcinomas is also influenced by the tumour microenvironment, which includes extracellular matrix, blood vasculature, inflammatory cells and fibroblasts. Recent studies reveal that fibroblasts have a more profound influence on the development and progression of carcinomas than was previously appreciated. These new findings have important therapeutic implications.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Urol Surg, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Bhowmick, NA (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	hal.moses@vanderbilt.edu	Thomson, Axel/A-7893-2013; Bhowmick, Neil/AAA-7302-2019	Bhowmick, Neil/0000-0001-8747-5989	NATIONAL CANCER INSTITUTE [R01CA108646] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA108646-01, R01 CA108646] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Amendt C, 1998, ONCOGENE, V17, P25, DOI 10.1038/sj.onc.1202161; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Bellusci S, 1997, DEVELOPMENT, V124, P53; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Bottinger EP, 1997, CANCER RES, V57, P5564; BRAUCHLE M, 1994, ONCOGENE, V9, P3199; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Cunha G R, 1989, Cancer Treat Res, V46, P159; CUNHA GR, 1980, ENDOCRINOLOGY, V107, P1767, DOI 10.1210/endo-107-6-1767; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; Dawe C, 1972, TISSUE INTERACTIONS, P305; Derksen PWB, 2004, P NATL ACAD SCI USA, V101, P6122, DOI 10.1073/pnas.0305855101; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Furuhashi M, 2004, CANCER RES, V64, P2725, DOI 10.1158/0008-5472.CAN-03-1489; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gorska AE, 2003, AM J PATHOL, V163, P1539, DOI 10.1016/S0002-9440(10)63510-9; Hayward SW, 2002, J UROLOGY, V168, P1165, DOI 10.1016/S0022-5347(05)64620-4; Hayward SW, 2001, CANCER RES, V61, P8135; Hayward SW, 2000, RADIOL CLIN N AM, V38, P1, DOI 10.1016/S0033-8389(05)70146-9; Itoh T, 1998, CANCER RES, V58, P1048; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; Koskinen PJ, 1991, GROWTH FACTORS, V5, DOI 10.3109/08977199109000292; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lu WQ, 1999, J BIOL CHEM, V274, P12827, DOI 10.1074/jbc.274.18.12827; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Marnett LJ, 2003, J CLIN INVEST, V111, P583, DOI 10.1172/JCI200318022; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Moinfar F, 2000, CANCER RES, V60, P2562; MOSES HL, 1985, CANCER CELL, V3, P65; Nakamura T, 1997, CANCER RES, V57, P3305; OHUCHIDA K, 2004, CANCER RES, V64, P3125; Olumi AF, 1999, CANCER RES, V59, P5002; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PIERCE DF, 1995, P NATL ACAD SCI USA, V92, P4254, DOI 10.1073/pnas.92.10.4254; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Russell PJ, 1998, CLIN CHEM, V44, P705; Sandler AB, 2004, CLIN CANCER RES, V10, p4258S, DOI 10.1158/1078-0432.CCR-040023; SCHOR SL, 1985, J CELL SCI, V73, P221; SCHOR SL, 1988, J CELL SCI, V90, P401; Shariat SF, 2001, J CLIN ONCOL, V19, P2856, DOI 10.1200/JCO.2001.19.11.2856; Shariat SF, 2001, CANCER-AM CANCER SOC, V92, P2985, DOI 10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsushima H, 2001, CLIN CANCER RES, V7, P1258; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WESSELLS NK, 1970, J EXP ZOOL, V175, P455, DOI 10.1002/jez.1401750405; Wirtzfeld DA, 2001, ANN SURG ONCOL, V8, P319, DOI 10.1245/aso.2001.8.4.319; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Xue CS, 2003, CANCER RES, V63, P3386; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	67	1731	1838	3	170	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					332	337		10.1038/nature03096	http://dx.doi.org/10.1038/nature03096			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549095	Green Accepted			2022-12-28	WOS:000225161400043
J	Salama, P; Spiegel, P; Talley, L; Waldman, R				Salama, P; Spiegel, P; Talley, L; Waldman, R			Lessons learned from complex emergencies over past decade	LANCET			English	Review							PUBLIC-HEALTH; REFUGEE POPULATIONS; RESIDENT POPULATIONS; SEVERE MALNUTRITION; NUTRITIONAL-STATUS; RWANDAN REFUGEES; MORTALITY-RATES; FAMINE; WAR; SOMALIA	Major advances have been made during the past decade in the way the international community responds to the health and nutrition consequences of complex emergencies. The public health and clinical response to diseases of acute epidemic potential has improved, especially in camps. Case-fatality rates for severely malnourished children have plummeted because of better protocols and products. Renewed focus is required on the major causes of death in conflict-affected societies-particularly acute respiratory infections, diarrhoea, malaria, measles, neonatal causes, and malnutrition-outside camps and often across regions and even political boundaries. in emergencies in sub-Saharan Africa, particularly southern Africa, HIV/AIDS is also an important cause of morbidity and mortality. Stronger coordination, increased accountability, and a more strategic positioning of non-governmental organisations and UN agencies are crucial to achieving lower maternal and child morbidity and mortality rates in complex emergencies and therefore for reaching the UN's Millennium Development Goals.	UNICEF, Kabul, Afghanistan; UNHCR, Geneva, Switzerland; Ctr Dis Control & Prevent, Atlanta, GA USA; Columbia Univ, Mailman Sch Publ Hlth, Ctr Global Hlth & Econ Dev, New York, NY USA	Centers for Disease Control & Prevention - USA; Columbia University	Salama, P (corresponding author), Suite 400,1325 G St, Washington, DC 20005 USA.	psalama@unicef.org	Spiegel, Paul/AAL-3238-2021	Spiegel, Paul/0000-0002-6158-6661				Aaby P, 1999, BRIT MED J, V319, P878, DOI 10.1136/bmj.319.7214.878; [Anonymous], 1997, REF HLTH APPR EM SIT; Assefa F, 2001, JAMA-J AM MED ASSOC, V286, P2723, DOI 10.1001/jama.286.21.2723; BARTLETT L, IN PRESS LANCET; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; BOSS LP, 1994, JAMA-J AM MED ASSOC, V272, P371, DOI 10.1001/jama.272.5.371; Briend A, 1999, LANCET, V353, P1767, DOI 10.1016/S0140-6736(99)01078-8; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1029; *CDCP, 1992, MMWR-MORBID MORTAL W, P41; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P304; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P104; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P979; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P475; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P363; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P701; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P14; Cheung Edith, 2003, Food and Nutrition Bulletin, V24, P247; Collins S, 1998, AM J CLIN NUTR, V68, P193, DOI 10.1093/ajcn/68.1.193; Collins S, 2001, LANCET, V358, P498, DOI 10.1016/S0140-6736(01)05630-6; COLLINS S, 1993, JAMA-J AM MED ASSOC, V270, P637; COLLINS S, 1995, NAT MED, V1, P810, DOI 10.1038/nm0895-810; Creusvaux H, 1999, LANCET, V354, P832, DOI 10.1016/S0140-6736(99)80016-6; de Ville de Goyet C., 1978, MANAGEMENT NUTR EMER; de Waal A, 2002, IDS BULL-I DEV STUD, V33, P120; Deng LB, 2002, IDS BULL-I DEV STUD, V33, P28, DOI 10.1111/j.1759-5436.2002.tb00041.x; Dunston C, 2001, AM J PUBLIC HEALTH, V91, P1574, DOI 10.2105/AJPH.91.10.1574; Ford N, 2002, LANCET, V360, P334, DOI 10.1016/S0140-6736(02)09559-4; Ford N, 2001, LANCET, V358, P1543, DOI 10.1016/S0140-6736(01)06588-6; FRIEDMAN C, 2000, W TIMOR MISSION REPO; GALL C, AFGHAN MOTHERHOOD FI; GESSNER BD, 1994, JAMA-J AM MED ASSOC, V272, P382, DOI 10.1001/jama.272.5.382; GLASS RI, 1980, LANCET, V1, P868; *GLOB IDP PROJ, 2002, INT DISPL PEOPL GLOB; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; Hammond L, 2002, DISASTERS, V26, P262, DOI 10.1111/1467-7717.00204; Hankins CA, 2002, AIDS, V16, P2245, DOI 10.1097/00002030-200211220-00003; *INT RESC COMM, 2003, MORT DEM REP CONG RE; *INT STAND COMM, 2003, GUID HIV AIDS INT EM; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Khaw AJ, 2000, DISASTERS, V24, P181, DOI 10.1111/1467-7717.00141; LAUTZE S, 1997, STRATEGIC HUMANITARI; Lautze S., 2003, RISK VULNERABILITY E; LAUTZE S, 2002, QAHTEPOOL CASH FAMIN; LAUTZE S, IN PRESS LANCET; MACRAE Joanna, 2000, 8 HPG OV DEV I; MAGAN AM, 1983, DISASTERS, V7, P94, DOI 10.1111/j.1467-7717.1983.tb00801.x; MARFIN AA, 1994, JAMA-J AM MED ASSOC, V272, P377, DOI 10.1001/jama.272.5.377; Maxwell D, 2002, IDS BULL-I DEV STUD, V33, P48, DOI 10.1111/j.1759-5436.2002.tb00043.x; MAYER J, 1969, POSTGRAD MED, V45, P236, DOI 10.1080/00325481.1969.11697106; MEARS C, 1994, HLTH CARE REFUGEES D; *MED FRONT, 2001, SEV FOOD CRIS REP CE; *MED FRONT, DEATH RAT ANG CONF E; MOLLICA RF, IN PRESS LANCET; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; MOREN A, 1990, PELLAGRA CASES MOZAM; Nabeth P, 1997, LANCET, V349, P59, DOI 10.1016/S0140-6736(05)62198-8; NEIBERG P, 1988, B WORLD HEALTH ORGAN, V66, P689; Noji EK, 1997, DISASTERS, V21, P366, DOI 10.1111/1467-7717.00068; NUTRISET SA, DIET TREATMENT SEVER; Palmer CA, 1999, SOC SCI MED, V49, P1689, DOI 10.1016/S0277-9536(99)00253-1; PAQUET C, 1994, LANCET, V344, P823, DOI 10.1016/S0140-6736(94)92381-7; *PHYS HUM RIGHTS, 1999, WAR CRIM KOS POP BAS; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; Robinson WC, 1999, LANCET, V354, P291, DOI 10.1016/S0140-6736(99)02266-7; Salama P, 2001, JAMA-J AM MED ASSOC, V286, P563, DOI 10.1001/jama.286.5.563; SALAMA P, 1999, ENN FIELD EXCHANGE, V6, P19; SALAMA P, 1998, ASSESSMENT HUMANITAR; Salignon P, 2000, LANCET, V356, P1762, DOI 10.1016/S0140-6736(00)03217-7; Schofield EC, 1996, DISASTERS, V20, P248, DOI 10.1111/j.1467-7717.1996.tb01037.x; Seal A, 2001, DISASTERS, V25, P136, DOI 10.1111/1467-7717.00166; SEAMAN J, 1987, P SEM MORT SOC SUBS; SEAMAN JA, 1972, LANCET, V2, P866; SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5; Simmonds S., 1983, REFUGEE COMMUNITY HL; *SPHER PROJ, 2004, SPHERE HUM CHART MIN; Spiegel P, 2002, LANCET, V360, P1927, DOI 10.1016/S0140-6736(02)11915-5; SPIEGEL P, 1999, ALBANIAN HLTH SURVEY; Spiegel PB, 2000, LANCET, V355, P2204, DOI 10.1016/S0140-6736(00)02404-1; Spiegel PB, 2004, JAMA-J AM MED ASSOC, V292, P613, DOI 10.1001/jama.292.5.613; Spiegel PB, 2001, LANCET, V357, P714, DOI 10.1016/S0140-6736(00)04143-X; Talley L., 2001, J REFUG STUD, V14, P412; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, J TROP PEDIATRICS, V34, P218, DOI 10.1093/tropej/34.5.218; TOOLE MJ, 1993, LANCET, V342, P190, DOI 10.1016/0140-6736(93)92292-2; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1995, LANCET, V345, P339, DOI 10.1016/S0140-6736(95)90338-0; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TOOLE MJ, 1995, INFECT DIS CLIN N AM, V9, P353; U.S. Committee for Refugees, 2000, WORLD REF SURV 2000; U.S. Committee for Refugees, 1992, WORLD REF SURV 1992; *UN HIGH COMM REF, 1999, REPR HLTH REF SIT IN; *UNHCR, 2002, STAT YB 2001 REF AS; *US COMM REF, 1993, WORLD REF SURV 1992; *US COMM REF, 1993, WORLD REF SURV 1993; *US COMM REF, 1995, WORLD REF SURV 1995; US Committee for Refugees, 2002, WORLD REF SURV 2002; Van Damme W, 1998, LANCET, V351, P1609, DOI 10.1016/S0140-6736(97)10348-8; VARAINE F, 1995, LANCET, V345, P1114, DOI 10.1016/S0140-6736(95)90845-5; *WHO, 1997, TUB CONTR REF SIT IN; World Health Organization, 1993, GUID CHOL CONTR; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; YOUNG H, 1987, DISASTERS, V11, P102, DOI 10.1111/j.1467-7717.1987.tb00622.x; YOUNG H, 1995, DISASTERS, V19, P94, DOI 10.1111/j.1467-7717.1995.tb00361.x	108	170	172	0	48	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1801	1813		10.1016/S0140-6736(04)17405-9	http://dx.doi.org/10.1016/S0140-6736(04)17405-9			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	870PQ	15541455				2022-12-28	WOS:000225070600035
J	Wang, CY				Wang, CY			Coping with endometriosis	LANCET			English	Editorial Material												wangcyen@yahoo.com							0	2	2	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	2004	364	9447					1800	1800		10.1016/S0140-6736(04)17404-7	http://dx.doi.org/10.1016/S0140-6736(04)17404-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541454				2022-12-28	WOS:000225070600034
J	Solan, M; Cardinale, BJ; Downing, AL; Engelhardt, KAM; Ruesink, JL; Srivastava, DS				Solan, M; Cardinale, BJ; Downing, AL; Engelhardt, KAM; Ruesink, JL; Srivastava, DS			Extinction and ecosystem function in the marine benthos	SCIENCE			English	Article							IN-SITU; SPECIES LOSS; BIODIVERSITY; COMMUNITY; DIVERSITY; RESPONSES; SEDIMENT; PATTERNS; RISK; SEA	Rapid changes in biodiversity are occurring globally, yet the ecological impacts of diversity loss are poorly understood. Here we use data from marine invertebrate communities to parameterize models that predict how extinctions will. affect sediment bioturbation, a process vital to the persistence of aquatic communities. We show that species extinction is generally expected to reduce bioturbation, but the magnitude of reduction depends on how the functional traits of individual species covary with their risk of extinction. As a result, the particular cause of extinction and the order in which species are lost ultimately govern the ecosystem-level consequences of biodiversity loss.	Auburn Univ, Newburgh AB41 6AA, Aberdeen, Scotland; Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA; Ohio Wesleyan Univ, Dept Zool, Delaware, OH 43015 USA; Univ Maryland, Ctr Environm Sci, Appalachian Lab, Frostburg, MD 21532 USA; Univ Washington, Dept Biol, Seattle, WA 98195 USA; Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of Aberdeen; University of California System; University of California Santa Barbara; Ohio Wesleyan University; University System of Maryland; University of Maryland Center for Environmental Science; University of Washington; University of Washington Seattle; University of British Columbia	Solan, M (corresponding author), Auburn Univ, Main St, Newburgh AB41 6AA, Aberdeen, Scotland.	m.solan@abdn.ac.uk	Langhamer, Olivia/J-3425-2012; Cardinale, Bradley J/I-7076-2013; Engelhardt, Katharina AM/H-8755-2013; Solan, Martin/E-9338-2012	Solan, Martin/0000-0001-9924-5574				Biles CL, 2003, J EXP MAR BIOL ECOL, V285, P165, DOI 10.1016/S0022-0981(02)00525-7; Bolam SG, 2002, ECOL MONOGR, V72, P599, DOI 10.1890/0012-9615(2002)072[0599:DBAEPI]2.0.CO;2; Davies KF, 2004, ECOLOGY, V85, P265, DOI 10.1890/03-0110; Doak DF, 1998, AM NAT, V151, P264, DOI 10.1086/286117; Duffy JE, 2003, ECOL LETT, V6, P680, DOI 10.1046/j.1461-0248.2003.00494.x; Emmerson MC, 2001, NATURE, V411, P73, DOI 10.1038/35075055; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fischer JM, 2001, ECOL APPL, V11, P1060, DOI 10.1890/1051-0761(2001)011[1060:CDIZCR]2.0.CO;2; Ives AR, 2004, NATURE, V429, P174, DOI 10.1038/nature02515; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; Jacobs DK, 1998, P NATL ACAD SCI USA, V95, P9396, DOI 10.1073/pnas.95.16.9396; Jenkins M, 2003, SCIENCE, V302, P1175, DOI 10.1126/science.1088666; Johnson CN, 1998, NATURE, V394, P272, DOI 10.1038/28385; Johnson KS, 1999, NATURE, V398, P697, DOI 10.1038/19511; Jonsson M, 2002, P ROY SOC B-BIOL SCI, V269, P1047, DOI 10.1098/rspb.2002.1979; Lawton J.H., 1995, POPULATION DYNAMIC P, P147; Malakoff D, 1997, SCIENCE, V277, P486, DOI 10.1126/science.277.5325.486; McKinney ML, 1997, ANNU REV ECOL SYST, V28, P495, DOI 10.1146/annurev.ecolsys.28.1.495; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; POORE GCB, 1993, NATURE, V361, P597, DOI 10.1038/361597a0; Raffaelli D, 2003, J SEA RES, V49, P133, DOI 10.1016/S1385-1101(02)00200-9; Ruesink JL, 2001, OIKOS, V93, P221, DOI 10.1034/j.1600-0706.2001.930206.x; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Schmid B, 2002, BIODIVERSITY AND ECOSYSTEM FUNCTIONING: SYNTHESIS AND PERSPECTIVES, P61; Smith MD, 2003, ECOL LETT, V6, P509, DOI 10.1046/j.1461-0248.2003.00454.x; Solan M, 2002, MAR ECOL PROG SER, V228, P179, DOI 10.3354/meps228179; Srivastava DS, 2002, OIKOS, V98, P351, DOI 10.1034/j.1600-0706.2002.980216.x; TRACY CR, 1992, AM NAT, V139, P102, DOI 10.1086/285315; TURNER RE, 1994, NATURE, V368, P619, DOI 10.1038/368619a0; Vitousek PM, 1997, SCIENCE, V277, P494, DOI 10.1126/science.277.5325.494; Witte U, 2003, NATURE, V424, P763, DOI 10.1038/nature01799	32	555	574	6	274	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1177	1180		10.1126/science.1103960	http://dx.doi.org/10.1126/science.1103960			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539601				2022-12-28	WOS:000225193100047
J	Wagner, D; Przybyla, D; Camp, ROD; Kim, C; Landgraf, F; Lee, KP; Wursch, M; Laloi, C; Nater, M; Hideg, E; Apel, K				Wagner, D; Przybyla, D; Camp, ROD; Kim, C; Landgraf, F; Lee, KP; Wursch, M; Laloi, C; Nater, M; Hideg, E; Apel, K			The genetic basis of singlet oxygen-induced stress responses of Arabidopsis thaliana	SCIENCE			English	Article							PHOTOSYSTEM-II; PHOTOSYNTHESIS; LEAVES; LIGHT	Plants under oxidative stress suffer from damages that have been interpreted as unavoidable consequences of injuries inflicted upon plants by toxic levels of reactive oxygen species (ROS). However, this paradigm needs to be modified. Inactivation of a single gene, EXECUTER1, is sufficient to abrogate stress responses of Arabidopsis thaliana caused by the release of singlet oxygen: External conditions under which these stress responses are observed and the amounts of ROS that accumulate in plants exposed to these environmental conditions do not directly cause damages. Instead, seedling lethality and growth inhibition of mature plants result from genetic programs that are activated after the release of singlet oxygen has been perceived by the plant.	Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland; Hungarian Acad Sci, Biol Res Ctr, Inst Plant Biol, H-6701 Szeged, Hungary	Swiss Federal Institutes of Technology Domain; ETH Zurich; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center	Apel, K (corresponding author), Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland.	klaus.apel@ipw.biol.ethz.ch	Kim, Chanhong/G-5506-2012; Laloi, Christophe/E-5685-2019; Kim, Chanhong/AAL-4930-2021	Laloi, Christophe/0000-0002-6576-5966; Kim, Chanhong/0000-0003-4133-9070; Lee, Keun Pyo/0000-0002-2025-9269				Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; Diner BA, 2002, ANNU REV PLANT BIOL, V53, P551, DOI 10.1146/annurev.arplant.53.100301.135238; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; Fryer MJ, 2002, J EXP BOT, V53, P1249, DOI 10.1093/jexbot/53.372.1249; Fufezan C, 2002, FEBS LETT, V532, P407, DOI 10.1016/S0014-5793(02)03724-9; Hideg E, 2002, PLANT CELL PHYSIOL, V43, P1154, DOI 10.1093/pcp/pcf145; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; op den Camp RGL, 2003, PLANT CELL, V15, P2320, DOI 10.1105/tpc.014662; PRZYBYLA D, UNPUB; Sharma J, 1997, J BIOL CHEM, V272, P3935, DOI 10.1074/jbc.272.7.3935; Trebst A, 2003, Z NATURFORSCH C, V58, P609; Wagner D., UNPUB	14	463	487	6	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1183	1185		10.1126/science.1103178	http://dx.doi.org/10.1126/science.1103178			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539603				2022-12-28	WOS:000225193100049
J	Soutschek, J; Akinc, A; Bramlage, B; Charisse, K; Constien, R; Donoghue, M; Elbashir, S; Geick, A; Hadwiger, P; Harborth, J; John, M; Kesavan, V; Lavine, G; Pandey, RK; Racie, T; Rajeev, KG; Rohl, I; Toudjarska, I; Wang, G; Wuschko, S; Bumcrot, D; Koteliansky, V; Limmer, S; Manoharan, M; Vornlocher, HP				Soutschek, J; Akinc, A; Bramlage, B; Charisse, K; Constien, R; Donoghue, M; Elbashir, S; Geick, A; Hadwiger, P; Harborth, J; John, M; Kesavan, V; Lavine, G; Pandey, RK; Racie, T; Rajeev, KG; Rohl, I; Toudjarska, I; Wang, G; Wuschko, S; Bumcrot, D; Koteliansky, V; Limmer, S; Manoharan, M; Vornlocher, HP			Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs	NATURE			English	Article							APOLIPOPROTEIN-B; RNA INTERFERENCE; MESSENGER-RNA; MICE; MODEL; CLEAVAGE; DIET	RNA interference (RNAi) holds considerable promise as a therapeutic approach to silence disease-causing genes, particularly those that encode so-called 'non-druggable' targets that are not amenable to conventional therapeutics such as small molecules, proteins, or monoclonal antibodies. The main obstacle to achieving in vivo gene silencing by RNAi technologies is delivery. Here we show that chemically modified short interfering RNAs (siRNAs) can silence an endogenous gene encoding apolipoprotein B (apoB) after intravenous injection in mice. Administration of chemically modified siRNAs resulted in silencing of the apoB messenger RNA in liver and jejunum, decreased plasma levels of apoB protein, and reduced total cholesterol. We also show that these siRNAs can silence human apoB in a transgenic mouse model. In our in vivo study, the mechanism of action for the siRNAs was proven to occur through RNAi-mediated mRNA degradation, and we determined that cleavage of the apoB mRNA occurred specifically at the predicted site. These findings demonstrate the therapeutic potential of siRNAs for the treatment of disease.	Alnylam Europe AG, D-95326 Kulmbach, Germany; Alnylam Pharmaceut Inc, Cambridge, MA 02142 USA		Soutschek, J (corresponding author), Alnylam Europe AG, Fritz Hornschuch Str 9, D-95326 Kulmbach, Germany.	jsoutschek@alnylam.de; hpvornlocher@alnylam.de	GARG, RAKESH/H-4591-2011	GARG, RAKESH/0000-0001-5842-8024; Venkitasamy, Kesavan/0000-0002-7720-0268				Bridge AJ, 2003, NAT GENET, V34, P263, DOI 10.1038/ng1173; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Burnett JR, 2002, CRIT REV CL LAB SCI, V39, P89, DOI 10.1080/10408360208951113; Damha M J, 1993, Methods Mol Biol, V20, P81; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Enjoji M, 2000, HUM GENE THER, V11, P2415, DOI 10.1089/104303400750038516; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; Glueck CJ, 1997, METABOLISM, V46, P625, DOI 10.1016/S0026-0495(97)90004-4; Hammad SM, 2003, METABOLISM, V52, P916, DOI 10.1016/S0026-0495(03)00058-1; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Lorenz C, 2004, BIOORG MED CHEM LETT, V14, P4975, DOI 10.1016/j.bmcl.2004.07.018; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Reich S, 2003, MOL VIS, V9, P210; Scherr M, 2003, OLIGONUCLEOTIDES, V13, P353, DOI 10.1089/154545703322617032; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zlot CH, 1999, J LIPID RES, V40, P76	22	1749	2205	7	236	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					173	178		10.1038/nature03121	http://dx.doi.org/10.1038/nature03121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538359				2022-12-28	WOS:000225020200035
J	Stone, JH; Dierberg, K; Aram, G; Dumler, JS				Stone, JH; Dierberg, K; Aram, G; Dumler, JS			Human monocytic ehrlichilosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN MONOCYTOTROPIC EHRLICHIOSIS; GRANULOMATOSIS ETANERCEPT TRIAL; MOUNTAIN SPOTTED-FEVER; NF-KAPPA-B; UNITED-STATES; WEGENERS-GRANULOMATOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE; GRANULOCYTIC EHRLICHIOSIS; TRANSPLANT RECIPIENT; AMBLYOMMA-AMERICANUM	A 56-year-old man with a history of Wegener granulomatosis presented with 6 days of sinus congestion, fever, malaise, myalgias, episcleritis, and a morbilliform rash. An exacerbation of Wegener granulomatosis was the principal concern because of the frequency of flares in that disease. The patient developed acute renal failure, thrombocytopenia, transaminitis, and, finally, severe myocarditis that led to congestive heart failure. Additional history-taking and the evolution of his clinical features led to empirical treatment with doxycycline for human monocytic ehrlichiosis (HME). The diagnosis of HME was confirmed by both a polymerase chain reaction assay for Ehrlichia chaffeensis and by the demonstration of morulae within peripheral blood mononuclear cells. The patient improved promptly following institution of doxycycline, and his cardiac function returned to normal over a period of 4 months.	Johns Hopkins Bayview Med Ctr, Johns Hopkins Vasculitis Ctr, Dept Med, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Johns Hopkins Vasculitis Ctr, Div Rheumatol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Med Microbiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University	Stone, JH (corresponding author), Johns Hopkins Bayview Med Ctr, Johns Hopkins Vasculitis Ctr, Dept Med, 5501 Hopkins Bayview Cir,1B 23, Baltimore, MD 21224 USA.	jstone@jhmi.edu		Dierberg, Kerry/0000-0001-8528-7159				Arav-Boger R, 2000, PEDIATR INFECT DIS J, V19, P173, DOI 10.1097/00006454-200002000-00023; Brantley RK, 2001, PEDIATR INFECT DIS J, V20, P231, DOI 10.1097/00006454-200102000-00028; BROUQUI P, 1992, ANTIMICROB AGENTS CH, V36, P2799, DOI 10.1128/AAC.36.12.2799; Childs JE, 2003, ANNU REV ENTOMOL, V48, P307, DOI 10.1146/annurev.ento.48.091801.112728; Childs JE, 1999, J CLIN MICROBIOL, V37, P2997, DOI 10.1128/JCM.37.9.2997-3000.1999; DUMLER JS, 1993, HUM PATHOL, V24, P391; Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145; Dumler JS, 2000, ARCH PEDIAT ADOL MED, V154, P847, DOI 10.1001/archpedi.154.8.847; DUNN BE, 1992, J CLIN MICROBIOL, V30, P2207, DOI 10.1128/JCM.30.8.2207-2210.1992; Ellerin T, 2003, ARTHRITIS RHEUM-US, V48, P3013, DOI 10.1002/art.11301; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; Feng HM, 2004, INFECT IMMUN, V72, P966, DOI 10.1128/IAI.72.2.966-971.2004; FICHTENBAUM CJ, 1993, AM J MED, V95, P351, DOI 10.1016/0002-9343(93)90302-6; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; Fritz CL, 1997, J INFECT DIS, V175, P1432, DOI 10.1086/516476; Gardner SL, 2003, ANN NY ACAD SCI, V990, P80, DOI 10.1111/j.1749-6632.2003.tb07341.x; Goldman EE, 1998, J VET INTERN MED, V12, P61, DOI 10.1111/j.1939-1676.1998.tb02096.x; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; Hopkins J, 2003, ARTHRITIS RHEUM-US, V48, P2299, DOI 10.1002/art.11075; Ismail N, 2004, J IMMUNOL, V172, P1786, DOI 10.4049/jimmunol.172.3.1786; Lee EH, 1997, INFECT IMMUN, V65, P2890, DOI 10.1128/IAI.65.7.2890-2897.1997; Liddell AM, 2002, CLIN INFECT DIS, V34, P1644, DOI 10.1086/340523; Lin M, 2004, CELL MICROBIOL, V6, P175, DOI 10.1046/j.1462-5822.2003.00355.x; MARINGARCIA J, 1983, CLIN CARDIOL, V6, P501, DOI 10.1002/clc.4960061006; Marshall GS, 2002, ARCH PEDIAT ADOL MED, V156, P166, DOI 10.1001/archpedi.156.2.166; MARTY AM, 1995, HUM PATHOL, V26, P920, DOI 10.1016/0046-8177(95)90017-9; McQuiston JH, 1999, EMERG INFECT DIS, V5, P635, DOI 10.3201/eid0505.990504; Mitchell TJ, 2003, NAT REV MICROBIOL, V1, P219, DOI 10.1038/nrmicro771; Mott J, 1999, INFECT IMMUN, V67, P1368, DOI 10.1128/IAI.67.3.1368-1378.1999; Olano JP, 2002, MED CLIN N AM, V86, P375, DOI 10.1016/S0025-7125(03)00093-2; Olano JR, 2003, EMERG INFECT DIS, V9, P1579, DOI 10.3201/eid0912.020733; Paddock CD, 2003, CLIN MICROBIOL REV, V16, P37, DOI 10.1128/CMR.16.1.37-64.2003; PADDOCK CD, 1993, NEW ENGL J MED, V329, P1164, DOI 10.1056/NEJM199310143291605; Paddock CD, 2001, CLIN INFECT DIS, V33, P1586, DOI 10.1086/323981; Patel RG, 1999, SOUTHERN MED J, V92, P333, DOI 10.1097/00007611-199903000-00017; Peters TR, 2000, PEDIATR INFECT DIS J, V19, P170, DOI 10.1097/00006454-200002000-00021; Reinhold-Keller E, 2000, ARTHRITIS RHEUM, V43, P1021, DOI 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J; Sadikot R, 1999, AM J NEPHROL, V19, P674, DOI 10.1159/000013540; Sehdev AES, 2003, AM J CLIN PATHOL, V119, P859, DOI 10.1309/F7EAB5P7321716LJ; Sehdev AES, 2002, CLIN INFECT DIS, V35, pE99, DOI 10.1086/342887; Sotomayor EA, 2001, AM J PATHOL, V158, P757, DOI 10.1016/S0002-9440(10)64018-7; Stone JH, 2002, CONTROL CLIN TRIALS, V23, P450; Talbot TR, 2003, EMERG INFECT DIS, V9, P1123; Tan HP, 2001, TRANSPLANTATION, V71, P1678, DOI 10.1097/00007890-200106150-00030; Vanek NN, 1996, CLIN INFECT DIS, V22, P386, DOI 10.1093/clinids/22.2.386; Varela AS, 2003, J WILDLIFE DIS, V39, P881, DOI 10.7589/0090-3558-39.4.881; Walker DH, 1997, LAB INVEST, V76, P129; Walker DH, 2000, ASM NEWS, V66, P287; WALKER DH, 1980, ARCH PATHOL LAB MED, V104, P171; Walker DH, 1997, ARCH PATHOL LAB MED, V121, P785; *WGET RES GROUP, IN PRESS N ENGL J ME; WILLIAMS JD, 1995, AM J MED, V98, P414, DOI 10.1016/S0002-9343(99)80324-6; Wolf L, 2000, J CLIN MICROBIOL, V38, P2795, DOI 10.1128/JCM.38.7.2795-2795.2000; Zhang JZ, 2003, FEMS MICROBIOL LETT, V227, P303, DOI 10.1016/S0378-1097(03)00696-7	54	34	34	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	2004	292	18					2263	2270		10.1001/jama.292.18.2263	http://dx.doi.org/10.1001/jama.292.18.2263			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PK	15536115				2022-12-28	WOS:000225070000029
J	Graham, DJ; Staffa, JA; Shatin, D; Andrade, SE; Schech, SD; La Grenade, L; Gurwitz, JH; Chan, KA; Goodman, MJ; Platt, R				Graham, DJ; Staffa, JA; Shatin, D; Andrade, SE; Schech, SD; La Grenade, L; Gurwitz, JH; Chan, KA; Goodman, MJ; Platt, R			Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COA REDUCTASE INHIBITORS; PLASMA-CONCENTRATIONS; GEMFIBROZIL; CERIVASTATIN; MYOPATHY; STATINS; ACID	Context Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available. Objective To estimate the incidence of rhabdomyolysis in patients treated with different statins and fibrates, alone and in combination, in the ambulatory setting. Design, Setting, and Patients Drug-specific inception cohorts of statin and fibrate users were established using claims data from 11 managed care health plans across the United States. Patients with at least 180 days of prior health plan enrollment were entered into the cohorts between January 1, 1998, and June 30, 2001. Person-time was classified as monotherapy or combined statin-fibrate therapy. Main Outcome Measure Incidence rates of rhabdomyolysis per 10000 person-years of treatment, number needed to treat, and relative risk of rhabdomyolysis. Results In 252460 patients treated with lipid-lowering agents, 24 cases of hospitalized rhabdomyolysis occurred during treatment. Average incidence per 10000 person-years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44 (95% confidence interval [CI], 0.20-0.84); for cerivastatin, 5.34 (95% Cl, 1.46-13.68); and for fibrate, 2.82 (95% Cl, 0.58-8.24). By comparison,. the incidence during unexposed person-time was 0 (95% Cl, 0-0.48; P=.056). The incidence increased to 5.98 (95% Cl, 0.72-216.0) for combined therapy of atorvastatin, pravastatin, or simvastatin with a fibrate, and to 1035 (95% Cl, 389-2117) for combined cerivastatin-fibrate use. Per year of therapy, the number needed to treat to observe 1 case of rhabdomyolysis was 22 727 for statin monotherapy, 484 for older patients with diabetes mellitus who were treated with both a statin and fibrate, and ranged from 9.7 to 12.7 for patients who were treated with cerivastatin plus fibrate. Conclusions Rhabdomyolysis risk was similar and low for monotherapy with atorvastatin, pravastatin, and simvastatin; combined statin-fibrate use increased risk, especially in older patients with diabetes mellitus. Cerivastatin combined with fibrate conferred a risk of approximately 1 in 10 treated patients per year.	US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA; Ctr Hlth Care Policy & Evaluat, Eden Prairie, MN USA; Fallon Fdn, Meyers Primary Care Inst, Worcester, MA USA; Univ Massachusetts, Sch Med, Amherst, MA 01003 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; HealthPartners Res Fdn, Minneapolis, MN USA	US Food & Drug Administration (FDA); University of Massachusetts System; University of Massachusetts Amherst; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard T.H. Chan School of Public Health; HealthPartners Institute for Education & Research	Graham, DJ (corresponding author), US FDA, Off Drug Safety, Ctr Drug Evaluat & Res, 5600 Fishers Ln,HFD-400, Rockville, MD 20857 USA.	grahamd@cder.fda.gov		Chan, Kinwei/0000-0001-8161-1986	FDA HHS [FD-U-002067, FD-U-002068] Funding Source: Medline	FDA HHS		Backman JT, 2002, CLIN PHARMACOL THER, V72, P685, DOI 10.1067/mcp.2002.128469; Backman JT, 2000, CLIN PHARMACOL THER, V68, P122, DOI 10.1067/mcp.2000.108507; Baker SK, 2001, CLIN INVEST MED, V24, P258; BALALNTYNE CM, 2003, ARCH INTERN MED, V163, P553; Barker BJ, 2003, DIABETES CARE, V26, P2482, DOI 10.2337/diacare.26.8.2482; Black C, 2002, PHARMACOTHERAPY, V22, P1524, DOI 10.1592/phco.22.17.1524.34130; Chan KA, 2000, PHARMACOEPIDEM DR S, P285; Clouatre Y, 1999, NEPHROL DIAL TRANSPL, V14, P1047, DOI 10.1093/ndt/14.4.1047; Cottrell DA, 2003, CURR OPIN CARDIOL, V18, P301, DOI 10.1097/00001573-200307000-00010; Evans M, 2002, DRUG SAFETY, V25, P649, DOI 10.2165/00002018-200225090-00004; Furberg CD, 2001, CURR CONTR TRIALS C, V2, P205, DOI 10.1186/CVM-2-5-205; Gaist D, 2001, EPIDEMIOLOGY, V12, P565, DOI 10.1097/00001648-200109000-00017; Gorriz JL, 1996, NEPHRON, V74, P437, DOI 10.1159/000189355; Kolata Gina, 2004, N Y Times Web, pA15; Kyrklund C, 2001, CLIN PHARMACOL THER, V69, P340, DOI 10.1067/mcp.2001.115542; Layne RD, 2004, ANN PHARMACOTHER, V38, P232, DOI 10.1345/aph.1D282; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; Omar MA, 2002, ANN PHARMACOTHER, V36, P288, DOI 10.1345/aph.1A289; Omar MA, 2001, ANN PHARMACOTHER, V35, P1096, DOI 10.1345/aph.10228; Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P1280, DOI 10.1124/dmd.30.11.1280; Prueksaritanont T, 2002, DRUG METAB DISPOS, V30, P505, DOI 10.1124/dmd.30.5.505; Rosenson RS, 2004, AM J MED, V116, P408, DOI 10.1016/j.amjmed.2003.10.033; SHATIN D, 2000, PHARMACOEPIDEM DR S, P295; Shek A, 2001, ANN PHARMACOTHER, V35, P908, DOI 10.1345/aph.10315; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; THOMPSON PDR, 2004, ZOCOR PHYS DESK REFE, P2113; THOMPSON PDR, 2004, LIPITOR PHYS DESK RE, P2543; Ucar M, 2000, DRUG SAFETY, V22, P441, DOI 10.2165/00002018-200022060-00003	30	627	660	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2585	2590		10.1001/jama.292.21.2585	http://dx.doi.org/10.1001/jama.292.21.2585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572716	Bronze			2022-12-28	WOS:000225409100021
J	Piorkowski, JD				Piorkowski, JD			Bayer's response to "Potential for conflict of interest in the evaluation of suspected adverse drug reactions: Use of cerivastatin and risk of rhabdomyolysis'	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HMG-COA REDUCTASE; GEMFIBROZIL THERAPY; PLASMA-CONCENTRATIONS; LOVASTATIN; SIMVASTATIN; INHIBITOR; SAFETY; STATINS; ACID		Law Off JD Piorkowski Jr, Washington, DC USA; Georgetown Univ, Ctr Law, Washington, DC USA	Georgetown University	Piorkowski, JD (corresponding author), 910 17th St NW,Suite 800, Washington, DC 20006 USA.	JPiorkowski@lawdoc1.com						ABDULGHAFFAR NUAMA, 1995, J CLIN GASTROENTEROL, V21, P340, DOI 10.1097/00004836-199512000-00027; Backman JT, 2000, CLIN PHARMACOL THER, V68, P122, DOI 10.1067/mcp.2000.108507; Bischoff H, 1998, Atherosclerosis, V139 Suppl 1, pS7; CORPIER CL, 1988, JAMA-J AM MED ASSOC, V260, P239, DOI 10.1001/jama.260.2.239; Davignon J, 1998, AM J CARDIOL, V82, p32J, DOI 10.1016/S0002-9149(98)00435-4; DESLYPERE JP, 1991, ANN INTERN MED, V114, P342, DOI 10.7326/0003-4819-114-4-342_1; HSU I, 1995, ANN PHARMACOTHER, V29, P743, DOI 10.1177/106002809502907-818; HUNNINGHAKE D, 1999, PHARMACOTHERAPY, V19, P1194; Knoll R W, 1993, Conn Med, V57, P593; Kuhlmann J, 1998, CARDIOVASC DRUG REV, V16, P236, DOI 10.1111/j.1527-3466.1998.tb00357.x; Kyrklund C, 2001, CLIN PHARMACOL THER, V69, P340, DOI 10.1067/mcp.2001.115542; MARAIS GE, 1990, ANN INTERN MED, V112, P228, DOI 10.7326/0003-4819-112-3-228; PAN HY, 1991, EUR J CLIN PHARMACOL, V40, pS15, DOI 10.1007/BF01409401; Pasternak RC, 2002, J AM COLL CARDIOL, V40, P567, DOI 10.1016/S0735-1097(02)02030-2; PIERCE LR, 1990, JAMA-J AM MED ASSOC, V264, P71, DOI 10.1001/jama.264.1.71; Prueksaritanont T, 2002, J PHARMACOL EXP THER, V301, P1042, DOI 10.1124/jpet.301.3.1042; SPENCE JD, 1995, AM J CARDIOL, V76, pA80; Tal A, 1997, SOUTHERN MED J, V90, P546, DOI 10.1097/00007611-199705000-00018; VanPuijenbroek EP, 1996, J INTERN MED, V240, P403, DOI 10.1046/j.1365-2796.1996.48879000.x; von Keutz E, 1998, AM J CARDIOL, V82, p11J, DOI 10.1016/S0002-9149(98)00424-X; 1998, MED LETT DRUGS THER, V40, P13	21	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	2004	292	21					2655	2657		10.1001/jama.292.21.2655	http://dx.doi.org/10.1001/jama.292.21.2655			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	875GU	15572725				2022-12-28	WOS:000225409100030
J	Gerst, A; Savage, MK				Gerst, A; Savage, MK			Seismic anisotropy beneath Ruapehu Volcano: A possible eruption forecasting tool	SCIENCE			English	Article							SHEAR-WAVE ANISOTROPY; NEW-ZEALAND; VELOCITY ANISOTROPY; FAULT; DEFORMATION; REGIONS; ROCK; VENT	The orientation of crustal seismic anisotropy changed at least twice by up to 80degrees because of volcanic eruptions at Ruapehu Volcano, New Zealand. These changes provide the basis for a new monitoring technique and possibly for future midterm eruption forecasting at volcanoes. The fast anisotropic direction was measured during three seismometer deployments in 1994, 1998, and 2002, providing an in situ measurement of the stress in the crust under the volcano. The stress direction changed because of an eruption in 1995-1996. Our 2002 measurements revealed a partial return to the pre-eruption stress state. These changes were probably caused by repeated filling and depressurizing of a magmatic dike system.	Victoria Univ Wellington, Sch Earth Sci, Inst Geophys, Wellington, New Zealand; Univ Karlsruhe, Karlsruhe, Germany	Victoria University Wellington; Helmholtz Association; Karlsruhe Institute of Technology	Gerst, A (corresponding author), Univ Hamburg, Inst Geophys, Bundesstr 55, D-20146 Hamburg, Germany.	publications@planet3.de	Savage, Martha K/F-1857-2011	Savage, Martha K/0000-0002-2080-0676				Angerer E, 2002, GEOPHYS J INT, V149, P267, DOI 10.1046/j.1365-246X.2002.01607.x; AUDOINE E, IN PRESS J GEOPHYS R; BABUSKA V, 1991, SEISMIC ANISOTROPY E; Bryan CJ, 1999, J VOLCANOL GEOTH RES, V90, P1, DOI 10.1016/S0377-0273(99)00016-5; CHEN TC, 1987, GEOPHYS J INT, V91, P287, DOI 10.1111/j.1365-246X.1987.tb05228.x; Crampin S, 2003, GEOPHYS J INT, V155, P221, DOI 10.1046/j.1365-246X.2003.02037.x; CRAMPIN S, 1994, GEOPHYS J INT, V118, P428, DOI 10.1111/j.1365-246X.1994.tb03974.x; Crampin S, 2002, GEOPHYS J INT, V151, pF1, DOI 10.1046/j.1365-246X.2002.01830.x; CRAMPIN S, 1985, GEOPHYS J ROY ASTR S, V83, P75, DOI 10.1111/j.1365-246X.1985.tb05157.x; DARBY DJ, 1995, J GEOPHYS RES-SOL EA, V100, P8221, DOI 10.1029/94JB03265; Del Pezzo E, 2004, B SEISMOL SOC AM, V94, P439, DOI 10.1785/0120030141; Dzurisin D, 2003, REV GEOPHYS, V41, DOI 10.1029/2001RG000107; GERST A, 2003, THESIS VICTORIA U WE; GLEDHILL KR, 1991, J GEOPHYS RES-SOL EA, V96, P21503, DOI 10.1029/91JB02049; Hackett W., 1985, THESIS VICTORIA U WE; Johnston DM, 2000, GEOL SOC AM BULL, V112, P720, DOI 10.1130/0016-7606(2000)112<0720:IOTARE>2.3.CO;2; LATTER JH, 1981, J VOLCANOL GEOTH RES, V10, P125, DOI 10.1016/0377-0273(81)90059-7; Liu Y, 1997, GEOPHYS J INT, V130, P771, DOI 10.1111/j.1365-246X.1997.tb01872.x; Miller V, 2001, SCIENCE, V293, P2231, DOI 10.1126/science.1063463; MUNSON CG, 1995, J GEOPHYS RES-SOL EA, V100, P20367, DOI 10.1029/95JB01288; Nairn IA, 1998, J VOLCANOL GEOTH RES, V86, P19, DOI 10.1016/S0377-0273(98)00085-7; Nakagawa M, 1999, B VOLCANOL, V61, P15, DOI 10.1007/s004450050259; NUR A, 1969, J GEOPHYS RES, V74, P6667, DOI 10.1029/JB074i027p06667; PARSONS T, 1991, SCIENCE, V253, P1399, DOI 10.1126/science.253.5026.1399; PETERSON DW, 1986, STUDIES GEOPHYSICS A, P2311; Roman DC, 2004, B SEISMOL SOC AM, V94, P2366, DOI 10.1785/0120030259; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; SAVAGE MK, 1989, TECTONOPHYSICS, V165, P279, DOI 10.1016/0040-1951(89)90053-X; Umakoshi K, 2001, J VOLCANOL GEOTH RES, V112, P117, DOI 10.1016/S0377-0273(01)00238-4; Zatsepin SV, 1997, GEOPHYS J INT, V129, P477, DOI 10.1111/j.1365-246X.1997.tb04488.x; Zinke JC, 2000, B SEISMOL SOC AM, V90, P1305, DOI 10.1785/0119990099	31	119	124	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1543	1547		10.1126/science.1103445	http://dx.doi.org/10.1126/science.1103445			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567860				2022-12-28	WOS:000225442700055
J	Pascal, JM; O'Brien, PJ; Tomkinson, AE; Ellenberger, T				Pascal, JM; O'Brien, PJ; Tomkinson, AE; Ellenberger, T			Human DNA ligase I completely encircles and partially unwinds nicked DNA	NATURE			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; DOMAIN; REPLICATION; FIDELITY; PCNA; CRYSTALLOGRAPHY; IDENTIFICATION; SPECIFICITY	The end-joining reaction catalysed by DNA ligases is required by all organisms and serves as the ultimate step of DNA replication, repair and recombination processes. One of three well characterized mammalian DNA ligases, DNA ligase I, joins Okazaki fragments during DNA replication. Here we report the crystal structure of human DNA ligase I ( residues 233 to 919) in complex with a nicked, 5' adenylated DNA intermediate. The structure shows that the enzyme redirects the path of the double helix to expose the nick termini for the strand-joining reaction. It also reveals a unique feature of mammalian ligases: a DNA-binding domain that allows ligase I to encircle its DNA substrate, stabilizes the DNA in a distorted structure, and positions the catalytic core on the nick. Similarities in the toroidal shape and dimensions of DNA ligase I and the proliferating cell nuclear antigen sliding clamp are suggestive of an extensive protein-protein interface that may coordinate the joining of Okazaki fragments.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Maryland, Sch Med, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	Harvard University; Harvard Medical School; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	tome@hms.harvard.edu						BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bhagwat AS, 1999, NUCLEIC ACIDS RES, V27, P4028, DOI 10.1093/nar/27.20.4028; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Dimitriadis EK, 1998, J BIOL CHEM, V273, P20540, DOI 10.1074/jbc.273.32.20540; Dionne I, 2003, MOL CELL, V11, P275, DOI 10.1016/S1097-2765(02)00824-9; Doherty AJ, 2000, NUCLEIC ACIDS RES, V28, P4051, DOI 10.1093/nar/28.21.4051; Doherty AJ, 1999, J MOL BIOL, V285, P63, DOI 10.1006/jmbi.1998.2301; Doherty AJ, 2000, J MOL BIOL, V296, P43, DOI 10.1006/jmbi.1999.3423; Gajiwala KS, 2004, STRUCTURE, V12, P1449, DOI 10.1016/j.str.2004.05.017; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Harrison C, 2002, CANCER RES, V62, P4065; Jeon HJ, 2004, FEMS MICROBIOL LETT, V237, P111, DOI 10.1016/j.femsle.2004.06.018; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LAFORTELLE E, 1997, METHOD ENZYMOL, V276, P472; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Liu PF, 2004, NUCLEIC ACIDS RES, V32, P4503, DOI 10.1093/nar/gkh781; Luo JY, 1996, NUCLEIC ACIDS RES, V24, P3079, DOI 10.1093/nar/24.15.3079; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Martin IV, 2002, GENOME BIOL, V3; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; MONTECUCCO A, 1988, NUCLEIC ACIDS RES, V16, P7369, DOI 10.1093/nar/16.15.7369; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Odell M, 1999, J BIOL CHEM, V274, P14032, DOI 10.1074/jbc.274.20.14032; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRIGENT C, 1994, MOL CELL BIOL, V14, P310, DOI 10.1128/MCB.14.1.310; Robinet E, 1998, J HEMATOTHER, V7, P205, DOI 10.1089/scd.1.1998.7.205; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; Sekiguchi J, 1997, BIOCHEMISTRY-US, V36, P9073, DOI 10.1021/bi970705m; Shuman S, 1995, BIOCHEMISTRY-US, V34, P16138, DOI 10.1021/bi00049a029; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P4618, DOI 10.1093/nar/26.20.4618; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; Sriskanda V, 2002, NUCLEIC ACIDS RES, V30, P903, DOI 10.1093/nar/30.4.903; Sriskanda V, 1998, NUCLEIC ACIDS RES, V26, P3536, DOI 10.1093/nar/26.15.3536; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; TERAOKA H, 1993, J BIOL CHEM, V268, P24156; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; TOMKINSON AE, 1992, BIOCHEMISTRY-US, V31, P11762, DOI 10.1021/bi00162a013; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R	50	251	256	2	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	2004	432	7016					473	478		10.1038/nature03082	http://dx.doi.org/10.1038/nature03082			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565146				2022-12-28	WOS:000225322100038
J	Giovannetti, V; Lloyd, S; Maccone, L				Giovannetti, V; Lloyd, S; Maccone, L			Quantum-enhanced measurements: Beating the standard quantum limit	SCIENCE			English	Review							NONDEMOLITION MEASUREMENTS; INTERFEROMETRIC DETECTION; OSCILLATOR; NOISE; ENTANGLEMENT; DISPLACEMENT; FEEDBACK; PHOTON; STATES; SPEED	Quantum mechanics, through the Heisenberg uncertainty principle, imposes limits on the precision of measurement. Conventional measurement techniques typically fail to reach these limits. Conventional bounds to the precision of measurements such as the shot noise limit or the standard quantum limit are not as fundamental as the Heisenberg limits and can be beaten using quantum strategies that employ "quantum tricks" such as squeezing and entanglement.	MIT, Elect Res Lab, Cambridge, MA 02139 USA; Ist Nazl Fis Mat, Natl Enterprise Nanosci & Nanotechnol, I-56126 Pisa, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy; MIT, Dept Mech Engn, Cambridge, MA 02139 USA; Univ Pavia, Dipartimento Fis A Volta, Quantum Informat Theory Grp, I-27100 Pavia, Italy	Massachusetts Institute of Technology (MIT); Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); Scuola Normale Superiore di Pisa; Massachusetts Institute of Technology (MIT); University of Pavia	Lloyd, S (corresponding author), MIT, Elect Res Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	slloyd@mit.edu	GIOVANNETTI, Vittorio/AAW-9290-2021	GIOVANNETTI, VITTORIO/0000-0002-7636-9002; Maccone, Lorenzo/0000-0002-6729-5312				Bagan E, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.257903; Barnett SM, 2003, EUR PHYS J D, V22, P513, DOI 10.1140/epjd/e2003-00003-3; BEKENSTEIN JD, 1981, PHYS REV D, V23, P287, DOI 10.1103/PhysRevD.23.287; BENCHEIKH K, 1995, PHYS REV LETT, V75, P3422, DOI 10.1103/PhysRevLett.75.3422; Bennink RS, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.113601; Bocko MF, 1996, REV MOD PHYS, V68, P755, DOI 10.1103/RevModPhys.68.755; Bollinger JJ, 1996, PHYS REV A, V54, pR4649, DOI 10.1103/PhysRevA.54.R4649; BONDURANT RS, 1984, PHYS REV D, V30, P2548, DOI 10.1103/PhysRevD.30.2548; Boto AN, 2000, PHYS REV LETT, V85, P2733, DOI 10.1103/PhysRevLett.85.2733; Bousso R, 2002, REV MOD PHYS, V74, P825, DOI 10.1103/RevModPhys.74.825; Braginskii V. B., 1975, Soviet Physics - Uspekhi, V17, P644, DOI 10.1070/PU1975v017n05ABEH004362; Braginsky V. B., 1992, QUANTUM MEASUREMENTS; BRAGINSKY VB, 1990, PHYS LETT A, V147, P251, DOI 10.1016/0375-9601(90)90442-Q; Buonanno A, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.042006; Callender C., 2001, PHYS MEETS PHILOS PL; CAVES CM, 1985, PHYS REV LETT, V54, P2465, DOI 10.1103/PhysRevLett.54.2465; CAVES CM, 1981, PHYS REV D, V23, P1693, DOI 10.1103/PhysRevD.23.1693; CAVES CM, 1980, REV MOD PHYS, V52, P341, DOI 10.1103/RevModPhys.52.341; CAVES CM, 1980, PHYS REV LETT, V45, P75, DOI 10.1103/PhysRevLett.45.75; Chiribella G, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.180503; Cohadon PF, 1999, PHYS REV LETT, V83, P3174, DOI 10.1103/PhysRevLett.83.3174; D'Angelo M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.013602; D'Ariano GM, 1999, NUOVO CIMENTO B, V114, P775; D'Ariano GM, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.047902; D'Ariano GM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.270404; De Martini F, 2003, PHYS REV A, V67, DOI 10.1103/PhysRevA.67.062307; DeWitt BS., 1962, GRAVITATION INTRO CU, P266; Dowling JP, 1998, PHYS REV A, V57, P4736, DOI 10.1103/PhysRevA.57.4736; EDELSTEIN WA, 1978, J PHYS E SCI INSTRUM, V11, P710, DOI 10.1088/0022-3735/11/7/030; Fabre C, 2000, OPT LETT, V25, P76, DOI 10.1364/OL.25.000076; Fei HB, 1997, PHYS REV LETT, V78, P1679, DOI 10.1103/PhysRevLett.78.1679; Fonseca EJS, 1999, PHYS REV LETT, V82, P2868, DOI 10.1103/PhysRevLett.82.2868; FRANSON JD, 1992, PHYS REV A, V45, P3126, DOI 10.1103/PhysRevA.45.3126; GANNAWAY JN, 1978, OPT QUANT ELECTRON, V10, P435, DOI 10.1007/BF00620308; Gatti A, 2004, PHYS REV A, V70, DOI 10.1103/PhysRevA.70.013802; Giovannetti V, 2001, NATURE, V412, P417, DOI 10.1038/35086525; Gisin N, 1999, PHYS REV LETT, V83, P432, DOI 10.1103/PhysRevLett.83.432; Grangier P, 1998, NATURE, V396, P537, DOI 10.1038/25059; Helstrom CW, 1976, QUANTUM DETECTION ES; HOLLAND MJ, 1993, PHYS REV LETT, V71, P1355, DOI 10.1103/PhysRevLett.71.1355; Huelga SF, 1997, PHYS REV LETT, V79, P3865, DOI 10.1103/PhysRevLett.79.3865; IMOTO N, 1985, PHYS REV A, V32, P2287, DOI 10.1103/PhysRevA.32.2287; JACOBSON J, 1995, APPL PHYS B-LASERS O, V60, P187, DOI 10.1007/BF01135861; JACOBSON J, 1995, PHYS REV LETT, V74, P4835, DOI 10.1103/PhysRevLett.74.4835; JAEKEL MT, 1990, EUROPHYS LETT, V13, P301, DOI 10.1209/0295-5075/13/4/003; Jozsa R, 2000, PHYS REV LETT, V85, P2010, DOI 10.1103/PhysRevLett.85.2010; Knobel RG, 2003, NATURE, V424, P291, DOI 10.1038/nature01773; Kok P., 2004, J OPT B-QUANTUM S O, V6, P5811; Kolobov MI, 2000, PHYS REV LETT, V85, P3789, DOI 10.1103/PhysRevLett.85.3789; Kolobov MI, 1999, REV MOD PHYS, V71, P1539, DOI 10.1103/RevModPhys.71.1539; LaHaye MD, 2004, SCIENCE, V304, P74, DOI 10.1126/science.1094419; Lloyd S, 2000, NATURE, V406, P1047, DOI 10.1038/35023282; Lloyd S, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.237901; Lugiato LA, 2002, J OPT B-QUANTUM S O, V4, pS176, DOI 10.1088/1464-4266/4/3/312; Mancini S, 1998, PHYS REV LETT, V80, P688, DOI 10.1103/PhysRevLett.80.688; Mandelstam L., 1945, J PHYS USSR, V9, P249, DOI DOI 10.1007/978-3-642-74626-0_8; Margolus N, 1998, PHYSICA D, V120, P188, DOI 10.1016/S0167-2789(98)00054-2; MILBURN GJ, 1983, PHYS REV A, V28, P2065, DOI 10.1103/PhysRevA.28.2065; Ng YJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.139902; Ng YJ, 2001, PHYS REV LETT, V86, P2946, DOI 10.1103/PhysRevLett.86.2946; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Nogues G, 1999, NATURE, V400, P239, DOI 10.1038/22275; Ou ZY, 1997, PHYS REV A, V55, P2598, DOI 10.1103/PhysRevA.55.2598; OZAWA M, 1988, PHYS REV LETT, V60, P385, DOI 10.1103/PhysRevLett.60.385; PACE AF, 1993, PHYS REV A, V47, P3173, DOI 10.1103/PhysRevA.47.3173; Peres A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.167901; PITTMAN TB, 1995, PHYS REV A, V52, pR3429, DOI 10.1103/PhysRevA.52.R3429; RATHE UW, 1995, LETT MATH PHYS, V34, P297, DOI 10.1007/BF01872783; Robertson HP, 1929, PHYS REV, V34, P163, DOI 10.1103/PhysRev.34.163; SANDERS BC, 1995, PHYS REV LETT, V75, P2944, DOI 10.1103/PhysRevLett.75.2944; SCULLY MO, 1991, NATURE, V351, P111, DOI 10.1038/351111a0; SUSSKIND L, 1995, J MATH PHYS, V36, P6377, DOI 10.1063/1.531249; 't Hooft G, 2001, SUBNUCL SER, V37, P72, DOI 10.1142/9789812811585_0005; Treps N, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.203601; Unruh W. G, 1983, QUANTUM OPTICS EXPT, P647; WIGNER EP, 1957, REV MOD PHYS, V29, P255, DOI 10.1103/RevModPhys.29.255; WISEMAN HM, 1995, PHYS REV A, V51, P2459, DOI 10.1103/PhysRevA.51.2459; XIAO M, 1987, PHYS REV LETT, V59, P278, DOI 10.1103/PhysRevLett.59.278; YUEN HP, 1983, PHYS REV LETT, V51, P719, DOI 10.1103/PhysRevLett.51.719; YURKE B, 1986, PHYS REV A, V33, P4033, DOI 10.1103/PhysRevA.33.4033; Yurtsever U, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.041302	82	1838	1864	28	276	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1330	1336		10.1126/science.1104149	http://dx.doi.org/10.1126/science.1104149			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550661	Green Submitted			2022-12-28	WOS:000225301600040
J	Lyon, BE; Eadie, JM				Lyon, BE; Eadie, JM			An obligate brood parasite trapped in the intraspecific arms race of its hosts	NATURE			English	Article							CONSPECIFIC NEST PARASITISM; CUCULUS-CANORUS; EGGS; DISCRIMINATION; RECOGNITION; COEVOLUTION; REJECTION; MIMICRY; ACCEPT; CHOICE	Reciprocal selection pressures often lead to close and adaptive matching of traits in coevolved species. A failure of one species to match the evolutionary trajectories of another is often attributed to evolutionary lags(1,2) or to differing selection pressures across a geographic mosaic(3,4). Here we show that mismatches in adaptation of interacting species-an obligate brood parasitic duck and each of its two main hosts-are best explained by the evolutionary dynamics within the host species. Rejection of the brood parasite's eggs was common by both hosts, despite a lack of detectable cost of parasitism to the hosts. Egg rejection markedly reduced parasite fitness, but egg mimicry experiments revealed no phenotypic natural selection for more mimetic parasitic eggs. These paradoxical results were resolved by the discovery of intraspecific brood parasitism and conspecific egg rejection within the hosts themselves. The apparent arms race between species seems instead to be an incidental by-product of within-species conflict, with little recourse for evolutionary response by the parasite.	Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA; Univ Calif Davis, Dept Wildlife Fish & Conservat Biol, Davis, CA 95616 USA	University of California System; University of California Santa Cruz; University of California System; University of California Davis	Lyon, BE (corresponding author), Univ Calif Santa Cruz, Dept Ecol & Evolutionary Biol, Santa Cruz, CA 95064 USA.	lyon@biology.ucsc.edu	Eadie, John/E-4820-2011; Lyon, Bruce E/E-8491-2011	Eadie, John/0000-0001-9573-2703				ARNOLD TW, 1990, FOOD LIMITATION ADAP; BROOKE MD, 1988, NATURE, V335, P630; Davies N.B., 2000, CUCKOOS COWBIRDS OTH; Davies NB, 1996, P ROY SOC B-BIOL SCI, V263, P925, DOI 10.1098/rspb.1996.0137; FREDERICK PC, 1986, J FIELD ORNITHOL, V57, P225; FREEMAN S, 1988, OSTRICH, V59, P49, DOI 10.1080/00306525.1988.9633694; Gibbs HL, 2000, NATURE, V407, P183, DOI 10.1038/35025058; Jackson WM, 1998, OX ORN SER, V9, P407; Jamieson IG, 2000, AUK, V117, P250, DOI 10.1642/0004-8038(2000)117[0250:HROCBP]2.0.CO;2; Lahti DC, 2002, ANIM BEHAV, V63, P1135, DOI 10.1006/anbe.2002.3009; LOTEM A, 1992, BEHAV ECOL, V3, P128, DOI 10.1093/beheco/3.2.128; LOTEM A, 1993, NATURE, V362, P743, DOI 10.1038/362743a0; LYON BE, 1994, NATURE, V371, P240, DOI 10.1038/371240a0; Lyon BE, 2003, NATURE, V422, P495, DOI 10.1038/nature01505; LYON BE, 1993, BEHAV ECOL SOCIOBIOL, V33, P87; LYON BE, 1991, BEHAV ECOL, V2, P309, DOI 10.1093/beheco/2.4.309; Marchetti K, 1998, SCIENCE, V282, P471, DOI 10.1126/science.282.5388.471; MASON P, 1987, AM NAT, V130, P161, DOI 10.1086/284703; McRae SB, 1997, IBIS, V139, P701; PAYNE RB, 1977, ANNU REV ECOL SYST, V8, P1, DOI 10.1146/annurev.es.08.110177.000245; ROSKAFT E, 1990, EVOL ECOL, V4, P35, DOI 10.1007/BF02270713; ROTHSTEIN SI, 1990, ANNU REV ECOL SYST, V21, P481, DOI 10.1146/annurev.es.21.110190.002405; Sorenson MD, 1997, BEHAV ECOL, V8, P153, DOI 10.1093/beheco/8.2.153; SORENSON MD, 1995, CONDOR, V97, P819, DOI 10.2307/1369192; Thompson JN, 2002, INTEGR COMP BIOL, V42, P381, DOI 10.1093/icb/42.2.381; Thompson JN, 1999, SCIENCE, V284, P2116, DOI 10.1126/science.284.5423.2116; Thomson DL, 1998, BIOL REV, V73, P293, DOI 10.1017/S0006323198005180; Todd, 1996, NATURAL HIST WATERFO; WELLER M W, 1968, Living Bird, V7, P169; WELLER MW, 1971, AUK, V88, P108, DOI 10.2307/4083965	30	35	37	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					390	393		10.1038/nature03036	http://dx.doi.org/10.1038/nature03036			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549105				2022-12-28	WOS:000225161400055
J	Parker, DE				Parker, DE			Climate - Large-scale warming is not urban	NATURE			English	Editorial Material									Hadley Ctr, Meteorol Off, Exeter EX1 3PB, Devon, England	Met Office - UK; Hadley Centre	Parker, DE (corresponding author), Hadley Ctr, Meteorol Off, Exeter EX1 3PB, Devon, England.	david.parker@metoffice.com						Diggle P. J., 1999, ANAL LONGITUDINAL DA; Easterling DR, 1997, SCIENCE, V277, P364, DOI 10.1126/science.277.5324.364; Folland CK, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P99; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; JOHNSON GT, 1991, BOUND-LAY METEOROL, V56, P275, DOI 10.1007/BF00120424; Jones PD, 1997, J CLIMATE, V10, P2548, DOI 10.1175/1520-0442(1997)010<2548:ESEILS>2.0.CO;2; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kalnay E, 2003, NATURE, V423, P528, DOI 10.1038/nature01675; PARKER DE, 1994, INT J CLIMATOL, V14, P1, DOI 10.1002/joc.3370140102; Peterson TC, 2003, J CLIMATE, V16, P2941, DOI 10.1175/1520-0442(2003)016<2941:AOUVRI>2.0.CO;2	10	119	137	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					290	290		10.1038/432290a	http://dx.doi.org/10.1038/432290a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549087				2022-12-28	WOS:000225161400031
J	Williford, PM; Feldman, SR				Williford, PM; Feldman, SR			Surgery for basal-cell carcinoma of the face	LANCET			English	Editorial Material									Wake Forest Univ Hlth Sci, Dept Dermatol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine	Williford, PM (corresponding author), Wake Forest Univ Hlth Sci, Dept Dermatol, Winston Salem, NC 27157 USA.	sfeldman@wfubmc.edu	Feldman, Steven R./AAH-6971-2021	Feldman, Steven R./0000-0002-0090-6289				Avril MF, 1997, BRIT J CANCER, V76, P100, DOI 10.1038/bjc.1997.343; Cook J, 1998, J AM ACAD DERMATOL, V39, P698, DOI 10.1016/S0190-9622(98)70041-6; DRAKE LA, 1992, J AM ACAD DERMATOL, V26, P117; GRAHAM GF, 1990, CLIN DERMATOL, V8, P101, DOI 10.1016/0738-081X(90)90072-9; Ratner D, 2003, DERMATOL SURG, V29, P899, DOI 10.1046/j.1524-4725.2003.29272.x; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P315, DOI 10.1111/j.1524-4725.1989.tb03166.x; ROWE DE, 1989, J DERMATOL SURG ONC, V15, P424, DOI 10.1111/j.1524-4725.1989.tb03249.x; Shuster S, 1999, ACTA DERM-VENEREOL, V79, P2; Thissen MRTM, 1999, ARCH DERMATOL, V135, P1177, DOI 10.1001/archderm.135.10.1177	9	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1732	1733		10.1016/S0140-6736(04)17411-4	http://dx.doi.org/10.1016/S0140-6736(04)17411-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541430				2022-12-28	WOS:000225070600004
J	Koropatnick, TA; Engle, JT; Apicella, MA; Stabb, EV; Goldman, WE; McFall-Ngai, MJ				Koropatnick, TA; Engle, JT; Apicella, MA; Stabb, EV; Goldman, WE; McFall-Ngai, MJ			Microbial factor-mediated development in a host-bacterial mutualism	SCIENCE			English	Article							BORDETELLA-PERTUSSIS; TRACHEAL CYTOTOXIN; LIGHT ORGAN; SOLUBLE PEPTIDOGLYCAN; VIBRIO-FISCHERI; LIPOPOLYSACCHARIDE; MORPHOGENESIS; RECOGNITION; ENDOTOXIN; SYMBIOSIS	Tracheal cytotoxin (TCT), a fragment of the bacterial surface molecule peptidoglycan (PGN), is the factor responsible for the extensive tissue damage characteristic of whooping cough and gonorrhea infections. Here, we report that Vibrio fischeri also releases TCT, which acts in synergy with lipopolysaccharide (LPS) to trigger tissue development in its mutualistic symbiosis with the squid Euprymna scolopes. As components of PGN and LIDS have commonly been linked with pathogenesis in animals, these findings demonstrate that host interpretation of these bacterial signal molecules is context dependent. Therefore, such differences in interpretation can lead to either inflammation and disease or to the establishment of a mutually beneficial animal-microbe association.	Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, Honolulu, HI 96813 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Georgia, Dept Microbiol, Athens, GA 30602 USA; Univ Wisconsin, Dept Med Microbiol & Immunol, Madison, WI 53706 USA	University of Hawaii System; Washington University (WUSTL); University of Iowa; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison	McFall-Ngai, MJ (corresponding author), Univ Hawaii, Kewalo Marine Lab, Pacific Biomed Res Ctr, 41 Ahui St, Honolulu, HI 96813 USA.	mjmcfallngai@wisc.edu		Goldman, William/0000-0002-1551-6718	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050661] Funding Source: NIH RePORTER; NCRR NIH HHS [NCRR12294] Funding Source: Medline; NIAID NIH HHS [R01-AI50661] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COOKSON BT, 1989, INFECT IMMUN, V57, P2223, DOI 10.1128/IAI.57.7.2223-2229.1989; COOKSON BT, 1989, BIOCHEMISTRY-US, V28, P1744, DOI 10.1021/bi00430a048; Doino JA, 1995, BIOL BULL, V189, P347, DOI 10.2307/1542152; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Foster JS, 2000, DEV BIOL, V226, P242, DOI 10.1006/dbio.2000.9868; GOLDMAN WE, 1982, INFECT IMMUN, V36, P782, DOI 10.1128/IAI.36.2.782-794.1982; Hooper LV, 2004, TRENDS MICROBIOL, V12, P129, DOI 10.1016/j.tim.2004.01.001; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Karl David M., 1998, P29; Liu ZQ, 2001, ARTHRITIS RES, V3, P375, DOI 10.1186/ar330; McFall-Ngai MJ, 2002, DEV BIOL, V242, P1, DOI 10.1006/dbio.2001.0522; MCFALLNGAI MJ, UNPUB; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; MELLY MA, 1984, J INFECT DIS, V149, P378, DOI 10.1093/infdis/149.3.378; Nyholm SV, 2000, P NATL ACAD SCI USA, V97, P10231, DOI 10.1073/pnas.97.18.10231; Nyholm SV, 2004, NAT REV MICROBIOL, V2, P632, DOI 10.1038/nrmicro957; Nyholm SV, 2002, APPL ENVIRON MICROB, V68, P5113, DOI 10.1128/AEM.68.10.5113-5122.2002; Pabst MJ, 1999, NEUROIMMUNOMODULAT, V6, P261, DOI 10.1159/000026384; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; ROSENTHAL RS, 1979, INFECT IMMUN, V24, P869, DOI 10.1128/IAI.24.3.869-878.1979; ROSENTHAL RS, 1987, INFECT IMMUN, V55, P2117, DOI 10.1128/IAI.55.9.2117-2120.1987; RUBY EG, 1977, APPL ENVIRON MICROB, V34, P164, DOI 10.1128/AEM.34.2.164-169.1977; Traub S, 2004, J BIOL CHEM, V279, P8694, DOI 10.1074/jbc.M310556200; Wray GM, 2001, SHOCK, V15, P135, DOI 10.1097/00024382-200115020-00010; Xu J, 2003, P NATL ACAD SCI USA, V100, P10452, DOI 10.1073/pnas.1734063100	25	267	274	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1186	1188		10.1126/science.1102218	http://dx.doi.org/10.1126/science.1102218			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539604				2022-12-28	WOS:000225193100050
J	Tapper, AR; McKinney, SL; Nashmi, R; Schwarz, J; Deshpande, P; Labarca, C; Whiteaker, P; Marks, MJ; Collins, AC; Lester, HA				Tapper, AR; McKinney, SL; Nashmi, R; Schwarz, J; Deshpande, P; Labarca, C; Whiteaker, P; Marks, MJ; Collins, AC; Lester, HA			Nicotine activation of alpha 4*receptors: Sufficient for reward, tolerance, and sensitization	SCIENCE			English	Article							CONDITIONED PLACE-PREFERENCE; VENTRAL TEGMENTAL AREA; ACETYLCHOLINE-RECEPTORS; UP-REGULATION; MICE; DOPAMINE; EXPOSURE; NEURONS; INFUSION; BLOCKADE	The identity of nicotinic receptor subtypes sufficient to elicit both the acute and chronic effects of nicotine dependence is unknown. We engineered mutant mice with alpha4 nicotinic subunits containing a single point mutation, Leu(9)' --> Ala(9)' in the pore-forming M2 domain, rendering alpha4* receptors hypersensitive to nicotine. Selective activation of alpha4* nicotinic acetylcholine receptors with low doses of agonist recapitulates nicotine effects thought to be important in dependence, including reinforcement in response to acute nicotine administration, as well as tolerance and sensitization elicited by chronic nicotine administration. These data indicate that activation of alpha4* receptors is sufficient for nicotine-induced reward, tolerance, and sensitization.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Leipzig, Dept Neurol, D-04103 Leipzig, Germany; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	California Institute of Technology; Leipzig University; University of Colorado System; University of Colorado Boulder	Lester, HA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	lester@caltech.edu		Nashmi, Raad/0000-0001-6596-2620	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P30DA015663, R01DA003194] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-3194, DA-15663] Funding Source: Medline; NIMH NIH HHS [MH-49716] Funding Source: Medline; NINDS NIH HHS [NS-11756] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUAS E, 1989, PSYCHOPHARMACOLOGY, V99, P151, DOI 10.1007/BF00442800; Berrendero F, 2002, J NEUROSCI, V22, P10935; CORRIGALL WA, 1994, BRAIN RES, V653, P278, DOI 10.1016/0006-8993(94)90401-4; CORRIGALL WA, 1989, PSYCHOPHARMACOLOGY, V99, P473, DOI 10.1007/BF00589894; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; Damaj MI, 1996, J PHARMACOL EXP THER, V277, P454; FUDALA PJ, 1985, PHARMACOL BIOCHEM BE, V22, P237, DOI 10.1016/0091-3057(85)90384-3; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; Konu O, 2001, BRAIN RES, V909, P194, DOI 10.1016/S0006-8993(01)02685-3; KSIR C, 1985, NEUROPHARMACOLOGY, V24, P527, DOI 10.1016/0028-3908(85)90058-9; KSIR C, 1987, PSYCHOPHARMACOLOGY, V92, P25, DOI 10.1007/BF00215474; Labarca C, 2001, P NATL ACAD SCI USA, V98, P2786, DOI 10.1073/pnas.041582598; Laviolette SR, 2003, PSYCHOPHARMACOLOGY, V166, P306, DOI 10.1007/s00213-002-1317-6; Li MD, 2002, MOL NEUROBIOL, V25, P265, DOI 10.1385/MN:25:3:265; Mansvelder HD, 2000, NEURON, V27, P349, DOI 10.1016/S0896-6273(00)00042-8; MARKS MJ, 1991, J PHARMACOL EXP THER, V259, P392; MARKS MJ, 1983, J PHARMACOL EXP THER, V226, P817; MARKS MJ, 1993, J PHARMACOL EXP THER, V266, P1268; Marubio LM, 2003, EUR J NEUROSCI, V17, P1329, DOI 10.1046/j.1460-9568.2003.02564.x; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; Nashmi R, 2003, J NEUROSCI, V23, P11554; Orr-Urtreger A, 2000, J NEUROCHEM, V74, P2154, DOI 10.1046/j.1471-4159.2000.0742154.x; Partridge JG, 2002, J NEUROSCI, V22, P2541, DOI 10.1523/JNEUROSCI.22-07-02541.2002; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Pidoplichko VI, 1997, NATURE, V390, P401, DOI 10.1038/37120; TAPPER A, UNPUB; WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z; Yates SL, 1995, BIOCHEM PHARMACOL, V50, P2001, DOI 10.1016/0006-2952(95)02100-0	28	523	539	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1029	1032		10.1126/science.1099420	http://dx.doi.org/10.1126/science.1099420			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528443				2022-12-28	WOS:000225001100042
J	Sateia, MJ; Nowell, PD				Sateia, MJ; Nowell, PD			Insomnia	LANCET			English	Review							COGNITIVE-BEHAVIORAL THERAPY; FATAL FAMILIAL INSOMNIA; PERIODIC LEG MOVEMENTS; DOUBLE-BLIND; SLEEP DISORDERS; PRACTICE PARAMETERS; DAYTIME ALERTNESS; DSM-IV; NONPHARMACOLOGICAL TREATMENT; DIFFERENTIAL-DIAGNOSIS	Effective management of insomnia begins with recognition and adequate assessment. Family doctors and other health care providers such as practice nurses and psychologists should routinely enquire about sleep habits as a component of overall health assessment. Identification and treatment of primary psychiatric disorders, medical conditions, circadian disorders, or specific physiological sleep disorders-eg, sleep apnoea and periodic limb movement disorder-are essential steps in management of insomnia. Conditioned aspects of insomnia can be primary (psychophysiological insomnia) or may complicate sleep disturbance owing to other causes. Approved hypnotic drugs have clearly been shown to improve subjective and objective sleep measures in various short-term situations. Despite widespread use of standard hypnotics and sedating antidepressants for chronic insomnia, their role for this indication still remains to be further defined by research evidence. Non-pharmacological treatments, particularly stimulus control and sleep restriction, are effective for conditioned aspects of insomnia and are associated with durable long-term improvement in sleep.	Dartmouth Hitchcock Sleep Disorders Ctr, Dartmouth Med Sch, Lebanon, NH 03756 USA	Dartmouth College	Sateia, MJ (corresponding author), Dartmouth Hitchcock Sleep Disorders Ctr, Dartmouth Med Sch, Lebanon, NH 03756 USA.	michael.j.sateia@dartmouth.edu			NHLBI NIH HHS [K07-HL03646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003646] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; Asnis GM, 1999, J CLIN PSYCHIAT, V60, P668, DOI 10.4088/JCP.v60n1005; Babar SI, 2000, J GERONTOL A-BIOL, V55, pM406, DOI 10.1093/gerona/55.7.M406; Babkoff H, 1996, J CLIN EPIDEMIOL, V49, P455, DOI 10.1016/0895-4356(95)00529-3; Backhaus J, 2001, EUR ARCH PSY CLIN N, V251, P35, DOI 10.1007/s004060170066; Baillargeon L, 2003, CAN MED ASSOC J, V169, P1015; BERNSTEIN MJ, 1984, JAMA-J AM MED ASSOC, V251, P2410; Bonnet MH, 1999, INT CLIN PSYCHOPHARM, V14, P81, DOI 10.1097/00004850-199903000-00004; Bonnet MH, 1996, SLEEP, V19, P453, DOI 10.1093/sleep/19.6.453; Bonnet MH, 1997, PSYCHOSOM MED, V59, P533, DOI 10.1097/00006842-199709000-00011; Bootzin RR., 1978, PROGR BEHAV MODIFICA, P1, DOI DOI 10.1016/B978-0-12-535606-0.50007-9; BORBELY AA, 1991, EUR ARCH PSY CLIN N, V241, P13, DOI 10.1007/BF02193749; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Bunney WE, 1999, ARCH GEN PSYCHIAT, V56, P349, DOI 10.1001/archpsyc.56.4.349; BUYSSE DJ, 1994, SLEEP, V17, P630, DOI 10.1093/sleep/17.7.630; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Buysse DJ, 1997, SLEEP, V20, P542, DOI 10.1093/sleep/20.7.542; Cardinali DP, 2002, NEUROENDOCRINOL LETT, V23, P9; Chesson A, 2000, SLEEP, V23, P237; Chesson AL, 1997, SLEEP, V20, P423, DOI 10.1093/sleep/20.6.423; Chesson AL, 1999, SLEEP, V22, P1128, DOI 10.1093/sleep/22.8.1128; Chevalier H, 1999, J PSYCHOPHARMACOL, V13, pS21, DOI 10.1177/026988119901304S04; Chilcott LA, 1996, PHARMACOECONOMICS, V10, P1, DOI 10.2165/00019053-199600101-00003; *CINP TASK FORC, 1992, EUR NEUROPSYCHOPHARM, V2, P167; Cluydts R, 1998, J INT MED RES, V26, P13, DOI 10.1177/030006059802600102; Cohen F L, 1996, Holist Nurs Pract, V10, P33; Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407; Davidson JR, 2002, SOC SCI MED, V54, P1309, DOI 10.1016/S0277-9536(01)00043-0; Davidson JR, 2001, PSYCHO-ONCOLOGY, V10, P389, DOI 10.1002/pon.525; Douglas NJ, 1998, CLIN CHEST MED, V19, P115, DOI 10.1016/S0272-5231(05)70436-6; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Eastman CI, 1995, J BIOL RHYTHM, V10, P157, DOI 10.1177/074873049501000208; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Elie R, 1999, J CLIN PSYCHIAT, V60, P536, DOI 10.4088/JCP.v60n0806; Espie CA, 2002, ANNU REV PSYCHOL, V53, P215, DOI 10.1146/annurev.psych.53.100901.135243; Espie CA, 2001, J CONSULT CLIN PSYCH, V69, P58, DOI 10.1037//0022-006X.69.1.58; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Foley DJ, 1999, SLEEP, V22, pS366; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FREEDMAN RR, 1982, J ABNORM PSYCHOL, V91, P380, DOI 10.1037/0021-843X.91.5.380; *GALL ORG, 1995, SLEEP AM; Ganguli M, 1996, J AM GERIATR SOC, V44, P778, DOI 10.1111/j.1532-5415.1996.tb03733.x; Georgievski AB, 2000, INT J REHABIL RES, V23, P1; GISLASON T, 1993, J INTERN MED, V234, P31, DOI 10.1111/j.1365-2796.1993.tb00701.x; Hajak G, 2003, ADDICTION, V98, P1371, DOI 10.1046/j.1360-0443.2003.00491.x; Hajak G, 2002, INT CLIN PSYCHOPHARM, V17, P9, DOI 10.1097/00004850-200201000-00002; Hajak G, 2001, J CLIN PSYCHIAT, V62, P453, DOI 10.4088/JCP.v62n0609; Hajak G, 2001, EUR ARCH PSY CLIN N, V251, P49, DOI 10.1007/s004060170052; Hajak Goran, 2002, Ann Clin Psychiatry, V14, P1; Harvey AG, 2002, BEHAV RES THER, V40, P869, DOI 10.1016/S0005-7967(01)00061-4; Hatoum HT, 1998, AM J MANAG CARE, V4, P79; HAURI P, 1986, SLEEP, V9, P38, DOI 10.1093/sleep/9.1.38; Hedner J, 2000, INT J GERIATR PSYCH, V15, P704, DOI 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.3.CO;2-J; Herrera-Arellano A, 2001, PLANTA MED, V67, P695, DOI 10.1055/s-2001-18344; HOHAGEN F, 1993, EUR ARCH PSY CLIN N, V242, P329, DOI 10.1007/BF02190245; HOHAGEN F, 1994, EUR ARCH PSY CLIN N, V244, P65, DOI 10.1007/BF02193521; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; Janson C, 2001, SLEEP, V24, P425, DOI 10.1093/sleep/24.4.425; Jensen E, 1998, J SLEEP RES, V7, P183, DOI 10.1046/j.1365-2869.1998.00118.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KALES A, 1983, PSYCHOSOM MED, V45, P341, DOI 10.1097/00006842-198308000-00008; KalogjeraSackellares D, 1997, PSYCHIAT RES, V70, P49, DOI 10.1016/S0165-1781(97)03078-3; Karadeniz D, 2000, EUR J NEUROL, V7, P331, DOI 10.1046/j.1468-1331.2000.00070.x; Katz DA, 1998, ARCH INTERN MED, V158, P1099, DOI 10.1001/archinte.158.10.1099; KLINK ME, 1992, ARCH INTERN MED, V152, P1634, DOI 10.1001/archinte.152.8.1634; Krakow B, 2001, CHEST, V120, P1923, DOI 10.1378/chest.120.6.1923; Kripke DF, 2002, ARCH GEN PSYCHIAT, V59, P131, DOI 10.1001/archpsyc.59.2.131; Krystal AD, 2003, SLEEP, V26, P793, DOI 10.1093/sleep/26.7.793; Krystal AD, 2002, SLEEP, V25, P630; KUMMER J, 1993, J INT MED RES, V21, P171; Kupfer DJ, 1997, NEW ENGL J MED, V336, P341, DOI 10.1056/NEJM199701303360506; LACKS P, 1983, BEHAV RES THER, V21, P291, DOI 10.1016/0005-7967(83)90211-5; LACKS P, 1986, BEHAV RES THER, V24, P365, DOI 10.1016/0005-7967(86)90197-X; Leger D, 2002, SLEEP, V25, P625; Leger D, 1999, CLIN SCI, V97, P193, DOI 10.1042/CS19990004; Lenhart SE, 2001, ANN PHARMACOTHER, V35, P1449; Lichstein KL, 2000, PSYCHOL AGING, V15, P232, DOI 10.1037/0882-7974.15.2.232; Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337; Lockley SW, 1999, SLEEP, V22, P616, DOI 10.1093/sleep/22.5.616; LUGARESI A, 1987, CLIN ENDOCRINOL, V26, P573, DOI 10.1111/j.1365-2265.1987.tb00812.x; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; MAAREK L, 1992, J INT MED RES, V20, P162, DOI 10.1177/030006059202000208; McCall WV, 2002, SLEEP MEDICINE, P169; MCCLUSKY HY, 1991, AM J PSYCHIAT, V148, P121; McNicholas WT, 2000, CHEST, V117, P48; Means MK, 2000, BEHAV RES THER, V38, P665, DOI 10.1016/S0005-7967(99)00091-1; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; Mendelson WB, 1996, SLEEP, V19, P219, DOI 10.1093/sleep/19.3.219; MENDELSON WB, 1995, SLEEP, V18, P698, DOI 10.1093/sleep/18.8.698; Moldofsky H, 2002, SLEEP MEDICINE, P471; Montgomery P, 2004, SLEEP MED REV, V8, P47, DOI 10.1016/S1087-0792(03)00026-1; MONTGOMERY P, 2002, COCHRANE LIB; Monti JM, 1996, INT CLIN PSYCHOPHARM, V11, P255, DOI 10.1097/00004850-199612000-00007; MONTI JM, 1993, EUR J CLIN PHARMACOL, V44, P525, DOI 10.1007/BF02440852; Montplaisir J, 2000, EUR J NEUROL, V7, P27, DOI 10.1046/j.1468-1331.2000.0070s1027.x; Morgan K, 2004, HEALTH TECHNOL ASSES, V8, piii; Morin CM, 1999, J PSYCHOSOM RES, V46, P103, DOI 10.1016/S0022-3999(98)00077-4; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; MORIN CM, 1993, PSYCHOL AGING, V8, P463, DOI 10.1037/0882-7974.8.3.463; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Morin CM., 1993, INSOMNIA PSYCHOL ASS; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; Nakra B R, 1992, Int Psychogeriatr, V4, P45, DOI 10.1017/S1041610292000899; NIERENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Nowell PD, 1997, AM J PSYCHIAT, V154, P1412; Nowell PD, 1999, J CLIN PSYCHIAT, V60, P89, DOI 10.4088/JCP.v60n0204; NOWELL PD, 2000, PRINCIPLES PRACTICE, P1290; NOWELL PD, 2002, GUIDE TREATMENTS WOR, P593; Ohayon M, 1996, SLEEP, V19, pS7, DOI 10.1093/sleep/19.suppl_3.S7; OHAYON MM, 1995, PROG NEURO-PSYCHOPH, V19, P421, DOI 10.1016/0278-5846(94)00023-B; Ohayon MM, 1997, BRIT J PSYCHIAT, V171, P382, DOI 10.1192/bjp.171.4.382; Ohayon MM, 2001, J AM GERIATR SOC, V49, P360, DOI 10.1046/j.1532-5415.2001.49077.x; OLDE RM, 2001, Z GERONTOL GERIATR, V34, P491; Pallesen S, 2003, BEHAV RES THER, V41, P31, DOI 10.1016/S0005-7967(01)00122-X; Pasche B, 1996, SLEEP, V19, P327, DOI 10.1093/sleep/19.4.327; Perlis ML, 1997, J SLEEP RES, V6, P179, DOI 10.1046/j.1365-2869.1997.00045.x; Perlis ML, 2001, J BEHAV MED, V24, P281, DOI 10.1023/A:1010770807823; Perlis ML, 2001, SLEEP, V24, P110, DOI 10.1093/sleep/24.1.110; Prinz PN, 2002, SLEEP MEDICINE, P497; Ray WA, 2000, J AM GERIATR SOC, V48, P682, DOI 10.1111/j.1532-5415.2000.tb04729.x; REGESTEIN QR, 1995, GEN HOSP PSYCHIAT, V17, P335, DOI 10.1016/0163-8343(95)00062-V; REGESTEIN QR, 1995, AM J PSYCHIAT, V152, P602; REGESTEIN QR, 1993, AM J PSYCHIAT, V150, P1529; Riemann D, 2002, PHARMACOPSYCHIATRY, V35, P165, DOI 10.1055/s-2002-34119; Roberts RE, 1999, PSYCHOSOM MED, V61, P188, DOI 10.1097/00006842-199903000-00011; ROEHRS T, 1992, PSYCHOPHARMACOLOGY, V108, P67, DOI 10.1007/BF02245287; ROEHRS T, 2000, PRINCIPLES PRACTICE, P414; ROGER M, 1993, CLIN THER, V15, P127; Rosen R, 2000, Curr Opin Pulm Med, V6, P512, DOI 10.1097/00063198-200011000-00009; ROTH T, 1991, J CLIN PSYCHIAT, V52, P38; Roth T, 2004, SLEEP, V27, P260; ROTH T, 1995, SLEEP, V18, P246, DOI 10.1093/sleep/18.4.246; Rubinstein ML, 1998, J ACQ IMMUN DEF SYND, V19, P260, DOI 10.1097/00042560-199811010-00008; Sack RL, 1997, SLEEP, V20, P908, DOI 10.1093/sleep/20.10.908; Sack RL, 2002, SLEEP MEDICINE, P255; Sateia MJ, 2000, SLEEP, V23, P243; Savard J, 2001, J CLIN ONCOL, V19, P895, DOI 10.1200/JCO.2001.19.3.895; SCHLICH D, 1991, J INT MED RES, V19, P271, DOI 10.1177/030006059101900313; Simon GE, 1997, AM J PSYCHIAT, V154, P1417; Skene DJ, 1999, ADV EXP MED BIOL, V467, P79; Skene DJ, 1999, BIOL SIGNAL RECEPT, V8, P90; Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5; Smith MT, 2001, J BEHAV MED, V24, P93, DOI 10.1023/A:1005690505632; SPIELMAN AJ, 1987, PSYCHIAT CLIN N AM, V10, P541; SPIELMAN AJ, 1987, SLEEP, V10, P45; STEPANSKI E, 1989, PSYCHOSOMATICS, V30, P421, DOI 10.1016/S0033-3182(89)72248-9; STEPANSKI E, 1988, SLEEP, V11, P54, DOI 10.1093/sleep/11.1.54; STOLLER MK, 1994, CLIN THER, V16, P873; SUGERMAN JL, 1985, BIOL PSYCHIAT, V20, P741, DOI 10.1016/0006-3223(85)90153-2; Terman M, 1999, J CLIN PSYCHIAT, V60, P799; Trenkwalder C, 2002, ADV NEUROL, V89, P145; *US DHEW, 1977, GUID CLIN EV HYPN DR; Verbeek I, 1999, J PSYCHOSOM RES, V47, P369, DOI 10.1016/S0022-3999(99)00030-6; Vgontzas AN, 1998, J PSYCHOSOM RES, V45, P21, DOI 10.1016/S0022-3999(97)00302-4; VGONTZAS AN, 1995, INT J NEUROSCI, V82, P47, DOI 10.3109/00207459508994289; Voderholzer U, 2001, EUR ARCH PSY CLIN N, V251, P117, DOI 10.1007/s004060170045; Walsh JK, 1999, SLEEP, V22, pS386; Walsh JK, 2004, SLEEP, V27, P259; Walsh JK, 1999, SLEEP, V22, P371; Walsh JK, 1999, AM FAM PHYSICIAN, V59, P3029; Weissman MM, 1997, GEN HOSP PSYCHIAT, V19, P245, DOI 10.1016/S0163-8343(97)00056-X; WEYERER S, 1991, SLEEP, V14, P392; *WHO, 1978, INT CLASS DIS; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; Zammit GK, 1999, SLEEP, V22, pS379; ZAMMIT GK, 1988, J CLIN PSYCHOL, V44, P123, DOI 10.1002/1097-4679(198803)44:2<123::AID-JCLP2270440206>3.0.CO;2-D; 2000, AM FAM PHYSICIAN, V62, P108	171	153	161	0	32	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1959	1973		10.1016/S0140-6736(04)17480-1	http://dx.doi.org/10.1016/S0140-6736(04)17480-1			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874BX	15567013				2022-12-28	WOS:000225327000035
J	Francis, NJ; Kingston, RE; Woodcock, CL				Francis, NJ; Kingston, RE; Woodcock, CL			Chromatin compaction by a polycomb group protein complex	SCIENCE			English	Article							STRUCTURAL BASIS; ACCESSIBILITY; DNA; MECHANISMS; REPRESSION; MOTIF	Polycomb group proteins preserve body patterning through development by maintaining transcriptional silencing of homeotic genes. A long-standing hypothesis is that silencing involves creating chromatin structure that is repressive to gene transcription. We demonstrate by electron microscopy that core components of Polycomb Repressive Complex 1 induce compaction of defined nucleosomal arrays. Compaction by Polycomb proteins requires nucleosomes but not histone tails. Each Polycomb complex can compact about three nucleosomes. A region of Posterior Sex Combs that is important for gene silencing in vivo is also important for chromatin compaction, linking the two activities. This mechanism of chromatin compaction might be central to stable gene silencing by the Polycomb group.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Amherst	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.	kingston@molbio.mgh.harvard.edu			NCRR NIH HHS [NIH-P41-RR01777] Funding Source: Medline; NIGMS NIH HHS [GM43786] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043786] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173; Beuchle D, 2001, DEVELOPMENT, V128, P993; Boivin A, 1998, GENETICS, V150, P1539; Ducker CE, 2000, EMBO J, V19, P400, DOI 10.1093/emboj/19.3.400; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fitzgerald DP, 2001, MOL CELL BIOL, V21, P6585, DOI 10.1128/MCB.21.19.6585-6597.2001; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; Georgel PT, 2003, J BIOL CHEM, V278, P32181, DOI 10.1074/jbc.M305308200; Hansen JC, 2002, ANNU REV BIOPH BIOM, V31, P361, DOI 10.1146/annurev.biophys.31.101101.140858; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KING I, UNPUB; King IFG, 2002, MOL CELL BIOL, V22, P7919, DOI 10.1128/MCB.22.22.7919-7928.2002; Lavigne M, 2004, MOL CELL, V13, P415, DOI 10.1016/S1097-2765(04)00006-1; Lessard J, 2003, EXP HEMATOL, V31, P567, DOI 10.1016/S0301-472X(03)00081-X; Marchetti M, 2003, DEVELOPMENT, V130, P3683, DOI 10.1242/dev.00587; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Porter IM, 2004, CURR BIOL, V14, pR554, DOI 10.1016/j.cub.2004.07.009; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Springhetti EM, 2003, J BIOL CHEM, V278, P43384, DOI 10.1074/jbc.M307635200; Thiru A, 2004, EMBO J, V23, P489, DOI 10.1038/sj.emboj.7600088; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	26	603	621	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1574	1577		10.1126/science.1100576	http://dx.doi.org/10.1126/science.1100576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567868				2022-12-28	WOS:000225442700065
J	Chen, JS; Li, L; Wang, JY; Barry, DA; Sheng, XF; Gu, WZ; Zhao, X; Chen, L				Chen, JS; Li, L; Wang, JY; Barry, DA; Sheng, XF; Gu, WZ; Zhao, X; Chen, L			Water resources - Groundwater maintains dune landscape	NATURE			English	Editorial Material									Hohai Univ, Inst Isotope Res, Nanjing 210098, Peoples R China; Hohai Univ, Ctr Ecoenvironm Modelling, Nanjing 210098, Peoples R China; Univ Queensland, Sch Engn, St Lucia, Qld 4072, Australia; Chinese Acad Sci, Inst Geol & Geophys, Beijing 100018, Peoples R China; Univ Edinburgh, Sch Engn & Elect, Edinburgh EH9 3JL, Midlothian, Scotland; Nanjing Univ, Dept Earth Sci, Inst Surficial Geochem, Nanjing 210093, Peoples R China	Hohai University; Hohai University; University of Queensland; Chinese Academy of Sciences; Institute of Geology & Geophysics, CAS; University of Edinburgh; Nanjing University	Chen, JS (corresponding author), Hohai Univ, Inst Isotope Res, Nanjing 210098, Peoples R China.		Li, Ling/E-5632-2010; Barry, D. Andrew/C-6077-2008	Li, Ling/0000-0001-8725-1221; Barry, D. Andrew/0000-0002-8621-0425				HUANG CY, 2003, CLIM ENV RES, V18, P84; HUANG SJ, 2001, ADV EARTH SCI, V1, P194; Liu ZH, 2000, SCI CHINA SER D, V43, P569, DOI 10.1007/BF02879500; Ren J, 1999, J GLACIOLOGY GEOCRYO, V21, P151; [杨小平 Yang Xiaoping], 2002, [第四纪研究, Quaternary Sciences], V22, P97; YANG XP, 2000, SCI REP, V45, P428	6	132	214	16	204	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	2004	432	7016					459	460		10.1038/432459a	http://dx.doi.org/10.1038/432459a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565142				2022-12-28	WOS:000225322100031
J	Nagoshi, E; Saini, C; Bauer, C; Laroche, T; Naef, F; Schibler, U				Nagoshi, E; Saini, C; Bauer, C; Laroche, T; Naef, F; Schibler, U			Circadian gene expression in individual fibroblasts: Cell-autonomous and self-sustained oscillators pass time to daughter cells	CELL			English	Article							PERIPHERAL-TISSUES; CLOCK; RHYTHMS; RECEPTOR; LIGHT; CYCLE; LIMB	The mammalian circadian timing system is composed of a central pacemaker in the suprachiasmatic nucleus (SCN) of the brain and subsidiary oscillators in most peripheral cell types. While oscillators in SCN neurons are known to function in a self-sustained fashion, peripheral oscillators have been thought to damp rapidly when disconnected from the control exerted by the SCN. Using two reporter systems, we monitored circadian gene expression in NIH3T3 mouse fibroblasts in real time and in individual cells. In conjunction with mathematical modeling and cell co-culture experiments, these data demonstrated that in vitro cultured fibroblasts harbor self-sustained and cell-autonomous circadian clocks similar to those operative in SCN neurons. Circadian gene expression in fibroblasts continues during cell division, and our experiments unveiled unexpected interactions between the circadian clock and the cell division clock. Specifically, the circadian oscillator gates cytokinesis to defined time windows, and mitosis elicits phase shifts in circadian cycles.	Univ Geneva, Dept Mol Biol, CH-1211 Geneva 4, Switzerland; Univ Geneva, NCCR Frontiers Genet, CH-1211 Geneva 4, Switzerland; Univ Geneva, NCCR Frontiers Genet Sci 2, CH-1211 Geneva 4, Switzerland; ISREC, CH-1066 Epalinges, Switzerland; NCCR Mol Oncol, CH-1066 Epalinges, Switzerland	University of Geneva; University of Geneva; University of Geneva; Swiss Institute Experimental Cancer Research	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol, 30 Quai Ernest Ansermet, CH-1211 Geneva 4, Switzerland.	ueli.schibler@molbio.unige.ch	Naef, Felix/C-9527-2011; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Nagoshi, Emi/0000-0002-6365-4074; Naef, Felix/0000-0001-9786-3037				Akashi M, 2000, GENE DEV, V14, P645; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Biederbick A, 1998, CELL TISSUE RES, V291, P277, DOI 10.1007/s004410050997; Bjarnason GA, 1999, AM J PATHOL, V154, P613, DOI 10.1016/S0002-9440(10)65306-0; Bjarnason GA, 2002, CHRONOBIOL INT, V19, P129, DOI 10.1081/CBI-120002595; Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4; DAAN S, 1976, J COMP PHYSIOL, V106, P267, DOI 10.1007/BF01417858; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Dekens MPS, 2003, CURR BIOL, V13, P2051, DOI 10.1016/j.cub.2003.10.022; Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Low-Zeddies SS, 2001, CELL, V105, P25, DOI 10.1016/S0092-8674(01)00294-X; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mihalcescu I, 2004, NATURE, V430, P81, DOI 10.1038/nature02533; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Pando MP, 2002, CELL, V110, P107, DOI 10.1016/S0092-8674(02)00803-6; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; Shen HM, 1997, J NEUROSCI, V17, P5221; Smaaland R, 2002, CHRONOBIOL INT, V19, P101, DOI 10.1081/CBI-120002594; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Yoo SH, 2004, P NATL ACAD SCI USA, V101, P5339, DOI 10.1073/pnas.0308709101; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	36	737	762	2	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2004	119	5					693	705		10.1016/S0092-8674(04)01054-2	http://dx.doi.org/10.1016/S0092-8674(04)01054-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	874ZP	15550250	Bronze			2022-12-28	WOS:000225389500014
J	Balachandran, S; Thomas, E; Barber, GN				Balachandran, S; Thomas, E; Barber, GN			A FADD-dependent innate immune mechanism in mammalian cells	NATURE			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; VIRAL-INFECTION; SIGNALING PATHWAY; TRANSCRIPTION FACTORS; ANTIVIRAL RESPONSES; DENDRITIC CELLS; DEATH DOMAIN; KINASE; ACTIVATION	Vertebrate innate immunity provides a first line of defence against pathogens such as viruses and bacteria. Viral infection activates a potent innate immune response, which can be triggered by double-stranded (ds) RNA produced during viral replication(1-3). Here, we report that mammalian cells lacking the death-domain-containing protein FADD(4,5) are defective in intracellular dsRNA-activated gene expression, including production of type I (a/b) interferons, and are thus very susceptible to viral infection. The signalling pathway incorporating FADD is largely independent of Toll-like receptor 3 and the dsRNA-dependent kinase PKR, but seems to require receptor interacting protein 1 as well as Tank-binding kinase 1-mediated activation of the transcription factor IRF-3. The requirement for FADD in mammalian host defence is evocative of innate immune signalling in Drosophila, in which a FADD-dependent pathway responds to bacterial infection by activating the transcription of antimicrobial genes(6). These data therefore suggest the existence of a conserved pathogen recognition pathway in mammalian cells that is essential for the optimal induction of type I interferons and other genes important for host defence.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.	gbarber@med.miami.edu						Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Diebold SS, 2003, NATURE, V424, P324, DOI 10.1038/nature01783; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Naitza S, 2002, IMMUNITY, V17, P575, DOI 10.1016/S1074-7613(02)00454-5; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	30	236	248	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					401	405		10.1038/nature03124	http://dx.doi.org/10.1038/nature03124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549108				2022-12-28	WOS:000225161400058
J	Sawyers, C				Sawyers, C			Targeted cancer therapy	NATURE			English	Article							CHRONIC MYELOID-LEUKEMIA; KINASE INHIBITOR; IMATINIB MESYLATE; EGFR MUTATIONS; HIGH-FREQUENCY; LUNG-CANCER; RESISTANCE; STI571; GENE; BEVACIZUMAB	Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Complex networks of regulatory factors, the tumour microenvironment and stress signals, such as those resulting from damaged DNA, dictate whether cancer cells proliferate or die. Recent progress in understanding the molecular changes that underlie cancer development offer the prospect of specifically targeting malfunctioning molecules and pathways to achieve more effective and rational cancer therapy.	Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sawyers, C (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Howard Hughes Med Inst, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016					Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; CHU S, 2004, BLOOD           0902; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DEANGELO DJ, 2003, BLOOD, V102; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; MOTZER, 2001, J CLIN ONCOL S, V22, P4500; Olumi AF, 1999, CANCER RES, V59, P5002; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; RATAIN, 2004, J CLIN ONCOL S, V22, P4501; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rubin BP, 2002, J CLIN ONCOL, V20, P3586, DOI 10.1200/JCO.2002.01.027; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; SMITH BD, 2003, P ASCO, V22, P194; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; STONE RM, 2003, P AN M AM SOC CLIN, V22, P563; WILLIAMS ME, 1993, LEUKEMIA, V7, P1437; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	31	828	879	3	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					294	297		10.1038/nature03095	http://dx.doi.org/10.1038/nature03095			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549090				2022-12-28	WOS:000225161400038
J	Wilson, RJ; Thomas, CD; Fox, R; Roy, DB; Kunin, WE				Wilson, RJ; Thomas, CD; Fox, R; Roy, DB; Kunin, WE			Spatial patterns in species distributions reveal biodiversity change	NATURE			English	Article							BRITISH BUTTERFLIES; GEOGRAPHIC RANGE; RED LIST; CONSERVATION; EXTINCTION; ABUNDANCE; HABITAT; CLIMATE; DECLINE; SCALE	Interpretation of global biodiversity change is hampered by a lack of information on the historical status of most species in most parts of the world(1-5). Here we show that declines and increases can be deduced from current species distributions alone, using spatial patterns of occupancy combined with distribution size. Declining species show sparse, fragmented distributions for their distribution size, reflecting the extinction process; expanding species show denser, more aggregated distributions, reflecting colonization. Past distribution size changes for British butterflies were deduced successfully from current distributions, and former distributions had some power to predict future change. What is more, the relationship between distribution pattern and change in British butterflies independently predicted distribution change for butterfly species in Flanders, Belgium, and distribution change in British rare plant species is similarly related to spatial distribution pattern. This link between current distribution patterns and processes of distribution change could be used to assess relative levels of threat facing different species, even for regions and taxa lacking detailed historical and ecological information.	Univ Leeds, Sch Biol, Ctr Biodivers & Conservat, Leeds LS2 9JT, W Yorkshire, England; Butterfly Conservat, Wareham BH20 5QP, Dorset, England; NERC, Ctr Ecol & Hydrol, Huntingdon PE28 2LS, Cambs, England	University of Leeds; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Wilson, RJ (corresponding author), Univ Rey Juan Carlos, Escuela Super Ciencias Expt & Tecnol, Area Biodiversidad & Conservac, Tulipan S-N, E-28933 Madrid, Spain.	rwilson@escet.urjc.es	Wilson, Robert J/I-8726-2014; Thomas, Chris D/A-1894-2012; Thomas, Chris D/A-1460-2014; Roy, David/A-6619-2009	Wilson, Robert J/0000-0003-4477-7068; Thomas, Chris D/0000-0003-2822-1334; Thomas, Chris D/0000-0003-2822-1334; Roy, David/0000-0002-5147-0331; Fox, Richard/0000-0001-6992-3522				Akcakaya HR, 2000, CONSERV BIOL, V14, P1001, DOI 10.1046/j.1523-1739.2000.99125.x; Asher J, 2001, MILLENNIUM ATLAS BUT; Brooks TM, 1999, CONSERV BIOL, V13, P1140, DOI 10.1046/j.1523-1739.1999.98341.x; BROWN JH, 1995, ECOLOGY, V76, P2028, DOI 10.2307/1941678; Bunge J., J AM STAT ASSOC, V88, P364, DOI 10.2307/2290733; CAUGHLEY G, 1994, J ANIM ECOL, V63, P215, DOI 10.2307/5542; Channell R, 2000, NATURE, V403, P84, DOI 10.1038/47487; Condit R, 2000, SCIENCE, V288, P1414, DOI 10.1126/science.288.5470.1414; Cowley MJR, 1999, P ROY SOC B-BIOL SCI, V266, P1587, DOI 10.1098/rspb.1999.0819; Groombridge B, 2002, WORLD ATLAS BIODIVER; Hanski I., 1999, METAPOPULATION ECOLO; Hartley S, 2003, CONSERV BIOL, V17, P1559, DOI 10.1111/j.1523-1739.2003.00015.x; Heath J., 1984, ATLAS BUTTERFLIES BR; Hill JK, 1999, P ROY SOC B-BIOL SCI, V266, P1197, DOI 10.1098/rspb.1999.0763; IUCN (World Conservation Union), 2001, IUCN RED LIST CAT VE; Johnson CN, 1998, NATURE, V394, P272, DOI 10.1038/28385; Keith DA, 2000, BIOL CONSERV, V94, P311, DOI 10.1016/S0006-3207(99)00194-9; Kunin WE, 1998, SCIENCE, V281, P1513, DOI 10.1126/science.281.5382.1513; Linder ET, 2000, ECOGRAPHY, V23, P678, DOI 10.1034/j.1600-0587.2000.230605.x; MACE GM, 1991, CONSERV BIOL, V5, P148, DOI 10.1111/j.1523-1739.1991.tb00119.x; Maes D, 2001, BIOL CONSERV, V99, P263, DOI 10.1016/S0006-3207(00)00182-8; Martins EP, 1997, AM NAT, V149, P646, DOI 10.1086/286013; MARTINS EP, 2004, COMPARE VERSION 4 6; Ostling A, 2000, Science, V290, P671; Rodriguez A, 2002, ECOGRAPHY, V25, P314, DOI 10.1034/j.1600-0587.2002.250308.x; Shigesada N., 1997, BIOL INVASIONS THEOR; THOMAS CD, 1995, BIOL CONSERV, V73, P59, DOI 10.1016/0006-3207(95)90065-9; Warren MS, 1997, BIOL CONSERV, V82, P317, DOI 10.1016/S0006-3207(97)00037-2; Warren MS, 2001, NATURE, V414, P65, DOI 10.1038/35102054; World Conservation Monitoring Centre, 1992, GLOBAL BIODIVERSITY	30	162	170	8	135	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	2004	432	7015					393	396		10.1038/nature03031	http://dx.doi.org/10.1038/nature03031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549106				2022-12-28	WOS:000225161400056
J	Gershon, D				Gershon, D			Quantum dots show their true colors	NATURE			English	Article																			0	4	4	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					247	247		10.1038/432247a	http://dx.doi.org/10.1038/432247a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538374	Bronze			2022-12-28	WOS:000225020200053
J	Bittle, CC				Bittle, CC			A horse-riding accident and haemolytic anaemia	LANCET			English	Article									Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Bittle, CC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Lubbock, TX 79430 USA.							Gibby WA, 2004, INVEST RADIOL, V39, P138, DOI 10.1097/01.rli.0000112789.57341.01; Puttagunta NR, 1996, INVEST RADIOL, V31, P739, DOI 10.1097/00004424-199612000-00001; Spencer A, 1998, HUM EXP TOXICOL, V17, P633, DOI 10.1191/096032798678908035	3	1	1	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 6	2004	364	9446					1728	1728		10.1016/S0140-6736(04)17362-5	http://dx.doi.org/10.1016/S0140-6736(04)17362-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530636				2022-12-28	WOS:000224921600038
J	An, SJ; Almers, W				An, SJ; Almers, W			Tracking SNARE complex formation in live endocrine cells	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; FLUORESCENT PROTEIN; PLASMA-MEMBRANE; CRYSTAL-STRUCTURE; SYNTAXIN; EXOCYTOSIS; SNAP-25; DOMAIN; RESONANCE; CALCIUM	Syntaxin, synaptosome-associated protein of 25 kD (SNAP25), and vesicle-associated membrane protein/synaptobrevin are collectively called SNAP receptor (SNARE) proteins, and they catalyze neuronal exocytosis by forming a "core complex." The steps in core complex formation are unknown. Here, we monitored SNARE complex formation in vivo with the use of a fluorescent version of SNAP25. In PC12 cells, we found evidence for a syntaxin-SNAP25 complex that formed with high affinity, required only the amino-terminal SNARE motif of SNAP25, tolerated a mutation that blocks formation of other syntaxin-SNAP25 complexes, and assembled reversibly when Ca2+ entered cells during depolarization. The complex may represent a precursor to the core complex formed during a Ca2+-dependent priming step of exocytosis.	Oregon Hlth Sci Univ, Vollum Inst L474, Portland, OR 97201 USA	Oregon Health & Science University	Almers, W (corresponding author), Oregon Hlth Sci Univ, Vollum Inst L474, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	almersw@ohsu.edu			NIMH NIH HHS [MH60600] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Axelrod D, 2001, J BIOMED OPT, V6, P6, DOI 10.1117/1.1335689; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Gonzalo S, 1999, J BIOL CHEM, V274, P21313, DOI 10.1074/jbc.274.30.21313; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Huang XH, 2001, AM J PHYSIOL-CELL PH, V281, pC740, DOI 10.1152/ajpcell.2001.281.3.C740; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Lang T, 2002, J CELL BIOL, V158, P751, DOI 10.1083/jcb.200203088; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Lu XH, 2003, CELL CALCIUM, V33, P267, DOI 10.1016/S0143-4160(03)00009-5; Misura KMS, 2001, J BIOL CHEM, V276, P41301, DOI 10.1074/jbc.M106853200; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; Rickman C, 2004, J BIOL CHEM, V279, P644, DOI 10.1074/jbc.M310879200; Steyer JA, 2001, NAT REV MOL CELL BIO, V2, P268, DOI 10.1038/35067069; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xiao WZ, 2001, NAT STRUCT BIOL, V8, P308, DOI 10.1038/86174	26	106	111	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1042	1046		10.1126/science.1102559	http://dx.doi.org/10.1126/science.1102559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528447				2022-12-28	WOS:000225001100046
J	McCarthy, M				McCarthy, M			As a doctor you believe in facts, but as a manager you must believe in perceptions	LANCET			English	Editorial Material									UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	McCarthy, M (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Torrington Pl, London WC1E 6BT, England.		McCarthy, Mark/C-1117-2009						0	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1991	1991		10.1016/S0140-6736(04)17483-7	http://dx.doi.org/10.1016/S0140-6736(04)17483-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567016				2022-12-28	WOS:000225327000038
J	Partridge, N; Scadding, J				Partridge, N; Scadding, J			The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials	LANCET			English	Editorial Material									INVOLVE, Eastleigh SO50 9FD, Hants, England; Royal Soc Med, London, England		Partridge, N (corresponding author), INVOLVE, Wessex House, Eastleigh SO50 9FD, Hants, England.	admin@invo.org.uk						Chalmers I, 2003, BRIT MED J, V327, P1017, DOI 10.1136/bmj.327.7422.1017; Chalmers Iain, 2004, BMJ, V328, P475, DOI 10.1136/bmj.328.7438.475; Tallon D, 2000, LANCET, V355, P2037, DOI 10.1016/S0140-6736(00)02351-5	3	100	100	2	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1923	1924		10.1016/S0140-6736(04)17494-1	http://dx.doi.org/10.1016/S0140-6736(04)17494-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566996				2022-12-28	WOS:000225327000010
J	Shelton, JD; Peterson, EA				Shelton, JD; Peterson, EA			The imperative for family planning in ART in Africa	LANCET			English	Editorial Material							ANTIRETROVIRAL NUCLEOSIDE; MATERNAL HIV; PREGNANCY; NEVIRAPINE; INFECTION; THERAPY; MALARIA		US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Shelton, JD (corresponding author), US Agcy Int Dev, Bur Global Hlth, Washington, DC 20523 USA.	jshelton@usaid.gov						Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002; DESCHAMPS MD, 2004, 15 INT AIDS C BANK; McIntyre J, 2003, BRIT MED BULL, V67, P127, DOI 10.1093/bmb/ldg012; Minkoff H, 2003, AM J OBSTET GYNECOL, V189, P552, DOI 10.1067/S0002-9378(03)00467-8; Mount AM, 2004, LANCET, V363, P1860, DOI 10.1016/S0140-6736(04)16354-X; Newell ML, 2003, JAIDS-J ACQ IMM DEF, V32, P380, DOI 10.1097/00126334-200304010-00006; Poirier MC, 2004, TOXICOL APPL PHARM, V199, P151, DOI 10.1016/j.taap.2003.11.034; Poirier MC, 2003, JAIDS-J ACQ IMM DEF, V33, P175, DOI 10.1097/00126334-200306010-00010; Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334-200202011-00005; SINGH S, 2004, ADD IT BEN INV SEX R; Ticconi C, 2003, JAIDS-J ACQ IMM DEF, V34, P289, DOI 10.1097/00126334-200311010-00005; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; *UNAIDS, 2002, REP GLOB HIV AIDS EP; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Wainberg MA, 2003, JAIDS-J ACQ IMM DEF, V34, pS2, DOI 10.1097/00126334-200309011-00002; WESTOFF CF, 2001, UNMET NEED END CENTU; WHO UNICEF and UNFPA (World Health Organization United Nations Children's Fund and United Nations Population Fund), 2003, MAT MORT 2000 EST DE; World Health Organization, 2003, ENTR POINTS ANT TREA; World Health Organization, 2003, SCAL ANT THER RES LT; 2003, LANCET, V362, P179	21	19	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1916	1918		10.1016/S0140-6736(04)17489-8	http://dx.doi.org/10.1016/S0140-6736(04)17489-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15566991				2022-12-28	WOS:000225327000005
J	Zhou, DP; Mattner, J; Cantu, C; Schrantz, N; Yin, N; Gao, Y; Sagiv, Y; Hudspeth, K; Wu, YP; Yamashita, T; Teneberg, S; Wang, DC; Proia, RL; Levery, SB; Savage, PB; Teyton, L; Bendelac, A				Zhou, DP; Mattner, J; Cantu, C; Schrantz, N; Yin, N; Gao, Y; Sagiv, Y; Hudspeth, K; Wu, YP; Yamashita, T; Teneberg, S; Wang, DC; Proia, RL; Levery, SB; Savage, PB; Teyton, L; Bendelac, A			Lysosomal glycosphingolipid recognition by NKT cells	SCIENCE			English	Article							MICE LACKING; ANTIGEN PRESENTATION; SPECIFICITY; LYMPHOCYTE; ACTIVATION; EXPRESSION; SYNTHASE; CD1D	NKT Celts represent a distinct lineage of T cells that coexpress a conserved alphabeta T cell receptor (TCR) and natural killer (NK) receptors. Although the TCR of NKT cells is characteristically autoreactive to CD1d, a lipid-presenting molecule, endogenous ligands for these cells have not been identified. We show that a lysosomal glycosphingolipid of previously unknown function, isoglobotrihexosylceramide (iGb3), is recognized both by mouse and human NKT cells. Impaired generation of lysosomal iGb3 in mice lacking beta-hexosaminidase b results in severe NKT cell deficiency, suggesting that this lipid also mediates development of NKT cells in the mouse. We suggest that expression of iGb3 in peripheral tissues may be involved in controlling NKT cell responses to infections and malignancy and in autoimmunity.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; Univ New Hampshire, Dept Chem, Durham, NH 03824 USA	University of Chicago; Scripps Research Institute; Brigham Young University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Gothenburg; Chinese Academy of Sciences; Institute of Biophysics, CAS; University System Of New Hampshire; University of New Hampshire	Zhou, DP (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	dzhou@midway.uchicago.edu; abendela@bsd.uchicago.edu	Savage, Paul B/HGB-3414-2022; Zhou, Dapeng/A-6446-2019; Savage, Paul B/E-1448-2011; Yin, NIng/C-8991-2011; zhou, dapeng/GXG-9715-2022; Mattner, Jochen/AAT-7866-2021; Proia, Richard L/A-7908-2012	Savage, Paul B/0000-0002-4642-6109; Zhou, Dapeng/0000-0003-1347-3811; Savage, Paul B/0000-0002-4642-6109; Proia, Richard/0000-0003-0456-1270	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI053725, R01AI050847, R01AI038339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK056000] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR16459] Funding Source: Medline; NIAID NIH HHS [AI053725, AI50847, R01 AI38339] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Beaudoin L, 2002, IMMUNITY, V17, P725, DOI 10.1016/S1074-7613(02)00473-9; Bendelac A, 2004, NAT IMMUNOL, V5, P557, DOI 10.1038/ni0604-557; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Cantu C, 2003, J IMMUNOL, V170, P4673, DOI 10.4049/jimmunol.170.9.4673; Chiu YH, 2002, NAT IMMUNOL, V3, P55, DOI 10.1038/ni740; Conzelmann E, 1980, Adv Exp Med Biol, V125, P295; Fischer K, 2004, P NATL ACAD SCI USA, V101, P10685, DOI 10.1073/pnas.0403787101; Galili U, 1999, Subcell Biochem, V32, P79; Gumperz JE, 2000, IMMUNITY, V12, P211, DOI 10.1016/S1074-7613(00)80174-0; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Honey K, 2002, NAT IMMUNOL, V3, P1069, DOI 10.1038/ni844; Kang SJ, 2004, NAT IMMUNOL, V5, P175, DOI 10.1038/ni1034; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Keusch JJ, 2000, J BIOL CHEM, V275, P25308, DOI 10.1074/jbc.M002629200; Prigozy TI, 2001, SCIENCE, V291, P664, DOI 10.1126/science.291.5504.664; Proia RL, 2003, PHILOS T R SOC B, V358, P879, DOI 10.1098/rstb.2003.1268; Sandhoff K, 2003, PHILOS T R SOC B, V358, P847, DOI 10.1098/rstb.2003.1265; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Smyth MJ, 2000, NAT IMMUNOL, V1, P459, DOI 10.1038/82698; Stanic AK, 2003, P NATL ACAD SCI USA, V100, P1849, DOI 10.1073/pnas.0430327100; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Teneberg S, 2004, GLYCOBIOLOGY, V14, P187, DOI 10.1093/glycob/cwh015; Winau F, 2004, NAT IMMUNOL, V5, P169, DOI 10.1038/ni1035; Wu DY, 2003, J EXP MED, V198, P173, DOI 10.1084/jem.20030446; Xu H, 2002, TRANSPLANTATION, V73, P1549, DOI 10.1097/00007890-200205270-00006; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; Zhou D., UNPUB; Zhou DP, 2004, SCIENCE, V303, P523, DOI 10.1126/science.1092009	32	784	838	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	2004	306	5702					1786	1789		10.1126/science.1103440	http://dx.doi.org/10.1126/science.1103440			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	878FA	15539565				2022-12-28	WOS:000225630800056
J	Iizuka, N; Hamamoto, Y; Oka, M				Iizuka, N; Hamamoto, Y; Oka, M			Predicting individual outcomes in hepatocellular carcinoma	LANCET			English	Editorial Material							GENE-EXPRESSION PROFILES; OLIGONUCLEOTIDE MICROARRAY; RECURRENCE		Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan; Yamaguchi Univ, Fac Engn, Dept Comp Sci & Syst Engn, Yamaguchi, Japan	Yamaguchi University; Yamaguchi University	Iizuka, N (corresponding author), Yamaguchi Univ, Sch Med, Dept Surg 2, Yamaguchi 7558505, Japan.	iizuka@yamaguchi-u.ac.jp						Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Iizuka N, 2002, CANCER RES, V62, P3939; Iizuka N, 2003, LANCET, V361, P923, DOI 10.1016/S0140-6736(03)12775-4; Kurokawa Y, 2004, J HEPATOL, V41, P284, DOI 10.1016/j.jhep.2004.04.031; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Llovet JM, 2004, J HEPATOL, V41, P336, DOI 10.1016/j.jhep.2004.06.002; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Locker J, 2004, HEPATOLOGY, V40, P521, DOI 10.1002/hep.20368; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	11	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1837	1839		10.1016/S0140-6736(04)17455-2	http://dx.doi.org/10.1016/S0140-6736(04)17455-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555651				2022-12-28	WOS:000225269300007
J	Zimmermann, R; Strauss, JG; Haemmerle, G; Schoiswohl, G; Birner-Gruenberger, R; Riederer, M; Lass, A; Neuberger, G; Eisenhaber, F; Hermetter, A; Zechner, R				Zimmermann, R; Strauss, JG; Haemmerle, G; Schoiswohl, G; Birner-Gruenberger, R; Riederer, M; Lass, A; Neuberger, G; Eisenhaber, F; Hermetter, A; Zechner, R			Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase	SCIENCE			English	Article							HORMONE-SENSITIVE LIPASE; ADIPOCYTE; DEFICIENCY; METABOLISM; PROTEIN; OBESITY	Mobilization of fatty acids from triglyceride stores in adipose tissue requires lipolytic enzymes. Dysfunctional lipolysis affects energy homeostasis and may contribute to the pathogenesis of obesity and insulin resistance. Until now, hormone-sensitive lipase (HSL) was the only enzyme known to hydrolyze triglycerides in mammalian adipose tissue. Here, we report that a second enzyme, adipose triglyceride lipase (ATGL), catalyzes the initial step in triglyceride hydrolysis. It is interesting that ATGL contains a "patatin domain" common to plant acyl-hydrolases. ATGL is highly expressed in adipose tissue of mice and humans. It exhibits high substrate specificity for triacylglycerol and is associated with lipid droplets. Inhibition of ATGL markedly decreases total adipose acyl-hydrolase activity. Thus, ATGL and HSL coordinately catabolize stored triglycerides in adipose tissue of mammals.	Graz Univ, Inst Mol Biosci, Graz, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria; Graz Univ Technol, Inst Biochem, A-8010 Graz, Austria	University of Graz; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Graz University of Technology	Zechner, R (corresponding author), Graz Univ, Inst Mol Biosci, Graz, Austria.	rudolf.zechner@uni-graz.at	Adiels, Martin/C-9278-2011; Birner-Gruenberger, Ruth/E-8623-2010; Lass, Achim/C-3332-2008; Birner-Gruenberger, Ruth/X-9433-2019	Birner-Gruenberger, Ruth/0000-0003-3950-0312; Lass, Achim/0000-0002-8190-7151; Birner-Gruenberger, Ruth/0000-0003-3950-0312; Haemmerle, Guenter/0000-0001-9900-5896; Zechner, Rudolf/0000-0001-5483-1182; Zimmermann, Robert/0000-0002-7354-870X; Schoiswohl, Gabriele/0000-0002-7346-2834; Bogner-Strauss, Juliane/0000-0003-2459-0124				ALTHENSTAEDT K, 2003, J BIOL CHEM, V278, P23317; Arner P, 2002, DIABETES-METAB RES, V18, pS5, DOI 10.1002/dmrr.254; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bergman RN, 2001, J INVEST MED, V49, P119, DOI 10.2310/6650.2001.34108; Blaak EE, 2003, P NUTR SOC, V62, P753, DOI 10.1079/PNS2003290; Boden G, 2002, EUR J CLIN INVEST, V32, P14, DOI 10.1046/j.1365-2362.32.s3.3.x; Collins S, 2001, RECENT PROG HORM RES, V56, P309, DOI 10.1210/rp.56.1.309; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; FREDRIKSON G, 1986, BIOCHIM BIOPHYS ACTA, V876, P288, DOI 10.1016/0005-2760(86)90286-9; FREDRIKSON G, 1981, J BIOL CHEM, V256, P6311; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; Jenkins CM, 2004, J BIOL CHEM, V279, P48968, DOI 10.1074/jbc.M407841200; Okazaki H, 2002, DIABETES, V51, P3368, DOI 10.2337/diabetes.51.12.3368; Oskolkova OV, 2003, CHEM PHYS LIPIDS, V125, P103, DOI 10.1016/S0009-3084(03)00085-9; Shewry PR, 2003, ANN BOT-LONDON, V91, P755, DOI 10.1093/aob/mcg084; Sztalryd C, 2003, J CELL BIOL, V161, P1093, DOI 10.1083/jcb.200210169; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; Villena JA, 2004, J BIOL CHEM, V279, P47066, DOI 10.1074/jbc.M403855200; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; YEAMAN SJ, 1994, ADV ENZYME REGUL, V34, P355, DOI 10.1016/0065-2571(94)90022-1; ZIMMERMAN R, UNPUB; Zimmermann R, 2003, J LIPID RES, V44, P2089, DOI 10.1194/jlr.M300190-JLR200	23	1448	1563	6	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1383	1386		10.1126/science.1100747	http://dx.doi.org/10.1126/science.1100747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550674				2022-12-28	WOS:000225301600055
J	Singh, SK; Hawkins, C; Clarke, ID; Squire, JA; Bayani, J; Hide, T; Henkelman, RM; Cusimano, MD; Dirks, PB				Singh, SK; Hawkins, C; Clarke, ID; Squire, JA; Bayani, J; Hide, T; Henkelman, RM; Cusimano, MD; Dirks, PB			Identification of human brain tumour initiating cells	NATURE			English	Article							ACUTE MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; STEM-LIKE CELLS; CANCER; HIERARCHY; ANTIGEN	The cancer stem cell (CSC) hypothesis suggests that neoplastic clones are maintained exclusively by a rare fraction of cells with stem cell properties(1,2). Although the existence of CSCs in human leukaemia is established(3,4), little evidence exists for CSCs in solid tumours, except for breast cancer(5). Recently, we prospectively isolated a CD133(+) cell subpopulation from human brain tumours that exhibited stem cell properties in vitro(6). However, the true measures of CSCs are their capacity for self renewal and exact recapitulation of the original tumour(1,2,7). Here we report the development of a xenograft assay that identified human brain tumour initiating cells that initiate tumours in vivo. Only the CD133(+) brain tumour fraction contains cells that are capable of tumour initiation in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mouse brains. Injection of as few as 100 CD133(+) cells produced a tumour that could be serially transplanted and was a phenocopy of the patient's original tumour, whereas injection of 10 5 CD133(-) cells engrafted but did not cause a tumour. Thus, the identification of brain tumour initiating cells provides insights into human brain tumour pathogenesis, giving strong support for the CSC hypothesis as the basis for many solid tumours(5), and establishes a previously unidentified cellular target for more effective cancer therapies.	Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Div Neurosurg, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Integrat Biol Program, Toronto, ON M5G 1X8, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto, ON M5G 2M9, Canada; St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON M5B 1W8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Dirks, PB (corresponding author), Univ Toronto, Hosp Sick Children, Arthur & Sonia Labatt brain Tumor Res Ctr, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	peter.dirks@sickkids.ca	Singh, Sheila K/W-2799-2018; Cusimano, Michael/X-4059-2019; Cusimano, Michael/GWR-1025-2022; Squire, Jeremy/A-9352-2012	Singh, Sheila K/0000-0003-1272-5300; Squire, Jeremy/0000-0002-9863-468X; Cusimano, Michael/0000-0002-9989-0650				Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Corbeil D, 1998, BLOOD, V91, P2625, DOI 10.1182/blood.V91.7.2625.2625_2625_2626; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Dick JE, 2003, P NATL ACAD SCI USA, V100, P3547, DOI 10.1073/pnas.0830967100; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; HOUCHENS DP, 1983, EUR J CANCER CLIN ON, V19, P799, DOI 10.1016/0277-5379(83)90012-3; Hu B, 2003, P NATL ACAD SCI USA, V100, P8904, DOI 10.1073/pnas.1533394100; Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Oliver TG, 2004, NEURON, V42, P885, DOI 10.1016/j.neuron.2004.06.011; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Potgens AJG, 2001, PLACENTA, V22, P639, DOI 10.1053/plac.2001.0701; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Russell D.S., 1989, PATHOLOGY TUMORS CEN; Singh SK, 2003, CANCER RES, V63, P5821; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720	28	5587	6029	13	647	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	2004	432	7015					396	401		10.1038/nature03128	http://dx.doi.org/10.1038/nature03128			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	871UX	15549107				2022-12-28	WOS:000225161400057
J	Stoll, BJ; Hansen, NI; Adams-Chapman, I; Fanaroff, AA; Hintz, SR; Vohr, B; Higgins, RD				Stoll, BJ; Hansen, NI; Adams-Chapman, I; Fanaroff, AA; Hintz, SR; Vohr, B; Higgins, RD			Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WHITE-MATTER DAMAGE; CEREBRAL-PALSY; BRAIN-DAMAGE; PERIVENTRICULAR LEUKOMALACIA; INTRAUTERINE INFECTION; PERINATAL INFECTION; PRETERM INFANT; NECROTIZING ENTEROCOLITIS; NATIONAL-INSTITUTE; RESEARCH NETWORK	Context Neonatal infections are frequent complications of extremely low-birth-weight (ELBW) infants receiving intensive care. Objective To determine if neonatal infections in ELBW infants are associated with increased risks of adverse neurodevelopmental and growth sequelae in early childhood. Design, Setting, and Participants Infants weighing 401 to 1000 g at birth (born in 1993-2001) were enrolled in a prospectively collected very low-birth-weight registry at academic medical centers participating in the National Institute of Child Health and Human Development Neonatal Research Network. Neurodevelopmental and growth outcomes were assessed at a comprehensive follow-up visit at 18 to 22 months of corrected gestational age and compared by infection group. Eighty percent of survivors completed the follow-up visit and 6093 infants were studied. Registry data were used to classify infants by type of infection: uninfected (n=2161), clinical infection alone (n=1538), sepsis (n=1922), sepsis and necrotizing enterocolitis (n=279), or meningitis with or without sepsis (n=193). Main Outcome Measures Cognitive and neuromotor development, neurologic status, vision and hearing, and growth (weight, length, and head circumference) were assessed at follow-up. Results The majority of ELBW survivors (65%) had at least 1 infection during their hospitalization after birth. Compared with uninfected infants, those in each of the 4 infection groups were significantly more likely to have adverse neurodevelopmental outcomes at follow-up, including cerebral palsy (range of significant odds ratios [ORs], 1.4-1.7), low Bayley Scales of Infant Development II scores on the mental development index (ORs, 1.3-1.6) and psychomotor development index (ORs, 1.5-2.4), and vision impairment (ORs, 1.3-2.2). Infection in the neonatal period was also associated with impaired head growth, a known predictor of poor neurodevelopmental outcome. Conclusions This large cohort study suggests that neonatal infections among ELBW infants are associated with poor neurodevelopmental and growth outcomes in early childhood. Additional studies are needed to elucidate the pathogenesis of brain injury in infants with infection so that novel interventions to improve these outcomes can be explored.	Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Stanford Univ, Med Ctr, Div Neonatol, Palo Alto, CA 94304 USA; Brown Univ, Dept Pediat, Providence, RI 02912 USA; NICHHD, Bethesda, MD 20892 USA	Emory University; Research Triangle Institute; Case Western Reserve University; Stanford University; Brown University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stoll, BJ (corresponding author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.			Hintz, Susan/0000-0001-7023-4433; Hansen, Nellie/0000-0003-4794-9646	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD040689, U10HD021364, U10HD040461, U10HD040492, U10HD034216, U10HD027904, U10HD027856, U10HD021385, U10HD027871, U10HD027853, U10HD027880, U10HD021373, U10HD027851] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD021415, U10HD027881, U10HD034167, U10HD040521, U10HD040498, U10HD021397, U01HD036790, U01HD019897] Funding Source: NIH RePORTER; NICHD NIH HHS [U10 HD40461, U10 HD40492, U10 HD40498, U10 HD40521, U10 HD40689, U01 HD19897, U01 HD36790, U10 HD21364, U10 HD21373, U10 HD21385, U10 HD21397, U10 HD21415, U10 HD27851, U10 HD27853, U10 HD27856, U10 HD27871, U10 HD27880, U10 HD27881, U10 HD27904, U10 HD34167, U10 HD34216] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexander GR, 1996, OBSTET GYNECOL, V87, P163, DOI 10.1016/0029-7844(95)00386-X; Back SA, 2002, J NEUROSCI, V22, P455, DOI 10.1523/JNEUROSCI.22-02-00455.2002; BAYLEY N, 1993, BAYLEY SCALES INFANT, V2; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Boylan GB, 2000, PEDIATR RES, V48, P12, DOI 10.1203/00006450-200007000-00005; Dammann O, 2000, J PEDIATR-US, V136, P433, DOI 10.1016/S0022-3476(00)90004-0; Dammann O, 2002, MENT RETARD DEV D R, V8, P46, DOI 10.1002/mrdd.10005; Dammann O, 1997, PEDIATR RES, V42, P1, DOI 10.1203/00006450-199707000-00001; Dammann O, 2001, TRENDS NEUROSCI, V24, P320, DOI 10.1016/S0166-2236(00)01811-7; Dammann O, 2000, CURR OPIN PEDIATR, V12, P99, DOI 10.1097/00008480-200004000-00002; Deguchi K, 1996, PEDIATR NEUROL, V14, P13, DOI 10.1016/0887-8994(95)00223-5; Dommergues MA, 2000, ANN NEUROL, V47, P54, DOI 10.1002/1531-8249(200001)47:1<54::AID-ANA10>3.3.CO;2-P; Dusick AM, 2003, SEMIN PERINATOL, V27, P302, DOI 10.1016/S0146-0005(03)00044-2; Dusick Anna, 1998, Pediatric Research, V43, p213A; Eschenbach DA, 1997, JAMA-J AM MED ASSOC, V278, P247, DOI 10.1001/jama.278.3.247; FAIX RG, 1985, PEDIATRICS, V76, P415; Fanaroff AA, 1999, NEW ENGL J MED, V341, P1229, DOI 10.1056/NEJM199910143411611; Fischel-Ghodsian N, 1999, ANN NY ACAD SCI, V884, P99, DOI 10.1111/j.1749-6632.1999.tb08639.x; Hack M, 2000, ARCH PEDIAT ADOL MED, V154, P725, DOI 10.1001/archpedi.154.7.725; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1989, AM J DIS CHILD, V143, P63, DOI 10.1001/archpedi.1989.02150130073018; HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403; Jeohn GH, 1998, J NEUROIMMUNOL, V85, P1, DOI 10.1016/S0165-5728(97)00204-X; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; Leviton A, 2002, NEUROPEDIATRICS, V33, P281, DOI 10.1055/s-2002-37089; LEVITON A, 1973, J NEUROL SCI, V18, P53, DOI 10.1016/0022-510X(73)90020-8; Lorenz JM, 1998, ARCH PEDIAT ADOL MED, V152, P425, DOI 10.1001/archpedi.152.5.425; Msall M E, 1994, J Perinatol, V14, P41; Murphy DJ, 1997, BMJ-BRIT MED J, V314, P404, DOI 10.1136/bmj.314.7078.404; Nelson KB, 2002, MENT RETARD DEV D R, V8, P1, DOI 10.1002/mrdd.10010; O'Shea TM, 1998, PAEDIATR PERINAT EP, V12, P72; O'Shea TM, 1998, PEDIATRICS, V101, P642, DOI 10.1542/peds.101.4.642; O'Shea TM, 2002, MENT RETARD DEV D R, V8, P135, DOI 10.1002/mrdd.10032; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Perlman JM, 1998, EARLY HUM DEV, V53, P99, DOI 10.1016/S0378-3782(98)00037-1; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; SAS Institute Inc, 1999, SAS STAT US GUID VER; Schendel DE, 2002, MENT RETARD DEV D R, V8, P39, DOI 10.1002/mrdd.10011; Stoll BJ, 2004, PEDIATRICS, V113, P1181, DOI 10.1542/peds.113.5.1181; Stoll BJ, 2002, PEDIATRICS, V110, P285, DOI 10.1542/peds.110.2.285; Tang HY, 2002, GENET MED, V4, P336, DOI 10.1097/00125817-200209000-00004; Thomas P, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.2.e21; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Wheater M, 2000, DEV MED CHILD NEUROL, V42, P364, DOI 10.1017/S0012162200000670; WILLOUGHBY RE, 1994, CLIN PERINATOL, V21, P307, DOI 10.1016/S0095-5108(18)30347-6; Wu YW, 2000, JAMA-J AM MED ASSOC, V284, P1417, DOI 10.1001/jama.284.11.1417; Yoon BH, 2000, AM J OBSTET GYNECOL, V182, P675, DOI 10.1067/mob.2000.104207; Yoon BH, 2003, BJOG-INT J OBSTET GY, V110, P124, DOI 10.1016/S1470-0328(03)00063-6	51	1026	1076	1	48	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2004	292	19					2357	2365		10.1001/jama.292.19.2357	http://dx.doi.org/10.1001/jama.292.19.2357			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PL	15547163	Bronze			2022-12-28	WOS:000225070100024
J	Fang, MC; Chang, YC; Hylek, EM; Rosand, J; Greenberg, SM; Go, AS; Singer, DE				Fang, MC; Chang, YC; Hylek, EM; Rosand, J; Greenberg, SM; Go, AS; Singer, DE			Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation	ANNALS OF INTERNAL MEDICINE			English	Article							BLEEDING COMPLICATIONS; ORAL ANTICOAGULATION; PHYSICIAN ATTITUDES; STROKE PREVENTION; THERAPY; METAANALYSIS; PREVALENCE; PREDICTION; ASPIRIN; OUTPATIENTS	Background: The risk for atrial fibrillation-associated stroke increases at low anticoagulation intensities. However, higher intensities increase hemorrhage risk. Optimal use of warfarin for atrial fibrillation requires precise information on the risk for intracranial hemorrhage as a function of patient age and anticoagulation intensity. Objective: To examine the relationship of age, anticoagulation intensity, and risk for intracranial hemorrhage. Design: Case-control study. Setting: Academic medical center. Patients: 170 case-patients who developed intracranial hemorrhage during warfarin therapy and 1020 matched controls who did not; both case-patients and controls were taking warfarin for atrial fibrillation. Measurements: The authors performed multivariable conditional logistic regression to determine the odds of intracranial hemorrhage with regard to age and international normalized ratio (INR), controlling for comorbid conditions and aspirin use. Results: Case-patients were older than controls (median age, 78 years vs. 75 years; P < 0.001) and had higher median INRs (2.7 vs. 2.3; P < 0.001). The risk for intracranial hemorrhage increased at 85 years of age or older (adjusted odds ratio, 2.5 [95% CI, 1.3 to 4.7]; referent age, 70 to 74 years) and at an INR range of 3.5 to 3.9 (adjusted odds ratio, 4.6 [CI, 2.3 to 9.4]; referent INR, 2.0 to 3.0). The risk for intracranial hemorrhage at INRs less than 2.0 did not differ statistically from the risk at INRs of 2.0 to 3.0 (adjusted odds ratio, 1.3 [CI, 0.8 to 2.2]). Limitations: Although duration of anticoagulation has been associated with hemorrhage in other studies, the current study could not control for this potential confounder. Conclusions: The risk for intracranial hemorrhage increases at age 85 years. International normalized ratios less than 2.0 were not associated with lower risk for intracranial hemorrhage compared with INRs between 2.0 and 3.0. Therefore, anticoagulation management should focus on maintaining INRs in the 2.0 to 3.0 range, even in elderly patients with atrial fibrillation, rather than targeting INRs less than 2.0. Similarly, INRs of 3.5 or greater should be avoided.	Univ Calif San Francisco, Div Gen Internal Med, Hospitalist Grp, San Francisco, CA 94143 USA; Kaiser Permanente, Oakland, CA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	University of California System; University of California San Francisco; Kaiser Permanente; Harvard University; Massachusetts General Hospital	Fang, MC (corresponding author), Univ Calif San Francisco, Div Gen Internal Med, Hospitalist Grp, 533 Parnassus Ave,Box 0131, San Francisco, CA 94143 USA.	mfang@medicine.ucsf.edu	Hug, Balthasar L./G-1568-2010; Go, Alan S./AAE-7745-2019; Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hylek, Elaine/0000-0001-8263-8304	NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER; NIA NIH HHS [AG15478] Funding Source: Medline; PHS HHS [5T32-HP-11001-14] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Antani MR, 1996, J GEN INTERN MED, V11, P713, DOI 10.1007/BF02598984; Arboix A, 2002, J AM GERIATR SOC, V50, P449, DOI 10.1046/j.1532-5415.2002.50109.x; Berwaerts J, 2000, STROKE, V31, P2558, DOI 10.1161/01.STR.31.11.2558; Berwaerts J, 2000, QJM-MON J ASSOC PHYS, V93, P513, DOI 10.1093/qjmed/93.8.513; Beyth RJ, 1996, J GEN INTERN MED, V11, P721, DOI 10.1007/BF02598985; Bungard TJ, 2000, ARCH INTERN MED, V160, P41, DOI 10.1001/archinte.160.1.41; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; Fang MC, 2004, ARCH INTERN MED, V164, P55, DOI 10.1001/archinte.164.1.55; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; Franke CL, 1997, ANN NEUROL, V42, P857; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; Fuster V, 2001, J AM COLL CARDIOL, V38, P1231, DOI 10.1016/S0735-1097(01)01587-X; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Gorter JW, 1999, NEUROLOGY, V53, P1319, DOI 10.1212/WNL.53.6.1319; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2000, ARCH NEUROL-CHICAGO, V57, P326, DOI 10.1001/archneur.57.3.326; He J, 1998, JAMA-J AM MED ASSOC, V280, P1930, DOI 10.1001/jama.280.22.1930; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hylek EM, 2003, NEW ENGL J MED, V349, P1019, DOI 10.1056/NEJMoa022913; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; Hylek EM, 2001, ANN INTERN MED, V135, P393, DOI 10.7326/0003-4819-135-6-200109180-00008; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887; Lackie CL, 2002, ANN PHARMACOTHER, V36, P200; LANDEFELD CS, 1989, AM J MED, V87, P144; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Levine MN, 2001, CHEST, V119, p108S, DOI 10.1378/chest.119.1_suppl.108S; MCBRIDE R, 1994, LANCET, V343, P687; MCCRORY DC, 1995, ARCH INTERN MED, V155, P277, DOI 10.1001/archinte.155.3.277; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; Palareti G, 2000, ARCH INTERN MED, V160, P470, DOI 10.1001/archinte.160.4.470; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Rosand J, 2000, NEUROLOGY, V55, P947, DOI 10.1212/WNL.55.7.947; ROSENBAUM PR, 1991, BIOMETRICS, V47, P87, DOI 10.2307/2532498; Rothman K., 1998, MODERN EPIDEMIOLOGY; Rubin DB., 1987, MULTIPLE IMPUTATION, DOI 10.1002/9780470316696; Segal JB, 2000, J GEN INTERN MED, V15, P56, DOI 10.1046/j.1525-1497.2000.04329.x; Smith EE, 2002, NEUROLOGY, V59, P193, DOI 10.1212/WNL.59.2.193; Thrift AG, 1996, STROKE, V27, P2020, DOI 10.1161/01.STR.27.11.2020; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; Vermeer SE, 2002, NEUROLOGY, V59, P205, DOI 10.1212/WNL.59.2.205; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	47	388	409	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					745	752		10.7326/0003-4819-141-10-200411160-00005	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545674				2022-12-28	WOS:000225206900001
J	Perez, F; Orne-Gliemann, J; Mukotekwa, T; Miller, A; Glenshaw, M; Mahomva, A; Dabis, F				Perez, F; Orne-Gliemann, J; Mukotekwa, T; Miller, A; Glenshaw, M; Mahomva, A; Dabis, F			Prevention of mother to child transmission of HIV: evaluation of a pilot programme in a district hospital in rural Zimbabwe	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLED-TRIAL; COTE-DIVOIRE; DOUBLE-BLIND; ZIDOVUDINE; NEVIRAPINE; AFRICA; INTRAPARTUM; LAMIVUDINE; EFFICACY	Problem Zimbabwe has one of the highest rates of HIV seroprevalence in the world. In 2001 only 4% of women and children in need of services for prevention of mother to child transmission of HIV were receiving them. Design Pilot implementation of the first programme for prevention of mother to child transmission of HIV in rural Zimbabwe. Setting 120 bed district hospital in Buhera district (285 000 inhabitants), Manicaland, Zimbabwe. Key measures for improvement Programme uptake indicators monitored for 18 months; impact of policy evaluated by assessing up-scaling of programme. Strategies for change Voluntary counselling and testing services for HIV were provided in the hospital antenatal clinic. Women identified as HIV positive and informed of their serostatus and their newborn were offered a single dose antiretroviral treatment of nevirapine; mother-child pairs were followed up through routine health services. Nursing staff and social workers were trained, and community mobilisation was conducted. Effects of change No services for prevention of mother to child transmission of HIV were available at baseline. Within 18 months, 2298 pregnant women had received pretest counselling, and the acceptance of HIV testing reached 93.0%. Of all 2137 women who had an HIV test, 1588 (74.3%) returned to collect their result; 326 of the 437 HIV positive women diagnosed had post-test counselling, and 104 (24%) mother-child pairs received nevirapine prophylaxis. Lessons learnt Minimum staffing, an enhanced training programme, and involvement of district health authorities are needed for the implementation and successful integration of services for prevention of mother to child transmission of HIV. Voluntary counselling and testing services are important entry points for HIV prevention and care and for referral to community networks and medical HIV care services. A district approach is critical to extend programmes for prevention of mother to child transmission of HIV in rural settings. The lessons learnt from this pilot programme have contributed to the design of the national expansion strategy for prevention of mother to child transmission of HIV in Zimbabwe.	Univ Bordeaux 2, ISPED, F-33076 Bordeaux, France; Minist Hlth & Child Welf, PMTCT Unit, AIDS & TB Programme, Harare, Zimbabwe	UDICE-French Research Universities; Universite de Bordeaux	Perez, F (corresponding author), Univ Bordeaux 2, ISPED, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Freddy.Perez@isped.u-bordeaux2.fr	Orne-Gliemann, Joanna/T-2787-2019; Perez, Freddy/AAN-3893-2020; DABIS, FRANCOIS/S-9298-2019	DABIS, FRANCOIS/0000-0002-1614-8857; Perez, Freddy/0000-0003-2001-0057				Dabis F, 2002, LANCET, V359, P2097, DOI 10.1016/S0140-6736(02)08909-2; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; Gregson S., 2001, Zimbabwe Science News, V35, P27; Horwood C, 2003, B WORLD HEALTH ORGAN, V81, P858; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; *MIN HLTH CHILD WE, 2003, PREV MOTH CHILD TRAN; *MIN HLTH CHILD WE, 2001, REP CONS PROV MED DI; *MIN HLTH CHILD WE, 2001, NAT ACT PLAN US NEV; *MIN HLTH CHILD WE, 2003, ZIMB NAT HIV AIDS ES; Mitka M, 2002, JAMA-J AM MED ASSOC, V288, P153, DOI 10.1001/jama.288.2.153; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Msellati P, 2001, B WORLD HEALTH ORGAN, V79, P641; Olliaro PL, 1995, B WORLD HEALTH ORGAN, V73, P735; Perez-Then E, 2003, JAIDS-J ACQ IMM DEF, V34, P506, DOI 10.1097/00126334-200312150-00010; Saba J, 2002, LANCET, V359, P1178; Saman M, 2002, AIDS, V16, P950, DOI 10.1097/00002030-200204120-00025; Songok EM, 2003, AM J TROP MED HYG, V69, P8, DOI 10.4269/ajtmh.2003.69.8; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Stringer JSA, 2003, LANCET, V362, P1850, DOI 10.1016/S0140-6736(03)14907-0; Temmerman M, 2003, AIDS, V17, P1239, DOI 10.1097/00002030-200305230-00016; UNAIDS, 2003, REP GLOB HIV AIDS EP; *WHO, 2001, HLTH SECT RESP HIV A; *WHO, 2004, ANT DRUGS PREV MOTH	23	57	57	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	2004	329	7475					1147	1150		10.1136/bmj.329.7475.1147	http://dx.doi.org/10.1136/bmj.329.7475.1147			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539670	Green Published			2022-12-28	WOS:000225169600021
J	Reidenberg, MM; Walley, T				Reidenberg, MM; Walley, T			Commentary: The pros and cons of essential medicines for rich countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Cornell Univ, Weill Med Coll, New York, NY 10021 USA; Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GF, Merseyside, England	Cornell University; University of Liverpool	Reidenberg, MM (corresponding author), Cornell Univ, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.	mmreid@med.cornell.edu						*AUSTR GOV, PHARM BEN SCHEM EXP; Bero LA, 1998, BMJ-BRIT MED J, V317, P465; Drahos P, 2004, BMJ-BRIT MED J, V328, P1271, DOI 10.1136/bmj.328.7451.1271; Hogerzeil HV, 2004, BRIT MED J, V329, P1169, DOI 10.1136/bmj.329.7475.1169; Kremer JM, 2001, ANN INTERN MED, V134, P695, DOI 10.7326/0003-4819-134-8-200104170-00013	5	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 13	2004	329	7475					1172	1172		10.1136/bmj.329.7475.1172	http://dx.doi.org/10.1136/bmj.329.7475.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871XJ	15539677	Green Published			2022-12-28	WOS:000225169600030
J	Fleming, A; Osley, MA				Fleming, A; Osley, MA			Silence of the rings	CELL			English	Editorial Material							TRANSCRIPTIONAL ACTIVATION; H2B UBIQUITYLATION; HISTONE H2B; PROTEIN; UBIQUITINATION		Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA	University of New Mexico	Fleming, A (corresponding author), Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA.							Baarends WM, 1999, DEV BIOL, V207, P322, DOI 10.1006/dbio.1998.9155; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; FANG J, 2004, IN PRESS J BIOL CHEM; GOLDKNOPF IL, 1975, J BIOL CHEM, V250, P7182; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; Osley MA, 2004, BBA-GENE STRUCT EXPR, V1677, P74, DOI 10.1016/j.bbaexp.2003.10.013; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985	14	5	6	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	2004	119	4					449	451		10.1016/j.cell.2004.11.001	http://dx.doi.org/10.1016/j.cell.2004.11.001			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	872CI	15537534	Bronze			2022-12-28	WOS:000225183200003
J	Rice, M				Rice, M			Superfluid helium-3 has a metallic partner	SCIENCE			English	Editorial Material							SUPERCONDUCTIVITY; SR2RUO4; PHYSICS		ETH Honggerberg, Inst Theoret Phys, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Rice, M (corresponding author), ETH Honggerberg, Inst Theoret Phys, CH-8093 Zurich, Switzerland.	maurice.rice@itp.phys.ethz.ch						Anderson PW, 2004, J PHYS-CONDENS MAT, V16, pR755, DOI 10.1088/0953-8984/16/24/R02; BARDEEN J, 1957, PHYS REV, V108, P1175, DOI 10.1103/PhysRev.108.1175; GESHKENBEIN VB, 1987, PHYS REV B, V36, P235, DOI 10.1103/PhysRevB.36.235; Mackenzie AP, 2003, REV MOD PHYS, V75, P657, DOI 10.1103/RevModPhys.75.657; MAENO Y, 1994, NATURE, V372, P32; Nelson KD, 2004, SCIENCE, V306, P1151, DOI 10.1126/science.1103881; RICE TM, 1995, J PHYS-CONDENS MAT, V7, pL643, DOI 10.1088/0953-8984/7/47/002; THALMEIER P, IN PRESS CONDENS MAT	10	13	13	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1142	1143		10.1126/science.1106019	http://dx.doi.org/10.1126/science.1106019			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539590				2022-12-28	WOS:000225193100033
J	Altman, DE; Clancy, C; Blendon, RJ				Altman, DE; Clancy, C; Blendon, RJ			Improving patient safety - Five years after the IOM report	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL ERRORS		Kaiser Family Fdn, Menlo Pk, CA 94025 USA; Agcy Healthcare Res & Qual, Rockville, MD USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Agency for Healthcare Research & Quality; Harvard University; Harvard T.H. Chan School of Public Health	Altman, DE (corresponding author), Kaiser Family Fdn, Menlo Pk, CA 94025 USA.							[Anonymous], 2004, NAT SURV CONS EXP PA; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; *LEAPFR GROUP, 2004, LEAPFR GROUP HOSP PA; *ROP CTR PUBL OP R, 2000, GALL POLL	5	151	156	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2041	2043		10.1056/NEJMp048243	http://dx.doi.org/10.1056/NEJMp048243			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537902				2022-12-28	WOS:000225007200003
J	Townes, CH				Townes, CH			Making waves	NATURE			English	Editorial Material									Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Townes, CH (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.								0	3	3	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	2004	432	7014					153	153		10.1038/432153a	http://dx.doi.org/10.1038/432153a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538346				2022-12-28	WOS:000225020200022
J	Van Hoof, C; Baert, K; Witvrouw, A				Van Hoof, C; Baert, K; Witvrouw, A			The best materials for tiny, clever sensors	SCIENCE			English	Editorial Material									IMEC, Microsyst Components & Packaging Div, B-3001 Louvain, Belgium	IMEC	Van Hoof, C (corresponding author), IMEC, Microsyst Components & Packaging Div, Kapeldreef 75, B-3001 Louvain, Belgium.	chris.vanhoof@imec.be	Witvrouw, Ann/P-5180-2018	Witvrouw, Ann/0000-0003-3693-9290; Van Hoof, Chris/0000-0002-4645-3326				ENDER F, 2004, APPL PHYS LETT, V84, P2673; Franke AE, 2003, J MICROELECTROMECH S, V12, P160, DOI 10.1109/JMEMS.2002.805051; Hornbeck LJ, 1997, P SOC PHOTO-OPT INS, V3013, P27, DOI 10.1117/12.273880; KUEHNEL W, 1994, SENSOR ACTUAT A-PHYS, V45, P7, DOI 10.1016/0924-4247(94)00815-9; LIN BCY, 2004, P MRS, V782, P43; Mehta A, 2004, PROC IEEE MICR ELECT, P721, DOI 10.1109/MEMS.2004.1290686; Sedky S, 2002, SENSOR ACTUAT A-PHYS, V97-8, P503, DOI 10.1016/S0924-4247(01)00811-1; SMITH JH, 1995, P INT EL DEV M WASH, P609	8	14	14	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					986	987						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528433				2022-12-28	WOS:000225001100029
J	Chen, L; Evans, T; Anand, S; Boufford, JI; Brown, H; Chowdhury, M; Cueto, M; Dare, L; Dussault, G; Elzinga, G; Fee, E; Habte, D; Hanvoravongchai, P; Jacobs, M; Kurowski, C; Michael, S; Pablos-Mendez, A; Sewankambo, N; Solimano, G; Stilwell, B; de Waal, A; Wibulpolprasert, S				Chen, L; Evans, T; Anand, S; Boufford, JI; Brown, H; Chowdhury, M; Cueto, M; Dare, L; Dussault, G; Elzinga, G; Fee, E; Habte, D; Hanvoravongchai, P; Jacobs, M; Kurowski, C; Michael, S; Pablos-Mendez, A; Sewankambo, N; Solimano, G; Stilwell, B; de Waal, A; Wibulpolprasert, S			Human resources for health: overcoming the crisis	LANCET			English	Article								in this analysis of the global workforce, the joint Learning Initiative-a consortium of more than 100 health leaders-proposes that mobilisation and strengthening of human resources for health, neglected yet critical, is central to combating health crises in some of the world's poorest countries and for building sustainable health systems in all countries. Nearly all countries are challenged by worker shortage, skill mix imbalance, maldistribution, negative work environment, and weak knowledge base. Especially in the poorest countries, the workforce is under assault by HIV/AIDS, out-migration, and inadequate investment. Effective country strategies should be backed by international reinforcement. Ultimately, the crisis in human resources is a shared problem requiring shared responsibility for cooperative action. Alliances for action are recommended to strengthen the performance of all existing actors while expanding space and energy for fresh actors.	Harvard Univ, Global Equity Initiat, Cambridge, MA 02138 USA; WHO, CH-1211 Geneva 27, Switzerland; Univ Oxford, Dept Econ, Oxford OX1 3QU, England; NYU, Robert F Wagner Grad Sch Publ Serv, New York, NY 10012 USA; Bangladesh Rural Advancement Comm, Dhaka 1212, Bangladesh; Univ Peruana Cayetano Heredia, Lima 18, Peru; African Council Sustainable Hlth Dev, Ibadan, Nigeria; World Bank Inst, Washington, DC 20433 USA; Natl Inst Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; NIH, Natl Lib Med, Bethesda, MD 20894 USA; World Bank, Washington, DC 20433 USA; Univ Cape Town, ZA-7925 Cape Town, South Africa; Makerere Univ, Fac Med, Kampala, Uganda; Univ Chile, Santiago, Chile; Minist Publ Hlth, Nonthaburi 11000, Thailand	Harvard University; World Health Organization; University of Oxford; New York University; Bangladesh Rural Advancement Committee BRAC; Universidad Peruana Cayetano Heredia; The World Bank; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); The World Bank; University of Cape Town; Makerere University; Universidad de Chile; Ministry of Public Health - Thailand	Hanvoravongchai, P (corresponding author), Harvard Univ, Global Equity Initiat, Cambridge, MA 02138 USA.	phanvora@hsph.harvard.edu	Dussault, Gilles/I-8495-2012; Hanvoravongchai, Piya/A-1569-2012	Hanvoravongchai, Piya/0000-0003-4256-1271; Sewankambo, Nelson/0000-0001-9362-053X; Dussault, Gilles/0000-0002-5976-3454				ALKIRE S, MED EXCEPTIONALISM I; Anand S, 2004, LANCET, V364, P1603, DOI 10.1016/S0140-6736(04)17313-3; BERMAN P, HLTH CARE FINANCING; de Bertodano I, 2003, B WORLD HEALTH ORGAN, V81, P626; de Waal A, 2003, LANCET, V362, P1234, DOI 10.1016/S0140-6736(03)14548-5; DOVLO D, 2003, CONS WORKSH HUM RES; Michaud C., 2003, DEV ASSISTANCE HLTH; Mutume G., 2003, AFRICA RECOVERY, V17, P1; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; Ncayiyana DJ, 1999, S AFR MED J, V89, P1107; TAWFIK L, 2003, IMPACT HIV AIDS HLTH; United Nations Development Programme, 1995, HUM DEV REP 1995 GEN; *WHO, 2004, WHO EST HLTH PERS PH; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Bank, 2004, WORLD DEV REP 2004 M; World Health Organization, 2000, WORLD HLTH REP 2000	16	802	815	2	99	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1984	1990		10.1016/S0140-6736(04)17482-5	http://dx.doi.org/10.1016/S0140-6736(04)17482-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567015				2022-12-28	WOS:000225327000037
J	Frank, MJ; Seeberger, LC; O'Reilly, RC				Frank, MJ; Seeberger, LC; O'Reilly, RC			By carrot or by stick: Cognitive reinforcement learning in Parkinsonism	SCIENCE			English	Article							MEDIUM SPINY NEURONS; BASAL GANGLIA; DOPAMINERGIC MEDICATION; DISEASE; REWARD; STRIATUM; INHIBITION; RECEPTORS; HUMANS	To what extent do we learn from the positive versus negative outcomes of our decisions? The neuromodulator dopamine plays a key role in these reinforcement learning processes. Patients with Parkinson's disease, who have depleted dopamine in the basal ganglia, are impaired in tasks that require learning from trial and error. Here, we show, using two cognitive procedural learning tasks, that Parkinson's patients off medication are better at learning to avoid choices that lead to negative outcomes than they are at learning from positive outcomes. Dopamine medication reverses this bias, making patients more sensitive to positive than negative outcomes. This pattern was predicted by our biologically based computational model of basal ganglia-dopamine interactions in cognition, which has separate pathways for "Go" and "NoGo" responses that are differentially modulated by positive and negative reinforcement.	Univ Colorado, Dept Psychol, Boulder, CO 80309 USA; Univ Colorado, Ctr Neurosci, Boulder, CO 80309 USA; Colorado Neurol Inst, Movement Disorders Ctr, Englewood, CO 80113 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Frank, MJ (corresponding author), Univ Colorado, Dept Psychol, Boulder, CO 80309 USA.	frankmj@psych.colorado.edu; oreilly@psych.colorado.edu	O'Reilly, Randall/A-5819-2008; Frank, Michael J/B-2979-2008		NIMH NIH HHS [MH069597-01] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069597] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ashby FG, 1998, PSYCHOL REV, V105, P442, DOI 10.1037/0033-295X.105.3.442; Aubert I, 2000, J COMP NEUROL, V418, P22; Centonze D, 2001, EUR J NEUROSCI, V13, P1071, DOI 10.1046/j.0953-816x.2001.01485.x; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; Cools R, 2001, CEREB CORTEX, V11, P1136, DOI 10.1093/cercor/11.12.1136; Delgado MR, 2003, COGN AFFECT BEHAV NE, V3, P27, DOI 10.3758/CABN.3.1.27; Delius JD, 1998, BEHAV PROCESS, V42, P107, DOI 10.1016/S0376-6357(97)00072-7; FRANK M, IN PRESS J COGNIT NE; FRANK M, IN PRESS MEM COGNIT; Frank MJ, 2001, COGN AFFECT BEHAV NE, V1, P137, DOI 10.3758/CABN.1.2.137; Frank MJ, 2003, HIPPOCAMPUS, V13, P341, DOI 10.1002/hipo.10084; GERFEN CR, 1992, ANNU REV NEUROSCI, V15, P285, DOI 10.1146/annurev.neuro.15.1.285; Hernandez-Lopez S, 2000, J NEUROSCI, V20, P8987; HernandezLopez S, 1997, J NEUROSCI, V17, P3334; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI 10.1037/0033-295X.109.4.679; Kaasinen V, 2001, P NATL ACAD SCI USA, V98, P13272, DOI 10.1073/pnas.231313198; KISH SJ, 1988, NEW ENGL J MED, V318, P876, DOI 10.1056/NEJM198804073181402; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Nishi A, 1997, J NEUROSCI, V17, P8147; OREILLY RC, 2004, ICS TECH REP U COLOR; Satoh T, 2003, J NEUROSCI, V23, P9913; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Shohamy D, 2004, BRAIN, V127, P851, DOI 10.1093/brain/awh100; Swainson R, 2000, NEUROPSYCHOLOGIA, V38, P596, DOI 10.1016/S0028-3932(99)00103-7; Tomer R, 2004, J NEUROL NEUROSUR PS, V75, P972, DOI 10.1136/jnnp.2003.024885; Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360; VONFERSEN L, 1991, J EXP PSYCHOL ANIM B, V17, P334, DOI 10.1037/0097-7403.17.3.334; Wickens J, 1997, NETWORK-COMP NEURAL, V8, pR77, DOI 10.1088/0954-898X/8/4/001; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; WYNNE CDL, 1995, ANIM LEARN BEHAV, V23, P207, DOI 10.3758/BF03199936; Zald DH, 2004, J NEUROSCI, V24, P4105, DOI 10.1523/JNEUROSCI.4643-03.2004; Zink CF, 2004, NEURON, V42, P509, DOI 10.1016/S0896-6273(04)00183-7	34	1312	1326	7	178	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	2004	306	5703					1940	1943		10.1126/science.1102941	http://dx.doi.org/10.1126/science.1102941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	879DC	15528409	Green Submitted			2022-12-28	WOS:000225695600046
J	Ostfeld, RS; Keesing, F				Ostfeld, RS; Keesing, F			Oh the locusts sang, then they dropped dead	SCIENCE			English	Editorial Material							PERIODICAL CICADAS		Inst Ecosyst Studies, Millbrook, NY 12545 USA; Bard Coll, Dept Biol, Annandale on Hudson, NY 12504 USA	Cary Institute of Ecosystem Studies	Ostfeld, RS (corresponding author), Inst Ecosyst Studies, Box AB, Millbrook, NY 12545 USA.	rostfetd@ecostudies.org		Ostfeld, Richard/0000-0002-3707-9301				Curran LM, 2000, ECOL MONOGR, V70, P101, DOI 10.1890/0012-9615(2000)070[0101:VRTSVI]2.0.CO;2; Janzen D. H., 1971, A Rev Ecol Syst, V2, P465, DOI 10.1146/annurev.es.02.110171.002341; Jedrzejewska B., 1998, PREDATION VERTEBRATE; Koenig WD, 2003, CAN J FOREST RES, V33, P1084, DOI 10.1139/X03-037; Ostfeld RS, 2000, TRENDS ECOL EVOL, V15, P232, DOI 10.1016/S0169-5347(00)01862-0; Pace ML, 1999, TRENDS ECOL EVOL, V14, P483, DOI 10.1016/S0169-5347(99)01723-1; Schmidt KA, 2003, ECOLOGY, V84, P406, DOI 10.1890/0012-9658(2003)084[0406:SPIFEP]2.0.CO;2; WHITE J, 1978, ECOL ENTOMOL, V3, P323, DOI 10.1111/j.1365-2311.1978.tb00933.x; WILLIAMS KS, 1993, ECOLOGY, V74, P1143, DOI 10.2307/1940484; Yang LH, 2004, SCIENCE, V306, P1565, DOI 10.1126/science.1103114; Yates TL, 2002, BIOSCIENCE, V52, P989, DOI 10.1641/0006-3568(2002)052[0989:TEAEHO]2.0.CO;2	11	3	3	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1488	1489		10.1126/science.1106582	http://dx.doi.org/10.1126/science.1106582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567844				2022-12-28	WOS:000225442700038
J	Robinson, CP				Robinson, CP			Revisiting the Baruch plan	NATURE			English	Editorial Material									Sandia Natl Labs, Albuquerque, NM 87185 USA	United States Department of Energy (DOE); Sandia National Laboratories	Robinson, CP (corresponding author), Sandia Natl Labs, POB 5800, Albuquerque, NM 87185 USA.								0	3	3	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	2004	432	7016					441	442		10.1038/432441a	http://dx.doi.org/10.1038/432441a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	874AA	15565128				2022-12-28	WOS:000225322100019
J	Mitchell, LE; Adzick, NS; Melchionne, J; Pasquariello, PS; Sutton, LN; Whitehead, AS				Mitchell, LE; Adzick, NS; Melchionne, J; Pasquariello, PS; Sutton, LN; Whitehead, AS			Spina bifida	LANCET			English	Review							NEURAL-TUBE DEFECTS; INTRAUTERINE MYELOMENINGOCELE REPAIR; FOLIC-ACID ANTAGONISTS; RISK-FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE; 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; FETAL SURGERY; BIRTH-DEFECTS; IN-UTERO; HUMAN T	Spina bifida results from failure of fusion of the caudal neural tube, and is one of the most common malformations of human structure. The causes of this disorder are heterogeneous and include chromosome abnormalities, single gene disorders, and teratogenic exposures. However, the cause is not known in most cases. Up to 70% of spina bifida cases can be prevented by maternal, periconceptional folic acid supplementation. The mechanism underlying this protective effect is unknown, but it is likely to include genes that regulate folate transport and metabolism. Individuals with spina bifida need both surgical and medical management. Although surgical closure of the malformation is generally done in the neonatal period, a randomised clinical trial to assess in utero closure of spina bifida has been initiated in the USA. Medical management is a lifelong necessity for individuals with spina bifida, and should be provided by a multidisciplinary team.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, Philadelphia, PA USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Pharmacogenet, Philadelphia, PA 19104 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Mitchell, LE (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	lmitchell@ibt.tamhsc.edu	Mustafa, Lava/AAE-7496-2019		NICHD NIH HHS [HD39195, HD39081] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039195, R01HD039081] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberg A, 2001, EARLY HUM DEV, V61, P85, DOI 10.1016/S0378-3782(00)00125-0; Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; Amorim MR, 2004, BRIT MED J, V328, P84, DOI 10.1136/bmj.37945.610914.EE; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 1995, MMWR Recomm Rep, V44, P1; [Anonymous], [No title captured], DOI DOI 10.1136/JMG2.3.160; Anteby EY, 2003, EUR J OBSTET GYN R B, V106, P5, DOI 10.1016/S0301-2115(02)00033-7; Barbera JPM, 2002, HUM MOL GENET, V11, P283, DOI 10.1093/hmg/11.3.283; Barkai G, 2003, LANCET, V361, P1331, DOI 10.1016/S0140-6736(03)13080-2; Bauer KA, 2002, J NEUROGENET, V16, P65, DOI 10.1080/01677060290024628; Bauer SB, 2003, BJU INT, V92, P23, DOI 10.1046/j.1464-410X.92.s1.2.x; Berry RJ, 1999, NEW ENGL J MED, V341, P1485, DOI 10.1056/NEJM199911113412001; Biggio JR, 2001, AM J OBSTET GYNECOL, V185, P1016, DOI 10.1067/mob.2001.117676; Blaasaas KG, 2002, OCCUP ENVIRON MED, V59, P92, DOI 10.1136/oem.59.2.92; Bolt J, 2001, AUST FAM PHYSICIAN, V30, P21; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Bowman RM, 2001, PEDIATR NEUROSURG, V34, P114, DOI 10.1159/000056005; Braekke K, 2003, ACTA OBSTET GYN SCAN, V82, P620, DOI 10.1034/j.1600-0412.2003.00180.x; Brody LC, 2002, AM J HUM GENET, V71, P1207, DOI 10.1086/344213; Brown LY, 2002, AM J MED GENET, V108, P128, DOI 10.1002/ajmg.10221; Bruner JP, 2004, AM J OBSTET GYNECOL, V190, P1305, DOI 10.1016/j.ajog.2003.10.702; Bruner JP, 1999, JAMA-J AM MED ASSOC, V282, P1819, DOI 10.1001/jama.282.19.1819; Bruner JP, 1999, AM J OBSTET GYNECOL, V180, P153, DOI 10.1016/S0002-9378(99)70167-5; Carrel T, 2001, AM J MED GENET, V98, P283, DOI 10.1002/1096-8628(20010122)98:3<283::AID-AJMG1089>3.0.CO;2-G; CARTER C O, 1968, Journal of Medical Genetics, V5, P81, DOI 10.1136/jmg.5.2.81; CARTER CO, 1973, J MED GENET, V10, P209, DOI 10.1136/jmg.10.3.209; Carter M, 1999, HUM MOL GENET, V8, P2199, DOI 10.1093/hmg/8.12.2199; Castilla EE, 2003, AM J MED GENET A, V123A, P123, DOI 10.1002/ajmg.a.20230; *CDC, 1998, JAMA-J AM MED ASSOC, V259, P2715; *CDC, 2000, MMWR-MORBID MORTAL W, V49, P962; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P362; Chambers CD, 1998, TERATOLOGY, V58, P251, DOI 10.1002/(SICI)1096-9926(199812)58:6<251::AID-TERA6>3.0.CO;2-L; CHAN A, 1993, BRIT MED J, V307, P703, DOI 10.1136/bmj.307.6906.703; CHARNEY EB, 1985, PEDIATRICS, V75, P58; CHATKUPT S, 1995, J MED GENET, V32, P200, DOI 10.1136/jmg.32.3.200; Cochrane DD, 1996, FETAL DIAGN THER, V11, P159, DOI 10.1159/000264297; Copp AJ, 2003, NAT REV GENET, V4, P784, DOI 10.1038/nrg1181; Cornel MC, 1997, TERATOLOGY, V55, P134; Correia-Pinto J, 2002, J PEDIATR SURG, V37, P488, DOI 10.1053/jpsu.2002.30872; Cortes RA, 2004, SEMIN PERINATOL, V28, P199, DOI 10.1053/j.semperi.2004.03.006; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; De Marco P, 2003, EUR J HUM GENET, V11, P245, DOI 10.1038/sj.ejhg.5200946; de Walle HEK, 2002, PREV MED, V35, P65, DOI 10.1006/pmed.2002.1040; de Walle HEK, 1999, LANCET, V353, P1187, DOI 10.1016/S0140-6736(05)74409-3; De Wals P, 2003, BIRTH DEFECTS RES A, V67, P919, DOI 10.1002/bdra.10124; DEMENAIS F, 1982, AM J MED GENET, V11, P287, DOI 10.1002/ajmg.1320110305; Dodds L, 2001, OCCUP ENVIRON MED, V58, P443, DOI 10.1136/oem.58.7.443; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; Doolin MT, 2002, AM J HUM GENET, V71, P1222, DOI 10.1086/344209; Drewek MJ, 1997, PEDIATR NEUROSURG, V27, P190, DOI 10.1159/000121250; Drugan A, 2001, CLIN PERINATOL, V28, P279, DOI 10.1016/S0095-5108(05)70083-X; ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; Felder B, 2002, EUR J HUM GENET, V10, P753, DOI 10.1038/sj.ejhg.5200875; Felkner M, 2003, BIRTH DEFECTS RES A, V67, P504, DOI 10.1002/bdra.10047; Feuchtbaum LB, 1999, GENET TEST, V3, P265, DOI 10.1089/109065799316572; Fine EL, 1999, DIABETES, V48, P2454, DOI 10.2337/diabetes.48.12.2454; Finnell RH, 2003, EPILEPSIA, V44, P14, DOI 10.1046/j.1528-1157.44.s3.5.x; Finnell RH, 2002, GENET TEST, V6, P47, DOI 10.1089/109065702760093915; Fleming A, 1998, SCIENCE, V280, P2107, DOI 10.1126/science.280.5372.2107; *FOOD STAND AG UK, 2002, BOARD REACH CONCL FO; Greene MF, 2001, TERATOLOGY, V63, P116, DOI 10.1002/tera.1021; HADDOW JE, 1986, LANCET, V1, P1330; Hall JG, 1998, MENT RETARD DEV D R, V4, P269, DOI 10.1002/(SICI)1098-2779(1998)4:4<269::AID-MRDD6>3.0.CO;2-8; Harris MJ, 2001, TERATOLOGY, V63, P165, DOI 10.1002/tera.1030; Hendricks K, 1999, EPIDEMIOLOGY, V10, P198, DOI 10.1097/00001648-199903000-00022; Hendricks KA, 2001, EPIDEMIOLOGY, V12, P630, DOI 10.1097/00001648-200111000-00009; Hernandez-Diaz S, 2001, AM J EPIDEMIOL, V153, P961, DOI 10.1093/aje/153.10.961; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Hertrampf E, 2003, J NUTR, V133, P3166, DOI 10.1093/jn/133.10.3166; Hiramatsu Y, 2002, DIABETES, V51, P2804, DOI 10.2337/diabetes.51.9.2804; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; Hol FA, 1996, J MED GENET, V33, P655, DOI 10.1136/jmg.33.8.655; Holmes NM, 2001, J UROLOGY, V166, P2383, DOI 10.1016/S0022-5347(05)65596-6; Howe EG, 2003, SEMIN PERINATOL, V27, P446, DOI 10.1053/j.semperi.2003.10.004; Hunt GM, 1999, EUR J PEDIATR SURG, V9, P5, DOI 10.1055/s-2008-1072302; HUNTER AGW, 1984, AM J MED GENET, V19, P45, DOI 10.1002/ajmg.1320190108; Hutchins GM, 1996, PEDIATR PATHOL LAB M, V16, P701, DOI 10.1080/107710496175327; *I MED, 2001, VET AG OR UPD 2000; *I MED, 1999, VET AG OR UPD 2000; Institute of.Medicine: Committee to Review the Health Rffects in Vietnam Veterans of Exposure to Herbicides, 1994, VET AG OR HLTH EFF H, DOI [10.1136/oem.52.2.144, DOI 10.1136/OEM.52.2.144]; *INT CLEARH BIRTH, 1998, ANN REP 1998 DAT 199; JANERICH DT, 1978, J MED GENET, V15, P101, DOI 10.1136/jmg.15.2.101; Janssen PA, 1996, PAEDIATR PERINAT EP, V10, P52, DOI 10.1111/j.1365-3016.1996.tb00026.x; JOHNSON MP, 2003, OBSTETRICS, V189, P482; Joosten PHLJ, 2001, NAT GENET, V27, P215, DOI 10.1038/84867; JUST M, 1990, PEDIATR RADIOL, V20, P262, DOI 10.1007/BF02019662; Kallen B, 1998, TERATOLOGY, V57, P56; Kalter H, 2000, REPROD TOXICOL, V14, P463, DOI 10.1016/S0890-6238(00)00093-9; Klootwijk R, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.4.e43; Klotz JB, 1999, EPIDEMIOLOGY, V10, P383, DOI 10.1097/00001648-199907000-00008; KNUDSEN LB, 1986, LANCET, V2, P227; Koren G, 1999, CAN FAM PHYSICIAN, V45, P1451; KORENROMP MJ, 1986, LANCET, V1, P917, DOI 10.1016/S0140-6736(86)91022-6; LAMMER EJ, 1987, TERATOLOGY, V35, P465, DOI 10.1002/tera.1420350319; Lapunzina P, 1996, AM J MED GENET, V67, P106, DOI 10.1002/(SICI)1096-8628(19960216)67:1<106::AID-AJMG19>3.3.CO;2-Q; Leibold S, 2000, EUR J PEDIATR SURG, V10, P26, DOI 10.1055/s-2008-1072410; Lennon CA, 1999, OBSTET GYNECOL, V94, P562, DOI 10.1016/S0029-7844(99)00399-3; LITTLE J, 1991, REPROD PERINATAL EPI, P251; LOFT AGR, 1990, J CLIN CHEM CLIN BIO, V28, P893; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; LUMLEY J, 1908, COCHRANE DB SYST REV, V3; Lyerly AD, 2001, OBSTET GYNECOL, V98, P689, DOI 10.1016/S0029-7844(01)01513-7; LYNBERG MC, 1994, AM J EPIDEMIOL, V140, P244, DOI 10.1093/oxfordjournals.aje.a117243; MacKenzie TC, 2001, J INTENSIVE CARE MED, V16, P251, DOI 10.1046/j.1525-1489.2001.00251.x; Mangels KJ, 2000, PEDIATR NEUROSURG, V32, P124, DOI 10.1159/000028916; Mansfield C, 1999, PRENATAL DIAG, V19, P808, DOI 10.1002/(SICI)1097-0223(199909)19:9<808::AID-PD637>3.0.CO;2-B; MARTIN L, 1988, LANCET, V1, P640; Matalon S, 2002, REPROD TOXICOL, V16, P9, DOI 10.1016/S0890-6238(01)00199-X; McDonnell GV, 2000, EUR J PEDIATR SURG, V10, P31, DOI 10.1055/s-2008-1072411; McDonnell RJ, 1999, J EPIDEMIOL COMMUN H, V53, P782, DOI 10.1136/jech.53.12.782; McLeod Lynne, 2002, Community Genet, V5, P33, DOI 10.1159/000064629; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; MICHEJDA M, 1986, PEDIATR NEUROSCI, V12, P90, DOI 10.1159/000120226; MILUNSKY A, 1992, JAMA-J AM MED ASSOC, V268, P882, DOI 10.1001/jama.268.7.882; Moore CA, 1997, AM J MED GENET, V73, P113; Moore LL, 2003, EPIDEMIOLOGY, V14, P200; Moore LL, 2001, EPIDEMIOLOGY, V12, P141, DOI 10.1097/00001648-200103000-00002; Morrison K, 1998, ANN HUM GENET, V62, P379, DOI 10.1046/j.1469-1809.1998.6250379.x; Morrison K, 1996, HUM MOL GENET, V5, P669, DOI 10.1093/hmg/5.5.669; NAMBISAN M, 2003, BIRTH DEFECTS RES A, V67; Neimanis IM, 1999, CAN FAM PHYSICIAN, V45, P1717; NIEVELSTEIN RAJ, 1993, TERATOLOGY, V48, P21, DOI 10.1002/tera.1420480106; Northrup H, 2000, Curr Probl Pediatr, V30, P313; O'Rahilly R, 1999, TERATOLOGY, V60, P39, DOI 10.1002/(SICI)1096-9926(199907)60:1<39::AID-TERA11>3.0.CO;2-I; O'Rahilly R, 2002, TERATOLOGY, V65, P162, DOI 10.1002/tera.10007; Orr M, 2002, INT J HYG ENVIR HEAL, V205, P19, DOI 10.1078/1438-4639-00126; OSAKA K, 1978, J NEUROSURG, V49, P711, DOI 10.3171/jns.1978.49.5.0711; Paek BW, 2000, AM J OBSTET GYNECOL, V183, P1119, DOI 10.1067/mob.2000.108867; Perez M, 2001, EUR J PEDIATR SURG, V11, P315, DOI 10.1055/s-2001-18554; Persad VL, 2002, CAN MED ASSOC J, V167, P241; Petrini J. R., 1999, Morbidity and Mortality Weekly Report, V48, P325; Pippenger CE, 2003, EPILEPSIA, V44, P24, DOI 10.1046/j.1528-1157.44.s3.3.x; Posey DL, 1996, LANCET, V347, P686, DOI 10.1016/S0140-6736(96)91236-2; Ray JG, 2002, LANCET, V360, P2047, DOI 10.1016/S0140-6736(02)11994-5; Ray JG, 2003, QJM-INT J MED, V96, P289, DOI 10.1093/qjmed/hcg043; RENWICK JH, 1972, BRIT J PREV SOC MED, V26, P67; Ringel S, 1999, TERATOLOGY, V60, P29, DOI 10.1002/(SICI)1096-9926(199907)60:1<29::AID-TERA8>3.0.CO;2-X; Rintoul NE, 2002, PEDIATRICS, V109, P409, DOI 10.1542/peds.109.3.409; Rogner UC, 2002, AM J MED GENET, V110, P208, DOI 10.1002/ajmg.10453; Rosano A, 1999, J EPIDEMIOL COMMUN H, V53, P630, DOI 10.1136/jech.53.10.630; Rosenquist TH, 1996, P NATL ACAD SCI USA, V93, P15227, DOI 10.1073/pnas.93.26.15227; Sadler TW, 2002, TERATOLOGY, V66, P169, DOI 10.1002/tera.10089; SCHORAH C J, 1991, Nutrition Research Reviews, V4, P33, DOI 10.1079/NRR19910006; Sepulveda W, 2004, ULTRASOUND OBST GYN, V23, P352, DOI 10.1002/uog.964; Shaw GM, 2000, PAEDIATR PERINAT EP, V14, P234, DOI 10.1046/j.1365-3016.2000.00274.x; Shaw GM, 1996, JAMA-J AM MED ASSOC, V275, P1093, DOI 10.1001/jama.275.14.1093; Shaw GM, 2000, TERATOLOGY, V61, P231, DOI 10.1002/(SICI)1096-9926(200003)61:3<231::AID-TERA11>3.3.CO;2-C; Shaw GM, 2002, AM J MED GENET, V108, P1, DOI 10.1002/ajmg.10195; Shaw GM, 1998, TERATOLOGY, V57, P1; Shaw GM, 1999, EPIDEMIOLOGY, V10, P60, DOI 10.1097/00001648-199901000-00011; Sheffield JS, 2002, OBSTET GYNECOL, V100, P925, DOI 10.1016/S0029-7844(02)02242-1; Shields DC, 1999, AM J HUM GENET, V64, P1045, DOI 10.1086/302310; Shields DC, 2000, AM J MED GENET, V92, P206; Shin JH, 1999, J NUTR, V129, P2070, DOI 10.1093/jn/129.11.2070; SHIOTA K, 1982, AM J MED GENET, V12, P281, DOI 10.1002/ajmg.1320120306; Singhal B, 1999, EUR J PEDIATR SURG, V9, P31, DOI 10.1055/s-2008-1072310; Speer MC, 2002, AM J MED GENET, V110, P215, DOI 10.1002/ajmg.10436; Stegmann K, 2001, TERATOLOGY, V63, P167, DOI 10.1002/tera.1031; Stegmann K, 1999, MUTAT RES-GENOMICS, V406, P63, DOI 10.1016/S1383-5726(99)00002-3; Stumpo DJ, 1998, GENOMICS, V49, P253, DOI 10.1006/geno.1998.5247; Suarez L, 2003, ANN EPIDEMIOL, V13, P81, DOI 10.1016/S1047-2797(02)00267-3; Sutton LN, 1999, JAMA-J AM MED ASSOC, V282, P1826, DOI 10.1001/jama.282.19.1826; Todoroff K, 2000, AM J EPIDEMIOL, V151, P505, DOI 10.1093/oxfordjournals.aje.a010236; Trembath D, 1999, TERATOLOGY, V59, P331, DOI 10.1002/(SICI)1096-9926(199905)59:5<331::AID-TERA4>3.0.CO;2-L; Tubbs RS, 2003, PEDIATR NEUROSURG, V38, P128, DOI 10.1159/000068818; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; Tulipan N, 1999, PEDIATR NEUROSURG, V31, P137, DOI 10.1159/000028849; Tulipan N, 1999, PEDIATR NEUROSURG, V31, P183, DOI 10.1159/000028859; Turner LA, 2001, EPIDEMIOLOGY, V12, P262, DOI 10.1097/00001648-200103000-00022; Vachha B, 2003, PEDIATR NEUROSURG, V39, P184, DOI 10.1159/000072469; van der Put NMJ, 1998, AM J HUM GENET, V62, P1044, DOI 10.1086/301825; VANALLEN MI, 1993, AM J MED GENET, V47, P723, DOI 10.1002/ajmg.1320470528; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; Velie EM, 1996, AM J EPIDEMIOL, V144, P473; Volcik KA, 2003, BIRTH DEFECTS RES A, V67, P924, DOI 10.1002/bdra.10029; Volcik KA, 2003, BIRTH DEFECTS RES A, V67, P154, DOI 10.1002/bdra.10008; Volcik KA, 2002, AM J MED GENET, V110, P203, DOI 10.1002/ajmg.10435; Volcik KA, 2002, TERATOLOGY, V66, P257, DOI 10.1002/tera.10097; Volcik KA, 2002, AM J MED GENET, V110, P195, DOI 10.1002/ajmg.10434; WALD N, 1993, ANN NY ACAD SCI, V678, P112; Wald NJ, 2001, LANCET, V358, P2069, DOI 10.1016/S0140-6736(01)07104-5; WALLER DK, 1994, AM J OBSTET GYNECOL, V170, P541, DOI 10.1016/S0002-9378(94)70224-1; Watkins ML, 1996, EPIDEMIOLOGY, V7, P507, DOI 10.1097/00001648-199609000-00009; Watkins ML, 2003, PEDIATRICS, V111, P1152; Watson M, 2001, AUST NZ J PUBL HEAL, V25, P389, DOI 10.1111/j.1467-842X.2001.tb00280.x; Werler MM, 1996, JAMA-J AM MED ASSOC, V275, P1089, DOI 10.1001/jama.275.14.1089; WHITEHEAD AS, 1995, QJM-MON J ASSOC PHYS, V88, P763; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; WILSON V, 1993, DEVELOPMENT, V117, P1321; WOLFE WH, 1995, EPIDEMIOLOGY, V6, P17, DOI 10.1097/00001648-199501000-00005; Wong LYC, 2001, PAEDIATR PERINAT EP, V15, P374, DOI 10.1046/j.1365-3016.2001.00371.x; Zackai E H, 1978, UCLA Forum Med Sci, V20, P99; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275; Zhu HP, 2003, MOL GENET METAB, V78, P216, DOI 10.1016/S1096-7192(03)00008-8; Zhu HP, 2003, AM J MED GENET A, V117A, P87, DOI 10.1002/ajmg.a.10841; Ziring PR, 2000, PEDIATRICS, V106, P854	196	354	370	3	65	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	2004	364	9448					1885	1895		10.1016/S0140-6736(04)17445-X	http://dx.doi.org/10.1016/S0140-6736(04)17445-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	873HA	15555669				2022-12-28	WOS:000225269300030
J	Chang, GY				Chang, GY			Left nasal discharge and meningitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									121st US Army Gen Hosp, Seoul 962050017, South Korea	United States Department of Defense; United States Army	Chang, GY (corresponding author), 121st US Army Gen Hosp, Seoul 962050017, South Korea.								0	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					E19	E19		10.1056/NEJMicm040170	http://dx.doi.org/10.1056/NEJMicm040170			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548770				2022-12-28	WOS:000225160600013
J	Hofman, PL; Regan, F; Jackson, WE; Jefferies, C; Knight, DB; Robinson, EM; Cutfield, WS				Hofman, PL; Regan, F; Jackson, WE; Jefferies, C; Knight, DB; Robinson, EM; Cutfield, WS			Premature birth and later insulin resistance	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADULT DISEASE; FETAL-GROWTH; GLUCOSE-TOLERANCE; DIABETES-MELLITUS; PRENATAL EXPOSURE; BLOOD-PRESSURE; SYNDROME-X; CHILDREN; WEIGHT; SENSITIVITY	Background: Term infants who are small for gestational age appear prone to the development of insulin resistance during childhood. We hypothesized that insulin resistance, a marker of type 2 diabetes mellitus, would be prevalent among children who had been born prematurely, irrespective of whether they were appropriate for gestational age or small for gestational age. Methods: Seventy-two healthy prepubertal children 4 to 10 years of age were studied: 50 who had been born prematurely (32 weeks' gestation or less), including 38 with a birth weight that was appropriate for gestational age (above the 10th percentile) and 12 with a birth weight that was low (i.e., who were small) for gestational age, and 22 control subjects (at least 37 weeks' gestation, with a birth weight above the 10th percentile). Insulin sensitivity was measured with the use of paired insulin and glucose data obtained by frequent measurements during intravenous glucose-tolerance tests. Results: Children who had been born prematurely, whether their weight was appropriate or low for gestational age, had an isolated reduction in insulin sensitivity as compared with controls (appropriate-for-gestational-age group, 14.2 x 10(-4) per minute per milliunit per liter [95 percent confidence interval, 11.5 to 16.2]; small-for-gestational-age group, 12.9 x 10(-4) per minute per milliunit per liter [95 percent confidence interval, 9.7 to 17.4]; and control group, 21.6 x 10(-4) per minute per milliunit per liter [95 percent confidence interval, 17.1 to 27.4]; P=0.002). There were no significant differences in insulin sensitivity between the two premature groups (P=0.80). As compared with controls, both groups of premature children had a compensatory increase in acute insulin release (appropriate-for-gestational-age group, 2002 pmol per liter [95 percent confidence interval, 2153 to 2432]; small-for-gestational-age group, 2253 pmol per liter [95 percent confidence interval, 1622 to 3128]; and control group, 1148 pmol per liter [95 percent confidence interval, 875 to 1500]; P<0.001). Conclusions: Like children who were born at term but who were small for gestational age, children who were born prematurely have an isolated reduction in insulin sensitivity, which may be a risk factor for type 2 diabetes mellitus.	Univ Auckland, Fac Med & Hlth Sci, Liggins Inst, Auckland 1, New Zealand; Univ Auckland, Dept Community Hlth, Hlth Res Council Biostat Unit, Auckland 1, New Zealand; Natl Womens Hosp Neonatal Unit, Auckland, New Zealand	University of Auckland; University of Auckland	Hofman, PL (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Liggins Inst, Private Bag 92019, Auckland 1, New Zealand.	p.hofman@auckland.ac.nz	Knight, David B/F-7437-2011; Jefferies, craig/ABA-1921-2021	Jackson, Wendy/0000-0001-5723-1131; Jefferies, Craig/0000-0002-0541-6094				*AUCKL DISTR HLTH, 2004, NEWB SERV NAT WOM AN; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; Barker DJP, 1997, CLIN OBSTET GYNECOL, V40, P853, DOI 10.1097/00003081-199712000-00019; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; BARKER DJP, 1992, BRIT J OBSTET GYNAEC, V99, P275, DOI 10.1111/j.1471-0528.1992.tb13719.x; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; Bazaes RA, 2004, J CLIN ENDOCR METAB, V89, P1267, DOI 10.1210/jc.2003-031239; Bloomfield FH, 2003, SCIENCE, V300, P606, DOI 10.1126/science.1080803; Boyko EJ, 2000, DIABETES CARE, V23, P1260, DOI 10.2337/diacare.23.9.1260; COLE TJ, 1995, ARCH DIS CHILD, V73, P25, DOI 10.1136/adc.73.1.25; CUTFIELD WS, 1990, J CLIN ENDOCR METAB, V70, P1644, DOI 10.1210/jcem-70-6-1644; DURANT RH, 1981, J AM DIET ASSOC, V78, P35; Facchini FS, 2001, J CLIN ENDOCR METAB, V86, P3574, DOI 10.1210/jc.86.8.3574; Gray IP, 2002, J CLIN ENDOCR METAB, V87, P4252, DOI 10.1210/jc.2001-011961; GRUNFELD B, 1994, HYPERTENSION S1, V23, P12; GUARAN RL, 1994, AUST NZ J OBSTET GYN, V34, P39, DOI 10.1111/j.1479-828X.1994.tb01037.x; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; Martin Joyce A, 2002, Natl Vital Stat Rep, V50, P1; MCLAREN DS, 1975, LANCET, V2, P219; Nyirenda MJ, 2001, J ENDOCRINOL, V170, P653, DOI 10.1677/joe.0.1700653; Petry CJ, 2000, HORM METAB RES, V32, P233, DOI 10.1055/s-2007-978627; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Roseboom TJ, 2001, MOL CELL ENDOCRINOL, V185, P93, DOI 10.1016/S0303-7207(01)00721-3; Scherrer U, 1997, CIRCULATION, V96, P4104; TRINDER P, 1969, J CLIN PATHOL, V22, P158, DOI 10.1136/jcp.22.2.158; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83	32	438	457	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2179	2186		10.1056/NEJMoa042275	http://dx.doi.org/10.1056/NEJMoa042275			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548778				2022-12-28	WOS:000225160600008
J	Hellmann, DBG				Hellmann, DBG			Update in rheumatology	ANNALS OF INTERNAL MEDICINE			English	Review							SYSTEMIC-LUPUS-ERYTHEMATOSUS		Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine	Hellmann, DBG (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Johns Hopkins Bayview Med Ctr, B-110,4940 Eastern Ave, Baltimore, MD 21224 USA.	GHellmann@jhmi.edu						Asanuma Y, 2003, NEW ENGL J MED, V349, P2407, DOI 10.1056/NEJMoa035611; UROWITZ MB, 1976, AM J MED, V60, P221, DOI 10.1016/0002-9343(76)90431-9	2	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2004	141	10					801	804		10.7326/0003-4819-141-10-200411160-00012	http://dx.doi.org/10.7326/0003-4819-141-10-200411160-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	872KU	15545680				2022-12-28	WOS:000225206900007
J	Lux, AL; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Newton, RW; O'Callaghan, FK; Verity, CM; Osborne, JP				Lux, AL; Edwards, SW; Hancock, E; Johnson, AL; Kennedy, CR; Newton, RW; O'Callaghan, FK; Verity, CM; Osborne, JP			The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial	LANCET			English	Article							VISUAL-FIELD CONSTRICTION; CHILDREN; ACTH; EPILEPSY; THERAPY	Background Infantile spasms, which comprise a severe infantile seizure disorder, have a high morbidity and are difficult to treat. Hormonal treatments (adrenocorticotropic hormone and prednisolone) have been the main therapy for decades, although little evidence supports their use. Vigabatrin has been recorded to have a beneficial effect in this disorder. We aimed to compare the effects of vigabatrin with those of prednisolone and tetracosactide in the treatment of infantile spasms. Methods The United Kingdom Infantile Spasms Study assessed these treatments in a multicentre, randomised controlled trial in 150 hospitals in the UK. The primary outcome was cessation of spasms on days 13 and 14. Minimum doses were vigabatrin 100 mg/kg per day, oral prednisolone 40 mg per day, or intramuscular tetracosactide depot 0.5 mg (40 IU) on alternate days. Analysis was by intention to treat. Findings Of 208 infants screened and assessed, 107 were randomly assigned to vigabatrin (n=52) or hormonal treatments (prednisolone n=30, tetracosactide n=25). None was lost to follow-up. Proportions with no spasms on days 13 and 14 were: 40 (73%) of 55 infants assigned hormonal treatments (prednisolone 21/30 [70%], tetracosactide 19/25 [76%]) and 28 (54%) of 52 infants assigned vigabatrin (difference 19%, 95% CI 1%-36%, p=0.043). Two infants allocated tetracosactide and one allocated vigabatrin received prednisolone. Adverse events were reported in 30 (55%) of 55 infants on hormonal treatments and 28 (54%) of 52 infants on vigabatrin. No deaths were recorded. Interpretation Cessation of spasms was more likely in infants given hormonal treatments than those given vigabatrin. Adverse events were common with both treatments.	Royal United Hosp Bath NHS Trust, Bath, Avon, England; Univ Bath, Sch Hlth, Bath BA2 7AY, Avon, England; Frenchay Hosp, Dept Paediat Neurol, Bristol BS16 1LE, Avon, England; Bristol Royal Hosp Children, Bristol, Avon, England; Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England; Univ Southampton, Southampton, Hants, England; Royal Manchester Childrens Hosp, Dept Paediat Neurol, Manchester M27 1HA, Lancs, England; Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England	University of Bath; Bristol Royal Hospital For Children; MRC Biostatistics Unit; University of Cambridge; University of Southampton; Royal Manchester Children's Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Osborne, JP (corresponding author), Royal United Hosp, Childrens Ctr, Bath BA1 3NG, Avon, England.	mpsjpo@bath.ac.uk	O'Callaghan, Finbar/AAT-4539-2021	O'Callaghan, Finbar/0000-0002-7499-6029				Aicardi J, 1996, EPILEPSIA, V37, P638, DOI 10.1111/j.1528-1157.1996.tb00627.x; Appleton RE, 1999, EPILEPSIA, V40, P1627, DOI 10.1111/j.1528-1157.1999.tb02049.x; Baram TZ, 1996, PEDIATRICS, V97, P375; Elterman RD, 2001, NEUROLOGY, V57, P1416, DOI 10.1212/WNL.57.8.1416; Gross-Tsur V, 2000, ANN NEUROL, V48, P60, DOI 10.1002/1531-8249(200007)48:1<60::AID-ANA9>3.0.CO;2-E; Hancock E, 1998, DEV MED CHILD NEUROL, V40, P500; Hancock E, 1999, J CHILD NEUROL, V14, P71, DOI 10.1177/088307389901400201; HANCOCK E, 2004, COCHRANE LIB; HRACHOVY RA, 1983, J PEDIATR-US, V103, P641, DOI 10.1016/S0022-3476(83)80606-4; HULL D, 1999, MED CHILDREN; Iannetti P, 2000, PEDIATRICS, V106, P838, DOI 10.1542/peds.106.4.838; LOW NL, 1958, PEDIATRICS, V22, P1165; Lux AL, 2000, BRIT MED J, V320, P1182, DOI 10.1136/bmj.320.7243.1182; SOREL L, 1958, Acta Neurol Psychiatr Belg, V58, P130; Vanhatalo S, 1999, NEUROLOGY, V52, P1713, DOI 10.1212/WNL.52.8.1713; Vigevano F, 1997, EPILEPSIA, V38, P1270; Wild JM, 1999, EPILEPSIA, V40, P1784, DOI 10.1111/j.1528-1157.1999.tb01599.x	17	238	258	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	2004	364	9447					1773	1778		10.1016/S0140-6736(04)17400-X	http://dx.doi.org/10.1016/S0140-6736(04)17400-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	870PQ	15541450				2022-12-28	WOS:000225070600030
J	Austin, CP; Brady, LS; Insel, TR; Collins, FS				Austin, CP; Brady, LS; Insel, TR; Collins, FS			NIH Molecular Libraries Initiative	SCIENCE			English	Editorial Material							DRUG DISCOVERY; HUMAN GENOME; INNOVATION; BIOLOGY		NHGRI, NIH, Bethesda, MD 20892 USA; NIMH, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Austin, CP (corresponding author), NHGRI, NIH, Bethesda, MD 20892 USA.	austinc@mail.nih.gov			NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIBHG200319, ZIAHG200319, Z01HG200319] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Austin CP, 2003, CURR OPIN CHEM BIOL, V7, P511, DOI 10.1016/S1367-5931(03)00083-8; Bleicher KH, 2003, NAT REV DRUG DISCOV, V2, P369, DOI 10.1038/nrd1086; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Collins FS, 2004, NAT REV DRUG DISCOV, V3, P640, DOI 10.1038/nrd1488; Couzin J, 2003, SCIENCE, V302, P218, DOI 10.1126/science.302.5643.218; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; JANSSEN D, 2004, BIO IT WORLD, V3, P1; Kaiser J, 2004, SCIENCE, V304, P1728; Lindsay MA, 2003, NAT REV DRUG DISCOV, V2, P831, DOI 10.1038/nrd1202; Savchuk NP, 2004, CURR OPIN CHEM BIOL, V8, P412, DOI 10.1016/j.cbpa.2004.06.003; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	13	286	296	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 12	2004	306	5699					1138	1139		10.1126/science.1105511	http://dx.doi.org/10.1126/science.1105511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15542455				2022-12-28	WOS:000225193100031
J	Chamberlain, JS				Chamberlain, JS			Cachexia in cancer - Zeroing in on myosin	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Sch Med, Senator Paul D Wellstone Muscular Dystrophy Coope, Seattle, WA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chamberlain, JS (corresponding author), Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.			Chamberlain, Jeffrey/0000-0001-5299-0059				Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Bergstrom DA, 2002, MOL CELL, V9, P587, DOI 10.1016/S1097-2765(02)00481-1; Rubin H, 2003, P NATL ACAD SCI USA, V100, P5384, DOI 10.1073/pnas.0931260100; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3	4	37	40	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2124	2125		10.1056/NEJMcibr042889	http://dx.doi.org/10.1056/NEJMcibr042889			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537911				2022-12-28	WOS:000225007200017
J	Dahl, DM; Mueller, PR; Young, RH; Kaufman, DS; Harisinghani, M; Young, RH; McDougal, WS				Dahl, DM; Mueller, PR; Young, RH; Kaufman, DS; Harisinghani, M; Young, RH; McDougal, WS			A man with right flank pain and Hematuria - Papillary transitional-cell carcinoma of the renal pelvis, low grade	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LAPAROSCOPIC NEPHROURETERECTOMY; MICROSCOPIC HEMATURIA; HELICAL CT; FOLLOW-UP; MANAGEMENT; UROGRAPHY		Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Dahl, DM (corresponding author), Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA.							Amin MB, 1997, AM J SURG PATHOL, V21, P1057, DOI 10.1097/00000478-199709000-00010; Cohen RA, 2003, NEW ENGL J MED, V348, P2330, DOI 10.1056/NEJMcp012694; Daneshmand S, 2003, CANCER, V98, P55, DOI 10.1002/cncr.11446; DONAT SM, 1997, UROLOGIC ONCOLOGY, P215; ELFATTOUH HA, 2002, EUR UROL, V42, P447; Fielding JR, 1998, AM J ROENTGENOL, V171, P1051, DOI 10.2214/ajr.171.4.9762995; Goel MC, 2003, J UROLOGY, V169, P925, DOI 10.1097/01.ju.0000050242.68745.4d; Grossfeld GD, 2001, UROLOGY, V57, P604, DOI 10.1016/S0090-4295(01)00920-7; GUTMAN AB, 1968, AM J MED, V45, P756, DOI 10.1016/0002-9343(68)90209-X; Hisataki T, 2000, UROLOGY, V55, P663, DOI 10.1016/S0090-4295(99)00563-4; JamisDow CA, 1996, RADIOLOGY, V198, P785, DOI 10.1148/radiology.198.3.8628872; Linehan WM, 2001, CANC PRINCIPLES PRAC, P1362; McNeill SA, 2000, BJU INT, V86, P619, DOI 10.1046/j.1464-410x.2000.00888.x; McNicholas MMJ, 1998, AM J ROENTGENOL, V170, P1261, DOI 10.2214/ajr.170.5.9574598; NOCKS BN, 1982, UROLOGY, V19, P472, DOI 10.1016/0090-4295(82)90601-X; Ong AM, 2003, J UROLOGY, V170, P1301, DOI 10.1097/01.ju.0000084660.73614.da; Schreyer HH, 2002, EUR RADIOL, V12, P575, DOI 10.1007/s003300101023	17	2	3	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2102	2110		10.1056/NEJMcpc049027	http://dx.doi.org/10.1056/NEJMcpc049027			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537909				2022-12-28	WOS:000225007200013
J	Carlberg, B; Samuelsson, O; Lindholm, LJ				Carlberg, B; Samuelsson, O; Lindholm, LJ			Atenolol in hypertension: is it a wise choice?	LANCET			English	Article							ANGIOTENSIN RECEPTOR ANTAGONIST; RANDOMIZED-TRIAL; CARDIOVASCULAR MORBIDITY; BETA-BLOCKERS; CALCIUM-ANTAGONIST; ELDERLY-PATIENTS; SWEDISH TRIAL; DOUBLE-BLIND; OLD PATIENTS; MORTALITY	Background Atenolol is one of the most widely used beta blockers clinically, and has often been used as a reference drug in randomised controlled trials of hypertension. However, questions have been raised about atenolol as the best reference drug for comparisons with other antihypertensives. Thus, our aim was to systematically review the effect of atenolol on cardiovascular morbidity and mortality in hypertensive patients. Methods Reports were identified through searches of The Cochrane Library, MEDLINE, relevant textbooks, and by persona communication with established researchers in hypertension. Randomised controlled trials that assessed the effect of atenolol on cardiovascular morbidity or mortality in patients with primary hypertension were included. Findings We identified four studies that compared atenolol with placebo or no treatment, and five that compared atenolol with other anti hypertensive drugs. Despite major differences in blood pressure lowering, there were no outcome differences between atenolol and placebo in the four studies, comprising 6825 patients, who were followed up for a mean of 4.6 years on all-cause mortality (relative risk 1.01 [95% Cl 0.89-1.15]), cardiovascular mortality (0.99 [0.83-1.18]), or myocardial infarction (0.99 [0.83-1.19]). The risk of stroke, however, tended to be lower in the atenolol than in the placebo group (0.85 [0.72-1.01]). When atenolol was compared with other antihypertensives, there were no major differences in blood pressure lowering between the treatment arms. Our meta-analysis showed a significantly higher mortality (1.13 [1.02-1.25]) with atenolol treatment than with other active treatment, in the five studies comprising 17 671 patients who were followed up for a mean of 4.6 years. Moreover, cardiovascular mortality also tended to be higher with atenolol treatment than with other antihypertensive treatment. Stroke was also more frequent with atenolol treatment. Interpretation Our results cast doubts on atenolol as a suitable drug for hypertensive patients. Moreover, they challenge the use of atenolol as a reference drug in outcome trials in hypertension.	Umea Univ Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Sahlgrens Univ Hosp, Dept Nephrol, S-41345 Gothenburg, Sweden	Umea University; Sahlgrenska University Hospital	Lindholm, LJ (corresponding author), Umea Univ Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	LarsHLindholm@fammed.umu.se						ABLAD B, 1991, J AM COLL CARDIOL, V17, P165; Alderman MH, 2003, HYPERTENSION, V42, P239, DOI 10.1161/01.HYP.0000086521.95630.5A; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1993, Stroke, V24, P543; Aronow WS, 2003, LANCET, V362, P591, DOI 10.1016/S0140-6736(03)14208-0; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; ERIKSSON S, 1995, CEREBROVASC DIS, V5, P21, DOI 10.1159/000107813; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Hjalmarson A, 1999, LANCET, V353, P2001; Klingbeil AU, 2003, AM J MED, V115, P41, DOI 10.1016/S0002-9343(03)00158-X; Law M, 2003, HLTH TECHNOL ASSESS, V7; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Lechat P, 1999, LANCET, V353, P9; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Messerli FH, 2003, AM J HYPERTENS, V16, P870, DOI 10.1016/S0895-7061(03)01017-3; PARKER GW, 1990, CIRC RES, V66, P259, DOI 10.1161/01.RES.66.2.259; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; SCHIFFRIN EL, 1995, AM J HYPERTENS, V8, P229, DOI 10.1016/0895-7061(95)96211-2; Schiffrin EL, 2000, CIRCULATION, V101, P1653; Schiffrin EL, 2002, J HYPERTENS, V20, P71, DOI 10.1097/00004872-200201000-00011; Sever PS, 2001, J HUM HYPERTENS, V15, pS11, DOI 10.1038/sj.jhh.1001212; Stearne MR, 1998, BRIT MED J, V317, P713; *STEER COMM HAPPHY, 1989, JAMA-J AM MED ASSOC, V262, P3273; Taddei S, 2000, Curr Hypertens Rep, V2, P64, DOI 10.1007/s11906-000-0061-8; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WIKSTRAND J, 1991, CIRCULATION, V84, P93; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD	38	400	418	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1684	1689		10.1016/S0140-6736(04)17355-8	http://dx.doi.org/10.1016/S0140-6736(04)17355-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530629				2022-12-28	WOS:000224921600031
J	Garner, EC; Campbell, CS; Mullins, RD				Garner, EC; Campbell, CS; Mullins, RD			Dynamic instability in a DNA-segregating prokaryotic actin homolog	SCIENCE			English	Article							FORMIN-INDUCED NUCLEATION; PLASMID R1; ESCHERICHIA-COLI; MECHANISM; PARM; POLYMERIZATION; HYDROLYSIS; FILAMENTS; PROTEIN; ATP	Dynamic instability-the switching of a two-state polymer between phases of steady elongation and rapid shortening-is essential to the cellular function of eukaryotic microtubules, especially during chromosome segregation. Since the discovery of dynamic instability 20 years ago, no other biological polymer has been found to exhibit this behavior. Using total internal reflection fluorescence microscopy and fluorescence resonance energy transfer, we observe that the prokaryotic actin homolog ParM, whose assembly is required for the segregation of large, low-copy number plasmids, displays both dynamic instability and symmetrical, bidirectional polymerization. The dynamic instability of ParM is regulated by adenosine triphosphate (ATP) hydrolysis, and filaments are stabilized by a cap of ATP-bound monomers. ParM is not related to tubulin, so its dynamic instability must have arisen by convergent evolution driven by a set of common constraints on polymer-based segregation of,DNA.	Univ Calif San Francisco, San Francisco, CA 94107 USA	University of California System; University of California San Francisco	Mullins, RD (corresponding author), Univ Calif San Francisco, 600 16th St, San Francisco, CA 94107 USA.	dyche@muttinslab.ucsf.edu	Garner, Ethan/J-4025-2014	Garner, Ethan/0000-0003-0141-3555; Campbell, Christopher/0000-0002-3927-344X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61010-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchoin L, 2002, BIOCHEMISTRY-US, V41, P597, DOI 10.1021/bi011214b; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; DAM M, 1994, J MOL BIOL, V236, P1289, DOI 10.1016/0022-2836(94)90058-2; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; GERDES K, 1986, J MOL BIOL, V190, P269, DOI 10.1016/0022-2836(86)90001-X; GERDES K, 1985, J BACTERIOL, V161, P292, DOI 10.1128/JB.161.1.292-298.1985; Gitai Z, 2004, P NATL ACAD SCI USA, V101, P8643, DOI 10.1073/pnas.0402638101; Jensen RB, 1997, J MOL BIOL, V269, P505, DOI 10.1006/jmbi.1997.1061; Jensen RB, 1999, EMBO J, V18, P4076, DOI 10.1093/emboj/18.14.4076; Kruse T, 2003, EMBO J, V22, P5283, DOI 10.1093/emboj/cdg504; MANDELKOW EM, 1988, EMBO J, V7, P357, DOI 10.1002/j.1460-2075.1988.tb02821.x; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Mitchison TJ, 2001, NAT CELL BIOL, V3, pE17, DOI 10.1038/35050656; Moller-Jensen J, 2003, MOL CELL, V12, P1477, DOI 10.1016/S1097-2765(03)00451-9; Moller-Jensen J, 2002, EMBO J, V21, P3119, DOI 10.1093/emboj/cdf320; NORDSTROM K, 1972, J BACTERIOL, V110, P562; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Panda D, 2002, BIOCHEMISTRY-US, V41, P1609, DOI 10.1021/bi011767m; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Romberg L, 2004, BIOCHEMISTRY-US, V43, P282, DOI 10.1021/bi035465r; Soufo HJD, 2003, CURR BIOL, V13, P1916, DOI 10.1016/j.cub.2003.10.024; van den Ent F, 2002, EMBO J, V21, P6935, DOI 10.1093/emboj/cdf672; Vinson VK, 1998, BIOCHEMISTRY-US, V37, P10871, DOI 10.1021/bi980093l; Vorobiev S, 2003, P NATL ACAD SCI USA, V100, P5760, DOI 10.1073/pnas.0832273100; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; WENDEL H, 1987, BIOCHIM BIOPHYS ACTA, V915, P199, DOI 10.1016/0167-4838(87)90300-1; Zigmond SH, 2004, CURR OPIN CELL BIOL, V16, P99, DOI 10.1016/j.ceb.2003.10.019	27	217	220	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 5	2004	306	5698					1021	1025		10.1126/science.1101313	http://dx.doi.org/10.1126/science.1101313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869RG	15528442				2022-12-28	WOS:000225001100040
J	Singh, JA				Singh, JA			Why AIDS in South Africa threatens stability and economic growth in other parts of Africa	LANCET			English	Editorial Material									Ctr AIDS Programme Res S Africa CAPRISA, Durban, South Africa; Univ KwaZulu Natal, Howard Coll Sch Law, ZA-4041 Durban, South Africa; Univ Toronto, Joint Ctr Bioeth, Toronto, ON, Canada	University of Kwazulu Natal; University of Toronto	Singh, JA (corresponding author), Ctr AIDS Programme Res S Africa CAPRISA, Durban, South Africa.	singhj9@ukzn.ac.za	Singh, Jerome Amir/ABG-1573-2021					*DEP DEF S AFR, 2004, PROJ PHID UPD B; *DEP DEF S AFR, 2002, CURR STAT HIV EP SA; *DEP DEF S AFR, MAS CAMP; *DEP HLTH S AFR, 2003, NAT HIV SYPH ANT SER; *PIC HEADL, 2004, HLTH ED ENV DEC DEM; *S AFR PRESS ASS, 2004, AFR BREEDS TERR SAYS; *STAT S AFR, CENS 2001; *UN POP FUND, 2004, UNFPA STAT WORLD POP; VERMUELEN A, 2004, S AFRICA CORPORATE F	9	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV-DEC	2004	364	9449					1919	1920		10.1016/S0140-6736(04)17491-6	http://dx.doi.org/10.1016/S0140-6736(04)17491-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	874BX	15566993				2022-12-28	WOS:000225327000007
J	Van Overmeire, B; Allegaert, K; Casaer, A; Debauche, C; Decaluwe, W; Jespers, A; Weyler, J; Harrewijn, I; Langhendries, JP				Van Overmeire, B; Allegaert, K; Casaer, A; Debauche, C; Decaluwe, W; Jespers, A; Weyler, J; Harrewijn, I; Langhendries, JP		MIPS Investigators	Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial	LANCET			English	Article							PATENT DUCTUS-ARTERIOSUS; CEREBRAL BLOOD-FLOW; PRETERM INFANTS; INTRAVENTRICULAR HEMORRHAGE; PULMONARY-HYPERTENSION; INDOMETHACIN; HEMODYNAMICS; PREVENTION	Background Ibuprofen is used for treatment and prevention of patent ductus arteriosus in low-birthweight infants. Its effects on regional circulations differ from those of indometacin. Because prophylactic indometacin reduces the frequency of severe intraventricular haemorrhage and patent ductus arteriosus, we aimed to study the efficacy of early ibuprofen in reducing these outcomes in a double-blind, multicentre trial. Methods Within 6 h after birth, 415 low-birthweight infants (gestational age <31 weeks) were randomly allocated ibuprofen-lysine (10 mg/kg then two doses of 5 mg/kg after 24 h and 48 h) or placebo intravenously. The primary outcome was occurrence of severe intraventricular haemorrhage; secondary outcomes were occurrence of patent ductus arteriosus and possible adverse effects of ibuprofen. Analysis was by intention to treat. Findings 17 (8%) of 205 infants assigned ibuprofen and 18 (9%) of 210 assigned placebo developed severe intraventricular haemorrhage (relative risk 0.97 [95% CI 0.51-1.82]). In 172 (84%) infants of the ibuprofen group, the ductus was closed on day 3 compared with 126 (60%) of the placebo group (relative risk 1.40 [1.23-1.59]). No important differences in other outcomes or side-effects were noted; however, urine production was significantly lower on day 1 and concentration of creatinine in serum was significantly higher on day 3 after ibuprofen. Interpretation Ibuprofen prophylaxis in preterm. infants does not reduce the frequency of intraventricular haemorrhage, but does decrease occurrence of patent ductus arteriosus.	Univ Antwerp Hosp, Dept Paediat, Neonatal Intens Care Unit, B-2650 Antwerp, Belgium; Katholieke Univ Leuven Hosp, Louvain, Belgium; St Jan Ziekenhuis, Brugge, Belgium; Clin Univ St Luc, B-1200 Brussels, Belgium; Ghent Univ Hosp, B-9000 Ghent, Belgium; Queen Paola Childrens Hosp Antwerp, Antwerp, Belgium; Univ Antwerp, Antwerp, Belgium; CHC Clin St Vincent Rocourt, Rocourt, Belgium	University of Antwerp; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Ghent University; Ghent University Hospital; University of Antwerp	Van Overmeire, B (corresponding author), Univ Antwerp Hosp, Dept Paediat, Neonatal Intens Care Unit, Wilrijkst 10, B-2650 Antwerp, Belgium.	bart.van.overmeire@uza.be	allegaert, karel/C-3611-2016; Weyler, Joost JJ/O-8594-2016	allegaert, karel/0000-0001-9921-5105; Weyler, Joost JJ/0000-0001-7271-5492				CHEMTOB S, 1991, PEDIATR RES, V30, P106, DOI 10.1203/00006450-199107000-00021; Clyman RI, 1996, J PEDIATR-US, V128, P601, DOI 10.1016/S0022-3476(96)80123-5; CooperPeel C, 1996, PHARMACOL TOXICOL, V79, P297, DOI 10.1111/j.1600-0773.1996.tb00012.x; COWAN F, 1986, J PEDIATR-US, V109, P341, DOI 10.1016/S0022-3476(86)80398-5; Dani C, 2000, ACTA PAEDIATR, V89, P1369, DOI 10.1080/080352500300002598; De Carolis MP, 2000, EUR J PEDIATR, V159, P364, DOI 10.1007/s004310051288; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; Evans N, 1996, ARCH DIS CHILD-FETAL, V75, pF183, DOI 10.1136/fn.75.3.F183; FOWLIE PW, 2003, COCHRANE LIB; Gournay V, 2002, LANCET, V359, P1486, DOI 10.1016/S0140-6736(02)08424-6; Guignard JP, 2002, SEMIN PERINATOL, V26, P398, DOI 10.1053/sper.2002.37310; Kluckow M, 1999, ARCH DIS CHILD-FETAL, V80, pF34, DOI 10.1136/fn.80.1.F34; MCCORMICK DC, 1993, PEDIATR RES, V33, P603, DOI 10.1203/00006450-199306000-00015; Ment LR, 1996, PEDIATRICS, V98, P714; MENT LR, 1994, PEDIATRICS, V93, P543; Mosca F, 2002, LANCET, V360, P1023, DOI 10.1016/S0140-6736(02)11109-3; Mosca F, 1997, J PEDIATR-US, V131, P549, DOI 10.1016/S0022-3476(97)70060-X; Patel J, 2000, PEDIATR RES, V47, P36, DOI 10.1203/00006450-200001000-00009; PATEL J, 1995, LANCET, V346, P255, DOI 10.1016/S0140-6736(95)91304-1; Pezzati M, 1999, J PEDIATR-US, V135, P733, DOI 10.1016/S0022-3476(99)70093-4; PRYDS O, 1988, EUR J PEDIATR, V147, P315, DOI 10.1007/BF00442705; Romagnoli C, 2000, CLIN PHARMACOL THER, V67, P676, DOI 10.1067/mcp.2000.107048; Schmidt B, 2002, LANCET, V360, P492, DOI 10.1016/S0140-6736(02)09658-7; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Seri I., 1998, AVERSY DIS NEWBORN, P372; SHANKARAN S, 1982, J PEDIATR-US, V100, P469, DOI 10.1016/S0022-3476(82)80462-9; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Van Overmeire B, 2001, CLIN PHARMACOL THER, V70, P336, DOI 10.1067/mcp.2001.118453; Van Overmeire B, 2001, J PEDIATR-US, V138, P205, DOI 10.1067/mpd.2001.110528; Varvarigou A, 1996, JAMA-J AM MED ASSOC, V275, P539, DOI 10.1001/jama.275.7.539; Volpe JJ., 2001, NEUROLOGY NEWBORN, P428	31	99	102	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV-DEC	2004	364	9449					1945	1949		10.1016/S0140-6736(04)17477-1	http://dx.doi.org/10.1016/S0140-6736(04)17477-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	874BX	15567010				2022-12-28	WOS:000225327000032
J	Bertone, P; Stolc, V; Royce, TE; Rozowsky, JS; Urban, AE; Zhu, XW; Rinn, JL; Tongprasit, W; Samanta, M; Weissman, S; Gerstein, M; Snyder, M				Bertone, P; Stolc, V; Royce, TE; Rozowsky, JS; Urban, AE; Zhu, XW; Rinn, JL; Tongprasit, W; Samanta, M; Weissman, S; Gerstein, M; Snyder, M			Global identification of human transcribed sequences with genome tiling arrays	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVITY; HUMAN-CHROMOSOME-22; CHROMOSOME-22; PSEUDOGENES; MICROARRAY; RESOURCES; COVERAGE; ENSEMBL; RNAS; DNA	Elucidating the transcribed regions of the genome constitutes a fundamental aspect of human biology, yet this remains an outstanding problem. To comprehensively identify coding sequences, we constructed a series of high-density oligonucleotide tiling arrays representing sense and antisense strands of the entire nonrepetitive sequence of the human genome. Transcribed sequences were located across the genome via hybridization to complementary DNA samples, reverse-transcribed from polyadenylated RNA obtained from human liver tissue. In addition to identifying many known and predicted genes, we found 10,595 transcribed sequences not detected by other methods. A large fraction of these are located in intergenic regions distal. from previously annotated genes and exhibit significant, homology to other mammalian proteins.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; NASA, Ames Res Ctr, Ctr Nanotechnol, Moffett Field, CA 94035 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Eloret Corp, Sunnyvale, CA 94087 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Yale University; Yale University	Gerstein, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.	mark.gerstein@yale.edu; michael.snyder@yale.edu	Bertone, Paul/A-6600-2013; Bertone, Paul/Z-3734-2019	Bertone, Paul/0000-0001-5059-4829; Bertone, Paul/0000-0001-5059-4829; Rozowsky, Joel/0000-0002-3565-0762; Rinn, John/0000-0002-7231-7539; Snyder, Michael/0000-0003-0784-7987; Zhu, Xiaowei/0000-0002-5731-3177	NHGRI NIH HHS [P50 HG02357] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002357] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Albert TJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng035; ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Mattick JS, 2003, BIOESSAYS, V25, P930, DOI 10.1002/bies.10332; Nuwaysir EF, 2002, GENOME RES, V12, P1749, DOI 10.1101/gr.362402; Pruitt KD, 2000, TRENDS GENET, V16, P44, DOI 10.1016/S0168-9525(99)01882-X; Rinn JL, 2003, GENE DEV, V17, P529, DOI 10.1101/gad.1055203; Selinger DW, 2000, NAT BIOTECHNOL, V18, P1262, DOI 10.1038/82367; Tjaden B, 2002, NUCLEIC ACIDS RES, V30, P3732, DOI 10.1093/nar/gkf505; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Yamada K, 2003, SCIENCE, V302, P842, DOI 10.1126/science.1088305; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	21	807	882	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 24	2004	306	5705					2242	2246		10.1126/science.1103388	http://dx.doi.org/10.1126/science.1103388			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	882PE	15539566				2022-12-28	WOS:000225950000042
J	Ostor, AJK; Crisp, AJ; Somerville, MF; Scott, DGI				Ostor, AJK; Crisp, AJ; Somerville, MF; Scott, DGI			Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab	BRITISH MEDICAL JOURNAL			English	Article							THERAPY		Addenbrookes Hosp, Dept Rheumatol, Cambridge CB2 2QQ, England; Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Ostor, AJK (corresponding author), Addenbrookes Hosp, Dept Rheumatol, Hills Rd, Cambridge CB2 2QQ, England.	andrew.ostor@addenbrookes.nhs.uk						Braun J, 2002, LANCET, V359, P1187, DOI 10.1016/S0140-6736(02)08215-6; Courtney PA, 2003, ARTHRIT RHEUM-ARTHR, V49, P617, DOI 10.1002/art.11187; Dotan I., 2001, Harefuah, V140, P289; Peno-Green L, 2002, CHEST, V122, P1858, DOI 10.1378/chest.122.5.1858	4	70	70	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 27	2004	329	7477					1266	1266		10.1136/bmj.329.7477.1266	http://dx.doi.org/10.1136/bmj.329.7477.1266			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	876FC	15564258	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000225480900015
J	Westfall, PJ; Ballon, DR; Thorner, J				Westfall, PJ; Ballon, DR; Thorner, J			When the stress of your environment makes you go HOG wild	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; RESPONSE REGULATOR; OSMOTIC-STRESS; KINASE PATHWAY; MAPK PATHWAY; YEAST; ACTIVATION; OSMOSTRESS; OSMOSENSOR; COMPONENTS	When exposed to increased dissolved solute in their environment (hyperosmotic stress), all eukaryotic cells respond by rapidly activating a conserved mitogen-activated protein kinase cascade, known in budding yeast Saccharomyces cerevisiae as the high osmolarity glycerol (HOG) pathway. Intensive genetic and biochemical analysis in this organism has revealed the presumptive osmosensors, downstream signaling components, and metabolic and transcriptional changes that allow cells to cope with this stressful condition. These findings have had direct application to understanding stress sensing and control of transcription by stress-activated mitogen-activated protein kinases in mammalian cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Thorner, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	jeremy@socrates.berkeley.edu	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, F32GM068343, R01GM021841] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-21841, GM-68343] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243; Cullen PJ, 2004, GENE DEV, V18, P1695, DOI 10.1101/gad.1178604; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; de Nadal E, 2002, EMBO REP, V3, P735, DOI 10.1093/embo-reports/kvf158; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; Lu JMY, 2003, EUKARYOT CELL, V2, P1304, DOI 10.1128/EC.2.6.1304-1314.2003; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; O'Rourke SM, 2004, MOL BIOL CELL, V15, P532, DOI 10.1091/mbc.E03-07-0521; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Proft M, 2004, CELL, V118, P351, DOI 10.1016/j.cell.2004.07.016; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Raitt DC, 2000, EMBO J, V19, P4623, DOI 10.1093/emboj/19.17.4623; Sato N, 2003, MOL CELL BIOL, V23, P6662, DOI 10.1128/MCB.23.18.6662-6671.2003; Uhlik MT, 2003, NAT CELL BIOL, V5, P1104, DOI 10.1038/ncb1071; WESTFALL PJ, 2004, SCI STKE         NOV; Winkler A, 2002, EUKARYOT CELL, V1, P163, DOI 10.1128/EC.1.2.163-173.2002; Zarrinpar A, 2004, MOL CELL, V14, P825, DOI 10.1016/j.molcel.2004.06.011	22	98	103	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	2004	306	5701					1511	1512		10.1126/science.1104879	http://dx.doi.org/10.1126/science.1104879			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	875ST	15567851				2022-12-28	WOS:000225442700045
J	Gao, LZ; Innan, H				Gao, LZ; Innan, H			Very low gene duplication rate in the yeast genome	SCIENCE			English	Article							CONVERSION; RECOMBINATION; MODEL	The gene duplication rate in the yeast genome is estimated without assuming the molecular clock model to be similar to0.01 to 0.06 per gene per billion years; this rate is two orders of magnitude lower than a previous estimate based on the molecular clock model. This difference is explained by extensive concerted evolution via gene conversion between duplicated genes, which violates the assumption of the molecular clock in the analyses of duplicated genes. The average length of the period of concerted evolution and the gene conversion rate are estimated to be similar to25 million years and similar to28 times the mutation rate, respectively.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health	Innan, H (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, 1200 Hermann Pressler, Houston, TX 77030 USA.	hideki.innan@uth.tmc.edu		Innan, Hideki/0000-0001-6375-9231				Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; ELDER JF, 1995, Q REV BIOL, V70, P297, DOI 10.1086/419073; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Hurles ME, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r55; Innan H, 2003, P NATL ACAD SCI USA, V100, P8793, DOI 10.1073/pnas.1031592100; Innan H, 2003, GENETICS, V163, P803; Jeffreys AJ, 2004, NAT GENET, V36, P151, DOI 10.1038/ng1287; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Langley CH, 2000, GENETICS, V156, P1837; Li W. H, 1997, MOL EVOLUTION; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Marais G, 2003, TRENDS GENET, V19, P330, DOI 10.1016/S0168-9525(03)00116-1; Ohno S., 1970, EVOLUTION GENE DUPLI; OHTA T, 1982, P NATL ACAD SCI-BIOL, V79, P3251, DOI 10.1073/pnas.79.10.3251; Ohta T., 1980, EVOLUTION VARIATION, V37, DOI [10.1007/978-3-642-93138-3, DOI 10.1007/978-3-642-93138-3]; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; Rokas A, 2003, NATURE, V425, P798, DOI 10.1038/nature02053; Rozen S, 2003, NATURE, V423, P873, DOI 10.1038/nature01723; Teshima KM, 2004, GENETICS, V166, P1553, DOI 10.1534/genetics.166.3.1553; Walsh B, 2003, GENETICA, V118, P279, DOI 10.1023/A:1024194802441; Wang W, 2004, GENETICS, V166, P1783, DOI 10.1534/genetics.166.4.1783; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yang ZH, 2000, MOL BIOL EVOL, V17, P32, DOI 10.1093/oxfordjournals.molbev.a026236; ZUCKERKANDL EMILE, 1965, P97	26	117	123	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	2004	306	5700					1367	1370		10.1126/science.1102033	http://dx.doi.org/10.1126/science.1102033			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550669				2022-12-28	WOS:000225301600050
J	Koo, B; Nottenburg, C; Pardey, PG				Koo, B; Nottenburg, C; Pardey, PG			Intellectual property - Plants and intellectual property: An international appraisal	SCIENCE			English	Article									Int Food Policy Res Inst, Washington, DC 20006 USA; Cougar Patent Law, Seattle, WA 98144 USA; Univ Minnesota, Dept Appl Econ, St Paul, MN 55108 USA	CGIAR; International Food Policy Research Institute (IFPRI); University of Minnesota System; University of Minnesota Twin Cities	Koo, B (corresponding author), Int Food Policy Res Inst, Washington, DC 20006 USA.	b.koo@cgiar.org; c.nottenburg@cougarlaw.com; ppardey@apec.umn.edu						Atkinson RC, 2003, SCIENCE, V301, P174, DOI 10.1126/science.1085553; Beachy RN, 2003, SCIENCE, V299, P473, DOI 10.1126/science.299.5606.473; Binenbaum E, 2003, ECON DEV CULT CHANGE, V51, P309, DOI 10.1086/346177; Brahmi P, 2004, CURR SCI INDIA, V86, P392; *CPVO, 2002, ANN REP; Fowler C, 1990, SHATTERING FOOD POLI; Heller MA, 1998, SCIENCE, V280, P698, DOI 10.1126/science.280.5364.698; Kennedy D, 2003, SCIENCE, V302, P357, DOI 10.1126/science.302.5644.357; KOO B, 2003, P038 U MINN DEP APPL; Pardey P. G., 2001, SLOW MAGIC AGR R D C	10	33	34	2	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	2004	306	5700					1295	1297		10.1126/science.1106760	http://dx.doi.org/10.1126/science.1106760			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	873SP	15550646				2022-12-28	WOS:000225301600025
J	Simons, FER				Simons, FER			Drug therapy - Advances in H-1-antihistamines	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEASONAL ALLERGIC RHINITIS; PLACEBO-CONTROLLED TRIAL; FEXOFENADINE HYDROCHLORIDE 120; HISTAMINE H-1 RECEPTORS; CENTRAL-NERVOUS-SYSTEM; QUALITY-OF-LIFE; DOUBLE-BLIND; ATOPIC-DERMATITIS; H-1-RECEPTOR ANTAGONISTS; YOUNG-CHILDREN		Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada; Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Fac Med, Canadian Inst Hlth Res Natl Allergy & Asthma Trai, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; University of Manitoba	Simons, FER (corresponding author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca						Aaronson DW, 1996, ANN ALLERG ASTHMA IM, V76, P440, DOI 10.1016/S1081-1206(10)63461-8; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Alter P, 2001, ANN INTERN MED, V135, P384, DOI 10.7326/0003-4819-135-5-200109040-00026; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; Baker AM, 2003, J FORENSIC SCI, V48, P425; Bakker RA, 2001, MOL PHARMACOL, V60, P1133, DOI 10.1124/mol.60.5.1133; Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Bender BG, 2001, J PEDIATR-US, V138, P656, DOI 10.1067/mpd.2001.112647; Black Anne Kobza, 2002, Clin Allergy Immunol, V17, P249; Bockholdt B, 2001, FORENSIC SCI INT, V119, P138, DOI 10.1016/S0379-0738(00)00393-5; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Breneman DL, 1996, ANN PHARMACOTHER, V30, P1075, DOI 10.1177/106002809603001001; Caron G, 2001, J IMMUNOL, V166, P6000, DOI 10.4049/jimmunol.166.10.6000; Chen CP, 2003, DRUG METAB DISPOS, V31, P312, DOI 10.1124/dmd.31.3.312; Chishty M, 2001, J DRUG TARGET, V9, P223, DOI 10.3109/10611860108997930; Ciprandi G, 1999, CLIN EXP ALLERGY, V29, P49, DOI 10.1046/j.1365-2222.1999.00012.x; Cobb DB, 2001, VET HUM TOXICOL, V43, P163; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; CORREN J, 1998, J ALLERGY CLIN IMMUN, V101, P792; *CTR EV BAS MED, LEV EV GRAD REC; Day JH, 2001, ANN ALLERG ASTHMA IM, V87, P474, DOI 10.1016/S1081-1206(10)62260-0; De Bruin ML, 2002, BRIT J CLIN PHARMACO, V53, P370, DOI 10.1046/j.1365-2125.2002.01569.x; Di Lorenzo G, 2004, J ALLERGY CLIN IMMUN, V114, P619, DOI 10.1016/j.jaci.2004.06.018; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; Finkle WD, 2002, ANN ALLERG ASTHMA IM, V89, P244, DOI 10.1016/S1081-1206(10)61950-3; Finn AF, 1999, J ALLERGY CLIN IMMUN, V104, P1071, DOI 10.1016/S0091-6749(99)70091-6; Fischel T, 2001, J CLIN PSYCHOPHARM, V21, P612, DOI 10.1097/00004714-200112000-00013; FLYNN CA, 2002, COCHRANE DB SYST REV, V1; FRIEDMAN BS, 1993, J ALLERGY CLIN IMMUN, V92, P520, DOI 10.1016/0091-6749(93)90076-R; Fujikura T, 2001, J ALLERGY CLIN IMMUN, V107, P123, DOI 10.1067/mai.2001.111236; Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P5937, DOI 10.1073/pnas.88.13.5937a; Geha RS, 2001, J ALLERGY CLIN IMMUN, V107, P752, DOI 10.1067/mai.2001.114239; Gordon CR, 2001, J PSYCHOPHARMACOL, V15, P167, DOI 10.1177/026988110101500311; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hall IP, 2000, EUR RESPIR J, V15, P449, DOI 10.1034/j.1399-3003.2000.15.04.x; Halpert AG, 2002, NEUROSCI BIOBEHAV R, V26, P61, DOI 10.1016/S0149-7634(01)00038-0; Higuchi M, 2000, NEUROSCIENCE, V99, P721, DOI 10.1016/S0306-4522(00)00230-X; Hindmarch I, 2002, CLIN EXP ALLERGY, V32, P133, DOI 10.1046/j.0022-0477.2001.01245.x; Hindmarch I, 2001, CURR MED RES OPIN, V17, P241, DOI 10.1185/0300799019117011; Holgate ST, 2003, CLIN EXP ALLERGY, V33, P1305, DOI 10.1046/j.1365-2222.2003.01769.x; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927, DOI 10.1016/S0091-6749(99)70070-9; Igaz P, 2001, INFLAMM RES, V50, P123, DOI 10.1007/s000110050735; Jumbelic MI, 1997, AM J FOREN MED PATH, V18, P65, DOI 10.1097/00000433-199703000-00012; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kaiser HB, 2001, CLIN DRUG INVEST, V21, P571, DOI 10.2165/00044011-200121080-00006; Kaplan AP, 2002, NEW ENGL J MED, V346, P175, DOI 10.1056/NEJMcp011186; Karppinen A, 2002, ALLERGY, V57, P534, DOI 10.1034/j.1398-9995.2002.13201.x; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kawashima M, 2003, BRIT J DERMATOL, V148, P1212, DOI 10.1046/j.1365-2133.2003.05293.x; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Kranke P, 2002, ACTA ANAESTH SCAND, V46, P238, DOI 10.1034/j.1399-6576.2002.t01-1-460303.x; LECONIAT M, 1994, HUM GENET, V94, P186, DOI 10.1007/BF00202867; Leelataweedwud P, 2001, J AM DENT ASSOC, V132, P1531, DOI 10.14219/jada.archive.2001.0086; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Lovenberg TW, 1999, MOL PHARMACOL, V55, P1101, DOI 10.1124/mol.55.6.1101; Ma RLZ, 2002, SCIENCE, V297, P620, DOI 10.1126/science.1072810; MacGlashan Donald Jr., 2003, Journal of Allergy and Clinical Immunology, V112, pS53, DOI 10.1016/S0091-6749(03)01877-3; Mann RD, 2000, BRIT MED J, V320, P1184, DOI 10.1136/bmj.320.7243.1184; McLeod RL, 1999, AM J RHINOL, V13, P391, DOI 10.2500/105065899781367483; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; Nadalin V, 2003, INT J CANCER, V106, P566, DOI 10.1002/ijc.11240; Nicholson AN, 2003, AVIAT SPACE ENVIR MD, V74, P809; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Okamura N, 2000, BRIT J PHARMACOL, V129, P115, DOI 10.1038/sj.bjp.0702994; Owens JA, 2003, PEDIATRICS, V111, pE628, DOI 10.1542/peds.111.5.e628; Radovanovic D, 2000, HUM EXP TOXICOL, V19, P489, DOI 10.1191/096032700671040438; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; Richardson GS, 2002, J CLIN PSYCHOPHARM, V22, P511, DOI 10.1097/00004714-200210000-00012; Ridout F, 2003, CLIN THER, V25, P1518, DOI 10.1016/S0149-2918(03)80137-6; Saengpanich S, 2003, ARCH OTOLARYNGOL, V129, P557, DOI 10.1001/archotol.129.5.557; Santiago-Palma J, 2001, J PAIN SYMPTOM MANAG, V22, P699, DOI 10.1016/S0885-3924(01)00311-6; SCHATZ M, 2002, HISTAMINE H1 ANTIHIS, P421; Scherer CR, 2002, BRIT J PHARMACOL, V137, P892, DOI 10.1038/sj.bjp.0704873; Schmelz M, 1997, J NEUROSCI, V17, P8003; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Schroeder JT, 2001, CLIN EXP ALLERGY, V31, P1369, DOI 10.1046/j.1365-2222.2001.01130.x; Shamsi Z, 2000, HUM PSYCHOPHARM CLIN, V15, pS3, DOI 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S; Simons FER, 1999, ANN ALLERG ASTHMA IM, V82, P157, DOI 10.1016/S1081-1206(10)62590-2; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P617, DOI 10.1067/mai.2003.168; SIMONS FER, 1994, NEW ENGL J MED, V330, P1663; Simons FER, 2001, J ALLERGY CLIN IMMUN, V107, P526, DOI 10.1067/mai.2001.113080; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; SIMONS FER, 2003, MIDDLETONS ALLERGY P, P834; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P141; SIMONS FER, 2002, HISTAMINE H1 ANTIHIS, P437; Soper JW, 2000, AVIAT SPACE ENVIR MD, V71, P1206; Spiller HA, 2002, J TOXICOL-CLIN TOXIC, V40, P525; Spitaler MM, 2002, CLIN EXP PHARMACOL P, V29, P711, DOI 10.1046/j.1440-1681.2002.03704.x; Stevenson J, 2002, PEDIATR RES, V52, DOI 10.1203/01.PDR.0000024060.49308.89; Sugimoto Y, 2004, CLIN EXP ALLERGY, V34, P456, DOI 10.1111/j.1365-2222.2004.01876.x; SUTTER AI, 2003, COCHRANE DB SYST REV, V3; Taglialatela M, 2000, TRENDS PHARMACOL SCI, V21, P52, DOI 10.1016/S0165-6147(99)01437-6; Tashiro M, 2002, LIFE SCI, V72, P409, DOI 10.1016/S0024-3205(02)02276-2; Thomson L, 2002, CLIN EXP ALLERGY, V32, P1187, DOI 10.1046/j.1365-2745.2002.01444.x; Timmerman H, 2000, ALLERGY, V55, P5, DOI 10.1034/j.1398-9995.2000.055supp60005.x; Triggiani M, 2001, J IMMUNOL, V166, P4083, DOI 10.4049/jimmunol.166.6.4083; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; van Steekelenburg J, 2002, ALLERGY, V57, P346, DOI 10.1034/j.1398-9995.2002.1s3426.x; VanGanse E, 1997, EUR RESPIR J, V10, P2216, DOI 10.1183/09031936.97.10102216; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WANDERER AA, 2000, ANN ALLERG ASTHMA IM, V85, P525; WANDERER AA, 2000, ANN ALLERG ASTHMA IM, V85, P532; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weiler JM, 2000, ANN INTERN MED, V132, P354, DOI 10.7326/0003-4819-132-5-200003070-00004; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Welch Michael J, 2002, Clin Allergy Immunol, V17, P337; WINBERY SL, 2002, HISTAMINE H1 ANTIHIS, P287; Woosley RL, 1996, ANNU REV PHARMACOL, V36, P233, DOI 10.1146/annurev.pa.36.040196.001313; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001; Yanai K, 1998, LIFE SCI, V62, P1607, DOI 10.1016/S0024-3205(98)00115-5; YAP YG, 2002, HISTAMINE H1 ANTIHIS, P389; Yokoyama H, 2001, BRAIN DEV-JPN, V23, P542, DOI 10.1016/S0387-7604(01)00261-3	121	432	472	3	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2004	351	21					2203	2217		10.1056/NEJMra033121	http://dx.doi.org/10.1056/NEJMra033121			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	871UU	15548781				2022-12-28	WOS:000225160600011
J	Politi, Y; Arad, T; Klein, E; Weiner, S; Addadi, L				Politi, Y; Arad, T; Klein, E; Weiner, S; Addadi, L			Sea urchin spine calcite forms via a transient amorphous calcium carbonate phase	SCIENCE			English	Article							ECHINOID EUCIDARIS-TRIBULOIDES; PRECURSOR; BIOMINERALIZATION; CRYSTALS; PROTEINS; SPICULES; EMBRYOS; TISSUES; FILMS	The skeletons of adult echinoderms comprise large single crystals of calcite with smooth convoluted fenestrated morphologies, raising many questions about how they form. By using water etching, infrared spectroscopy, electron diffraction, and environmental scanning electron microscopy, we show that sea urchin spine regeneration proceeds via the initial deposition of amorphous calcium carbonate. Because most echinoderms produce the same type of skeletal material, they probably all use this same mechanism. Deposition of transient amorphous phases as a strategy for producing single crystals with complex morphology may have interesting implications for the development of sophisticated materials.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Chem Res Support Unit, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Addadi, L (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	lia.addadi@weizmann.ac.il						Addadi L, 2003, ADV MATER, V15, P959, DOI 10.1002/adma.200300381; Aizenberg J, 2003, SCIENCE, V299, P1205, DOI 10.1126/science.1079204; Beniash E, 1999, J STRUCT BIOL, V125, P50, DOI 10.1006/jsbi.1998.4081; Beniash E, 1997, P ROY SOC B-BIOL SCI, V264, P461, DOI 10.1098/rspb.1997.0066; BERMAN A, 1988, NATURE, V331, P546, DOI 10.1038/331546a0; BRECEVIC L, 1989, J CRYST GROWTH, V98, P504, DOI 10.1016/0022-0248(89)90168-1; Carpenter W.B., 1847, BR ASS ADV SCI, V15, P93; Dubois P, 2001, MICROSC RES TECHNIQ, V55, P427, DOI 10.1002/jemt.1188; Dubois P., 1989, Echinoderm Studies, V3, P109; Gower LB, 2000, J CRYST GROWTH, V210, P719, DOI 10.1016/S0022-0248(99)00749-6; HEATFIELD BM, 1971, J EXP ZOOL, V178, P233, DOI 10.1002/jez.1401780208; LIPPMANN F, 1973, SEDIMENTARY CARBOATE; Loste E, 2001, CHEM COMMUN, P901, DOI 10.1039/b101563j; Lowenstam HA, 1989, BIOMINERALIZATION; MARKEL K, 1983, ZOOMORPHOLOGY, V103, P25, DOI 10.1007/BF00312056; MARKEL K, 1989, ZOOMORPHOLOGY, V109, P79, DOI 10.1007/BF00312313; MARKEL K, 1983, ZOOMORPHOLOGY, V103, P43, DOI 10.1007/BF00312057; OKAZAKI KAYO, 1960, EMBRYOLOGIA, V5, P283, DOI 10.1111/j.1440-169X.1960.tb00096.x; PILKINGTON JB, 1969, J MAR BIOL ASSOC UK, V49, P857, DOI 10.1017/S0025315400037991; RAUP DM, 1959, J GEOL, V67, P661, DOI 10.1086/626624; Raz S, 2003, ADV FUNCT MATER, V13, P480, DOI 10.1002/adfm.200304285; Simkiss K, 1989, BIOMINERALIZATION CE; TOWE KM, 1967, SCIENCE, V157, P1048, DOI 10.1126/science.157.3792.1048; Tsountas C., 1892, SVEN VETENSK AKAD HA, P1; Weiner S, 2000, MAT SCI ENG C-BIO S, V11, P1, DOI 10.1016/S0928-4931(00)00141-7; Weiss IM, 2002, J EXP ZOOL, V293, P478, DOI 10.1002/jez.90004; Wilt FH, 2002, ZOOL SCI, V19, P253, DOI 10.2108/zsj.19.253; Xu GF, 1998, J AM CHEM SOC, V120, P11977, DOI 10.1021/ja9819108	28	766	784	12	371	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 12	2004	306	5699					1161	1164		10.1126/science.1102289	http://dx.doi.org/10.1126/science.1102289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	872FM	15539597				2022-12-28	WOS:000225193100041
J	Borg, LE; Shearer, CK; Asmerom, Y; Papike, JJ				Borg, LE; Shearer, CK; Asmerom, Y; Papike, JJ			Prolonged KREEP magmatism on the Moon indicated by the youngest dated lunar igneous rock	NATURE			English	Article							NORTHWEST AFRICA-773; MARE BASALTS; CHRONOLOGY; CRYSTALLIZATION; HIGHLANDS; VOLCANISM; EVOLUTION; ORIGIN; SUITE	Primordial solidification of the Moon (or its uppermost layer) resulted in the formation of a variety of rock types that subsequently melted and mixed to produce the compositional diversity observed in the lunar sample suite(1,2). The initial rocks to crystallize from this Moon-wide molten layer (the magma ocean) contained olivine and pyroxene and were compositionally less evolved than the plagioclase-rich rocks that followed. The last stage of crystallization, representing the last few per cent of the magma ocean, produced materials that are strongly enriched in incompatible elements including potassium (K), the rare earth elements (REE) and phosphorus (P)-termed KREEP3-5. The decay of radioactive elements in KREEP, such as uranium and thorium, is generally thought to provide the thermal energy necessary for more recent lunar magmatism(4,6,7). The ages of KREEP-rich samples are, however, confined to the earliest periods of lunar magmatism between 3.8 and 4.6 billion years (Gyr) ago(8,9), providing no physical evidence that KREEP is directly involved in more recent lunar magmatism. But here we present evidence that KREEP magmatism extended for an additional 1 Gyr, based on analyses of the youngest dated lunar sample.	Univ New Mexico, Inst Meteorit, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA	University of New Mexico	Borg, LE (corresponding author), Univ New Mexico, Inst Meteorit, Dept Earth & Planetary Sci, Albuquerque, NM 87131 USA.	lborg@unm.edu						Borg LE, 2003, GEOCHIM COSMOCHIM AC, V67, P3519, DOI 10.1016/S0016-7037(03)00094-2; DASH EJ, 1989, LUN PLAN SCI C, V20, P218; Fagan TJ, 2003, METEORIT PLANET SCI, V38, P529, DOI 10.1111/j.1945-5100.2003.tb00025.x; Fernandes VA, 2003, METEORIT PLANET SCI, V38, P555, DOI 10.1111/j.1945-5100.2003.tb00026.x; Hess PC, 2001, J GEOPHYS RES-PLANET, V106, P28023, DOI 10.1029/2000JE001416; Hiesinger H, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE001985; HUGHES SS, 1988, GEOCHIM COSMOCHIM AC, V52, P2379, DOI 10.1016/0016-7037(88)90295-5; Jolliff BL, 2003, GEOCHIM COSMOCHIM AC, V67, P4857, DOI 10.1016/j.gca.2003.08.012; LUDWIG KR, 2001, BERKELEY GEOCHRONO A, V1; NYQUIST LE, 1992, GEOCHIM COSMOCHIM AC, V56, P2213, DOI 10.1016/0016-7037(92)90185-L; NYQUIST LE, 1977, P LUNAR PLANET SCI C, P1383; PAPANASTASSIOU DA, 1976, P LUNAR PLANET SCI C, P2035; SHIH CY, 1993, GEOCHIM COSMOCHIM AC, V57, P915, DOI 10.1016/0016-7037(93)90178-Y; SHIH CY, 1992, EARTH PLANET SC LETT, V108, P203, DOI 10.1016/0012-821X(92)90023-O; Smith J. A., 1970, P AP 11 LUN SCI C, P1149; SNYDER GA, 1992, GEOCHIM COSMOCHIM AC, V56, P3809, DOI 10.1016/0016-7037(92)90172-F; SNYDER GA, 1995, GEOCHIM COSMOCHIM AC, V59, P1185, DOI 10.1016/0016-7037(95)00034-W; SNYDER GA, 1995, J GEOPHYS RES-PLANET, V100, P9365, DOI 10.1029/95JE00575; SNYDER GA, 2000, CHRONOLOGY ISOTOPIC, P361; Warren P.H., 1988, P LUNAR PLANET SCI C, V18, P233; WARREN PH, 1979, REV GEOPHYS, V17, P73, DOI 10.1029/RG017i001p00073; WARREN PH, 1989, WORKSH MOON TRANS AP, P149; Wieczorek MA, 2000, J GEOPHYS RES-PLANET, V105, P20417, DOI 10.1029/1999JE001092; Wood JA, 1970, GEOCHIM COSM SUPPL, V1, P965	24	65	68	4	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 11	2004	432	7014					209	211		10.1038/nature03070	http://dx.doi.org/10.1038/nature03070			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	869YG	15538366				2022-12-28	WOS:000225020200043
J	Coenen, MJH; Antonicka, H; Ugalde, C; Sasarman, F; Rossi, R; Heister, JGAMA; Newbold, RF; Trijbels, FJMF; van den Heuvel, LP; Shoubridge, EA; Smeitink, JAM				Coenen, MJH; Antonicka, H; Ugalde, C; Sasarman, F; Rossi, R; Heister, JGAMA; Newbold, RF; Trijbels, FJMF; van den Heuvel, LP; Shoubridge, EA; Smeitink, JAM			Mutant mitochondrial elongation factor G1 and combined oxidative phosphorylation deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSLATIONAL-INITIATION; FACTOR TS; FACTOR TU; EXPRESSION; IDENTIFICATION; SEQUENCE; CLONING; GENES; DISORDERS; RIBOSOME	Although most components of the mitochondrial translation apparatus are encoded by nuclear genes, all known molecular defects associated with impaired mitochondrial translation are due to mutations in mitochondrial DNA. We investigated two siblings with a severe defect in mitochondrial translation, reduced levels of oxidative phosphorylation complexes containing mitochondrial DNA (mtDNA)-encoded subunits, and progressive hepatoencephalopathy. We mapped the defective gene to a region on chromosome 3q containing elongation factor G1 (EFG1), which encodes a mitochondrial translation factor. Sequencing of EFG1 revealed a mutation affecting a conserved residue of the guanosine triphosphate (GTP)-binding domain. These results define a new class of gene defects underlying disorders of oxidative phosphorylation.	Radboud Univ Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, Nijmegen, Netherlands; Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen Ctr Mitochondrial Disorders, Nijmegen, Netherlands; McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; Klinikum Neukolln, Dept Pediat, Berlin, Germany; Brunel Univ, Fac Life Sci, Brunel Inst Canc Genet & Pharmacogenom, Uxbridge UB8 3PH, Middx, England	Radboud University Nijmegen; Radboud University Nijmegen; McGill University; McGill University; VIivantes Klinikum Neukolln; Brunel University	Smeitink, JAM (corresponding author), Univ Med Ctr Nijmegen, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.	j.smeitink@cukz.umcn.nl	Smeitink, Jan/C-1351-2013; van den Heuvel, L.P.W.J./H-8044-2014; Smeitink, Jan A.M./D-6064-2011; Coenen, Marieke/A-2159-2010; van den Heuvel, Lambertus/AAM-1772-2021; Ugalde, Cristina/P-7533-2016	van den Heuvel, L.P.W.J./0000-0003-3917-6727; Coenen, Marieke/0000-0001-8796-2031; van den Heuvel, Lambertus/0000-0003-3917-6727; Ugalde, Cristina/0000-0002-9742-1877; Antonicka, Hana/0000-0002-2525-2867				BOULET L, 1992, AM J HUM GENET, V51, P1187; Cai YC, 2000, J BIOL CHEM, V275, P20308, DOI 10.1074/jbc.M001899200; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; FOURNIER REK, 1981, P NATL ACAD SCI-BIOL, V78, P6349, DOI 10.1073/pnas.78.10.6349; Gao J, 2001, GENOMICS, V74, P109, DOI 10.1006/geno.2001.6536; Hammarsund M, 2001, HUM GENET, V109, P542, DOI 10.1007/s00439-001-0610-5; Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285; Katunin VI, 2002, BIOCHEMISTRY-US, V41, P12806, DOI 10.1021/bi0264871; Kenmochi N, 2001, GENOMICS, V77, P65, DOI 10.1006/geno.2001.6622; Koc EC, 2002, J BIOL CHEM, V277, P35541, DOI 10.1074/jbc.M202498200; Ling MF, 1997, GENE, V197, P325, DOI 10.1016/S0378-1119(97)00279-5; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Rodnina MV, 2000, BIOL CHEM, V381, P377, DOI 10.1515/BC.2000.050; RubioGozalbo ME, 1997, EUR J PEDIATR, V156, P931, DOI 10.1007/s004310050745; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x; XIN H, 1995, J BIOL CHEM, V270, P17243, DOI 10.1074/jbc.270.29.17243; ZHAN GY, 1998, BIOCHIM BIOPHYS ACTA, V1443, P245; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	25	142	148	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2004	351	20					2080	2086		10.1056/NEJMoa041878	http://dx.doi.org/10.1056/NEJMoa041878			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	869TM	15537906	Green Published			2022-12-28	WOS:000225007200009
J	Gissen, P; Kelly, D				Gissen, P; Kelly, D			New hope for treatment of neonatal haemochromatosis	LANCET			English	Editorial Material							HEREDITARY HEMOCHROMATOSIS; HEPCIDIN; PROGRESS; DISEASE		Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England	University of Birmingham	Kelly, D (corresponding author), Birmingham Childrens Hosp, Liver Unit, Birmingham B4 6NH, W Midlands, England.	Deirdre.Kelly@bch.nhs.uk	Gissen, Paul/A-4352-2010	Gissen, Paul/0000-0002-9712-6122				Ahmad KA, 2002, BLOOD CELL MOL DIS, V29, P361, DOI 10.1006/bcmd.2002.0575; Beutler E, 2002, LANCET, V359, P211, DOI 10.1016/S0140-6736(02)07447-0; Birchall JE, 2003, BRIT J HAEMATOL, V122, P275, DOI 10.1046/j.1365-2141.2003.04408.x; Flynn DM, 2003, ARCH DIS CHILD-FETAL, V88, pF124, DOI 10.1136/fn.88.2.F124; Griffiths W, 2000, HUM MOL GENET, V9, P2377, DOI 10.1093/hmg/9.16.2377; Kelly AL, 2001, J MED GENET, V38, P599, DOI 10.1136/jmg.38.9.599; METZMAN R, 1989, J PEDIATR GASTR NUTR, V9, P112; Pietrangelo A, 2004, NEW ENGL J MED, V350, P2383, DOI 10.1056/NEJMra031573; Roetto A, 2003, NAT GENET, V33, P21, DOI 10.1038/ng1053; SCHOENLEBE J, 1993, AM J DIS CHILD, V147, P1072, DOI 10.1001/archpedi.1993.02160340058014; SHNEIDER BL, 1994, J PEDIATR-US, V124, P234, DOI 10.1016/S0022-3476(94)70310-8; Verloes A, 1996, J MED GENET, V33, P444, DOI 10.1136/jmg.33.6.444	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2004	364	9446					1644	1645		10.1016/S0140-6736(04)17367-4	http://dx.doi.org/10.1016/S0140-6736(04)17367-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	868NZ	15530606				2022-12-28	WOS:000224921600005
